#CLS_PREDICTION_ENTITY|MASK_PREDICTION_ENTITY|ACTUAL_ENTITY|CLS_PREDICTIONS|MASKED_PREDICTIONS|MASKED_WORD|SENTENCE
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|lithium carbonate sodium potassium fumarate|carbamazepine lithium vpa gabapentin isoniazid|lithium|is being evaluated as a monotherapy and in the iti-007-402 trial , lumateperone is being evaluated as an adjunctive therapy with entity or valproate .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|lithium carbonate sodium potassium fumarate|lithium antipsychotics antidepressants benzodiazepines stimulants|lithium|current drug therapy for bipolar disorder includes the use of entity and anti-depressants .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|lithium carbonate sodium potassium fumarate|lithium antidepressants benzodiazepines antipsychotics ssris|lithium|mood-stabilizing drugs can treat bipolar symptoms when they are present , including entity and anticonvulsants , such as valproic acid and lamotrigine .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium carbonate sodium potassium fumarate|cigarettes brand tobacco commercial disposable|lithium|retail sales of energizers entity and rechargeable products increased 22% in the quarter while our price-oriented product sales declined 12% .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lithium carbonate sodium potassium fumarate|thalidomide sunitinib minocycline everolimus nivolumab|lithium|to date , the only drug that interacted with zs-9 is entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|lithium carbonate sodium potassium fumarate|pharmaceutical biomedical gene healthcare global|lithium|mr . friess and mr . schwartz sold most of their shares of pisv for $275 , 000 and pisv became china entity technologies inc . listed on the otcbb symbol ( cltt ) .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium carbonate sodium potassium fumarate|battery electrically pacemaker self externally|lithium|chairman of cardiac pacemakers , inc . , a company founded by mr . villafana to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium carbonate sodium potassium fumarate|powered battery energy electrical portable|lithium|the e-go is an all-electric vehicle powered by advanced entity batteries .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lithium carbonate sodium potassium fumarate|lithium single metal platinum carbon|lithium|inc . , a company that is engaged in the manufacture , commercialization and distribution of a wide variety of standard and customized entity ion rechargeable batteries .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|lithium carbonate sodium potassium fumarate|naltrexone lithium fluoxetine clozapine antidepressants|lithium|these adjunctive agents may include atypical antipsychotics , like aripiprazole and quetiapine , or other agents such as buproprion and entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 3)])|drug|lithium carbonate sodium potassium fumarate|sildenafil antidepressants clonidine gabapentin fluoxetine|lithium|in the last few years several academic research initiatives were conducted to explore the efficacy of approved drugs such as entity , varenicline ( chantix ® ) , riluzol and dalfampridine .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|lithium carbonate sodium potassium fumarate|lithium carbamazepine olanzapine antidepressants vpa|lithium|for the treatment of patients with depressive episodes associated with bipolar i disorder as monotherapy and as adjunctive therapy with entity or valproate , which expires in june 2016 .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium carbonate sodium potassium fumarate|battery electrically pacemaker self electrical|lithium|( now a division of guidant corporation ) , a company founded by mr . villafaña to develop , manufacture and market a new generation of entity powered pacemakers .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|lithium carbonate sodium potassium fumarate|lithium carbamazepine antidepressants antidepressant olanzapine|lithium|in the iti-007-402 trial , patients receive lumateperone or placebo adjunctive to their existing mood stabilizer entity or valproate .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|lithium carbonate sodium potassium fumarate|lithium carbon platinum hydrogen metal|lithium|and as director to aug 2015 where he led a team of scientists and entrepreneurs for the development of solid-state entity ion battery for electric vehicles and smart grid applications .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|lithium carbonate sodium potassium fumarate|lithium metal single battery double|lithium|the car is all-electric and powered by advanced entity ion batteries .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|lithium carbonate sodium potassium fumarate|cytokines glucose toxins metabolites electrolytes|lithium|· with further investment , other patches can be developed which are able to measure alternative analytes , including lactates , uric acid , entity and drugs .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|lithium carbonate sodium potassium fumarate|batteries electricity battery pumps electronics|lithium|recently , higher power , higher priced entity and rechargeable batteries have grown in response to more demanding power needs of more advanced devices .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|lithium carbonate sodium potassium fumarate|lithium carbamazepine olanzapine antidepressants risperidone|lithium|abilify®  in february , the fda approved abilify as an adjunct to mood stabilizers entity or valproate for the maintenance treatment of bipolar i disorder .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lithium carbonate sodium potassium fumarate|carbon nickel chromium lithium platinum|lithium|the u . s . retail battery category is defined as alkaline , carbon zinc , entity , rechargeable and specialty batteries .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|atropine magnesium propofol fentanyl sevoflurane|vecuronium|( sugammadex ) injection 100 mg / ml was approved by the fda for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|atropine magnesium propofol phenylephrine sevoflurane|vecuronium|is specifically designed to reverse the effects of certain muscle relaxants , marketed in the united states as zemuron ( r ) ( rocuronium bromide ) and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|sodium potassium lithium magnesium ethyl|vecuronium|we initiated a recall of a batch of entity bromide , a product we 43 market on behalf of a third party , in february 2001 due to concerns with filtration-testing
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|neuromuscular relax fentanyl tracheal nerve|vincristine morphine cyclophosphamide gentamicin bleomycin|vecuronium|the first u . s . regulatory approvals on products that are difficult to produce , such as etoposide ( with gll ) , bleomycin , pancuronium and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|ethidium magnesium sodium sildenafil nicotine|vecuronium|the company is manufacturing and marketing entity bromide prior to expiration of the patent covering this product pursuant to a licensing arrangement .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|calcitonin dexamethasone bisphosphonates atorvastatin pioglitazone|vecuronium|nevzat ilac sanayii a . s . , a subsidiary of amgen , inc . , ( mn ) to acquire the rights to three products : methylprednsilone sodium succinate , entity and pamidronate disodium .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|atropine propofol magnesium fentanyl sevoflurane|vecuronium|in december 2015 , the fda approved bridion for the reversal of neuromuscular blockade induced by rocuronium bromide and entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|propofol sevoflurane fentanyl atropine midazolam|vecuronium|of a clinical trial site for sugammadex , mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|atropine magnesium propofol fentanyl bromide|vecuronium|demand of bridion ( sugammadex ) injection 100 mg / ml , a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or entity bromide in adults undergoing surgery .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|neuromuscular relax fentanyl tracheal nerve|carboplatin docetaxel bevacizumab gemcitabine trastuzumab|vecuronium|in addition , we have been able to help alleviate market shortages through the launches of entity and paclitaxel .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|sodium ethidium magnesium potassium lithium|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity bromide under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|atropine midazolam potassium propofol magnesium|vecuronium|for purposes of this paragraph , the term " krypton products " refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|propofol sevoflurane fentanyl atropine morphine|vecuronium|sugammadex sodium injection is mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|bromide lithium magnesium nicotine sodium|vecuronium|dosage product portfolio are 45 products for which the company is currently the sole generic source , one of which is entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|cobalt nickel magnesium lithium potassium|vecuronium|due to deviations from the fda  s manufacturing regulations , we are conducting voluntary product recalls of entity bromide and pte-4 products .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|etanercept infliximab prp rituximab bevacizumab|vecuronium|in march 2000 , the company resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|sodium potassium lithium magnesium ethyl|vecuronium|we initiated a recall of a batch of entity bromide , a product we market on behalf of a third party , in february 2001 due to concerns with filtration- testing
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|neuromuscular relax fentanyl tracheal nerve|midazolam atropine propofol potassium magnesium|vecuronium|for purposes of this paragraph , the term krypton products refers to glipizide , glyburide , ismn , midazolam hcl and entity bromide .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|propofol sevoflurane fentanyl atropine midazolam|vecuronium|for odanacatib for osteoporosis , suvorexant for insomnia and sugammadex sodium injection for reversal of neuromuscular blockade induced by rocuronium or entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|neuromuscular relax fentanyl tracheal nerve|tablets etanercept novartis infliximab rituximab|vecuronium|in march 2000 , schein resumed the manufacture and commercial distribution of entity under the expedited certification procedures provided in the consent agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone gentamicin ciprofloxacin colistin vancomycin|avibactam|the ceftazidime / entity combination product forest expects will receive three years of hatch-waxman exclusivity upon approval .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone ciprofloxacin gentamicin vancomycin imipenem|avibactam|for cre infections , physicians have resorted to older drugs such as colistin or more recently drugs such as tigecycline and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|resistant strain multidrug mdr resistance|this minocycline which ciprofloxacin that|avibactam|entity is a novel , non beta-lactam , beta lactamase inhibitor , quite a mouthful , itself as a molecule does not possess intrinsic antibacterial
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|resistant strain multidrug mdr resistance|bevacizumab vancomycin irinotecan minocycline this|avibactam|entity is currently being developed in combination with ceftazidime , a cephalosporin antibiotic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|colistin gentamicin mannitol magnesium vancomycin|avibactam|the addition of entity to ceftazidime protects ceftazidime from breakdown by β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone imipenem penicillin ciprofloxacin ampicillin|avibactam|it consists of a combination of entity and ceftazidime - a third generation antipseudomonal cephalosporin with a well-established efficacy and safety profile .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|colistin gentamicin ciprofloxacin vancomycin minocycline|avibactam|the addition of entity protects ceftazidime from being broken down by beta-lactamases that are produced by resistant bacteria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|imipenem ceftriaxone vancomycin colistin azithromycin|avibactam|it has structural similarities to entity , a bli recently approved in combination with ceftazidime ( avycaz ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone ciprofloxacin imipenem colistin azithromycin|avibactam|almirall for las100977   0 . 25 licensing payment to astrazeneca for entity and ceftazidime / entity   0 . 75 rounding  
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone imipenem ampicillin ciprofloxacin gentamicin|avibactam|actavis and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|resistant strain multidrug mdr resistance|this funding fda gsk medicine|avibactam|entity is also protected by an issued united states patent directed to combinations with an antibiotic that expires in 2026 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|resistant strain multidrug mdr resistance|ceftriaxone this minocycline ciprofloxacin carbapenem|avibactam|entity is a first-in-class broad-spectrum β-lactamase inhibitor , which protects ceftazidime against degradation by class a , c and some d , β-lactamases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|resistant strain multidrug mdr resistance|this science pmc tm funding|avibactam|in addition , entity is protected by a united states composition-of-matter patent that expires in 2022 , without pte .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone ciprofloxacin vancomycin imipenem gentamicin|avibactam|based on the results of these studies , we and astrazeneca initiated phase iii studies for ceftazidime / entity in patients with ciai in december 2011 and in patients with cuti in july 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone ciprofloxacin imipenem vancomycin colistin|avibactam|in fiscal 2013 , these costs were largely related to clinical trials for nebivolol / valsartan , aclidinium / formoterol , vilazodone , memantine , and ceftazidime / entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone ampicillin imipenem ciprofloxacin gentamicin|avibactam|actavis plc and astrazeneca plc are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|resistant strain multidrug mdr resistance|again here more first together|avibactam|so we are very excited to introduce to you entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|resistant strain multidrug mdr resistance|ceftriaxone gentamicin imipenem ciprofloxacin vancomycin|avibactam|forest laboratories and astrazeneca are developing ceftazidime / entity and ceftaroline / entity for pneumonia and complicated urinary and intra-abdominal infections .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan docetaxel capecitabine bevacizumab platinum|irinotecan|erbitux product labeling to include overall survival data as a single agent in egfr-expressing mcrc patients after failure of both entity- and oxaliplatin-based regimens .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan cpt doxorubicin hydrochloride oxaliplatin|irinotecan|sn38 is the active metabolite of cpt-11 ( entity ) , which is approved for the treatment of colorectal cancer .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan capecitabine oxaliplatin celecoxib doxorubicin|irinotecan|the fda approved entity as camptosar in 1994 for use in colorectal cancer .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|oxaliplatin bevacizumab irinotecan capecitabine cetuximab|irinotecan|erbitux ( r ) is approved in united states , austria , canada , germany and switzerland for metastatic colorectal in combination with entity in entity-refractory patients .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan 001 101 341 bevacizumab|irinotecan|we did observe statistically significant improvements in progression free survival , or pfs , and other efficacy endpoints for ha-entity compared with irinotecan alone .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|etoposide gemcitabine docetaxel irinotecan carboplatin|irinotecan|entity and cisplatin are two established anticancer drugs which together constitute an active combination for treating sclc .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan bevacizumab oxaliplatin capecitabine carboplatin|irinotecan|note : chemotherapy regimens included temozolomide and entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|bevacizumab irinotecan trastuzumab sunitinib erlotinib|irinotecan|is to assess the safety and pharmacokinetics of mm-121 in combination with cetuximab and mm-121 in combination with cetuximab and entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|thalidomide celecoxib mp bortezomib bevacizumab|irinotecan|one of our clinical development strategies is to replace the use of entity with mm-398 by demonstrating that mm-398 has favorable efficacy and safety characteristics compared to entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|infliximab biologics adalimumab etanercept rituximab|irinotecan|that are currently conducted by aventis , together with certain patents and other assets relating to territories where pfizer currently markets entity , including the united states .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|capecitabine irinotecan gemcitabine bevacizumab cetuximab|irinotecan|” the study was initiated following the demonstration of synergy between nimotuzumab and entity in the laboratories of daiichi sankyo in gastric cancer cell lines .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan capecitabine fluorouracil bevacizumab docetaxel|irinotecan|advanced colorectal cancer in which nuc-3373 will be combined with many of the agents typically combined with 5-fu , including leucovorin , entity , oxaliplatin and monoclonal antibodies .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|vs first therapies versus v1|irinotecan|clinical development of mm-398 we are pursuing two approaches in the ongoing clinical development of mm-398 : replace entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan etoposide docetaxel capecitabine doxorubicin|irinotecan|two camptothecin derivatives , topotecan and entity , have been approved by the fda for the treatment of small-cell lung , ovarian , and colorectal cancers .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan capecitabine bevacizumab docetaxel fluorouracil|irinotecan|most systemic therapies for colorectal cancer include 5-fu , either as monotherapy or in combination with another chemotherapeutic , typically oxaliplatin or entity .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan capecitabine fluorouracil docetaxel bevacizumab|irinotecan|this study enrolled 463 patients with metastatic colorectal cancer who had failed standard entity- and oxaliplatin-containing chemotherapy .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|irinotecan doxorubicin oxaliplatin docetaxel capecitabine|irinotecan|these two adcs facilitate targeted delivery of sn-38 , the active metabolite of entity , an effective , yet toxic chemotherapeutic , directly to tumor cells .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|gemcitabine irinotecan carboplatin docetaxel doxorubicin|irinotecan|entity and cisplatin combinations were evaluated systematically for drug ratio-dependent synergy in vitro using a panel of 20 tumor cell lines .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|thalidomide methotrexate interferon cyclophosphamide rituximab|irinotecan|our clinical strategy is to administer birinapant with therapies ( for example , azacitidine or entity ) that induce the production of tnf or related molecules .
OrderedDict([('DRUG', 4), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|drug|irinotecan capecitabine oxaliplatin bevacizumab hydrochloride|warfarin atorvastatin chloroquine erlotinib simvastatin|irinotecan|since that time he has had increasing responsibility for overseeing the global research plans and teams for entity and dalteparin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|lot entity part particular little|minocycline|“its quite unique in that its a entity topical ; i dont like a lot of the entity oral [ products ] , but entity topical – i can certainly get excited about .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|antibiotics ciprofloxacin metronidazole antibiotic vancomycin|minocycline|reported novel imaging techniques , suggesting that bpx-01 effectively targets p . acnes in the skin without the systemic side effects of oral entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|cream gel retinoid corticosteroid tetracycline|minocycline|in october , they received approval for their first product , amzeeq , a topical entity formulation for the treatment of acne .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|lidocaine capsaicin cream diclofenac gel|minocycline|in this study , no serious adverse events were observed and the treatment-related adverse events were related to dermal irritation in the 2% entity treatment arm .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|minocycline metronidazole tetracycline doxycycline erythromycin|minocycline|our lead product candidate , fmx101 for moderate-to-severe acne , is a novel topical foam formulation of the antibiotic entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|peg hcl verapamil phenylephrine bupivacaine|minocycline|in september 1999 we recognized a gain of $2 . 7 million on the sale of our vectrin ( r ) entity hcl product line .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|retinoid formulation corticosteroid preparation antibiotic|minocycline|solodyn , a branded oral entity , the current standard of care for moderate-to-severe acne , accounted for nearly one half of the total branded oral market for
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|propionate citrate glucose lactate acetate|minocycline|thus , it has been demonstrated that the amount of either entity or edetate that leaks into the serum is very low or none at all .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|minocycline gentamicin vancomycin metronidazole doxycycline|minocycline|limitations of use : this formulation of entity has not been evaluated in the treatment of infections .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|etanercept celecoxib minocycline ibuprofen sildenafil|minocycline|are marketed outside the u . s . during 1998 , the company filed anda  s for two products previously selected , from which one product , entity , received approval in march 1999 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|melanin erythema bsa uvb epidermis|minocycline|dose a resulted in 5 mg / cm2 of entity , which translates to approximately about 1 mg / g of skin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|retinoid antibiotics pharmacotherapy corticosteroid medicine|minocycline|limitations of current standard of care for acne : oral entity , such as solodyn , is the current standard of care for moderate-to-severe acne .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|antibiotic antimicrobial multidrug antiviral therapeutic|minocycline|mpts in blood serum and saliva in order to observe the drug release profile , and to assess the development of entity resistance .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|celecoxib curcumin bevacizumab buprenorphine minocycline|minocycline|bpx-04 is designed to deliver the active , entity , into the skin without further irritating the skin .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|annual commercial monthly yearly domestic|minocycline|the prior year sales included $6 , 373 of entity sales which the company stopped selling in late 1999 because of deteriorating market conditions .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|retinoid minocycline scaling azithromycin tetracycline|minocycline|oral entity has been a commonly used treatment for acne for years .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|irinotecan oxaliplatin sunitinib bortezomib curcumin|minocycline|this approach was via structure-activity relationship chemistry-based modifications of the seven and nine positions of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|tetracycline minocycline natural new novel|minocycline|used its expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the entity core structure .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|gel sodium transdermal vaginal hydrogel|minocycline|success in iga @ week 12 difference from vehicle fmx103 entity foam , 1 . 5% 10-week study epsolay® ( † ) sol-gel did not conduct a head-to-head comparison trial or study .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|minocycline tetracycline cyclosporine cardiomyopathy methotrexate|both its all available new|minocycline|or the cipan agreement , which provides the terms and conditions under which cipan will manufacture and supply to the company entity starting material and crude omadacycline .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrochloride available versus xl xa|gdnf others thalidomide minocycline bevacizumab|rasagiline|that are intended to alter the course of the disease , including the investigational drugs known as cep-1347 , gdnf , tch-346 and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|levodopa three four 200 16|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|hydrochloride available versus xl xa|fluoxetine mao clozapine risperidone olanzapine|rasagiline|a number of mao inhibitors are approved for pd therapy , including zelapar ( selegiline / valeant ) and azilect ( entity ; teva / lundbeck ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride available versus xl xa|final necessary mandatory fda latest|rasagiline|teva and its strategic partner h . lundbeck a / s recently submitted the entity regulatory file to the european agency for evaluation of medicinal products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|hydrochloride available versus xl xa|levodopa three four metal whole|rasagiline|about azilect® ( united states ) indication azilect® ( entity tablets ) is indicated for the treatment of the signs and symptoms of parkinsons disease ( pd ) both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrochloride available versus xl xa|resveratrol melatonin sildenafil minocycline curcumin|rasagiline|youdim has published numerous articles describing entity  s neuroprotective and neurorescue activities in various laboratory models .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride available versus xl xa|three four 16 14 five|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|hydrochloride available versus xl xa|gabapentin levodopa naloxone naltrexone dopamine|rasagiline|completion of the two phase iii clinical trials in march , teva submitted to the fda a new drug application for entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|hydrochloride available versus xl xa|levodopa these dopaminergic dopamine both|rasagiline|developed by teva , entity tablets are approved in over 40 countries for the treatment of parkinsons disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|levodopa three four 16 five|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to grow in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|hydrochloride available versus xl xa|caffeine dopamine tryptophan midazolam ketamine|rasagiline|selectivity was tested by evaluating the interaction between tyramine and entity in healthy subjects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|levodopa three four 16 five|rasagiline|our once-daily treatment for parkinsons disease , azilect® ( entity tablets ) , continued to establish itself in the u . s . and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride available versus xl xa|three four 16 whole 14|rasagiline|azilect® ( entity tablets ) , tevas once-daily treatment for parkinsons disease and its second innovative drug , is now available in 29 countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride available versus xl xa|tablets adalimumab vaccines pharmaceuticals tm|rasagiline| teva pharmaceutical industries ltd . ( israel ) : we are in collaboration with teva pharmaceutical industries ltd . to develop and commercialize entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|tablets tm usp tablet sr|rasagiline|about azilect&reg azilect&reg tablets ( entity ) 1 mg / day are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|hydrochloride available versus xl xa|adalimumab nivolumab approval ipilimumab etanercept|rasagiline|teva expects to market entity in europe with h . lundbeck a / s , and in the united states with its new strategic partner eisai inc . teva
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride available versus xl xa|single three generic both 16|rasagiline|about azilect &reg azilect&reg 1 mg tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinson  s disease both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|three four levodopa single both|rasagiline|azilect® ( entity tablets ) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride available versus xl xa|both 3m 16 300 three|rasagiline|about azilect® azilect® tablets ( entity tablets ) are indicated for the treatment of the signs and symptoms of parkinsons disease both as initial therapy alone and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride available versus xl xa|three four levodopa both single|rasagiline|azilect® ( entity tablets ) is indicated as an initial monotherapy and as an adjunct to levodopa for the treatment of the signs and
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sodium verapamil metabolite cyclosporine fumarate|lithium magnesium sodium zinc potassium|bethanechol|according to wolters kluwer , total sales of generic entity chloride 5mg , 10mg and 25mg tablets at awp were $56 million in 2007 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|antidepressant nor prophylactic mao containing|prednisone dexamethasone prednisolone methotrexate methylprednisolone|nortriptyline|crx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|antidepressant nor prophylactic mao containing|fluoxetine carbamazepine antidepressants clozapine serotonin|nortriptyline|clinical trials of the antiepileptic agents gabapentin and lamotrigine and the antidepressants entity and amitriptyline have all been negative .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antidepressant nor prophylactic mao containing|prednisone diclofenac prednisolone vehicle methotrexate|nortriptyline|on multiple measures such as psoriatic infiltrate thickness , erythema and clinical skin condition and produced greater improvements than mometasone and entity alone .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antidepressant nor prophylactic mao containing|opioids dexamethasone gabapentin ketamine irinotecan|nortriptyline|the 2 most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|antidepressant nor prophylactic mao containing|melatonin midazolam benzodiazepines gabapentin diazepam|nortriptyline|procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|antidepressant nor prophylactic mao containing|melatonin gabapentin midazolam benzodiazepines fluoxetine|nortriptyline|license from procom , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5mg to 10mg ) of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|drug|antidepressant nor prophylactic mao containing|they etanercept tnf this infliximab|nortriptyline|crx-170 did not show a modulation of the inflammatory marker cd163 from the treatment baseline , although entity clearly did decrease cd163 on its own .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('DIS', 2), ('OTHER', 2)])|drug|antidepressant nor prophylactic mao containing|carbamazepine fluoxetine dexamethasone antidepressants lithium|nortriptyline|crx-191 contains a mid- potency glucocorticosteroid , mometasone , and a low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('DIS', 2), ('OTHER', 2)])|drug|antidepressant nor prophylactic mao containing|carbamazepine fluoxetine antidepressants dexamethasone lithium|nortriptyline|crx-191 contains a mid-potency glucocorticosteroid , mometasone , and a very low dose of the tricyclic anti-depressant , entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antidepressant nor prophylactic mao containing|opioids dexamethasone gabapentin melatonin nsaids|nortriptyline|the most common adverse events related to crx-170 were dry mouth , drowsiness , constipation and headache ; known effects of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|antidepressant nor prophylactic mao containing|melatonin midazolam benzodiazepines gabapentin clonidine|nortriptyline|license from procom one , u . s . patent no . 6 , 344 , 487 , claims a method of treating insomnia with low dosage forms ( 0 . 5 mg to 10 mg ) of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|antidepressant nor prophylactic mao containing|dexamethasone melatonin midazolam antidepressants diazepam|nortriptyline|about crx-170 crx-170 is an oral synergistic combination drug candidate containing low doses of the steroid prednisolone and the anti-depressant entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate vincristine antiretroviral combination containing|formulations agents vaccines medicines statins|terbinafine|we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate vincristine antiretroviral combination containing|fluconazole metronidazole tacrolimus vancomycin amphotericin|terbinafine|mycova™ combines an existing , approved drug for nail fungus , entity , with the nexact® technology that enhances the absorption of the drug through the skin .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|methotrexate vincristine antiretroviral combination containing|medicines pharmaceuticals medicine antibiotics vaccines|terbinafine|consistent with this strategy , during fiscal 2006 we commenced sales of generic entity in certain european markets through an out-licensing arrangement .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate vincristine antiretroviral combination containing|everolimus erlotinib adalimumab dasatinib docetaxel|terbinafine|“novartis formulation”means any topical formulation of entity ( other than the nexmed formulation ) developed by or on behalf of novartis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate vincristine antiretroviral combination containing|fluconazole ciprofloxacin metronidazole vancomycin doxycycline|terbinafine|nm100060 is topically applied , and incorporates entity , a currently marketed oral anti-fungal drug , with the nexact® technology , which facilitates the permeation of the drug through the nail
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methotrexate vincristine antiretroviral combination containing|hydrochloride sodium hcl bromide acetate|terbinafine|aerosol no protection lamisil entity ( entity hydrochloride ) fungal infection of the skin and nails caused by dermatophyte fungi tinea capitis fungal infections of the skin
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate vincristine antiretroviral combination containing|generic medicinal marketed combination commercial|terbinafine|worldwide sales of the branded entity product lamisil , the most prescribed systemic drug for onychomycosis , were $1 . 2 billion in 2004 and $978 million in 2006 , when
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate vincristine antiretroviral combination containing|proposed three main new pivotal|terbinafine|umang vohra though the entity trials are ongoing , we have not got an early read kind of a methodology for that trial and we hope
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate vincristine antiretroviral combination containing|risperidone metformin olanzapine pioglitazone rosiglitazone|terbinafine|significant product launches in fiscal 2006 included glimepiride tablets and zonisamide tablets in the united states and entity tablets in the united kingdom .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|methotrexate vincristine antiretroviral combination containing|fluconazole metronidazole azithromycin methotrexate chloroquine|terbinafine|treatments are segmented into two approaches , either oral therapies , such as entity , or topical products , such as jublia , an azole , and kerydin , an oxaborole .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate vincristine antiretroviral combination containing|own marketed new previous commercial|terbinafine|evolved for promius pharma as a whole and how do you see that going forward and some update on your entity product for which you had phase three already enrolled?
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|methotrexate vincristine antiretroviral combination containing|fluoxetine risperidone olanzapine haloperidol lithium|terbinafine|new product launches in fiscal 2006 included the generic versions of glimepiride , lansoprazole , lisinopril , sertraline and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|methotrexate vincristine antiretroviral combination containing|erythromycin risperidone midazolam fluconazole azithromycin|terbinafine|during fiscal 2008 , we launched carvedilol tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , entity and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methotrexate vincristine antiretroviral combination containing|formulations agents sildenafil nsaids asa|terbinafine|despite its high labeled efficacy ( 38% ) , we believe the usage of branded and generic entity has been limited due to safety concerns related to liver toxicity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate vincristine antiretroviral combination containing|lam tm lev fluconazole gold|terbinafine|lamisil ( entity ) , a systemic drug approved for onychomycosis , had worldwide peak sales of $1 . 2 billion in 2004 , before generic entry .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methotrexate vincristine antiretroviral combination containing|fluconazole metronidazole carbamazepine erythromycin amphotericin|terbinafine|preclinical studies have shown that itraconazole , the antifungal agent in hyphanox , has a broader spectrum of activity than entity , the antifungal agent in lamisil .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|methotrexate vincristine antiretroviral combination containing|fluoxetine benzodiazepines ssris lithium antidepressants|terbinafine|however , this was offset to some extent by a decrease in sales of entity and sertraline .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate vincristine antiretroviral combination containing|metformin ibuprofen simvastatin warfarin gabapentin|terbinafine|period ending june 30 , 2010 , 1 . 4 million new prescriptions were filled in the united states for both branded and generic versions of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate vincristine antiretroviral combination containing|tm lam xl lp hcl|terbinafine|lamisil ( entity ) is a treatment for fungal nail infection ( onychomycosis ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate vincristine antiretroviral combination containing|however xl generic lev novartis|terbinafine|a generic version of lamisil , entity , recently became available .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin tenofovir sof ns5a monotherapy|ledipasvir|harvoni combines the ns5a inhibitor entity with sofosbuvir and is indicated for an eight , 12 or 24 week treatment duration depending on prior treatment history , cirrhosis
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin tenofovir peg sof lamivudine|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni , a entity / sofosbuvir combination for patients with genotype 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin tenofovir lamivudine interferon sof|ledipasvir|pending patent applications directed to the use of combinations for the treatment of hcv , and , specifically , to the combination of entity and sofosbuvir .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin lamivudine interferon tenofovir sof|ledipasvir|gilead sciences markets harvoni as a  cure  for hepatitis c . it combines two drugs : sovaldi ( sofosbuvir ) and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|backbone boosted kappa without antiretroviral|bortezomib aluminum lactose mannitol everolimus|ledipasvir|additionally , abbvie has obtained canadian patent no . 2 , 857 , 339 ( the 339 patent ) which purports to cover a solid composition that contains entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin interferon tenofovir lamivudine nucleoside|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin graz aspart metformin lamivudine|ledipasvir|in october 2014 , we also received approval of the fixed-dose combination of entity and sofosbuvir , now known commercially as harvoni .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|backbone boosted kappa without antiretroviral|ribavirin ns5a tenofovir everolimus taf|ledipasvir|in october 2014 the fda approved gileads interferon-free harvoni® , a fixed-dose combination of sofosbuvir and entity ( a ns5a inhibitor ) for patients with genotype 1 hcv .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|backbone boosted kappa without antiretroviral|ns5a interferon treatments therapeutics ifn|ledipasvir|the hcv ns5a drug resistance assay assesses resistance to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|backbone boosted kappa without antiretroviral|ribavirin ns5a taf ftc sof|ledipasvir|resistance to sofosbuvir , which was approved as a single daa in 2013 and as a co-formulation with the ns5a inhibitor , entity , in 2014 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|backbone boosted kappa without antiretroviral|ribavirin sof peg graz bms|ledipasvir|separately , results from a phase 2 study demonstrated the safety and efficacy of entity / sofosbuvir in patients with genotypes 4 or 5 infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ribavirin interferon tenofovir lamivudine nucleoside|ledipasvir|classes of compounds that provide better safety and efficacy such as nucleotide polymerase inhibitors sofosbuvir ( sovaldi® ) and the sofosbuvir and entity combination ( harvoni ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone boosted kappa without antiretroviral|ns5a ribavirin tenofovir ifnα ifn|ledipasvir|entity inhibits the ns5a hcv viral protein .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine antidepressant ssri parox anticonvuls|that this proportions cure ours|fluoxetine|as cured ( with a ham-d score lower than 8 ) , we had between 37% and 39% , of a similar order to entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|fluoxetine antidepressant ssri parox anticonvuls|fluoxetine norepinephrine serotonin cocaine risperidone|fluoxetine|vilazodone has greater in vitro potency and selectivity for serotonin reuptake than compounds such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|fluoxetine antidepressant ssri parox anticonvuls|fluoxetine gabapentin ssris olanzapine celecoxib|fluoxetine|compete with newer generation anti-depressants used to treat hot 17 table of contents flash frequency , such as venlafaxine by wyeth , entity by eli lilly and paroxetine by glaxo smith kline .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|fluoxetine antidepressant ssri parox anticonvuls|this risperidone fluoxetine olanzapine gabapentin|fluoxetine|entity is the generic equivalent of eli lilly  s prozac antidepressant , which is patent protected and had annual sales of $1 . 7 billion for the twelve months ended september 30 , 1997 .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|fluoxetine antidepressant ssri parox anticonvuls|fluoxetine ssri ketamine risperidone ssris|fluoxetine|in the same preclinical studies , the ssri entity did not induce rapid onset antidepressant-like responses .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine antidepressant ssri parox anticonvuls|cotton tablet ginseng empty 1g|fluoxetine|entity capsules central nervous system anti-psychotic rs .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|fluoxetine antidepressant ssri parox anticonvuls|tamoxifen estrogens estrogen contraceptives estradiol|fluoxetine|product sales , excluding entity and tamoxifen , were approximately $122 million during the third quarter .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 3)])|drug|fluoxetine antidepressant ssri parox anticonvuls|lithium fluoxetine antidepressants ssri antidepressant|fluoxetine|commonly prescribed drugs for other symptoms include ditropan or detrol for bladder dysfunction , provigil for fatigue , entity for depression , and amitriptyline for pain .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|fluoxetine antidepressant ssri parox anticonvuls|medicine people them acupuncture nsaids|fluoxetine|you can see that the adverse effects are relatively traditional for entity : essentially digestive , gastrointestinal orders and nausea and disappear in function of time .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 3)])|drug|fluoxetine antidepressant ssri parox anticonvuls|fluoxetine clozapine risperidone clonidine haloperidol|fluoxetine|major marketed brands include tofranil ( imipramine ) , prozac ( entity ) , paxil ( paroxetine ) , luvox ( fluoxamine ) and zoloft ( sertaline ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine antidepressant ssri parox anticonvuls|formulation tablet component substance preparation|fluoxetine|the api entity has been the subject of multiple studies in humans and has been approved for use in humans for decades .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|fluoxetine antidepressant ssri parox anticonvuls|patents approval patent funding marketing|fluoxetine|the company filed its application for entity in january 1996 , and has been sued for patent infringement by eli lilly , initiating the patent challenge process .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|fluoxetine antidepressant ssri parox anticonvuls|pharmaceuticals lilly sildenafil technology medicine|fluoxetine|based on a recent federal court of appeals ruling , lilly  s composition of matter patent on entity will expire in the summer of 2001 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antidepressant versus taper combination testosterone|nicotine naltrexone caffeine atropine acetylcholine|bupropion|/ mecamylamine tablets formulation and method of making tablets containing entity and mecamylamine issued march 9 , 2010 expires july 25 , 2027 us appl .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|antidepressant versus taper combination testosterone|nicotine naltrexone bup methadone pharmacotherapy|bupropion|neuropsychiatric reactions in patients taking entity for smoking cessation serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antidepressant versus taper combination testosterone|carbamazepine gabapentin diclofenac dexamethasone warfarin|bupropion|adverse events and laboratory findings appeared to be consistent with the individual components of empatic , entity and zonisamide .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|antidepressant versus taper combination testosterone|naloxone naltrexone buprenorphine gabapentin risperidone|bupropion|however , we could be exposed to potential patent infringement liability from other third parties who hold patents on various formulations of entity and naltrexone .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antidepressant versus taper combination testosterone|saline vehicle sham naltrexone tau|bupropion|approximately 60 smokers interested in quitting will be randomized in a 1 : 1 ratio to receive either axs-05 or entity for 4 weeks .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|antidepressant versus taper combination testosterone|dexamethasone peg metformin celecoxib ibuprofen|bupropion|for all doses tested , administration of dm in combination with entity resulted in substantial increases in auc0‑12 and cmax values of dm on day 8 as compared to day 1 of dosing .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|antidepressant versus taper combination testosterone|caffeine resveratrol minocycline atorvastatin nicotinamide|bupropion|in addition , empatic contains entity , the same active ingredient that gave rise to the fdas concerns regarding the cardiovascular safety profile of nb32 , which depending
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antidepressant versus taper combination testosterone|tetracycline carbamazepine risperidone isoniazid tamoxifen|bupropion|aplenzin is a once-daily formulation of entity hydrobromide and has been approved in 174mg , 348mg , and 522mg extended-release tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antidepressant versus taper combination testosterone|sham saline controls vehicle risperidone|bupropion|we are very encouraged by the magnitude of superiority in responders over entity , the active control .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|antidepressant versus taper combination testosterone|propranolol clonidine nifedipine losartan metformin|bupropion|in 2001 , we licensed our once-daily formulation of entity hcl to gsk and have been collaborating with them to seek regulatory approval of wellbutrin xl .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antidepressant versus taper combination testosterone|risperidone naltrexone er olanzapine morphine|bupropion|for this period also includes a $3 . 0 million bond received from glaxo to settle all patent infringement litigation relating to entity hcl , er 100 mg and 150 mg tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|drug|antidepressant versus taper combination testosterone|pth bisphosphonates calcitonin dexamethasone pioglitazone|bupropion|that we are pursuing ; however , generic forms of the active ingredients of our product candidates , including zoledronic acid , dm , and entity , are available and could be used off‑label .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antidepressant versus taper combination testosterone|its naltrexone buprenorphine naloxone methadone|bupropion|we have entered into long-term supply agreements for the supply of naltrexone and entity api .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|antidepressant versus taper combination testosterone|propranolol clonidine buprenorphine nifedipine dexmedetomidine|bupropion|biovail also acquired the right to market its once-daily formulation of entity hcl in canada under the trade name wellbutrin® xl if regulatory approval is received .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|antidepressant versus taper combination testosterone|vaccines etanercept adalimumab tacrolimus bevacizumab|bupropion|for example , we have in-licensed from glaxosmithkline certain formulation patents related to entity that expand our formulation options as we develop our commercial formulation of contrave .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antidepressant versus taper combination testosterone|naltrexone risperidone olanzapine mph caffeine|bupropion|the basis of the pet results , we added a second set of patients randomized either to 32mg naltrexone plus 400mg entity sr or a double placebo .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|antidepressant versus taper combination testosterone|fluoxetine fumarate risperidone olanzapine naltrexone|bupropion|forfivo xl® ( entity extended-release ) is the first 450 mg bupropion hcl tablet indicated for major depressive disorder , approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|antidepressant versus taper combination testosterone|fluoxetine carbamazepine lithium risperidone haloperidol|bupropion|cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 2)])|drug|antidepressant versus taper combination testosterone|fluoxetine carbamazepine lithium risperidone haloperidol|bupropion|: cpi-300 is a higher strength of the antidepressant entity hcl , the active ingredient in wellbutrin xl® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|well correctly properly poorly accurately|others pasteur gsk novartis vaccinia|albuterol|for which we provide sterile manufacturing services include several influenza 2 table of contents vaccines , xopenex® , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|industry medicare europe france others|albuterol|in the respiratory market , we compete primarily against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|well correctly properly poorly accurately|atropine theophylline propranolol lidocaine phenylephrine|albuterol|we also evaluated rpl554 administered as an add-on therapy to either entity or ipratropium , in each case as compared to entity or ipratropium alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|well correctly properly poorly accurately|ics controls prednisone comparator vehicle|albuterol|symbicort demonstrated a 51% reduction in the rate of annual asthma exacerbations , compared to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|well correctly properly poorly accurately|epinephrine brand theophylline buprenorphine abbott|albuterol|xopenex inhalation solution and generic entity inhalation solution currently account for the majority of beta-agonist inhalation solution prescriptions in the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|hcl hydrochloride ph h1 saline|albuterol|the second quarter 2007 to institute a new , bundled payment amount for xopenexò brand leventity hcl inhalation solution and generic entity inhalation solution products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|well correctly properly poorly accurately|atropine theophylline sevoflurane fentanyl midazolam|albuterol|effective january 1 , 2007 , cms established new billing codes and payment methodologies for other compounded inhalation drugs , including entity and ipratropium .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|well correctly properly poorly accurately|magnesium fentanyl morphine nicotine lidocaine|albuterol| proair digihaler ( entity sulfate 117 mcg ) inhalation powder is the first and only digital inhaler with built-in sensors which connects to a companion
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|injectable experimental identical optimized innovative|albuterol|in 1998 , ivax also applied for approval to market an entity non-cfc formulation in various european countries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|well correctly properly poorly accurately|this dpi ics which theophylline|albuterol|entity is the most widely used mdi product approved for the treatment of asthma , accounting for nearly $680 million in sales
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|well correctly properly poorly accurately|adalimumab etanercept bevacizumab sildenafil infliximab|albuterol|entity is marketed by glaxowellcome plc ( " glaxowellcome " ) , schering-plough and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|entity entities prototype potency aerosol|albuterol|with xopenex hfa , we compete with generic chlorofluorocarbon-based entity metered-dose inhalers and brand-name hfa entity metered-dose inhalers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|hf copd cf dual combination|albuterol|cfc-containing entity mdis are required to be phased-out before the end of 2008 , with patients increasingly transitioning to hfa 2 mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|well correctly properly poorly accurately|prednisone prednisolone dexamethasone methylprednisolone theophylline|albuterol|there was no difference in the exacerbation rate between symbicort and twice-daily maintenance budesonide plus entity , despite a 52% reduction in the mean steroid dose with symbicort .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|well correctly properly poorly accurately|atropine theophylline fentanyl morphine sildenafil|albuterol|upon commercialization , zambon will be entitled to certain royalties on payments received by us for entity , ipratropium and cromolyn sales for specified periods .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|this which dpi cartridge that|albuterol|entity has been marketed for many years , is well established and sells at prices substantially lower than xopenex inhalation solution .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|containing based into nasal bromide|albuterol|this increase was principally due to the continued transition of patients previously using chlorofluorocarbon ( cfc ) entity mdis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|containing based plus filled without|albuterol|almost one-half of the market is still comprised of cfc entity mdis , representing a sizeable remaining market opportunity for the xopenex hfa product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|royal cambridge nhs cash french|albuterol|non-refundable $65 million cash deposit and issuance of letters of credit for the remaining balance , to be held by the entity settlement trust fund as security for potential future payments .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|well correctly properly poorly accurately|ige lactose generic egg allergen|albuterol|this reflected the impact of generic entity substitutes on ventolin in the us , the impact of covid-19 pandemic related destocking in europe and allergy market contraction in
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|hydrochloride hcl acetate sodium succinate|tromethamine|pursuant to the sprix purchase agreement , the company acquired specified assets and liabilities associated with sprix ( ketorolac entity )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|acetate sodium hydrochloride phosphate hcl|tromethamine|entities acting in concert with them , are enjoined from making any preparations to make , sell , or offer for sale ketorolac entity ophthalmic solution 0 . 5% in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|rectal sodium hydrochloride gel hcl|tromethamine|district court for the eastern district of texas alleging patent infringement claims against the company relating to the 0 . 4% ketorolac entity formulation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|usp hcl hydrochloride sr sodium|tromethamine|egalet has two approved products : oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|hydrochloride hcl sodium acetate succinate|tromethamine|the company has two vda drug candidates currently being tested in clinical trials , fosbretabulin entity , or fosbretabulin , and oxi4503 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|methylene tro sodium diphenyl nitrate|hydrochloride tablet formulation antibody monotherapy|tromethamine|the fosbretabulin entity is being provided to ctep under a cooperative research and development agreement ( crada ) with oxigene and the bevacizumab is being
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|sodium acetate hydrochloride hcl succinate|tromethamine|for example , ketorolac entity is an injectable nsaid that had significant sales prior to the fdas imposing a black box warning limiting the combined
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|hcl usp hydrochloride sodium sulfate|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|hcl usp hydrochloride sodium sulfate|tromethamine|the company has two approved products : oxaydo ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methylene tro sodium diphenyl nitrate|sodium hydrochloride acetate hcl sulfate|tromethamine|drug substances the api used in sprix nasal spray is ketorolac entity , in oxaydo is oxycodone hydrochloride , in arymo er is morphine sulfate , and in egalet‑002 is oxycodone hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|hydrochloride hcl sodium acetate succinate|tromethamine|pursuant to which the company engaged jhs to provide certain services related to the manufacture and supply of sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|usp hcl hydrochloride sulfate sodium|tromethamine|use only cii , developed using egalets proprietary guardian technology , oxaydo® ( oxycodone hci , usp ) tablets for oral use only cii and sprix® ( ketorolac entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|usp hcl hydrochloride sr sodium|tromethamine|we are marketing two innovative pain products , sprix® ( ketorolac entity ) nasal spray and oxaydotm ( oxycodone hci , usp ) tablets for oral use onlycii .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methylene tro sodium diphenyl nitrate|phosphate hydrochloride sodium hcl sulfate|tromethamine|our lead compound is ca4p , which is also known as combretastatin a4-phosphate , fosbretabulin entity , fosbretabulin and zybrestat® .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methylene tro sodium diphenyl nitrate|hydrochloride sodium hcl acetate succinate|tromethamine|pursuant to the purchase agreement , the company acquired specified assets and liabilities associated with sprix® ( ketorolac entity )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methylene tro sodium diphenyl nitrate|hcl usp hydrochloride sr sodium|tromethamine|the company is currently marketing sprix® ( ketorolac entity ) nasal spray ( “sprix nasal spray” ) and oxaydo® ( oxycodone hci , usp ) tablets for oral use only—cii ( “oxaydo” ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|iron clopidogrel aspirin erythropoietin sildenafil|ceftriaxone|the increase in other u . s . sales was primarily due to increased sales of new products ( entity and deferoxamine ) to alternate site healthcare customers .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ceftriaxone doxycycline ampicillin metronidazole ciprofloxacin|ceftriaxone|the current standard of treatment for bacterial urethritis / gonorrhea requires combination therapy including both an intramuscular injection of entity and oral azithromycin ( 1000 mg ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|antibiotics vancomycin antimicrobials colistin ciprofloxacin|ceftriaxone|cdi , c . difficile associated diarrhea ( cdad ) and aad in patients hospitalized for a lower respiratory tract infection and receiving iv entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|medicine medicines contraceptives naltrexone pharmaceuticals|ceftriaxone|to utilize ihma  s expertise and experience in " bridge " oral drug delivery techniques to research , develop and commercialize oral forms of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|both raw combined each processed|ceftriaxone|included in the amount pending approval at june 30 , 2005 was $7 . 4 million of entity raw material and finished product .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|money compensation ipilimumab dollars funding|ceftriaxone|included in the amount pending approval at december 31 , 2005 was $7 . 4 million of entity , which was approved by the fda in february 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|amoxicillin azithromycin ciprofloxacin doxycycline erythromycin|ceftriaxone|study with a single oral dose of 1000 mg of solithromycin compared with the standard of care , 500 mg of entity administered intramuscularly and 1000 mg of oral azithromycin .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ceftriaxone doxycycline ciprofloxacin ampicillin antibiotics|ceftriaxone|current treatment of bacterial urethritis includes two drugs : entity administered intramuscularly and oral azithromycin , which is added to treat co-infections with chlamydia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|bevacizumab experimental sunitinib combination nivolumab|ceftriaxone|there was one treatment-related serious adverse event in the entity group .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ciprofloxacin ampicillin metronidazole ceftriaxone tetracycline|ceftriaxone|in a recent survey , 95% and 76% of the esbl isolates of escherichia coli found in utis were resistant to entity and levofloxacin , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ceftriaxone azithromycin inoculation doxycycline gentamicin|ceftriaxone|intramuscular entity now represents the last-resort treatment option for gonorrhea , although resistant strains are beginning to emerge .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|minocycline gentamicin metronidazole azithromycin colistin|ceftriaxone|of the most common treatments for serious bacterial infections , vancomycin , daptomycin , entity and tigecycline are only available as injectable or iv formulations .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|po ciprofloxacin sc vancomycin azithromycin|ceftriaxone|treatment related diarrhea was reported by one subject following sulopenem single dose iv , and by a further two subjects following entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|sq sc intramuscular 2g 1g|ceftriaxone|itt patients were similar on each regimen ( 9 / 10 , 9 / 11 and 7 / 12 , on sulopenem single iv dose , sulopenem multidose iv and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ceftriaxone azithromycin amoxicillin ampicillin ciprofloxacin|ceftriaxone|of a single 1000 mg dose of oral solithromycin in patients with uncomplicated gonorrhea and chlamydia infections compared with intramuscular entity plus oral azithromycin .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|imipenem vancomycin ciprofloxacin azithromycin ceftriaxone|ceftriaxone|treatment-emergent adverse events were reported in six subjects each in the sulopenem groups and eight subjects in the entity group .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|irinotecan bevacizumab sildenafil adalimumab this|ceftriaxone|entity is currently only marketed in an intravenous formulation .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|ceftriaxone amoxicillin azithromycin doxycycline ciprofloxacin|ceftriaxone|the current standard of treatment for gonorrhea is a single intramuscular injection of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|irinotecan sildenafil naltrexone pioglitazone bevacizumab|ceftriaxone|there is no oral formulation of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ceftriaxone antibacterial ciprofloxacin ampicillin minocycline|cab bevacizumab cetuximab this docetaxel|ceftriaxone|develop existing pre-clinical and clinical candidates , including cab-175 and an oral version of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|succinate losartan versus antihypertensive verapamil|vi vii ix xi iib|vilanterol|for the treatment of copd , the collaboration is developing combination products , relovair and the lama / laba ( gsk573719 / entity or 719 / vi ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate losartan versus antihypertensive verapamil|vi fumarate citrate sildenafil iodide|vilanterol|anoro™ ellipta® ( umeclidinium bromide / entity , umec / vi ) on april 28 , 2014 , gsk and theravance announced that anoro™ ellipta® , the first once-daily product approved in the u . s .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|succinate losartan versus antihypertensive verapamil|lactose propionate hydrocortisone theophylline prednisolone|vilanterol|are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|succinate losartan versus antihypertensive verapamil|sildenafil lithium magnesium sodium atorvastatin|vilanterol|the lead laba candidate , entity trifenatate ( or vi ) , is a gsk-discovered laba and gsk and we have jointly determined to focus the collaborations laba development
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|succinate losartan versus antihypertensive verapamil|propionate prednisone prednisolone ics theophylline|vilanterol|therefore fluticasone furoate / entity should be used with caution in patients with severe cardiovascular disease .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate losartan versus antihypertensive verapamil|metformin either its testosterone combination|vilanterol|our economic interest will not include any payments associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|succinate losartan versus antihypertensive verapamil|sildenafil prednisolone vi simvastatin ribavirin|vilanterol|· fluticasone furoate ( ff ) and entity trifenatate ( vi ) are promising agents for a combined , long-acting , once-daily treatment of asthma .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|succinate losartan versus antihypertensive verapamil|adalimumab its either testosterone etanercept|vilanterol|our economic interest does not include any payments by gsk associated with relvar® ellipta® / breo® ellipta® , anoro® ellipta® or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate losartan versus antihypertensive verapamil|propionate bromide fumarate magnesium novartis|vilanterol|anoro® ellipta® ( umeclidinium / entity ) to be reimbursed in australia for chronic obstructive pulmonary disease - administered using a new dry powder inhaler called
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|succinate losartan versus antihypertensive verapamil|prednisone prednisolone propionate theophylline ics|vilanterol|donohue october 26 , 2014 , 1 : 30 pm - 3 : 00 pm cdt efficacy and safety of once-daily umeclidinium added to fluticasone furoate / entity in chronic obstructive pulmonary disease :
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|succinate losartan versus antihypertensive verapamil|vi vii xi ix v6|vilanterol|lama / laba combination ( gsk573719 / entity or 719 / vi ) the phase 3a program for the once-daily lama / laba dual bronchodilator 719 / vi is progressing well .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate losartan versus antihypertensive verapamil|its combination bevacizumab metformin this|vilanterol|our economic interest will not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate losartan versus antihypertensive verapamil|bevacizumab its metformin combination this|vilanterol|our economic interest does not include any payments associated with relvar ellipta / breo ellipta , anoro ellipta or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate losartan versus antihypertensive verapamil|vi sildenafil verapamil simvastatin ciprofloxacin|vilanterol|closed triple or ff / umec / vi ( fluticasone furoate / umeclidinium bromide / entity )
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|succinate losartan versus antihypertensive verapamil|sildenafil theophylline prednisolone propionate fumarate|vilanterol|at 24h being developed for use as a monotherapy for asthma and in combination with a once-daily long-acting beta2 agonist ( laba ) , entity trifenatate ( vi , gw642444m ) , for asthma and copd .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|succinate losartan versus antihypertensive verapamil|propionate simvastatin sildenafil ribavirin prednisolone|vilanterol|had , or were at high-risk for , cardiovascular disease ; the primary objective was to evaluate the impact of fluticasone furoate ( ff ) / entity ( vi ) on all-cause mortality .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|succinate losartan versus antihypertensive verapamil|sildenafil ribavirin methylprednisolone vi verapamil|vilanterol|breo is a fixed-dose combination of the inhaled corticosteroid ( ics ) fluticasone furoate ( ff ) and the long-acting beta2-agonist ( laba ) entity ( vi ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate losartan versus antihypertensive verapamil|lactose propionate azithromycin mannitol theophylline|vilanterol|ellipta is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate , entity , or any of the excipients .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antibody bevacizumab irinotecan hydrochloride sunitinib|cea cetuximab bevacizumab erlotinib trastuzumab|arcitumomab|we continue to strengthen our u . s . and european sales and marketing effort for cea-scan ( r ) ( entity ) as well as our european effort for leukoscan ( r ) ( sulesomab ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|cmv cytomegalovirus lamivudine pcv haart|ganciclovir|cell / bone marrow and solid organ transplant patients at risk for cmv infection or with active cmv disease receive entity or valentity ( both marketed by f . hoffmann-la roche ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|cmv lamivudine ribavirin azt merck|ganciclovir|valcyte , the oral pro-drug of cytovene ( entity ) , is the most widely prescribed anti-cmv medication in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|ribavirin interferon lamivudine influenza ifn|ganciclovir|demonstrated activity in cell culture against both clinical isolates and viruses which have become resistant to current therapies , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|pharmacists industry physicians pharmaceuticals pharmacies|ganciclovir|in 2008 , the market for cmv drugs was $600 million with entity controlling over 90% of the market .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|gel cream novartis sun adap|ganciclovir|development of products that have achieved cumulative sales of close to $2 , 000 , 000 , 000 , including monistat ; delfen cream , for herpes virus infection ; entity ; solaraze ; and maci .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|cytomegalovirus lamivudine cyclophosphamide chloroquine cyclosporine|ganciclovir|currently approved drugs for cmv retinitis are entity , foscarnet , cidofovir and fomivirsen , or vitravene .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|ribavirin cmv ivig haart lamivudine|ganciclovir|the company is aware that a number of physicians have prescribed cytogam in combination with entity for the prevention of cmv disease in certain patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|gel cream novartis sun solar|ganciclovir|products that have achieved cumulative sales of close to two billion dollars including , monistat , delfen cream for herpes virus infectons , entity , solaraze , and maci .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|bleomycin cells reagents doxorubicin gene|ganciclovir|the hytk gene was used to mark the cells and allow for ablation of the cells by administration of entity if undesirable side effects resulted from the therapy .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|vitro tandem facs vivo parallel|ganciclovir|cells will be stimulated with anti-ig antibodies , and selected in entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|lamivudine cmv cytomegalovirus ribavirin azt|ganciclovir|drug therapies approved or commonly used for cmv infection include antiviral compounds such as entity , valentity , cidofovir and foscarnet .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|virus cells toxin viruses interferon|ganciclovir|cells containing the tk reporter will be killed by the entity unless a peptide inhibitor is present which inhibits the gene  s expression ( appendix h ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|bevacizumab adalimumab this dexamethasone nivolumab|ganciclovir|entity is available in intravenous and oral doses , as well as in an intraocular implant form .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|thymidine dna azt p53 flt|ganciclovir|in vivo activity for a bacterial strain which expresses the herpes simplex virus thymidine kinase gene for the conversion of entity to its toxic phosphorylated forms .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|azt mmf bv lamivudine rituximab|ganciclovir|in spite of trials conducted with entity for cmv prevention , entity is approved for use only as a preemptive therapy or treatment for cmv in hct .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|this but thalidomide bevacizumab cyclophosphamide|ganciclovir|entity was limited in its ability to be used as a preventive therapy by the risk of significant neutropenia , which has
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|cytomegalovirus lamivudine cmv ribavirin novartis|ganciclovir|dr . martin is the co-inventor of entity , a pharmaceutical now used for treatment of cytomegalovirus infection .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|fluconazole contraceptives prednisone azithromycin cyclosporine|ganciclovir|the company believes that , with the exception of oral entity , none of the drugs described above are currently administered prophylactically prior to manifestation of cmv retinitis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|cyclophosphamide methotrexate rituximab interferon cyclosporine|ganciclovir|our one commercial product , vitrasert , primarily competes with treatments involving the systemic delivery of entity , a roche holdings ag product , and other drugs .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiviral cyclosporine antiretroviral prophylactic nucleoside|ribavirin lamivudine cytomegalovirus gemcitabine gefitinib|ganciclovir|such as tumor cells , the tk gene renders these cells sensitive to the toxic effect of the fda-approved antiviral drug , entity ( " gcv " ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|bevacizumab bortezomib everolimus lapatinib dasatinib|talazoparib|bmn-673 means sellers proprietary compound known as bmn-673 or entity , having the chemical structure set forth in schedule 1 ( d ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|industry money france economics funding|talazoparib|good presentation , and i agree that the offer from sanofi really substantially undervalued the business and the pipeline and especially entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|rituximab infliximab thalidomide etanercept immunotherapy|talazoparib|we are excited about entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|nivolumab bevacizumab parp capecitabine crizotinib|talazoparib|for a select group of patients with hr-d breast cancer , entity , an oral parp inhibitor , was approved by the fda in 2018 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|access pay submit reimbursement pharmaceuticals|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc . ### 11
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|approval funding data also entirely|talazoparib|through acquisition of medivation in aug , 2016 , medivation acquired entity from biomarin in 2015 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|rituximab etanercept adalimumab infliximab ipilimumab|talazoparib|trials , and our future drug development activities , including those with respect to pidilizumab ( which is referred to as mdv9300 ) and entity ( which is referred to as mdv3800 ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|tm llc crizotinib novartis pfizer|talazoparib|business development at medivation , identified and led the acquisition of a compound that was subsequently developed and approved as talzenna ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|development testing application approval validation|talazoparib|to start potential registrational trials  many of which will be the first initiated for a parp inhibitor  for entity in multiple other tumor types by the end of 2016 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|market medicine industry biologics marketing|talazoparib|similarly , the company acquired the worldwide rights to entity just seven months ago from biomarin , again demonstrating an ability to move quickly and boldly by 9 table of
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|this that these which they|talazoparib|entity would complement our solid tumor pipeline with potential in a variety of cancers , both in our current pipeline such as
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|bevacizumab docetaxel everolimus sunitinib capecitabine|talazoparib|based on these data , we initiated a phase 1 / 2 clinical trial of the combination of telaglenastat plus entity in patients with rcc and tnbc in march 2019 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|access pay reimbursement submit pharmaceuticals|talazoparib|and twelve months ended december 31 , 2015 , represents the net gain on the sale of the companys world-wide rights to entity to medivation inc .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|rituximab etanercept infliximab adalimumab nivolumab|talazoparib|xtandi , we are well positioned for long-term sustainable growth with a promising pipeline that includes two late-stage wholly owned assets : entity and pidilizumab .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|data materials samples material specimens|talazoparib|bofa merrill lynch - analyst can you talk a little bit about the process that you went through to acquire entity from biomarin?
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|malate bevacizumab sunitinib irinotecan hydrochloride|nivolumab irinotecan parp parp1 bevacizumab|talazoparib|approved parp inhibitors include olaparib , entity and niraparib .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|risperidone levodopa succinate tremor olanzapine|transdermal potential gel prototype new|ropinirole|partner for jzp-4 , its potential treatment for epilepsy and bipolar , disorder and will no longer pursue development of jzp-7 , its entity gel product candidate for restless legs syndrome .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|risperidone levodopa succinate tremor olanzapine|medicinal new pharmaceutical commercial marketed|ropinirole|we were previously targeting an nda submission for our entity product candidate in calendar 2008 .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|risperidone levodopa succinate tremor olanzapine|platform technology development project platforms|ropinirole|staccato entity we have identified two new preclinical product candidates for development based on the single-dose staccato platform currently being manufactured in
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|risperidone levodopa succinate tremor olanzapine|this lidocaine propofol atropine morphine|ropinirole|entity oral spray is ideal for the geriatric population who may be suffering from dysphagia ( difficulty swallowing ) ; 85% of sufferers of
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 3)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa clonidine fentanyl dexmedetomidine gabapentin|ropinirole|our formulation of entity oral spray may represent a more convenient way for the patient or healthcare provider to deliver entity to patients suffering stiffness and / or tremors .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa dopamine gabapentin dbs this|ropinirole|entity is indicated for the treatment of the signs and symptoms of idiopathic parkinson  s disease .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|risperidone levodopa succinate tremor olanzapine|dopamine levodopa agonists dbs agents|ropinirole|we completed a non-clinical study with long-term delivery of dopamine agonists which supports the potential to develop an implant delivering entity for treating parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|risperidone levodopa succinate tremor olanzapine|pfizer gsk novartis merck lilly|ropinirole|commonly prescribed dopamine agonists that directly activate dopamine receptors include agents such as mirapex ( pramipexole / bi ) and requip ( entity / glaxosmithkline ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa others olanzapine dopamine risperidone|ropinirole|japan , and in 2006 in the u . s . the competition for parkinson  s disease drugs includes l-dopa , cabergoline , bromocriptine , pergolide , lisuride and entity .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa dopamine gabapentin sildenafil risperidone|ropinirole|the new prolonged release tablet of entity is taken once daily , and is indicated for the treatment of parkinson  s disease ( pd ) .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa dopamine dopa amphetamine dbs|ropinirole|we have performed the preclinical development work on a transdermal formulation of entity , a proven and fda-approved dopamine agonist for treating parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|risperidone levodopa succinate tremor olanzapine|technology therapeutics pharmaceuticals technologies agents|ropinirole|our proprietary pipeline also includes corplex entity for the treatment of parkinsons disease .
OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 2)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 2)])|drug|risperidone levodopa succinate tremor olanzapine|levodopa dopamine dopa this risperidone|ropinirole|entity is a dopamine agonist currently available in daily or more frequently dosed oral formulations for the treatment of parkinson  s disease
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|dor bradycardia antihypertensive versus plus|diabetes cf amd ms melanoma|nebivolol|the decrease in research and development expenses is the result of the completion of clinical studies related to entity , for which a nda was filed on april 30 , 2004 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|dor bradycardia antihypertensive versus plus|doxorubicin sildenafil morphine sunitinib bupivacaine|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan inc . ( mylan ) and expires in 2020 and we submitted a patent term extension application to
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|worsening managing possible new having|nebivolol|could you give us a little bit more color on the timing of the nda filing for entity congestive heart failure?
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dor bradycardia antihypertensive versus plus|tm novartis russia pfizer losartan|nebivolol|bystolic® ( entity ) , a beta-blocker for the treatment of hypertension , recorded sales of $142 . 9 millionin in the fourth quarter 2014 , an increase of
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|dor bradycardia antihypertensive versus plus|doxorubicin sildenafil naltrexone bupivacaine morphine|nebivolol|the u . s . composition of matter patent covering entity hydrochloride is licensed from mylan laboratories inc . and expires in 2020 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|dor bradycardia antihypertensive versus plus|metformin arb losartan pioglitazone atorvastatin|nebivolol|* trial 305 ( general population ) trial 202 ( african-american patients ) add-on therapy vs . placebo trial 321 ( entity added to current antihypertensive treatment )
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dor bradycardia antihypertensive versus plus|amd ra mm melanoma bms|nebivolol|brand segment r&d is primarily the result of the completion , during fiscal 2004 , of the phase iii clinical studies for entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|application applications license agreement rights|nebivolol|today , we are announcing that the best available option is to out license entity to a major brand pharmaceutical company , which will co develop and commercialize this product .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|travel remaining financial others insurance|nebivolol|eps to gaap diluted eps : adjusted diluted eps $ 0 . 26 mylan bertek and entity expenses ( $0 . 05 ) restructuring charges and other non-recurring expenses ( $0 . 02 ) contingent legal liability
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|proposed enhanced integrated nih new|nebivolol|we expect to experience increased research and development expenses in support of the entity clinical program , as well as milestone payments under our license agreement .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dor bradycardia antihypertensive versus plus|acupuncture genetics aging neuroimaging therapeutics|nebivolol|the restructuring , while r&d expense increased as a result of an increase in ongoing studies , including those with respect to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|medicaid medicare funds funding gdp|nebivolol|the overall decrease is primarily the result of the outlicensing of entity , which occurred late in fiscal 2006 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|france sweden brazil denmark italy|nebivolol|the irs regarding whether the proceeds received by the company in connection with the 2008 sale of its rights in entity constituted a capital gain or ordinary income .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|dor bradycardia antihypertensive versus plus|amd ms diabetes cf epilepsy|nebivolol|the increase was primarily attributable to research and development expense due to ongoing clinical studies related to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|dor bradycardia antihypertensive versus plus|medicare pharmacy price medicine medicaid|nebivolol|number one , ed , can you walk me through the five-cent charge in entity and bertek expenses and point me to where i can find it on the p&l?
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|this cvd cardiology cme facebook|nebivolol|the opportunity to launch entity will significantly expand our existing cardiovascular franchise .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|acquisition this recruitment consideration access|nebivolol|changes of the king business and the lack of appropriate other acquisition alternatives we have chosen a different course for entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|dor bradycardia antihypertensive versus plus|sildenafil simvastatin ginseng celecoxib nifedipine|nebivolol|our flagship product , altaceò . this is a perfect fit with mylan because of its growing pipeline of proprietary products , including entity , a hypertension product .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|dor bradycardia antihypertensive versus plus|russia switzerland sweden denmark uk|nebivolol|bystolic ( entity ) , our beta-blocker indicated for the treatment of hypertension launched in january 2008 , achieved sales of $59 , 522 , an increase of $21 , 857
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|dor bradycardia antihypertensive versus plus|theophylline ics azithromycin sildenafil erythromycin|nebivolol|for the same period last year , third party development costs were largely related to clinical trials for entity , aclidinium / formoterol , vilazodone and roflumilast .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|vaginal containing condom prophylactic metronidazole|metronidazole trimethoprim azithromycin doxycycline ciprofloxacin|tinidazole|nitroimidazoles for use in the invention include metronidizole , ornidazole , secnidazole , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|vaginal containing condom prophylactic metronidazole|entity entities edge identical unique|tinidazole|entity vaginal effervescent tablet the key component of entity vaginal effervescent tablet is entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|vaginal containing condom prophylactic metronidazole|metronidazole fmt antibiotics ciprofloxacin vancomycin|tinidazole|six ulcerative colits patients with ipaa ( 3 refractory pouchitis , 2 crohns disease , 1 irritable pouch syndrome ) received entity plus xifaxan or ciprofloxacin for 2-4 weeks .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|cytokine gene cell intron subcutaneously|others dasatinib pq pioglitazone arsenic|lifitegrast|( “r&d” ) was up 6% particularly due to investment in new uses for ldx ( the active ingredient in vyvanse ) , shp602 and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|cytokine gene cell intron subcutaneously|psoriasis japan ipf bevacizumab sunitinib|lifitegrast|the new drug application for entity included data from four randomized , controlled clinical trials with more than 1 , 800 patients .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|cytokine gene cell intron subcutaneously|tacrolimus lidocaine ciprofloxacin dexamethasone epinephrine|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|cytokine gene cell intron subcutaneously|cetuximab rgd αvβ3 bevacizumab etanercept|lifitegrast| shire plc has a small molecule integrin antagonist , entity , which is formulated for topical , ophthalmic delivery and is currently in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|cytokine gene cell intron subcutaneously|immunotherapy treatments pharmacotherapy adalimumab biologics|lifitegrast| if approved , shire would benefit from the launch of entity for dry eye disease in 2016 , and hopes to increase awareness , diagnosis and treatment of this condition .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|cytokine gene cell intron subcutaneously|sar trastuzumab rituximab etanercept lapatinib|lifitegrast|leukocytes [ ] selected based on its properties for further development as a candidate to treat dry eye disease [ graphic omitted ] entity ( formerly sar 1118 ) mw 610 g / mol 1 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|cytokine gene cell intron subcutaneously|tacrolimus ciprofloxacin lidocaine diclofenac dexamethasone|lifitegrast|these relate to the xiidra ( entity ophthalmic solution ) product which takeda had subsequently announced a sale agreement for .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cytokine gene cell intron subcutaneously|science medicine technology this vision|lifitegrast|“our commitment to moving entity forward reflects our intent to grow in the ophthalmics therapeutic category in areas of unmet patient need .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|cytokine gene cell intron subcutaneously|novartis etanercept adalimumab application propranolol|lifitegrast|shire plc recently received fda approval to market entity for the treatment of dry eye and will be launching the product in the u . s . restasis , and other products , have
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|cytokine gene cell intron subcutaneously|etanercept naltrexone adalimumab novartis llc|lifitegrast|shire plc is developing its product candidate , entity , and is in pivotal phase 3 clinical trials in the u . s . shire has said it plans to resubmit an nda for entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|cytokine gene cell intron subcutaneously|treatments immunotherapy approval therapies indications|lifitegrast|press release www . shire . com shire plans to submit a new drug application to fda for entity for dry eye disease in adults · fda submission planned for 1st quarter 2015 · shire forms business
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|cytokine gene cell intron subcutaneously|tacrolimus dexamethasone ciprofloxacin lidocaine gentamicin|lifitegrast|these relate to the xiidra® ( entity ophthalmic solution ) product which takeda has subsequently announced a sale agreement for , as included in note 33 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|drug|cytokine gene cell intron subcutaneously|marketing approval melanoma reimbursement psoriasis|lifitegrast|of any of our product candidates , such as our planned submission of a new drug application to the fda for entity , may be delayed for any number of reasons and , once submitted ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|cytokine gene cell intron subcutaneously|others funding novartis none applications|lifitegrast|on shp602 ( formerly known as spd602 ) for iron overload and on development programs acquired through business development in 2013 , including entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|cytokine gene cell intron subcutaneously|tacrolimus epinephrine lidocaine dexamethasone novartis|lifitegrast|novartis entered into an agreement with takeda pharmaceutical company limited ( takeda ) to acquire the assets associated with xiidra&#xae ; ( entity ophthalmic solution ) 5% worldwide .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|cytokine gene cell intron subcutaneously|occasion date going contrary reflection|lifitegrast|maybe to refresh the topic , on entity , obviously the other key near-term event with the october 25 pdufa date .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|cytokine gene cell intron subcutaneously|pioglitazone bevacizumab nivolumab peg sunitinib|lifitegrast|opus-3 , a randomized , double-masked , 12-week phase 3 study enrolled 711 patients to evaluate the efficacy and safety of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|cytokine gene cell intron subcutaneously|doxycycline melatonin bevacizumab adalimumab dexamethasone|lifitegrast|in addition , patients treated with entity showed a statistically significant improvement in ocular discomfort and eye dryness , symptoms of dry eye disease , as reported by patients
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|cytokine gene cell intron subcutaneously|tears sham atropine prk pdt|lifitegrast|when i look at restasis relative to entity , in terms of efficacy measures , sustaining tear production and goblet cell density , i think restasis is a great option .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|cytokine gene cell intron subcutaneously|tacrolimus lidocaine prednisolone dexamethasone cyclosporine|lifitegrast|in the united states , yet only two drugs are approved for dry eye disease treatment , restasis® ( cyclosporine 0 . 05% ) and xiidra® ( entity 5% ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|flox phosphate containing incorporated methotrexate|oxaliplatin cetuximab bevacizumab docetaxel carboplatin|floxuridine|the 1 : 1 molar ratio of irinotecan : entity was frequently synergistic and avoided antagonism whereas other ratios exhibited a loss of synergy and in some cases the appearance
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|flox phosphate containing incorporated methotrexate|oxaliplatin doxorubicin fluorouracil carboplatin vincristine|floxuridine|range of preclinical solid tumor models , cpx-1 consistently provided dramatic improvements in therapeutic efficacy over the unencapsulated free-drug cocktail of irinotecan : entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|flox phosphate containing incorporated methotrexate|liposomal liposome doxorubicin liposomes nanoparticle|floxuridine| cpx-1 is a liposomal formulation of irinotecan : entity , which is a clinical stage product candidate ;  cpx-8 is a hydrophobic docetaxel prodrug nanoparticle which is a preclinical stage
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|flox phosphate containing incorporated methotrexate|oxaliplatin capecitabine carboplatin cetuximab gemcitabine|floxuridine|scientific rationale of cpx-1 the combination of irinotecan and entity was screened for drug ratio dependent synergy in vitro in a panel of tumor cell lines .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|flox phosphate containing incorporated methotrexate|fluorouracil gemcitabine capecitabine oxaliplatin doxorubicin|floxuridine|from 7 . 8 months to 12 . 0 months ( p = 0 . 05 ) for patients with advanced , unresectable colorectal liver metastases receiving sir-spheres and entity ( fudr ) vs fudr alone .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|methotrexate sodium containing vincristine nor|eu ec 2016 spain 2014|eszopiclone|additionally , in early 2003 , sepracor filed an nda for estorra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|etanercept infliximab biologics adalimumab pharmaceuticals|eszopiclone|in exchange , sepracor permitted aventis to assign sepracors obligation to pay a royalty on sales of entity in the u . s . to a third party .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|melatonin gabapentin sildenafil olanzapine clonidine|eszopiclone|in addition , patients on entity reported improved daytime alertness ( p less than 0 . 005 ) and improved daytime ability to function ( p less than 0 . 001 ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|melatonin risperidone olanzapine gabapentin fluoxetine|eszopiclone|furthermore , patients treated with entity 2 mg reported significant improvements in daytime alertness ( p<0 . 03 ) and sense of physical well-being ( p<0 . 05 ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate sodium containing vincristine nor|pharmaceuticals compounds medicines substances cannabis|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity outside of the united states , canada and mexico and with respect to several other compounds .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate sodium containing vincristine nor|new experimental proposed medicinal novel|eszopiclone|our entity product will be marketed by gsk in its territory primarily as lunivia® brand entity for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|methotrexate sodium containing vincristine nor|bevacizumab sunitinib thalidomide mtx sildenafil|eszopiclone|no decline in therapeutic effect was observed on any outcome parameter over the course of the trial , and entity was well tolerated .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate sodium containing vincristine nor|testosterone resveratrol doxycycline melatonin sildenafil|eszopiclone|upon approval of estorra , during which the fda would not approve an abbreviated new drug application for any product containing entity , the active ingredient of estorra .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|methotrexate sodium containing vincristine nor|risperidone these naltrexone clopidogrel dexamethasone|eszopiclone|has filed an abbreviated new drug application ( anda ) with the u . s . food and drug administration ( fda ) for generic versions of entity tablets ( 1 mg , 2 mg and 3 mg ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate sodium containing vincristine nor|formulation brand tablets version us|eszopiclone|products that we launched in the united states during the year ended march 31 , 2015 : product innovatorsbrand innovator entity lunesta® seprocor fenofibrate capsules
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methotrexate sodium containing vincristine nor|melatonin novartis gabapentin ortho pfizer|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , which was approved in december 2004 by the fda and launched in the first quarter of 2005 , and rozerem® ( ramelteon ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|irinotecan tmz ribavirin buprenorphine naloxone|eszopiclone|in clinical trials with entity , one case of overdose with up to 36 mg of entity was reported in which the subject fully recovered .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|methotrexate sodium containing vincristine nor|sales ingredients combinations name members|eszopiclone|the fda is currently reviewing our nda for estorra brand entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate sodium containing vincristine nor|price sales market financial trade|eszopiclone|as a result of this policy , we capitalized $1 , 735 , 000 of lunesta brand entity inventory during the first quarter of 2005 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|methotrexate sodium containing vincristine nor|metformin ginseng curcumin minocycline sildenafil|eszopiclone|we have entered into out-licensing arrangements with respect to the sale of entity in japan and with respect to several other compounds .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|methotrexate sodium containing vincristine nor|new proposed next first final|eszopiclone|we cannot assure you that we adequately responded to the fdas concerns or that the entity nda will be approved .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate sodium containing vincristine nor|melatonin xl lp tm novartis|eszopiclone|other branded prescription sleep aids include lunesta® ( entity ) , marketed by sepracor , inc . , which was approved in december 2004 by the fda and launched in the first quarter of
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|sale marketing ec ms acne|eszopiclone|assuming favorable results from the ongoing studies , we anticipate submitting an nda for entity to the fda , in 2002 , which , if approved , we would market under the name estorra .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate sodium containing vincristine nor|sr ir generic tablets fd|eszopiclone|other events on april 4 , 2005 , sepracor commercially launched lunesta brand entity 1 mg , 2 mg and 3 mg tablets for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methotrexate sodium containing vincristine nor|propofol midazolam ketamine diazepam morphine|eszopiclone|individuals have fully recovered from racemic zopiclone overdoses up to 340 mg ( 56 times the maximum recommended dose of entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|atropine prophylactic intranasal intravenously nitrate|lidocaine fentanyl bupivacaine saline morphine|atropine|between august and october , 2010 , we reintroduced entity , morphine , dextrose , and epinephrine prefilled syringes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|atropine prophylactic intranasal intravenously nitrate|magnesium morphine atropine ferrous chondroitin|atropine|in november 2000 , we received our first fda approval to manufacture and sell diphenoxylate with entity sulfate tablets .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|propranolol atropine morphine magnesium methadone|atropine|for propranolol er driven by price , tempered by the impact of the second quarter 2017 launch of diphenoxylate hydrochloride and entity sulfate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|atropine prophylactic intranasal intravenously nitrate|gel cream acetate sodium solution|atropine|while macrodose entity 1% is currently fda-approved for pupil dilation in the united states , its significant side effect profile has impeded clinical utility
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|gentamicin atropine morphine ceftriaxone magnesium|atropine|trobigard is designed for intramuscular self- or buddy-administration of entity sulfate and obidoxime chloride for pre-hospital intervention .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|tacrolimus methylprednisolone minocycline phosphate pmma|atropine|anticipated milestone : initiate and complete phase iii vision trials in 2020 about micropine for progressive myopia micropine ( entity ophthalmic solution )
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|morphine magnesium gentamicin methylprednisolone heparan|atropine|“micropine product” means entity sulfate , as the sole active pharmaceutical ingredient , formulated and loaded into a cartridge for delivery using , and delivered by means
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|atropine prophylactic intranasal intravenously nitrate|melatonin silicone iol atropine dexamethasone|atropine|for example , our micropine program which is a micro-formulation of entity , is intended to slow myopia progression in the pediatric population .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|atropine prophylactic intranasal intravenously nitrate|ketamine lidocaine bupivacaine atropine propofol|atropine|exposed to approximately 75% less nerve agent and then treated immediately with the current standard therapy , a three-drug cocktail of entity , 2-pam and diazepam .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|atropine prophylactic intranasal intravenously nitrate|lidocaine bupivacaine epinephrine atropine naloxone|atropine|contract by dod valued at up to approximately $23 million to develop a multi-drug auto-injector for nerve agent antidote delivery ( entity and pralidoxime chloride ) , which we refer to as d4 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|atropine prophylactic intranasal intravenously nitrate|laser treatments pdt solutions therapies|atropine|despite activity , safety concerns such as pupil dilation , photosensitivity and accommodation difficulties associated with standard entity , 1% have tempered initial clinical adoption .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|silicone dexamethasone tacrolimus bevacizumab everolimus|atropine|the first pipeline opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|atropine prophylactic intranasal intravenously nitrate|silicone atropine dexamethasone melatonin tacrolimus|atropine|the first pipeline 4 table of contents opportunity is micropine , which is a micro-therapeutic formulation of entity to target myopia ( or near sightedness ) progression .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|atropine prophylactic intranasal intravenously nitrate|benzodiazepines anesthetics antioxidants atropine analgesics|atropine|the standard of care for post-exposure treatment involves repeated doses of a cocktail of drugs including entity , oxime reactivators ( " 2-pam " ) and anti-convulsants .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|atropine prophylactic intranasal intravenously nitrate|lidocaine ketamine gabapentin atropine fentanyl|atropine|the director ( nih od ) , and the ninds competition the current standard of care for nerve agent exposure is entity® and benzodiazepines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|hydrochloride plus class sulfon nor|tm everolimus novartis acth simvastatin|naldemedine| acquired rights to commercialize symproic® ( entity ) tablets 0 . 2 mg in the u . s . on april 4 , with bdsis sales force fully trained and actively promoting symproic as of may
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrochloride plus class sulfon nor|naltrexone naloxone buprenorphine morphine gabapentin|naldemedine|shionogi & co . is developing entity , another mu-opioid receptor antagonist , for patients with oic .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|gsk amphetamine meth mph pcp|methacholine|the only fda-approved direct test is provocholine® ( entity ) , marketed by methapharm inc .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|ozone nicotine sevoflurane vap n2o|methacholine|entity is inhaled as a vapour and causes bronchial constriction in asthmatic patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bronchial bronchodil histamine intranasal meth|acetylcholine endotoxin ozone mannitol allergen|methacholine|the first category , known as direct challenge tests , use either histamine or entity to directly cause airway narrowing .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|bronchial bronchodil histamine intranasal meth|acetylcholine lps epinephrine endotoxin crp|methacholine|the response from the direct tests ( entity and histamine ) are not dependent on the presence of inflammatory cells and their mediators and have a poor sensitivity for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bronchial bronchodil histamine intranasal meth|allergen histamine mannitol bronchial pc2|methacholine|volume in 1 second ( fev1 ) > 65% ;  increase in fev1 of at least 12% with bronchodilator use over baseline fev1 ;  entity challenge test with a pc20 £ 8mg / ml .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bronchial bronchodil histamine intranasal meth|allergen nasal peak between mean|methacholine|entity challenge treatment differences ( pc20 ) performed 25h post-dose and 24h following an inhaled allergen challenge table 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|allergen bronchial histamine nasal challenge|methacholine|the primary phenotypes for analysis include lifetime history of asthma , age of asthma onset , entity challenge response , smoking history , and skin prick tests for twelve common allergens .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|bronchial bronchodil histamine intranasal meth|acetylcholine reversibility spirometry mannitol adenosine|methacholine|aridol also had similar specificity to entity , ( 66% versus 70% respectively ) in subjects without exercise induced bronchoconstriction .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|allergen bronchial histamine saline gold|methacholine|efficacy will be evaluated using standard measures of respiratory function , e . g . , fev1 , entity challenge , serial spirometry .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|bronchial bronchodil histamine intranasal meth|histamine acetylcholine epinephrine adenosine endotoxin|methacholine|s . spector et al . , mannitol inhalational challenge : will it replace entity or histamine?
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|bronchial bronchodil histamine intranasal meth|electrically mechanically partially experimentally maximally|methacholine|moreover , ck-2018571 relaxed entity pre-constricted tracheal rings in a concentration-dependent manner , suggesting its potential utility as a bronchodilator .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bronchial bronchodil histamine intranasal meth|bronchial histamine capsaicin allergen saline|methacholine|the 500 mg tid treatment group , including serial spirometry , morning and evening peak flow rates and pc20 values in a entity challenge test ( common measures of respiratory function ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|bronchial nasal histamine basophil ics|methacholine|· adding vi to ff also provided further reduction of ahr as measured by entity responsiveness 24h after the allergen provocation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|bronchial bronchodil histamine intranasal meth|sodium hypertonic sweat lithium acetylcholine|methacholine|provocholine diagnosis of bronchial airway hyperactivity in subjects who do not have clinically apparent asthma entity chloride immunoglobulins ivig 5% treatment
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|bronchial bronchodil histamine intranasal meth|spirometry gold fvc bronchoscopy kit|methacholine|in comparison entity , an approved lung function test in the u . s . , identified 54% of cases .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|bronchial bronchodil histamine intranasal meth|acetylcholine serotonin histamine ige bradykinin|methacholine|examples include entity and histamine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|bronchial bronchodil histamine intranasal meth|bronchial histamine allergen ozone nasal|methacholine|to an individual or company to sell a product meta-analysis pooling and examining data from a number of studies entity inhalation test a test used in the diagnosis of asthma .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|bronchial bronchodil histamine intranasal meth|viz sildenafil fluorescein gold bevacizumab|methacholine|of 501 patients , and the study showed that aridol performed as well or better than the only currently approved test , entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|methotrexate morphine bevacizumab dexamethasone mtx|cytarabine|for safety reasons , continuous intrathecal infusion of entity is not a viable option .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|cyclophosphamide carboplatin vincristine irinotecan etoposide|cytarabine|these patients typically receive frontline therapy , usually chemotherapy , including entity and an anthracycline , a therapy that has not changed in over 40 years .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|doxorubicin dexamethasone liposome docetaxel autologous|cytarabine|products the products prepared for enzon by skyepharma are defined in the supply agreement including depocyt® , ( entity liposome injection , sky0101 ) formulation 1 . 5 ( us ) iii .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|cyclophosphamide methotrexate etoposide doxorubicin mtx|cytarabine|% can be achieved , and patients with good-risk or standard-risk chromosomal changes will typically receive post-remission therapy with high dose entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|thalidomide sunitinib cyclophosphamide bevacizumab docetaxel|cytarabine|entity is one of several drugs most commonly used for this therapy .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|atra dasatinib dexamethasone etoposide methotrexate|cytarabine|in may 2007 , our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda after accrual of 268 patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|cyclophosphamide cytosine doxorubicin methotrexate carboplatin|cytarabine|from the trial showed positive safety and response rate data for subjects treated with a combination of motixafortide and high-dose entity ( ara-c ) , or hidac .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|dasatinib atra dexamethasone imatinib thalidomide|cytarabine|an investigator-sponsored phase i / ii trial in combination with entity for elderly patients with previously untreated aml was initiated in may 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|doxorubicin capecitabine vincristine fluorouracil docetaxel|cytarabine|a number of nucleoside drugs , such as gemcitabine and entity , also known as ara-c , both generic drugs , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|dasatinib cyclophosphamide doxorubicin methotrexate carboplatin|cytarabine|is in the efficacy portion of a phase 2 clinical trial for acute myeloid leukemia ( “aml” ) in combination with low-dose entity ( “ldac” ) and in combination with decitabine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|bevacizumab dexamethasone minocycline etanercept infliximab|cytarabine|because the therapeutic half-life of entity in the csf is relatively short , frequent and repeated injections are necessary for effective treatment .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|aspirin curcumin atorvastatin resveratrol ginseng|cytarabine|certain compositions containing vosaroxin , with expiry in 2030 ; and · u . s . patent no . 7 , 968 , 565 claims a combination of vosaroxin and entity , with expiry in 2026 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|combination comparator aspirin combined monotherapy|cytarabine|the rate of serious adverse events was 55 . 5% in the vosaroxin combination arm compared to 35 . 7% in the placebo and entity arm .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|etanercept preparations medicine formulations preparation|cytarabine|clinical trials have demonstrated , however , that depocyt provides certain clinical advantages versus generic entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|cyclophosphamide methotrexate doxorubicin carboplatin conditioning|cytarabine|patients who achieve a cr after induction will go on to receive consolidation therapy with high dose entity ( hidac ) with ento or placebo as per their randomization assignment .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|doxorubicin capecitabine vincristine cyclophosphamide irinotecan|cytarabine|a number of nucleoside drugs , such as gemcitabine , or gemzar® , from eli lilly , and entity , also known as ara-c , a generic drug , are in wide use as conventional chemotherapies .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|doxorubicin anthracycline vincristine etoposide dox|cytarabine|our lead product is vyxeostm , a nano-scale liposomal formulation of entity : daunorubicin , completed a phase 3 clinical trial for the treatment of acute myeloid leukemia ( aml ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|cyclophosphamide etoposide carboplatin vincristine methotrexate|cytarabine|high-intensity induction chemotherapy is typically entity plus an anthracycline ( so called 7+3 ) administered over a 28-day cycle .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|atra dasatinib dexamethasone etoposide methotrexate|cytarabine|our phase iii trial of onrigintm in combination with entity in relapsed aml was put on clinical hold by the fda in may 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|intrathecal doxorubicin anthracycline backbone nucleoside|bortezomib this gemcitabine also oxaliplatin|cytarabine|entity acts by inhibiting a vital enzyme in dna synthesis , resulting in death of a dividing cell .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|methotrexate containing mom doxorubicin cyclosporine|all rectal subsequent further prophylactic|mometasone|three of the patients who responded received entity steroids tapered to zero by day 21 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate containing mom doxorubicin cyclosporine|hydrocortisone dexamethasone prednisone tacrolimus prednisolone|mometasone|we are also developing a topical water-based hydrogel formulation of entity , a medium-potency steroid , primarily for the treatment of atopic dermatitis .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|ics nicotine sildenafil testosterone propionate|mometasone|to $160 million in the first six months of 2013 compared with the same periods of 2012 . global sales of dulera ( entity furoate / formoterol fumarate dihydrate )
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate containing mom doxorubicin cyclosporine|dexamethasone prednisone prednisolone hydrocortisone propionate|mometasone|^ nasonex and entity are currently the only other intranasal steroids approved for the treatment of nasal polyps .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate containing mom doxorubicin cyclosporine|this silicone our porcine biodegradable|mometasone|we are currently in formulation development with entity hydrogel and expect to file an investigational new drug application , or ind , in 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate containing mom doxorubicin cyclosporine|theophylline ics spacer gold controller|mometasone|indacaterol as a single agent and in combination with an ics ( entity ) , is being developed by novartis and schering-plough .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|hydrocortisone prednisone prednisolone propionate sodium|mometasone|respiratory global sales of nasonex ( entity furoate monohydrate ) , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , increased 3% in the first quarter of
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methotrexate containing mom doxorubicin cyclosporine|propyl methyl sodium ethyl delta|mometasone|sc loading dose followed by q8w 150mg sc and ( iii ) placebo , in each case concomitant with 400 micrograms daily of entity furoate nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|methotrexate containing mom doxorubicin cyclosporine|dexamethasone hydrocortisone prednisone methylprednisolone prednisolone|mometasone|crx-191 contains a mid-potency glucocorticoid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|sildenafil testosterone nicotine propyl sodium|mometasone|a decision issued in june 2013 held that the merck patent covering entity furoate monohydrate was valid , but that it was not infringed by apotex corp . s proposed product .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|methotrexate containing mom doxorubicin cyclosporine|prednisone dexamethasone hydrocortisone prednisolone methylprednisolone|mometasone|crx-191 contains a mid-potency glucocorticosteroid , entity , and a very low dose of the tricyclic anti-depressant , nortriptyline .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|prednisone prednisolone hydrocortisone propyl ics|mometasone|patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo , each in combination with entity furoate nasal spray as background therapy .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|methotrexate containing mom doxorubicin cyclosporine|theophylline prednisone azithromycin ics sildenafil|mometasone|sch 418131 , mff , is a combination of two previously approved drugs for the treatment of asthma : entity ( asmanex ) and formoterol ( foradil ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|methotrexate containing mom doxorubicin cyclosporine|psoriasis corticosteroid ice antibiotic acne|mometasone|ovixan® is an improved prescription entity cream for the treatment of psoriasis and eczema , and oviderm® is a moisturizer for the treatment of dry skin .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|prednisolone propionate propyl ics sildenafil|mometasone| qmf149 ( indacaterol acetate / entity furoate ) is a once daily fixed-dose combination being investigated in asthmatic patients who are uncontrolled on an inhaled corticosteroid .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|methotrexate containing mom doxorubicin cyclosporine|theophylline ics atropine propionate nicotine|mometasone|novartiss qvm-149 ( entity / glycopyrronium / indacaterol ) is under review by the ema for asthma .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|propionate prednisone prednisolone hydrocortisone azithromycin|mometasone|during the first quarter of 2004 is primarily due to the purchase of raw materials related to the eligard , atrisone , entity and fluticasone products .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|methotrexate containing mom doxorubicin cyclosporine|tcs ss cs sc ts|mometasone|prior to treatment with nomacopan ( coversin ) , two out of the three patients were already on topical corticosteroids ( entity ) while a third was naïve to steroid treatment .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate containing mom doxorubicin cyclosporine|theophylline prednisone prednisolone propionate dexamethasone|mometasone|new combinations of formoterol with ciclesonide , fluticasone or entity are being developed by sanofi-aventis , abbott ( with skyepharma ) , and novartis ( with schering-plough ) respectively .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|methotrexate containing mom doxorubicin cyclosporine|sodium propyl sildenafil levo propionate|mometasone|nasonex , or entity furoate nasal spray , is currently the only other branded ins approved by the fda for the treatment of nasal polyps .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine hydrocortisone bupivacaine fluorouracil lidocaine|prilocaine|phn to receive the qutenza patch application after a 60-minute pretreatment with an fda-approved topical anesthetic ( 2 . 5% lidocaine / 2 . 5% entity ) .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|bupivacaine capsaicin epinephrine lidocaine diclofenac|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two , well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine bupivacaine diclofenac alginate acetate|prilocaine|emla ( lidocaine + entity ) is a local anaesthetic for topical application .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|lidocaine intrathecal epidural bupivacaine amide|bupivacaine capsaicin lidocaine epinephrine propofol|prilocaine|psd502 is a unique , proprietary , rapidly absorbed formulation of two well-established local anesthetics , lidocaine and entity , dispensed in a metered dose spray .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine bupivacaine diclofenac erythromycin ibuprofen|prilocaine|> emla ( lidocaine and entity ) is used as a local anaesthetic for topical application to prevent pain associated with injections and superficial surgical procedures .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine lidocaine diclofenac bupivacaine ethanol|prilocaine|the skin permeation data compares a 2 . 5% lidocaine gel and the emla cream , which contains 2 . 5% lidocaine and 2 . 5% entity .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine bupivacaine diclofenac lidocaine capsaicin|prilocaine|this product in the third quarter of 2018 . on july 2 , 2018 , we announced approval of an anda for lidocaine and entity cream usp , 2 . 5% / 2 . 5% .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|bupivacaine epinephrine lidocaine hydrochloride saline|prilocaine|local intracervical anesthetic block is achieved using 8 . 8 ml citanest ( entity ) with octapressin .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|lidocaine bupivacaine epinephrine capsaicin diclofenac|prilocaine|in particular , the dojs subpoena to impax focused on four generic medications : digoxin tablets , terbutaline sulfate tablets , entity / lidocaine cream , and calcipotriene topical solution .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|lidocaine intrathecal epidural bupivacaine amide|hydrochloride hcl sodium lidocaine chloride|prilocaine|number of products marketed under lidocaine entity topical cream 1 number of product
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine bupivacaine acetate diclofenac alginate|prilocaine|> emla ( lidocaine + entity ) is used as a local anaesthetic for topical application .
OrderedDict([('DRUG', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|lidocaine intrathecal epidural bupivacaine amide|epinephrine iodine metronidazole saline acrylic|prilocaine|for example , one non-injectable , subsurface local anesthetic commercially available today is oraqix® ( lidocaine and entity periodontal gel ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|doxorubicin methotrexate nor containing combination|doxorubicin anthracycline dox trastuzumab docetaxel|dexrazoxane|totect&#xa0 ; &#xae ; &#xa0 ; ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|doxorubicin methotrexate nor containing combination|tacrolimus methotrexate cyclophosphamide dexamethasone theophylline|dexrazoxane|bulk drug substances the muscle relaxants atracurium besylate , pancuronium bromide and vecuronium bromide , the immunosuppressant drug cyclosporine and the prodrug entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|doxorubicin methotrexate nor containing combination|doxorubicin anthracycline irinotecan docetaxel dox|dexrazoxane|totect® ( entity hcl ) is a marketed , injectable treatment for anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|doxorubicin methotrexate nor containing combination|these its anthracycline such doxorubicin|dexrazoxane|entity metabolites trap the iron ions involved in the process which leads to myocardial damage caused by anthracycline oncolytic agents such as doxorubicin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|doxorubicin methotrexate nor containing combination|supplies supply pharmaceuticals pharmacies donors|dexrazoxane|we launched totect during a national shortage of entity in late 2017 , resulting in strong initial demand for the product .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|doxorubicin methotrexate nor containing combination|this bevacizumab etanercept infliximab prp|dexrazoxane|entity is manufactured using a proprietary process covered by patents filed in several countries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|doxorubicin methotrexate nor containing combination|this interest doxorubicin cyclophosphamide its|dexrazoxane|( f ) " cardioxane-trademark- " means the substance known by the chemical name of entity , and any analogues or derivatives thereof .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|doxorubicin methotrexate nor containing combination|tablets this prp silicone them|dexrazoxane|sicor s . p . a . manufactures entity according to a proprietary process covered by process patents filed in many countries .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|doxorubicin methotrexate nor containing combination|irinotecan vincristine doxorubicin gemcitabine docetaxel|dexrazoxane|the companys entry into the oncology specialty includes two initial supportive care medications : ethyol® ( amifostine ) injection and totect® ( entity hydrochloride ) injection .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|doxorubicin methotrexate nor containing combination|prepared preparation ready formulation available|dexrazoxane|zinecard ( r ) ( entity for injection ) sold in the u . s . and canada , is a preparation for reducing cardiac side effects in women with metastatic
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|doxorubicin methotrexate nor containing combination|customers supplies sales employees companies|dexrazoxane|he oversaw the distribution of our new totect brand during a national shortage of entity resulting in many new customer relationships for the company .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|doxorubicin methotrexate nor containing combination|doxorubicin irinotecan tamoxifen docetaxel trastuzumab|dexrazoxane|apricus bio currently markets totect® ( entity hcl ) , the only drug approved in the us for the treatment of anthracycline extravasation .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|doxorubicin methotrexate nor containing combination|expertise activities work responsibilities services|dexrazoxane|sicor s . p . a . developed entity with chiron bv , including performing clinical trials , developing dosage form manufacturing , marketing and sales .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|doxorubicin methotrexate nor containing combination|commercial market marketing therapeutic manufacturing|dexrazoxane|totect was acquired by clinigen in march 2016 to expand its entity portfolio and enter the u . s . market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|doxorubicin methotrexate nor containing combination|merck novartis tm japan trastuzumab|dexrazoxane|” about totect® ( entity ) totect is an anthracycline extravasation agent approved by the united states food and drug administration .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|doxorubicin methotrexate nor containing combination|doxorubicin bupivacaine docetaxel irinotecan anthracycline|dexrazoxane|totect® ( entity hcl ) was approved by the fda in 2007 for the treatment of anthracycline extravasation , which is the leaking of chemotherapy
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|drug|doxorubicin methotrexate nor containing combination|adenovirus viruses cart cells immunotherapy|dexrazoxane|administration of entity with such oncolytic agents protects tissues of the heart and allows for higher dosages of the oncolytic agent .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|doxorubicin methotrexate nor containing combination|tm novartis trastuzumab roche doxorubicin|dexrazoxane|about totect® ( entity ) injectiontotect is an anthracycline extravasation agent approved by the fda .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|doxorubicin methotrexate nor containing combination|commercial marketing potential available therapeutic|dexrazoxane|totect was acquired by clinigens specialty pharmaceuticals ( sp ) division in march 2016 to expand its entity portfolio for the u . s . market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|doxorubicin methotrexate nor containing combination|irinotecan sildenafil tetracycline naltrexone buprenorphine|dexrazoxane|totect® cumberland announced fda approval of new labeling of totect® ( entity hydrochloride ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|containing from ingredients formulation plus|phenylephrine|each 5ml dose contains the api entity hci , pyrilamine maleate and dextromethorphan hbr .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|diclofenac bupivacaine morphine ibuprofen lidocaine|phenylephrine|european medicines agencys committee for medicinal products for human use had adopted a positive opinion for omeros drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|lidocaine aspirin capsaicin ibuprofen diclofenac|phenylephrine|pse also competes against entity , an alternate nasal decongestant available in non-prescription products .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|phenylephrine clonidine norepinephrine dopamine propranolol|phenylephrine|biorphen ( entity hcl injection ) is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|bupivacaine lidocaine phenylephrine diclofenac atropine|phenylephrine|the companys drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% is marketed for use during cataract surgery or intraocular lens ( iol ) replacement to maintain
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|pharmacy pharmaceutical commercial water pharmacist|phenylephrine|ongoing entity supply disruptions from 503b compounding facilities , including the announced shutdown of compounding industry leader pharmedium in january , have highlighted the
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|lidocaine capsaicin ibuprofen caffeine melatonin|phenylephrine|otc products contain any one of several active ingredients including glycerin , entity , pramoxine , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|bupivacaine lidocaine diclofenac dexamethasone atropine|phenylephrine|our marketed drug product omidria® ( entity and ketorolac injection ) 1% / 0 . 3% was broadly launched in the u . s . in april 2015 for use during cataract surgery or intraocular
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|verapamil nifedipine sildenafil atropine losartan|phenylephrine|ventrus is also required to reimburse s . l . a . for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|verapamil nifedipine sildenafil propranolol losartan|phenylephrine|is also required to reimburse s . l . a . pharma for clinical development costs associated with the technology development of both diltiazem and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|fentanyl midazolam morphine naloxone dexamethasone|phenylephrine|these products generally contain active ingredients such as acetaminophen , dextromethorphan , diphenhydramine , guaifenesin , loratadine , entity , and pseudoephedrine .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|lidocaine capsaicin diclofenac metronidazole hypertonic|phenylephrine|: 267  270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|dexamethasone midazolam lidocaine aspirin hydrocortisone|phenylephrine|aldex ct is an antihistamine / decongestant combination administered orally in a chewable tablet form containing the api diphenhydramine hcl and entity hcl .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|bupivacaine lidocaine dexamethasone diclofenac atropine|phenylephrine|our marketed drug product omidria™ ( entity and ketorolac injection ) 1% / 0 . 3% is approved in the u . s . for use during cataract surgery or intraocular lens , or iol , replacement
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 1)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|phenylephrine prednisolone dexamethasone propofol lidocaine|phenylephrine|microdose delivery of entity 10% ( pe - µd ) was associated with significantly less systemic exposure than traditional eye drops ( pe 10% ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|bupivacaine morphine diclofenac ibuprofen lidocaine|phenylephrine|application seeking approval from the u . s . food and drug administration to market a generic version of the companys drug omidria® ( entity and ketorolac injection ) 1% / 0 . 3% .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|bupivacaine verapamil gabapentin irinotecan vincristine|phenylephrine|on june 28 , 2013 , the group filed an nda for vazculep ( entity hydrochloride injection ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|metronidazole rectal fecal vaginal collagen|phenylephrine|entity gel ( ven 308 ) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis , an fda orphan indication .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|vancomycin lidocaine uv warfarin ven|phenylephrine|because of the extensive patient exposure to entity , we intend to develop ven 308 as a topical formulation through a section 505 ( b ) nda .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|phenylephrine dopamine acetylcholine vasopressin norepinephrine|lidocaine capsaicin metronidazole diclofenac hypertonic|phenylephrine|: 267 - 270 , 1999 normal subjects , entity gel ( 5% , 10% , 20% , 30% ) applied once to anal verge resting anal pressure increased by 8% to 33% , effect
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|platinum backbone commercial containing cytotoxic|bevacizumab dexamethasone gemcitabine sunitinib capecitabine|pemetrexed|in the th-302 plus entity arm , th-302 is administered intravenously on days 1 and 8 of a 21 day cycle .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|chloroquine ciprofloxacin methotrexate trimethoprim doxycycline|pemetrexed|obtain approval for talotrexin , we will compete with existing antifolate therapies currently being sold by pfizer ( trimetrexate ) , eli lilly & co . ( entity ) and novartis ( edatrexate ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|platinum backbone commercial containing cytotoxic|wk wo mo st month|pemetrexed|pth-305 : nsclc ( w / entity ) 2 / 2006 to 6 / 2007 400 , 600 136 138 os was lower in talabostat vs placebo .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|platinum backbone commercial containing cytotoxic|pem erlotinib everolimus docetaxel celecoxib|pemetrexed|eagle  s solution : ep-5101 ( pemfexy™ ) ep-5101 is an rtd liquid formulation of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|etoposide bevacizumab everolimus rituximab cyclophosphamide|pemetrexed|interim data conducted on a small number of patients showed encouraging response rates with the combination of carboplatin , entity and bavituximab .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|platinum backbone commercial containing cytotoxic|thalidomide methotrexate crizotinib nivolumab bevacizumab|pemetrexed|administered as monotherapies , these include entity ( alimta® ) , docetaxel ( taxotere® ) , or erlotinib ( tarceva® ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|bevacizumab etoposide docetaxel gemcitabine taxol|pemetrexed|the addition of apatorsen to carboplatin and entity therapy did not demonstrate an overall survival benefit in the study ( hr= 1 . 067 ; 80% ci : 0 . 838-1 . 359 ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|platinum backbone commercial containing cytotoxic|2016 2015 2017 2014 ltd|pemetrexed|entity , supply agreement term sheet in december 2016 , we entered into a binding term sheet with nang-kuang pharmaceutical co . , ltd and
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|platinum backbone commercial containing cytotoxic|gemcitabine erlotinib carboplatin docetaxel capecitabine|pemetrexed|of the thirty-two patients with relapsed or refractory nsclc treated with th-302 in combination with either docetaxel or entity , eight patients achieved prs and fourteen patients achieved sd .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|etoposide gemcitabine docetaxel bevacizumab erlotinib|pemetrexed|·a phase ib ist evaluating bavituximab in combination with carboplatin and entity in up to 25 patients with previously untreated stage iv nsclc .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|platinum backbone commercial containing cytotoxic|docetaxel gemcitabine carboplatin doxorubicin bleomycin|pemetrexed|with docetaxel in metastatic squamous nsclc that has progressed after previous therapy ( arm b ) ; or · in combination with entity and cisplatin in mesothelioma ( arm c ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|platinum backbone commercial containing cytotoxic|irinotecan bevacizumab capecitabine ipilimumab pioglitazone|pemetrexed|entity is dosed according to its package insert .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|platinum backbone commercial containing cytotoxic|medicine energy nicotine medicines storage|pemetrexed|which we allege infringement against apotex inc . ( apotex ) in response to its application to market products using alternative forms of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|bevacizumab etoposide docetaxel gemcitabine taxol|pemetrexed|the aim of the trial is to determine if adding apatorsen to carboplatin and entity therapy could extend pfs outcome .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|platinum backbone commercial containing cytotoxic|bortezomib thalidomide dexamethasone rituximab dasatinib|pemetrexed|the second 400-patient trial , evaluating the combination of talabostat with entity versus placebo and entity opened to enrollment in february 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|platinum backbone commercial containing cytotoxic|crizotinib thalidomide bevacizumab gefitinib cetuximab|pemetrexed|each study will combine pf-3512676 with either avastin® ( bevacizumab ) , erbitux® ( erlotinib ) or alimta® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|treated treatments concurrently immunotherapy monotherapy|pemetrexed|patients continued entity with weekly apatorsen or placebo infusions as maintenance treatment until disease progression if they completed a minimum of 3 cycles of chemotherapy treatment .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|platinum backbone commercial containing cytotoxic|thalidomide sildenafil infliximab mtx adalimumab|pemetrexed|some of our competitors include pfizer ( trimetrexate ) , eli lilly & co . ( entity ) , novartis ( edatrexate ) , and allos ( pdx ) , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|platinum backbone commercial containing cytotoxic|erlotinib gefitinib crizotinib cetuximab monotherapy|pemetrexed|strata 1 and 3 also had maintenance entity or continued egfr-tki therapy , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|platinum backbone commercial containing cytotoxic|docetaxel bevacizumab erlotinib gemcitabine etoposide|pemetrexed|the denali trial is testing demcizumab with entity and carboplatin versus entity and carboplatin alone in first-line advanced non-small cell lung cancer patients .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin rifampicin containing vancomycin metronidazole|these like containing available plus|moxidectin|both products  entity formulations offer numerous advantages over traditional deworming agents .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ciprofloxacin rifampicin containing vancomycin metronidazole|medicinal natural new pharmaceutical commercial|moxidectin|cydectin , a entity product to control parasites in animals , will have patent protection until at least 2011 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin rifampicin containing vancomycin metronidazole|injectable marketed gel available new|moxidectin|the first entity formulation for horses , equest gel , was launched in new zealand .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|first sham comparator monotherapy experimental|oxaliplatin|this data represents a five-fold improvement to results seen from the entity arm of the study .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|therapeutic survival potential adjuvant biomarker|oxaliplatin|also performed a gene identification study which analyzed over 700 new genes , and identified 16 genes as being predictive of entity benefit for use in patients with stage iii disease .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|medicines pharmaceuticals medicine biologics nicotine|oxaliplatin|in 2010 ) , following a court ruling barring manufacturers of generics in the u . s . from selling their unapproved generic versions of entity from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin irinotecan bevacizumab gemcitabine capecitabine|oxaliplatin|currently in clinical trials , including trials for hormone refractory prostate cancer , inoperable liver cancer , and in combination with capecitabine or entity .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin irinotecan capecitabine fluorouracil adjuvant|oxaliplatin|the company began offering the oncotype dx colon cancer test for use in patients with stage iii disease treated with entity containing adjuvant therapy .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin lapatinib irinotecan capecitabine bevacizumab|oxaliplatin|other chemotherapies include capecitabine ( xeloda® ) , entity ( eloxatin® ) , fluorouracil or leucovorin .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|medicines medicine pharmaceuticals vaccines biologics|oxaliplatin|in the first half of 2010 ) after a court ruling barred generics manufacturers from selling their unauthorized generic versions of entity in the united states from june 30 , 2010 .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|chemotherapeutic combination three irinotecan multiple|oxaliplatin|two weeks in patients with advanced non-small cell lung cancer ; and ø a u . s . phase iii trial in patients undergoing treatment with entity regimens for advanced colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin carboplatin irinotecan capecitabine platinum|oxaliplatin|marketed products in oncology include padexol injection ( paclitaxel ) , didox capsule ( doxifluridine ) , oxp injection ( entity ) and crabcan injection ( irrinotecan ) .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|platinum carboplatin oxaliplatin platin cyclophosphamide|oxaliplatin|entity , a formulation of dach platinum , is a chemotherapeutic which was initially approved in france and in europe in 1999 for
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|proprietary this commercial patent brand|oxaliplatin|on june 30 , 2010 , the company ceased selling sun pharmas entity product in the united states market , pending the appeal .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|bevacizumab gemcitabine oxaliplatin cyclophosphamide docetaxel|oxaliplatin|the originator of the drug , and several generic manufacturers ; ▪ carboplatin , marketed by bristol-myers squibb in the us ; and ▪ entity , marketed exclusively by sanofi-aventis .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|intramuscular subcutaneous oxytocin novartis vasopressin|oxaliplatin|entity injection 50mg / 10ml and 100mg / 20ml are the ab-rated generic versions of eloxatin® , which had annual sales of approximately $1 . 4 billion for
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin carboplatin doxorubicin etoposide fluorouracil|oxaliplatin|other combinations of gemcitabine with cisplatin , entity , irinotecan or docetaxel tested in phase 3 trials have not been of superior benefit to gemcitabine alone .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin irinotecan fluorouracil capecitabine docetaxel|oxaliplatin|for most patients , initial chemotherapy is based on folfox ( 5-fu , leucovorin and entity ) , or similar agents .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|pharmaceuticals medicines biologics etanercept opioids|oxaliplatin|the growth was driven by an increase in specialty injectable pharmaceuticals , primarily a result of the third-quarter launch of entity in solution form in the united states .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|gemcitabine single low 3m cyclophosphamide|oxaliplatin|demonstrated preliminary evidence of efficacy but grade 2 innate immune adverse effects were seen with standard doses of gemcitabine and entity and 10 µg / kg doses of mt-3724 .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|oxaliplatin irinotecan capecitabine gemcitabine fluorouracil|oxaliplatin|aroplatin aroplatin is a novel liposomal formulation of a third-generation platinum chemotherapeutic structurally similar to entity , a recently approved treatment for colorectal cancer .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|intramuscular subcutaneous gelatin epinephrine lidocaine|oxaliplatin|on august 11 , 2009 , teva commenced sales of its 50mg / 10ml and 100mg / 20ml entity injection products .
OrderedDict([('DRUG', 5), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|irinotecan capecitabine oxaliplatin carboplatin docetaxel|platinum carboplatin oxaliplatin platin cddp|oxaliplatin|entity , a compound of dach platinum , is a chemotherapeutic which was initially approved in europe in 1999 for the treatment of
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|hormone thyroxine tsh corticosteroid replacement|levothyroxine|skin reactions , hypothyroidism in patients taking entity replacement , gi perforation , in some cases fatal and tumor lysis syndrome , which can be life threatening , have also been reported
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|diclofenac potassium lactose sodium fluoride|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales decreased to $26 million during the second quarter ended june 30 , 2007 from $29 million during the second
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|diclofenac tetracycline furosemide levo lactose|levothyroxine|if the fda were to determine that another entity sodium product is bioequivalent to levoxyl® , generic substitution for levoxyl® may become possible which could result in a decrease in
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|diclofenac sodium lithium nicotinic fluoride|levothyroxine|could be affected by future actions of the fda and by uncertainty in the entity sodium product market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|levo replacement methotrexate substitution hormone|paris florida france sweden llc|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|potassium diclofenac fluoride sodium lactose|levothyroxine|levoxylò ( entity sodium tablets , usp ) net sales totaled $32 million during the fourth quarter and $100 million for the year ended december 31 , 2007 , compared
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|atorvastatin diclofenac simvastatin losartan tenofovir|levothyroxine|in december 2004 , the entity sodium tablet product received the ab rating to synthroid® .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|levo replacement methotrexate substitution hormone|diclofenac sodium lithium potassium high|levothyroxine|on august 14 , 1997 , the fda announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|morphine levo diclofenac bupivacaine estradiol|levothyroxine|net sales of levoxyl ( r ) ( entity sodium tablets , usp ) equaled $28 . 7 million during the first quarter ended march 31 , 2004 , a decrease of 14% from $33 . 2
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|levo replacement methotrexate substitution hormone|tablets pharmaceuticals sildenafil vials medicines|levothyroxine|volumes were favorably impacted due to increased sales of entity as customer demand increased in anticipation of the transition of the product .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|levo replacement methotrexate substitution hormone|medicine labor employment work service|levothyroxine|complementing our second quarter performance was a well-executed plan associated with the transition of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|diclofenac fentanyl morphine penicillin ampicillin|levothyroxine|nitrofurantoin during our 180-day exclusivity period ; the delay in the launch of our fentanyl product and the regulatory actions surrounding entity sodium .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|levo replacement methotrexate substitution hormone|resveratrol sucrose diclofenac ginseng losartan|levothyroxine|worldwide agreement with jerome stevens pharmaceuticals , inc . to market and distribute jerome stevens  nda ( new drug application ) approved form of entity sodium , usp tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|diclofenac atorvastatin simvastatin naltrexone lithium|levothyroxine|of $2 , 220 , 931 due to an improvement in timely collections , and the launch of the company  s new product sales campaign for entity sodium tablets in april 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|diclofenac lithium fluoride magnesium sodium|levothyroxine|drug administration , which we refer to as the fda ,  announced in the federal register ( 62 fr 43535 ) that orally administered entity sodium drug products are new drugs .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|warfarin potassium atorvastatin new diclofenac|levothyroxine|this dual approval will now allow pharmacists to substitute entity sodium tablets for both dominant brands .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|levo replacement methotrexate substitution hormone|thyroxine thyro calcitonin diclofenac fluoride|levothyroxine|thyromed chewable tablets contain the active ingredient entity sodium , which is a clinically proven replacement for the naturally occurring hormone secreted by the thyroid gland .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|levo replacement methotrexate substitution hormone|thyroxine testosterone sodium hydrocortisone dexamethasone|levothyroxine|these chewable tablets , which are administered daily for the life of the dog , provide entity sodium , a replacement therapy for the hormone normally produced by the dog .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|levo replacement methotrexate substitution hormone|payment medicare medicaid reimbursement excellence|levothyroxine|of upfront payment represents the amortization of the upfront payment made to lannett in connection with our transition agreement for entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|levo replacement methotrexate substitution hormone|diclofenac fluoride new high nicotinic|levothyroxine|application for an equivalent product after august 14 , 2001 must submit an anda seeking approval of a generic substitute for a entity sodium product with an approved nda .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|drug|neomycin carrier gene prophylactic virus|tacrolimus atopic gel corticosteroid paraffin|neomycin|triamcinolone acetonide and entity paste used for neurodermatitis circumscripta and chronic eczema .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin carrier gene prophylactic virus|gentamicin azithromycin kanamycin doxycycline minocycline|neomycin|existing drugs , such as tobramycin , entity , zithromax® and zyvox® , demonstrate that successful medicines can modulate rna function .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|neomycin carrier gene prophylactic virus|gentamicin tetracycline minocycline doxycycline kanamycin|neomycin|our products that contain virginiamycin , oxytetracycline or entity are classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin carrier gene prophylactic virus|tetracycline gentamicin doxycycline minocycline azithromycin|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antibacterials .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin carrier gene prophylactic virus|gentamicin magnesium neomycin streptomycin chondroitin|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|neomycin carrier gene prophylactic virus|vancomycin tetracycline ciprofloxacin amoxicillin penicillin|neomycin|the company believes that current antibiotic therapies , including entity and metronidazole , are inadequate treatments , however , due to their limited antibacterial spectrum and side effects .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|neomycin carrier gene prophylactic virus|glucose creatine albumin leucine tryptophan|neomycin|the abnormal plasma amino acid pattern characterized by decreased levels of bcaas and elevated levels of aaas , as compared to entity , which was used as an active control .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|neomycin carrier gene prophylactic virus|fluconazole dexamethasone warfarin ciprofloxacin prednisone|neomycin|nexavar exposure decreases when coadministered with oral entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin carrier gene prophylactic virus|tetracycline gentamicin doxycycline minocycline azithromycin|neomycin|our products that contain virginiamycin , oxytetracycline or entity have previously been classified by the fda as medically important antimicrobials .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|neomycin carrier gene prophylactic virus|gentamicin neomycin streptomycin magnesium chondroitin|neomycin|neoflo is a dressing that incorporates the triple antibiotic , polymyxin b sulfate , bacitracin zinc and entity sulfate ( neosporin-registered trademark- ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tenofovir tdf lamivudine fumarate antiviral|df either cmv tenofovir hbv|tenofovir|the later stages of the phase iii clinical trials for adefovir dipivoxil will not arise in the clinical trials for entity df or that we will achieve adequate treatment benefits .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir lamivudine ribavirin adv hbv|tenofovir|initiate in 2017 the phase 2b clinical trial to evaluate sb 9200 as a monotherapy and in combination with viread ( entity ) targeting approximately 200 patients with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir lamivudine interferon ribavirin chloroquine|tenofovir|entity has potent activity against chronic hepatitis b . it is particularly useful in patients who have developed drug resistance to other
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir verapamil fumarate magnesium celecoxib|tenofovir|unenforceable and / or will not be infringed by teva  s manufacture , use or sale of a generic fixed-dose combination of emtricitabine and entity disoproxil fumarate .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|lamivudine tenofovir tdf nucleoside ribavirin|tenofovir|the most commonly used therapy for chronic hbv is life-long suppressive therapy with nrtis , like entity or entecavir .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir lamivudine atorvastatin fumarate naltrexone|tenofovir| viread sales of viread® ( entity disoproxil fumarate ) were $189 . 4 million in the third quarter of 2005 , a two percent decrease from $193 . 9 million in the
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir resistance azt inhibitors lamivudine|tenofovir|use of viread should be considered for treating adult patients with hiv-1 strains that are expected to be susceptible to entity as assessed by laboratory testing or treatment history .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|tdf nvp vf vv taf|tenofovir|nrtis , such as epivir ( 3tc ) , emtriva ( ftc ) , viread ( entity ) , retrovir ( azt ) and zerit ( d4t ) , have become the predominant class of drugs in hiv therapy .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir ribavirin lamivudine interferon nucleoside|tenofovir|txl is a highly potent analog of the antiviral drug entity df ( viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|injectable liposomal tenofovir sodium containing|tenofovir|which gilead is funding and conducting a phase 2 clinical trial examining the co-administration of inarigivir and vemlidy® 25 mg ( entity alafenamide ) in patients infected with chronic hbv .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir merck pfizer fumarate celecoxib|tenofovir|addendum to entity disoproxil fumarate manufacturing supply agreement the parties hereby acknowledge and agree to the following :
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|ribavirin lamivudine tenofovir interferon nvp|tenofovir|nucleotide compound , uses the same proprietary lipid technology as cmx001 to deliver high intracellular concentrations of another potent antiviral drug , entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir warfarin atorvastatin fumarate ibuprofen|tenofovir|and in april 2013 , gilead and teva reached an agreement in principle to settle the lawsuit on the patents covering entity disoproxil fumarate contained in the atripla*
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|tenofovir tdf lamivudine fumarate antiviral|previous proposed first fda new|tenofovir|we cannot predict the outcome of these proceedings on our entity df patent application .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|ribavirin vaccines vials formulations tablets|tenofovir|in addition , in late 2011 , generic entity also became available in turkey , which resulted in an increase in the rebate for viread in turkey .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir this df bayer adv|tenofovir|entity df is in the same class of drugs as adefovir dipivoxil .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir lamivudine tdf boosted triple|tenofovir|of cmx157 in healthy volunteers and are on track to complete the ongoing phase 2a head-to-head study of cmx157 vs . entity df ( tdf , gileads viread® ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir lamivudine ribavirin tdf interferon|tenofovir|entity and entecavir have emerged as the standard of care in this disease with very low rates of resistance over five
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tdf lamivudine fumarate antiviral|ribavirin interferon lamivudine ifn tenofovir|tenofovir|the replicor 401 study , a study of naps in combination with entity and pegylated interferon , reported a 39% functional cure rate .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tenofovir tdf lamivudine fumarate antiviral|tenofovir fumarate lamivudine carbamazepine naltrexone|tenofovir|in the notice related to teva  s anda for a generic version of truvada , teva challenged four patents related to entity disoproxil fumarate and two additional patents related to emtricitabine .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|dexamethasone cyclophosphamide methotrexate prednisone carboplatin|amifostine|we are also aware of research relating to the use of high doses of entity ( a drug used to control some of the side effects of chemotherapy and radiation therapy ) for the protection of hearing
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|gemcitabine irinotecan capecitabine bevacizumab docetaxel|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|tm xt alk lt mt|amifostine|we anticipate that ethyolregistered trademark ( entity ) will be a meaningful product for medimmune following our merger .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|rt tr tm rct alk|amifostine|sales of ethyol-registered trademark- ( entity ) increased 48% and 23% for the quarter and six months ended june 30 , 1999 , respectively , compared to the same periods
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|merck tm novartis roche pfizer|amifostine|medical applications the arsenal of medical radiation-protectors is limited to ethyol™ ( entity ) , sold by medimmune , and acquired by astrazeneca international .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|carbamazepine fluconazole erythromycin simvastatin crizotinib|amifostine|mycelex-registered trademark- ( clotrimazole ) troche , which alza began marketing in the second half of 1997 , and increased sales of ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|bevacizumab cetuximab hydrochloride cyclophosphamide celecoxib|amifostine|entity ( ethyolâ ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|carboplatin tmz cyclophosphamide dexamethasone adenosine|amifostine|we are also aware of research relating to the use of high dose entity for the protection of hearing in connection with platinum-based chemotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|azithromycin carbamazepine ribavirin simvastatin erythromycin|amifostine|we market synagis ( palivizumab ) , flumist ( influenza virus vaccine live , intranasal ) , ethyol ( entity ) and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|tm novartis 16 18 17|amifostine|sun pharmaceutical industries limited has submitted an abbreviated new drug application to the fda for a generic version of ethyol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|cyclophosphamide methotrexate hydrochloride celecoxib losartan|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|etanercept ribavirin rituximab adalimumab infliximab|amifostine|the company markets synagis ( palivizumab ) , ethyol ( entity ) , and cytogam ( cytomegalovirus immune globulin intravenous ( human ) ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|cyclophosphamide erythropoietin minocycline selenium doxorubicin|amifostine|neupogen ( r ) currently faces market competition from a competing csf product , granulocyte macrophage colony stimulating factor ( " gm-csf " ) and from the chemoprotectant , entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|bleomycin celecoxib minocycline tamoxifen cyclophosphamide|amifostine|entity ( ethyol® ) is approved by the fda as a radioprotector .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|tm rt tr tmt rx|amifostine|in december 1995 , alza entered into a marketing and distribution agreement with u . s . bioscience , inc . ( " u . s . bioscience " ) for ethyol-registered trademark- ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|cyclophosphamide everolimus bortezomib tacrolimus celecoxib|amifostine|entity ( ethyol® ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity and radiation-induced xerostomia ( damage to the
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|cyclophosphamide celecoxib methotrexate hydrochloride tenofovir|amifostine|entity ( ethyol ) is marketed by medimmune , inc . for use in reduction of chemotherapy-induced kidney toxicity associated with repeated administration of cisplatin
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|thalidomide gabapentin bevacizumab celecoxib cyclophosphamide|amifostine|there is one drug , entity , approved for use in reducing side effects from radiation therapy .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|gemcitabine irinotecan capecitabine bevacizumab docetaxel|amifostine|he played key consulting roles in registration strategy and post-registration development of recent products such as entity , docetaxel , cpt-11 , and irofulven .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine hydrochloride verapamil|2010 2012 2011 11 usa|amifostine|product sales of $66 million , including $33 million in worldwide sales of synagis and $25 million in sales of ethyol® ( entity ) .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|bupivacaine epinephrine propofol dexmedetomidine lidocaine|hydrocortisone|· igi will formulate four combination products of entity and lidocaine at different strengths : 1 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|diclofenac lps dexamethasone etanercept adalimumab|hydrocortisone|at 4 µm , 42% at 8 µm and 52% at 16 µm . therefore , the ic50 was 16 µm . by comparison , entity at 10 µm caused a 54% reduction in il-8 expression .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|hydrocortisone prednisolone methylprednisolone dexamethasone prednisone|hydrocortisone|in canada , 0 . 5% entity , a common anti-inflammatory product , described in the monograph , hydrocortisone topical published by health canada on january 22 , 2007 , can be
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|injectable new generic subcutaneous risperidone|hydrocortisone|on november 15 , 2011 , we acquired rights to plenadren® ( entity , modified release tablet ) for treatment of ai .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|diclofenac corticosteroid hydrocortisone capsaicin methylprednisolone|hydrocortisone|entity rectal cream is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|its this fluconazole tenofovir everolimus|hydrocortisone|discuss how fda views our package of the us experience with ketoconazole and entity combination and discuss how much value in the historical experience will be accepted .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|sodium ethyl propionate hydrocortisone propyl|hydrocortisone|this was partially offset by the product launch of entity butyrate lotion .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|antibiotics irrigation spray lidocaine ciprofloxacin|hydrocortisone|the launch of entity with acetic acid along with strong sales of sulfamethoxazole with trimethoprim and fluticasone propionate nasal spray also contributed to the
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|fluoride phosphate lidocaine hydrocortisone diclofenac|hydrocortisone|-jun-11 t36® 0 . 5% entity ointment 80026139 30-jun-11 pedia-safe polyvitamin drops1 80001571 05-apr-06 ferroheme2 1 licensed to the company by canagen in an agreement dated
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|celecoxib curcumin lps ibuprofen infliximab|hydrocortisone|cbn was similar to entity with respect to anti-inflammatory activity in this model .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|analgesic analgesics capsaicin corticosteroid antibiotic|hydrocortisone|anamantlehc , launched in january 2003 , is a prescription cream containing a topical anesthetic and entity , which treats hemorrhoids and anal fissures .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|capsaicin honey lidocaine diclofenac curcumin|hydrocortisone|the combination of aloe vera and entity offers therapeutic benefits for skin irritations such as minor burns , allergic itch , insect bite itch , sun burn itch , eczema in
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|subcutaneous intramuscular intra needle by|hydrocortisone|entity injection toxic symptom caused by various infections , hypocorticoidism caused by various infections , anaphylactic shock .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|olanzapine clopidogrel paracetamol metformin atorvastatin|hydrocortisone|cma issued a statement of objections to a third party and the company in relation to the supply of 10mg entity tablets in the u . k . between 2013 and 2016 .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|estradiol resveratrol tocopherol ethanol magnesium|hydrocortisone|both products are formulated with aloe vera and cortiveraä contains 0 . 5% entity and cortivera plusä contains 1% entity .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|whole viscous dry vaginal solid|hydrocortisone|formulation design up to 8 78 , 600 · igi will formulate a entity cream product .
OrderedDict([('DRUG', 5), ('OTHER', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|hydrocortisone dexamethasone corticosteroid cyclosporine testosterone|aspirin curcumin melatonin ibuprofen dexamethasone|hydrocortisone|lidamantle®hc also contains entity , which helps to reduce inflammation .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|pioglitazone rosiglitazone diclofenac butyrate metformin|rosiglitazone|commonly prescribed drugs include diabetic medicines such as metformin , entity and sulfonylurea .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|11 13 16 18 17|rosiglitazone|for the district of colorado into the group  s us sales and promotional practices and for product liability cases regarding avandia ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|everolimus atorvastatin ribavirin tenofovir pioglitazone|rosiglitazone|a fixed combination product of starlix and entity was approved by fda in 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|rosiglitazone metformin pioglitazone simvastatin losartan|rosiglitazone|will compete with cs-917 include the insulin sensitizers actos , or pioglitazone , co-marketed by takeda and eli lilly , and avandia , or entity , marketed by glaxosmithkline .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|pioglitazone rosiglitazone metformin sucrose risperidone|rosiglitazone|cvr number : 24256790 the three lead® studies showed that liraglutide in combination with either glimepiride or metformin or metformin and entity is well tolerated .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|pioglitazone rosiglitazone metformin atorvastatin diclofenac|rosiglitazone|the study investigated the effect of different doses of liraglutide in combination with metformin and entity , and included 533 patients with type 2 diabetes .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|testosterone sildenafil caffeine wine resveratrol|rosiglitazone|june 2007 the group voluntarily dismissed its infringement claims in respect of the patent covering the maleate salt form of entity ( the active ingredient in avandia ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|metformin pioglitazone rosiglitazone glucose atorvastatin|rosiglitazone|starlix ( diabetes ) was also filed in the us in december for use in combination with entity , a commonly used oral antidiabetic .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|metformin rosiglitazone pioglitazone atorvastatin olanzapine|rosiglitazone|with respect to avandamet ( entity maleate / metformin hydrochloride ) tablets , the company anticipates resupplying the distribution channels within two weeks .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|metformin pioglitazone rosiglitazone statins hba1c|rosiglitazone|this weight loss was achieved with blood sugar-lowering efficacy comparable to entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|fluoxetine naltrexone ketamine gabapentin oxytocin|rosiglitazone|site at cidra , puerto rico ; product liability and anti-trust litigation relating to paxil ( paroxetine ) , and product liability cases regarding avandia ( entity ) and other products .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|testosterone sildenafil estradiol atorvastatin resveratrol|rosiglitazone|for example , recent studies have suggested an increased cardiovascular risk in patients using avandia® ( entity maleate ) .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|pioglitazone rosiglitazone statins nsaids metformin|rosiglitazone|there also have been concerns of other cardiovascular issues with entity and also concerns raised regarding bladder cancer associated with treatment with tzds .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|rosiglitazone metformin simvastatin agonists pioglitazone|rosiglitazone|insulin sensitizing agents approved to treat t2d are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|metformin pioglitazone monotherapy hba1c fpg|rosiglitazone|of starlix® ( nateglinide ) improves glycemic control and is well-tolerated in patients whose type 2 diabetes is inadequately controlled by taking entity alone .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|pioglitazone rosiglitazone metformin hypoglycaemia atorvastatin|rosiglitazone|after a run-in period of metformin and entity , patients in the study were randomised to add-on treatment with either liraglutide or placebo .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|rosiglitazone metformin pioglitazone everolimus leptin|rosiglitazone|entity ( avandia® ) and pioglitazone ( actos® ) fall into this category of anti-diabetic agent .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|rosiglitazone metformin pioglitazone simvastatin rifampicin|rosiglitazone|tzds include pioglitazone , marketed by eli lilly & company and takeda pharmaceutical company limited as actos , and entity , marketed by glaxosmithkline plc as avandia .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|entity carbamazepine vehicle propranolol olanzapine|rosiglitazone|a comparator with entity , which has been shown to have some efficacy in humans , indicates the mgl-3196 performs better than entity in this study .
OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|rosiglitazone pioglitazone risperidone calcitonin nifedipine|rosiglitazone metformin simvastatin pioglitazone resveratrol|rosiglitazone|insulin sensitizing agents approved to treat type 2 diabetes are the ppar gamma agonists pioglitazone and entity .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|epinephrine bupivacaine diclofenac lidocaine capsaicin|tetracaine|we entered into a license agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch ( zars agreement ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|epinephrine diclofenac bupivacaine lidocaine capsaicin|tetracaine|license agreement with zars pharma that will give it the exclusive north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|bupivacaine propofol epinephrine ibuprofen midazolam|tetracaine|the drug formulation is a eutectic mixture of lidocaine 70 mg and entity 70 mg .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|bupivacaine epinephrine lidocaine capsaicin ethanol|tetracaine|this product combines our peel technology with a proprietary formulation of lidocaine and entity to safely and efficiently anesthetize contoured areas of the body .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|epinephrine bupivacaine diclofenac lidocaine capsaicin|tetracaine|we entered into a license agreement with zars pharma for the north american rights to synera® ( lidocaine 70 mg and entity 70 mg ) topical patch , referred to as the zars agreement .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|epinephrine ethanol bupivacaine iodine lidocaine|tetracaine|allergy u . s . rx lidocaine ointment xylocaine™ dermatologics and topicals u . s . rx lidocaine / entity gel pliaglis® dermatologics and topicals u . s . rx loratadine solution claritin® allergy
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|lidocaine sodium intrathecal amide hydrochloride|bupivacaine epinephrine propofol dexmedetomidine ibuprofen|tetracaine|it uses our chadd technology and a proprietary formulation of lidocaine and entity to provide more convenient and faster anesthetic effect compared to the most commonly used product .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|lidocaine sodium intrathecal amide hydrochloride|this its commercial each another|tetracaine|the fda has specified a limit of 1 . 5% tetra acid relative to entity assay .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|lidocaine sodium intrathecal amide hydrochloride|by under which per before|tetracaine|must demonstrate an acceptable level of tetra acid , which is a compound that is formed as the active product ingredients , entity assay , degrade over time .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|lidocaine sodium intrathecal amide hydrochloride|epinephrine diclofenac bupivacaine capsaicin lidocaine|tetracaine|we entered into an agreement with zars pharma for the north american rights to syneratm ( lidocaine 70 mg and entity 70 mg ) topical patch .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|psoriasis fully well accurately completely|lidocaine morphine gabapentin opioids ketamine|pramoxine|current phn treatments are symptomatic , affecting the pain signaling circuit ( such as novocaine , entity , capsaicin , etc . ) , and do not produce lasting control .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|psoriasis fully well accurately completely|hydrochloride succinate acetate sulphate citrate|pramoxine|manufacture had to be obtained by copley before it shipped in interstate commerce and distributed for human use , brompheril , hydrocortisone entity , potassium chloride or procainamide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|psoriasis fully well accurately completely|lidocaine atropine bupivacaine diclofenac epinephrine|pramoxine|preparation h® or similar products for symptomatic relief ( active ingredients can vary by country but generally include glycerin , phenylephrine hcl , entity hcl , and white petrolatum ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|psoriasis fully well accurately completely|capsaicin lidocaine ibuprofen epinephrine caffeine|pramoxine|otc products contain any one of several active ingredients including glycerin , phenylephrine , entity , white petrolatum , shark liver oil and / or witch hazel , for symptomatic relief .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|free thyroxine concentration estradiol peak|also this novartis finally llc|liothyronine|entity , a concordia product , was included in the initial draft .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|free thyroxine concentration estradiol peak|sildenafil pioglitazone etanercept adalimumab minocycline|liothyronine|we believe that due to the fact that the market for entity is small , the manufacture and sale of generic forms of this compound are not economically attractive to potential competitors .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|free thyroxine concentration estradiol peak|diclofenac glycine fluoride lactose penicillin|liothyronine|entity sodium , one of the company  s products , was included in the initial draft .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|free thyroxine concentration estradiol peak|penicillin kanamycin gentamicin diclofenac ampicillin|liothyronine|the company recorded a total impairment charge of $301 , 538 , primarily related to entity sodium - $128 , 191 , fusidic acid -
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|free thyroxine concentration estradiol peak|replace reduce supplement contain deliver|liothyronine|during the second quarter of 2017 , the company also became aware of the anticipated launch of a competitive product to entity sodium .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|free thyroxine concentration estradiol peak|tetracycline erythromycin doxycycline methotrexate penicillin|liothyronine|amcos product portfolio in the united kingdom is its largest and is predominantly comprised of products such as levothyroxine , entity and nitrofurantoin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|free thyroxine concentration estradiol peak|diclofenac warfarin atorvastatin losartan lactose|liothyronine|generic entity sodium tablets are also available from coastal pharmaceuticals , mylan , and sigma pharmaceuticals .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|free thyroxine concentration estradiol peak|diclofenac furosemide warfarin lithium dexamethasone|liothyronine|the remaining decrease of 13% is due to volume declines on key products including entity sodium , prednisolone and nefopam .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|free thyroxine concentration estradiol peak|three four seven tablet lactose|liothyronine|the cma pricing investigation , which commenced in october 2016 , relates to three products , including entity tablets .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|free thyroxine concentration estradiol peak|doxycycline penicillin metronidazole tetracycline ciprofloxacin|liothyronine|concordia international sells products such as entity , nitrofurantoin and levothyroxine within this category of the pharmaceutical market .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|recombinant cell vaginal myeloma anticancer|fsh lh e2 apo estradiol|urofollitropin|entity - this is fsh derived from the urine of postmenopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|recombinant cell vaginal myeloma anticancer|fsh this testosterone metformin oxytocin|urofollitropin|entity is used in research to develop fertility drugs and in basic endocrinology research .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|recombinant cell vaginal myeloma anticancer|exosomes proteins prp antibodies erythrocytes|urofollitropin|sicor currently expects to file a process patent covering purification of entity in early 1997 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|recombinant cell vaginal myeloma anticancer|prp etanercept fviii exosomes bevacizumab|urofollitropin|sicor currently expects to file a process patent covering purification of entity in 1997 and is in discussions with potential partners about marketing the product in the u . s . and europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|drug|recombinant cell vaginal myeloma anticancer|available necessary designed developed expensive|urofollitropin|in order to commercialize therapeutics , initially entity , the company must outsource the manufacturing to a fda-regulated facility .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|recombinant cell vaginal myeloma anticancer|fsh spermatozoa semen thrombin testosterone|urofollitropin|the company  s present product candidates targeted to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|recombinant cell vaginal myeloma anticancer|glycoprotein hsp90 igg peg muc1|urofollitropin|in addition , at its facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|drug|recombinant cell vaginal myeloma anticancer|exosomes ctcs biomarkers estrogens proteins|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post- menopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|recombinant cell vaginal myeloma anticancer|fsh oxytocin melatonin estrogen estradiol|urofollitropin|entity is involved in the stimulation of ovulation and is used in the treatment of certain types of infertility .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|drug|recombinant cell vaginal myeloma anticancer|exosomes ctcs biomarkers estrogens proteins|urofollitropin|sicor is developing a process for the isolation of entity from the urine of post-menopausal women .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|recombinant cell vaginal myeloma anticancer|glycoprotein igg peg albumin hsp90|urofollitropin|in addition , at its santhia facility outside of turin , sicor is developing a glycoprotein , entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|recombinant cell vaginal myeloma anticancer|fsh spermatozoa semen oocytes testosterone|urofollitropin|the company  s present products envisioned to treat infertility include purified entity ( " vitropin ( tm ) " ) for injection .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|xl vs av everolimus commercial|this infliximab etanercept nivolumab sildenafil|eravacycline|we may be unable to develop and commercialize entity or any other product candidate and , even if we do , may never achieve profitability .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|xl vs av everolimus commercial|pharmaceutical these its medicines our|eravacycline|our operations to date have been limited to financing and staffing our company , developing our technology and developing entity and other product candidates .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|xl vs av everolimus commercial|rx tm xl sq fq|eravacycline|the companys commercial product , xerava ( entity ) , a fully synthetic fluorocycline , is an intravenous ( iv ) antibiotic that is approved for use as a first-line empiric monotherapy for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|xl vs av everolimus commercial|technology this bevacizumab medicine everolimus|eravacycline|our current plan is to commercialize entity outside the united states with collaborators .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|xl vs av everolimus commercial|antibiotics vancomycin ciprofloxacin imipenem colistin|eravacycline|xerava was investigated for the treatment of ciai as part of the companys ignite ( investigating gram-negative infections treated with entity )
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|xl vs av everolimus commercial|minocycline tetracycline doxycycline azithromycin tm|eravacycline|the companys lead product candidate , entity , is a fully synthetic tetracycline derivative that the company is developing as a broad-spectrum intravenous and oral antibiotic for use
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|xl vs av everolimus commercial|treatments therapies antibiotics interventions vaccines|eravacycline|tetraphase pharmaceuticals is developing entity for complicated urinary and intra-abdominal infections , as well as pneumonia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|xl vs av everolimus commercial|novartis bevacizumab they infliximab bortezomib|eravacycline|for example , although entity achieved favorable results in the lead-in part of our phase 3 clinical trial in cuti , the pivotal portion of the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|xl vs av everolimus commercial|curcumin zinc iron eggs folate|eravacycline|this may make it difficult for entity to compete with these products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|xl vs av everolimus commercial|infliximab ipilimumab approval fda etanercept|eravacycline|its phase 3 clinical trials ( ignite1 and ignite4 ) would be sufficient to support submission of a new drug application for entity for the treatment of ciai .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|xl vs av everolimus commercial|antibiotics imipenem vancomycin colistin ciprofloxacin|eravacycline|approval of xerava was based on our ignite ( investigating gram-negative infections treated with entity ) phase 3 program .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|xl vs av everolimus commercial|this coverage they insurance reimbursement|eravacycline|moreover , the company does not believe that the statement indicates in any respect that entity covers any or all of these infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|xl vs av everolimus commercial|bevacizumab infliximab adalimumab metformin etanercept|eravacycline|if clinical trials of entity or of any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|xl vs av everolimus commercial|this infliximab etanercept adalimumab bevacizumab|eravacycline|if entity is approved , it may be priced at a significant premium over other competitive products .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|xl vs av everolimus commercial|goods medicines pharmaceuticals material medicine|eravacycline|prior written notice if any governmental agency takes any action that prevents the company from importing , exporting , purchasing or selling entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|xl vs av everolimus commercial|tablets tm xl cro tablet|eravacycline|tetraphase is currently selling xeravatm ( entity ) in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|xl vs av everolimus commercial|colistin imipenem minocycline this infliximab|eravacycline|however , we do not believe these limitations would apply to entity or any of our other investigational antibiotics .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|xl vs av everolimus commercial|this which these that technology|eravacycline|entity , along with the companys proprietary drug discovery platform technology , make tetraphase an exceptional opportunity that i look forward to being
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|xl vs av everolimus commercial|bevacizumab irinotecan docetaxel sunitinib everolimus|eravacycline|case based on our achievement of company goals with respect to the development of the intravenous and oral formulations of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ion nucleoside hydrochloride kinase anticancer|lidocaine bupivacaine epinephrine propofol capsaicin|dyclonine|a bema ( tm ) product containing entity as a local anesthetic prior to dental procedures and for the treatment of canker sores has been consumer tested .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|ion nucleoside hydrochloride kinase anticancer|bio pb glp pbp liquid|dyclonine|mucosal surfaces single claim  layered bioerodable pharmaceutical ( entity only ) carrier device .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir tablets av antiretroviral su|by via vaginal oxytocin intrauterine|atosiban|the safety and pharmacokinetics of obe022 administered to pregnant women , who are receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tenofovir tablets av antiretroviral su|oxytocin antagonist losartan naloxone antagonists|atosiban|these effects were blocked by the oxytocin receptor antagonist , entity , indicating the effects of intranasal oxytocin were mediated by oxytocin receptors .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tenofovir tablets av antiretroviral su|oxytocin ibuprofen dexamethasone nifedipine indomethacin|atosiban|in singleton pregnancies , 12 . 5% of women receiving ebopiprant plus entity delivered within 48 hours compared to 26 . 8% receiving entity only ( or 90% ci : 0 . 39 ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|tenofovir tablets av antiretroviral su|llc corporation gmbh ltd tm|atosiban|ferring pharmaceuticals entity , an oxytocin receptor antagonist , has been used in investigator initiated trials in connection with ivf outside the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir tablets av antiretroviral su|tm pfizer merck celecoxib novartis|atosiban|with respect to obe022 , tractocile ( entity ) is approved to delay preterm birth outside of the united states , and we anticipate potential competition as a single agent ,
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|tenofovir tablets av antiretroviral su|oxytocin naltrexone losartan dexamethasone vasopressin|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tenofovir tablets av antiretroviral su|oxytocin dexamethasone losartan naltrexone indomethacin|atosiban|to exacerbate behavioral changes , entity , an oxytocin antagonist , was administered to the pups by slow intravenous push .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tenofovir tablets av antiretroviral su|metformin ketamine aspirin lidocaine oxytocin|atosiban|two groups were given placebo in place of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|tenofovir tablets av antiretroviral su|oxytocin vaginal intrauterine epidural by|atosiban|the safety and pharmacokinetics of obe022 in pregnant women , who were already receiving standard of care therapy for preterm labor , entity infusion .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|tenofovir tablets av antiretroviral su|oxytocin clonidine vasopressin losartan propranolol|atosiban|entity , an oxytocin antagonist , is available in europe , but was denied regulatory approval in the u . s . the usefulness of these ß2-adrenergic
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate risperidone vehicle sodium everolimus|others 550 novartis v4 thereof|suvorexant|franchises grew · fda approved grastek and ragwitek sublingual allergen extract immunotherapy tablets and accepted filings for v503 and entity
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate risperidone vehicle sodium everolimus|orexin melatonin naltrexone gabapentin saha|suvorexant|these may include the following :  entity , an orexin receptor antagonist , is being developed by merck & co . , inc . for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|succinate risperidone vehicle sodium everolimus|gabapentin clonidine benzodiazepines midazolam melatonin|suvorexant|three of these medicines were filed in the u . s . ( entity for insomnia ; sugammadex for neuromuscular blockade and a combination of ezetimibe and atorvastatin for atherosclerosis ) .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate risperidone vehicle sodium everolimus|sale marketing application market approval|suvorexant|the company is continuing with plans to seek approval for entity in other countries around the world .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|succinate risperidone vehicle sodium everolimus|insomnia pfizer novartis korea acupuncture|suvorexant|· received a complete response letter from the fda regarding the new drug application for entity , mercks investigational medicine for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate risperidone vehicle sodium everolimus|this melatonin they naltrexone these|suvorexant|if approved , entity would be the first in a new class of medicines , called orexin receptor antagonists , for use in patients with insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate risperidone vehicle sodium everolimus|orexin bel naltrexone boc berlin|suvorexant|in august 2014 , merck & co . s dual orexin receptor antagonist , entity , was approved by the fda and is currently marketed under the name belsomra® .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|succinate risperidone vehicle sodium everolimus|opioids benzodiazepines dexmedetomidine morphine levodopa|suvorexant|the effects produced by doras on rem sleep explain the motor effects and other side effects seen with entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate risperidone vehicle sodium everolimus|data this they these substances|suvorexant|entity will be evaluated by the controlled substance staff of the fda during nda review .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|succinate risperidone vehicle sodium everolimus|merck everolimus tm crizotinib lapatinib|suvorexant|for the treatment of advanced melanoma and metastatic nsclc in patients whose disease has progressed after other therapies , and belsomra ( entity ) for the treatment of insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate risperidone vehicle sodium everolimus|marketing gsk novartis bms nivolumab|suvorexant|merck has announced that it plans to file regulatory applications for entity in 2012 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate risperidone vehicle sodium everolimus|pfizer gsk novartis merck xl|suvorexant|merck is marketing belsomra® ( entity ) , which is a dual orexin receptor anatomist indicated for insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate risperidone vehicle sodium everolimus|gsk gabapentin buprenorphine bd pfizer|suvorexant|in august 2014 , merck announced that the fda approved belsomra ( entity ) for the treatment of adults with insomnia who have difficulty falling asleep and / or staying asleep .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|succinate risperidone vehicle sodium everolimus|gabapentin naltrexone sildenafil risperidone pharmacotherapy|suvorexant|seeing significant progress in the pipeline this year , and we expect six major filings over the next 18 months , including entity for insomnia and odanacatib for osteoporosis .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate risperidone vehicle sodium everolimus|tm sr melatonin ox sb|suvorexant|neurosciencebelsomra ( entity ) , an orexin receptor antagonist indicated for the treatment of insomnia , characterized by difficulties with sleep onset and / or sleep maintenance .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate risperidone vehicle sodium everolimus|bortezomib nivolumab bevacizumab bms marketing|suvorexant|both fda approval and a separate scheduling determination by the u . s . drug enforcement administration are required before merck can introduce entity in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate risperidone vehicle sodium everolimus|gabapentin celecoxib minocycline bms ketamine|suvorexant|on may 22 , 2013 , the fdas peripheral and central nervous system drugs advisory committee will meet to discuss the nda for entity ( mk-4305 ) tablets .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate risperidone vehicle sodium everolimus|llc however germany pfizer usa|suvorexant|mk-4305 , entity , is an investigational insomnia medicine in a new class of medicines called orexin receptor antagonists for use in patients with
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab infliximab etanercept minocycline thalidomide|guselkumab|entity is currently being investigated in clinical studies in several indications , including plaque psoriasis , pediatric psoriasis , psoriatic arthritis , crohns disease , hidradenitis
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab infliximab etanercept antibody 223|guselkumab|entity ( tremfya® ) is the first approved antibody binding the p19 subunit of il-23 .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|etanercept infliximab tm adalimumab novartis|guselkumab|in july , subsequent to the quarter , the fda approved tremfya™ ( entity ) for the treatment of adults living with moderate to severe plaque psoriasis .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|infliximab adalimumab etanercept ipilimumab biologics|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand and are specific to the il-23 pathway , which is believed to be
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|infliximab adalimumab biologics mmf etanercept|guselkumab|of morphosys ag , said : we are very pleased that our licensee janssen has further expanded the clinical development program of entity by initiating a clinical study in ulcerative colitis .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|tm etanercept merck infliximab novartis|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosyss proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|etanercept infliximab adalimumab rituximab nivolumab|guselkumab|to the same period a year ago driven by strong uptake of stelara® ( ustekinumab ) and the u . s . launch of tremfya® ( entity ) .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|bevacizumab sunitinib antibody vegf thalidomide|these this all individual such|guselkumab|more information about entity clinical studies is available on clinicaltrials . gov .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab infliximab etanercept thalidomide minocycline|guselkumab|moreover , entity is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2 / 3 clinical study program in crohns disease .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|cetuximab adalimumab etanercept antibody bevacizumab|guselkumab|entity ( tremfya ® ) overview guselkumab ( tremfya ® ) is a human hucal antibody targeting the p 19 subunit of il - 23 that is being
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|infliximab etanercept adalimumab tm rituximab|guselkumab|in july 2018 , morphosys announced that its licensee , janssen , initiated a clinical development program with tremfya® ( entity ) in crohns disease .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|infliximab adalimumab etanercept ipilimumab biologics|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il‑23 ligand and are specific to the il‑23 pathway , which is believed to be
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|etanercept infliximab adalimumab tm novartis|guselkumab|the european commission approved tremfya® ( entity ) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab etanercept infliximab bevacizumab monotherapy|guselkumab|entity is currently approved in the eu for the treatment of moderate to severe plaque psoriasis in adults who are candidates
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|etanercept infliximab adalimumab rituximab nivolumab|guselkumab|in november 2017 , the eu commission granted european approval of entity ( tremfya® ) for the treatment of patients with moderate-to-severe plaque psoriasis .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|tm etanercept infliximab merck rituximab|guselkumab|in 2017 , tremfya® ( entity ) , marketed by janssen , became the first therapeutic antibody based on morphosys  s proprietary technology to receive marketing approval for the treatment
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab etanercept infliximab this thalidomide|guselkumab|entity is currently being investigated in clinical studies in several indications , including additional studies in plaque psoriasis , pediatric psoriasis , psoriatic arthritis ,
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|bevacizumab sunitinib antibody vegf thalidomide|adalimumab infliximab etanercept ipilimumab biologics|guselkumab|next-generation ibd antibody drugs , such as entity , target the p19 subunit of the il-23 ligand to confer specificity for the il-23 pathway that is believed to be
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|peptide doxorubicin sunitinib liposome hydrochloride|none this everyone all registration|triptorelin|entity is in pre-registration in the united states .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|peptide doxorubicin sunitinib liposome hydrochloride|testosterone estrogen estradiol microspheres dexamethasone|triptorelin|two additional agents are also currently marketed , trelstar by watson , delivers entity , and zoladex marketed by astrazeneca , a biodegradable rod , that contains goserelin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|peptide doxorubicin sunitinib liposome hydrochloride|everolimus bevacizumab gabapentin capecitabine erlotinib|triptorelin|in addition , in europe or certain other parts of the world , entity ( debiopharm s . a . ) and buserelin ( hoechst marion roussel , inc . ) are also approved and being marketed .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|peptide doxorubicin sunitinib liposome hydrochloride|dexamethasone 1m metformin zero rosiglitazone|triptorelin|women were randomized to one of four mvt-602 dose groups ( 0 . 1 µg , 0 . 3 µg , 1 µg or 3 µg ) , to entity , 0 . 2 mg , or to placebo .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|peptide doxorubicin sunitinib liposome hydrochloride|testosterone gnrh also estradiol recently|triptorelin|entity marketed as trelstar® ( watson pharmaceuticals ) and marketed as decapeptyl® ( ipsen ) is also a lhrh agonist .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|capecitabine irinotecan bevacizumab erlotinib gemcitabine|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|bevacizumab capecitabine irinotecan gemcitabine erlotinib|rasburicase|dr . bizzari was the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of oxaliplatin , docetaxel and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|tuber mang biomass strain bark|bayer novartis roche tm merck|rasburicase|a specific r&d effort has already culminated in the launch of fasturtec® ( entity ) in 2001 , for prevention of the increase in blood uric acid levels during chemotherapy of acute leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|capecitabine irinotecan erlotinib gemcitabine bevacizumab|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|capecitabine irinotecan erlotinib gemcitabine bevacizumab|rasburicase|for sanofi-aventis ( formerly rhône-poulenc , rhône-poulenc rorer and aventis ) where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|capecitabine irinotecan gemcitabine erlotinib bevacizumab|rasburicase|the vice president , clinical oncology development for sanofi-aventis where he oversaw the approval of eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) and elitek® ( entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|tuber mang biomass strain bark|capecitabine irinotecan bevacizumab erlotinib gemcitabine|rasburicase|in that role , he had key product sales responsibility for eloxatin® ( oxaliplatin ) , taxotere® ( docetaxel ) , anzemet® ( dolasetron mesylate ) , and elitek® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|sodium clopidogrel magnesium lithium nicotine|clopidogrel|to $5 . 3 billion in 2007 compared to 2006 due to loss of exclusivity of pravachol and the impact of generic entity bisulfate , partially offset by growth in other key products .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel atorvastatin tenofovir prednisolone sodium|clopidogrel|filed a revocation action before the scottish court of session seeking to invalidate the sanofi-aventis patent in the uk claiming entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|sodium lithium potassium oxalate magnesium|clopidogrel|apotex filed a notice of appeal appealing the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|ims all this its each|clopidogrel|growth in total prescriptions ( trx ) of entity 82 table of contents bisulfate remained strong , at 11 . 8% ( ims npa 3 channels  q4 2006 ) in the fourth
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|this combination dasatinib warfarin simvastatin|clopidogrel|however , the presence of less common cyp2c10 non-functional alleles or variation in other genes may negatively impact the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel by entitled aspirin from|clopidogrel|drug interactions medco health solutions inc . robert epstein , said it is an example of the " law of unintended consequences " entity ( plavix ( r ) )
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|aspirin ppi clopidogrel simvastatin versus|clopidogrel|medco outcomes study entity alone 0 . 18 entity+ppi 0 . 25 relative risk 1 . 50 ( 1 . 39-1 . 62 ) podium-presented at american heart association 11 / 11 / 08 *
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel aspirin warfarin anticoagulants asa|clopidogrel|however , this is confounded by the fda warning against the use of certain ppis , such as omeprazole , with entity ( plavix ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|irinotecan sunitinib capecitabine midazolam warfarin|clopidogrel|o comment : entity is expected to be converted efficiently to its active metabolite in patients with this genotype .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|sodium lithium clopidogrel atorvastatin trimethoprim|clopidogrel|on august 12 , 2008 , the federal court of australia held that claims of patent no . 597784 covering entity bisulfate , hydrochloride , hydrobromide , and taurocholate salts were valid .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel formulation thrombolysis solution anticoagulation|clopidogrel|captisol-enabled intravenous entity is an intravenous formulation of the anti-platelet medication designed for situations where the administration of oral platelet inhibitors is not
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|pla clopidogrel ppc cp mps|clopidogrel|plavix® / iscover® plavix® ( entity ) , a platelet adenosine diphosphate ( adp ) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|sodium lithium potassium oxalate magnesium|clopidogrel|genrx-apotex appealed the holding of validity of the entity bisulfate , hydrochloride , hydrobromide , and taurocholate claims .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel this ppi combination cyp2c19|clopidogrel|the presence of less common cyp2c19 alleles or variations in other genes may additionally enhance or reduce the efficacy of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel aspirin atorvastatin pci reference|clopidogrel|stent thrombosis at 48 hours had been met , as cangrelor demonstrated statistically significant improvement for this endpoint as compared to entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|ginseng water gentamicin minocycline ciprofloxacin|clopidogrel|the federal court also held that the process claims , pharmaceutical composition claims , and claim directed to entity and its pharmaceutically acceptable salts were invalid .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|midazolam celecoxib dexamethasone vehicle ibuprofen|clopidogrel|when pa32540 and entity were dosed 10 hours apart , data from the study indicate no ex-vivo drug-drug interaction based on the study  s pre-specified primary analysis .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|sodium clopidogrel ethyl lithium magnesium|clopidogrel|and the minister of health in response to a notice of allegation from apotex directed against canadian patent 1 , 336 , 777 covering entity bisulfate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel aspirin warfarin simvastatin capecitabine|clopidogrel|us launch of tacrolimus ( prograf® ) ; and the launches in various european countries of pantoprazole ( marketed in the us as protonix® ) , entity ( plavix® ) , and esomeprazole ( nexium® ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|clopidogrel aspirin antiplatelet versus prophylactic|clopidogrel warfarin pla antiplatelet aspirin|clopidogrel|according to present plans , all patients will receive background treatment including heparin , aspirin and entity ( plavix® ) , if not contraindicated .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|included containing vaginal ciprofloxacin plus|penicillin amoxicillin ampicillin gentamicin antibiotics|cefadroxil|crude bulk drugs of the cephalosporin division and cefalexin and entity of the penicillin division were new products the company introduced during the six-month period of 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone ampicillin amoxicillin penicillin gentamicin|cefadroxil|cefalexin and entity are penicillin g downstream products that are widely used to treat urinary tract infections , respiratory tract , skin and soft tissue
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|included containing vaginal ciprofloxacin plus|buprenorphine opioids morphine naltrexone methadone|cefadroxil|the increase was lead by increases in market share for medroxyprogesterone , naltrexone , danazol and sales of entity , which the company launched in june 1999 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|included containing vaginal ciprofloxacin plus|thalidomide cyclosporine cyclophosphamide methotrexate tamoxifen|cefadroxil|the increase was led by higher sales of warfarin sodium , naltrexone , medroxyprogesterone , danazol , entity and hydroxyurea .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|included containing vaginal ciprofloxacin plus|lactose fumarate magnesium mannitol fructose|cefadroxil|for sake of clarity and avoidance of doubt , " product " does not include any non-oral suspension forms or formulations of duricef ( r ) ( entity monohydrate ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone ciprofloxacin penicillin amoxicillin cef|cefadroxil|cefzil* cefprozil , an oral cephalosporin used in the treatment of respiratory infections and sinusitis duricef* entity , an oral cephalosporin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone penicillin antibiotic amoxicillin ciprofloxacin|cefadroxil|offset by the decrease in gross margins in cephalosporin crude bulk drugs , cephalosporin formulation drugs as well as cefalexin and entity divisional revenues and gross margin analysis
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|included containing vaginal ciprofloxacin plus|doxycycline azithromycin this minocycline amoxicillin|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|included containing vaginal ciprofloxacin plus|bulk surface antibiotic deep foam|cefadroxil|% 9 . 94 % cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|included containing vaginal ciprofloxacin plus|doxycycline azithromycin this minocycline amoxicillin|cefadroxil|entity is for use to treat strep throat , skin and urinaru tract infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|included containing vaginal ciprofloxacin plus|bevacizumab infliximab sildenafil etanercept nivolumab|cefadroxil|although ivax remains the only fda approved generic manufacturer of entity , the company marketing the brand name version of this drug is marketing its own generic form of this product .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|included containing vaginal ciprofloxacin plus|pharmaceuticals infliximab sildenafil etanercept azithromycin|cefadroxil|net revenues attributable to sales of entity , approved in march 1996 , were $17 . 1 million in the 1996 second quarter .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|included containing vaginal ciprofloxacin plus|bulk surface antibiotic deep foam|cefadroxil|% 9 . 94% cefalexin / entity sterilized bulk drug / bulk cephalexin is used in treating urinary tract infections , repiratory tract infections , skin and soft tissue infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone azithromycin amoxicillin ciprofloxacin penicillin|cefadroxil|sales for the cefalexin and entity for the first quarter of 2010 were approximately 3% lower than the same period in 2009 , because of a 4%
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone penicillin amoxicillin ampicillin gentamicin|cefadroxil|the penicillin division currently operates the production and sales of clavulanic acid , cefalexin and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|included containing vaginal ciprofloxacin plus|ceftriaxone ciprofloxacin penicillin azithromycin amoxicillin|cefadroxil|cefalexin and entity were launched and included in the companys product portfolio only at the beginning of 2008 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|docetaxel everolimus tamoxifen bevacizumab lapatinib|alpelisib|qd : once daily 111 table of contents we also assessed the anti-tumor activity of zn-c5 , alongside fulvestrant and entity , in each case as monotherapy , in preclinical models .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sunitinib everolimus bevacizumab malate kinase|formerly pfizer merck everolimus recently|alpelisib|• byl719 ( entity , approved in the us as piqray ) is an orally bioavailable , alpha-specific pi3k inhibitor approved in combination with fulvestrant for the
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sunitinib everolimus bevacizumab malate kinase|tm everolimus tnbc trastuzumab simvastatin|alpelisib|· byl719 ( entity ) phase iii solar-1 trial data presented at esmo showed byl719 plus fulvestrant nearly doubles median progression free survival in patients with
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|pivotal prime neoadjuvant tnbc pfs|alpelisib|· byl719 ( entity ) solar-1 trial of the investigational alpha-specific inhibitor byl719 in combination with fulvestrant met its primary endpoint showing an improvement in
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sunitinib everolimus bevacizumab malate kinase|tm erlotinib merck pfizer everolimus|alpelisib| byl719 ( entity ) is an orally bioavailable , alpha isoform-specific pi3k inhibitor .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sunitinib everolimus bevacizumab malate kinase|gsk novartis pi3k pfizer company|alpelisib|·entity ( byl719 ) is on track for a us submission in pik3ca-related overgrowth spectrum ( pros ) in 2021 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|everolimus erlotinib ly294002 pi3k bevacizumab|alpelisib|% of pi3k mutated late stage breast cancer patients achieved an objective response in a phase iii clinical trial with entity , a recently approved pi3k inhibitor .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|sunitinib everolimus bevacizumab malate kinase|rituximab ipilimumab thalidomide etanercept bevacizumab|alpelisib|therapy in this population , including ibrance , kisqali , afinitor , verzenio , and other therapies currently in phase 3 clinical development such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|everolimus ly294002 erlotinib bevacizumab pi3k|alpelisib|biomedical research , inc . , or novartis , to evaluate the combination of op-1250 and novartis ribociclib , a cdk4 / 6 inhibitor , as well as entity , their pi3kα inhibitor .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|sunitinib everolimus bevacizumab malate kinase|tamoxifen docetaxel e2 everolimus doxorubicin|alpelisib|we also observed that the combination of zn-c5 and entity had more potent anti-tumor activity than the combination therapy using 3 mg / dose of fulvestrant and 50 mg / kg of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|docetaxel capecitabine bevacizumab trastuzumab tamoxifen|alpelisib|zn-c5 and fulvestrant were also assessed in combination with entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|everolimus erlotinib lapatinib bevacizumab gefitinib|alpelisib|more recently piqray® ( entity ) , an inhibitor of the alpha isoform phosphatidylinositol-3-kinase , became the first agent approved for use in a specific subpopulation of hr+
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sunitinib everolimus bevacizumab malate kinase|lapatinib gefitinib trastuzumab merck pfizer|alpelisib|about piqray® ( entity ) piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women , and men , with hr+ / her2- ,
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|doxorubicin docetaxel cyclophosphamide carboplatin gemcitabine|alpelisib|even greater anti-tumor activity was observed with the combination of 1 mg / kg of zn-c5 and 50 mg / kg of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sunitinib everolimus bevacizumab malate kinase|everolimus erlotinib bevacizumab pi3k crizotinib|alpelisib|fulvestrant used in combination with entity , an oral pi3k inhibitor marketed as piqray® by novartis approved by the fda in may 2019 , has demonstrated improved clinical
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|drug|sunitinib everolimus bevacizumab malate kinase|glioblastoma glioma melanoma bevacizumab nsclc|alpelisib|approved may 2019 ( breast cancer ) [ accelerated approval ] limited toxicities to date does not cross blood-brain barrier ü û ü piqray ( entity )
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|everolimus erlotinib bevacizumab ly294002 pi3k|alpelisib|entity , marketed as piqray® by novartis , is the only fda-approved inhibitor for cancers with mutated pi3kα .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sunitinib everolimus bevacizumab malate kinase|bevacizumab sunitinib irinotecan nivolumab oxaliplatin|alpelisib|the study showed that entity added toxicity with only marginal additional activity , therefore the beacon crc trial will replace it with binimetinib in the triplet
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|sunitinib everolimus bevacizumab malate kinase|ly294002 everolimus erlotinib bevacizumab gefitinib|alpelisib|in contrast , entity and gdc-0077 ( an orthosteric pi3kα inhibitor currently in development ) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|sunitinib everolimus bevacizumab malate kinase|pi3k bevacizumab dasatinib crizotinib pten|alpelisib|while these factors limit the clinical utility of entity , these data nonetheless establish mutant pi3kα as a clinically validated target in breast cancer .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|bevacizumab nivolumab infliximab adalimumab sildenafil|omadacycline|to depend on independent clinical investigators and cros to conduct our clinical trials , including our planned phase 3 trials of entity in absssi .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|this funding project novartis which|omadacycline|entity is ready to advance into phase 3 , the final stage of clinical development .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|minocycline methotrexate tacrolimus infliximab adalimumab|omadacycline|entity ( paratek pharmaceuticals ) and lefamulin ( nabriva therapeutics ) , and dalafloxcacin ( melinta ) all are expected to be pursued as a possible treatment for
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|amd ms osa epilepsy diabetes|omadacycline|in hong kong and three pending patent applications in taiwan , respectively that relate to different methods of treatment related to entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|novartis pfizer pharmaceuticals everolimus gsk|omadacycline|under the novartis agreement , novartis was to have led development activities for entity , and the company was to have co-developed and contributed a share of the development expense .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|they azithromycin ciprofloxacin this ceftriaxone|omadacycline|if approved by the fda , entity will also compete with other antibiotics in the community-acquired pneumonia market .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|melanoma amd cf uc gbm|omadacycline|payment of $50 , 000 to tufts for achieving the first milestone following commencement of the phase 3 non-registration clinical trial for entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|approval fda its this them|omadacycline|this prsu was awarded under the 2015 plan and vests upon fda approval of entity , and shall , upon achievement of the milestone , be eligible to vest as to 100% of the prsus subject to the
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|minocycline vancomycin colistin doxycycline ceftriaxone|omadacycline|our success is currently dependent on the successful development and commercialization of our most advanced product candidates , entity and sarecycline .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|potential fda possible proposed promising|omadacycline|to working with the fda as it considers the comments from the committee members and completes its review of the entity new drug applications .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|bevacizumab tmz nivolumab dasatinib gabapentin|omadacycline|in all three studies , entity met all primary and secondary efficacy outcomes designated by the fda and was generally safe and well-tolerated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|etanercept rituximab adalimumab minocycline bevacizumab|omadacycline|in addition , achaogen , inc . developed and gained approval for plazomicin and paratek pharmaceuticals , inc . developed and gained approval for entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|funding industry www this none|omadacycline|to obtain a return on the investments we have made in our or any of our partners product candidates , including entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|cure abortion medicine justice adherence|omadacycline|“crude entity” has the meaning set forth in the recitals hereto .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|this that they these tdcs|omadacycline|we believe entity , if approved , will be used in the emergency room , hospital and community care settings .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|vancomycin colistin minocycline doxycycline ceftriaxone|omadacycline|if entity and sarecycline are not successfully developed and commercialized , we will not have any product candidates under development from which we
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|minocycline azithromycin adalimumab infliximab vancomycin|omadacycline|under our spa agreement , we plan to commence a pivotal registration program including two phase 3 registration trials of entity for the treatment of absssi in the second half of 2012 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|prof www novartis ltd viz|omadacycline|substantial additional funding in connection with the companys continuing operations to support commercial activities associated with its lead product candidate , entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|minocycline vancomycin doxycycline colistin azithromycin|omadacycline|our two lead antibacterial product candidates are entity and sarecycline .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|hydrochloride metabolite backbone antimalarial antiretroviral|olanzapine metformin erlotinib atorvastatin fluconazole|omadacycline|for oral therapy , patients randomized to entity received 200 mg of entity ( dosed as two 100 mg capsules ) every 24 hours .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|tobacco cannabis marijuana nicotine cigarettes|tamoxifen|increased product sales were due mainly to the introduction of fluoxetine in august 2001 , as well as , increased sales of entity and other products .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|tamoxifen sildenafil sodium estradiol testosterone|tamoxifen|soltamox ( entity citrate ) oral solution , our first proprietary , fda approved product , is a drug primarily used to treat breast cancer .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|brachytherapy tamoxifen hormones androgens testosterone|tamoxifen|external beam radiation and entity are both used to treat gynecomastia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|sodium magnesium potassium lithium sildenafil|tamoxifen|the company acquired exclusive u . s . marketing rights to its &#160 ; first commercial , fda-approved proprietary product license &#160 ; soltamox&#174 ; ( entity citrate ) oral solution .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|tamoxifen docetaxel soc capecitabine nvp|tamoxifen|femara is generally well tolerated and adverse reactions rates in the first-line study in which femara was compared to entity were similar with those seen in second-line studies .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|sildenafil sodium lithium citrate magnesium|tamoxifen|the alamo sales team , in addition to promoting our products soltamox ( entity citrate ) and gelclair , also promotes two mission products : ferralet® 90 , and aquoral® .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|this endocrine hormone tamoxifen trastuzumab|tamoxifen|entity therapy is currently indicated by the fda for breast cancer patients for five years .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|sildenafil testosterone naltrexone melatonin oxytocin|tamoxifen|nevertheless , we believe that soltamox being the first and only liquid form of entity to successfully make some in roads in to that market .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|tamoxifen hrt estrogen metformin estrogens|tamoxifen|during 2001 , we announced the issuance of an u . s . patent on the use of our anti-estrogen compound in combination with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|brachytherapy mastectomy lymphadenectomy dcis reconstruction|tamoxifen|a dcis score result , to help guide treatment decision-making in women with dcis treated by local excision , with or without entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|licensing insurance state grant regulatory|tamoxifen|we maintain $20 million of product liability insurance and have an indemnification provision in our entity agreement .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|commercial marketed new experimental own|tamoxifen|us revenues for nolvadex fell 27% to $337 million , as sales of our entity products fell as a result of the expiry of our distribution agreement with barr laboratories .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|methotrexate thalidomide cyclosporine minocycline interferon|tamoxifen|however , a number of medical therapies have been used to treat peyronies including vitamin e , colchicine , potassium aminobenzoate ( potaba ) , entity , interferon a2a and corticosteroids .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|hormone tamoxifen adjuvant endocrine estrogen|tamoxifen|women were assessed for risk of developing breast cancer using the brevagen test to determine eligibility for five years of entity therapy .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|pharmacy commercial sales medicaid tobacco|tamoxifen|entity sales increased 56% from $145 , 161 to $226 , 749 .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|clopidogrel others aspirin titanium pioglitazone|tamoxifen|due to its proven superiority over entity , it has won category leadership in france , spain , belgium , mexico , switzerland and australia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|bevacizumab sunitinib gemcitabine nivolumab docetaxel|tamoxifen|treatment was stopped due to toxicities in three patients in the everolimus plus entity arm and in four patients in the entity-only arm .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|therapeutic chemotherapeutic potential adjuvant biomarker|tamoxifen|oncotype dx predicts likelihood of recurrence because it predicts both prognosis and entity benefit .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|were they cases them individuals|tamoxifen|the plaintiff in this action , however , asserts that the companys alleged misclassification of entity improperly denied plan benefits and breached an alleged fiduciary duty under erisa .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|tamoxifen adjuvant combined hormone neoadjuvant|tamoxifen estradiol testosterone estrogen e2|tamoxifen|entity , the most commonly used serm treatment for breast cancer , also inhibits this action by estradiol , but with less affinity for
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|this furosemide losartan metformin pioglitazone|lesinurad|entity is a selective inhibitor of urat1 , a transporter in the proximal tubule cells of the kidney that regulates uric acid
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|tz cz ez xl bz|lesinurad|about zurampic ( entity ) 200mg tablets zurampic ( entity ) works in combination with xanthine oxidase inhibitors ( xois ) to treat hyperuricemia associated with uncontrolled gout .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|first liver planned therapeutic emergency|lesinurad|closing of the entity transaction is subject to the expiration or termination of the waiting period under the hart-scott-rodino antitrust improvements act of 1976 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|all new from each whole|lesinurad|the write-down was recorded as write-down of entity commercial supply to net realizable value in the companys condensed consolidated statement of operations .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|market business trade industry driver|lesinurad|to $140 million ) , and · amortization of intangible assets to be $8 million ( not applicable prior to the u . s . entity license ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|psoriasis everolimus myeloma ataxia ja|fluconazole rifampicin chloroquine cyclosporine atorvastatin|lesinurad|astrazeneca entered into a licensing agreement with ironwood pharmaceuticals for the exclusive us rights to zurampic and the fixed-dose combination of entity and allopurinol .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|psoriasis everolimus myeloma ataxia ja|lam nivolumab sunitinib dasatinib this|lesinurad|however , entity , like all other ults , has been shown to increase flares upon initiation of treatment .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|metformin this furosemide pioglitazone losartan|lesinurad|entity is an oral inhibitor of urat1 , which is the transporter that mediates reuptake of uric acid from the proximal tubules of the kidney and drives renal elimination of uric acid .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|psoriasis everolimus myeloma ataxia ja|this nivolumab dasatinib erlotinib bevacizumab|lesinurad|entity is a drug in phase 3 development by astrazeneca plc .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|psoriasis everolimus myeloma ataxia ja|sildenafil compounds metformin dasatinib tablets|lesinurad|we are developing entity to be used as both monotherapy and in combination with drugs like allopurinol and febuxostat to treat the large number
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|furosemide metformin pioglitazone colchicine rosiglitazone|lesinurad|for patients who require more control or who are contraindicated , the uricosuric agent , entity , may be prescribed .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|this new another that single|lesinurad|entity entity , our most advanced product candidate , previously called rdea594 , is an inhibitor of urat1 , a transporter in the kidney that regulates uric acid excretion from the body .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|tested commercial tobacco experimental three|lesinurad|we calculated gross product revenue based on the wholesale acquisition cost that we charged our distributors for the entity products .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|psoriasis everolimus myeloma ataxia ja|metformin colchicine pioglitazone methotrexate sildenafil|lesinurad|entity has been shown to normalize the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|rituximab adalimumab etanercept infliximab ipilimumab|lesinurad|these drugs are entity , sifalimumab , anifrolumab , mavrilimumab and brodalumab .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|psoriasis everolimus myeloma ataxia ja|irinotecan sunitinib capecitabine dexamethasone bevacizumab|lesinurad|entity carries a black box warning associated with renal toxicity and is contraindicated in patients with renal impairment .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|psoriasis everolimus myeloma ataxia ja|new us original cambridge uk|lesinurad|january 2007 , as amended , for our cambridge , massachusetts corporate headquarters and a reduction in reimbursement obligations to astrazeneca under the entity license .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|metformin this losartan pioglitazone gout|lesinurad|entity normalizes the amount of uric acid excreted by gout patients .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|psoriasis everolimus myeloma ataxia ja|which this that metformin sildenafil|lesinurad|entity is being studied as an add-on treatment to allopurinol patients not reaching target sua levels , as an add-on to febuxostat
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|psoriasis everolimus myeloma ataxia ja|fluconazole simvastatin atorvastatin methotrexate cyclosporine|lesinurad|the combination of entity and allopurinol has been generally well tolerated in the ongoing extension portion of study 203 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|hydrochloride base containing antihypertensive diuretic|metronidazole ibuprofen celecoxib gabapentin fluoxetine|prucalopride|compared to the group receiving entity ( an fda approved drug for the treatment of chronic idiopathic constipation ) , the pcs12852 dose groups showed higher stool frequency for
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|hydrochloride base containing antihypertensive diuretic|metronidazole this sildenafil gabapentin fmt|prucalopride|entity has been approved for commercialization in certain european countries for the treatment of chronic constipation in women but has not yet been launched .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|hydrochloride base containing antihypertensive diuretic|dmd psoriasis etanercept ms novartis|prucalopride|shire has discussed with the fda the requirements for filing an nda for entity and is currently working towards fulfilling those requirements in anticipation of an nda submission .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|hydrochloride base containing antihypertensive diuretic|this market adalimumab etanercept technology|prucalopride|entity was launched in several european markets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|males females us uk usa|prucalopride|phase 3 globally global ( excluding italy and latin america ) resolor ( entity ) chronic constipation ( males ) phase 3 in eu europe spd 556 ( m0002 )
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride base containing antihypertensive diuretic|treatments applications therapies tablets apps|prucalopride|shire intends to develop entity in the united states for cc .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hydrochloride base containing antihypertensive diuretic|others probiotics peg ibuprofen fmt|prucalopride|alan has played a major role in development of gastroenterology products such as motilium® and entity and has considerable experience and knowledge of the gastrointestinal ( gi ) space .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|market trade markets sale purchase|prucalopride|johnson & johnson has rights to entity in north american and certain european countries and we expect entity to provide competition in markets around the world .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|hydrochloride base containing antihypertensive diuretic|tm etanercept minocycline novartis mmf|prucalopride|shire plc obtained approval of motegrity™ ( entity ) in the u . s . for the treatment of cic in adults in december 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride base containing antihypertensive diuretic|gabapentin ketamine acupuncture morphine celecoxib|prucalopride|sloots ej , et al . efficacy and safety of entity in patients with chronic non-cancer pain suffering from oic .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|applications application technology software services|prucalopride|movetis was acquired by shire in september 2010 , which intends to develop entity in the u . s . for cc .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|derived obtained released available produced|prucalopride|another prokinetic compound in development in europe , with the potential for commercialization in the united states and asia , is entity from movetis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|hydrochloride base containing antihypertensive diuretic|tablets sc tm pharmaceuticals infliximab|prucalopride|shire has recently announced it acquired rights to develop and commercialize entity in the u . s . for the cc indication .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|this project recruitment ict epic|prucalopride|entity was launched in germany in january 2010 , in the u . k . in march 2010 and in belgium in september 2010 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hydrochloride base containing antihypertensive diuretic|metronidazole celecoxib ibuprofen indomethacin ciprofloxacin|prucalopride|pcs12852 increased stool frequency with faster onset when compared to entity , an fda approved drug for the treatment of chronic idiopathic constipation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|others peg both similar pfizer|prucalopride|a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|others both peg similar pfizer|prucalopride|held a number of leadership positions within johnson & johnson focusing on development of gastroenterology products including propulsid® , motilium® , aciphex® and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|hydrochloride base containing antihypertensive diuretic|fmt gabapentin probiotics naloxone sildenafil|prucalopride|janssen belgium exclusive license agreement to develop and market entity as a treatment for chronic constipation in the u . s . motegrity , approved in december 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|hydrochloride base containing antihypertensive diuretic|probiotics sildenafil metformin fmt curcumin|prucalopride|trials are on-going in europe testing entity in the treatment of chronic constipation in men .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|hydrochloride base containing antihypertensive diuretic|13 rd 18 11 2013|prucalopride|the most recent entrant to the cc marketplace , solely in europe , is resolor ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|new proposed future final us|polidocanol|additional manufacturing information and documentation is also being prepared by kreussler for submission to the fda to support the entity nda .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 2), ('DIS', 1)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|propofol lidocaine ketamine fentanyl bupivacaine|polidocanol|in contrast , aethoxysklerol contains entity , a chemical with anesthetic properties , which we believe may be one of the key advantages of aethoxysklerol .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|fda final submitted approval first|polidocanol|entity nda submission and review  in july 2009 , bioform medicals partner , chemische fabrik kreussler & co . gmbh ( kreussler ) , submitted
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|pharmaceuticals biologics infliximab vaccines medicines|polidocanol|the $0 . 7 million milestone payment pursuant to our agreement with kreussler for exclusive united states licensing and distribution rights of entity .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|marketed registered medicinal experimental potential|polidocanol|the definition of product ( s ) may be amended from time to time to include additional entity product ( s ) in accordance with article ii ( b ) .
OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|methotrexate doxorubicin cyclosporine vincristine antiretroviral|bevacizumab silicone etanercept bleomycin prp|polidocanol|our partner , kreussler , is also making good progress in the nda review of entity , our future sclerotherapy product .  31 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|succinate sodium hydrochloride nifedipine vaginal|diclofenac nicotinic dexamethasone losartan cyclosporine|nedocromil|brannan jd , anderson sd , freed r , leuppi jd , koskela h , chan h-k . entity sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|succinate sodium hydrochloride nifedipine vaginal|diclofenac sodium fluorescein potassium lithium|nedocromil|the basic chemical patents for sodium cromoglycate have already expired , and such patents for entity sodium expire principally between 1998 and 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate sodium hydrochloride nifedipine vaginal|diclofenac mannitol its lactose fluorescein|nedocromil|“bulk form” means cromolyn sodium micronized stage 9 ( the “intal bulk form” ) and entity sodium dried stage 11 ( the “tilade bulk form” ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|backbone antiretroviral containing boosted combination|tm ec eng tec env|etravirine|during 2008 , the company received regulatory approval in the u . s . , canada and european union for intelencetm ( entity ) for hiv combination therapy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|backbone antiretroviral containing boosted combination|etanercept lamivudine ribavirin adalimumab rituximab|etravirine|while at johnson & johnson , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|backbone antiretroviral containing boosted combination|llc however usa ltd germany|etravirine|tibotecs drug , entity , received fda marketing approval in early 2008 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|backbone antiretroviral containing boosted combination|tm azt gsk novartis eng|etravirine|in january 2008 , the company received accelerated approval from the u . s . food and drug administration ( fda ) for intelence ( entity ) tablets , an anti-hiv medication .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|backbone antiretroviral containing boosted combination|etanercept lamivudine ribavirin adalimumab rituximab|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|backbone antiretroviral containing boosted combination|etanercept lamivudine ribavirin adalimumab rituximab|etravirine|while at j&j , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|backbone antiretroviral containing boosted combination|lamivudine tenofovir ribavirin integrase azt|etravirine|two new drugs , intelence ( entity ) and prezista ( darunavir ) from tibotec therapeutics , a division of ortho biotech products , l . p . , are included in the revised drug resistance
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|backbone antiretroviral containing boosted combination|etanercept lamivudine ribavirin adalimumab rituximab|etravirine|in this role , ms . mchugh oversaw the development and launches of several products , including remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|backbone antiretroviral containing boosted combination|etanercept lamivudine ribavirin adalimumab rituximab|etravirine|the development and launches of several products , including page 1 of 3 remicade® ( infliximab ) , prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|backbone antiretroviral containing boosted combination|lamivudine tenofovir ribavirin integrase ccr5|etravirine|company group chairman for johnson & johnsons worldwide virology business unit , where she oversaw the launches of prezista® ( darunavir ) and intelence® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate cyclosporine hydrochloride sodium ultraviolet|intramuscular subcutaneous lipid therapeutic injectable|dimercaprol|bal in oil is a therapeutic entity injection used to treat arsenic , gold and mercury poisoning .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|polyphenols extracts anthocyanins antioxidants flavonoids|galantamine|reminyl was launched using natural entity extracted from daffodil bulbs .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|acetylcholine acetylcholinesterase choline levodopa simvastatin|galantamine|related to ad , patients with ad are prescribed drugs for enhancing their cognition , and include acetylcholinesterase inhibitors such as , donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|both these all risperidone novartis|galantamine|entity ir tablets are the ab-rated generic versions of ortho-mcneil and janssen&#8217 ; s razadyne &#174 ; , which had annual sales of approximately
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|brand own naltrexone price prescribed|galantamine|successful in their allegations of patent infringement , barr could be required to pay damages relating to the sale of its entity ir tablets .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|also others treatments recently possibly|galantamine|he contributed to the clinical development of currently marketed drugs in epilepsy ( topiramate and levetiracetam ) and entity in alzheimers .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|minocycline simvastatin ketamine melatonin lithium|galantamine|seeking a declaration to nullify the supplementary protection certificate ( " spc " ) for ep 236684 ( the patent that claims the use of entity for the treatment of alzheimer  s disease ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|atorvastatin simvastatin minocycline dexamethasone aspart|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimers drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|tdcs ivig probiotics cbt tms|galantamine|deemed to include all parents licensed to shire or its affiliates in the territory in respect of the use of entity for cfs ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|olanzapine estradiol risperidone fluoxetine bid|galantamine|in october 2008 , barr commenced sales of its 8 mg , 16 mg and 24 mg entity extended release ( er ) capsules .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|levodopa simvastatin acetylcholine choline dexamethasone|galantamine|other drugs commonly used to treat ad , such as donepezil and entity , inhibit acetylcholinesterase but not butyrylcholinesterase .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|acetylcholine acetylcholinesterase choline levodopa simvastatin|galantamine|treatments for ad patients are only indicated for enhancing cognition in ad patients , and include acetylcholinesterase inhibitors such as donepezil , entity , rivastigmine and memantine .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|etanercept bevacizumab adalimumab infliximab sildenafil|galantamine|the first european application for marketing of entity was submitted in march 1999 ; subsequently , various other applications have been made .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|simvastatin atorvastatin minocycline dexamethasone gabapentin|galantamine|the new drugs were new drug types such as the antimalarial arteether , echinocandin- derived antifungal caspofungin and the anti-alzheimer  s drug entity .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|lithium tetracycline doxorubicin tenofovir naltrexone|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|melatonin olanzapine risperidone nicotine tablet|galantamine|entity er capsules are the ab-rated generic versions of ortho-mcneil and janssens razadyne er® , which had annual sales of approximately $110
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|vad azt mvc acetylcholinesterase acetylcholine|galantamine|in a pre-clinical animal model of cognition , prx-03140 demonstrated synergistic activity when combined with the acetylcholinesterase inhibitor entity ( razadyne ) .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|simvastatin tau levodopa acetylcholinesterase atorvastatin|galantamine|namzaricin the market for alzheimers disease treatments , namzaric competes or will compete with branded and generic products such as entity , rivastigmine , memantine , and donepezil .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|lithium tetracycline doxorubicin tenofovir naltrexone|galantamine|infringed u . s . patent no . 4 , 663 , 318 ( the 318 patent ) by submitting a paragraph iv certification to the fda for approval of tablets containing entity hydrobromide .
OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|acetylcholinesterase available dopamine levodopa hydrochloride|fd generic usp ibuprofen bd|galantamine|in august 2008 , barr commenced sales of its 4 mg , 8 mg and 12 mg entity immediate release ( ir ) tablets .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|sodium sulfate prot vitamin amine|warfarin clopidogrel aspirin ibuprofen bevacizumab|protamine|entity , a drug that reverses the anticoagulant effect of heparin , is rarely used in pci due to its unpredictable effect and
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sodium sulfate prot vitamin amine|sildenafil ketamine dexmedetomidine digoxin thalidomide|protamine|in medical studies , entity has been associated with adverse side effects , such as abnormal changes in blood pressure , depression of heart function and acute
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|its warfarin aspirin anticoagulant clopidogrel|protamine|phase ii clinical trials indicate that neutralase can reverse heparin anticoagulation without the adverse changes in blood pressure associated with entity usage .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium sulfate prot vitamin amine|newly jet emulsion previously nanoparticle|protamine|our preclinical data demonstrated improved antigen expression at the site of injection if the entity formulated vaccine was injected via a needle free jet device .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium sulfate prot vitamin amine|collagenase gelatin amylase lipase elastase|protamine|one patient that died was found to have used entity and not neutralase .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|warfarin aspirin clopidogrel aprotinin thrombin|protamine|although entity is available as an antidote for heparin , it does not work with lmwh and there currently are no antidotes for
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sodium sulfate prot vitamin amine|aspirin clopidogrel warfarin asa bevacizumab|protamine|arc183 has shown potential in preclinical studies to be equally effective , with fewer side effects than heparin and entity in combination .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium sulfate prot vitamin amine|previously recently newly egg formulation|protamine|bi1361849 was administered via conventional needle based intradermal injection , later shown to be a suboptimal mode of injection for the entity formulated rabies vaccine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|entity naltrexone warfarin this aptamer|protamine|in the ufh antagonist market , entity is the only available antidote for and antagonist to ufh and , as such , entity currently dominates this market .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium sulfate prot vitamin amine|kp logistic this io eds|protamine|because of entitys virtual monopoly of the ufh antidote / antagonist market , we believe that it may be
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|aspirin warfarin epinephrine asa cpb|protamine|be safely used in the general cardiac surgery patient population by demonstrating similar results to a regimen of heparin plus entity reversal .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium sulfate prot vitamin amine|these its this pharmacodynamic such|protamine|because of entitys potentially problematic side effect profile , we believe that our heptagonist products may penetrate into
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sodium sulfate prot vitamin amine|warfarin aspirin clopidogrel theophylline anticoagulants|protamine|in addition , the effects of heparin are routinely reversed with entity , the use of which has been associated with an allergic reaction and a subsequent increase in the risk of death
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|aspirin warfarin clopidogrel thus which|protamine|reversed at the end of the procedure and which does not have the significant side effects associated with heparin and entity would result in improved outcomes for patients undergoing ohs .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium sulfate prot vitamin amine|aprotinin warfarin thrombin fibrinogen platelets|protamine|that directly or indirectly support clotting , such as vitamin k ; fresh frozen plasma , or ffp ; prothrombin complex concentrates , or pccs ; entity ; and recombinant factor viia , or rfviia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sodium sulfate prot vitamin amine|thrombin warfarin this clopidogrel fibrinogen|protamine|currently , entity is the only product commercially available for the reversal of heparin anticoagulation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sodium sulfate prot vitamin amine|warfarin clopidogrel aspirin ffp vehicle|protamine|the efficacy of rpf4 for the reversal of the anticoagulant effects of heparin in cardiac catheterization patients in comparison to entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium sulfate prot vitamin amine|still sodium today now warfarin|protamine|market opportunity unfractionated heparin ( ufh ) entity is the only available reversing agent for ufh .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|drug|sodium sulfate prot vitamin amine|proteins dna dystrophin p53 antibodies|protamine|an antigenic protein that is expressible in human cells as well as the same mrna formed as a complex with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium sulfate prot vitamin amine|pcc platelets hes both ffp|protamine|k , ffp and , more recently , pccs , while low molecular weight heparin patients needing reversal are often managed with ffp or entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|sr versus antidepressant nor risperidone|metformin rosiglitazone pioglitazone aspirin naltrexone|escitalopram|( n=301 ) for the first eight weeks , followed by a two-week period in which patients discontinued study drug but continued receiving entity and placebo .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|fluoxetine risperidone clozapine olanzapine celecoxib|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) , effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|sr versus antidepressant nor risperidone|fluoxetine ketamine ssri haloperidol serotonin|escitalopram|these results showed an increase of serotonin and dopamine after a single dose of min-117 , unlike the reference antidepressant entity which only induced a modest and transient increase .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|lithium risperidone caffeine olanzapine atorvastatin|escitalopram|to approximately 195 legal actions asserting product liability claims relating to the use of celexa® ( citalopram hbr ) ( celexa ) or lexapro® ( entity oxalate ) ( lexapro ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|lithium magnesium sodium fluoxetine caffeine|escitalopram|sales of lexapro® ( entity oxalate ) , an ssri indicated for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder in adults ,
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|drug|sr versus antidepressant nor risperidone|fluoxetine ssri antidepressant antidepressants ect|escitalopram|is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with entity , an anti-depressant drug .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sr versus antidepressant nor risperidone|new prototype novel experimental proposed|escitalopram|our entity thin film is currently in pre-clinical development .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|sr versus antidepressant nor risperidone|nivolumab erlotinib crizotinib everolimus bms|escitalopram|cns clinical research division ; and forest laboratories , as director , cns clinical development , where he was involved in the development of entity ( lexapro ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sr versus antidepressant nor risperidone|145 143 146 144 142|escitalopram|ranitidine 170 152 gemcitabine 153 143 entity oxalate 128 227 others 2 , 246 3 , 105
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sr versus antidepressant nor risperidone|new novel prototype experimental innovative|escitalopram|our entity thin film is currently in pre-clinical development and we expect to conduct pilot bioavailability / bioequivalence clinical trials during the first half
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|fluoxetine ssris ssri sert risperidone|escitalopram|that affect the serotonin system , as 176 table of contents shown recently in generalized anxiety disorder trials with the ssris entity and paroxetine .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|risperidone olanzapine fluoxetine clozapine carbamazepine|escitalopram|major brands include prozac ( fluoxetine ) , lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertraline ) and effexor xr ( venlafaxine ) and wellbutrin® .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|sr versus antidepressant nor risperidone|potassium lithium oxalate magnesium sodium|escitalopram|patent infringement based on tevas filing of an abbreviated new drug application for a generic equivalent to our lexapro brand entity oxalate .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|etanercept infliximab pioglitazone gabapentin sildenafil|escitalopram|this reduction was principally due to the launch of entity in the first quarter of 2012 , our most significant product launch with shared exclusivity in the prior year .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sr versus antidepressant nor risperidone|poverty medicare medicaid gdp inflation|escitalopram|excluding the impact of entity in both periods , third party net revenues in north america were essentially flat on a year-over-year basis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sr versus antidepressant nor risperidone|lithium fluoxetine caffeine sodium magnesium|escitalopram|· lexapro® ( entity oxalate ) , an ssri for the initial and maintenance treatment of mdd in adults and adolescents and generalized anxiety disorder in
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sr versus antidepressant nor risperidone|this which ibuprofen clopidogrel celecoxib|escitalopram|entity is marketed by forest laboratories , inc . under the brand name lexapro® and generated sales of $2 . 0 billion in 2006 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sr versus antidepressant nor risperidone|this another its each that|escitalopram|entity oxalate entity is in a class of drugs called selective serotonin reuptake inhibitors .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sr versus antidepressant nor risperidone|lithium losartan magnesium olanzapine sodium|escitalopram|lexapro® : lexapro ( entity oxalate ) , our single isomer version of citalopram hbr , for the treatment of mdd in adults and adolescents and generalized anxiety
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|sr versus antidepressant nor risperidone|fluoxetine risperidone clozapine olanzapine haloperidol|escitalopram|major marketed brands include lexapro ( entity ) , paxil ( paroxetine ) , zoloft ( sertaline ) and effexor xr ( venlafaxine ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|nitrate bromide marketed levo available|theophylline ics prednisone sildenafil gold|tiotropium|boehringer-ingelheim is developing a combination product with entity and the long-acting beta agonist bi-1744 for the treatment of copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nitrate bromide marketed levo available|losartan matching azithromycin either vehicle|tiotropium|explore efficacy and safety at doses of 15 . 6 to 125mcg od and 15 . 6mcg and 31 . 25mcg twice daily ( bid ) compared with entity od or placebo in subjects with copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|nitrate bromide marketed levo available|prednisone prednisolone azithromycin hydrocortisone theophylline|tiotropium|significantly greater than placebo and similar in magnitude to a combination therapy active control of salmeterol dosed twice daily plus entity dosed once daily .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|nitrate bromide marketed levo available|gold theophylline aspirin rosiglitazone azithromycin|tiotropium|separately , a phase iii study showed that once-daily nva237 is superior to placebo and similar to entity in improving lung function in patients with moderate-to-severe copd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|nitrate bromide marketed levo available|reference spirometry controls saline soc|tiotropium|% of the patients in the study , yupelri demonstrated nominally statistically significant and clinically relevant improvements in trough fev1 versus entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nitrate bromide marketed levo available|theophylline ics sildenafil spirometry gold|tiotropium|the studies showed that when used in conjunction with entity , indacaterol produces a significantly greater improvement in lung function than entity alone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|nitrate bromide marketed levo available|theophylline gold ics sildenafil adenosine|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity , a commonly used long-acting bronchodilator , in approximately 30 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|nitrate bromide marketed levo available|bevacizumab sunitinib bortezomib dexamethasone trastuzumab|tiotropium|this trial is evaluating rpl554 as an add-on therapy to entity in approximately 30 patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nitrate bromide marketed levo available|theophylline gold ics sildenafil spirometry|tiotropium|phase 2a clinical trial in the united kingdom evaluating rpl554 in approximately 30 patients with copd as an add-on therapy to entity , a commonly used bronchodilator .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|nitrate bromide marketed levo available|gold ics soc copd theophylline|tiotropium|no : p27 ( a6797 ) umec / vi as step-up therapy from entity in moderate symptomatic copd : a randomized , 12-week study exhibit 99 . 4 press release issued : wednesday 18th may 2016
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|nitrate bromide marketed levo available|predicted expected earlier observed previously|tiotropium|early post-dose spirometry data suggested a more rapid onset of action than entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|nitrate bromide marketed levo available|theophylline ics adenosine atropine isoproterenol|tiotropium|mg and 6 mg , or placebo , dosed twice-daily for three days , in addition to a dual bronchodilator therapy comprising entity and olodaterol , a commonly used lama / laba , dosed once daily .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|nitrate bromide marketed levo available|celecoxib warfarin metformin bevacizumab ibuprofen|tiotropium|the primary analysis was to determine non-inferiority ( based on a margin of -50ml ) or superiority of umeclidinium to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|nitrate bromide marketed levo available|extension treatments formulation sunitinib monotherapy|tiotropium|showed that nva237 was well-tolerated with a similar incidence of adverse events for patients treated with nva237 , placebo and open-label entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|nitrate bromide marketed levo available|olanzapine risperidone naltrexone mtx fd|tiotropium|· in both studies , placebo and open-label od entity 18mcg were comparators .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|nitrate bromide marketed levo available|conventional gold optimized soc copd|tiotropium|•verona pharma announced positive data in a 4-week phase 2b copd trial with nebulized ensifentrine on top of entity therapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|nitrate bromide marketed levo available|bromide ipr atropine bronchial bronchodil|tiotropium|table of contents  braltus® ( entity bromide ) , a long-acting muscarinic antagonist , indicated for adult patients with copd , delivered via the zonda® inhaler , was launched in europe
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|nitrate bromide marketed levo available|fumarate prostaglandin ol midazolam lactose|tiotropium|when compared to placebo , glycopyrronium 50 mcg was also numerically higher than ol entity 18 mcg versus placebo at all-time points for trough fev1 ( day 1 and weeks 12 , 26 and 52 ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|nitrate bromide marketed levo available|gold bronchodil ipr copd sildenafil|tiotropium|been playing a central role in the management of copd , and are currently the most common therapy in copd ( e . g . , entity bromide ; a long-acting bronchodilator ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|nitrate bromide marketed levo available|midazolam dexamethasone diazepam risperidone ibuprofen|tiotropium|patients were randomised 1 : 1 to umeclidinium 62 . 5mcg inhalation powder or entity 18mcg .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 2)])|drug|dummy vs versus nor compared|simvastatin atorvastatin levodopa gabapentin pioglitazone|flutemetamol|in october 2013 , the fda approved entity , under the name vizamyltm , for adults being evaluated for ad and dementia with pet brain imaging .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dummy vs versus nor compared|adni amyloid dtpa pib rage|flutemetamol|in addition to fluorbetapir , there are two other beta-amyloid imaging agents available : florbetaben from piramal enterprises , imaging division , and entity from ge healthcare .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|dummy vs versus nor compared|fdg flt fluoride naf 18f|flutemetamol|the filing also includes data from a recently completed [ 18f ] entity pet image reader training validation study , results of which will be presented at a scientific forum in coming months .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|dummy vs versus nor compared|amyloid tau simvastatin acetylcholinesterase acetylcholine|flutemetamol|as an aid to the evaluation of patients with signs of alzheimers disease : amyvid® ( florbetapir ) , marketed by lilly , and vizamyl® ( entity ) , marketed by ge healthcare .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|dummy vs versus nor compared|amyloid adni flor pib dtpa|flutemetamol|in addition to fluorbetipir , there are two other beta-amyloid imaging agents in late stage development : florbetaben from bayer schering and entity from general electric .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|hormone gonadotropin nor versus gnrh|leup gnrh lup lh lan|goserelin|among the different classes of peptides , gnrh / lhrh agonists ( leuprorelin , entity ) account for almost 50 percent of the market .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|testosterone estradiol gnrh tamoxifen docetaxel|goserelin|formulations such as lupron and eligard , which deliver leuprolide , trelstar , which delivers triptorelin , and zoladex , a biodegradable rod , which delivers entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|hormone gonadotropin nor versus gnrh|prednisolone dexamethasone gnrh irinotecan testosterone|goserelin|patients in the second arm will receive bnt112 combined with entity acetate and cemiplimab , and patients in the third arm will receive bnt112 combined with entity acetate alone .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|hormone gonadotropin nor versus gnrh|gnrh prednisolone dexamethasone tamoxifen prednisone|goserelin|primary objective of this study will be to establish the safety and tolerability of bnt112 alone , or in combination with entity acetate with or without cemiplimab .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|testosterone gnrh tamoxifen estradiol leup|goserelin|zoladex ( entity acetate implant ) is a lhrh agonist for treating prostate and breast cancer .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|gnrh testosterone estradiol estrogen tamoxifen|goserelin|for all classes , the only astrazeneca drug at issue is zoladex™ ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|gnrh testosterone estradiol estrogen tamoxifen|goserelin|astrazeneca announced that it had entered into an agreement with tersera therapeutics llc ( tersera ) for the commercial rights to zoladex ( entity acetate implant ) in the u . s . and canada .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hormone gonadotropin nor versus gnrh|testosterone docetaxel everolimus dexamethasone bevacizumab|goserelin|launches of generic entity ( the active ingredient in zoladex ) are expected in europe during 2012 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|gnrh testosterone estradiol tamoxifen leup|goserelin|zoladex ( entity acetate implant ) , available in one month and three month depots , is the worlds second largest lhrh agonist by value .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|gnrh testosterone estradiol estrogen tamoxifen|goserelin|in the us , the us department of justice has been conducting an investigation into the sales and marketing of zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|testosterone docetaxel everolimus estradiol gnrh|goserelin|competition in the lhrh agonist market is expected to increase in europe during 2011 , with further launches of generic entity ( the active ingredient in zoladex ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|hormone gonadotropin nor versus gnrh|testosterone gnrh estradiol tamoxifen dexamethasone|goserelin|examples of commercially marketed lhrh agonists are lupron® ( leuprolide acetate ) , zoladex® ( entity acetate ) , viadur® ( leuprolide acetate ) and eligard® ( leuprolide acetate ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|hormone gonadotropin nor versus gnrh|ai tamoxifen trastuzumab adt er|goserelin|lee011 + tamoxifen + entity or nsai + entity hr+ / her2- premenopausal abc 1st line 2018 iii - fully enrolled lee011 + fulvestrant hr+ / her2- postmenopausal abc 1st / 2nd line 2018 iii
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|hormone gonadotropin nor versus gnrh|gnrh testosterone estrogen estradiol tamoxifen|goserelin|for all classes , the only astrazeneca drug at issue is zoladex ( entity acetate implant ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|sacral gait single versus view|lidocaine bupivacaine morphine midazolam methadone|biperiden|increases over the same quarter in the prior year in certain molecules including cyclizine hydrochloride , codeine phosphate + paracetomol and entity hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|somatostatin hormone acetate sodium vs|adalimumab somatostatin oxytocin single intact|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|somatostatin hormone acetate sodium vs|propionate hydrochloride acetate sodium alpha|lanreotide|somatuline entity ( " somatuline " ) is another long- acting somatostatin analog .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|somatostatin gh its igf1 corticosteroid|lanreotide|we look forward to advancing mycapssa as a preferred treatment option for patients with acromegaly treated with octreotide and entity injectables ,  mr . kannan concluded .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|both everolimus somatostatin analogs gh|lanreotide|on june 26 , 2020 , chiasma received fda approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|somatostatin hormone acetate sodium vs|targeted studied experimental tested intended|lanreotide|we do not have composition of matter patent coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® depot ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|somatostatin hormone acetate sodium vs|somatostatin gh dexamethasone saline prednisone|lanreotide|receptor type 2 ( sst2 ) biased agonist , in patients with acromegaly whose disease is not biochemically controlled by octreotide lar or entity depot alone .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|somatostatin hormone acetate sodium vs|whole targeted experimental gelatin tested|lanreotide|we do not have patent composition coverage on the entity molecule ( the active pharmaceutical ingredient of somatuline® autogel® ) alone .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|somatostatin subcutaneous by gnrh its|lanreotide|hormone levels used to measure disease at 24 weeks versus continued treatment with the long acting release form of octreotide , or entity autogel , meeting the primary endpoint .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|somatostatin hormone acetate sodium vs|somatostatin everolimus gh dexamethasone metformin|lanreotide|week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand ( srl ) depot of either octreotide or entity monotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|drug|somatostatin hormone acetate sodium vs|hormone substances substance proteins hormones|lanreotide|the somatuline® autogel® formulation requires no excipient other than water and releases entity over a period of at least 28 days and up to 56 days .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|both somatostatin everolimus analogs gh|lanreotide|approval of mycapssa for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|somatostatin hormone acetate sodium vs|bevacizumab sunitinib trastuzumab gemcitabine cetuximab|lanreotide|a pilot trial involving six children with neuroblastoma cancer and seven adults with neuroendocrine cancer has been completed using entity as the targeting agent .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|somatostatin hormone acetate sodium vs|somatostatin prednisolone gnrh hydrocortisone subcutaneous|lanreotide|these products include sandostatin lar depot ( octreotide / im injection ) by novartis a . g . , and somatuline depot ( entity acetate ) by tercica inc .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|somatostatin hormone acetate sodium vs|somatostatin dexamethasone leptin hydrocortisone glucagon|lanreotide|active substance the active substance in somatuline® depot is entity , which inhibits the growth and secretion of several endocrine , exocrine and paracrine functions .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|somatostatin hormone acetate sodium vs|somatostatin lan sst everolimus arginine|lanreotide|somatuline® depot is an injectable sustained-release formulation containing entity , a somatostatin analogue .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|somatostatin analogs everolimus lan both|lanreotide|surgical removal of the pituitary tumor consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|somatostatin analogs lan everolimus both|lanreotide|care for patients diagnosed with acromegaly consists of lifelong , once-monthly injections of an extended release somatostatin analog , primarily octreotide or entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|somatostatin hormone acetate sodium vs|somatostatin everolimus analogs gastrin lan|lanreotide|long-acting analogues of the hormone somatostatin , such as octreotide and entity have established themselves as a primary treatment of neuroendocrine tumors , although with limited efficacy .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|somatostatin hormone acetate sodium vs|somatostatin everolimus sst lan igf1|lanreotide|somatostatin analogs octreotide ( marketed as sandostatin ) and entity ( marketed as somatuline ) are selective for sst2 receptors and are the preferred first-line pharmacologic treatments .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|somatostatin hormone acetate sodium vs|acth sst somatostatin gh ss|lanreotide|acromegaly in the united states : sandostatin lar ( octreotide ) marketed by novartis ; signifor lar ( pasireotide ) marketed by novartis ; and somatuline depot ( entity ) marketed by ipsen .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|spectrum antiviral prophylactic vaginal antibiotic|gentamicin metronidazole amoxicillin rifampicin colistin|cefotetan|entity disodium injectable ( vial ) 1gr , 2gr , 10gr vials entity ® nda / anda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ceftriaxone ciprofloxacin cef amoxicillin gentamicin|cefotetan|entity is a second-generation cephalosporin with a broad range of anti-microbial activity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|spectrum antiviral prophylactic vaginal antibiotic|gentamicin metronidazole colistin vancomycin ciprofloxacin|cefotetan|entity disodium 20mg / ml injectable ( bag ) 50ml bags entity ® nda indicated for the treatment of various bacterial infections .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ready ceftriaxone preparation ciprofloxacin vial|cefotetan|we received fda approval for and launched our first injectable product , cefotan® ( entity for injection ) , in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|spectrum antiviral prophylactic vaginal antibiotic|them company industry this companies|cefotetan|we launched entity in september 2007 and are currently the only company to market entity in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|spectrum antiviral prophylactic vaginal antibiotic|docetaxel bevacizumab carboplatin thalidomide doxorubicin|cefotetan|march 31 , 2007 were $23 . 6 million of paclitaxel ( whole plant ) , $3 . 9 million in other abraxane® related materials and $3 . 0 million of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ciprofloxacin ceftriaxone preparation amoxicillin antibiotic|cefotetan|and ·in december 2015 , the company received approval of its supplemental new drug application from the fda for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ciprofloxacin ceftriaxone preparation antibiotic amoxicillin|cefotetan|received approval of the company  s supplemental new drug application ( snda ) from the u . s . food and drug administration ( fda ) for cefotan® ( entity for injection ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|spectrum antiviral prophylactic vaginal antibiotic|vials them this vial companies|cefotetan|we launched entity in september 2007 and are currently the only company to market entity vials in the united states .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ceftriaxone ciprofloxacin penicillin amoxicillin preparation|cefotetan|we have received fda approval for our first product in this portfolio , cefotan® ( entity for injection ) , which we launched in the first quarter of 2016 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|spectrum antiviral prophylactic vaginal antibiotic|ceftriaxone ciprofloxacin ampicillin amoxicillin penicillin|cefotetan|·the company launched cefotan® ( entity disodium for injection ) and lidocaine 5% ointment in march of 2016 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|spectrum antiviral prophylactic vaginal antibiotic|penicillin vancomycin amoxicillin ibuprofen which|cefotetan|entity is often used for surgical prophylaxis and offers the longest half-life of any cephalopsorin .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|spectrum antiviral prophylactic vaginal antibiotic|diclofenac ibuprofen naltrexone dexamethasone atorvastatin|cefotetan|in the third quarter , app launched entity disodium for injection .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|av sodium antiepileptic succinate anticonvuls|lidocaine methadone cocaine caffeine ketamine|topiramate|an overactive thyroid ; by patients taking a type of anti-depressant called maoi ; or by patients who are allergic to phentermine , entity , or any of the ingredients in qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|av sodium antiepileptic succinate anticonvuls|metformin naltrexone rosiglitazone pioglitazone rifampicin|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus :
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|av sodium antiepileptic succinate anticonvuls|fda us original marketed existing|topiramate|we anticipate that the label for qnexa , if approved , will contain the similar suicidality warnings to those contained in the entity label .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|av sodium antiepileptic succinate anticonvuls|arsenic pcbs eggs cyclophosphamide pesticides|topiramate|the exercise primarily includes identifying these mother-infant pairs exposed to entity at the doses that the fda has recommended .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|naltrexone methadone buprenorphine lidocaine clonidine|topiramate|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , phentermine / entity , under the trade name qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|carbamazepine risperidone fluoxetine olanzapine gabapentin|topiramate|immediate release formulations of entity and oxcarbazepine are available in generic form and are marketed under the brand names of topamax and trileptal , respectively .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|av sodium antiepileptic succinate anticonvuls|carbamazepine gabapentin olanzapine risperidone lithium|topiramate|et-104 is one of etons three neurology-focused liquid product candidates , along with et-105 ( lamotrigine oral suspension ) and et-101 ( entity oral solution ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|carbamazepine gabapentin risperidone diazepam olanzapine|topiramate|the company has two marketed products for epilepsy , oxtellar xr ( extended-release oxcarbazepine ) and trokendi xr ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|av sodium antiepileptic succinate anticonvuls|vehicle controls eggs sham saline|topiramate|in the qnexa studies , which included 15 offspring from women exposed to qnexa or entity , there were no reports of congenital malformations .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|av sodium antiepileptic succinate anticonvuls|metformin rosiglitazone pioglitazone naltrexone gabapentin|topiramate|controlled-release phentermine / entity therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus : authors : w . timothy garvey , md ( a ) ; craig a .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|av sodium antiepileptic succinate anticonvuls|gabapentin ketamine carbamazepine vpa lidocaine|topiramate|entity is believed to work in epilepsy through various mechanisms .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|naltrexone methadone carbamazepine fluoxetine buprenorphine|topiramate|in addition , we currently do not have manufacturing agreements in place for entity or phentermine .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|av sodium antiepileptic succinate anticonvuls|naltrexone verapamil losartan celecoxib methadone|topiramate|in july 2012 , vivus , inc . obtained fda approval for its combination product , phentermine / entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|carbamazepine gabapentin risperidone diazepam midazolam|topiramate|the company has two marketed products for epilepsy , oxtellar xr® ( extended-release oxcarbazepine ) and trokendi xr® ( extended-release entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|naltrexone fluoxetine gabapentin methadone carbamazepine|topiramate|and patient market research to assess potential growth of the obesity therapeutics market as well as preference shares between nb32 , phentermine / entity and lorcaserin .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|av sodium antiepileptic succinate anticonvuls|sildenafil aspirin gabapentin ibuprofen everolimus|topiramate|the pharmaceutical company performing research of entity alone announced they had discontinued development of a time-release formulation due to side effects at high doses .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|methadone naltrexone isoniazid carbamazepine fluoxetine|topiramate|<a  leland wilson> : we typically characterize our product as the low-dose combination of phentermine and entity , so thats what thats referring to , yes .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|av sodium antiepileptic succinate anticonvuls|tm pfizer merck 510 atorvastatin|topiramate|u . s . attorneys office in boston , massachusetts seeking documents relating to the marketing , including alleged off-label marketing , of the drug topamax® ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|av sodium antiepileptic succinate anticonvuls|naltrexone metformin fluoxetine clonidine olanzapine|topiramate|qsymia® ( phentermine and entity extended release ) is approved by fda for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|av sodium antiepileptic succinate anticonvuls|gabapentin lithium olanzapine dexamethasone others|topiramate|or aeds , available in the united states and worldwide , including the generic products levetiracetam , lamotrigine , carbamazepine , oxcarbazepine , valproic acid and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|dexamethasone theophylline docetaxel adenosine sildenafil|theophylline|fully funds a 36 patient phase 1 / 2 investigator-sponsored phase 1 / 2 study for use of hs-110 as a combination therapy with entity and oxygen .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline midazolam fluoxetine digoxin erythromycin|theophylline|therapeutic monitoring of cyp1a2 substrates with a narrow therapeutic index ( e . g . entity and tizanidine ) is recommended when coadministered with ocaliva .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|these trough bilirubin such irinotecan|theophylline|monitor entity levels if concurrent administration cannot be avoided .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|acetylcholine theophylline also sildenafil bromide|theophylline|entity relaxes the smooth muscle of the bronchial airways and thus acts mainly as a bronchodilator .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|its warfarin aspirin this his|theophylline|when taking zyflo , entity dose should be reduced by 50% and appropriately monitored ; patients taking propranolol or warfarin should be monitored and doses adjusted
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|formulation brand generic company option|theophylline|respiratory sales growth was moderated in 1995 by lower sales of theo-dur , a sustained-action entity , due to increased generic competition .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|licensed marketed commercial registered market|theophylline|the company noted that it discontinued marketing its u . s . entity products in june 2001 and that proventil repetabs have not been available since july 2001 .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline adenosine sildenafil gold atropine|theophylline|the most commonly used oral bronchodilator is entity , a drug with good efficacy but which is capable of producing certain undesirable side effects such as disturbances in heart
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline ics benzodiazepines agonists antagonists|theophylline|the bronchodilator agents most often used are ß2 agonists , anticholinergics , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline xanthine colchicine phosphatidylcholine acetylcholine|theophylline|euphyllin , a drug based on a substance called entity , is used for the treatment of asthma and copd .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|patent ingredients vitamins generic price|theophylline|[ * * * ] entity ( including product sold under the theochron ( r ) trademark )
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline acetylcholine prednisone sildenafil isoproterenol|theophylline|entity and albuterol are frequently prescribed to produce dilation of bronchioles for both emphysema and chronic bronchitis .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|mmf dexamethasone cyclophosphamide tmz everolimus|theophylline|patients taking zyflo cr and entity should reduce the entity dose by 50% .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 3), ('DRUG', 3)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|usp lactose lidocaine prednisone azithromycin|theophylline|decree also includes a recall , initiated in early may 2002 and directed to u . s . trade accounts , of all lots of entity , usp tablets and proventil ( albuterol sulfate , usp ) repetabs .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline atropine adenosine dexamethasone epinephrine|theophylline|antihistamines , antiemetics , histamine h-2 receptor antagonists , barbiturates , prostoglandins , and bronchial dilators selected from the group consisting of terbutaline , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|phosphatidylcholine choline acetylcholine atropine milk|theophylline|other products choledyl ( r ) choledyl ( r ) ( oxtriphylline ) is the choline salt of entity .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|available supplied tablets both presented|theophylline|[ * * * ] entity in elixir form sold under the elixophyllin ( r ) trademark [
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|prednisone prednisolone ics theophylline glucocorticoids|theophylline|offices and central labs to measure patient blood drug levels for the most commonly prescribed therapeutic drugs to control asthma ( entity ) and epilepsy ( carbamazepine , and phenytoin ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|theophylline caffeine xanthine ciprofloxacin sildenafil|theophylline|bronchodilators dilate the airways and include beta agonists ( such as albuterol and bitolterol ) , xanthines ( such as entity ) and anticholinergics ( such as ipratropium ) .
OrderedDict([('OTHER', 5), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|theophylline cyclosporine prophylactic methotrexate xanthine|metronidazole gentamicin vancomycin irinotecan ceftriaxone|theophylline|serious and fatal reactions have been reported in patients receiving concur-rent administration of ciprofloxacin and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|der sin wil wort stock|novartis etanercept pfizer bayer sildenafil|inotersen|the company holds the rights for the commercialization of tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) for the treatment of rare diseases in countries in latin america and the caribbean .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|der sin wil wort stock|others pfizer buprenorphine naltrexone released|inotersen|slower rate than revenue with the increase primarily due to higher sg&a expenses as ionis prepares to commercialize volanesorsen and entity this year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|inventory commercial financial reimbursement insurance|inotersen|commercial entity inventory acquired from ionis commercial inventory acquired clinical material acquired from ionis clinical material acquired liability for costs incurred and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|ttr this irb us registration|inotersen|that the defendants breached their fiduciary duties in connection with the licensing transaction that we and ionis entered into regarding entity and akcea-ttr-lrx .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|der sin wil wort stock|aav oligonucleotide bortezomib thalidomide antisense|inotersen|akcea has received marketing approval for an antisense drug , entity that was developed by ionis , in the u . s . , the eu and canada , for the treatment of hattr amyloidosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|ttr medicare emr registry markets|inotersen|the parties agree to maintain books and records for entity and ionis-ttr-lrx that will allow each party to provide the other party with net revenues , expenses ( including each cost category
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|drug|der sin wil wort stock|ttr etanercept both attr others|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  potentially best-in-class oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|novartis basel bayer pfizer roche|inotersen|today announced a collaboration under which ptc will commercialize two of akceas rare disease drugs in latin america ( latam ) : tegsedi™ ( entity ) and waylivra™ ( volanesorsen ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|pfizer lilly novartis bayer janssen|inotersen|both entity and volanesorsen are progressing toward regulatory filings for marketing authorization .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|der sin wil wort stock|losartan celecoxib dexamethasone naltrexone midazolam|inotersen|icon clinical research limited , inc research toronto , inc . and medpace for the clinical studies for our drugs , including volanesorsen and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|der sin wil wort stock|etanercept simvastatin losartan bortezomib atorvastatin|inotersen|ag10 also will not be the first treatment on the market for attr-pn as tafamidis , patisiran , and entity are approved for the treatment of attr-pn in a variety of countries globally .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|tm ttr tg ts teg|inotersen|we created tegsedi™ ( entity ) the worlds first rna-targeted therapeutic approved for the treatment of polyneuropathy of hereditary transthyretin ( ttr ) amyloidosis ( attr ) in adult patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|der sin wil wort stock|ttr etanercept both attr simvastatin|inotersen|tafamidis , patisiran and entity are currently marketed for attr-pn in various geographies our product concept  oral small molecule ttr stabilizer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|der sin wil wort stock|development manufacturing recruitment design discovery|inotersen|for ionis , this transaction achieves all the goals we laid out at the outset of our entity process .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate celecoxib ac irinotecan available|lidocaine diclofenac dexamethasone bupivacaine celecoxib|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%fda approval received for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|methotrexate celecoxib ac irinotecan available|tacrolimus dexamethasone erythromycin ciprofloxacin everolimus|nepafenac|ilevro ( entity ophthalmic suspension ) , 0 . 3%launched in the us , received ema approval and launched in europe , and received health canada approval for the
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|methotrexate celecoxib ac irinotecan available|new novel nsaid marketed formulation|nepafenac|entity , new formulation anti-inflammatory us 2011 eu 2012 approved approved - ilevro approved in q4 2012 - ilevro approved q2 2013
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate celecoxib ac irinotecan available|tacrolimus dexamethasone prednisolone diclofenac lidocaine|nepafenac|· alcon received approval to market ilevro , a new formulation of entity ophthalmic suspension ( 0 . 3% ) , in the us .
OrderedDict([('OTHER', 4), ('DRUG', 3)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|methotrexate celecoxib ac irinotecan available|lidocaine celecoxib bupivacaine diclofenac dexamethasone|nepafenac|in august 2005 , the fda approved nevanac ( entity ophthalmic suspension ) 0 . 1% for the treatment of pain and inflammation associated with cataract surgery .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|legal official us domestic administrative|phentermine|sus has been named as a defendant in a total of 4 , 196 such entity lawsuits , in respect of which sus has been dismissed as a defendant in 3 , 936 cases .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|naltrexone pioglitazone olanzapine gabapentin risperidone|phentermine|marketed in the united states under the name belviq and in september 2012 , vivus , inc . commercially launched its combination product , entity / topiramate , under the trade name qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|gabapentin olanzapine carbamazepine ketamine lithium|phentermine|qnexa is our investigational drug candidate involving low doses of entity and topiramate .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|carbamazepine clozapine methadone fluoxetine amphetamine|phentermine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including entity , phendimetrazine , mazindol , benzphetamine and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|morphine naltrexone buprenorphine risperidone lithium|phentermine|entity hcl , usp sales in the year ended december 31 , 2001 reflected an increase in unit volume from the refilling of distribution
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|gabapentin clozapine carbamazepine olanzapine risperidone|phentermine|in particular , it is possible that patients will seek to acquire entity and topiramate , the generic components of qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|cocaine methamphetamine amphetamine propranolol naltrexone|phentermine|a defendant in more than two thousand five hundred multi-defendant lawsuits involving the manufacture and sale of dexfenfluramine , fenfluramine , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|minocycline bupivacaine ketamine dexmedetomidine propofol|phentermine|the lawsuits allege that the manufacturers of entity knew that its use could cause serious side effects , but failed to warn against those dangers .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|pioglitazone metformin rosiglitazone naltrexone gabapentin|phentermine|to fisons ) and 585 ( as to rugby ) personal injury lawsuits in the u . s . ( including class actions ) concerning the weight-loss drug entity ( fisons brand name ionamin ) .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|risperidone midazolam naltrexone gabapentin carbamazepine|phentermine|the equate study also contained a mid-dose of qnexa containing 46 mg of topiramate cr and 7 . 5 mg of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|metformin gabapentin pioglitazone naltrexone carbamazepine|phentermine|drug candidate for the treatment of obesity , incorporating low doses of active ingredients from two previously approved products , topiramate and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|metformin fluoxetine ssris clonidine gabapentin|phentermine|contrary to the approved labelling of these products , physicians in the us co-prescribed entity with fenfluramine or dexfenfluramine for management of obesity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|olanzapine risperidone gabapentin naltrexone metformin|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( &#x201c ; fda&#x201d ; ) for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|metformin pioglitazone rosiglitazone this olanzapine|phentermine|entity is the largest selling antiobesity therapeutic and is available in several generic forms .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|risperidone fluoxetine olanzapine buprenorphine erythromycin|phentermine|&#160 ; the company had one approved and marketed product , suprenza ( entity hydrochloride ) , which it had out licensed for promotion in the united states , canada and mexico .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|risperidone naltrexone haloperidol fluoxetine midazolam|phentermine|to a decline in both unit volume and selling prices of fluvoxamine maleate and a decline in unit volume of entity hcl , usp .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|olanzapine risperidone rosiglitazone pioglitazone metformin|phentermine|as expected , the chmp recommended against approval of the marketing authorization application ( maa ) for qsiva ( entity / topiramate er ) for the treatment of obesity in the european union .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|this etanercept nivolumab adalimumab infliximab|phentermine|entity is sold at much lower prices than we charge for qsymia .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|metformin statins pioglitazone ssris antidepressants|phentermine|there are a number of generic pharmaceutical drugs that are prescribed for obesity , predominantly entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|antiepileptic anticonvuls cyclosporine containing methotrexate|olanzapine risperidone metformin naltrexone gabapentin|phentermine|qsymia ( entity and topiramate extended release ) is approved by the u . s . food and drug administration ( “fda” ) for chronic weight management .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 2)])|drug|sodium antihypertensive verapamil succinate losartan|quercetin colchicine ginseng curcumin resveratrol|carvedilol|which is available as both an oral and an iv formulation , and querto® , a therapeutic based on a substance called entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|sodium antihypertensive verapamil succinate losartan|propranolol succinate citrate propofol fumarate|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|sodium antihypertensive verapamil succinate losartan|propranolol digoxin furosemide verapamil nifedipine|carvedilol|coreg ( entity ) is a beta-blocker indicated for the treatment of congestive heart failure and flomax ( tamsulosin ) is indicated for the treatment of
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|sodium antihypertensive verapamil succinate losartan|sodium creatine magnesium alk potassium|carvedilol|flamel technologies has collaborations with a number of leading pharmaceutical and biotechnology companies , including glaxosmithkline ( coreg cr® , entity phosphate ) .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|sodium antihypertensive verapamil succinate losartan|sodium inorganic potassium magnesium creatine|carvedilol|entity phosphate is indicated for the treatment of hypertension and heart failure .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium antihypertensive verapamil succinate losartan|coreg new everolimus novartis tablet|carvedilol|teva and numerous other generic producers began selling their entity tablets ( the generic version of coreg® ) in september of 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sodium antihypertensive verapamil succinate losartan|atorvastatin rosiglitazone bevacizumab class bupivacaine|carvedilol|european marketing application submitted in october 2014 ; and ( ix ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium antihypertensive verapamil succinate losartan|novartis new gsk everolimus tablet|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sodium antihypertensive verapamil succinate losartan|sodium lithium magnesium sildenafil creatine|carvedilol|this technology has successfully transitioned to commercial stage with coreg cr® , a micropump-based controlled-release formulation of entity phosphate , sold in the us since 2007 by gsk .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|sodium antihypertensive verapamil succinate losartan|coreg propofol tacrolimus hydrocortisone ketamine|carvedilol|first part of the market includes generic drugs based on the immediate release of the generic active ingredient known as entity ( such as coreg® produced by glaxosmithkline ) .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|sodium antihypertensive verapamil succinate losartan|sodium magnesium lithium sildenafil tenofovir|carvedilol|when we entered into a license agreement for use of our micropump platform for an extended release formulation of entity phosphate .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|sodium antihypertensive verapamil succinate losartan|class rosiglitazone atorvastatin formulation combination|carvedilol|planned for the third quarter of 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 4), ('OTHER', 4), ('DIS', 1)])|drug|sodium antihypertensive verapamil succinate losartan|rosiglitazone atorvastatin class bevacizumab bupivacaine|carvedilol|european marketing application submitted in october 2014 ; and ( viii ) rhb-101 - a once-daily oral pill formulation of the cardio drug entity .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5)])|drug|sodium antihypertensive verapamil succinate losartan|risperidone midazolam naltrexone metformin olanzapine|carvedilol|during fiscal 2008 , we launched entity tablets , meprobamate tablets , omeprazole , finasteride , ceterizine otc , ranitidine otc , zolpidem tablets , terbinafine and ciprofloxacin er tablets .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sodium antihypertensive verapamil succinate losartan|gsk marketed own patent commercial|carvedilol|teva would be permitted to continue selling its entity products , given that gsk  s patent has expired .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|sodium antihypertensive verapamil succinate losartan|losartan propranolol nifedipine sildenafil clonidine|carvedilol|since 1991 , entity has been approved as a treatment for hypertension in several european countries , and in september 1995 , it was approved by
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium antihypertensive verapamil succinate losartan|diuretic comparator combination comparison similar|carvedilol|bucindolol in sort of all comers , what you see is a data set that compares favorably to metoprolol or a entity , at least on the data that are available .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium antihypertensive verapamil succinate losartan|marketed patent own commercial medicinal|carvedilol|successful in its allegations of patent infringement , teva could be required to pay damages relating to past sales of its entity products .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sodium antihypertensive verapamil succinate losartan|novartis new gsk everolimus tablet|carvedilol|teva and eight other generic producers began selling their entity tablets ( the generic version of gsks coreg® ) in september 2007 .
OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|sodium antihypertensive verapamil succinate losartan|propranolol succinate citrate propofol fumarate|carvedilol|toprol-xl and coreg have generic equivalents commercially available in the u . s . ( metoprolol succinate and entity , respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|succinate sodium malate carbonate antiretroviral|naltrexone gabapentin melatonin orexin olanzapine|lemborexant|merck is marketing belsomra® ( suvorexant ) and eisai is marketing dayvigo® ( entity ) which are dual orexin receptor antagonists indicated for insomnia .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|succinate sodium malate carbonate antiretroviral|pfizer melatonin novartis gsk naltrexone|lemborexant|in december 2019 , eisai announced u . s . fda approval of dayvigo™ ( entity ) , a dual orexin receptor antagonist for the treatment of insomnia in adult patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|succinate sodium malate carbonate antiretroviral|melatonin naltrexone gabapentin orexin losartan|lemborexant|purdue and eisai are developing entity and glaxosmithkline is developing sb-649868 which are also dual orexin receptor antagonists .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ring amide prophylactic tablet combination|oxaliplatin erlotinib carboplatin capecitabine docetaxel|lansoprazole|volume was flat as a result of competition on us sales of enoxaparin , lost us authorized generics of gemcitabine and entity in the prior year , and lower sales in germany .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|po ppi ca roche tm|lansoprazole|the principal indications for prevacid ( entity ) , a proton pump inhibitor , are for short-term treatment of duodenal ulcers , gastric ulcers and erosive esophagitis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|ring amide prophylactic tablet combination|iron testosterone gelatin atorvastatin tablet|lansoprazole|in september 2008 , abbott and takeda settled that patent infringement lawsuit against apotex and apotex was allowed to begin selling generic entity capsules in canada on may 1 , 2009 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 1)])|drug|ring amide prophylactic tablet combination|thalidomide etanercept minocycline tpa sildenafil|lansoprazole|the original united states compound patent covering entity is licensed by tap from takeda and will expire in 2009 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|own respective individual original specific|lansoprazole|with tap pharmaceutical products inc . , or tap , granting tap the right to develop one or more products based on its entity ppi product and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ring amide prophylactic tablet combination|ppi erythromycin ppis amoxicillin ibuprofen|lansoprazole|in the treatment of reflux oesophagitis , it provides healing and symptom relief in more patients than losec / prilosec , entity or pantoprazole .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|entities entity nature companies employees|lansoprazole|to tap the north american rights to develop , manufacture and sell products resulting from the use of our technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|ring amide prophylactic tablet combination|etanercept sildenafil tacrolimus adalimumab dasatinib|lansoprazole|our ongoing work with tap pharmaceuticals on an improved formulation of entity continues to progress smoothly .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|its all similar commercially several|lansoprazole|million ) , which caused pricing to decline , as well as nearly usd 100 million of prior-year sales of sandozs gemcitabine and entity authorized generics .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|ring amide prophylactic tablet combination|ibuprofen erythromycin dexamethasone aspirin theophylline|lansoprazole|dosage forms of acetaminophen , and an improved method of manufacturing for drugs requiring protection from stomach acid , such omeprazole and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ring amide prophylactic tablet combination|metronidazole amoxicillin ppi midazolam azithromycin|lansoprazole|with respect to omeprazole and entity , we believe that we have created an improved method of manufacture , requiring less time and producing higher purity amid better
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ring amide prophylactic tablet combination|entities ingredients entity pharmaceuticals patents|lansoprazole|the north american rights to develop , manufacture and sell products resulting from the use of our immediate-release ppi technology with entity and derivatives of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ring amide prophylactic tablet combination|erythromycin ppis ppi amoxicillin ibuprofen|lansoprazole|nexium ( esomeprazole ) is the first proton pump inhibitor ( ppi ) to offer significant clinical improvements over losec / prilosec and its main competitors , entity and pantoprazole .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|trap ttr rt prs rpt|lansoprazole|tap also markets prevacid-registered trademark- ( entity ) , a proton pump inhibitor , and has a co-promotion arrangement with the company for prevacid-registered trademark- .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ring amide prophylactic tablet combination|celecoxib capecitabine ibuprofen diclofenac aspirin|lansoprazole|prevonco™ for the treatment of solid tumors , contains a currently third-party marketed anti-ulcer compound , entity , for the treatment of solid tumors .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|ring amide prophylactic tablet combination|novartis sildenafil etanercept infliximab buprenorphine|lansoprazole|sales of entity , which was launched in december 2004 , accounted for 8% of our branded pharmaceutical revenues during the six months ended june 30 , 2005
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|ring amide prophylactic tablet combination|ppis ppi tablets clopidogrel warfarin|lansoprazole|pantoprazole faces competition from various other branded ppis , including takedas entity and astrazenecas esomeprazole .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ring amide prophylactic tablet combination|celecoxib capecitabine diclofenac ibuprofen aspirin|lansoprazole|prevonco™ for the treatment of solid tumors , contains a marketed anti-ulcer compound , entity , that could be used alone or in combination with other chemotherapeutic agents .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|ring amide prophylactic tablet combination|roche merck tablets tm ppi|lansoprazole|tap also markets prevacid® ( entity ) , a proton pump inhibitor .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|drug|ring amide prophylactic tablet combination|approval success japan drs benefits|lansoprazole|preceding these notable launches , takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990s with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|antifungal potent imidazole ring antiretroviral|fluconazole imidazole metronidazole erythromycin ciprofloxacin|terconazole|prescription drugs in the antifungal field include nizoral ( ketoconazole ) , sporanox ( itraconazole ) , terazol ( entity ) and daktarin ( miconazole nitrate ) antifungal products .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antifungal potent imidazole ring antiretroviral|fluconazole amphotericin erythromycin metronidazole ciprofloxacin|terconazole|product in this category which does not contain a fungicide such as 95 table of contents clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|antifungal potent imidazole ring antiretroviral|fluconazole metronidazole ciprofloxacin theophylline azithromycin|terconazole|the approved prescription therapies for vvc are diflucan ( fluconazole ) and terazol ( entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|antifungal potent imidazole ring antiretroviral|fluconazole erythromycin amphotericin metronidazole ciprofloxacin|terconazole|a probiotic , purfem is the only product in this category which does not contain a fungicide such as clotrimazole , miconazole , entity or nystatin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|drug|amine containing amide amino methylene|tm acth sq novartis leptin|azelastine|the astelin ( entity ) tablet nda for asthma will be withdrawn as soon as it is no longer needed to support the other two
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|amine containing amide amino methylene|tm sq novartis acth er|azelastine|the astelin ( entity ) tablet nda for rhinitis is pending at the fda .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|drug|amine containing amide amino methylene|sq ast sr ar acth|azelastine|division the division had a successful year highlighted by the first full year of marketing a new antihistamine , 2 astelin ( entity ) nasal spray .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|drug|amine containing amide amino methylene|histamine h1 dexamethasone theophylline hcl|azelastine|in august 2002 , we entered into an agreement with medpointe inc . to co-promote medpointe  s nasal-spray antihistamine , astelin® ( entity hcl ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|amine containing amide amino methylene|histamine theophylline h1 dexamethasone morphine|azelastine|in august 2002 , we signed an agreement with medpointe , inc . for the co-promotion of astelin® ( entity hcl ) , a nasal-spray antihistamine .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|amine containing amide amino methylene|name formulation generic er sodium|azelastine|on october 1 , 2004 , we terminated our co-promotion agreement with medpointe , inc . , or medpointe , for the co-promotion of astelin brand entity hcl for the treatment of allergic rhinitis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|del versus av vs express|tablets tablet novartis nvp roche|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of april 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|del versus av vs express|novartis bortezomib bayer furosemide tm|patiromer|on october 21 , 2015 , the u . s . food and drug administration , or fda , approved our first drug , veltassa® ( entity ) for oral suspension , or veltassa , for the treatment of hyperkalemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|proposed available tested studied developed|patiromer|relypsas lead product candidate is entity , which is also known as rly5016 , is a non-absorbed potassium binder that is currently being evaluated for the treatment of
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|del versus av vs express|zs both potassium furosemide lithium|patiromer|also aware of two products for which regulatory approval in the united states has been sought for treatment of hyperkalemia , entity from relypsa and zs-9 from zs pharma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|drug|del versus av vs express|ms sci his diabetes ours|patiromer|veitinger , a member of our board of directors , under which dr . veitinger provides certain consulting services to us in connection with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|del versus av vs express|tablets novartis tablet merck roche|patiromer|to hospitals / other institutions for the full month of march and the three month period ended march 31 , 2016 for veltassa ® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|development dsm preparation ad sm|patiromer|the agreement , dsm fine chemicals has agreed to manufacture and supply for commercial sale the active pharmaceutical ingredient ( api ) for entity , the companys lead product candidate .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|this existing marketed fda these|patiromer|drug discovery technology or by selectively pursuing the in-licensing or acquisition of additional compounds that would be commercially synergistic with entity fos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|drug|del versus av vs express|melanoma psoriasis ipf cf epilepsy|patiromer|if the companys new drug application for entity is not accepted by the fda on or before december 31 , 2013 , 25% of the shares subject to the option shall
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 3), ('OTHER', 3)])|drug|del versus av vs express|bortezomib azt nvp tm merck|patiromer|we are substantially dependent on the success of our first and only drug , veltassa® ( entity ) for oral suspension , or veltassa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|del versus av vs express|pharmaceuticals fda pay market medicines|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the u . s . until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|these new all our this|patiromer|we are not permitted to market entity fos in the u . s . until we receive approval of our nda from the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|this these its fos new|patiromer|in this offer to purchase ) with vifor fresenius medical care renal pharma ltd . ( vfmcrp ) , an affiliate of galenica , to commercialize entity fos outside of the united states and japan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|drug|del versus av vs express|tablets tablet novartis nvp roche|patiromer|new patient starts , outpatient prescriptions and units sold to hospitals / other institutions for the full month of february 2016 for veltassa® ( entity ) for oral suspension ( veltassa ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|del versus av vs express|pharmaceuticals market fda pay medicines|patiromer|relypsa has global royalty-free commercialization rights to entity for oral suspension , which has intellectual property protection in the united states until at least 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|these this all new its|patiromer|relypsa intends to commercialize entity fos , if approved , with its own dedicated u . s . -based commercial team and specialty sales force of approximately 120 sales representatives .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|drug|del versus av vs express|potassium edta citrate furosemide magnesium|patiromer|the challenge all potassium binders ( e . g . entity ) have limited efficacy on per gram basis therapeutic dose for kayexelate , entity or zs-9 substantially the same ( 15-30 g / day )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|drug|del versus av vs express|affairs institute oncology services model|patiromer|business entity clinical development program—pivotal phase 3 trial , page 101 please expand your discussion of your results to identify the serious adverse
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|del versus av vs express|this chitosan polymer gelatin cellulose|patiromer|entity is a non-absorbed , potassium binding polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|del versus av vs express|tm formerly el sodium peg|patiromer|veltassa ( entity fos ) , an oral , polymer-based potassium binder , was approved for marketing by the fda in october 2015 and was commercially launched
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 2)])|drug|intramuscular cyclosporine positive did diethyl|methadone haloperidol amphetamine fluoxetine cocaine|benzphetamine|several older agents , indicated for short-term administration , are amphetamine-like compounds including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|isoniazid carbamazepine methadone propranolol fluoxetine|benzphetamine|in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|carbamazepine fluoxetine propranolol isoniazid erythromycin|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|intramuscular cyclosporine positive did diethyl|carbamazepine methadone isoniazid haloperidol fluoxetine|benzphetamine|several older drugs , indicated for short-term administration , include phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|compounds antidepressants vitamins derivatives medicine|benzphetamine|the treatment of obesity , and several older agents , indicated for short-term administration , including phentermine , phendimetrazine , 33 table of contents entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|isoniazid methadone carbamazepine propranolol fluoxetine|benzphetamine|products in the united states for the treatment of obesity , and several older agents , indicated for short-term administration , phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 2)])|drug|intramuscular cyclosporine positive did diethyl|methadone haloperidol carbamazepine fluoxetine clozapine|benzphetamine|several older drugs , indicated for short-term administration , have an amphetamine-like profile , including phentermine , phendimetrazine , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|simvastatin atorvastatin citrate metformin losartan|benzphetamine|mg tab mysoline® promethazine 12 . 5 , 25 , 50mg tab ( 2 separate andas ) phenergan® fenofibrate 54 , 160mg tab lofibra® entity 50mg tab didrex® not currently marketed .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|intramuscular cyclosporine positive did diethyl|methadone propranolol naltrexone carbamazepine fluoxetine|benzphetamine|in addition , a number of generic pharmaceutical products are prescribed for obesity , including phentermine , phendimetrazine , mazindol , entity and diethylpropion .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|kanamycin ciprofloxacin ceftriaxone gentamicin tetracycline|ciprofloxacin|infecton® is the proprietary combination of the widely used antibiotic , entity , with technetium ( 99mtc ) , the most commonly used radioisotope in nuclear medical imaging .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|antipsychotics benzodiazepines anticoagulants nsaids analgesics|ciprofloxacin|should inform their physician if they are taking , or planning to take , any prescription or over-the-counter drugs , especially antidepressants and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|ciprofloxacin gentamicin antibiotic amoxicillin injectable|ciprofloxacin|about otiprio® otiprio ( entity otic suspension ) is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|injectable antibiotic azithromycin tablet ciprofloxacin|ciprofloxacin|bayer corporation has developed a once-daily entity product for the treatment of urinary tract infections , which is currently marketed by schering-plough corporation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|irinotecan sildenafil doxorubicin gemcitabine dexmedetomidine|ciprofloxacin|and we agreed to settle the then pending litigation regarding bayer  s patent protecting entity hydrochloride .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|new original licensed marketing issued|ciprofloxacin|carlsbad has withdrawn all other defenses it had originally raised challenging the validity and enforceability of bayer ag  s entity patent .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|naltrexone ibuprofen pioglitazone sildenafil gabapentin|ciprofloxacin|we intend to begin marketing and selling the tablet dosage form of entity through our alliance with lannett if and when anda approval is given by the fda and following the expiration of
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 2)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|bupivacaine gentamicin lidocaine dexamethasone sodium|ciprofloxacin|otiprio ( entity otic suspension ) is the first drug approved in the united states for use during tympanostomy tube placement ( ttp ) surgery and
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|metronidazole ciprofloxacin amoxicillin vancomycin azithromycin|ciprofloxacin|entity is approved as therapy for infectious diarrhea with a dosing regimen of twice daily administrations for five to seven days .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|money medicaid 2007 industry applications|ciprofloxacin|if we lost our patent protection for entity , or if the expiration of the patent were accelerated to october 2002 , we believe that we would forego significant revenue .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|this another new our that|ciprofloxacin|if we are not already distributing the product , we , along with our partner , will have the right to begin distributing entity product manufactured by bayer .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|new marketed commercial proprietary registered|ciprofloxacin|the decrease in the quarter reflects the launch of the company  s entity product on june 9 , 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|amoxicillin metronidazole ampicillin ceftriaxone azithromycin|ciprofloxacin|limitations of entity , rifaximin and tmp / smx , three of the most commonly prescribed treatments for infectious diarrhea , include one or more of the following :
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|pharmaceuticals marijuana cannabis tobacco lithium|ciprofloxacin|based on the plaintiffs expert testimony in the california case , estimated sales of entity in california were approximately $500 million during the alleged damages period .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|nivolumab funds materials bevacizumab vaccines|ciprofloxacin|pursuant to the terms of the agreement , we began distributing entity on june 9 , 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|philadelphia hcl chicago nci bethesda|ciprofloxacin|year ended march 31 , 2002 2003 entity hcl rs .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|ciprofloxacin amoxicillin fq tetracycline ceftriaxone|ciprofloxacin|gyra and parc are the targets of the fluoroquinolone class of antibacterial agents , such as entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|rituximab peg eos acth comparator|ciprofloxacin|the fda placed the valortim® / entity study on partial clinical hold pending the outcome of the investigation .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|ciprofloxacin metronidazole doxycycline azithromycin amoxicillin|ciprofloxacin|proquin® xr ( entity hydrochloride ) is a once-daily treatment for uncomplicated urinary tract infections that the company no longer manufactures or markets .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|drug|ciprofloxacin metronidazole prophylactic antibiotic antiviral|own patent existing unique new|ciprofloxacin|we intend to continue taking vigorous action to maintain our entity patent rights in the united states through their normal expiry in december 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulfon sodium vincristine sclerosis containing|nitrate chloride containing silver based|sulfadiazine|the most common topical antimicrobial agent used is silver entity cream .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulfon sodium vincristine sclerosis containing|nitrate phosphate sulfate gel peroxide|sulfadiazine|wound epithelialization was 11 days for patients treated with transcyte as compared to 18 days for patients treated with silver entity cream .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulfon sodium vincristine sclerosis containing|dressing nitrate gel silver sulfate|sulfadiazine|as compared to silver entity , dermagraft-tc may reduce the pain , time and cost associated with once or twice daily dressing changes and excision .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|nitrate dressing gel cream spray|sulfadiazine|a number of studies have been conducted which compared the efficacy of collagenase santyl ( r ) to standard treatment ( silver entity ) for deep second degree burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|ions salts spray cream nitrate|sulfadiazine|intended for delivery through the skin ) for the treatment of burns that is expected to not only reduce infection ( silver entity ) , but also enhance tissue growth .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|value values ratio substance metabolite|sulfadiazine|in this same model , d2a21 demonstrated significant improvement in percent survival ( 85% versus 0% in the control group , p entity ( ssd ) and sulfamylon .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|nitrate dressing gel cream patches|sulfadiazine|in a clinical trial under a physician  s ide , transcyte was evaluated as an alternative to silver entity in the treatment of patients with limited to moderate partial-thickness burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|dressing nitrate gel spray cream|sulfadiazine|transcyte was compared to silver entity which had twice daily dressing changes and wound debridement as per the burn center  s standard practice .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|drug|sulfon sodium vincristine sclerosis containing|nitrate particles phosphate silver crystals|sulfadiazine|sildaflo is a dressing that incorporates silver 6 entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|dressing gel nitrate cream paste|sulfadiazine|in partial-thickness burns , dermagraft-tc , as compared to silver entity , has been shown to significantly reduce pain and to heal burns faster and with less scarring .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulfon sodium vincristine sclerosis containing|silver new injectable novel marketed|sulfadiazine|entity silver ointment health product designed to assist in the prevention of infections related to burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|nitrate dressing gel paste peroxide|sulfadiazine|transcyte , as compared to silver entity in treating second degree burns , has been shown to heal burns faster .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|drug|sulfon sodium vincristine sclerosis containing|nitrate oxide dioxide nanoparticles sulfate|sulfadiazine|sildaflo is a dressing that incorporates silver entity , the most widely-used topical antimicrobial for the treatment of burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|sulfon sodium vincristine sclerosis containing|silver injectable dressing antimicrobial antibacterial|sulfadiazine|entity silver ointment designed to the treatment or the prevention of infections related to burns .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|sulfon sodium vincristine sclerosis containing|silver sodium methyl isopropyl diclofenac|sulfadiazine|banlangen tablets , dansheng tablets and entity silver ointment remain listed in the updated state insurance catalogue .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|drug|sulfon sodium vincristine sclerosis containing|silver sodium liquid plain pure|sulfadiazine|at present , xuesaitong soft capsules and entity silver ointment have already been listed in the insurance catalogue .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|drug|av versus press vs best|furosemide olanzapine dexamethasone losartan lithium|conivaptan|the study evaluated both 20 and 40 mg / day doses of entity in hyponatremic patients and was conducted at 26 u . s . and 2 international centers .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 3)])|drug|av versus press vs best|tm epinephrine buprenorphine propofol lidocaine|conivaptan|of an open label multicenter study adding to the growing body of literature supporting the efficacy and use of vaprisol ( entity ) injection .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4), ('DIS', 1)])|drug|av versus press vs best|sodium aldosterone arginine vasopressin lithium|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 2)])|drug|av versus press vs best|sodium aldosterone arginine furosemide vasopressin|conivaptan|about vaprisol® ( entity hydrochloride ) injectionvaprisol is an intravenous treatment for hyponatremia used in the critical care setting .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|naltrexone pioglitazone risperidone olanzapine buprenorphine|roflumilast|two of our newest products , daliresp ( entity ) and viibryd ( vilazodone hcl ) became available to patients during the june 2011 quarter and were formally launched in late august
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|atropine propranolol isoproterenol phenylephrine digoxin|roflumilast|and these products were nebivolol , milnacipran , ceftaroline , entity , aclidinium , linaclotide , levomilnacipran and cariprazine .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|nicotine entity this estrogen olive|roflumilast|pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing entity cream , entity foam , arq-252 or arq-255 .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|sildenafil theophylline pioglitazone dpi rosiglitazone|roflumilast|one such treatment is an oral formulation of a pde4 inhibitor ( entity ) with anti-inflammatory properties , although frequency of adverse events has limited its use in copd patients .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|sildenafil pioglitazone rosiglitazone theophylline tm|roflumilast|this year in addition to teflaro . in addition , we are hopeful to obtain fda approval later this quarter for daxas ( entity ) , for the treatment of copd .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|r2 irinotecan m2 dd r1|roflumilast|q31 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|µg mcg tablets μg tablet|roflumilast|* forced expiratory volume in 1 second , primary endpoint of the ratio trial table of contents pharmaceuticals 9 entity , administered at a daily dose of 500 µg , is an effective product .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|dmd dpi dp dt dx|roflumilast|daliresp ( entity ) , our selective phosphodiesterase 4 ( pde4 ) enzyme inhibitor indicated for the treatment to reduce risk of exacerbations in patients with severe
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|others copd adults japan developed|roflumilast|as oral administration ariflo® ( cilomilast ) of glaxosmithkline pharmaceuticals , recently found approvable for maintenance of lung function in certain patients , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|2014 2016 2011 2017 2012|roflumilast|daliresp ( entity ) us patent proceedings in 2015 and subsequently , in response to paragraph iv notices from multiple anda filers , astrazeneca filed patent
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|agents therapies treatments antimicrobials tacrolimus|roflumilast|each of these areas present a variety of treatment challenges which may be well suited to treatment with topical entity .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|sildenafil theophylline gold rosiglitazone pioglitazone|roflumilast|in addition , we did not observe the gastrointestinal or other side effects associated with entity , the only pde4 inhibitor currently on the market approved for the treatment of copd .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|sildenafil theophylline erlotinib adalimumab dexmedetomidine|roflumilast|entity was generally well tolerated in the treatment of patients with copd .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|2016 2015 2014 gsk uk|roflumilast|daliresp ( entity ) patent proceedings in the us in april 2015 , astrazeneca received several paragraph iv notices challenging certain patents listed in the
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|r2 irinotecan dd m2 tmz|roflumilast|q34 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|sildenafil pioglitazone rosiglitazone losartan sunitinib|roflumilast|our clinical trials , and has not been observed to result in the gastrointestinal or other side effects commonly associated with entity , the only pde4 inhibitor currently on the market .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|r2 irinotecan m2 egfr q3|roflumilast|q33 ) what is the status of daxas ( entity ) ?
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|cer rd dc usd df|roflumilast|daliresp / daxas ( entity ) copd $215m , up 14% ( 15% at cer ) growth driven by favourable affordability-programme changes and inventory movements in the us .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('DRUG', 3), ('OTHER', 3), ('DIS', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|oxaliplatin midazolam irinotecan tmz concentration|roflumilast|we therefore elected to reduce the maximum concentration from 0 . 5% entity to 0 . 3% entity for subsequent development .
OrderedDict([('OTHER', 5), ('DRUG', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|drug|succinate methotrexate cyclosporine sunitinib inhibitor|tablet commercial computer pharmaceutical mobile|roflumilast|page 4 investment projects 2003 altana pharma will establish an ultra-modern entity tablet-producing factory in cork , ireland .
OrderedDict([('OTHER', 5), ('DRUG', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 5), ('DIS', 1)])|drug|sodium cyclosporine gabapentin risperidone verapamil|losartan sildenafil atorvastatin simvastatin nifedipine|levamlodipine|simceres strategic cardiovascular portfolio also continues to grow with our recently launched cholesterol lowering drug rosuvastatin and hypertension drug entity both performing well .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tablet but strong potent ring|potassium magnesium sodium silver lithium|butoconazole|the caption immediately below the picture of gynazole-1 ( r ) reads : " gynazole-1 ( r ) ( entity nitrate ) vaginal cream 2% only one dose .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tablet but strong potent ring|silver sodium potassium magnesium lidocaine|butoconazole|the product combines roche  s proprietary entity nitrate with kv  s proprietary site release ( r ) drug delivery technology .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|tablet but strong potent ring|sodium silver potassium magnesium nitrate|butoconazole|its licensing partner , ferring , inc . of canada has received approval from the canadian regulatory agency , hpb to market kv  s gynazole-1 ( r ) ( entity nitrate 2% vaginal cream ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|drug|tablet but strong potent ring|silver sodium magnesium potassium lithium|butoconazole|important safety information for gynazole-1 ( entity nitrate vaginal cream usp , 2% ) 5 . 7% of patients enrolled in the gynazole●1 clinical trials reported complaints such as vulvar / vaginal
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|drug|tablet but strong potent ring|silver sodium potassium candida fluconazole|butoconazole|gynazole-1 ( r ) ( entity nitrate 2% ) is a rapidly growing branded prescription vaginal antifungal product indicated for the local treatment of vulvovaginal candidiasis in butoconazole 
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|familial scoliosis simplex malformation developmental|dmd sma adhd asd jia|achondroplasia|january 2014 , we announced the initiation of a phase 2 clinical trial for vosoritide for the treatment of children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial scoliosis simplex malformation developmental|dmd adhd jia t1dm asd|achondroplasia|the phase 3 study is a randomized , placebo-controlled study of vosoritide in approximately 110 children with entity ages 5-14 for 52 weeks .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|familial scoliosis simplex malformation developmental|amd ad cf ms als|achondroplasia|currently , there are no medical therapies for entity approved by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|familial scoliosis simplex malformation developmental|osteoporosis ms dmd cnp osteogenesis|achondroplasia|in animal models of entity , administration of synthetic cnp and cnp analogues rescued the impaired bone growth phenotype without significant adverse effects .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|familial scoliosis simplex malformation developmental|neuroblastoma medulloblastoma mm retinoblastoma myeloma|achondroplasia|we announced the initiation of a phase 2 clinical trial for bmn 111 for the treatment of children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial scoliosis simplex malformation developmental|diabetes schizophrenia depression dementia ms|achondroplasia|this is approximately 25 percent of people with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial scoliosis simplex malformation developmental|diabetes schizophrenia ms dementia depression|achondroplasia|this is approximately 25% of people with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial scoliosis simplex malformation developmental|melanoma mesothelioma nsclc glioblastoma cll|achondroplasia| bmn-111 for entity : the company expects to initiate a phase 2 trial in patients in mid 2013 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|familial scoliosis simplex malformation developmental|dmd sma jia adhd asd|achondroplasia|on july 23 , 2020 , the company announced that it had submitted the maa for vosoritide for the treatment of children with entity to the ema .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|familial scoliosis simplex malformation developmental|cnp migraine cf amd ms|achondroplasia|the goal is to provide a safer and more efficacious therapy for entity , than daily administration of short-acting cnp analogues .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial scoliosis simplex malformation developmental|dmd jia t1dm ms adhd|achondroplasia|global phase 2 multiple dose , randomized study to assess the safety , tolerability , pharmacokinetics and efficacy of recifercept in children with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial scoliosis simplex malformation developmental|dmd t1dm jia sma t1d|achondroplasia|continuing studies include our phase 3 study of vosoritide in approximately 110 children with entity for 52 weeks and a long-term open-label phase 2 study of approximately 23 children .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial scoliosis simplex malformation developmental|dwarf stature osteogenesis ds dmd|achondroplasia|transcon cnp is being developed for the treatment of entity , the most common form of dwarfism .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|disease|familial scoliosis simplex malformation developmental|neuroblastoma mesothelioma amyloidosis tumors chf|achondroplasia|genetically-defined cancers , and bmn-111 , a modified c-natriuretic peptide , which is currently in phase i clinical development for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial scoliosis simplex malformation developmental|neuroblastoma dmd diabetes nf1 osteogenesis|achondroplasia|natriuretic peptide , or cnp , is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause entity resulting in dwarfism .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|familial scoliosis simplex malformation developmental|osteoarthritis osteoporosis fibromyalgia oa diabetes|achondroplasia|rapid clinical development and ( iv ) the possible approval and commercialization of biomarins product candidates , including vosoritide for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial scoliosis simplex malformation developmental|gestational infants diabetes asd chronological|achondroplasia|the phase 2 study is a randomized , placebo-controlled study of vosoritide in approximately 70 infants and young children with entity ages zero to less than 60 months for 52 weeks .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|dermatology ophthalmology rheumatology alcoholism neurology|adrenoleukodystrophy|we will also regain control of the preclinical programs in entity ( ald ) and two ophthalmic programs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|poorly adren psoriasis alzheimer fully|palsy degeneration aneurysms glioma hemorrhage|adrenoleukodystrophy|european medicines agency ( ema ) granted an accelerated assessment to elivaldogene autotemcel ( eli-cel , lenti-d gene therapy ) for the treatment of cerebral entity ( cald ) .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|poorly adren psoriasis alzheimer fully|tr recessive gene toxicity break|adrenoleukodystrophy|trb : x-linked entity , plans current status evaluation of vk0214 ongoing , encouraging in vitro results in vivo model in progress poc results expected 2016
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|poorly adren psoriasis alzheimer fully|development network biobank neuroprotection neuroscience|adrenoleukodystrophy|cerebral entity ( cald ) the cald platform includes three patent portfolios , described below .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|melanoma ad amd ms diabetes|adrenoleukodystrophy|our lenti-d product candidate has been granted orphan drug status by the fda and the ema for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|poorly adren psoriasis alzheimer fully|ald alcoholism ataxia amyloidosis hypercholesterolemia|adrenoleukodystrophy|our second trß agonist is vk0214 , which we are evaluating in the orphan disease known as x-linked entity , or x-ald .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|poorly adren psoriasis alzheimer fully|aneurysms degeneration palsy glioma atrophy|adrenoleukodystrophy|our lenti-d product candidate to treat cerebral entity ( cald ) •
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|poorly adren psoriasis alzheimer fully|mapping palsy plasticity organoids cortex|adrenoleukodystrophy|on our two most advanced programs in tdt and cerebral entity , these data will dictate the timing and path for future regulatory submissions in the us and europe .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|poorly adren psoriasis alzheimer fully|ald alcoholism cholestasis ataxia hypercholesterolemia|adrenoleukodystrophy|vk0214 is being evaluated as a potential treatment for x-linked entity ( x-ald ) , a devastating disease caused by a defect in a peroxisomal transporter called abcd1 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|ophthalmology vision cataract amd cornea|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('BIO', 1)])|disease|poorly adren psoriasis alzheimer fully|palsy gliomas glioma tumors aneurysms|adrenoleukodystrophy|clinical study of our bb2121 product candidate in relapsed / refractory multiple myeloma and updates on our lenti-d program in cerebral entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|poorly adren psoriasis alzheimer fully|others thalassemia diabetes amyloidosis sarcoidosis|adrenoleukodystrophy|diseases treatable with hematopoietic stem cell transplants include inherited metabolic diseases , such as krabbe syndrome , metachromatic leukodystrophy , hurler syndrome and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|ophthalmology vision cataract amd cornea|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the three discovery programs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|poorly adren psoriasis alzheimer fully|palsy blindness hemorrhage degeneration lupus|adrenoleukodystrophy|bio intends to use the net proceeds of this offering primarily to advance its clinical studies in ccald ( childhood cerebral entity ) , beta-thalassemia major and sickle cell disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|ald pbc nafld alcoholism nash|adrenoleukodystrophy|the worldwide incidence rate for entity , or ald , the superset of ccald , is approximately one in 20 , 000 newborn males .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|poorly adren psoriasis alzheimer fully|alcoholism ald encephalopathy sclerosis fibrosis|adrenoleukodystrophy|entity , or ald , is a genetically determined neurological disorder that affects 1 in every 17 , 900 boys worldwide or 1 in 50 , 000
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|ophthalmology vision cataract interest myopia|adrenoleukodystrophy|in february 2016 , the company announced biogens selection of entity as the non-ophthalmic indication of the discovery programs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|poorly adren psoriasis alzheimer fully|this neuroblastoma eclampsia preeclampsia gbs|adrenoleukodystrophy|entity is a rare , often fatal condition believed to occur with an incidence of approximately one in 17 , 000 births .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|poorly adren psoriasis alzheimer fully|ald alcoholism ataxia amyloidosis ad|adrenoleukodystrophy|▪ evaluation of vk0214 in an in vivo model of x-linked entity ( x-ald ) recently completed .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|poorly adren psoriasis alzheimer fully|ald ataxia amyloidosis alcoholism ad|adrenoleukodystrophy|▪ advancing ind-enabling work for vk0214 in x-linked entity ( x-ald ) ; ind filing planned in 2h19 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|malformation twin spinal cleft hydrocephalus|hydrocephalus scoliosis medulloblastoma deafness autism|anencephaly|ntds include often devastating abnormalities such as spina bifida and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|single low propionate high basal|spasticity als sma sci dystonia|argininemia|own decreased spasticity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|single low propionate high basal|myopathy gout thalassemia pancreatitis diabetes|argininemia|enzyme activity adapted from sakiyama et al “a successful trial of enzyme replacement therapy in a case of entity” j exp med .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|bronchial childhood rhinitis condition asthmatic|psoriasis lupus eczema colitis diabetes|asthma|acute inflammatory disease , as well as an oral anti-cytokine therapy that could be directed at chronic inflammatory diseases such as entity , rheumatoid arthritis and crohns disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|immunology immunotherapy anaphylaxis inflammation dermatitis|asthma|we currently have programs in entity / allergy , autoimmunity , transplant rejection , rheumatoid arthritis / inflammatory bowel disease , and tumor growth .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|disease|bronchial childhood rhinitis condition asthmatic|bevacizumab nivolumab bortezomib ipilimumab irinotecan|asthma|we remain on track to initiate a phase 1a single ascending dose clinical trial for entity in the second quarter with preliminary data anticipated by the end of 2014 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|atopic psoriasis eczema iga dermatology|asthma|•we reported positive , pivotal , phase 2b data for dupilumab in the entity indication and completed enrollment of three phase 3 studies of dupilumab in atopic dermatitis .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|bronchial childhood rhinitis condition asthmatic|hematology neurology oncology rheumatology immunology|asthma|acuspheres three initial product candidates are designed to address large unmet clinical needs within cardiology , oncology and entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|bronchial childhood rhinitis condition asthmatic|atherosclerosis ms ad vl epilepsy|asthma|vla-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bronchial childhood rhinitis condition asthmatic|ms amd ad migraine epilepsy|asthma|the primary focus of the collaboration will be to discover orally available vla-4 antagonists as treatments for entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|rhinitis asthmatics copd eczema bronchitis|asthma|cromolyn is considered first line therapy in mild persistent entity and is frequently prescribed for children .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|bronchial childhood rhinitis condition asthmatic|rhinitis dermatitis diseases colitis eczema|asthma|is designed to mediate the suppression of ige and ige-producing cells and originally was developed for the treatment of allergic entity and other ige-mediated diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bronchial childhood rhinitis condition asthmatic|copd ad chf angina hf|asthma|development program to date for prv-300 included studies in healthy adult volunteers and adult patients with stable ( mild to moderate ) entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|bronchial childhood rhinitis condition asthmatic|diseases autoimmunity inflammation dermatitis autoimmune|asthma|are engaged in the discovery , development and commercialization of novel therapeutics based on synthetic dna for the treatment of cancer , entity / allergies and infectious diseases .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|bronchial childhood rhinitis condition asthmatic|gastroenteritis colitis eczema pneumonia neutropenia|asthma|glaxosmithklines , or gsk  s , mepolizumab ( nucala ) which targets il-5 was approved for severe eosinophilic entity in adults and children older than 12 in 2015 .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|bronchial childhood rhinitis condition asthmatic|copd bronchitis inflammation emphysema airways|asthma|beclomethasone is a steroid used to treat the inflammatory component of entity and certain symptoms of copd .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|bronchial childhood rhinitis condition asthmatic|copd these older such all|asthma|receptor subtypes , it can cause unwanted side effects including flushing , dyspnea and headache , and it should not be used in entity patients .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|psoriasis ipf ra nsclc melanoma|asthma|the first human proof-of-concept data being obtained in a phase 2 study of genentechs anti-il-13 antibody lebrikizumab for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bronchial childhood rhinitis condition asthmatic|thrombotic migraine myocardial cold rejection|asthma|however , in certain instances , the process may be overly active , such as during an acute entity attack where an immediate inflammatory reaction occurs .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|bronchial childhood rhinitis condition asthmatic|autoimmune autoimmunity psoriasis inflammation immunology|asthma|xmab7195 were developing for entity and allergic disease .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|spasm obstruction reactivity inflammation desensitization|asthma|it is a prophylactic agent indicated for the management of bronchial entity and exercise-induced bronchospasm .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|bronchial childhood rhinitis condition asthmatic|cf t1d mf ms ipf|asthma|clinical development program for zyflo consisted of 21 safety and efficacy trials in an aggregate of approximately 3 , 000 patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|bronchial childhood rhinitis condition asthmatic|gout psoriasis ms rls osteoporosis|asthma|and sales infrastructure to promote zyflo and the controlled-release formulation of zileuton that we are developing for the treatment of entity upon regulatory approval from the fda .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|chord dural cell dura meningioma|osteosarcoma gist glioblastoma mesothelioma melanoma|chordoma|we are conducting a multi-cohort , global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|chord dural cell dura meningioma|evaluable new female remaining experimental|chordoma|the other three entity subjects in the study have been diagnosed with progressive disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chord dural cell dura meningioma|melanoma nsclc relapsed glioblastoma unresectable|chordoma|the trial was an open-label , phase 1 trial and enrolled 38 patients with metastatic cancer or entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chord dural cell dura meningioma|melanoma adults humans japan pediatrics|chordoma| a phase 2 study in entity is being prepared for initiation at the nci .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chord dural cell dura meningioma|nsclc hnscc glioblastoma melanoma npc|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|chord dural cell dura meningioma|new million evaluable hundred 000|chordoma|the company believes that the summary results from the 11 entity patients enrolled in this trial compare favorably with historically published data .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chord dural cell dura meningioma|melanoma lymphomas mesothelioma nsclc myeloma|chordoma|additional phase ib / ii clinical trials in various indications are newly opened , including for colorectal and hepatocellular cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|chord dural cell dura meningioma|others lymphomas sarcomas mds neuroblastoma|chordoma|trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|chord dural cell dura meningioma|melanoma nsclc cll gist glioblastoma|chordoma|we are excited about the recent initiation of the phase 2 trial of gi-6301 at the nci for patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chord dural cell dura meningioma|melanoma glioblastoma lymphomas neuroblastoma myeloma|chordoma|mva-bn brachyury for the treatment of metastatic cancer and entity mva-bn brachyury is a cancer immunotherapy developed using our proprietary validated mva-bn platform .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|chord dural cell dura meningioma|dlbcl rms aml mcl cml|chordoma|we have obtained orphan drug designations for tazemetostat for the treatment of patients with fl , entity , malignant rhabdoid tumors , or mrt , soft tissue sarcoma , or sts , and mesothelioma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chord dural cell dura meningioma|nsclc hnscc glioblastoma npc melanoma|chordoma|clinical trial designed to investigate the safety and efficacy of evaluating gi-6301 in combination with radiation therapy in patients with entity is still enrolling patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|chord dural cell dura meningioma|expansion fourth latter validation 2nd|chordoma|we added the entity cohort due to the high rate of enrollment of these patients in the other ini1-negative cohort and the observed clinical
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|chord dural cell dura meningioma|melanoma hcc cholangiocarcinoma lymphomas hbv|chordoma|the clinical and commercial landscape for pancreas cancer , non-small cell lung cancer , colorectal cancer , mtc , entity and chronic hepatitis b infection is rapidly changing .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|chord dural cell dura meningioma|others sarcomas nos all medulloblastoma|chordoma|which we collectively refer to as ini1-negative tumors , including epithelioid sarcoma , malignant rhabdoid tumors , or mrt , other ini1-negative tumors , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|chord dural cell dura meningioma|chord our hope this his|chordoma|dr . mahony also serves on the board of entity foundation , a nonprofit organization dedicated to improving the lives of those affected by chordoma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|chord dural cell dura meningioma|melanoma gist osteosarcoma neuroblastoma nsclc|chordoma|are conducting a multi-cohort global phase 2 trial of tazemetostat in adults with ini1-negative tumors , including epithelioid sarcoma or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|chord dural cell dura meningioma|these most some such nsclc|chordoma|it is believed that radiation therapy can reduce the risk of recurrence after surgery and prolong survival for entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chord dural cell dura meningioma|all melanoma myeloma nsclc multiple|chordoma|the company believes that the gi-6301 tarmogen® , exclusively licensed to celgene corporation , has demonstrated promising initial results in entity patients evaluated in a recent phase 1 study .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|chord dural cell dura meningioma|adolescent paediatric 18 15 young|chordoma|the cohort of patients in the phase 2 study of entity patients is ongoing , and we are evaluating tazemetostat in the dose-expansion portion of a phase 1 study in pediatric patients
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|simplex familial inherited dystrophy gene|ms als psoriasis epilepsy fibromyalgia|choroideremia|the company&#8217 ; s lead product candidate , nsr-rep1 , for the treatment of entity is in phase 3 clinical development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|simplex familial inherited dystrophy gene|thalassemia dmd others ert diabetes|choroideremia|products for the treatment of the indications for which we have product candidates , including fabry disease , cystic fibrosis , xlrp and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|simplex familial inherited dystrophy gene|amd ad aav ms cf|choroideremia|we are aware that biogen inc . , or biogen , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|simplex familial inherited dystrophy gene|ribavirin others biologics vaccines roche|choroideremia|the designation of the first [ *** ] such roche product classes under section 2 . 2 ( including entity ) is included in the initiation payment set forth in section 12 . 1 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|simplex familial inherited dystrophy gene|melanoma glioblastoma gbm crpc ad|choroideremia|the pipeline also includes spk-7001 in an ongoing phase 1 / 2 clinical trial for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|simplex familial inherited dystrophy gene|amd cnv myopia rpe uveitis|choroideremia|spk-rpe65 to address a broad spectrum of blinding conditions , starting with the development of spk-chm for the potential treatment of entity , currently in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|simplex familial inherited dystrophy gene|cataract myopia amd blindness retinoblastoma|choroideremia|these diseases include entity , diabetic retinopathy , glaucoma , lebers congenital amaurosis ( lca ) , macular telangiectasia , retinitis pigmentosa , wet amd and xlrs , among others .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex familial inherited dystrophy gene|psoriasis melanoma gout epilepsy ms|choroideremia|spk-7001 has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex familial inherited dystrophy gene|psoriasis epilepsy melanoma ad diabetes|choroideremia|has been granted orphan product designation by the european commission and fda for its product candidate for the treatment of entity that is in a phase 1 / 2 clinical trial .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|simplex familial inherited dystrophy gene|ch cftr ige npc1 btk|choroideremia|our pipeline includes : a product candidate targeting entity , or chm , currently in a phase 1 / 2 clinical trial ; a product candidate for hemophilia a , currently in a phase 1 / 2
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|simplex familial inherited dystrophy gene|cataract choroid migraine cytomegalovirus retinoblastoma|choroideremia|some irds , such as retinitis pigmentosa ( rp ) , usher syndrome , or entity ( chm ) are associated with a gradual loss of vision , eventually leading to complete blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|simplex familial inherited dystrophy gene|europe japan brazil australia 2013|choroideremia|in addition , roche currently holds a license to 4d-110 in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|simplex familial inherited dystrophy gene|ad amd adhd ms als|choroideremia|we are aware that nightstarx is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex familial inherited dystrophy gene|psoriasis melanoma epilepsy ms gout|choroideremia|spk-chm has also been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|simplex familial inherited dystrophy gene|justification introduction overview narrative significance|choroideremia|entity : spark therapeutics is enrolling patients in its first phase 1 / 2 clinical trial of spk-chm , an aav-based gene therapy for the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|simplex familial inherited dystrophy gene|epilepsy migraine fibromyalgia psoriasis ms|choroideremia|our first such follow-on product candidate is spk-chm for the treatment of entity , or chm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|simplex familial inherited dystrophy gene|ch migraine chc hit epilepsy|choroideremia|our lead product candidate , nsr-rep1 , for the treatment of entity , or chm , is entering phase 3 clinical development in the first half of 2018 and represents the most clinically advanced
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex familial inherited dystrophy gene|psoriasis epilepsy melanoma ms gout|choroideremia|spk-chm has been granted orphan drug designation by fda and the european commission for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|simplex familial inherited dystrophy gene|malaria melanoma psoriasis ad leishmaniasis|choroideremia|as a result , we have not sought , and may be unable to seek , patent protection for spk-chm to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|simplex familial inherited dystrophy gene|adhd schizophrenia rls osa als|choroideremia|we are aware that nightstar therapeutics plc , or nightstar , is developing an aav-based gene therapy for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|kinetic homocysteine concentration vitamin arteriovenous|diabetes diabetic dm ckd t2dm|citrullinemia|current therapy for entity type 1 is considered difficult for patients and generally ineffective , including diet restriction and nitrogen scavengers , and the only curative
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|kinetic homocysteine concentration vitamin arteriovenous|diabetes dm diabetic epilepsy autism|citrullinemia|individuals with entity type i can build-up excessive levels of ammonia and citrulline in their blood , potentially resulting in neurological deficits and other toxicities .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|kinetic homocysteine concentration vitamin arteriovenous|pk dmd epilepsy cml als|citrullinemia|*** revision to work plans for pku and entity
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|kinetic homocysteine concentration vitamin arteriovenous|diabetic liver diabetes underlying mitochondrial|citrullinemia|to evaluate the therapeutic response to dtx601 , we plan to measure ammonia levels , which is a well-established measure of entity type i disease status .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|kinetic homocysteine concentration vitamin arteriovenous|wilson pk both thalassemia ald|citrullinemia|you know , wilson , or pku or entity?
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|kinetic homocysteine concentration vitamin arteriovenous|diabetes dm t1dm thalassemia t2dm|citrullinemia|the incidence of entity type 1 is estimated at approximately 1 per 250 , 000 live births , affecting more than 2 , 000 individuals worldwide .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|nephropathy homocysteine electrolyte gene unexplained|thalassemia immunodeficiency thrombocytopenia insufficiency mutation|afibrinogenemia|entity , the condition where the factor i is completely absent , is estimated to afflict one in one million , or 300 patients
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene hereditary genetic|cf ckd gout epilepsy amd|homocystinuria|the company is orphan medical  s exclusive direct-to-patient distributor for cystadane ( tm ) , indicated for patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|france 2016 2015 2013 2012|homocystinuria|acn00177 in entity in the second quarter of 2020 , we announced the approval of our clinical trial application , or cta , by the united
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial inherited gene hereditary genetic|melanoma gbm nsclc glioblastoma amd|homocystinuria|there are approximately 1 , 000 patients with entity in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|familial inherited gene hereditary genetic|humans hypothyroidism thalassemia hyperlipidemia rare|homocystinuria|humans and an antidote for methanol or suspected methanol ingestion in humans ; and cystadane® ( betaine anhydrous for oral solution ) , for entity , a genetic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene hereditary genetic|epilepsy endometriosis migraine acne diabetes|homocystinuria|cystadane is a known compound which has already been used to treat entity and is , therefore , not patentable for this indication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|familial inherited gene hereditary genetic|endometriosis gout constipation hematuria bph|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene hereditary genetic|myopathy dm diabetes cholestasis sclerosis|homocystinuria|elevated blood levels of this amino acid arise in the rare genetic disease of classical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|familial inherited gene hereditary genetic|atherosclerosis ad ms als hf|homocystinuria|for aeb4104 demonstrating decreases in plasma homocysteine levels that improved important disease-related abnormalities and survival in a preclinical model of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial inherited gene hereditary genetic|psoriasis ms gout periodontitis sclerosis|homocystinuria|( “orphan” ) , a privately held , clinical-stage biopharmaceutical company focused on the development of product candidate ot-58 for the treatment of classical entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial inherited gene hereditary genetic|stillbirth this ntd preeclampsia prematurity|homocystinuria|it has been estimated that entity occurs about once in every 200 , 000 live births worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|this our metabolic that single|homocystinuria|understanding entity entity is an inherited disorder of methionine metabolism that results in elevated homocysteine and homocystine , or thcy , in plasma and urine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene hereditary genetic|endometriosis gout hematuria syphilis bph|homocystinuria|the company obtained orphan drug status for cystadane for the treatment of entity , which provided marketing exclusivity to the company through october 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|humans vivo vitro adults japan|homocystinuria|acn00177 in entity overview : our product candidate , acn00177 , is a novel pegylated , or polyethylene glycol modified , human enzyme engineered to degrade free homocysteine and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|familial inherited gene hereditary genetic|technology cyp2d6 approach this sildenafil|homocystinuria|we believe classical entity represents a viable market opportunity with significant unmet medical need , which we plan to address by continuing our preclinical development
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|familial inherited gene hereditary genetic|diabetes hyperlipidemia nafld t2dm hypercholesterolemia|homocystinuria|it is the first agent approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|rare complex condition mps vhl|homocystinuria|the board of hcu network america , a non-profit which provides advocacy and support for patients affected by the rare disease entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene hereditary genetic|endometriosis gout constipation hematuria epilepsy|homocystinuria|the company has obtained orphan drug status for cystadane for the treatment of entity , which provides marketing exclusivity to the company through october 24 , 2003 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial inherited gene hereditary genetic|diabetes gout epilepsy hypothyroidism pcos|homocystinuria|cystadane is approved by the fda for the treatment of entity , an inherited metabolic disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|these affected cf such all|homocystinuria|the majority of entity patients suffer mutations of a gene that regulates the production of the enzyme known as cystathionine beta-synthase , or cbs , which
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene hereditary genetic|europe manufacturing japan france 2011|homocystinuria|trial in patients with arginase 1 deficiency and closing cancer trials ; offset by a ramp-up in manufacturing for acn00177 in entity and higher personnel-related expenses .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|pkd hypercholesterolemia cholestasis ckd mutations|cystinuria|tablets ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|development testing itself genomics therapeutics|cystinuria|aeglea has an active discovery platform , with the most advanced program for entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|this cyst kidney ckd which|cystinuria|entity is an inherited disease that causes stones made of the amino acid cystine to form in the kidneys , bladder and / or
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|electrolyte nephropathy sodium single familial|copd these older gerd female|cystinuria|our patent-pending customizable delayed-release tiopronin medications that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|electrolyte nephropathy sodium single familial|foundation funding resources through infrastructure|cystinuria|aeglea has two programs in ind-enabling studies for homoentity and cystinuria and an active discovery pipeline .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|electrolyte nephropathy sodium single familial|melanoma ad psoriasis als mesothelioma|cystinuria|additionally , we have commenced ind-enabling studies for our aeb5100 program for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|hypercholesterolemia cholestasis hyperparathyroidism ckd pkd|cystinuria|( tiopronin ) is approved in the united states for the prevention of cystine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|electrolyte nephropathy sodium single familial|amd gout psoriasis amyloidosis sle|cystinuria|evaluating sparsentan for fsgs and iga nephropathy , and the recent approval and launch of thiola ec for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|ckd amd cml proteinuria gout|cystinuria|captopril is not fda approved for the treatment of entity but has been prescribed for patients with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|amyloidosis glomerulonephritis proteinuria sarcoidosis others|cystinuria|evaluating the suitability of our ersg library for development in additional renal disorders , including autosomal dominant polycystic kidney disease , and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|electrolyte nephropathy sodium single familial|gout ckd hyperparathyroidism nephropathy pancreatitis|cystinuria|and cysteine , decreased the amount of cystine in the urine and reduced kidney stone formation in a preclinical model of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|electrolyte nephropathy sodium single familial|epilepsy cf ckd ms amyloidosis|cystinuria|aeb5100 in patients with entity aeb5100 is a novel recombinant human enzyme that degrades plasma cystine and cysteine .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|electrolyte nephropathy sodium single familial|copd these ra osteoporosis older|cystinuria|our patent-pending tiopronin delayed-release compounded formulations that may be prescribed by physicians as a lower-cost alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|electrolyte nephropathy sodium single familial|this usually commonly ckd typically|cystinuria|entity occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|electrolyte nephropathy sodium single familial|gout psoriasis amd acne copd|cystinuria|thiola•in 2018 , the company expects an nda to be filed for its new formulation of thiola for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|electrolyte nephropathy sodium single familial|this cyst ckd which that|cystinuria|entity is a chronic genetic disease that causes stones made of the amino acid cystine to form in the kidneys , bladder
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|electrolyte nephropathy sodium single familial|cholestasis hypercholesterolemia hyperparathyroidism ckd fibrosis|cystinuria|( tiopronin ) is approved in the united states for the prevention of cysteine ( kidney ) stone formation in patients with severe homozygous entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|electrolyte nephropathy sodium single familial|esrd pkd ckd ald rcc|cystinuria|clinical development programs and evaluating the suitability of our ersg library for development in additional renal disorders , including adpkd and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|electrolyte nephropathy sodium single familial|hemodialysis these diabetic gout older|cystinuria|citrate delayed release compounded formulations that may be prescribed by physicians as a lower-cost therapeutic alternative to fda-approved thiola® for entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|electrolyte nephropathy sodium single familial|melanoma amd nsclc cll myeloma|cystinuria|the company believes there are 10 , 000-12 , 000 patients with entity in the united states , of which 4 , 000-5 , 000 patients may be appropriate candidates for treatment .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|all these twelve six three|galactosemia|entity patients will be eligible for treatment up to 28 days total ( single dose followed by 27 consecutive days of dosing ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|recessive inherited homozygous familial gene|diabetes t2d nafld t2dm ms|galactosemia|therapeutics plans to leverage recent fda guidance permitting biomarker-based development in low prevalence , slowly progressing rare metabolic diseases , such as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|recessive inherited homozygous familial gene|diabetes inflammation osteoarthritis dyslipidemia retinopathy|galactosemia|in particular , the company is currently targeting treatments for cardiovascular disease , entity and diabetic complications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|opinion key academic educational industry|galactosemia|we also hosted an educational symposium featuring a panel of entity experts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|recessive inherited homozygous familial gene|aml oncology myeloma hsct als|galactosemia|we will continue to characterize at-007 long-term safety in adult entity patients and intend to initiate a pediatric study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|ar all these ra crpc|galactosemia|the key biomarker outcome of the study was reduction in galactitol , an aberrant toxic metabolite of galactose , formed by ar in entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|recessive inherited homozygous familial gene|ms hemodialysis diabetic t2dm cf|galactosemia|at-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in adult entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|recessive inherited homozygous familial gene|melanoma nsclc aml crpc mesothelioma|galactosemia|” recent highlights ·presented data on at-007 for treatment of entity at the entity foundation 2020 virtual conference .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|all either these 16 both|galactosemia|at-007 was well tolerated , with no drug-related adverse events noted to date in entity patients or in the 72 healthy volunteers treated in part 1 of the trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|2010 2012 2009 2005 2013|galactosemia|· received fda orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|recessive inherited homozygous familial gene|neuroblastoma myeloma melanoma aml osteosarcoma|galactosemia|· presented data highlighting at-007 for the treatment of entity at the ashg annual meeting .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|entity entities unique origin nature|galactosemia|·announced start of at-007 pediatric entity study ; released additional 40mg / kg data from adult entity study .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|recessive inherited homozygous familial gene|humans mice adults combination rats|galactosemia|june 2020 , we announced additional supportive biomarker efficacy and safety data for at-007 in entity at 40 mg / kg .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|japan brazil korea france europe|galactosemia|in may 2019 , we received orphan drug designation for at-007 in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|recessive inherited homozygous familial gene|ms t2d t2dm t1d ad|galactosemia|in june 2019 we initiated a pivotal phase 1 / 2 study in healthy volunteers and adults with entity to evaluate safety , pharmacokinetics , and biomarker endpoints in adults with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|recessive inherited homozygous familial gene|japan brazil korea europe taiwan|galactosemia|we initiated a phase 1 / 2 study of at-007 in entity in june 2019 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|acidosis cyst myc tuberculosis bacillus|particular contrast humans vitro turn|galactosialidosis|in entity , the missing protease , cathepsin a , is a lysosomal stabilizing agent for the two other enzymes : sialidase and beta-galactosidase .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|acidosis cyst myc tuberculosis bacillus|lsd mps pancreatitis npc1 sma|galactosialidosis|rhppca is in preclinical development as an enzyme replacement therapy for entity , a rare lysosomal storage disease for which there are no currently approved drug therapies .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|acidosis cyst myc tuberculosis bacillus|this funded now plus that|galactosialidosis|emil : well entity is another small enzyme therapy program like our mps7 program .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|acidosis cyst myc tuberculosis bacillus|google others atlas commons project|galactosialidosis|how the opportunities at dimension compared to those in your own pipeline at a similar stage such as arcturus and entity?
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|acidosis cyst myc tuberculosis bacillus|gout diseases atherosclerosis diabetes amd|galactosialidosis|currently no issued patents that cover the rhppca composition of matter or the use of rhppca for the treatment of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cns ependym cell intracranial brain|psoriasis ad melanoma gout epilepsy|glioma|in january 2013 , the ema also granted orphan drug protection to val-083 for the treatment of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cns ependym cell intracranial brain|glioma gliomas glioblastoma astrocytoma lymphomas|glioma|in february 2018 , an investigator-sponsored trial was initiated evaluating day101 in pediatric low-grade entity ( plgg ) , for which sunesis believes the scientific rationale is compelling .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cns ependym cell intracranial brain|melanoma glioblastoma glioma psoriasis acne|glioma|california , san francisco , which is conducting phase 2 clinical trials of prophage series g-100 and g-200 for the treatment of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cns ependym cell intracranial brain|melanoma mesothelioma nsclc myeloma cholangiocarcinoma|glioma|research our primary business focus is the clinical development of litx for the treatment of hepatoma , metastatic colorectal cancer , entity and one or more possible follow-on indications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cns ependym cell intracranial brain|rcc japan germany korea asia|glioma|rcc tumors received and approximately 85% of the tumors received from patients in our ongoing phase 2 clinical trials in entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|cns ependym cell intracranial brain|tumors melanoma gliomas glioma neoplasms|glioma|by nih , a third party might be able to develop a cintredekin besudotox based drug for the treatment of malignant entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|cns ependym cell intracranial brain|melanoma tumors mesothelioma glioma neoplasms|glioma|the company has completed a phase ii clinical trial for use of su101 as a treatment for refractory malignant entity and has recently initiated a phase iii clinical trial in first relapse entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cns ependym cell intracranial brain|melanoma glioblastoma nsclc mesothelioma myeloma|glioma|investigator sponsored trials include a phase 2 clinical trial in colorectal cancer and a phase 1 clinical trial in entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cns ependym cell intracranial brain|melanoma mesothelioma hematologic glioma hyperthermia|glioma|the median survival time was over 609 days ( approximately 21 months ) , which compares favorably to the survival historically recorded for malignant entity patients ( approximately 12 months ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cns ependym cell intracranial brain|gbm glioblastoma gliomas glioma melanoma|glioma|in vivo studies that cannabinoids have a synergistic effect with temozolomide , the standard chemotherapeutic agent used in the treatment of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|cns ependym cell intracranial brain|psoriasis melanoma gout cll cml|glioma|sl-701 was awarded orphan drug designation from the fda for the treatment of entity in january 2015 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cns ependym cell intracranial brain|glioma gbm brain cns glioblastoma|glioma|hypericin compounds to inactivate viruses and retroviruses , as a therapeutic or preventative for viral or retroviral diseases , and for anti- entity ( brain tumor ) indications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cns ependym cell intracranial brain|osteoporosis myeloma pancreatitis psoriasis diabetes|glioma|ca4p has been granted orphan drug designation for the treatment of entity in the united states .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|cns ependym cell intracranial brain|glioma gliomas tumors neoplasms tumours|glioma|orphan drug act , gliadel® wafer became entitled to seven years of market exclusivity for the treatment of patients with malignant entity undergoing primary surgical resection .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|cns ependym cell intracranial brain|glioblastoma gbm glioma gliomas astrocytoma|glioma|phase 2 clinical trials in a range of indications and is currently in a phase 2 clinical trial in recurrent entity , a type of brain cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|cns ependym cell intracranial brain|glioma melanoma tumors gliomas mesothelioma|glioma|the first of these trials was a phase i / ii recurrent malignant entity clinical trial .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|cns ependym cell intracranial brain|cholangiocarcinoma prostate ovarian colorectal others|glioma|is overexpressed in numerous difficult to treat tumors including lung , breast , bladder , gastric , ovarian , endometrial , cervical , melanoma , esophageal , pancreatic , and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cns ependym cell intracranial brain|psoriasis epilepsy osteoarthritis osteoporosis eczema|glioma|our product pipeline also includes compounds in phase 1 and 2 clinical development for entity , ulcerative colitis type 2 diabetes and schizophrenia .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cns ependym cell intracranial brain|these melanoma crc nsclc hcc|glioma|the crada also covers research to determine whether expression of a component of this pathway correlates with prognosis in entity patients .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|cns ependym cell intracranial brain|malignancies cancers tumors neoplasms gliomas|glioma|granted protection under the orphan drug act by the united states food and drug administration ( “fda” ) for the treatment of entity , including gbm .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|mitochondrial genetic familial als storage|progeria|we are also developing lonafarnib monotherapy for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|proposed new project global future|progeria|( a ) the parties acknowledge that a priority review voucher may be available and awarded to eiger as the sponsor of the entity nda ( “entity prv” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|gene premature familial inherited complex|cardiomyopathy fibrosis premature pa phosphate|progeria|eiger has initiated a rolling new drug application ( nda ) submission process for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|gene premature familial inherited complex|cardiomyopathy uremic fibrosis dystrophic phenomenon|progeria|licensed field of use under the merck agreement to include all uses of lonafarnib related to the treatment of hutchinson-gilford entity syndrome ( entity ) in humans .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|entire original german whole project|progeria|eiger agrees not to retain the entity prv for itself or any of its affiliates .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|lamin genetic familial scd als|progeria|with prf any proceeds from the monetization of any prv that we may receive for lonafarnib for the treatment of entity and progeroid laminopathies to support future entity research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|gene premature familial inherited complex|fibrosis pa cardiomyopathy degeneration diamond|progeria|eiger is preparing an nda and maa for lonafarnib to treat hutchinson-gilford entity syndrome ( hgps or entity ) and progeroid laminopathies with plans to file in q4 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|genetic storage mitochondrial lamin familial|progeria|the u . s . food and drug administration ( fda ) accepted the new drug application ( nda ) for accelerated review of zokinvytm ( lonafarnib ) for treatment of entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|gene premature familial inherited complex|lamin storage als genetic mitochondrial|progeria|and data controlled by prf to prepare and file any new drug application ( “nda” ) for a product containing lonafarnib for entity and progeroid laminopathies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|gene premature familial inherited complex|humans mice vivo vitro aging|progeria|that progerin may make the nucleus unstable , and that cellular instability may lead to the process of premature aging in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|gene premature familial inherited complex|fibrosis dystrophy cardiomyopathy onset degeneration|progeria|hutchinson-gilford entity syndrome ( entity ) overview ultra-rare , fatal , premature aging pediatric disease point mutation in the lamin a gene results in a farnesylated aberrant protein ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|gene premature familial inherited complex|chd diabetes hcm ms t1d|progeria|children with entity die of the same heart disease that affects millions of normally aging adults ( arteriosclerosis ) , but at an average age of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|gene premature familial inherited complex|hcc nsclc aml epilepsy crpc|progeria|as a result we may not successfully obtain approval by the fda of an nda for lonafarnib for entity in the near term , or at all .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|dizziness nausea vomiting insomnia hypotension|hydrocephalus|two events occurred in one patient , these were headache and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus obstructive shunt secondary nph|hydrocephalus|prevents obstruction in the cerebrospinal fluid ( csf ) catheters implanted in the ventricle of the brain of patients who suffer from entity or normal pressure hydrocephalus ( nph ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|csf intracranial lumbar spinal brain|hydrocephalus|we believe that our cerebral spinal fluid ( csf ) pressure management product line , including the advanced orbis sigma ii entity shunt , is unsurpassed in the industry .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|these most intracranial some many|hydrocephalus|entity shunt designs have changed little since their introduction in the 1950s .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|paralysis deafness headaches weakness headache|hydrocephalus|bone sclerosis impinges cranial nerve and spinal foramina with resulting neurologic abnormalities , including entity , progressive blindness and auditory impairment .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus this thrombocytopenia hemorrhage thrombosis|hydrocephalus|entity has also been reported in children with severe hypoplasminogenemia , apparently related to the deposition of fibrin in the cerebral ventricular
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus nephropathy headache hypotension htn|hydrocephalus|the same condition , known as normal pressure entity ( nph ) , presented mostly in the elderly population , causing thinking and reasoning problems , difficulty walking , etc .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|ascites peritonitis sepsis drainage abscess|hydrocephalus|implantable drainage valve for treatment of entity - french patent application no . 9306356 filed june 27 , 1993 ( docket 91087 ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|fluids fluid edema ascites diuretics|hydrocephalus|this slow accumulation means that the fluid pressure may not be as high as in other types of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus epilepsy migraine ms aneurysms|hydrocephalus|wayne state university , which supports the scstms potential as a viable technology for preventing occlusion in shunts used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus ms epilepsy icp headaches|hydrocephalus|shunts in the brain to help drain excess csf either externally or into the body for reabsorption to help treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|stillbirth preeclampsia ntd abortion diabetes|hydrocephalus|entity occurs in about 1 in every 500 births in the u . s . alone1 , 2 over 1 , 000 , 000 people in the united states currently
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|nph rls hydrocephalus ms migraine|hydrocephalus|microbot is developing scs as a device for the treatment of entity and nph and is developing tipcat as an endoscopic tool , with colonoscopy as the most immediate application of the tipcat
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus shunt nph obstructive asd|hydrocephalus|virob platform , microbot is currently developing its first product candidate : the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus brain gbm cns epilepsy|hydrocephalus|tuberous sclerosis complex is also associated with a variety of resulting disorders including seizures , swelling in the brain ( entity ) , developmental delays and skin lesions , , .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus this shunt asd cdh|hydrocephalus|entity is most often treated by the surgical insertion of a shunt system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|reaction edema nephropathy complications dermatitis|hydrocephalus|mannitol injection entity , glaucoma , edema caused by deep burning or scald , acute renal failure and ascites .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|arrhythmias valves prolapse bradycardia regurgitation|hydrocephalus|silicone products , state of the art implanted application systems for spinal opiates and market leading valve systems for treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus shunt asd obstructive nph|hydrocephalus|using the virob platform , microbot is currently developing the self cleaning shunt , or scstm , for the treatment of entity and normal pressure hydrocephalus , or nph .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hydrocephalus shunt cerebrospinal leak ventricular|hydrocephalus scs csf icp ms|hydrocephalus|the proposed indication for use of the scs device would be for the treatment of entity as a component of a shunt system when draining or shunting of csf is indicated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|pituitary familial hypothalamic causes hypothyroidism|hypothyroidism hyperthyroidism hyperinsulinemia pcos hyperplasia|hyperprolactinemia|both sgas and fgas can cause entity , a hormonal imbalance resulting from d2 receptor blockade , which can lead to enlargement of breast tissue in males and infertility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|pituitary familial hypothalamic causes hypothyroidism|tumors osteoporosis prolactin hyperplasia hyperthyroidism|hyperprolactinemia|x213 could be developed to treat entity in prolactinomas , a condition of benign tumors on the pituitary gland that leads to sexual dysfunction , infertility , and osteoporosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|pituitary familial hypothalamic causes hypothyroidism|cohort cycle phase part step|hyperprolactinemia|treated for potential oncology indications for up to 48 weeks ; doses up to 20x higher than expected clinical dose for entity 1 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|pituitary familial hypothalamic causes hypothyroidism|diabetes epilepsy osteoporosis hyperthyroidism fibromyalgia|hyperprolactinemia|by fda for use in humans for more than 15 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pituitary familial hypothalamic causes hypothyroidism|interest aging inflammation diabetes immunodeficiency|hyperprolactinemia|corporation ) , and we exercised our right to bring the product back into our portfolio to develop it for diseases of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|pituitary familial hypothalamic causes hypothyroidism|hypothyroidism hyperthyroidism diabetes dystonia epilepsy|hyperprolactinemia|respect to the other approved indications , and bromocriptine remains on the market for the treatment of parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|pituitary familial hypothalamic causes hypothyroidism|melanoma cll mm tnbc amd|hyperprolactinemia|finalized the design of a proof-of-concept study for xoma 213 , which may offer a new therapeutic option for patients with entity , and anticipate initiating the study midyear .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pituitary familial hypothalamic causes hypothyroidism|epilepsy dystonia diabetes schizophrenia parkinsonism|hyperprolactinemia|upjohn announced nda submissions to the fda for pramipexole for parkinson  s disease , remisar ( r ) for bladder cancer and dostinex ( r ) ( cabergoline ) for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pituitary familial hypothalamic causes hypothyroidism|parkinsonism neurotoxicity dystonia dizziness tremor|hyperprolactinemia|this mechanism likely contributes to the favorable safety profile of iti-007 , with reduced risk for entity , akathisia , extrapyramidal symptoms , and other motoric side effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|pituitary familial hypothalamic causes hypothyroidism|alopecia neurotoxicity dizziness hepatotoxicity hypoglycemia|hyperprolactinemia|the favorable safety profile of iti-007 with reduced risk for akathisia , extrapyramidal side effects and other motoric side effects , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pituitary familial hypothalamic causes hypothyroidism|rls parkinsonism dystonia crpc adhd|hyperprolactinemia|cabergoline was recently launched in certain european countries for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|pituitary familial hypothalamic causes hypothyroidism|neurotoxicity toxicity contraindications hypoglycemia hepatotoxicity|hyperprolactinemia|iti- 2 007 likely contributes to its favorable clinical profile with motoric tolerability similar to placebo and without entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|pituitary familial hypothalamic causes hypothyroidism|diabetes epilepsy osteoporosis hyperthyroidism fibromyalgia|hyperprolactinemia|approved by fda for use in humans for approximately 20 years for several indications , including treating parkinson  s disease , acromegaly , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|pituitary familial hypothalamic causes hypothyroidism|prolactin igf1 others aromatase leptin|hyperprolactinemia|our endocrine portfolio also includes a phase 2-ready product candidate , xoma 213 , targeting the prolactin receptor , and entity , and multiple research-stage programs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|pituitary familial hypothalamic causes hypothyroidism|prolactin ais prl pcos ms|hyperprolactinemia|inhibit prolactin secretion with no reported effect on other pituitary hormones and are therefore generally the drugs of choice for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|pituitary familial hypothalamic causes hypothyroidism|hypothesis conclusion conclusions abstract hypotheses|hyperprolactinemia|entity : as with other drugs that antagonize dopamine d2 receptors , fanapttm elevates prolactin levels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|poorly psoriasis completely fully negatively|cf dmd amd osteosarcoma cp|hypophosphatasia|asfotase alfa has shown very compelling phase ii clinical data in infants and juveniles with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|poorly psoriasis completely fully negatively|osteoarthritis hyperparathyroidism osteoporosis gout osteosarcoma|hypophosphatasia|we note that other examples of animal models of bone disease such as osteoporosis and entity have previously translated in vivo findings into the clinic .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|poorly psoriasis completely fully negatively|hyperparathyroidism osteoporosis periodontitis psoriasis pancreatitis|hypophosphatasia|time investing in preparations for the anticipated 2015 launch of our second commercial product , asfotase alfa for the treatment of entity ( hpp ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|kur ku herpes al christ|us fda common trade super|kuru|and related stockholder matters market information our common stock is traded on the nasd  s over-the-counter bulletin board under the symbol " entity ob " since november 6 , 2008 .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis erythematosus cure sclerosis complex|most some these many all|leprechaunism| type a and type b syndrome  rabson-mendenhall syndrome  entity type a syndrome patients have high circulating concentrations of insulin with impaired glucose tolerance or diabetes .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|syphilis erythematosus cure sclerosis complex|others diabetes pcos both pancreatitis|leprechaunism|defects in the insulin receptor or insulin signaling pathways and include type a and type b syndromes , rabson-mendenhall syndrome and entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|syphilis erythematosus cure sclerosis complex|others nos thalassemia sarcoidosis hypothyroidism|leprechaunism|these conditions include :  type a and type b syndrome ,  rabson-mendenhall syndrome , and  entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial simplex hereditary sclerosis cutaneous|lam melanoma mtc mct leiomy|lymphangioleiomyomatosis|the exist-2 study will evaluate everolimus in patients with angiomyolipoma associated with either ts or sporadic entity ( lam ) 9 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma osteosarcoma glioblastoma neuroblastoma meningioma|medulloblastoma|the following tumor types were treated thus far : high-grade glioma , entity , neuroblastoma , and ependymoma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma neuroblastoma osteosarcoma retinoblastoma melanoma|medulloblastoma|of five childhood cancers typically treated with intensive cisplatin therapy , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma glioblastoma glioma retinoblastoma gliomas|medulloblastoma|the work at nih has now extended to the most common brain tumor of children , entity , and to the most common cancer of children , neuroblastoma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma glioblastoma glioma retinoblastoma osteosarcoma|medulloblastoma|the work at nih was then extended to the most common brain tumor of children , entity , and to the most common extracranial solid tumor of children , neuroblastoma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma melanoma glioma retinoblastoma neuroblastoma|medulloblastoma|in addition , compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme , neuroblastoma , and entity , all cancers of neural tissue .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma glioblastoma astrocytoma meningioma glioma|medulloblastoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , entity , and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma osteosarcoma melanoma neuroblastoma glioma|medulloblastoma|joint patent applications with nih have been filed for the treatment of glioblastoma multiforme , entity , and neuroblastoma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma retinoblastoma neuroblastoma osteosarcoma melanoma|medulloblastoma|of one of five childhood cancers typically treated with intensive cisplatin therapy , including hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|medulloblastoma ependym cell oligo molecular|endometrial melanoma ovarian prostate uterine|medulloblastoma|in 2016 , the fda also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|medulloblastoma ependym cell oligo molecular|tumors sarcomas nsclc malignancies cancers|medulloblastoma|ii - paragon-hf to start aug . 2014 29 lde225 solid tumors ≥ 2018 i entity ≥ 2018 iii lee011 breast cancer 2016 iii - phase iii registration study enrolling solid tumors ≥
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|medulloblastoma ependym cell oligo molecular|pancreatic ovarian colorectal prostate lung|medulloblastoma|sl-301 has demonstrated activity against brain and pancreatic cscs and tumor bulk in vitro , and against glioblastoma and entity cscs in in vivo animal models .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma tumors gliomas glioblastoma glioma|medulloblastoma|have presented data indicating that val-083 offers potential therapeutic alternatives for the treatment of pediatric brain tumors including shh-p53 mutated entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|medulloblastoma ependym cell oligo molecular|nsclc mesothelioma glioblastoma hcc hh|medulloblastoma|phase i clinical trials that are designed to evaluate dose and safety of gdc-0449 in pediatric and adult patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|medulloblastoma ependym cell oligo molecular|keratinocytes melanoma humans melanocytes mice|medulloblastoma|emory studies so far have indicated that entity may be particularly vulnerable to the ability of wp1066 to block the activated form of stat3 , a key signaling protein
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|medulloblastoma ependym cell oligo molecular|osteosarcoma medulloblastoma melanoma neuroblastoma myeloma|medulloblastoma|treated with intensive cisplatin therapy for localized and disseminated disease , including newly diagnosed hepatoblastoma , germ cell tumor , osteosarcoma , neuroblastoma , and entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|medulloblastoma ependym cell oligo molecular|medulloblastoma meningioma glioblastoma neuroblastoma gbm|medulloblastoma|no conventional therapy exists , or a relapsed brain tumor with a predilection for lm dissemination ( primitive neuroectodermal tumor , rhabdoid tumor , entity ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|medulloblastoma ependym cell oligo molecular|melanoma endometrial prostate ovarian uterine|medulloblastoma|the fda has also granted orphan drug protection to val-083 for the treatment of entity and ovarian cancer .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|medulloblastoma ependym cell oligo molecular|glioma benign medulloblastoma gliomas glioblastoma|medulloblastoma|pre-clinical studies of lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , entity and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|medulloblastoma ependym cell oligo molecular|melanoma mesothelioma myeloma nsclc lymphomas|medulloblastoma|we have been granted orphan drug designation in the united states for gbm , ovarian cancer , and entity , and in europe for gbm .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|meningioma dural arteriovenous intracranial brain|astrocytoma glioma melanoma gliomas mesothelioma|meningioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , oligodendroglioma , mixed glioma , medulloblastoma , and malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma dural arteriovenous intracranial brain|epilepsy melanoma meningioma psoriasis neuroblastoma|meningioma|in february 2012 , the fda granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|meningioma dural arteriovenous intracranial brain|epilepsy melanoma meningioma neuroblastoma psoriasis|meningioma|the fda has granted two orphan drug designations for ar-42 for the treatment of entity and the treatment of schwannoma of the central nervous system .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|meningioma dural arteriovenous intracranial brain|meningioma glioma melanoma sarcomas neuroblastoma|meningioma|in addition , preclinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness , neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|meningioma dural arteriovenous intracranial brain|meningioma melanoma glioma neuroblastoma medulloblastoma|meningioma|in addition , pre-clinical models have demonstrated anti-tumor activity in tumor types ( schwannoma and entity ) that are associated with the genetic illness neurofibromatosis type 2 ( nf2 ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|meningioma dural arteriovenous intracranial brain|meningioma glioma schwann astrocytoma gliomas|meningioma|entity and schwannoma are rare , benign tumors that can present in different locations within the brain and the spinal cord and
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|meningioma dural arteriovenous intracranial brain|meningioma glioma medulloblastoma melanoma glioblastoma|meningioma|intend to collaborate with ohio state to conduct a phase 0 investigator-initiated study of ar-42 in patients with schwannoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|meningioma dural arteriovenous intracranial brain|melanoma pneumothorax neoplasm rcc aml|meningioma|this patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|meningioma dural arteriovenous intracranial brain|glioma gliomas astrocytoma melanoma mesothelioma|meningioma|lb-100 that showed anti-cancer activity in models of a variety of human brain tumors , including glioblastomamultiforme ( gbm ) , medulloblastoma and malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|meningioma dural arteriovenous intracranial brain|meningioma melanoma neuroblastoma glioma glioblastoma|meningioma|in preclinical studies , ar-42 has demonstrated anti-tumor activity in both entity and schwannoma .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|conditions illnesses diseases comorbidities diabetes|obesity|in the majority of these men , often with co-morbid entity , t replacement is not optimal and indeed may be counterproductive .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|financial economic medicaid compensation tax|obesity|eps growth  restating 2012 to exclude the 2012 entity impact of $0 . 10 and including the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|fda orphan unrelated indication experimental|obesity|development of the pyy compound and has recently announced that it expects to file an ind on pyy for an entity indication in 2003 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|pivotal sponsored therapeutic extension ra|obesity|exhibit 99 . 01 regeneron initiate phase ii entity clinical trial tarrytown , new york ( march 28 , 2000 ) - regeneron pharmaceuticals , inc . ( nasdaq : regn ) announced that it has initiated a
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|mutations syndromes phenotype phenotypes diagnosis|obesity|with open-label one year extensions , and was planned to include approximately four to six patients with genetically confirmed pomc deficiency entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|reproductive fertility sexual reproduction vaginal|obesity|-k . about vivus vivus , inc . is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing entity and sexual health .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|diabetes osteoporosis bph epilepsy depression|obesity|the company also has drug candidates or development programs for entity , erectile dysfunction , cardiovascular diseases , pulmonary diseases , inflammatory diseases and dermatologic diseases .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|from each all per single|obesity|strong business momentum continues to accelerate sales & eps growth * sales growth in local currency retrospectively adjusted to exclude entity intervention business .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|development grant funding marketing sponsored|obesity|in addition , outsourced clinical expenses in the companys entity program increased by $0 . 3 million in 2007 for phase 1 clinical trials on the companys lead compound , ngd-4715 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|epilepsy ms depression migraine schizophrenia|obesity|tolerability of topiramate , which was the scientific rationale for combining these two agents at low doses for the treatment of entity and related co-morbidities .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|endocrinology genetics inflammation hematology cardiology|obesity|dr . amatruda was the senior vice president and franchise head , diabetes and entity at merck research laboratories .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|medicaid financial economic gdp government|obesity|* 2012 eps growth includes the 2012 entity impact of $0 . 10 and the 2012 r&d tax credit impact of $0 . 06 .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|diabetes inflammation diseases hyperglycemia complications|obesity|axokine is being developed for the treatment of entity and complications of entity such as type ii diabetes .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|alcoholism toxins injuries diseases chemicals|obesity|incontinence may be caused by a wide range of factors , including childbirth , menopause , surgery , entity , drugs and neurological damage .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|inflammation glucose hyperglycemia cytokine glucocorticoid|obesity|academic researchers have increasingly linked chronic entity induced inflammation with type 2 diabetes and the potential role of inflammation in promoting insulin resistance in type 2 diabetes
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|waist pattern distribution features location|obesity|● increased waist circumference ( central or apple-shaped entity ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|osteoporosis osteoarthritis oa diabetes scoliosis|obesity|about orexigen therapeutics orexigen therapeutics , inc . is a biopharmaceutical company focused on the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|schizophrenia diabetes ad osa t2dm|obesity|we believe that this discovery indicates that overactivity of this gpcr may be associated with entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|development this testing angiogenesis immunogenicity|obesity|the companys lead combination product candidates targeted for entity are contrave , which is in phase 3 clinical trials , and empatic , which is in the later stages of phase 2
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|disease|hypothalamic dyslipidemia complex adolescence subclinical|atherosclerosis hyperlipidemia diabetes overweight dyslipidemia|obesity|conversely , transgenic mice that overexpress dgat-1 in adipose tissue are predisposed to entity when fed a high-fat diet and have elevated levels of circulating free fatty acids .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteoporosis fracture tab osteop state|vap diabetes schizophrenia pneumonia malaria|osteoporosis|the revenue decline in the second quarter largely reflects lower sales of fosamax for the treatment and prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|osteoporosis fracture tab osteop state|healthcare oncology diabetic chinese individual|osteoporosis|ystps trademarks xiangbala jidan and zangyu in particular are well recognized in china among physicians and hospital administrators , pharmacists and entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis fracture tab osteop state|potential targeted endocrine proposed experimental|osteoporosis|other entity therapies include estrogen replacement therapy , selective estrogen receptor modulators , bisphosphonates and several new biologics that are under development .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteoporosis fracture tab osteop state|dementia angina diabetes copd cardiomyopathy|osteoporosis|and outcomes management programs targeted at major categories of disease commonly found in the elderly , such as congestive heart failure , entity and atrial fibrillation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|osteoporosis fracture tab osteop state|osteoporosis osteosarcoma myeloma malignancies bisphosphonates|osteoporosis|a key set of parameters in the monitoring of entity , both before and after therapy , are biochemical markers of bone metabolism .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|osteoporosis fracture tab osteop state|sale marketing adults pharmaceuticals purchase|osteoporosis|under the asset purchase agreement , par acquired certain assets pertaining to calcitonin nasal spray for entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteoporosis fracture tab osteop state|osteoporosis complications hemorrhage menopause depression|osteoporosis|and estraderm mx ( estradiol ) transdermal patches are treatments for symptoms of estrogen deficiency in post-menopausal women , and prevention of post-menopausal entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|osteoporosis fracture tab osteop state|osteoporosis bisphosphonates gout osteomyelitis myeloma|osteoporosis|▪ approved for treatment of adult entity ▪ synthetic analogues of pyrophosphate ▪ inhibit bone resorption ▪ can be given orally or intravenously , depending on compound ▪
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|osteoporosis fracture tab osteop state|dyslipidemia hyperlipidemia hypothyroidism hypercholesterolemia osteoporosis|osteoporosis|portfolio will include two drug candidates in advanced clinical trials for the treatment of types 1 and 2 diabetes , severe entity and polycystic ovary syndrome .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteoporosis fracture tab osteop state|sarcopenia diabetes osteoporosis others anorexia|osteoporosis|currently in preclinical development as a potential treatment for age-related muscle loss , frailty , weight loss associated with cancer cachexia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|osteoporosis fracture tab osteop state|diabetes metabolism medicine pediatrics physiology|osteoporosis|since 1990 , he has been the organizer and chairman of the international symposia on nutrition and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis fracture tab osteop state|schizophrenia epilepsy science innovation vision|osteoporosis|he is treasurer of the international foundation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|osteoporosis fracture tab osteop state|services activities practices treatments materials|osteoporosis|also organize free community healthcare activities , such as arranging for bone density tests and organizing seminars on our products and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|osteoporosis fracture tab osteop state|copd emphysema burn osa hf|osteoporosis|we believe this study population contains a patient population reflective of the type of severe entity patients that specialists will treat in their practices .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|osteoporosis fracture tab osteop state|diabetes dyslipidemia hyperlipidemia osteoarthritis insomnia|osteoporosis|we also anticipate using our sales force to promote pharmaceutical products that address other midlife conditions such as hypertension , entity , depression and incontinence .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis fracture tab osteop state|others cancers malignancies arrhythmias deaths|osteoporosis|is also associated with a wide range of adverse events , including high blood pressure , weight gain , diabetes , serious infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteoporosis fracture tab osteop state|osteoporosis epilepsy ms scd als|osteoporosis|company and sb will continue to work together to develop one or more novel therapeutic approaches to the treatment of entity utilizing the company  s calcium receptor technology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|osteoporosis fracture tab osteop state|osteoporosis hyperparathyroidism pth hpt myeloma|osteoporosis|we have licensed worldwide rights to our manufacturing and delivery technologies for pth for the treatment of entity to gsk .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteoporosis fracture tab osteop state|depression schizophrenia epilepsy ptsd diabetes|osteoporosis|pursuant to a tenth amendment , we have been granted the exclusive right to negotiate an expansion of the field of use to include treatment of entity ( the &#8220 ; option&#8221 ; ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|osteoporosis fracture tab osteop state|tuberculosis syphilis malaria alcoholism influenza|osteoporosis|hepatitis c , and multiple sclerosis business categories , as well as other lower margin business categories , including human immunodeficiency virus and entity , versus the prior year .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma rcc both hyperparathyroidism bph|paraganglioma|we will make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|cell brain neuroendocrine dural intracranial|rcc neuroblastoma hyperparathyroidism mtc cholangiocarcinoma|paraganglioma|administration ( fda ) has designated azedra as a breakthrough therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma prostate rcc melanoma metastasis|paraganglioma|agent for prostate cancer phase 2 testing completed azedra™ treatment of pheochromocytoma and entity phase 2b registrational trial under special protocol assessment ( spa ) relistor®
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma rcc cholangiocarcinoma melanoma gist|paraganglioma|study of azedra demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers , pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cell brain neuroendocrine dural intracranial|rcc metastasis hyperthyroidism neuroblastoma glucagon|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma rcc vhl hyperparathyroidism both|paraganglioma|a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , pheochromocytoma , and entity are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cell brain neuroendocrine dural intracranial|mtc pheochrom rcc hyperplasia adenoma|paraganglioma|to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with pheochromocytoma / entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|cell brain neuroendocrine dural intracranial|lung pancreatic melanoma prostate ovarian|paraganglioma|twenty-four subjects were enrolled ( 11 female , 13 male ) , and seven subjects experienced stable disease in breast , neuroendocrine , entity , head / neck or colorectal cancer .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma glucagon pancreas metastasis others|paraganglioma|about pheochromocytoma and entity pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cell brain neuroendocrine dural intracranial|rcc hyperthyroidism neuroblastoma metastasis calcitonin|paraganglioma|first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant pheochromocytoma and entity , an ultra-orphan indication .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cell brain neuroendocrine dural intracranial|rcc neuroblastoma vhl others diabetes|paraganglioma|under compassionate use and named patient programs in 10 european countries in almost 1 , 300 patients , including those with pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|cell brain neuroendocrine dural intracranial|prostate lung ovarian nsclc endometrial|paraganglioma|or disease stabilization was observed in several cancer types , including parotid gland adenocarcinoma , colon , kaposi  s sarcoma , melanoma , ovarian , pancreatic and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cell brain neuroendocrine dural intracranial|nec sclc nets thus mct|paraganglioma|dysregulation of hif-2α under pseudohypoxia is thought to contribute to pah and entity , a neuroendocrine tumor .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|cell brain neuroendocrine dural intracranial|rcc neuroblastoma glucagon medulloblastoma mtc|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine tumors .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|cell brain neuroendocrine dural intracranial|rcc glucagon neuroblastoma metastasis calcitonin|paraganglioma|in addition to potentially treating pheochromocytoma and entity , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma rcc melanoma hyperparathyroidism meningioma|paraganglioma|candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cell brain neuroendocrine dural intracranial|neuroblastoma rcc nets glucagon calcitonin|paraganglioma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable pheochromocytoma and entity , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cell brain neuroendocrine dural intracranial|rcc neuroblastoma mtc meningioma metastasis|paraganglioma|other than azedra , there are currently no approved anticancer treatments in the u . s . for malignant , recurrent , and / or unresectable pheochromocytoma and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|cell brain neuroendocrine dural intracranial|prostate lung ovarian endometrial nsclc|paraganglioma|stable disease was observed in several cancer types , including melanoma , ovarian , kaposi  s sarcoma , angiosarcoma , parotid gland adenocarcinoma , colorectal , pancreatic and entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene phenyl mutation|annual recent world academic 2011|phenylketonuria|camp km , et al . entity scientific review conference : state of the science and future research needs .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial inherited gene phenyl mutation|pk dmd uc epilepsy ks|phenylketonuria|table of contents until march 2020 , we had been developing rtx-134 for the treatment of entity , or pku .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|familial inherited gene phenyl mutation|epilepsy pk pediatrics metabolism genetics|phenylketonuria|page 2 of 3 about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|familial inherited gene phenyl mutation|pk epilepsy pks phenylalanine pah|phenylketonuria|kuvan is a commercialized product for the treatment of patients with entity ( pku ) and / or for primary bh4 deficiency in certain countries .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|familial inherited gene phenyl mutation|epilepsy pk myopathy phenylalanine pah|phenylketonuria|privately held biotechnology company focused on developing therapies for orphan metabolic diseases , to evaluate sepiapterin ( " cnsa-001 " ) for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial inherited gene phenyl mutation|epilepsy pk myopathy gout psoriasis|phenylketonuria|company will use intrexons technology relating to the development and commercialization of novel biotherapeutics for the treatment of patients with entity ( pku ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|familial inherited gene phenyl mutation|humans ra psoriasis melanoma tumors|phenylketonuria|or in-license are currently pending patent applications except that we own one issued u . s . patent directed to methods of treating entity with rtx-134 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|familial inherited gene phenyl mutation|epilepsy pk dystonia phenylalanine myopathy|phenylketonuria|privately held biotechnology company focused on developing therapies for the orphan metabolic diseases , is developing cnsa-001 for the treatment of entity ( " pku " ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|familial inherited gene phenyl mutation|pk irinotecan japan prothrombin warfarin|phenylketonuria|· october 1 , 2015 , biomarin to acquire rights to entity ( pku ) franchise from merck serono : the company announced that it has entered into a definitive agreement to acquire all
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial inherited gene phenyl mutation|amyloidosis glomerulonephritis glioblastoma epilepsy japan|phenylketonuria|• pegvaliase for entity ( pku ) : pivotal results for the phase 3 prism-2 study ( formerly referred to as 165-302 ) that pegvaliase met the primary endpoint
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|familial inherited gene phenyl mutation|epilepsy psoriasis gout hyperlipidemia juvenile|phenylketonuria|investigational product candidates include phenoptin ( sapropterin hydrochloride ) , a phase 3 product candidate for the treatment of entity ( pku ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial inherited gene phenyl mutation|osteoporosis france adults gout osteoarthritis|phenylketonuria|and in the third quarter of 2017 , both france and germany had their first commercial sales . • kuvan® for entity :
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene phenyl mutation|half 10000 double 300 5000|phenylketonuria|about entity ( pku ) pku , a genetic disorder affecting at least 50 , 000 diagnosed patients under the age of 40 in the developed
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene phenyl mutation|vi iiib type complex variant|phenylketonuria|mucopolysaccharidosis iv type a , or mps iva mucopolysaccharidosis vi , or mps vi entity , or pku 6 kuvan has been granted orphan drug status in the eu , which together with pediatric
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|familial inherited gene phenyl mutation|diabetes overweight myopia alcoholism hyperlipidemia|phenylketonuria|substantial progress has been made over the past six decades , beginning with the first report of dietary control of entity in the early 1950s .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|familial inherited gene phenyl mutation|pah phenyl phenylalanine phe epilepsy|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad ) and entity ( mead johnson phenyl-free ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|familial inherited gene phenyl mutation|pah phenyl phenylalanine phe epilepsy|phenylketonuria|nutritional management of individuals with rare , inborn errors of metabolism such as maple syrup urine disease ( mead johnson bcad® ) and entity ( mead johnson phenyl-free® ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|familial inherited gene phenyl mutation|half 300 5000 3000 4000|phenylketonuria|about entity ( pku ) pku is caused by a defect in the gene encoding phenylalanine hydroxylase ( pah ) , a liver enzyme that metabolizes phe .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma melanoma rcc glioblastoma osteosarcoma|pheochromocytoma|we will make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|melanoma mesothelioma gliomas glioma lymphomas|pheochromocytoma|azedra program " means the company  s therapeutic program for the treatment of malignant entity , pediatric neuroblastoma and carcinoid cancers with ultratrace iobenguane i 131 .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma islet ganglion pheochrom gist|pheochromocytoma|trial to evaluate the efficacy and safety of the administration of two therapeutic doses of azedra in patients with entity / paraganglioma .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma gliomas pheochrom gist sns|pheochromocytoma|although the majority of entity and paragangliomas are benign , approximately 10-25% of these tumors present with metastasis , and up to 35% of these cases are
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|melanoma neuroblastoma cml aml osteosarcoma|pheochromocytoma|we are currently pursuing adult clinical trials for entity and pediatric clinical trials for neuroblastoma , which are detailed below .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma medulloblastoma melanoma sclc ovarian|pheochromocytoma|the company is conducting azedra pivotal trials for both adult entity and pediatric neuroblastoma neuroendocrine tumor indications .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma sclc melanoma medulloblastoma neuroendocrine|pheochromocytoma|azedra clinical development plan azedra is under development for the systemic treatment of the metastatic neuroendocrine cancers entity and neuroblastoma .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma melanoma rcc osteosarcoma nsclc|pheochromocytoma|to become a preeminent , patient-centric oncology company and we intend to make a difference in how patients with prostate cancer , entity , and paraganglioma are diagnosed and treated .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|melanoma neuroblastoma mesothelioma glioma hyperthermia|pheochromocytoma|that the first patient had been dosed in the resumed pivotal phase 2 study of azedra™ in patients with malignant entity and paraganglioma .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|melanoma glioma mesothelioma hyperthermia gliomas|pheochromocytoma|two product candidates for prostate cancer , and resumed a pivotal phase 2 trial of an ultra-orphan radiotherapy candidate for malignant entity and paraganglioma .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroendocrine pancreatic gist colorectal pituitary|pheochromocytoma|azedra is currently in a phase 1 trial for entity or carcinoid tumors , and has received orphan drug status and a fast track designation by the united states food and
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma gist pancreas pancreatic melanoma|pheochromocytoma|we are developing azedra as a treatment for patients with malignant , recurrent , and / or unresectable entity and paraganglioma , which are rare neuroendocrine tumors .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|tumors neuroblastoma nets pancreatic pancreas|pheochromocytoma|about entity and paragangliomas entitys and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuroblastoma ganglion islet pheochrom rcc|pheochromocytoma|perelman school of medicine presented preliminary dosimetry data from the phase 2 study in patients with iobenguane-avid metastatic and / or recurrent entity / paraganglioma .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|neuronal neuroblastoma brain ventricular model|pheochromocytoma|pharmacology 2005 ; 74 : 65-78 . " local anesthetic procaine protects rat entity pc12 cells against beta-amyloid-induced neurotoxicity " .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|melanoma rcc adenocarcinoma osteosarcoma gist|pheochromocytoma|in addition to potentially treating entity and paraganglioma , azedra may also have utility in treating neuroblastoma and other neuroendocrine diseases .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|pheochrom neuroendocrine hormone arteriovenous solitary|acc rcc neuroblastoma cholangiocarcinoma melanoma|pheochromocytoma|patients harboring a rare head and neck cancer , known as paraganglioma , and a rare adrenal or extra-adrenal cancer , known as entity , and rare subset clear cell rcc .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hormone pituitary familial hypothalamic tumoral|prolactin this pituitary prl adenoma|prolactinoma|entity is a condition in which a non-cancerous tumor of the pituitary gland overproduces prolactin .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|hormone pituitary familial hypothalamic tumoral|schizophrenia parkinsonism clozapine adhd neuroprotection|prolactinoma|study for xoma 213 , which , if successful , will allow us to advance the compound into a phase 2 study for entity and potentially into anti-psychotic medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hormone pituitary familial hypothalamic tumoral|myeloma melanoma ms copd new|prolactinoma|for ten percent of the 140 , 000 entity patients in the united states , existing therapies are poorly tolerated or not effective .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hormone pituitary familial hypothalamic tumoral|this meningioma pituitary nf1 adenoma|prolactinoma|entity is a condition of benign tumors on the pituitary gland .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hormone pituitary familial hypothalamic tumoral|hypothyroidism hyperthyroidism parkinsonism conditions crpc|prolactinoma|we intend to move xoma 213 into clinical development , initially for symptomatic entity potentially followed by medication-induced hyperprolactinemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial gene single homozygous genetic|fh rock apex golden tof|sitosterolemia|treatment experience with zetia in the pediatric population is limited to 4 patients ( 9 to 17 years ) in the entity study and 5 patients ( 11 to 17 years ) in the hofh study .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|familial gene single homozygous genetic|diabetes malaria inflammation ms lupus|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain blood test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|familial gene single homozygous genetic|adhd syphilis ds ad asd|sitosterolemia|this finding indicated that the infant definitely has entity , despite the prior contradictory test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial gene single homozygous genetic|diabetes immunodeficiency ms autoimmunity inflammation|sitosterolemia|doctors ruled out a diagnosis of a disease called entity , based on certain test results .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|familial gene single homozygous genetic|fh hypercholesterolemia hf fd hl|sitosterolemia|treatment experience with ezetimibe in the pediatric population is limited to 4 patients ( 9 to 17 years ) with homozygous entity and 5 patients ( 11 to 17 years ) with hofh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|diagnosis childhood comorbid sexual generalized|schizophrenia adhd insomnia benzodiazepines ocd|trichotillomania|patent claims the use of opioid antagonists , including nalmefene , for the treatment of impulse control disorders with the exception of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|diagnosis childhood comorbid sexual generalized|adhd depression ptsd schizophrenia autism|trichotillomania|dr . blochs research interests focus on studying tourette syndrome , ocd , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|diagnosis childhood comorbid sexual generalized|schizophrenia autism ocd epilepsy depression|trichotillomania|yale school of medicine - n oted researcher on the study of tourette syndrome , obsessive - compulsive disorder and entity prof . daniele piomelli
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|diagnosis childhood comorbid sexual generalized|depression ptsd schizophrenia mdd adhd|trichotillomania|dr . blochs research interests focus on studying ts , ocd , and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis dermatitis dermatology acne inflammation|vitiligo|has registered a variety of domain names and established an initial website to include in depth information regarding psoriasis , eczema , entity , and the psoria-light device .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|tregs antibodies treg immunity tils|vitiligo|two prior clinical trials of immunotherapies conducted by others suggest that the development of entity was correlated with a favorable response to therapy in melanoma patients .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|uc ad psoriasis ta oa|vitiligo|the enrollment and / or results for a number of phase 2 studies with ati-502 for the topical treatment of aa and entity , including results from its auatb-201 study .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis eczema dermatitis acne alopecia|vitiligo|specified dermatological conditions , including alopecia areata , or aa , androgenetic alopecia , or aga , also known as male or female pattern baldness , entity and atopic dermatitis .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis acne eczema melanoma alopecia|vitiligo|raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts , alopecia areata , and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|alopecia psoriasis dermatitis both eczema|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the patient significant psychosocial stress .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|alopecia psoriasis dermatitis both eczema|vitiligo|psoriasis , eczema , and entity , are common skin conditions that can be challenging to treat , and often cause the client significant psychosocial stress .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|alopecia keratitis neurotoxicity fibrosis immunosuppression|vitiligo|to date , some patients have experienced entity and uveitis , but there has been no other evidence of off-target effects associated with til therapy .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|eczema dermatitis psoriasis rhinitis acne|vitiligo|pharos 2 excimer laser system is fda-cleared and is used as a tool in the treatment of psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|melanoma diabetes ms melanomas psoriasis|vitiligo|we have demonstrated that plasma from individuals with entity contains anti-melanoma activities , and we are attempting to develop vitigam for the treatment of stage iii and stage iv melanoma .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|eczema dermatitis psoriasis acne rhinitis|vitiligo|pharos was granted ce mark clearance in september of 2016 for use in the treatment of psoriasis , entity , atopic dermatitis and leukoderma by the application of uvb ultraviolet light .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis melanoma viti lupus ms|vitiligo|vitigam is an igg-based product manufactured from the plasma of donors with entity , a benign skin condition affecting up to 2% of the general population .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis dermatitis scaling eczema alopecia|vitiligo|the continued development of arq-151 for atopic dermatitis , arq-154 for seborrheic dermatitis and scalp psoriasis , arq-252 for hand eczema and entity , and arq-255 for alopecia areata .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|melanoma psoriasis glioblastoma amd ad|vitiligo|we plan to commence a phase 2 clinical trial for ati-50002 , for the treatment of entity , in the second half of 2017 .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|eczema dermatitis psoriasis rhinitis acne|vitiligo|the fda has granted 510 ( k ) clearance to market pharos in the u . s . for psoriasis , entity , atopic dermatitis , and leukoderma .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|toxicity recurrence thrombocytopenia thrombosis neutropenia|vitiligo|as of september 8 , 2011 , entity was observed in four out of 25 ( 16% ) patients .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|psoriasis melanoma acne eczema dermatitis|vitiligo|we also plan to develop ati-50001 and ati-50002 as potential treatments for entity , a disorder in which white patches of skin appear on different parts of the body .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|eczema dermatitis psoriasis acne rhinitis|vitiligo|otc aoxing ointment walnut meat and camphor used to treat psoriasis , entity and various dermatitis .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|melanoma this ms mm sle|vitiligo|entity is an autoimmune condition in which the patient  s immune system attacks melanoctyes , the cells responsible for skin pigmentation and potential melanoma cancer cells .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis autoimmune sclerosis erythematosus alopecia|eczema acne dermatitis psoriasis scarring|vitiligo|developing the xtrac laser system to be the standard of care for psoriasis , and expanded its utilization to include dermatitis , entity and leukoderma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|cell dural chondro rare synovial|glioblastoma gist melanoma meningioma mesothelioma|angiosarcoma|first quarter highlights , we recently announced the fda has granted us orphan drug designation for oraxol for the treatment of entity , a rare form of malignant blood vessel cancer .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|cell dural chondro rare synovial|adults sarcomas sts japan gist|angiosarcoma|a phase 3 study in entity is planned , and stratification of pfs in the phase 2 trial by tumor endoglin expression may identify other sarcoma histologies
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|cell dural chondro rare synovial|sepsis melanoma cll dlbcl ms|angiosarcoma|¡ in addition , one patient with entity who had a dramatic initial response on skin lesions was not evaluable for response due to death from sepsis ( not
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cell dural chondro rare synovial|melanoma nsclc crpc glioblastoma tnbc|angiosarcoma|we are also evaluating oral paclitaxel in the treatment of entity and in combination with other therapies , including anti-vegf and anti-pd-1 therapies .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|cell dural chondro rare synovial|reducing achieving median decreasing maintaining|angiosarcoma|cr cr trc105 + votrient is active in entity pfs in 13 vegf inhibitor-naïve patients of 7 . 8 months vs . 3 month pfs expected with votrient most vegf inhibitor patients
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cell dural chondro rare synovial|melanoma malignancies cancers scc melanomas|angiosarcoma|in may 2019 , we announced early and complete response data from a clinical study of oral paclitaxel in cutaneous entity , and the study is continuing to enroll .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cell dural chondro rare synovial|humans adults aml nsclc crpc|angiosarcoma|• announcement of the results of the interim analysis from the phase 3 pivotal tappas trial of trc105 in entity is expected in the second half of 2018 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|cell dural chondro rare synovial|glioblastoma gbm melanoma neuroblastoma osteosarcoma|angiosarcoma|we are initially focused on entity which is a tumor that highly expresses endoglin , the target of trc105 , and therefore may be more responsive to treatment
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cell dural chondro rare synovial|europe melanoma japan glioblastoma brazil|angiosarcoma|trc105 is currently being studied in a pivotal phase 3 trial in entity and multiple phase 2 clinical trials , in combination with vegf inhibitors .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cell dural chondro rare synovial|rcc nsclc melanoma hcc pdac|angiosarcoma|efficacy in the phase 3 tappas trial evaluating trc105 in combination with votrient® ( pazopanib ) in patients with advanced or metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|disease|cell dural chondro rare synovial|melanoma cancers malignancies leishmaniasis tumors|angiosarcoma|xiangxue life sciences ( xlifesc )  reported promising clinical results from a clinical study of oraxol in cutaneous entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|cell dural chondro rare synovial|gist osteosarcoma sts sarcomas mesothelioma|angiosarcoma|a total of five patients with entity , a sarcoma subtype known to express high levels of endoglin , have been evaluated for response in the phase 1b / 2 study .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|disease|cell dural chondro rare synovial|bortezomib nivolumab ipilimumab bevacizumab dexamethasone|angiosarcoma|one of these patients , with entity , has an ongoing complete response at month 4 of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|cell dural chondro rare synovial|osteosarcoma melanoma sarcomas glioblastoma gist|angiosarcoma|received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue sarcoma , including entity , in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|cell dural chondro rare synovial|brazil 2010 asia europe japan|angiosarcoma|we have leveraged this platform in all of our ongoing clinical trials including our international phase 3 tappas trial in entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|cell dural chondro rare synovial|glioblastoma neuroblastoma melanoma gist gbm|angiosarcoma|we are particularly excited by the ongoing complete responses seen in entity , a tumor type known to express high levels of endoglin , and expect to initiate a phase 3 trial in this
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cell dural chondro rare synovial|melanoma nsclc crc cancers glioblastoma|angiosarcoma| presented preclinical data on oraxol in the treatment of entity at the american association for cancer research ( aacr ) annual meeting on april 3 , 2019  announced acceptance of
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|cell dural chondro rare synovial|france brazil germany japan europe|angiosarcoma|we plan to initiate a phase 3 study in entity in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|cell dural chondro rare synovial|japan asia europe germany 2011|angiosarcoma|we have seen complete ongoing responses in these tumor types and plan to initiate initial phase 3 development in entity and an international multicenter phase 2 trial in gtn in 2016 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|cell dural chondro rare synovial|rcc nsclc pdac tumors cancers|angiosarcoma|phase 3 tappas trial ( a randomized phase 3 trial of trc105 and pazopanib versus pazopanib alone in patients with advanced entity ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|chi virus transmitted by should|challenge tested influenza ebola treated|chikungunya|the interim analysis has shown that with a single dose administered , up to 98% of study participants produced a neutralizing antibody response against the entity virus by day 7 .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chi virus transmitted by should|hev zikv campylobacter jev ebv|chikungunya|is vector test systems , inc . , vector test systems , inc . markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|chi virus transmitted by should|tuberculosis diabetes others influenza syphilis|chikungunya|to manufacture virus-like particle based vaccines for third parties for indications other than respiratory viruses , certain allergies , hiv , malaria and entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|chi virus transmitted by should|dengue malaria syphilis ebola cholera|chikungunya|hds is also in the process of developing the platform for the qualitative testing for other infectious diseases including typhoid , entity , zika and other diseases .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chi virus transmitted by should|chlamydia syphilis dengue ebola influenza|chikungunya|there are also a number of emerging markets for lateral flow tests for infectious diseases such as burkholderia , entity , lassa , leptospirosis , marburg , rickettsia and zika .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|chi virus transmitted by should|vaccinia ebola zika bk dengue|chikungunya|•antibody against entity virus ( mrna-1944 ) : we announced positive interim data in the first analysis of safety and activity in a phase 1 clinical
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chi virus transmitted by should|influenza measles varicella malaria poliovirus|chikungunya|vaxart may consider developing vaccines targeting other infectious diseases including entity , ebola , hepatitis b , herpes simplex virus 2 , or hsv-2 , and venezuelan equine encephalitis .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chi virus transmitted by should|vietnam zika syphilis uganda campylobacter|chikungunya|chembio to fund the 12-month development of a dpp® fever panel assay to simultaneously detect malaria , dengue , ebola , lassa , marburg , and entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|chi virus transmitted by should|influenza hpv pneumococcal this experimental|chikungunya|solicited aes after each study vaccination for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo % ( no . with
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|chi virus transmitted by should|hev jev ebv zikv campylobacter|chikungunya|is vector test systems inc . vector test systems inc markets and sells a product for the rapid detection of wnv , entity , malaria , dengue , sle , eee and wee among other tests . .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|chi virus transmitted by should|cmv therapeutic protective neutralizing ebv|chikungunya|specifically , the positive phase 1 results from our cmv vaccine and entity antibody programs provide important validation for our approach as we move ahead .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|chi virus transmitted by should|malaria syphilis leishmaniasis hev campylobacter|chikungunya|today announced the signing of a long-term agreement with bio-manguinhos to commercialize chembios poc diagnostic tests for dengue , zika and entity in brazil .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|disease|chi virus transmitted by should|vietnam leishmaniasis malaria schistosomiasis leishmania|chikungunya|expanding beyond sexually transmitted disease , to include future poc tests for fever and tropical diseases such as malaria , dengue , zika , entity , ebola , lassa and marburg .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|chi virus transmitted by should|influenza vaccinia ebola measles zoster|chikungunya|all subjects reported full resolution by day 4 post vaccination , and thereby distinct from the persistent type observed in post entity virus infection arthralgias .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|chi virus transmitted by should|pneumococcal influenza hpv this dna|chikungunya|unsolicited aes reported for the safety set in the phase 1 trial for entity vaccine ( mrna-1388 ) 25 µg 50 µg 100 µg placebo no . , % of
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|chi virus transmitted by should|malaria cholera ebola tuberculosis influenza|chikungunya|zydus cadilaindiapartnership agreement to address the global threat of entity and develop a entity vaccine an emerging infectious disease in africa , asia and the indian subcontinent .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|chi virus transmitted by should|vaccinia ebola zika influenza dengue|chikungunya|the antibody against entity virus is our first systemic secreted therapeutic for which we have filed an ind .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|chi virus transmitted by should|zika dengue japanese measles rabies|chikungunya|cepis priority diseases include ebola virus , lassa virus , middle east respiratory syndrome coronavirus , nipah virus , rift valley fever and entity virus .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|chi virus transmitted by should|vaccinia rsv influenza vzv hpv|chikungunya|vaccine pre-clinical phase i hiv-1 x rsv on hold hsv on hold malaria x influenza x entity x 5 hiv-1 and aids hiv-1 ( human immunodeficiency virus type 1 ) is a retrovirus
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|chi virus transmitted by should|elisa dpp detection assay rapid|chikungunya|of vaccines , diagnostics and biopharmaceuticals , primarily to meet the demands of brazil  s national public health system , related to the dpp® entity assay .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|simplex sclerosis cataract neuromuscular cystic|encephalitis influenza diabetes gastroenteritis measles|botulism|in addition , our botvax® b vaccine has successfully protected hundreds of thousands of horses and foals against type b entity ( commonly known as shaker foal syndrome ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|disease|simplex sclerosis cataract neuromuscular cystic|cyanide pesticide copper metal iron|botulism|of the national institutes of health ( contract no . hhsn272200800028c ) , to support ongoing development of drug candidates for the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 2)])|disease|simplex sclerosis cataract neuromuscular cystic|syphilis tuberculosis rabies schistosomiasis malaria|botulism|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , tularemia , and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|simplex sclerosis cataract neuromuscular cystic|botulinum paralysis this epilepsy tetanus|botulism|entity is a frequently fatal disease caused by botulinum toxins produced by the bacterium clostridium botulinum .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|simplex sclerosis cataract neuromuscular cystic|toxin water egg poison pesticide|botulism|zebra mussels are also believed to be the source of deadly avian entity poisoning that has killed tens of thousands of birds in the great lakes since the late 1990s .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|simplex sclerosis cataract neuromuscular cystic|cyanide ethanol pesticide arsenic metal|botulism|an additional contract with niaid to support our on-going development of drug candidates toward clinical trials in the treatment of entity poisoning .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|simplex sclerosis cataract neuromuscular cystic|vaccinia tetanus malaria influenza measles|botulism|we evaluated the use of mrna for passive immunization in two indications , rabies and entity , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|simplex sclerosis cataract neuromuscular cystic|diseases encephalitis vaccines medicine anaphylaxis|botulism|sales of neogens vaccine for equine entity and amvet veterinary pharmaceuticals experienced strong increases as they continued to gain market acceptance .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex sclerosis cataract neuromuscular cystic|influenza diabetes encephalitis gastroenteritis streptococcus|botulism|in addition , the companys botvax b vaccine has successfully protected thousands of high-value horses and foals against type b entity , commonly known as shaker foal syndrome .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|disease|simplex sclerosis cataract neuromuscular cystic|streptococcus virus bacterial vaccinia salmonella|botulism|the companys boxvax b vaccine is also produced in the tampa , facility , utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|simplex sclerosis cataract neuromuscular cystic|neurotoxicity copd ptsd hepatotoxicity paralysis|botulism|supply of 200 , 000 doses of bat that are intended for treating individuals who have been exposed to the toxins that cause entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|simplex sclerosis cataract neuromuscular cystic|diabetes influenza cholera gastroenteritis streptococcus|botulism|our botvax® b product is the only usda-approved vaccine for the prevention of type b entity in horses .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|simplex sclerosis cataract neuromuscular cystic|protection benefits employment tobacco toxicity|botulism|david scarlett a complaint was filed on july 16 , 2008 by counsel representing mr . scarlett in ohio who alleges to have contracted entity from a castleberrys product .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|simplex sclerosis cataract neuromuscular cystic|paralysis they this botulinum that|botulism|entity can also be contracted if botulinum bacteria contaminate wounds or colonize in the intestine of infants , which is referred to as infant botulism .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|simplex sclerosis cataract neuromuscular cystic|poliovirus measles varicella influenza rabies|botulism|expands our capabilities in biological warfare defense research and allows for the development of vaccines for smallpox , anthrax and plague , entity and other biological pathogens .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|simplex sclerosis cataract neuromuscular cystic|copper arsenic liver apap cyanide|botulism|other companies are developing other products targeting entity poisoning , and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2), ('BIO', 1)])|disease|simplex sclerosis cataract neuromuscular cystic|streptococcus bacterial virus vaccinia aspergillus|botulism|the companys botvax ®b vaccine is also produced in the lansing facility utilizing type b entity seed cultures and a traditional fermentation process .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|disease|simplex sclerosis cataract neuromuscular cystic|copper liver apap arsenic bilirubin|botulism|other companies are developing other products targeting entity poisoning and these products may prove more effective than xoma 3ab .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|simplex sclerosis cataract neuromuscular cystic|td spasticity paralysis bont dysphagia|botulism|bat is indicated for the treatment of symptomatic entity following documented or suspected exposure to botulinum neurotoxin serotypes a , b , c , d , e , f , or g in adults and
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|simplex sclerosis cataract neuromuscular cystic|influenza cholera poliovirus tetanus botulinum|botulism|in the veterinary market , neogen markets botvax b , the only usda approved vaccine for the prevention of entity type b in horses .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|syphilis tuberculosis mycobacterium virus gene|cfs sf scf cf hfs|bartonellosis|entity ( cat scratch fever ) vaccine bartonella henselae is the causative agent of cat scratch fever .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|tort spasm transverse anterior plantar|180° 30° 90° 0° 45°|torticollis|the patient  s head may turn to the right or left ( entity ) , may tilt to one side ( laterocollis ) , or may tilt upwards ( retrocollis ) or downwards ( anterocollis ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tort spasm transverse anterior plantar|dystonia spasm depression reflex muscle|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( “twstrs” ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tort spasm transverse anterior plantar|dystonia tremor spasm ataxia muscle|torticollis|also known as spasmodic entity , cervical dystonia is a painful and debilitating neurological movement disorder .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tort spasm transverse anterior plantar|dystonia tremor spasm ataxia voice|torticollis|cervical dystonia ( also referred to as spasmodic entity ) may be primary ( meaning that it is the only apparent neurological disorder , with or without a family history ) or may
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|tort spasm transverse anterior plantar|spasm dystonia muscle depression spasticity|torticollis|units or 250 units showed a statistically significant greater change from baseline as measured on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|tort spasm transverse anterior plantar|bowel movement dystonia muscle tort|torticollis|cervical dystonia affects approximately three in every 10 , 000 people , or about 90 , 000 people in the united states , according to the national spasmodic entity association .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tort spasm transverse anterior plantar|dystonia spasm depression reflex muscle|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) -total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tort spasm transverse anterior plantar|dystonia spasm depression muscle reflex|torticollis|primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the toronto western spasmodic entity rating scale ( twstrs ) total score .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|tort spasm transverse anterior plantar|spasm dystonia muscle tremor spasticity|torticollis|treatment until the return of signs and symptoms that warrant retreatment , based on subjects reaching their target toronto western spasmodic entity rating scale ( twstrs ) score .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|disease|hodgkin cell cns cutaneous al|cancers tumors malignancies lymphomas cells|lymphoma|first , the cd19 antigen is used in the clinic to distinguish entity derived from b cells from those derived from t cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas tumors cll glioma gliomas|lymphoma|plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin entity and chronic lymphocytic leukemia .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas tumors hl diseases cll|lymphoma|for which a u . s . marketing application is currently being reviewed by the fda for the treatment of relapsed aggressive non-hodgkin  s entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas dlbcl tumors leukaemia cancers|lymphoma|inc . yeah , so invariably we want to look for drugs which are active in diffuse large b-cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hodgkin cell cns cutaneous al|ad constipation spasticity anorexia anaphylaxis|lymphoma|we currently have two products ( at-004 and at-005 ) for treatment of entity in dogs which have received a conditional license from the u . s . department of agriculture , or the usda .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|hodgkin cell cns cutaneous al|toxicities anaphylaxis hepatotoxicity toxicity immunogenicity|lymphoma|the treatment of generalized lipodystrophy , and carries a boxed warning for the risks of anti-metreleptin antibodies with neutralizing activities and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hodgkin cell cns cutaneous al|lymphomas lymphoid lymphocyte lymphocytic lung|lymphoma|type : debit period type : duration x - definitionrepresents the maximum amount of grants to be received from the leukemia and entity society ( lls ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|tumors dlbcl lymphomas condition malignancies|lymphoma|approximately 50% to 60% of dlbcl patients are cured with first-line therapy and do not have recurrence of their entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas hl tumors dlbcl diseases|lymphoma|to finance the analysis of unblinded data on biovaxidtm , an active immunotherapeutic in a pivotal phase 3 study of non-hodgkins entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas tumors malignancies carcinomas cancers|lymphoma|phase ii clinical trials to assess the oms electroimmunotherapy technology in patients with melanoma , merkel cell carcinoma and cutaneous t-cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas all tumors malignancies hl|lymphoma|we are also aware of other potentially competitive biologic therapies for non-hodgkin  s entity in development .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas tumors diseases lymphocyte gliomas|lymphoma|this trial will seek to treat both non-hodgkins entity and chronic lymphocytic leukemia patients that have failed venetoclax .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas tumors diseases neoplasms lymphocytes|lymphoma|morphosys will continue to be responsible for its ongoing clinical studies with tafasitamab in non-hodgkins entity ( nhl ) , cll , r / r dlbcl and first-line dlbcl .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|hodgkin cell cns cutaneous al|lymphomas leukemias myeloma mds melanoma|lymphoma|an open-labeled , uncontrolled , dose-escalation , phase i clinical trial of cudc-427 ( nct01226277 ; iam4914g ) began in patients with refractory solid tumors or entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas dlbcl malignancies tumors cll|lymphoma|one of the issues is even in the novel space there are a limited number of agents which have significant activity in diffuse large b-cell entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hodgkin cell cns cutaneous al|lymphomas cancers myeloma melanoma others|lymphoma|cancers because the therapy can deplete all b cells or t cells including normal and cancer cells in leukemia and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas cll malignancies hl diseases|lymphoma|designed to assess the safety and tolerability of vegf trap in patients with solid tumor malignancies and subjects with non-hodgkins entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hodgkin cell cns cutaneous al|cll lymphomas leukaemia positive malignancies|lymphoma|a large proportion of t-cell entity patients are refractory to or relapse following treatment with standard therapies and there remains a need to develop an effective
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas leukaemia neoplasms neoplasm tumors|lymphoma|in february 2013 , we received clia approval for matba®-dlbcl , our proprietary microarray for diagnosis , prognosis and patient monitoring in diffuse large b cell entity ( dlbcl ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|hodgkin cell cns cutaneous al|lymphomas hl cll dlbcl fl|lymphoma|process for review of inds , initiate a clinical trial of adi-001 targeting cd20 for the treatment of patients with non-hodgkins entity and treat the first patient in the first half of 2021 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|cerebrospinal hernia spinal cleft repair|sb bifid spin asd ts|myelomeningocele|dr . moise is also actively involved in the open fetal surgical repair program for entity ( spina bifida ) at the fetal center .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis sclerosis encephalopathy pml lesions|leukoencephalopathy|this decision was based on reports of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|retinopathy demyelinating focal cns vasculitis|pml leukaemia lesions encephalitis eruption|leukoencephalopathy|these include : fatal infusion reactions , tumor lysis syndrome ( tls ) with associated acute renal failure , severe mucocutaneous reactions and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|sclerosis encephalopathy encephalitis pml demyelination|leukoencephalopathy|in immunosuppressed individuals , jc virus is responsible for a life-threatening infection of the brain and spinal cord called progressive multifocal entity , or pml .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis encephalopathy lesions atrophy sclerosis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain which usually leads to death or severe disability .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|retinopathy demyelinating focal cns vasculitis|lesions fibrosis edema degeneration atrophy|leukoencephalopathy|dyspnea and bronchospasm have been reported , and due to the mechanism of action , increased risk for infections and progressive multifocal entity must be advised and monitored .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis encephalopathy sclerosis lesions pml|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalopathy sclerosis atrophy encephalitis neurodegeneration|leukoencephalopathy|identifies anti-jcv antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|lesions encephalitis encephalopathy sclerosis pml|leukoencephalopathy| progressive multifocal entity ( pml ) : jc virus infection resulting in pml and death has been reported in adcetris-treated patients .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis sclerosis pml encephalopathy lesions|leukoencephalopathy|these events involved two cases of progressive multifocal entity ( pml ) , a rare and potentially fatal , demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|retinopathy demyelinating focal cns vasculitis|lesions pml leukaemia leuk glioma|leukoencephalopathy|shown a reduction in arr of 67% , but it may cause serious side effects including increased risk of progressive multifocal entity ( pml ) , a rare and potentially fatal viral disease .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis encephalopathy lesions atrophy sclerosis|leukoencephalopathy|tysabri increases the risk of progressive multifocal entity ( pml ) , an opportunistic viral infection of the brain that usually leads to death or severe disability .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis encephalopathy lesions sclerosis pml|leukoencephalopathy|the new label identifies anti-jc virus ( jcv ) antibody status as a risk factor for progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|retinopathy demyelinating focal cns vasculitis|classification diagnosis diseases term lesions|leukoencephalopathy|however , tysabri  s association with progressive multifocal 69 table of contents entity , " pml , " has limited its usage to patients for whom other treatment has failed .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|lesions leukaemia pml encephalitis encephalopathy|leukoencephalopathy|several initiatives under way that may lead to defi ning patients who are at greater risk of developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|encephalitis lesions encephalopathy pml sclerosis|leukoencephalopathy|inclusion of anti-jcv antibody status as an additional factor to aid in stratifying patients at risk for developing progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|retinopathy demyelinating focal cns vasculitis|lesions encephalitis encephalopathy sclerosis leukaemia|leukoencephalopathy|we have also begun animal studies related to two orphan diseases , multiple system atrophy ( msa ) and progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|pml leukaemia sclerosis encephalopathy leuk|leukoencephalopathy|collaboration will focus on the discovery and development of therapeutics based on rnai for the potential treatment of progressive multifocal entity ( pml ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|pml encephalitis sclerosis encephalopathy leukaemia|leukoencephalopathy|progressive multifocal entity ( pml )  a rare and potentially fatal demyelinating disease of the central nervous system .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|retinopathy demyelinating focal cns vasculitis|lesions encephalopathy sclerosis atrophy demyelination|leukoencephalopathy|biologics used for multiple sclerosis increased the risk of infections and progressive multifocal entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|retinopathy demyelinating focal cns vasculitis|lesions leukaemia pml neoplasia leuk|leukoencephalopathy|to inform physicians and patients of the benefits and risks of tysabri treatment and minimize potential risk of progressive multifocal entity ( pml ) .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|dme uveitis myopia keratitis diabetes|keratoconus|in 2000 , this patient underwent corneal transplantation caused by entity , simultaneously with extraction of a cataract and implantation of an artificial lens .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal myopia kerat cornea refractive|tears cataract keratitis myopia tear|keratoconus|are the only fda-approved riboflavin ophthalmic formulations used with our kxl system to treat progressive 122 table of contents entity and corneal ectasia following refractive surgery .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|corneal myopia kerat cornea refractive|these diabetic all corneal affected|keratoconus|literature estimates that as many as 20% of entity patients ultimately require a corneal transplant , a costly and invasive procedure with high failure rates .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|myopia astigmatism refraction correction crowding|keratoconus|trial underway ; us clinical trial planned • 38 globally issued patents with 59 pending patent applications vision correction pipeline $3b entity $15b presbyopia $8b low myopia
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal myopia kerat cornea refractive|cataract amd uveitis which myopia|keratoconus|typically diagnosed in a patients teenage years , entity is characterized by progressive thinning and weakening of the cornea , resulting in vision loss .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|corneal myopia kerat cornea refractive|uveitis cataract fibrosis epilepsy osteoarthritis|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|cataract amd melanoma corneal fibrosis|keratoconus|ten patients with advanced entity , or severe corneal scarring , were implanted with the recombinant collagen implants and have been followed for more than five years .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|corneal myopia kerat cornea refractive|degeneration dystrophy cataract myopia cornea|keratoconus|entity is a degenerative corneal disease that impairs vision and is characterized by progressive thinning of the cornea and the development
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal myopia kerat cornea refractive|myopia cataract prk cornea amd|keratoconus|one significant cause of night myopia is entity , an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|corneal myopia kerat cornea refractive|hsv syphilis herpes diabetes me|keratoconus|i  d say there  s  if you look at the prevalence now , there  s 1 . 1 million eyes that are available that have entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|disease|corneal myopia kerat cornea refractive|interferon ms corticosteroid pah retinoid|keratoconus|unlike conventional entity treatments , studies have found that avedros photrexa® actually slows or halts disease progression .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|uveitis cataract fibrosis keratitis blindness|keratoconus|of the enzyme hyaluronidase 7 8 to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|diabetes epilepsy ms t1d schizophrenia|keratoconus|we believe that there are approximately 400 , 000 people in the united states , western europe and japan who currently have entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|corneal myopia kerat cornea refractive|proposed own new experimental gene|keratoconus|avedro estimates the total u . s . opportunity for its entity therapy to be approximately $3 billion .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|uveitis cataract neovascularization inflammation blindness|keratoconus|to digest proteoglycans to treat a variety of eye diseases and conditions , including vitreous hemorrhage , diabetic retinopathy , corneal opacification and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5)])|disease|corneal myopia kerat cornea refractive|this them that me something|keratoconus|know were going to probably get bogged down in migs shortly but just when you think a little bit about entity , arguably an undiagnosed or under diagnosed , i should say , disease state .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|corneal myopia kerat cornea refractive|uveitis cataract osteoarthritis epilepsy fibrosis|keratoconus|purified formulations of the enzyme hyaluronidase to treat diseases and conditions such as vitreous hemorrhage , diabetic retinopathy , corneal opacification , and entity .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|corneal myopia kerat cornea refractive|glioblastoma melanoma gbm gliomas ad|keratoconus|for our latest-generation kxl system , its associated investigational drug formulations and our investigational boost goggles for the treatment of progressive entity in an epi-on procedure .
OrderedDict([('DIS', 5), ('OTHER', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|corneal myopia kerat cornea refractive|cataract myopia diabetes amd burns|keratoconus|keraform we are developing keraform , our proprietary system for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|fracture oste aseptic subchondral vertebral|osteoporosis fibromyalgia rheumatology fractures osteoarthritis|osteonecrosis|thus , we expect that new clinical indications may include orthopedics , secondary osteoporosis ( including glucocorticoid induced osteoporosis ) , entity , and osteoarthritis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('BIO', 1)])|disease|fracture oste aseptic subchondral vertebral|osteoarthritis fractures fracture tumors oa|osteonecrosis|in march 2006 , our proprietary trcs received an orphan drug designation from the fda for use in the treatment of entity of the femoral head .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|fracture oste aseptic subchondral vertebral|damage injuries harm irritation danger|osteonecrosis|plaintiffs allege aredia causes entity to the jaw .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fracture oste aseptic subchondral vertebral|necrosis dead extreme hypoxia dying|osteonecrosis|“entity” means the death of bone cells due to decreased blood flow .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|fracture oste aseptic subchondral vertebral|degeneration necrosis fracture destruction damage|osteonecrosis|entity of the femoral head involves the death of cells in the bone and marrow within the femur head and in
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|fracture oste aseptic subchondral vertebral|neutropenia neurotoxicity toxicity osteomyelitis nephrotoxicity|osteonecrosis|in our original ind submission , we described a finding of entity ( microscopic evidence of bone and bone marrow death ) in a toxicity study of gen-003 conducted in mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|fracture oste aseptic subchondral vertebral|fracture fractures osteosarcoma split extraction|osteonecrosis|there have been no cases of entity of the jaw or atypical femoral fracture in the entire tymlos development program .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|fracture oste aseptic subchondral vertebral|fractures bisphosphonates osteoporosis fracture bones|osteonecrosis|describing changes to the label for zometa and aredia , another intravenous bisphosphonate used to treat metastatic bone disease , relating to entity of the jaw .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|fracture oste aseptic subchondral vertebral|osteoporosis cancers tumors diabetes malignancies|osteonecrosis|additional patent applications are for specific methods of manufacturing strontium salts and for other clinical indications , such as treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|fracture oste aseptic subchondral vertebral|sae hypotension toxicity pancreatitis hepatotoxicity|osteonecrosis|there were no events of entity observed in the trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|fracture oste aseptic subchondral vertebral|fractures amputation complications ulcers potentially|osteonecrosis|more severe complications can occur , such as deep tissue infections and entity threatening life of the limb .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|disease|fracture oste aseptic subchondral vertebral|swelling fractures fracture tumors enlargement|osteonecrosis|plaintiffs claim to have experienced entity of the jaw after having been treated with zometa or aredia , which are used to treat patients whose cancer has
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|fracture oste aseptic subchondral vertebral|osteoarthritis fractures fracture degeneration necrosis|osteonecrosis|the orthopaedic institute , könig-ludwig-haus , university of würzburg , germany , involving the first use of our brcs to treat patients suffering from entity of the femoral head .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|fracture oste aseptic subchondral vertebral|osteoarthritis osteosarcoma opening fracture osteoporosis|osteonecrosis|entity of the jaw ( onj ) : onj has been reported in patients with cancer receiving treatment including bisphosphonates , chemotherapy and / or corticosteroids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|fracture oste aseptic subchondral vertebral|osteoarthritis fractures osteoporosis fracture necrosis|osteonecrosis|aastrom product candidates to treat entity of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the fda .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|fracture oste aseptic subchondral vertebral|fracture fractures osteosarcoma tumors osteomyelitis|osteonecrosis|the most frequent serious adverse reactions were entity of the jaw , bone giant cell tumor , anemia , pneumonia , and back pain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|fracture oste aseptic subchondral vertebral|fractures osteoporosis osteoarthritis tumors deformities|osteonecrosis|other potential orthopedic applications include wrist fractures , poor-healing fractures , and entity , or conditions of bone degeneration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|fracture oste aseptic subchondral vertebral|swelling fracture ulceration enlargement fractures|osteonecrosis|the most frequent adverse reaction resulting in discontinuation of xgeva® was entity of the jaw .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|pneumonia osteomyelitis endocarditis sepsis candidiasis|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing , such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|osteomyelitis complex fung virus av|oncology copd tuberculosis cf immunocompromised|osteomyelitis|most entity patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|osteomyelitis complex fung virus av|pharmaceutical tobacco french dental commercial|osteomyelitis|increase in marketing expenses , which increased from $43 , 000 to $95 , 000 as a result of a commissioned research study on the entity market .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|osteomyelitis complex fung virus av|osteomyelitis tuberculosis periodontitis leprosy sepsis|osteomyelitis|lefamulin has shown substantial tissue penetration and activity against the most common causative organism in all forms of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis complex fung virus av|endocarditis pneumonia abscess bacteremia dissemination|osteomyelitis|invasive pneumococcal disease includes bacteremic pneumonia , bacteremia , sepsis , meningitis and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|bacteremia sepsis osteomyelitis pneumonia endocarditis|osteomyelitis|up to 90% of cases of hematogenous entity , most frequently in children , are caused by s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|bacteremia osteomyelitis sepsis thrombosis pneumonia|osteomyelitis|these data indicate that s . aureus bloodstream infections including infective endocarditis and entity may be a potentially promising area of clinical development with ceftobiprole .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|osteomyelitis complex fung virus av|endocarditis sepsis osteomyelitis abscess abscesses|osteomyelitis|is exebacase , a lysin which targets staph aureus , including methicillin-resistant strains , which causes serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|sepsis abscess osteomyelitis endocarditis pneumonia|osteomyelitis|organisms , such as methicillin-resistant staph aureus ( mrsa ) and p . aeruginosa , which can cause serious infections such as bacteremia , pneumonia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis complex fung virus av|osteomyelitis fracture periodontitis osteoporosis osteosarcoma|osteomyelitis|are currently one of the few resorbable bone void fillers available in international markets for the prevention and treatment of entity , an acute or chronic infection of the bone .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis complex fung virus av|osteomyelitis ulcers periodontitis osteoarthritis wounds|osteomyelitis|could fulfill the need for a safe , long-term oral therapy to treat chronic infections such as prosthetic joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|osteomyelitis complex fung virus av|osteoporosis special herbal inflammation new|osteomyelitis|sui yan pian kang gu sui yan pian ( entity treatment tablets ) is used to treat bone and bone marrow inflammations .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteomyelitis complex fung virus av|pneumonia sepsis vap mortality endocarditis|osteomyelitis|gram-positive bacteria can also cause other serious illnesses , including pediatric and adult entity , community- and habp , including vabp , bacteremia and diabetic foot infection .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|osteomyelitis complex fung virus av|osteomyelitis osteoporosis periodontitis fracture inflammation|osteomyelitis|medicated pellets are currently the only synthetic resorbable bone void filler available on the international market for the treatment of entity , an acute or chronic inflammation of bone .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|osteomyelitis complex fung virus av|osteoporosis osteoarthritis gout osteomyelitis fibromyalgia|osteomyelitis|for example , applications of mdp-25 include metastatic bone disease , pagets disease , arthritic disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|osteomyelitis complex fung virus av|melanoma malignancies ra osteoarthritis diabetes|osteomyelitis|mtf-101 , a diaminopyrimidine that may be suitable for testing in clinical trials to demonstrate safety and efficacy in patients with entity and patients with prosthetic joint infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|pneumonia osteomyelitis endocarditis sepsis candidiasis|osteomyelitis|that torezolid phosphate may offer a safer alternative to linezolid for infections requiring longer term dosing such as bacteremia and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|osteomyelitis complex fung virus av|osteomyelitis periodontitis osteoporosis diabetes sepsis|osteomyelitis|the need for a safe , long-term oral therapy to treat chronic infections such as refractory bone and joint infections and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|osteomyelitis complex fung virus av|amd psoriasis melanoma ad adhd|osteomyelitis|our goal is to develop an effective therapy for entity that permits infrequent dosing .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|osteomyelitis complex fung virus av|ra psoriasis ibd fap uc|osteomyelitis|we believe that lefamulin has the potential to be an effective treatment option for entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|pivotal sponsored biologics ms funded|dermatomyositis|entity clinical program update corbus is currently evaluating anabasum in an on-going phase 2 study for the treatment of skin-predominant dermatomyositis .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|dermatitis lupus dermatology psoriasis depression|dermatomyositis|change in the cutaneous entity activity and severity index ( “cdasi” ) activity score is a secondary efficacy outcome .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|lupus sle eczema ra vasculitis|dermatomyositis|above disease programs , we performed phase i pilot clinical trials with eculizumab in patients afflicted with the chronic autoimmune disorders entity , psoriasis , and bullous pemphigoid .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|myopathy fibromyalgia amyloidosis polym vasculitis|dermatomyositis|servier also began testing gevokizumab in a variety of small clinical studies , including polymyositis / entity and schnitzler syndrome .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|ra others fibromyalgia vasculitis ms|dermatomyositis|in patients with any one of the following six different autoimmune diseases : cle , sle , sjögrens syndrome , systemic sclerosis , polymyositis and entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|psoriasis vasculitis amyloidosis forms ssc|dermatomyositis|resunab is currently in phase 2 studies for the treatment of diffuse cutaneous systemic sclerosis and skin-predominant entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2), ('DRUG', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|fibromyalgia lupus sle vasculitis sarcoidosis|dermatomyositis|two rare autoimmune connective tissue conditions , polymyositis and entity , have been alleged to occur with increased frequency in patients who have received cosmetic collagen treatments .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|myopathy fibromyalgia dmd sma ms|dermatomyositis|new drug application with the fda to commence a phase ib pilot clinical study trial with 5g1 . 1 in patients with entity , a severe inflammatory muscle disorder .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|dmd myopathy ssc sma dm1|dermatomyositis|based on these ongoing efforts , we have focused our development strategy on entity , a form of the disease in which there is muscle and skin involvement .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|psoriasis fibromyalgia epilepsy diabetes gout|dermatomyositis|lenabasum is currently being evaluated in entity and systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|myopathy fibromyalgia dmd dystrophin als|dermatomyositis|age , and the treatment of certain rheumatology related conditions , including the treatment of the rare and closely related neuromuscular disorders entity and polymyositis .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|diabetes psoriasis lupus melanoma epilepsy|dermatomyositis|continue to increase as we advance to clinical trials for indications for the treatment of cystic fibrosis , systemic sclerosis and entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|lupus sle fibromyalgia vasculitis glomerulonephritis|dermatomyositis|forms of b-cell lymphoma , including waldenströms macroglobulinemia and diffuse large b-cell lymphoma , and in orphan autoimmune diseases , including polymyositis and entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|melanoma cll myeloma itp cml|dermatomyositis|we are developing imo-8400 for the treatment of a rare disease called entity .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|psoriasis epilepsy sarcoidosis diabetes fibromyalgia|dermatomyositis|lenabasum is currently being evaluated in systemic sclerosis , cystic fibrosis , entity , and systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|epilepsy diabetes psoriasis sarcoidosis fibromyalgia|dermatomyositis|lenabasum is not approved for the treatment of systemic sclerosis , entity , cystic fibrosis or systemic lupus erythematosus .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|myopathy fibromyalgia amyloidosis vasculitis multiplex|dermatomyositis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / entity , schnitzler syndrome , and giant cell arteritis .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|psoriasis melanoma myeloma diabetes osteoarthritis|dermatomyositis|dose in the phase 2 clinical trials currently underway and recently completed with jbt-101 in cystic fibrosis , systemic sclerosis and entity , respectively .
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|this sle ms myopathy lupus|dermatomyositis|entity is an autoimmune disorder in which the immune system attacks the patients muscles and skin , which may cause extensive rash
OrderedDict([('DIS', 4), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|vasculitis erythematosus sclerosis lupus cutaneous|diabetes myopathy dm muscular demyelination|dermatomyositis|by therapeutic area paid prescriptions multiple sclerosis ( ms ) nephrotic syndrome ( ns ) infantile spasms ( is ) entity / polymyositis ( dm / pm ) ** jan-10 67 6 26 feb-10 72
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|ms leprosy sle cf syphilis|leprosy|enl , a complication of entity , is a chronic bacterial disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|tuberculosis leprosy syphilis complex mycobacterium|sepsis osteomyelitis pneumonia colitis periodontitis|leprosy|enl , an inflammatory complication of entity , is a chronic bacterial disease associated with excess tumor necrosis factor alpha , or tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|tuberculosis leprosy syphilis complex mycobacterium|malaria tuberculosis schistosomiasis ebola measles|leprosy|novartis as the pharmaceutical partner in the global alliance set up by the who for the elimination of entity takes great pride in having been able to contribute to this achievement .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|disease|tuberculosis leprosy syphilis complex mycobacterium|diabetes tuberculosis malaria schistosomiasis leprosy|leprosy|we expanded our programs designed to facilitate the supply of drugs to indigent patients suffering from entity , malaria , tuberculosis and chronic myeloid leukemia ( cml ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tuberculosis leprosy syphilis complex mycobacterium|ms sle ra diabetes gout|leprosy|from the fda which allowed us to market thalomid® for the treatment and suppression of enl , an inflammatory complication of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|enl sle all leprosy these|leprosy|enl occurs in about 30% of entity patients , and is characterized by cutaneous lesions , acute inflammation , fever , and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tuberculosis leprosy syphilis complex mycobacterium|sle ms diabetes sepsis vasculitis|leprosy|enl is an inflammatory complication of entity associated with excess tnf ( alpha ) production .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|leprosy immunocompromised young african diabetic|leprosy|approval from the fda to market thalidomide for the treatment of erythema nodosum leprosum , an inflammatory skin condition of some entity patients .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|tuberculosis leprosy syphilis complex mycobacterium|antimalarial these malaria new all|leprosy|the group provided further support for patients in developing countries by supplying entity drugs free of charge and by selling coartem , our new antimalarial treatment , to the who at cost .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|tuberculosis leprosy syphilis complex mycobacterium|immunosuppression leprosy immunodeficiency autoimmunity inflammation|leprosy|market and sell thalomid ( thalidomide ) for the treatment of erythema nodosum leprosum ( enl ) , a severe and debilitating condition associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5)])|disease|tuberculosis leprosy syphilis complex mycobacterium|this our these us such|leprosy|we have given entity medication free of charge since the year 2000  again to 3 million patients and on an ongoing basis .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('DRUG', 4), ('OTHER', 4)])|disease|tuberculosis leprosy syphilis complex mycobacterium|schistosomiasis leishmaniasis tuberculosis dengue leprosy|leprosy|this approval reinforces the company  s commitment to reduce the burden of neglected tropical diseases including fascioliasis , entity and malaria .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2)])|disease|tuberculosis leprosy syphilis complex mycobacterium|tuberculosis psoriasis leprosy epilepsy diabetes|leprosy|when given orally , dapsone is used for the treatment of such diseases as entity , malaria and dermatitis herpetiformis , an autoimmune skin disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|sle this nf1 leprosy copd|leprosy|entity afflicts millions worldwide , although the disease is relatively rare in the united states .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|enl sle all these leprosy|leprosy|enl occurs in about 30% of entity patients and is characterized by skin lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|eczema diabetes wounds cancers tumors|leprosy|infection caused by a protozoal parasite that affects the skin and abdominal organs , causing ulcers or skin disorders that resemble entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|enl sle all leprosy immunocompetent|leprosy|enl occurs in about 30% of entity patients and is characterized by cutaneous lesions , acute inflammation , fever and anorexia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|cancers malignancies myeloma autoimmune tumors|leprosy|approved for sale in the u . s . , thalidomide has been used as an investigational agent to treat thousands of patients for entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|this amd cml diagnosis hl|leprosy|although entity is relatively rare in the united states , the disease afflicts millions worldwide .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|tuberculosis leprosy syphilis complex mycobacterium|myopathy thrombocytopenia immunosuppression inflammation hemolysis|leprosy|the fda an approvable letter for its nda for thalomid for the treatment of enl , a disease state associated with entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|bacillus genus encephalitis mycobacterium tuberculosis|infectious canine animal zoonotic parasitic|ehrlichiosis|entity diseases quilvax-l ( tm ) 10 million licensing schering- product to prevent dogs at risk efficacy and plough .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|bacillus genus encephalitis mycobacterium tuberculosis|malaria syphilis encephalitis schistosomiasis cytomegalovirus|ehrlichiosis|the most prevalent and well known tick-borne disease is lyme disease , but there are others such as anaplasmosis , entity , and babesiosis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|bacillus genus encephalitis mycobacterium tuberculosis|neoplasms malignancies diseases neoplasm neoplasia|ehrlichiosis|aquila also has several issued and pending patents in the field of lyme disease and human granulocytic entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|bacillus genus encephalitis mycobacterium tuberculosis|igm c3 neutrophils eosinophils granulocytes|ehrlichiosis|x2 ehrlichia equi igg & igm ( hge ) abs each [ *** ] * 7846 86609x2 ; 86618x2 entity ( granulocytic ) & lyme disease evaluation each
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|mum herpes virus childhood measles|varicella cholera tetanus influenza zoster|mumps|other diseases such as rubella , polio , measles , entity , chickenpox , and typhoid are nowhere near as common as they were a hundred years ago .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|mum herpes virus childhood measles|influenza varicella zoster rabies cholera|mumps|polio , measles , entity and many other viral illnesses are now controllable and smallpox has been eradicated from nature .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|varicella measles mum influenza tetanus|mumps|the company recently applied for regulatory clearance in canada to market episcreen for the detection of measles , entity and rubella .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|mum herpes virus childhood measles|feline rat canine dog sheep|mumps|product portfolio includes vaccines against hepatitis a and b , seasonal influenza , h5n1 pandemic influenza ( avian flu ) , h1n1 influenza ( swine flu ) , entity and canine rabies .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|mum herpes virus childhood measles|candidate pneumococcal new novartis registered|mumps|in december 2011 , sinovac dalian , an operating subsidiary of the company obtained the production license from the sfda for its entity vaccine .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mum herpes virus childhood measles|zoster varicella measles mum influenza|mumps|legionella and influenza ,  epstein barr virus , and  other viral pathogens , including measles , entity , rubella and varicella .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|varicella measles influenza mum tetanus|mumps|mercks sales of m‑m‑r ii , a vaccine to help protect against measles , entity and rubella , were $103 million for the third quarter of 2015 compared with $86 million for the third quarter of
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mum herpes virus childhood measles|zoster measles varicella mum influenza|mumps|these viruses include measles , entity , rubella , varicella , and epstein-barr and may be involved in the pathogenesis of ms in several ways : transient or persistent
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|varicella tetanus influenza poliovirus rabies|mumps|( e ) annual medical report indicating satisfactory health status , including immunization for communicable disease such as hepatitis b , entity , measles , rubeola and tuberculosis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|mum herpes virus childhood measles|varicella measles herpes malaria influenza|mumps|conjugate , enterovirus 71 ( ev71 ) ( against hand , foot & mouth disease ) , japanese encephalitis , animal and human rabies , hib and epidemic meningitis , chickenpox , entity and rubella .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|mum herpes virus childhood measles|gbs malaria cmv pneumonia measles|mumps|while death from entity is rare , it can be associated with a number of serious complications , such as meningitis and encephalitis , especially in older
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|varicella influenza tetanus measles mum|mumps|live virus vaccines , including those for smallpox , polio , measles , entity , rubella and chicken pox , have had a long record of preventing disease .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|mum measles tetanus varicella influenza|mumps|examples include the measles , entity , rubella ( mmr ) , yellow fever ( a flavivirus ) , varicella , influenza , smallpox and the oral vaccine against polio , which has been widely deployed
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|rabies influenza varicella tetanus poliovirus|mumps|company overview china bio-immunity corporation ( the “company” or “we” ) , a nevada corporation , is a leading provider of rabies and entity vaccines in the peoples republic of china ( “prc” ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1), ('DIS', 1)])|disease|mum herpes virus childhood measles|adjuvant mva virus dna mpl|mumps|things , that the company defrauded the u . s . government by falsifying data in connection with a clinical study conducted on the entity component of the companys m-m-r ii vaccine .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|mum herpes virus childhood measles|vaccinia herpes influenza pox live|mumps|dth skin tests have been commonly used to detect t cell responses to tuberculosis , fungal pathogens , and entity virus .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|mum herpes virus childhood measles|mum tetanus varicella measles influenza|mumps|claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and / or the measles , entity and rubella ( mmr ) vaccine .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|mum herpes virus childhood measles|veterinary plant foreign vector bird|mumps|&nbsp ; revenue for animal and entity vaccines without a right of return provided to customers is recognized when delivery has occurred .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|mum herpes virus childhood measles|tetanus varicella influenza measles bcg|mumps|priorix tetra , which builds on gsks existing entity , measles and rubella vaccine with the addition of varicella protection , will be filed in european and international markets .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|mum herpes virus childhood measles|varicella tetanus influenza cholera poliovirus|mumps|these cell lines have been successfully used to produce a number of human vaccines ( rubella , entity , measles , rabies and hepatitis a ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|asbestos neoplasia sclerosis psoriasis latent|mesothelioma melanoma particular instance date|asbestosis|that entity , lung cancer , and other rare types of cancer have been associated with exposure primarily in asbestos-related industries where
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|asbestos neoplasia sclerosis psoriasis latent|mesothelioma pneumonia fibrosis cancers tuberculosis|asbestosis|when inhaled , asbestos fibers can cause certain diseases , including entity , mesothelioma and lung cancer ( and risks for smokers are dramatically compounded ) .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos neoplasia sclerosis psoriasis latent|mesothelioma pneumonia fibrosis lung copd|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity and cancer ) increases .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|asbestos neoplasia sclerosis psoriasis latent|pneumonia mesothelioma fibrosis lung copd|asbestosis|if inhaled , asbestos fibers can accumulate in the lungs and , as exposure increases , the risk of disease ( such as entity or cancer ) increases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|enteric complex tuberculosis transmission gastroenteritis|pneumonia tuberculosis malaria cf influenza|legionellosis|of contents serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|enteric complex tuberculosis transmission gastroenteritis|pneumonia cf tuberculosis pcp ipd|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 73 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|enteric complex tuberculosis transmission gastroenteritis|pneumonia tuberculosis malaria influenza cf|legionellosis|against several serotypes of legionella pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are commonly used to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|enteric complex tuberculosis transmission gastroenteritis|pneumonia cf tuberculosis pcp ipd|legionellosis|pneumophila compared to other macrolides , particularly erythromycin and azithromycin , which are 75 table of contents commonly used to treat entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|oste neuromuscular skeletal inorganic inherited|fibrosis pathology inflammation grading this|osteomalacia|entity was characterized by the pathologist as improving from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|oste neuromuscular skeletal inorganic inherited|nephrotoxicity neurotoxicity nephropathy myopathy toxicity|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|oste neuromuscular skeletal inorganic inherited|nephropathy nephrotoxicity neurotoxicity myopathy toxicity|osteomalacia|used because aluminum absorbed from the intestinal tract accumulates in the tissues of patients with chronic kidney failure , causing aluminum-related entity , anemia and dialysis dementia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|oste neuromuscular skeletal inorganic inherited|toxicity immunosuppression hyperthermia thrombocytopenia analgesia|osteomalacia|with respect to the tumor-induced entity indication , this goal measured completion of enrollment for our phase 2 study , generation of data to support proof of concept
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|oste neuromuscular skeletal inorganic inherited|osteoporosis swelling hyperparathyroidism cachexia edema|osteomalacia|tio results from typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , bone fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|oste neuromuscular skeletal inorganic inherited|inflammation immunosuppression thrombocytopenia hypoxia osteogenesis|osteomalacia| krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|oste neuromuscular skeletal inorganic inherited|osteoporosis osteogenesis osteosarcoma oste osteoarthritis|osteomalacia|crysvita is being studied for the treatment of tumor induced entity ( tio ) , a rare disease that impairs bone mineralization .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|oste neuromuscular skeletal inorganic inherited|fibrosis differentiation inflammation grading bmd|osteomalacia|the bone biopsy data demonstrated substantial improvement in entity from severe to mild disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|oste neuromuscular skeletal inorganic inherited|osteoporosis this fracture osteoarthritis sarcopenia|osteomalacia|entity leads to severe bone pain , fatigue , muscle weakness and risk of recurring bone fractures .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|oste neuromuscular skeletal inorganic inherited|osteoporosis hyperparathyroidism scoliosis calcification osteosarcoma|osteomalacia|bone growth plates at the end of adolescence , in addition to continuing vascular and organ calcification , enpp1 deficiency manifests as entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|oste neuromuscular skeletal inorganic inherited|vision hrqol qol hearing cognition|osteomalacia|in our past discussions with fda , they emphasized that improvement in entity could also be considered an important outcome for adults with xlh .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|oste neuromuscular skeletal inorganic inherited|hyperparathyroidism gout hyperthyroidism myeloma nephropathy|osteomalacia|of pth lead to excessive release of calcium and phosphorus from bones , causing debilitating metabolic bone diseases , such as osteoporosis , entity , rickets and renal osteodystrophy .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|oste neuromuscular skeletal inorganic inherited|hypoxia inflammation thrombocytopenia immunosuppression osteogenesis|osteomalacia|krn23 ( ux023 ) for the treatment of tio krn23 is also intended for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|oste neuromuscular skeletal inorganic inherited|osteoporosis swelling edema deformities cachexia|osteomalacia|for tio , a disease characterized by typically benign tumors that produce excess levels of fgf23 , which can lead to severe entity , fractures , bone and muscle pain , and muscle weakness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|oste neuromuscular skeletal inorganic inherited|osteogenesis osteosarcoma osteoporosis oste ossification|osteomalacia|crysvita is being developed to treat xlh and tumor-induced entity ( tio ) , diseases characterized by excess levels of fgf23 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|oste neuromuscular skeletal inorganic inherited|inflammation immunosuppression hypoxia thrombocytopenia angiogenesis|osteomalacia|krn23 ( ux023 ) for the treatment of tio we are also developing krn23 for the treatment of tumor-induced entity , or tio .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|familial autosomal ataxia mendelian leuk|ataxia syndromes cataract dementia sclerosis|leukodystrophy|trauma has a neurosteroid compound intended to treat rare brain disorders , such as als , niemann picks disease , krabbes disease , metachromatic entity and other leukodystrophies .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial autosomal ataxia mendelian leuk|neurodegeneration condition neurodegenerative demyelination dementia|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain , which prevents proper synaptic communication of neurons .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial autosomal ataxia mendelian leuk|neurodegeneration demyelination neurodegenerative condition dementia|leukodystrophy|the disease is a entity , caused by degradation of white matter in the brain .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|disease|familial autosomal ataxia mendelian leuk|syndromes diseases polyposis ataxia cancers|leukodystrophy|with regard to our biomarker for metachromatic entity , we own two separate patent families .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1), ('BIO', 1)])|disease|subsp strains that sa strain|malaria measles poliovirus virus hbv|pertussis|and one of the ways of blocking the transmission of entity to newborns is to create an immunized cocoon around them so that all of the adults that are in contact
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|subsp strains that sa strain|tetanus diphther pneumococcal rabies dt|pertussis|accordingly , the company has been selling its acellular entity toxoid to ssi for formulation into dtap and dtap-ipv for sale in sweden and 12 denmark , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|disease|subsp strains that sa strain|pseudomonas candida yeast listeria salmonella|pertussis|to date , we have initiated development of a mab therapy for the treatment of entity and acinetobacter infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|subsp strains that sa strain|influenza malaria measles pneumonia varicella|pertussis|the incidence of entity is increasing in association with exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated , exposure
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|subsp strains that sa strain|pneumococcal yellow lyme hib rabies|pertussis|certiva [ trademark ] is the company  s investigational vaccine against diphtheria , tetanus and entity disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|subsp strains that sa strain|malaria dengue syphilis measles hbv|pertussis|entity is an endemic disease , but epidemics occur every 3 - 5 years .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|disease|subsp strains that sa strain|antigens conjugate yellow bcg hib|pertussis|quadracel® , a quadrivalent booster vaccine ( fifth dose ) including diphtheria , tetanus , accelular entity and ipv is being developed for the u . s . market .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|subsp strains that sa strain|botulinum cholera pseudomonas tetanus clostridium|pertussis|the validity of the italian counterpart of connaught  s european patent 0 322 115 ( the "  115 patent " ) which allegedly relates to entity toxin mutants .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|subsp strains that sa strain|pneumococcal hbv poliovirus h1n1 rotavirus|pertussis|full-year polio / entity / hib vaccines sales were down 0 . 7% to 1 , 749 million .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|subsp strains that sa strain|nec cf pneumonia sepsis rds|pertussis|infants with entity often require hospitalization in pediatric intensive care units , frequently requiring mechanical ventilation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|disease|subsp strains that sa strain|pneumococcal hbv hib dtpa ppv|pertussis|reported 2013 reported change on a reported basis change at constantexchange rates polio / entity / hib vaccines ( including pentacel® and pentaxim® ) 1 , 154 1 , 148 +0 . 5% +1 . 9%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|subsp strains that sa strain|adjuvant component combination gelatin influenza|pertussis|the company  s manufacturing operations for neisvac-c ( tm ) , certiva ( r ) and its acellular entity vaccine are located principally in one facility .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|subsp strains that sa strain|melanoma als cml leprosy ms|pertussis|worldwide , nearly 50 million cases of entity are diagnosed annually and about 350 , 000 people die of the disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|disease|subsp strains that sa strain|strain assay virus probiotic toxin|pertussis|illumigene® bordetella entity ( whooping cough )  commercialized in march 2014 6 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|subsp strains that sa strain|pneumococcal hbv h1n1 hib measles|pertussis|+33 . 3 % total vaccines 1 , 800 1 , 422 +26 . 6 % +24 . 5 % polio / entity / hib vaccines posted 2017 first-half net sales of 901 million , up 41 . 3% cer .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 2)])|disease|malformation cleft single duplication ntd|atrophy fibrosis ulceration edema inflammation|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin atrophy .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|malformation cleft single duplication ntd|atrophy fibrosis ulceration thinning pigmentation|syndactyly|however , the severity of the condition does increase with age due to scarring , entity and generalized skin 82 table of contents atrophy .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis pth hpt ra|hypoparathyroidism|we believe transcon pth may provide patients suffering from entity with a pth replacement therapy that is designed to fully address all aspects of the disease more than standard of
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|osteoarthritis diabetes osteoporosis gout fibromyalgia|hypoparathyroidism|we now have the financial resources to fund the continued u . s . development of preos in a variety of indications , including entity and osteoporosis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|depression conditions toxicity copd toxicities|hypoparathyroidism|treatment , even with the less frequent regimens , may be an effective treatment option for those patients suffering from less severe entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|glioblastoma melanoma endometriosis epilepsy ascites|hypoparathyroidism|eb612 for the treatment of entity we believe eb612 may offer several advantages over natpara for the following reasons : • eb612 is designed to be dosed
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|amd crpc melanoma osa ad|hypoparathyroidism|would enable us to seek u . s . marketing approval of npsp558 as a new standard of care for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis pth shp hpt|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|sb crs bms ks sts|hypoparathyroidism|we believe positive results from steps and replace will enable us to seek u . s . marketing approval of gattex for sbs and npsp558 for entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|menopause females osteoporosis hypothyroidism pcos|hypoparathyroidism|origin ] injection ) is being evaluated in a phase 3 registration study known as replace as a hormone replacement therapy for entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis pth shp hpt|hypoparathyroidism|our lead oral pth product candidate , eb612 , has successfully completed a phase 2a trial for entity , a rare condition in which the body fails to produce sufficient amounts of pth .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism ckd osteoporosis myeloma cin|hypoparathyroidism|showed the predicted pharmacokinetic and pharmacodynamic response , suggesting the ability to normalize serum and urinary calcium levels in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis osteoarthritis myeloma diabetes|hypoparathyroidism|candidate we chose to pursue was pth , which has the potential for therapeutic use in a number of indications including entity , osteoporosis and non-union fractures .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|humans pts males sbs adults|hypoparathyroidism|( sbs ) and a phase 3 registration study has been completed for natpara ( recombinant human parathyroid hormone ( rhpth [ 1-84 ] ) in adult entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|sbs ss ibd ds sma|hypoparathyroidism|while sbs and entity are relatively rare disorders , we believe they represent a substantial commercial opportunity to us due to the significant unmet need
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|osteoporosis osteoporotic parathyroid hemodialysis myeloma|hypoparathyroidism|replace , a phase 3 registration study of npsp558 , the companys bioengineered replica of human parathyroid hormone ( rhpth 1-84 ) , in adult entity patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|osteoporosis hyperparathyroidism ds pth ckd|hypoparathyroidism|the symptoms of entity are typically managed with large doses of oral calcium supplementation and active vitamin d therapy to reduce the severity of
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis pth hyperthyroidism diabetes|hypoparathyroidism|short bowel syndrome ) and our study of npsp558 is known as replace ( recombinant parathyroid hormone to normalize calcium and treat entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|migraine epilepsy fibromyalgia constipation gout|hypoparathyroidism|criteria for 20 , 250 of these options was satisfied when the fda accepted the bla for natpara for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|humans pediatrics mm progress ms|hypoparathyroidism|we are committed to advancing the development of preos in entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|itp migraine pancreatitis pah hypothyroidism|hypoparathyroidism|we are also developing natpara® ( rhpth [ 1-84 ] ) for the treatment of adult entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|hypothyroidism carrier autoimmune insufficiency hormone|hyperparathyroidism osteoporosis t2dm ckd myeloma|hypoparathyroidism|reported the fdas approval of natpara as an adjunct to calcium and vitamin d to control hypocalcemia in patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|strain tuberculosis strains spor nod|varicella syphilis tuberculosis chlamydia malaria|typhus|doxycycline is an antibiotic used to treat anthrax , rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|strain tuberculosis strains spor nod|varicella herpes chlamydia hsv cholera|typhus|diseases that can be acquired from such accidents include hiv / aids , hbv , hcv , diphtheria , gonorrhea , entity , herpes simplex virus , malaria , syphilis and tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|strain tuberculosis strains spor nod|syphilis varicella chlamydia tuberculosis malaria|typhus|doxycycline is an antibiotic used to treat rocky mountain spotted fever , entity and mycoplasma pneumonia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies virus encephalitis herpes zoster|zika influenza malaria cytomegalovirus measles|rabies|these efforts , we will continue the development of these drugs , as well as our other drug development endeavors that include entity , dengue viruses , and ebola / marburg viruses .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|syphilis measles varicella malaria tuberculosis|rabies|talecris also has a line of hyperimmune therapies that provide treatment for tetanus , entity , hepatitis b , hepatitis a and rh factor control during pregnancy and at birth .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|ebola influenza vaccinia zika dengue|rabies|the candidate ligands for this nanoviricide were designed by the company using publicly available information regarding the interaction of the entity virus with cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|live pneumococcal rotavirus hpv measles|rabies| an additional phase ii study in healthy adults evaluating crucells monoclonal antibody in combination with a entity vaccine is scheduled to start in india in the second quarter of 2009 .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|syphilis cytomegalovirus tuberculosis dengue malaria|rabies|seasonal influenza , hiv , oral and genital herpes ( hsv ) , viral diseases of the eye including ekc and herpes keratitis , hepatitis c , entity , dengue fever , and ebola virus , among others .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|rabies virus encephalitis herpes zoster|rabies rab retinoblastoma ebola recombinant|rabies|cv7202 is an mrna that encodes the entity virus glycoprotein , rabv-g , formulated with lnps .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|rabies virus encephalitis herpes zoster|polyclonal free recombinant gamma kappa|rabies|sales volume for human albumin and human immunoglobulin for intravenous decreased by 19 . 4% and 24 . 3% , respectively , while human entity immunoglobulin recorded an increase of 94 . 9% .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|melanoma cml epilepsy ms als|rabies|nihe thereafter requested that we develop a drug for entity , a request to which we agreed .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|syphilis cytomegalovirus tuberculosis adenovirus poliovirus|rabies|types i , ii , iii , & iv ; · hepatitis b virus ( hbv ) ; · hepatitis c virus ( hcv ) ; · entity ; · ebola and marburg viruses ; · japanese encephalitis ; and · west nile virus .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|rabies influenza malaria varicella vaccinia|rabies|our lead vaccine program , cv7202 , is being developed for prophylactic vaccination against entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies virus encephalitis herpes zoster|rabies ebola influenza rab ebov|rabies|rabicide , a nanoviricide against entity finished its first set of animal studies in the first quarter of 2007 in vietnam .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|rabies virus encephalitis herpes zoster|tested influenza varicella vaccinated vaccines|rabies|[ **** ] against rsv , para influenza , cmv pneumo ( including s . pneumoniae , branhamalla , non-typable haemophilus influenza and otitis media ) and entity in the field in the territory .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|rabies virus encephalitis herpes zoster|cholera malaria sepsis tuberculosis rabies|rabies|we evaluated the use of mrna for passive immunization in two indications , entity and botulism , that can be considered prototypes for anti-pathogen and anti-toxin therapies , respectively .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|rabies virus encephalitis herpes zoster|phospholipid lymphocyte tetanus cd20 hbs|rabies|anti-entity immune globulin therapy is prescribed for individuals suspected of recent exposure to the entity virus .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies virus encephalitis herpes zoster|rabies malaria ebola rab ebov|rabies|entity is commonly transmitted by infectious saliva from the bite of a rabid animal .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|rabies virus encephalitis herpes zoster|candidate rabies new live novel|rabies|since 2010 , isconova and vetbiochem have collaborated on the development of entity vaccines for dogs and cats .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|rabies virus encephalitis herpes zoster|melanoma cll adults aml humans|rabies|in january 2020 , we reported preliminary data from our phase 1 trial of cv7202 in entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|rabies virus encephalitis herpes zoster|influenza dengue measles rabies zika|rabies|have entered into work orders for the preclinical development of a lassa virus vaccine , a yellow fever vaccine and our entity virus vaccine .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|disease|rabies virus encephalitis herpes zoster|zoster hbv syphilis ebola pneumococcal|rabies|licenses in perpetuity for technologies developed by theracour for the virus types : hiv , hcv , herpes , asian ( bird ) flu , influenza and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|rabies virus encephalitis herpes zoster|zika poliovirus leishmania influenza syphilis|rabies|further , the company has identified highly active nanoviricide drug candidates against ebola / marburg , and against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|collapse ja brook cross trans|syphilis varicella dengue tuberculosis malaria|psittacosis|dr . moore has conducted clinical research on infectious diseases such as venezuelan equine encephalitis , tuberculosis , listeriosis , entity , human orf , malaria , and hiv / aids .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|iri chlamydia conjunctiv puncta cholangi|trachoma|chlamydia entitytis also causes the ocular disease entity , which is a form of vesicular conjunctivitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|disease|trach aver sti ring antiretroviral|diseases malaria bacteria tuberculosis syphilis|trachoma|through the iti , we donate the antibiotic zithromax to combat blinding entity in developing countries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|trach aver sti ring antiretroviral|diseases blindness malaria syphilis tuberculosis|trachoma|we intend to help the world health organization achieve its goal of eliminating blinding entity by the year 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|trach aver sti ring antiretroviral|syphilis malaria azithromycin chlamydia measles|trachoma|increase in annual dividends to $1 . 36 from $0 . 80•since 2010 , donated more than 580 million doses of zithromax ( azithromycin ) to treat entity , the leading cause of infectious blindness .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|technology transition transport transfer transit|trachoma|internationally , we have two innovative access programs : the international entity initiative ( iti ) and the diflucan partnership program ( dpp ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|trach aver sti ring antiretroviral|malaria global development priority immunization|trachoma|dr . feczko is a member of the technical expert committee for the international entity initiative of the task force for global health .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|trachomatis chlamydia iri puncta pneumoniae|trachoma|because c . entitytis also causes entity , the world  s most common form of preventable blindness , the who estimates chlamydia is responsible for at least 15 percent of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|developing childhood preventable color getting|trachoma|in response , the number of people at risk of entity blindness worldwide has been reduced to 158 million from more than 300 million in 2010 . shantanu narayen , lead independent director of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|iri nod disci cholangi arteri|trachoma|because c . entitytis also causes entity , the worlds most common form of preventable blindness , the who estimates c . entitytis is responsible for at least 15 percent of the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|trach aver sti ring antiretroviral|cataract amd blindness myopia uveitis|trachoma|entity is the leading cause of preventable blindness worldwide .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|trach aver sti ring antiretroviral|abscess sepsis bacteremia endocarditis osteomyelitis|trachoma|medicine for human diseases to treat a host of bacterial infections , including acute otitis media infection , pharyngitis , pneumonia , skin infection , entity , and etc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|development its these demonstration gsk|trachoma|the iti , in which pfizer is a partner , has initiated entity programs in nine developing countries to date and plans to launch programs in an additional 10 countries .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|trach aver sti ring antiretroviral|trachomatis chlamydia iri puncta psi|trachoma|because c . entitytis also causes entity , the worlds most common form of 4 preventable blindness , the who estimates chlamydia is responsible for at least 15 percent
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sclerosis ja virus poli project|osteomyelitis abscess abscesses cellul bacteremia|erysipelas|in this trial , patients with wound infections , major abscesses , and entity / cellulitis were enrolled in equal numbers .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|sclerosis ja virus poli project|necrosis osteomyelitis dermatitis abscess eczema|erysipelas|a lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|sclerosis ja virus poli project|abscess osteomyelitis abscesses necrosis dermatitis|erysipelas|is defined as a bacterial infection of the skin with a lesion size area of at least 75 cm and includes cellulitis / entity , wound infections , and major cutanenous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sclerosis ja virus poli project|osteomyelitis abscess bacteremia sepsis pneumonia|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection and major cutaneous abscess .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|sclerosis ja virus poli project|necrosis dermatitis osteomyelitis edema eczema|erysipelas|lesion size of at least 75 cm2 ( lesion size measured by the area of redness , edema or induration ) , and includes cellulitis / entity , wound infections and major cutaneous abscesses .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|disease|sclerosis ja virus poli project|females males others outliers null|erysipelas|reported for at least 0 . 1% of subjects and for which p<0 . 01 included concussion ( denosumab <0 . 1% , n=1 ; placebo 0 . 3% , n=11 ) and entity ( denosumab 0 . 2% , n=7 ; placebo 0% , n=0 ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|sclerosis ja virus poli project|abscess osteomyelitis abscesses fistula necrosis|erysipelas|examples of absssi are cellulitis / entity , wound infection , major cutaneous abscess and burn infections .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sclerosis ja virus poli project|malaria measles dengue sepsis pneumonia|erysipelas|in pairs or chains , many species of which destroy red blood cells and cause various diseases in human beings , including entity , scarlet fever , and septic sore throat .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|sclerosis ja virus poli project|osteomyelitis abscess bacteremia sepsis pneumonia|erysipelas|were more than 4 . 8 million hospital admissions of adults with absssi from 2005 through 2011 , which included patients with cellulitis , entity , wound infection , and major cutaneous abscess .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|ph pah cf gerd itp|sarcoidosis|the primary treatment for entity is corticosteroids ; however , the outcome of this treatment on the ph is unclear .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|inflammation carcinogenesis tumorigenesis apoptosis angiogenesis|sarcoidosis|there are a number of different mechanisms linking ph with entity .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|fibrosis sarcoidosis nodules ild embolism|sarcoidosis|we selected pulmonary entity as our first ild indication and we are currently enrolling a proof-of-concept phase 1b / 2a clinical trial .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|sarcoidosis sarc sarcopenia amyloidosis sma|sarcoidosis|in 2018 , we also initiated development of inopulse for the treatment of ph associated with entity ( ph-sarc ) .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|this our its first design|sarcoidosis|entity initial phase ii trial completed .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|cf pah sarcoidosis ipf vasculitis|sarcoidosis|that we are exploring in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah , and entity .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|fibrosis embolism edema sarcoidosis malignancies|sarcoidosis|phase 1b / 2a clinical trial and , if that trial is successful , we believe we can expedite development of atyr1923 for pulmonary entity towards regulatory approval .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|fibrosis sarcoidosis ild embolism nodules|sarcoidosis|we selected pulmonary entity as our first ild indication and initiated a phase 1b / 2a proof-of-concept clinical trial in december 2018 .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|sarcoidosis tuberculosis granuloma fibrosis granulomas|sarcoidosis|entity is a multi-system disease which is characterized by the growth of granulomas ( inflammatory cells ) in one or more organs .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|sepsis ards pneumonia shock emphysema|sarcoidosis|by mondobiotech and the ema has designated aviptadil an orphan medicinal product for the treatment of acute lung injury and entity .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|copd asthmatics sarcoidosis pah ild|sarcoidosis|for example , we are just now beginning to explore the potential for acthar in symptomatic entity with a small pilot selling effort to pulmonologists .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|cf sarcoidosis pah ipf ild|sarcoidosis|that we are evaluating in multiple rare diseases of unmet medical need , including methicillin-resistant staph aureus ( mrsa ) , ntm , pah and entity .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|hcc nsclc tumors gbm bm|sarcoidosis|the presence of ph in entity is associated with a poor prognosis .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|sarcoidosis sarc myopathy sma amyloidosis|sarcoidosis|inopulse for ph-sarc we are also developing inopulse for the treatment of ph associated with entity , or ph-sarc .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|cf mds osa gerd cirrhosis|sarcoidosis|there is no approved therapy for ph associated with entity .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|ph pah ipf ild copd|sarcoidosis|who group v consists of ph with multifactorial mechanisms , of which we are focusing on a subset of patients with entity that has caused ild .
OrderedDict([('DIS', 5), ('DRUG', 2), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|sarcoidosis vasculitis erythematosus uveitis tuberculosis|sarcoidosis sarc sma scd sarcopenia|sarcoidosis|in 2018 , we initiated development of inopulse for the treatment of ph associated with entity ( “ph-sarc” ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus diphther wheat toxoplasma mycobacterium|tetanus|the same participants when stimulated with 85 table of contents cytomegalovirus ( cmv ) , epstein barr virus ( ebv ) , influenza virus and entity toxoid-derived immuno- dominant peptide panels .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|tab tetanus rev poli tet|tetanus toxin conjugate tox component|tetanus|and is manufacturing and marketing , a line of vaccines including whole virus and split virus influenza vaccines , a combined diphtheria entity vaccine and a vaccine to prevent tuberculosis .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|tab tetanus rev poli tet|tetanus botulinum recombinant toxin this|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus varicella bcg cholera influenza|tetanus|response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , diphtheria and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tab tetanus rev poli tet|tetanus varicella cytomegalovirus measles rabies|tetanus|hyperimmune products currently available include hepatitis b , entity , rabies cytomegalovirus and rhod immune globulins .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|tab tetanus rev poli tet|hpv influenza pneumococcal cholera rotavirus|tetanus|during 2000 , we anticipate that innovaccines will begin to scale up an oral entity vaccine to take into human clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tab tetanus rev poli tet|recombinant surface polyclonal leukocyte gamma|tetanus|human entity immunoglobulin – 250iu mainly used for the prevention and therapy of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus cholera dtpa pneumococcal hib|tetanus|if ssi fails to continue to supply the company with these components , the company has a royalty-bearing license to produce diphtheria and entity toxoids for this purpose .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus rabies cholera vaccinia diphther|tetanus|then the antigenic proteins , entity toxoid and candida albicans were applied topically to the treated skin sites .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|tab tetanus rev poli tet|tetanus botulinum recombinant toxin this|tetanus|particularly applied to patients who have allergic reactions to entity antitoxin .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|tab tetanus rev poli tet|both all rabbit therapeutic recombinant|tetanus|for our plasma products , entity immunoglobulin , factor viii and pcc are included on the life-saving essential drug list in most chinese provinces , for which drug
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tab tetanus rev poli tet|rabies tetanus measles varicella horse|tetanus|three of our approved products , human albumin , human rabies immunoglobulin and human entity immunoglobulin are affected by the 2013 adjustments .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus cholera measles tuberculosis malaria|tetanus|vaccines against two life-threatening bacterial diseases , diphtheria and entity , came into use early in this century .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|tab tetanus rev poli tet|cmv ebv mouse gbm cd19|tetanus|xmab5871 inhibited anti-entity antibody responses in mice engrafted with human b cells and immunized with entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|tab tetanus rev poli tet|tetanus recombinant surface polyclonal free|tetanus|human entity immunoglobulin  250iu mainly used for the prevention and therapy of tetanus .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tab tetanus rev poli tet|varicella tetanus syphilis others influenza|tetanus|ivig product enriched with naturally occurring polyclonal anti-pathogen antibodies , such as streptococcus pneumonia , h . influenza type b , cytomegalovirus , measles and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 2), ('DRUG', 1)])|disease|tab tetanus rev poli tet|tetanus bcg cholera hib influenza|tetanus|sales of adacel ( adult entity / diphtheria / whooping cough booster ) , launched in the united states in july 2005 , reached 154 million in 2006 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|tab tetanus rev poli tet|tetanus cholera measles varicella dtpa|tetanus|sp0173 : the current adacel® ( tdap booster vaccine containing entity toxoid , diphtheria toxoid , and 5-component acellular pertussis ) is not indicated in the us for persons aged over 64 .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tab tetanus rev poli tet|varicella rotavirus influenza zoster ebv|tetanus|streptococcus pneumoniae , h . influenza type b , cmv , measles , entity etc . ) as well as high levels of antibodies targeted to respiratory syncytial virus , or rsv .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|tab tetanus rev poli tet|tetanus cholera hib shigella cold|tetanus|food and drug administration ( " fda " ) to market its dtap vaccine ( certiva ( registered ) ) in the united states for the prevention of diphtheria , entity , and pertussis ( whooping cough ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|toxin complex tox subsp strains|conjugate encephalitis dna polysaccharide influenza|diphtheria|vaccines business segment :  march 27 , 2007 : akorn announced the signing of a three-year exclusive distribution agreement for tetanus entity vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|toxin complex tox subsp strains|influenza varicella measles pneumonia tuberculosis|diphtheria|they have eradicated smallpox and dramatically reduced the mortality and morbidity associated with many other infectious diseases , such as entity , measles , polio and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|toxin complex tox subsp strains|influenza varicella pneumococcal rabies herpes|diphtheria|adaptive immune response is the basis for preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|toxin complex tox subsp strains|influenza varicella pneumococcal rabies bcg|diphtheria|adaptive immune response facilitates the use of preventative vaccines that protect against viral and bacterial infections such as measles , polio , entity , and tetanus .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|toxin complex tox subsp strains|influenza measles malaria pneumonia diphther|diphtheria|vaccines against two life-threatening bacterial diseases , entity and tetanus , came into use early in this century .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|toxin complex tox subsp strains|diphther pneumococcal influenza measles yellow|diphtheria|under supply agreements , the company manufactures the acellular pertussis component , and ssi manufactures the entity , tetanus and ipv components for the dtap and dtap-ipv vaccines .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|toxin complex tox subsp strains|measles malaria influenza tetanus pneumonia|diphtheria|total sales of rotarix , for rotavirus , boostrix , for prevention of entity , tetanus and whooping cough , and influenza vaccines , fluarix / flulaval , reached £274 million , up 91% .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|toxin complex tox subsp strains|tetanus botulinum cholera this rabies|diphtheria|according to the world health organization , the majority of the western world  s population is immunized to entity toxin .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|toxin complex tox subsp strains|pneumococcal diphther influenza measles tetanus|diphtheria|the company produces the monocomponent acellular pertussis toxoid and formulates the final product with entity and tetanus toxoids manufactured and supplied by ssi .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|toxin complex tox subsp strains|tetanus diphther chicken usually bacillus|diphtheria|the peptide is joined to a carrier , entity toxoid , to enhance the immune response .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|toxin complex tox subsp strains|influenza measles diphther tetanus malaria|diphtheria|vaccination against entity , tetanus and pertussis is mandated by most states for all children with a total of five doses administered at two ,
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|toxin complex tox subsp strains|botulinum cholera dna tetanus bacterial|diphtheria|using a plasmid with an expression cassette of the entity toxin , no immune response will be encountered as happens when using a virus ; moreover , people born in western countries are routinely
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|toxin complex tox subsp strains|tetanus cholera diphther botulinum pneumococcal|diphtheria| crm197  we have several development and commercial partnerships in place for crm197 , which is a non-toxic mutant of entity toxin .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|toxin complex tox subsp strains|diphther tetanus dt cholera diabetes|diphtheria|we obtain some of the key components , including entity toxoid ( dt ) and tetanus toxoid ( tt ) , through a supply contract with aventis pasteur , one of our strategic collaborators .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|toxin complex tox subsp strains|by without against via like|diphtheria|gtb-1550 binds to cancer cells , the cancer cells internalize gtb-1550 , and are killed due to the action of drugs cytotoxic entity toxin payload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|toxin complex tox subsp strains|influenza rotavirus shigella hpv tetanus|diphtheria|expanded its internal research and development efforts with emphasis on a mucosal vaccine against chlamydia and a mucosal vaccine against entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|toxin complex tox subsp strains|tetanus diphther cholera difficile botulinum|diphtheria|biocancell  s leading drug , bc-819 , is a double stranded dna plasmid construct that incorporates the gene for entity toxin ( dta ) under the regulation of the promoter sequence for h19 gene .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|toxin complex tox subsp strains|influenza measles diphther varicella hib|diphtheria|daptacel® , a trivalent vaccine against pertussis , entity and tetanus , was launched in the united states in 2002 and has become a strong sales contributor due to its
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|toxin complex tox subsp strains|diphther measles tetanus pneumococcal rabies|diphtheria|the supply commitment of materials suitable for human use consists of entity toxoid and / or tetanus toxoid .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|toxin complex tox subsp strains|influenza diphther measles yellow malaria|diphtheria|also launched in 1995 was infanrix , the combined acellular vaccine for entity , tetanus and pertussis ( whooping cough ) in switzerland .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cyst sclerosis uveitis involvement vasculitis|blindness sight work zero vision|choroiditis|as a student during the 1950s he had lost much of the sight in his right eye to entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|cyst sclerosis uveitis involvement vasculitis|glomerulonephritis uveitis keratitis fibrosis vasculitis|choroiditis|no vasculitis , retinitis , or entity were observed .
OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|cyst sclerosis uveitis involvement vasculitis|uveitis sarcoidosis cmv iri pex|choroiditis|this type of uveitis is called entity .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|single malformation cleft duplication ntd|deafness blindness myopathy retinopathy ataxia|polydactyly|early onset obesity and hyperphagia often associated with bbs , a rare genetic disorder that is also characterized by vision loss , entity , kidney abnormalities , and other symptoms .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|single malformation cleft duplication ntd|retinopathy deafness diabetes epilepsy myopathy|polydactyly|it is a rare monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|single malformation cleft duplication ntd|deafness cardiomyopathy diabetes retinopathy epilepsy|polydactyly|bardet-biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|single malformation cleft duplication ntd|section per appendix table please|polydactyly|acrania / turner syndrome / prader willi syndrom / left ventricular hypoplasia entity 112 table of contents in the trial , ongoing pregnancies were followed up to 28 days post-delivery .
OrderedDict([('OTHER', 4), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|single malformation cleft duplication ntd|deafness cardiomyopathy diabetes retinopathy epilepsy|polydactyly|bardet‑biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as well as vision loss , entity , kidney abnormalities , and other signs and symptoms .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|neutropenia thrombocytopenia neurotoxicity toxicity alopecia|listeriosis|entity has also been reported as a grade 3 ae .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|dizziness hypotension tachycardia irritability dyspnea|listeriosis|examples of the aes experienced include , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity among others .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|dizziness hypotension irritability tachycardia dyspnea|listeriosis|examples of the aes experienced include among others , fevers , chills , nausea , vomiting , fatigue , headaches , hypotension and entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|pancreatitis sae pml anaphylaxis vte|listeriosis|the event was diagnosed by the treating investigator as being a case of entity .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|pneumonia listeria bacteremia gastroenteritis sepsis|listeriosis|when ingested , some strains of listeria can cause entity , which affects primarily the elderly , pregnant women , newborns and adults with weakened immune systems .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|irinotecan g3 thrombocytopenia ipilimumab nivolumab|listeriosis|one grade 3 serious ae of entity was reported .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|tetanus rabies malaria worm rotavirus|listeriosis|the overhalla facility was purchased by the aahd in november 1994 and presently manufactures ringworm vaccines for cattle and entity vaccines for sheep and goats .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|vaccines immunology medicine biology genetics|listeriosis|dr . lorbers major interest in infectious diseases is in human entity , an area in which he is regarded as an international authority .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|toxicity complications protection toxicities immunosuppression|listeriosis|the attenuation of the listeria strains used in advaxis immunotherapies , these listeria are nonpathogenic and therefore limit the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|tuberculosis endocarditis syphilis encephalitis childhood|protection immunity benefits toxicity immunogenicity|listeriosis|advaxis immunotherapies , the listeria do not replicate and spread from cell to cell at this point , limiting the potential for entity from our immunotherapies .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|parasite asymptomatic tuberculosis latent ban|malaria parasite schistosomiasis vector mosquito|onchocerciasis|apply outside the disease endemic countries , or in relation to sales of the product for purposes other than filariasis or entity control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|properly negatively correctly successfully accurately|scoliosis legs pelvis neck extremities|clubfoot|hips at birth , prominent chin and forehead , flat feet , soft skin , floppy heart valve ( mitral valve prolapse ) , curved spine and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|sensory residual gastrointestinal appendix transit|technique approach maneuver strategy tablet|gastroparesis|dr . aurora reported that this entity can result in up to an 80% slower rate of digestion , or gastric motility , in migraineurs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sensory residual gastrointestinal appendix transit|constipation complications colitis ulcers encephalopathy|gastroparesis|this protein may have utility in the treatment of post-operative ileus and gastrointestinal motility disorders , such as diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|complications retinopathy nephropathy ulcers colitis|gastroparesis|agonist of the motilin receptor that enhances esophageal motility in gerd patients and accelerates gastric emptying in patients with diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|sensory residual gastrointestinal appendix transit|eczema psoriasis inflammation migraine fibromyalgia|gastroparesis| the results of the recent atopic dermatitis ( epione ) , entity ( vly686-2301 ) and motion sickness ( motion sifnos ) studies have all been submitted to peer-review publications .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|dysphagia gastritis gerd pancreatitis inflammation|gastroparesis|post-surgical entity is often associated with peptic ulcer surgery , bariatric procedures or esophageal procedures and is thought to result from damage / desensitization of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|complications nephropathy hypoglycemia attacks retinopathy|gastroparesis|results from a phase 3 clinical trial of gimoti in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sensory residual gastrointestinal appendix transit|migraine adhd osa ad ocd|gastroparesis|we believe our novel intranasal delivery formulation will address a significant unmet market need for patients with the symptoms of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sensory residual gastrointestinal appendix transit|dysphagia constipation gerd ibs fap|gastroparesis|in march 2015 , we initiated a phase 2b study of velusetrag for the treatment of patients with entity and other gastrointestinal motility disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|sensory residual gastrointestinal appendix transit|complications nephropathy ulcers episodes attacks|gastroparesis|are the only products currently approved in the united states to treat the symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sensory residual gastrointestinal appendix transit|ibs ibd constipation gerd fap|gastroparesis|ati-7505 has potential use in five indications : chronic constipation , functional dyspepsia , gerd , entity and ibs with constipation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|sensory residual gastrointestinal appendix transit|exacerbations rhinitis attacks ulcers exacerbation|gastroparesis|spray , the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|sensory residual gastrointestinal appendix transit|psoriasis eczema pruritus dermatitis fibromyalgia|gastroparesis|neurokinin-1 receptor ( nk-1r ) antagonist , which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|nephropathy retinopathy complications hyperglycemia foot|gastroparesis|the results of these clinical trials support our belief that relamorelin has the potential to be a safe and effective treatment for diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|complications nephropathy retinopathy hypoglycemia foot|gastroparesis|in april 2014 , we commenced a phase 3 clinical trial of evk-001 in female patients with symptoms associated with acute and recurrent diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sensory residual gastrointestinal appendix transit|both none migraine epilepsy others|gastroparesis|subjects with no history of migraine , migraineurs experienced , to varying degrees , paralysis of the muscles of the stomach , or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|sensory residual gastrointestinal appendix transit|complications retinopathy nephropathy cachexia conditions|gastroparesis|motus has the worldwide rights to rm-131 ( relamorelin ) , a peptide ghrelin agonist being developed for the treatment of diabetic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|sensory residual gastrointestinal appendix transit|nausea vomiting complications edema retinopathy|gastroparesis|the company believes that emitasol ( r ) , when given intranasally , may be effective in treating diabetic entity and in preventing delayed onset emesis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|sensory residual gastrointestinal appendix transit|nausea vomiting rls constipation ocd|gastroparesis|metoclopramide is the only product currently approved in the united states to treat entity , and is currently available only in oral and intravenous forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|sensory residual gastrointestinal appendix transit|gerd als dysphagia rls amd|gastroparesis|the primary endpoint will be the effect of velusetrag on symptoms in subjects with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|sensory residual gastrointestinal appendix transit|complications hyperglycemia retinopathy nephropathy mellitus|gastroparesis|emitasol ( r ) is proposed as a method to control diabetic entity and to prevent delayed emesis associated with cancer chemotherapy .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|melanoma psoriasis ms ad amd|cryptococcosis|in addition , the fda has granted orphan drug designation to mat2203 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|annual official updated cdc recent|cryptococcosis|according to entity statistics maintained on the centers for disease control and preventions website from february 2014 , the greatest burden of this disease
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|this mortality malaria incidence syphilis|cryptococcosis|cryptococcal meningitis has become the most common cause of adult meningitis in many parts of africa , where entity now rivals tuberculosis in all-case mortality .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|melanoma psoriasis ms gout amd|cryptococcosis|●as previously reported , during the fourth quarter of 2019 , fda granted mat2203 orphan drug designation for the treatment of entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|tuberculosis cytomegalovirus syphilis aspergillus mycobacteria|cryptococcosis|the three major types of these infections are candidiasis , aspergillosis and entity .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 2)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|this tuberculosis neoformans pneumonia sarcoidosis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DRUG', 4), ('DIS', 3)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|aspergillus tuberculosis syphilis mycobacteria leishmaniasis|cryptococcosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , coccidioidomycosis , entity and zycomycosis .
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|neoformans pneumonia tuberculosis this candidiasis|cryptococcosis|entity is an infectious disease of the lungs caused by the fungus cryptococcus neoformans and is one of the most common life-threatening fungal
OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|tuberculosis fungal syphilis mycobacterium disseminated|tuberculosis malaria influenza pneumonia syphilis|cryptococcosis|in april 2015 , the ema granted two orphan drug designations for ar-12 for the treatment of entity and tularaemia .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|cyst sclerosis epidural cerebrospinal vasculitis|hepatotoxicity poisoning toxicity neurotoxicity damage|arachnoiditis|if left untreated , chemical entity may be fatal .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|cyst sclerosis epidural cerebrospinal vasculitis|interactions toxicity hepatotoxicity aes reaction|arachnoiditis|the incidence and severity of chemical entity can be reduced by coadministration of dexamethasone .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cyst sclerosis epidural cerebrospinal vasculitis|sickness neurotoxicity intoxication toxicity encephalopathy|arachnoiditis|patients receiving depocyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|disease|cyst sclerosis epidural cerebrospinal vasculitis|sickness toxicity nausea vomiting neurotoxicity|arachnoiditis|in all clinical studies , chemical entity , a syndrome manifested primarily by nausea , vomiting , headache and fever , was a common adverse event .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|species complex genus strain entom|new novel newer innovative similar|aniridia|entity therapeutic interventions , such as artificial iris implantation , are being developed by humanoptics ag . •emflaza for dmd .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|species complex genus strain entom|nonsense nmd dmd fap ar|aniridia|we estimate that approximately one-third of all entity cases are due to a nonsense mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|species complex genus strain entom|this pax6 myopia ds amd|aniridia|entity is a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|disease|species complex genus strain entom|humans mice vivo pigs mouse|aniridia|· translarna pipeline will expand with a proof of concept study in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|species complex genus strain entom|myopia retinoblastoma cataract this amd|aniridia|entity is a rare genetic disorder that results in disruption in the development of the eye .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|species complex genus strain entom|myopia pax6 blindness retinoblastoma amd|aniridia|for example , investigators studying entity , a genetic disorder due to mutations in the pax6 gene associated with loss of eyesight and other symptoms in which
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|species complex genus strain entom|carriers families probands homozygotes carrier|aniridia|ptc plans to initiate a phase 2 proof of concept study in nonsense mutation entity by year end 2015 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|species complex genus strain entom|iia iib vi iiia iiib|aniridia|in addition to its advanced dmd and cf programs , ptc is now pursuing two additional indications , mps i and entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|immunodeficiency diseases immunity protection malaria|malaria|other pox virus vectors are being evaluated in experimental models of human entity and , in a hybrid regimen combining doses of a modified live virus , with a subunit hiv vaccine to protect high
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|malaria falciparum al uncomplicated transmission|malaria candidate dengue recombinant rabies|malaria|ema regulatory decision on glaxosmithklines entity vaccine candidate rts , s , which contains agenuss qs-21 stimulon® adjuvant .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 2)])|disease|malaria falciparum al uncomplicated transmission|influenza candidate vaccinia hbv pneumococcal|malaria| entity vaccine based on advac® / per . c6® technologies : crucell and its collaborator , the us national institute of allergy and infectious diseases ( niaid ) , part
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|malaria falciparum al uncomplicated transmission|mosquito malaria dengue insect anopheles|malaria|the global plan for insecticide resistance management in entity vectors , released in 2012 , contains a five-pillar strategy on managing the threat of insecticide resistance .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|malaria falciparum al uncomplicated transmission|malaria medicines wellcome world vaccines|malaria|as per the entity foundation international , malaria now kills more people than it did 3 decades ago .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|malaria falciparum al uncomplicated transmission|epilepsy migraine schizophrenia malaria gout|malaria|quinine , a natural product from the bark of the cinchona tree , was one of the first treatments for entity and appeared in the 17 ( th ) century .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|malaria falciparum al uncomplicated transmission|breeding nih phd genetic expansion|malaria|in 2004 , the entity program revenue was limited to breeding activities to create a new founder line .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|malaria falciparum al uncomplicated transmission|malaria mosquitoes dengue anopheles mosquito|malaria|currently pursuing our negotiation with several countries in africa to introduce our larvicide product , greenex™ as a prevention agent for entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|medicines copd lung people lungs|malaria|dr . rosenberg also serves on the boards of directors of lovelace respiratory research institute , karo bio ab , and medicines for entity venture .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|malaria falciparum al uncomplicated transmission|cmv ebv vzv syphilis malaria|malaria|we expect similarly to advance our novel non-clinical prophylactic vaccine and immunotherapy programs against chlamydia , hsv-2 and entity through human 3 table of contents proof of concept .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|malaria falciparum al uncomplicated transmission|vector malaria mosquito pest insecticide|malaria|mosquito resistance to at least one insecticide used for entity control has been identified in 64 countries around the world .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|disease|malaria falciparum al uncomplicated transmission|entity brand prototype type platform|malaria|currently , both our cassette entity pf and entity pf / pv have been listed under the who procurement process .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|malaria ebola global tuberculosis influenza|malaria|we are collaborating with the bill & melinda gates foundation on entity vaccine research .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|malaria vaccines immunization ssa access|malaria|the who has made the roll back of entity , by 50% during the decade ending 2011 , one of its 4 major objectives of the current decade .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|gene medicinal commercial new cell|malaria|in the case of our entity product candidate , we may encounter difficulties in finding potential patients because our initial regimen requires patients to first fail other
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|malaria falciparum al uncomplicated transmission|endocarditis colitis osteomyelitis sepsis bacteremia|malaria|as well as an extended spectrum of activity against ca-mrsa , streptococci , haemophilus , enterococci , mycobacterium avium and in animal models of entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|malaria falciparum al uncomplicated transmission|malaria cases vivax particularly but|malaria|who currently recommends chloroquine for the treatment of p . vivax entity where the drug remains effective .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|malaria falciparum al uncomplicated transmission|malaria influenza cdc syphilis hbv|malaria|the kemri / cdc research and public health collaboration has well-developed entity , hiv , microbiology , and tuberculosis laboratories that perform a range of standard diagnostic procedures .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|malaria falciparum al uncomplicated transmission|malaria cases vivax parasites strains|malaria|who recommends acts for the treatment of chloroquine-resistant p . vivax entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|malaria falciparum al uncomplicated transmission|zika influenza measles malaria varicella|malaria|u . s . naval medical research center ( nmrc ) allowing them to use our proprietary adenovector technology for the development of vaccines against entity and dengue virus .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|fungal bacillus species blast mycobacterium|fungi blast fungus aspergillus mycobacteria|blastomycosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|fungal bacillus species blast mycobacterium|blast fungi malaria bacteremia aspergillus|blastomycosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|fungal bacillus species blast mycobacterium|tuberculosis aspergillus pneumonia bronchitis cytomegalovirus|blastomycosis|examples of such infections include aspergillosis , entity , candidiasis , coccidioidomycosis , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fungal bacillus species blast mycobacterium|blast fungi malaria amyloidosis bacteremia|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|fungal bacillus species blast mycobacterium|blast fungi malaria bacteremia amyloidosis|blastomycosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , histoplasmosis and entity ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps type diabetes skeletal hunter|mucopolysaccharidosis|if approved , this would be the first human enzyme replacement therapy for the treatment of hunter syndrome , also known as entity ii ( mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps type scid htlv dmd|mucopolysaccharidosis|entity i , or mps i lambert eaton myasthenic syndrome , or lems firdapse has not received
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps type arginase collagen dystrophy|mucopolysaccharidosis|the u . s . patent and trademark office issued to us the u . s . patent no . 6 , 426 , 208 covering aldurazyme for the treatment of entity i ( or mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|inherited lysosomal hereditary gene mutation|mps type phosphodiesterase muscular multiple|mucopolysaccharidosis|alpha-n-acetylglucosaminidase ( naglu ) with a peptide derived from insulin-like growth factor 2 ( igf2 ) for the treatment of sanfilippo b syndrome or entity iiib ( mps iiib ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|inherited lysosomal hereditary gene mutation|phase stage part step cohort|mucopolysaccharidosis|hgt- 1410 for sanfilippo a syndrome ( entity iiia ) hgt- 1410 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|inherited lysosomal hereditary gene mutation|phase stage part step cohort|mucopolysaccharidosis|shp610 for sanfilippo a syndrome ( entity iiia ) shp610 is in development as an ert delivered intrathecally for the treatment of sanfilippo a syndrome , a lysosomal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|inherited lysosomal hereditary gene mutation|mps diabetes immunodeficiency dystrophy thrombocytopenia|mucopolysaccharidosis|our most advanced programs are for the treatment of two severe genetic diseases , homozygous familial hypercholesterolemia ( hofh ) and entity type i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|inherited lysosomal hereditary gene mutation|mps type collagen dystrophy diabetes|mucopolysaccharidosis|entity i , or mps i , is a rare genetic disorder that affects many body systems and that leads to organ damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps hunter skeletal immunodeficiency muscular|mucopolysaccharidosis|elaprase elaprase is a treatment for hunter syndrome ( also known as entity type ii or mps ii ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|inherited lysosomal hereditary gene mutation|mps lam bd cf dmd|mucopolysaccharidosis|alexion decided to reduce its investment in sbc-103 , a recombinant form of the naglu enzyme being evaluated in patients with entity iiib , or mps iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps type diabetes glycoprotein multiple|mucopolysaccharidosis|naglazyme is a recombinant form of n-acetylgalactosamine 4-sulfatase ( arylsulfatase b ) indicated for patients with entity vi ( mps vi ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|inherited lysosomal hereditary gene mutation|mps type muscular skeletal multiple|mucopolysaccharidosis|agreement with genzyme to establish a joint venture ( biomarin / genzyme llc ) for the worldwide development and commercialization of aldurazyme to treat entity i ( mps i ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|inherited lysosomal hereditary gene mutation|mps glycoprotein lysosomal lysosomes immunodeficiency|mucopolysaccharidosis|our initial programs are focused on lsds such as entity ( mps ) iiia and iiib .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|inherited lysosomal hereditary gene mutation|diabetes mps collagen dystrophy thalassemia|mucopolysaccharidosis|this model , initially focused on gaucher disease , has extended to fabry disease , entity type i , and pompe disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|inherited lysosomal hereditary gene mutation|mps type diabetes dystrophy trisomy|mucopolysaccharidosis|decreased levels of the alpha-l-iduronidase enzyme result in -------------- individuals having entity i ( " mps i " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|uveitis chamber keratitis inflammation tears|uveitis|we believe that reproxalap and certain of our other product candidates may qualify as an orphan drug for noninfectious anterior entity , and possibly other diseases that we may test .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis completely fully properly correctly|uveitis chamber tears chambers keratitis|uveitis|patients with noninfectious anterior entity generally experience severe pain , sensitivity to light , and vision loss .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|uveitis periodontitis keratitis tmd teeth|uveitis| clinical trials in 2015 , pending successful ind submissions , we intend to initiate clinical trials in sls and noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|amd cnv myopia uveitis diabetes|uveitis|in december 2018 for xipere , and , if approved , xipere will be the first therapy indicated for macular edema associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|psoriasis completely fully properly correctly|colitis psoriasis osteoarthritis diabetes pancreatitis|uveitis|we have conducted with our mc1r peptide drug candidates have shown positive results in experimental models of inflammatory bowel disease , entity and nephritis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis completely fully properly correctly|amd uveitis others both cataract|uveitis|the company is planning phase ii studies for age-related macular degeneration ( later diabetic macular edema , proliferative vitreoretinopathy and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|neovascularization amd uveitis retinopathy pdr|uveitis|value . ”about ebi-031 eleven biotherapeutics  most advanced preclinical product candidate is ebi-031 for treatment of diabetic macular edema , or dme , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis completely fully properly correctly|specific registry sponsored consortium driven|uveitis|and drug administration ( fda ) to review the phase 3 eyeguard-b data together with the data from the two behçets disease entity phase 2 studies conducted independently by xoma and servier .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis completely fully properly correctly|amd diabetes dme cnv pdr|uveitis|also demonstrate comparability of the proposed drug , which we believe may require a clinical trial in macular edema associated with entity , against our product , unless a biowaiver is obtained .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|uveitis chamber vitrectomy fossa cataract|uveitis|both the sjögren-larsson syndrome ( sls ) trial and noninfectious anterior entity trial have begun enrollment and we expect to begin to provide preliminary data for these indications by the end of
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|uveitis amd retinopathy neovascularization prp|uveitis|lombs ) product retisert ( a surgically implanted intravitreal drug delivery device containing fa approved for the treatment of chronic non-infectious posterior entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|psoriasis completely fully properly correctly|diseases colitis inflammation uveitis conditions|uveitis|due to its th17 activity , we believe vtp-43742 will be most effective in psoriasis , ms , behcet  s disease and autoimmune entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis completely fully properly correctly|diabetes epilepsy inflammation tinnitus psoriasis|uveitis|develop and sell psividas proprietary delivery device for indications for diseases outside of the eye or for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|psoriasis completely fully properly correctly|amd cf melanoma crpc ipf|uveitis|the second quarter of 2016 ; and ( ii ) planning on initiating a phase ii study of cf101 for the treatment of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|psoriasis completely fully properly correctly|uveitis amd cataract dme retinopathy|uveitis|bausch + lomb markets retisert , an intravitreal implant of the corticosteroid fluocinolone acetonide , for the treatment of non-infectious entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis completely fully properly correctly|uveitis keratitis cataract inflammation dry|uveitis|diseases , including inflammatory bowel disease , nephritis , which is inflammation of the kidneys , and rheumatoid arthritis , and ocular indications such as entity and dry eye .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|psoriasis completely fully properly correctly|uveitis chamber keratitis vitrectomy inflammation|uveitis|trial of the ns2 eye drop formulation in a serious and , we believe , poorly treated ocular disease called noninfectious anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis completely fully properly correctly|uveitis keratitis tears chamber teeth|uveitis|in noninfectious anterior entity , aldehydes may mediate , at least in part , inflammation , pain , fibrotic changes , and lipid destruction leading to dryness and surface irritation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|psoriasis completely fully properly correctly|uveitis retina amd vitrectomy tears|uveitis|novartis ( esba105 ) and eyegate pharmaceuticals , inc . ( egp-437 ) have conducted or are conducting clinical trials in anterior entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|psoriasis completely fully properly correctly|amd pdr cnv pcv dme|uveitis|in addition to entity , rvo and wet amd , there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|complex strain enter childhood type|yellow dengue hay rheumatic hemorrhagic|typhoid|these vaccines , which currently include vaccines to prevent urinary tract infections and entity fever , are all in basic research or preclinical stage of development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|complex strain enter childhood type|pneumococcal rabies influenza malaria varicella|typhoid|company also anticipates continued investment in its advanced product development pipeline , including an anthrax ig therapeutic , hepatitis b therapeutic and entity vaccine , among others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|complex strain enter childhood type|yellow dengue enteric hemorrhagic chicken|typhoid|innovative vector vaccine delivery , manufacturing and preservation technologiesthe technology behind our single dose , oral , rapidly protecting vaccines for cholera and entity fever .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|complex strain enter childhood type|cholera influenza poliovirus pneumococcal rotavirus|typhoid|establishing a travel vaccines franchise through its us-based subsidiary berna products corporation , which markets vivotif® , the worlds only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|complex strain enter childhood type|new rabies live pneumococcal dna|typhoid|a two-year extension of the development program with brookwood pharmaceuticals and a commercial evaluation license with nih for developing a entity vaccine with gelsiteò polymer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|complex strain enter childhood type|yellow chicken dengue rheumatic hemorrhagic|typhoid|avant is also developing an oral entity fever vaccine , ty800 , for global health needs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|complex strain enter childhood type|influenza poliovirus hbv hpv measles|typhoid|one oral entity vaccine and one injectable entity vaccine are currently approved and administered in the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|complex strain enter childhood type|yellow hemorrhagic dengue heat rheumatic|typhoid|of health ( nih ) initiated a phase 1 / 2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|complex strain enter childhood type|hpv cholera poliovirus influenza pneumococcal|typhoid|acambis  us-based subsidiary berna products corporation markets vivotif ( r ) , the world  s only licensed oral entity vaccine , in north america .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|complex strain enter childhood type|hemorrhagic yellow enteric intestinal epidemic|typhoid|status bacterial vaccines global health choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 travelers  etec enterotoxigenic e coli infection  pre-clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|complex strain enter childhood type|shigella influenza zoster rotavirus malaria|typhoid|patents for the technology used in the cholera and entity vaccines expire between 2013 and 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|complex strain enter childhood type|this phase sponsored randomised pivotal|typhoid|entity phase 2 medeva tolerising peptide ( rye grass ) . . . . .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|complex strain enter childhood type|syphilis malaria varicella leprosy tetanus|typhoid|emergent biosolutions program pipeline currently includes programs focused on anthrax , tuberculosis , entity , influenza and chlamydia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|complex strain enter childhood type|yellow hay dengue enteric hemorrhagic|typhoid|a broad portfolio of vaccines against viral and bacterial diseases , including single-dose oral vaccines aimed at protecting travelers from cholera , entity fever and other illnesses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|complex strain enter childhood type|hemorrhagic yellow enteric intestinal like|typhoid|pre-clinical infectious disease choleragarde® ty800 cholera entity fever ivi nih phase 2b phase 2 etec enterotoxigenic e coli infection nih pre-clinical
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 2)])|disease|complex strain enter childhood type|syphilis malaria leprosy schistosomiasis rabies|typhoid|emergents clinical pipeline includes programs focused on anthrax , botulism , entity , tuberculosis , hepatitis b and chlamydia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|complex strain enter childhood type|yellow dengue hemorrhagic heat chicken|typhoid|to conduct a phase i in-patient dose ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|complex strain enter childhood type|yellow dengue hay hemorrhagic heat|typhoid|niaid to conduct a phase i in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of the ty800 entity fever vaccine .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|complex strain enter childhood type|yellow enteric hay hemorrhagic rheumatic|typhoid|thus immunity to an intestinal disease such as entity fever , is best induced by giving the vaccine orally , so that the antigens are presented directly to the lining of
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|complex strain enter childhood type|syphilis malaria varicella cytomegalovirus herpes|typhoid|including rheumatoid arthritis , or ra , and systemic lupus erythematosus , or sle ; and other infectious diseases such as tuberculosis , influenza and entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|porph simplex cutaneous complex erythematosus|amd diabetes adhd melanoma epilepsy|porphyria|people with entity should not be treated with visudyne .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|porph simplex cutaneous complex erythematosus|hypoglycemia hypoxia paralysis insomnia thrombosis|porphyria|the most advanced of these programs are the following : amt-021 for acute intermittent entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|porph simplex cutaneous complex erythematosus|diabetes epilepsy depression schizophrenia psoriasis|porphyria|people with entity should not be treated .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|disease|porph simplex cutaneous complex erythematosus|bacterial porphyrin iron apoptotic microbial|porphyria|doses of aln-as1 resulted in lowering of aminolevulinic acid ( ala ) and porphobilinogen ( pbg ) , the toxic heme synthesis intermediates that mediate entity attacks .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|porph simplex cutaneous complex erythematosus|pancreatitis aip itp thrombocytopenia headache|porphyria|or pnh ;  filed a cta to initiate a phase 1 trial with aln-as1 in acute intermittent entity , or aip patients ;  initiated a phase 1 trial with aln-pcssc in normal human volunteers with elevated
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porph simplex cutaneous complex erythematosus|aip pancreatitis itp cah thrombocytopenia|porphyria|this trial are encouraging , the data are preliminary in nature , based on a limited number of patients with acute intermittent entity , or aip .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porph simplex cutaneous complex erythematosus|pancreatitis cholestasis thrombocytopenia phosphatase peritonitis|porphyria|we and our collaborator digna biotech are developing amt-021 as a gene therapy for acute intermittent entity , or aip , a severe liver disorder .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|porph simplex cutaneous complex erythematosus|migraine hemorrhagic panic hypoglycemic anaphylaxis|porphyria|excluding entity attacks , three patients had four saes , including one previously reported fatal episode of hemorrhagic pancreatitis ; none of these saes were
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porph simplex cutaneous complex erythematosus|migraine headache panic attacks ms|porphyria| present data from the ongoing phase 1 study  including initial data in patients that experience recurring entity attacks  in late 2016 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|porph simplex cutaneous complex erythematosus|phase cholestasis intermittent pancreatitis liver|porphyria|acute intermittent entity aip disease and market background aip is a rare metabolic liver disorder resulting from mutations in the pbgd gene .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|porph simplex cutaneous complex erythematosus|encephalopathy insufficiency necrosis pancreatitis acidosis|porphyria|advanced investigational rnai therapeutic , givosiran , targets aminolevulinic acid synthase 1 , or alas1 , for the treatment of patients with acute hepatic entity , or ahp .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|porph simplex cutaneous complex erythematosus|encephalopathy pancreatitis insufficiency peritonitis decompens|porphyria|food and drug administration ( fda ) approved givlaari ( givosiran ) injection for subcutaneous use for the treatment of adults with acute hepatic entity ( ahp ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|porph simplex cutaneous complex erythematosus|migraine headache gout epilepsy neurologic|porphyria|defined mutation in the pbgd gene and elevated urinary levels of ala and pbg , but no current entity attacks .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|porph simplex cutaneous complex erythematosus|porph pancreatitis psoriasis thrombocytopenia parkinsonism|porphyria|amt-021 for acute intermittent entity we are developing amt-021 as a gene therapy for acute intermittent porphyria , or aip , a severe liver disorder .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|bacillus tuberculosis fungal etiological etiology|malaria dengue measles varicella syphilis|coccidioidomycosis|status in the united states for vt-1129 for the treatment of cryptococcal meningitis and for vt-1598 for the treatment of entity , also known as valley fever .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 3)])|disease|bacillus tuberculosis fungal etiological etiology|malaria dengue tuberculosis leishmaniasis aspergillus|coccidioidomycosis|our third program , vt-1598 for the treatment of entity , a fungal infection in the southwestern united states also known as valley fever , is in ind-enabling studies targeting an ind
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|bacillus tuberculosis fungal etiological etiology|dengue malaria vivax encephalitis syphilis|coccidioidomycosis|these diseases include entity , commonly known as valley fever .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|disease|bacillus tuberculosis fungal etiological etiology|tuberculosis syphilis cytomegalovirus sarcoidosis aspergillus|coccidioidomycosis|examples of such infections include aspergillosis , blastomycosis , candidiasis , entity , cryptococcosis and zycomycosis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|bacillus tuberculosis fungal etiological etiology|malaria dengue rv africa chikv|coccidioidomycosis|vt-1598 for entity ( valley fever ) vt-1598 is an orally available inhibitor of fungal cyp51 that has shown high potency and selectivity in in vitro studies .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|scoliosis skeletal osteoporosis vertebral familial|osteosarcoma osteoporosis neoplasms neoplasm osteogenesis|osteopetrosis|infantile malignant entity ( imo ) : imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|scoliosis skeletal osteoporosis vertebral familial|oi itp nec malaria myopathy|osteopetrosis|imo is a severe form of entity that typically presents in the first year of life and is associated with severe manifestations leading to death within the
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|diseases lymphomas conditions neutropenia melanoma|osteopetrosis|hcv collaboration with roche and sales of actimmune® , which is approved for two indications , chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|lymphomas neutropenia diseases conditions gvhd|osteopetrosis|actimmune is currently approved in the united states for the treatment of chronic granulomatous disease ( cgd ) and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|scoliosis skeletal osteoporosis vertebral familial|osteosarcoma osteoporosis osteogenesis oste neoplasms|osteopetrosis|infantile malignant entity ( “imo” ) imo is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|diseases conditions lymphomas tumors neoplasms|osteopetrosis|is approved in the united states and numerous other countries for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|lymphomas diseases conditions neutropenia tumors|osteopetrosis|actimmune has been approved by the fda f16 for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|scoliosis skeletal osteoporosis vertebral familial|melanoma mesothelioma neoplasms splenomegaly metaplasia|osteopetrosis|frequency and severity of serious infections associated with chronic granulomatous disease ( cgd ) and to slow the worsening of severe malignant entity ( smo ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|tumors diseases melanoma lymphomas conditions|osteopetrosis|the fda approved actimmune as a treatment to delay the time to disease progression in patients with severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|melanoma diseases conditions tumors mds|osteopetrosis|in the united states , the company estimates that there are approximately 1 , 200 patients with cgd and less than 500 patients with severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|hyperthermia neoplasms tumors melanoma neoplasm|osteopetrosis|is also targeting research in other diseases such as pyruvate kinase deficiency ( pkd ) , leukocyte adhesion deficiency-i ( lad-i ) , and infantile malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|diseases lymphomas conditions tumors melanoma|osteopetrosis|actimmune we currently market our lead product , actimmune , for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|smo splenomegaly sarcoidosis mesothelioma mds|osteopetrosis|actimmune is approved by the fda for use in children and adults with chronic granulomatous disease ( cgd ) and severe , malignant entity ( smo ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|humans particular osteoporosis contrast turn|osteopetrosis|in entity , the cells that break down bone ( osteoclasts ) do not work properly , which leads to the bones becoming thicker and not as healthy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|scoliosis skeletal osteoporosis vertebral familial|psoriasis sle ad lupus anaphylaxis|osteopetrosis|for example , we have ongoing phase 4 post-marketing commitments to the fda relating to actimmune for the treatment of entity , including a registry and drug interaction study .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|disease|scoliosis skeletal osteoporosis vertebral familial|diseases lymphomas tumors melanoma conditions|osteopetrosis|we currently market actimmune in the united states for the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|scoliosis skeletal osteoporosis vertebral familial|osteoporosis scoliosis osteogenesis this ds|osteopetrosis|entity is a disorder of bone development in which the bones become thickened .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|scoliosis skeletal osteoporosis vertebral familial|osteoporosis diabetes ra ms oa|osteopetrosis|in people with entity , this balance is not maintained and the resorption of old bone material decreases while the formation of new bone continues .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|scoliosis skeletal osteoporosis vertebral familial|neuroblastoma melanoma hyperthermia mds glioma|osteopetrosis|severe , malignant entity is a life-threatening , congenital disorder that primarily affects children .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|disease|scoliosis skeletal osteoporosis vertebral familial|lymphomas diseases conditions neutropenia immunosuppression|osteopetrosis|actimmune has been approved by the fda for use in the treatment of chronic granulomatous disease and severe , malignant entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|aspergillus fungal mold bacillus atypical|pneumonia aspergillus mold candidiasis fumigatus|aspergillosis|entity , a fungal infection caused by aspergillus , begins as an upper airway infection and can become a systemic fungal infection in
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|aspergillus fungal mold bacillus atypical|candidiasis candida fungal yeast aspergillus|aspergillosis|astellas commercially launched isavuconazole in the united states in april 2015 for the treatment of invasive entity and invasive mucormycosis in adults .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|disease|aspergillus fungal mold bacillus atypical|candidiasis candida tuberculosis leishmaniasis aspergillus|aspergillosis|overview until recently , we were focused on developing our novel antifungal vl-2397 , for the treatment of patients with invasive entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|disease|aspergillus fungal mold bacillus atypical|candidiasis tuberculosis influenza listeria mycobacteria|aspergillosis|the fda has also granted vical qualified infectious disease product ( qidp ) , orphan drug and fast track designations for vl‑2397 for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|aspergillus fungal mold bacillus atypical|aml crpc nsclc ifi gbm|aspergillosis|compound , cancidastm ( caspofungintm ) or mk-0991 , in the same class as our v-echinocandin , recently received fda approval for salvage therapy in entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|aspergillus fungal mold bacillus atypical|tuberculosis syphilis malaria sarcoidosis schistosomiasis|aspergillosis|indications currently being explored for mat2203 include resistant candidiasis , cryptococcal meningoencephalitis , entity and leishmaniasis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|candidiasis fungal fungi diseases aspergillus|aspergillosis|it is indicated for primary treatment of acute invasive entity and salvage therapy for rare but serious fungal infections caused by the pathogens scedosporium apiospermum and fusarium spp .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|malignancies melanoma cancers mesothelioma neoplasia|aspergillosis|fda has advised that vl‑2397 would be eligible for a limited use indication ( lui ) approval for the treatment of invasive entity for patients with limited treatment options .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|candidiasis aspergillus candida tuberculosis mold|aspergillosis|with soc vs . aspergillus spp . , we plan to initiate a phase 2 study of oral scy-078 in patients with invasive entity in the third quarter of 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|candidiasis aspergillus candida fungal tuberculosis|aspergillosis|we market amphotec® worldwide for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|aspergillus fungal mold bacillus atypical|indications purposes surgeries biopsies neurosurgery|aspergillosis|although we market amphotec for invasive entity , we do not believe that it will provide sufficient revenue to us in the near future , if ever , and , consequently ,
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|aspergillus fungal mold bacillus atypical|tuberculosis leishmaniasis candidiasis pneumonia keratitis|aspergillosis|development history of mat2203 mat2203 was extensively studied in animal model studies of various fungal infections including invasive candidiasis , entity , and visceral leichmaniasis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|disease|aspergillus fungal mold bacillus atypical|candidiasis aspergillus candida tuberculosis leishmaniasis|aspergillosis|amphotec is an fda-approved lipid-complexed form of amphotericin b indicated for the treatment of invasive entity , a life-threatening systemic fungal infection .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|aspergillus fungal mold bacillus atypical|melanoma nsclc cancers tuberculosis candidiasis|aspergillosis|an estimated 200 , 000 cases of invasive entity are diagnosed annually worldwide .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|disease|aspergillus fungal mold bacillus atypical|fungal candida aspergillus bacterial mycobacterial|aspergillosis|sequus is conducting a phase iii double-blind , randomized study comparing amphotec with amphotericin b in treating patients with first-line entity infections .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|aspergillus fungal mold bacillus atypical|aspergillus candida bacillus saccharomyces clostridium|aspergillosis|the amphotericin b cochleate demonstrated reasonable activity against at least one strain of entity fumigatus and one strain of candida albicans in vitro .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|aspergillus fungal mold bacillus atypical|fibrosis candidiasis diseases sarcoidosis asperg|aspergillosis| received a second qidp status for pulmazole to treat fungal infections in the airways of allergic bronchopulmonary entity patients .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|melanoma candidiasis cancers malignancies mesothelioma|aspergillosis|cancidas  has not been studied as an initial therapy for invasive entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|aspergillus fungal mold bacillus atypical|candidiasis tuberculosis candida fungal fungi|aspergillosis|hepatitis c virus ( hcv ) , infections , and amphotec® ( amphotericin b cholesteryl sulfate complex for injection ) , approved for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|aspergillus fungal mold bacillus atypical|candidiasis cancers malignancies melanoma endometriosis|aspergillosis|we have world-wide marketing rights to amphotec for the treatment of invasive entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria parasites worms mosquitoes|schistosomiasis|three months ended march 31 , 2012 , approximately 60% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('DRUG', 3), ('OTHER', 3)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria schistosomiasis tuberculosis parasitic leishmaniasis|schistosomiasis|deuterated praziquantel in collaboration with the therapeutics for rare and neglected diseases division of the nih for the treatment of entity and other parasitic diseases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites leishmaniasis|schistosomiasis|three months ended june 30 , 2009 , approximately $943 , 137 or 15 . 52% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria leishmaniasis leprosy schistosomiasis syphilis|schistosomiasis|lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria parasites worms mosquitoes|schistosomiasis|three months ended june 30 , 2011 , approximately 22% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites mosquitoes|schistosomiasis|the three months march 31 , 2010 , approximately $830 , 600 , or 17% of total revenues , resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites leishmaniasis|schistosomiasis|ended december 31 , 2010 , approximately $12 , 198 , 522 or 25 . 7% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites mosquitoes|schistosomiasis|three months ended september 30 , 2009 , approximately $3 , 330 , 000 or 26% of total revenue resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|schistosomiasis tuberculosis cutaneous para cross|parasites worms nematodes malaria helminth|schistosomiasis|it is an anthelmintic effective against entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria schistosomiasis leishmaniasis helminth parasitic|schistosomiasis|entity is a parasitic disease that affects both animals and humans .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites leishmaniasis|schistosomiasis|during the three months ended june 30 , 2010 , approximately $1 , 864 , 203 or 33 . 7% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria this cholera schistosomiasis dengue|schistosomiasis|entity is prevalent in southern china where there are a lot of fresh water lakes and rivers .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria parasites worms mosquitoes|schistosomiasis|nine months ended september 30 , 2012 , approximately 44% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites leprosy|schistosomiasis|during the three months ended september 30 , 2010 , approximately $5 , 104 , 961 or 41% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria leishmaniasis leprosy schistosomiasis epilepsy|schistosomiasis|table of contents lucanthone was originally used as an antiparasitic agent for the treatment of entity in the 1950s and 1960s , and has a demonstrated safety profile .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites tuberculosis|schistosomiasis|during year ended december 31 , 2011 , approximately 36% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria worms parasites leishmaniasis|schistosomiasis|during the three months ended march 31 , 2011 , approximately 1 , 058 , 132 or 15% resulted from the sale of praziquantel tablets which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria tuberculosis worms parasites|schistosomiasis|praziquantel is a compound of pyrazine and isoquinolin designed to treat and prevent entity in livestock .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|schistosomiasis tuberculosis cutaneous para cross|schistosomiasis malaria parasites worms mosquitoes|schistosomiasis|three months ended september 30 , 2011 , approximately 26% of total revenue resulted from the sale of praziquantel tablets , which treats entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|schistosomiasis tuberculosis cutaneous para cross|malaria tuberculosis syphilis sarcoidosis diabetes|schistosomiasis|examples of analytes in this field are : aspergillus , candida , markers or antibodies associated with entity , giardia lamblia , leishmaniasis , lyme disease , chagas , toxoplasmosis .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|lymphangi dural rupture cyst cystic|melanoma meningioma neoplasm tumors metastasis|lymphangioma|aortic body and other paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|lymphangi dural rupture cyst cystic|meningioma melanoma neoplasm tumors hematoma|lymphangioma|paraganglia coccygeal body glomus jugulare para-aortic body 227 . 8 other 227 . 9 endocrine gland , site unspecified 228 hemangioma and entity , any site includes :
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|enteric enter rectal cholera cholerae|uk previous influenza 2009 london|cholera|during the entity outbreak we responded to a further specific request for antibiotics and donated £250 , 000 to the british red cross to support
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|enteric enter rectal cholera cholerae|influenza salmonella poliovirus virus measles|cholera|quarter of 2000 , will test the safety , immunogenecity and protective capacity of the vaccine against a challenge with live virulent entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|disease|enteric enter rectal cholera cholerae|encephalitis pneumonia virus carrier endocarditis|cholera|qilian shan® oxytetracycline api used for treating following diseases : rickettsia , mycoplasma infection , chlamydia infection , regression fever , brucellosis entity , rabbit fever and plague .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|enteric enter rectal cholera cholerae|cholera cdi gastroenteritis shigella diarrhoea|cholera|( the causative agent of entity ) are often confused with travelers diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|enteric enter rectal cholera cholerae|cholera rotavirus cf gastroenteritis influenza|cholera|in human patients with various types of watery diarrhea , including traveler  s diarrhea , hiv-related diarrhea and other acute infectious diarrheas , including entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|enteric enter rectal cholera cholerae|cf ibs ibd fd ss|cholera|in addition , an early stage cftr inhibitor program is planned for the treatment of secretory diarrhea disorders , including entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|enteric enter rectal cholera cholerae|cholera gastroenteritis malaria rotavirus shigella|cholera|entity is an acute diarrheal illness that kills thousands of people worldwide each year due to rapid dehydration in the first 2 -18 hours after infection .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|malaria cholera measles dengue hbv|cholera|and supported the start of phase ii trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|malaria dengue peru cholera tuberculosis|cholera|investigation , peru-15 may be an excellent candidate as a potential single dose , oral vaccine for travelers going to areas where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|enteric enter rectal cholera cholerae|cholera cholerae diarrhoea gastroenteritis vibrio|cholera|entity / general watery diarrhea we are investigating lechlemer for the indication of cholera / general watery diarrhea in adults and children .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|bacterial candidate pneumococcal mucosal live|cholera|development of a safe , effective entity vaccine is the first step in establishing avants single-dose , oral bacterial vaccine franchise .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|enteric enter rectal cholera cholerae|cholera poliovirus influenza measles rotavirus|cholera|ctb has already been administered to hundreds of thousands of patients worldwide and is a major component of an existing oral entity vaccine and traveler  s diarrhea vaccine .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|enteric enter rectal cholera cholerae|challenge infecting tested encapsulated causative|cholera|published results have shown the vaccine to be well tolerated and immunogenic against the entity organism in the adult portion of this trial .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|disease|enteric enter rectal cholera cholerae|cholera ctb tetanus clostridium bacterial|cholera|maxvax mucosal vaccine carrier / adjuvant platform maxvax is a mucosal vaccine carrier / adjuvant platform based on the entity toxin b subunit ( ctb ) .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|cholera pneumococcal influenza tetanus measles|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminium-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|cholera pneumococcal influenza varicella poliovirus|cholera|crucell also markets travel vaccines , such as an oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|malaria cholera dengue measles hbv|cholera|this vaccine and supported the start of phase 2 trials in december 2002 with the international vaccine institute ( ivi ) in bangladesh where entity is endemic .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|candidate new experimental hpv pneumococcal|cholera|we will then determine our commercialization strategy with respect to the entity vaccine based on clinical data from the trial .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|enteric enter rectal cholera cholerae|cholera pneumococcal influenza varicella poliovirus|cholera|crucell also markets travel vaccines , such as the only oral anti-typhoid vaccine , an oral entity vaccine and the only aluminum-free hepatitis a vaccine on the market .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|enteric enter rectal cholera cholerae|amd melanoma cf mm ad|cholera|in addition , a second-generation proprietary anti-secretory agent is in development for entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|familial autosomal genetic inherited rare|immunodeficiency insufficiency psoriasis epidermal blindness|ichthyosis|the loss of tgm-1-activity results in the severe genetic skin disease autosomal recessive congenital entity ( arci ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|anomalies malformations defects hypothyroidism malformation|ichthyosis|there is no prescription drug currently approved in the united states that is indicated for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial autosomal genetic inherited rare|deafness immunodeficiency defects anomalies malformations|ichthyosis|announced that the united states food and drug administration ( fda ) granted adx-102 orphan drug designation for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|psoriasis acne ich delta lupus|ichthyosis|entity vulgaris is the most common form of ichthyosis affecting around one in 250 people worldwide .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|familial autosomal genetic inherited rare|dermatitis alopecia acne eczema psoriasis|ichthyosis|moisturizers that are used for the treatment of dry skin or certain inflammatory skin conditions , such as psoriasis , eczema or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|familial autosomal genetic inherited rare|dermatitis psoriasis acne immunodeficiency eczema|ichthyosis| liarozolean oral therapeutic for the treatment of congenital entity , a rare genetic disease characterized by dryness and scaling of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|immunodeficiency ataxia myopathy cholestasis blindness|ichthyosis|kb105 , delivers functional human transglutaminase-1 , or tgm1 genes using our gene therapy platform to patients with tgm1-deficient autosomal recessive congenital entity , or arci .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|familial autosomal genetic inherited rare|psoriasis dermatitis myopathy alopecia pruritus|ichthyosis|a dermatologic form of adx-102 is in late-stage clinical development for the treatment of entity due to sjögren-larsson syndrome , an inborn error of aldehyde metabolism .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|psoriasis dermatitis cutaneous dermal fibrosis|ichthyosis|thus , ns2 may be partially or wholly effective in preventing and treating entity or other dermal symptoms , signs , or pathologies in sls .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|familial autosomal genetic inherited rare|phenotype involvement presentation condition immunodeficiency|ichthyosis|sls patients are generally diagnosed as neonates given the severe entity that presents at birth .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|immunodeficiency myopathy insufficiency insomnia cholestasis|ichthyosis|- dosing of the 4th patient in the phase 1 / 2 study of kb105 in patients with tgm1 deficient autosomal recessive congenital entity ( arci ) has completed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|keratitis fibrosis necrosis fractures cysts|ichthyosis|compared to the same periods 2006 due to the completion of our phase 2 / 3 trial for the treatment of lamellar entity in april 2007 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|hypothyroidism malformations sterility anomalies infertility|ichthyosis|in june , barrier therapeutics announced that liarozole was granted orphan drug status from the fda for the treatment of congenital entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|familial autosomal genetic inherited rare|acne psoriasis lupus diabetes psoriatic|ichthyosis|frequently results in lethargy and reduced libido in men above the age of 40 , and glylorin ( tm ) , a novel treatment for entity vulgaris , a debilitating skin disease .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|alopecia cutaneous dermatitis simplex psoriasis|ichthyosis|“primary indication” means the netherton syndrome , also known as comel-netherton syndrome , ns , bamboo hair syndrome , and entity linearis cirumflexa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial autosomal genetic inherited rare|dermatitis keratitis eczema burns psoriasis|ichthyosis|barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis , lamellar entity , acne , psoriasis and fungal infections .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|familial autosomal genetic inherited rare|myopathy cardiomyopathy diabetes cataract blindness|ichthyosis|of fatty aldehydes in sjögren-larsson syndrome , an orphan disease caused by mutations in fatty acid aldehyde dehydrogenase , lead to severe entity , retinal disease and neurological disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial autosomal genetic inherited rare|psoriasis acne eczema ad psoriatic|ichthyosis|table of contents was licensed to ohr cosmetics for dermatological uses was evaluated in a moisturizer formulation in subjects with entity vulgaris at a non-us testing site .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|familial autosomal genetic inherited rare|psoriasis fibrosis dystrophy dermatitis acne|ichthyosis|in april 2017 , we announced that the fda granted reproxalap orphan drug designation for the treatment of congenital entity , a severe skin disease characteristic of sls .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|familial autosomal genetic inherited rare|immunodeficiency dermatitis defects eczema neutropenia|ichthyosis|in or entering phase 3 clinical trials for the treatment of seborrheic dermatitis , fungal infections , including vaginal candidiasis , and congenital entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hist tox ocular fungal opportunistic|tuberculosis cytomegalovirus aspergillus pneumonia syphilis|histoplasmosis|among the most common systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hist tox ocular fungal opportunistic|melanoma amyloidosis inflammation traction atrophy|histoplasmosis|visudyne is also used for the treatment of subfoveal cnv due to pathologic myopia , or severe near-sightedness , and presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|hist tox ocular fungal opportunistic|aspergillus candidiasis tuberculosis hist fungus|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto , " respectively ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('DRUG', 4), ('OTHER', 3)])|disease|hist tox ocular fungal opportunistic|tuberculosis aspergillus sarcoidosis candidiasis leishmaniasis|histoplasmosis|in conjunction with fujisawa , is conducting two phase iii clinical trials of ambisome in the u . s . for the treatment of entity and for the treatment of cryptococcus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|disease|hist tox ocular fungal opportunistic|melanoma tumors amyloidosis retinoblastoma sarcoidosis|histoplasmosis|other macular neovascular conditions such as minimally classic and occult with no classic amd lesions , pathologic myopia and presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hist tox ocular fungal opportunistic|amyloidosis melanoma neovascularization atrophy amd|histoplasmosis|in some countries , including the u . s . and canada , visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|disease|hist tox ocular fungal opportunistic|tuberculosis cytomegalovirus aspergillus pneumonia encephalitis|histoplasmosis|among the most common 5 8 systemic fungal infections that may infect these patients include candidiasis , aspergillosis , entity , and cryptococcal meningitis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|disease|hist tox ocular fungal opportunistic|aspergillus fungi candidiasis yeast yeasts|histoplasmosis|endemic mycoses are caused by coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) found in the soil of certain regions of the united states .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|hist tox ocular fungal opportunistic|cure this melanoma success leishmaniasis|histoplasmosis|the trial for entity is being monitored and analyzed by the mycology study group of the national institutes of health .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hist tox ocular fungal opportunistic|cytomegalovirus herpes ebv syphilis cmv|histoplasmosis|many antibody drugs are immunosuppressive , which may lead to increased risk of serious or opportunistic infection , such as tuberculosis , entity and hepatitis b , or malignancy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|hist tox ocular fungal opportunistic|aspergillus candidiasis tuberculosis fungus yeast|histoplasmosis|there are three basic forms of endemic mycoses : coccidiomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hist tox ocular fungal opportunistic|surface retraction down motility compartment|histoplasmosis|visudyne has recently been launched for two new indications , pathologic myopia ( in the united states and europe ) and ocular entity syndrome ( in the united states ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hist tox ocular fungal opportunistic|amyloidosis melanoma atrophy neovascularization inflammation|histoplasmosis|in some countries ( including the u . s . and canada ) visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|disease|hist tox ocular fungal opportunistic|aspergillus candidiasis tuberculosis hist yeast|histoplasmosis|there are three basic forms of endemic mycoses : coccidioidomycosis ( valley fever ) , entity and blastomycosis ( " cocci , " " histo " and " blasto " ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hist tox ocular fungal opportunistic|candidiasis hygiene herpes surface fungal|histoplasmosis|presumed ocular entity syndrome ( ohs ) is a condition caused by a fungal infection endemic to certain areas in the central and eastern u . s .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|hist tox ocular fungal opportunistic|amyloidosis melanoma neovascularization atrophy detachment|histoplasmosis|in some countries visudyne is also approved for presumed ocular entity or other macular diseases .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hist tox ocular fungal opportunistic|melanoma glioblastoma europe adults agents|histoplasmosis|entity phase iii cryptococcal meningitis phase iii daunoxome advanced kaposi  s sarcoma approved for marketing in the u . s . , canada and 12 western
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hist tox ocular fungal opportunistic|toxicity involvement absorption irritation penetration|histoplasmosis|in the us , visudyne has received an additional approval for cnv due to presumed ocular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hist tox ocular fungal opportunistic|surface hypoxia hyperplasia aging genetic|histoplasmosis|due to pathologic myopia in the united states , canada and the european union and for cnv due to presumed ocular entity syndrome ( " ohs " ) in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|generalized complex refractory partial residual|epilepsy diagnosis aed conception knowledge|epilepsy|mothers exposed to other antiepileptic drugs , or aeds , and a purported prevalence of 0 . 07% in infants born to mothers without entity or treatment with other aeds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|generalized complex refractory partial residual|copd rhinitis eczema immunology lung|epilepsy|the company has clinical stage programs in entity and asthma .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|generalized complex refractory partial residual|diabetes atherosclerosis osteoarthritis neurology inflammation|epilepsy|the company is conducting research and development activities in a number of disease areas , including entity , pain and inflammation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|generalized complex refractory partial residual|epilepsy autism adhd schizophrenia asd|epilepsy|we are also preparing for the potential commercial launch of diazepam nasal spray , a treatment for people with entity who experience cluster seizures .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|generalized complex refractory partial residual|headaches headache osteoporosis insomnia depression|epilepsy|the products are intended to treat a variety of disorders including the following : hypertension , arthritis , seizures , entity , diabetes and pain management .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|generalized complex refractory partial residual|its this new cooperative another|epilepsy|continue making payments to parteq of c$108 , 000 each quarter as a result of the renewal of the alzheimers agreement and entity agreement with parteq .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|generalized complex refractory partial residual|new these suicidal psychotropic marketed|epilepsy|in 2005 , the fda requested that all makers of entity drugs analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|generalized complex refractory partial residual|spike reflex movements tremor type|epilepsy|myoclonic entity 0 1 ( 3 . 4% ) 2 ( 6 . 9% ) serious aes , or saes , of seizure were reported
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|generalized complex refractory partial residual|epilepsy ad schizophrenia neurosurgery tdcs|epilepsy|to evaluate cbd and cbdvhs ( and possibly additional cbd-derivatives ) in a human in vitro neural model with an application to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|generalized complex refractory partial residual|infant births neonatal epilepsy maternal|epilepsy|the uk entity and pregnancy register reported a similarly increased prevalence of oral clefts ( 3 . 2% ) among infants born to mothers exposed to topiramate
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|generalized complex refractory partial residual|aging als neurodegeneration neurology cognition|epilepsy|amarins cns development pipeline includes two programs in parkinsons disease , one in entity and one in memory and cognition .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|generalized complex refractory partial residual|candidate fusion mutant family receptor|epilepsy|a patent application relating to the epm1 entity gene is pending in the uspto .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|generalized complex refractory partial residual|epilepsy autism insomnia schizophrenia asd|epilepsy|patients with refractory focal seizures , which we refer to as the star 1 ( synthetic transdermal cannabidiol for the treatment of entity ) trial .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|generalized complex refractory partial residual|epilepsy ms ad migraine tsc|epilepsy|in chronic use for the treatment of entity , vigabatrin has been generally well tolerated with lower than average neurological side effects compared to other approved entity therapies .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|generalized complex refractory partial residual|diabetes depression epilepsy schizophrenia gout|epilepsy|sales of drugs for the treatment of entity decreased by approximately $967 , 000 in the second quarter of fiscal 2008 compared to the second quarter of fiscal 2007 because
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|generalized complex refractory partial residual|epilepsy dystonia migraine fibromyalgia tinnitus|epilepsy|electrical neurostimulation technology has seen growing use in recent years for numerous applications– such as chronic pain , parkinsons , essential tremor , entity , and others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|generalized complex refractory partial residual|novartis dream lilly fisher french|epilepsy|this study was sponsored by the entity foundation , and conducted in 2013 in the laboratory of dr . annamaria vezzani at the mario negri institute for pharmacological research
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|generalized complex refractory partial residual|psoriasis melanoma ad cml amd|epilepsy|we are developing sage-217 so that it will have what we believe is an optimal profile as a monotherapy for entity in many forms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|generalized complex refractory partial residual|psoriasis melanoma crpc amd ms|epilepsy|with janssen pharmaceuticals , inc . , is scheduled to enter a phase 2a proof of concept clinical study for the treatment of entity in h1 2021 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|generalized complex refractory partial residual|new marketed potential experimental commercial|epilepsy|our two entity product candidates are spn-538 ( extended release topiramate ) , for which we submitted a new drug application , or nda , that was accepted
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis cholecystectomy gastritis gallbladder cholecyst|cholecystitis|these include entity ( gallbladder inflammation ) , seizure , palpitations , paresthesia and vertigo .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|thrombocytopenia hepatotoxicity neutropenia pancreatitis myopathy|cholecystitis|there was one report of entity in a phase 1 clinical trial of lum001 and one report of elevated levels of alanine aminotransferase and aspartate aminotransferase ,
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cyst appendicitis gout cholecyst cholecystectomy|fistula obstruction colitis pancreatitis stricture|cholecystitis|ciai diagnoses include intra-abdominal abscess , stomach or intestinal perforation , peritonitis , appendicitis , entity , or diverticulitis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis appendicitis cholestasis gastritis cholecyst|cholecystitis|a single patient during the extension study developed acute entity and cholelithiasis later treated with cholecystectomy .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis hemorrhage inflammation gvhd hepatotoxicity|cholecystitis|one subject had a baseline pro-c3 of 9 . 9 ng / ml , experienced a serious ae of acute entity , stopped taking axa1125 at the end of week 1 and then discontinued from the study on week 5 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|cyst appendicitis gout cholecyst cholecystectomy|vomiting headache diarrhoea anorexia constipation|cholecystitis|serious adverse events reported in the trial included disease progression , pyrexia , mastitis , pneumonia , nausea , entity and pain in extremity , each of which was reported only once .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis toxicity neutropenia diarrhoea dyspnea|cholecystitis|a single patient during the extension study experienced acute entity classified as a serious adverse event but deemed unlikely related to sbc-102 by the investigator .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|cyst appendicitis gout cholecyst cholecystectomy|interest nausea pancreatitis aes gastroenteritis|cholecystitis|the one subject who received akr-001 70mg iv had a serious adverse event of entity initially reported as abdominal pain beginning on day 11 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis pneumonia dermatitis bronchitis colitis|cholecystitis|two study group subjects experienced saes , severe acute entity and moderate cellulitis , with the latter subject discontinuing treatment prior to end of treatment .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis abscess cholecystectomy colitis abscesses|cholecystitis|serious adverse events included skin infection ( cellulitis , two cases ) , abdominal pain and inflammation of the gall bladder ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis inflammation cholestasis appendicitis gastritis|cholecystitis|findings from a subsequent cholecystectomy were consistent with chronic entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis ascites sludge cysts cholestasis|cholecystitis|with respect to hepatobiliary events , more patients ( 3% ) on oca 25 mg experienced gallstones or entity compared to <1% on placebo and 1% on oca 10 mg .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cyst appendicitis gout cholecyst cholecystectomy|cholestasis pancreatitis malignancies cirrhosis cancers|cholecystitis|the biliary system is a significant target for many conditions , including drug toxicities , entity , and liver-related abnormal function associated with the cystic fibrosis mutation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis gallbladder cholecystectomy cholestasis biliary|cholecystitis|this potentially represents a previously unrecognized factor in the development of entity and cholelithiasis disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis atherosclerosis inflammation periodontitis nash|cholecystitis|the project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory ( entity ) and calcific pathologic ( cholelithiasis ) disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pneumonia pancreatitis osteomyelitis dermatitis keratitis|cholecystitis|there were two serious aes reported , acute entity and right toe infection , which were deemed not reasonably associated with the study product , and more likely due to subject  s
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cyst appendicitis gout cholecyst cholecystectomy|inflammation flare phase crp hemolysis|cholecystitis|the subject  s end-of-study pro-c3 level was 31 . 9 ng / ml , reflecting both the acute inflammatory state ( i . e . , acute entity ) and also likely a washout effect of axa1125 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pneumonia pancreatitis hypoglycemia thrombocytopenia neutropenia|cholecystitis|one patient was hospitalized for entity , a serious ae , two days after receiving seven days of treatment with torezolid phosphate , which the clinical investigator determined to
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|cyst appendicitis gout cholecyst cholecystectomy|pancreatitis gallbladder cholecystectomy gastritis nafld|cholecystitis|both consisted of entity , or gall bladder inflammation , which is common in people who experience rapid or significant weight loss .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|disease|cyst appendicitis gout cholecyst cholecystectomy|inflammation pancreatitis others necrosis hematuria|cholecystitis|lidan paishi pian clear heat and promote diuresis , cholagogue and remove calculi , biliary tract infection , entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|endocarditis encephalitis syphilis tuberculosis tular|varicella dengue malaria measles rabies|tularemia|category is category a . the six agents that the cdc has classified as category a are anthrax , botulism , plague , smallpox , entity and viral hemorrhagic fevers .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera tuberculosis malaria salmonella campylobacter|tularemia|barda is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|rabies malaria measles varicella cholera|tularemia|equally compelling , restanza has shown effectiveness against several lethal pathogens , including anthrax , plague , and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|malaria rabies tuberculosis cholera measles|tularemia|cethromycin is also being developed as a biodefense agent for use in the treatment of anthrax , plague and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera influenza varicella measles malaria|tularemia|these two bacteria species are considered potential bioweapons and are the causative agents for plague and entity , respectively .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|endocarditis encephalitis syphilis tuberculosis tular|vaccinia adenovirus bcg rabies poliovirus|tularemia|the company has been in contractual negotiations for the first two products , entity and vaccinia .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|varicella cholera rabies malaria measles|tularemia|preliminary data from our preclinical experiments indicates that our product candidates have potent activity against biowarfare agents that cause anthrax , entity and plague .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|malaria pneumonia rabies tuberculosis varicella|tularemia|these tests have been completed in non-human primates and have shown that solithromycin is effective in treating anthrax and entity when the infection was initiated by the pulmonary route .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 2)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera syphilis tuberculosis rabies schistosomiasis|tularemia|the department of homeland security has identified 13 such threats , including anthrax , smallpox , ebola / marburg , entity , and botulism .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|malaria rabies measles others tuberculosis|tularemia|the bicyclolides are to be used as medical countermeasures against multiple biodefense bacteria found in anthrax , plague and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|varicella rabies malaria measles cholera|tularemia|the fda has granted cethromycin an orphan drug designation for the prophylactic treatment of inhalation anthrax , plague and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|syphilis malaria encephalitis dengue schistosomiasis|tularemia|other tick-borne diseases include rocky mountain spotted fever , babesiosis , erlichiosis , anaplasmosis , powassan disease , tick-borne relapsing fever and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|disease|endocarditis encephalitis syphilis tuberculosis tular|malaria encephalitis varicella rabies measles|tularemia|· received fda orphan drug designation for restanza in plague and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|disease|endocarditis encephalitis syphilis tuberculosis tular|dengue ebola malaria influenza rabies|tularemia|a non-exclusive , royalty-bearing license to use certain of our patents and related know how for the prevention or treatment of entity and viral hemorrhagic fever indications .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera salmonella tuberculosis malaria campylobacter|tularemia|barda funded studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera measles campylobacter rabies malaria|tularemia|for the treatment of serious hospital infections as well as the treatment of bioterror pathogens , such as anthrax , plague and entity after signs and symptoms are present .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera measles varicella rabies malaria|tularemia|is focused on the development of antibiotic compounds to treat biowarfare agents , including the highly infectious bacteria that cause anthrax , entity and plague .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|disease|endocarditis encephalitis syphilis tuberculosis tular|campylobacter salmonella cholera rabies tetanus|tularemia|solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens , specifically anthrax and entity .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|disease|endocarditis encephalitis syphilis tuberculosis tular|cholera salmonella tuberculosis malaria campylobacter|tularemia|barda also is funding studies to test the efficacy of solithromycin in treating bioterror pathogens such as entity and anthrax .
OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|disease|endocarditis encephalitis syphilis tuberculosis tular|mice humans animals rabbits vivo|tularemia|after symptoms developed ; · pivotal primate study showing protective efficacy in plague ; · pivotal animal study showing 100% survival in entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|hep hb subtype part amyloid|hemophilia|used in the trial consistently led to long-term expression of the hfix transgene at therapeutic levels in patients with severe entity b , without acute or long-lasting toxicity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|hem viii prophylactic hereditary inhibitor|aurora hep influenza amphotericin part|hemophilia|we further note that you cite uniqure and spark therapeutics as competitors with treatments for entity b in phase 3 clinical trials .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|hem viii prophylactic hereditary inhibitor|hep type hb dengue hem|hemophilia|human coagulation factor ix prevention and control of bleeding in patients who suffer from entity b . completed the clinical trial and preparing documentation for the registration purpose .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|hem viii prophylactic hereditary inhibitor|malaria thalassemia thrombocytopenia diabetes hemolysis|hemophilia|kedrion markets therapies globally for entity , hemolytic disease of the newborn , immune and neurological disorders .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|france bax marketing europe development|hemophilia|he has served as baxters global franchise head for entity since june 2012 and is expected to continue in that role until the separation is completed .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|france marketing meetings europe industry|hemophilia|he served as baxters global franchise head for entity from 2012 until the separation .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|disease|hem viii prophylactic hereditary inhibitor|melanoma tumors gvhd epilepsy cancers|hemophilia|for example : · porcine spleen tissue was successfully implanted into a mouse , effectively treating entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|hem viii prophylactic hereditary inhibitor|hcc nafld nash fibrosis cirrhosis|hemophilia| continue to build a liver-directed gene therapy platform , with an initial focus on the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|being funding such developing development|hemophilia|spark hereby grants pfizer the exclusive right to negotiate an agreement with spark with respect to the entity a program subject to the terms of this section 2 . 9 .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hem viii prophylactic hereditary inhibitor|replacement ert hit monotherapy hemodialysis|hemophilia|the treatment concept is similar to entity , in which a patient is treated regularly with the particular clotting factor in which he is deficient .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|hem viii prophylactic hereditary inhibitor|itp scd vwf sle vw|hemophilia|vwd may experience mild symptoms , but some patients can experience severe bleeding events similar to bleeding experienced by patients with entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|disease|hem viii prophylactic hereditary inhibitor|hit type hem ich asia|hemophilia|an improved next-generation coagulation factor viia variant , cb 813d , that has successfully completed a phase 1 clinical trial in severe entity a and b patients .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|disease|hem viii prophylactic hereditary inhibitor|hem lupus thalassemia immunoglobulin type|hemophilia|therapeutic proteins are increasingly used to treat diseases , including interferon beta for multiple sclerosis , factor viii for entity a , and monoclonal antibodies for various disorders .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|hep type stage portal vitamin|hemophilia|of our collaboration agreement for the development of coagulin-b , our product candidate that we were developing for the treatment of entity b , involving administration to the liver .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|entity entities aim formulation institution|hemophilia| entity b . entity b patients typically are treated by a variety of plasma-derived , recombinant or long-acting products that are produced by a number of companies , including pfizer .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|hem viii prophylactic hereditary inhibitor|immunoglobulin immunoglobulins albumin cytokines rituximab|hemophilia|in june 2014 , we acquired medpro , a specialty pharmacy focused on specialty infusion including entity and immune globulin .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|hem viii prophylactic hereditary inhibitor|hep amphotericin aurora influenza part|hemophilia|many other companies are developing gene therapies to treat entity b , including baxter , uniqure and dimension .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|fix type part hep ham|hemophilia|preliminary data in entity b mice indicate that treatment with amt-060 induces normalization of fix levels as well as clotting time .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|hem viii prophylactic hereditary inhibitor|thrombocytopenia ich itp thrombosis vwf|hemophilia|in december 2013 , we acquired ahf , which provides specialty drugs and infusion services for bleeding disorders , principally entity .
OrderedDict([('OTHER', 4), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|disease|hem viii prophylactic hereditary inhibitor|part phase stage step project|hemophilia|outlook 2017 in 2017 we plan to : · drive our entity b program towards late stage clinical development ; · continue non-clinical and preclinical studies that are expected to support an ind
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|final new experimental proposed medicinal|leptospirosis|we are completing the manufacture of the entity product so that we can provide evaluation lots and documentation to fiocruz for their regulatory approval submission of this product
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|syphilis wil pathogenic transmission encephalitis|syphilis cmv hpv ppd pcr|leptospirosis|similar increases in both clinical and analytical sensitivity were observed for our human tb and entity assays .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|syphilis malaria tuberculosis vl ppd|leptospirosis|agreements are for the following rapid test products : i ) dpp® hiv 1 / 2 screen , ii ) dpp® hiv 1 / 2 confirmatory , iii ) dpp® entity and iv ) dpp® leishmaniasis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 3)])|disease|syphilis wil pathogenic transmission encephalitis|malaria leprosy schistosomiasis sarcoidosis syphilis|leptospirosis|we also have licensed the antigens used in other tests including our syphilis , tuberculosis , entity , leishmaniasis and chagas tests , and we may enter other license agreements .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis wil pathogenic transmission encephalitis|grant award project funding r01|leptospirosis|dpp® entity – in june 2009 , as we previously reported , we were awarded a three-year $3 million small business innovative research ( sbir )
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis wil pathogenic transmission encephalitis|where this relationship title which|leptospirosis|entity [ member ] refers to agreements relates to research and development arrangements .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|influenza tuberculosis malaria cholera pneumonia|leptospirosis|in addition to viral vaccines , diamond also manufactures vaccines against bacterial infections , such as entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|disease|syphilis wil pathogenic transmission encephalitis|malaria tuberculosis syphilis leprosy schistosomiasis|leptospirosis|the five products under agreement with fiocruz are for dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|syphilis wil pathogenic transmission encephalitis|syphilis chlamydia malaria hpv ppd|leptospirosis|believe fiocruz will receive during 2011 the required approvals from anvisa for the second dpp® syphilis test and the dpp® entity test , although there can be no assurance of this .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis wil pathogenic transmission encephalitis|dpp elisa assay detection panel|leptospirosis|with respect to chembio  s dpp® entity test , bio-manguinhos had not qualified to request the technology transfer .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis wil pathogenic transmission encephalitis|project grant 2020 funding foundation|leptospirosis|dpp® entity – we have approximately nine months left of the three-year $3 million small business innovative research ( sbir ) phase ii grant
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|disease|syphilis wil pathogenic transmission encephalitis|syphilis tuberculosis malaria leprosy schistosomiasis|leptospirosis|separate right to request a technology transfer for that product only are : dpp® products for hiv screening , hiv confirmatory , leishmaniasis , entity and syphilis .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|disease|syphilis wil pathogenic transmission encephalitis|measles cholera malaria varicella endocarditis|leptospirosis|bacterial vaccines are bacterial products that are used on a routine basis to prevent diseases such as black leg , entity , red water and shipping fever .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|malaria influenza syphilis ebola tuberculosis|leptospirosis|from the united states national institutes of health ( nih ) to fully develop , validate , and commercialize a rapid diagnostic test for entity for general use worldwide .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|disease|syphilis wil pathogenic transmission encephalitis|project 2020 funded foundation registry|leptospirosis|· dpp® entity phase ii grant – in 2009 we were awarded a three year , $1 . 9 million small business innovative research ( sbir ) phase
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|leishmaniasis leishmania fourth first remaining|leptospirosis|three of these products ( leishmaniasis and the hiv screening and confirmation tests ) , and we have substantially completed development of the entity test .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|syphilis wil pathogenic transmission encephalitis|syphilis malaria ppd hpv cmv|leptospirosis|this new patent-pending platform , including the testing of our current hiv test strip ( as well as our human tb and entity assays ) that was recently approved in this new platform .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|disease|syphilis wil pathogenic transmission encephalitis|depression diabetes alcoholism schizophrenia syphilis|leptospirosis|to be completed three-year grant from the united states national institutes of health to complete development of a test for entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|syphilis wil pathogenic transmission encephalitis|diabetes application testing applications diagnostics|leptospirosis|a press release entitled “chembio awarded three year $3mm nih sbir phase ii grant to complete dpp® test for human entity ” .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|syphilis wil pathogenic transmission encephalitis|nih r01 sci medicine funding|leptospirosis|three year , $3mm phase ii nih grant for entity awarded june 2009 .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5)])|disease|malformation scoliosis cleft malformations craniofacial|down turner craniofacial metabolic dwarf|craniosynostosis|of limb and lungs and unregulated fgf signaling leads to a variety of human bone morphogenic disorders , including dwarfism and entity syndromes .
OrderedDict([('OTHER', 4), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|malformation scoliosis cleft malformations craniofacial|osteogenesis ossification osteoporosis fracture osteosarcoma|craniosynostosis|his research interests include the molecular mechanism of entity , which is the premature fusion of calvarial suture line in infants and tissue engineering of bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|familial hereditary gene family inherited|thalassemia cirrhosis ida gout mds|hemochromatosis|u . s . safety information for auryxia® ( ferric citrate ) contraindication auryxia® ( ferric citrate ) is contraindicated in patients with iron overload syndromes , e . g . , entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|disease|familial hereditary gene family inherited|cf fibrinogen clotting ec fda|hemochromatosis|prontotm prothrombin ( factor ii ) approved f9923 prontotm thromborisktm approved f9949 prontotm entity approved f9904 prontotm fmf basic approved f9946 prontotm cf euro i
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 2)])|disease|familial hereditary gene family inherited|thalassemia iron ferritin hemolysis anaemia|hemochromatosis|beta thalassemia patients suffering from iron overload and the initiation of a phase 2 study for ljpc-401in patients with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|familial hereditary gene family inherited|diseases syndromes conditions cancers polyposis|hemochromatosis|it is also estimated that one million americans are afflicted with hereditary entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|disease|familial hereditary gene family inherited|thalassemia alpha iron scd mds|hemochromatosis|we are developing ljpc-401 for the treatment of conditions characterized by iron overload , such as entity and beta thalassemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 3)])|disease|familial hereditary gene family inherited|cirrhosis fibrosis diseases iron hypercholesterolemia|hemochromatosis|hereditary entity hereditary hemochromatosis is an iron overload disease that can lead to life-threatening conditions such as cirrhosis , liver cancer , diabetes , heart failure and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|disease|familial hereditary gene family inherited|leukemias syndromes mds thrombocytopenia thalassemia|hemochromatosis|treatment of patients with polycythemia vera , myelodysplastic syndromes and hereditary entity may represent additional opportunities for future development of ptg-300 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|disease|familial hereditary gene family inherited|diabetes inflammation osteoporosis atherosclerosis thrombosis|hemochromatosis|in addition , savyon  s products are used in clinical laboratories performing pre-disposition testing ( thrombosis , entity , certain cancers and several other diseases and conditions ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|disease|familial hereditary gene family inherited|humans thalassemia taiwan india adults|hemochromatosis|and chief executive officer of bond biosciences , inc . , a private start-up biotechnology company focused on addressing the iron overload in entity , from july 2016 to may 2018 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|disease|familial hereditary gene family inherited|ferritin thalassemia iron fibrosis anaemia|hemochromatosis|ferisk ( tm ) is intended to become a standard in the screening , diagnosis and follow-up of hereditary entity patients , as well as others who suffer from iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|disease|familial hereditary gene family inherited|thalassemia cirrhosis gout ckd anaemia|hemochromatosis|important safety information contraindication : patients with iron overload syndrome , e . g . entity , should not take auryxia ( ferric citrate ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 2)])|disease|familial hereditary gene family inherited|ferritin hepcidin iron thalassemia splenomegaly|hemochromatosis|in addition , hereditary entity and the more severe form , juvenile hemochromatosis , are both inherited disorders of reduced hepcidin production and consequently iron overload .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|familial hereditary gene family inherited|thalassemia others ferritin lupus thrombocytopenia|hemochromatosis|iron levels can be found in disorders such as cooley  s anemia , sickle cell anemia and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|disease|familial hereditary gene family inherited|syndromes diseases conditions anaemia deficiencies|hemochromatosis|iron overload is also associated with hereditary entity where a genetic defect in a protein involved in iron absorption leads to excess absorption of iron and iron overload
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|familial hereditary gene family inherited|hh hepcidin hemolysis haemoglobin thalassemia|hemochromatosis|evaluate the safety and efficacy of ljpc-401 , la jollas proprietary formulation of synthetic human hepcidin , as a treatment for hereditary entity ( hh ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|species taxa spp cocc strain|hemolysis encephalopathy cholestasis cirrhosis thalassemia|kernicterus|in june 2001 , the center for disease control  s morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|species taxa spp cocc strain|this qi colonoscopy quality healthcare|kernicterus|the national quality forum has in the past described entity as a “never event , ” one which physicians should ensure never occurs in their practice .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|species taxa spp cocc strain|recurrence rejection complications cirrhosis fibrosis|kernicterus|however , phototherapy rapidly becomes less effective following puberty , increasing the risk for entity , resulting in the need for liver transplantation to control the disease .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|disease|species taxa spp cocc strain|hepatotoxicity overdose toxicity hypoglycemia nephrotoxicity|kernicterus|use : atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|disease|species taxa spp cocc strain|articles each papers journals manuscripts|kernicterus|the center for disease controls morbidity and mortality weekly report published four case studies of 7 table of contents entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|species taxa spp cocc strain|this epilepsy neurotoxicity als ms|kernicterus|entity is a completely preventable condition that often results in permanent neurological damage brought on by the known toxic effects of
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|disease|species taxa spp cocc strain|hemolysis cirrhosis bilirubin diabetes alcoholism|kernicterus|the center for disease controls report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|disease|species taxa spp cocc strain|hemolysis encephalopathy cholestasis cirrhosis thalassemia|kernicterus|in june 2001 , the center for disease controls morbidity and mortality weekly report published four case studies of entity , a form of hyperbilirubinemia which is preventable .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|disease|species taxa spp cocc strain|cirrhosis cholestasis encephalopathy pancreatitis gvhd|kernicterus|bilirubin toxicity can ultimately result in a chronic , severe , and disabling condition called entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|species taxa spp cocc strain|neurotoxicity ns cns pns pn|kernicterus|the total loss of ugt1a1 activity and the resulting severe jaundice and risk of neurological sequelae ( entity ) are associated with cn type 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|disease|species taxa spp cocc strain|thrombocytopenia hemolysis neutropenia thrombosis hypoglycemia|kernicterus|its effects on the fetus or newborn include hemolytic anemia , hyperbilrubinemia , entity , or intrauterine deaths due to hydrous fetalis .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|disease|species taxa spp cocc strain|hemolysis cirrhosis prematurity bilirubin cholestasis|kernicterus|the center for disease control  s report stated that early detection of hyperbilirubinemia is critical to prevent the irreversible effects of entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|disease|species taxa spp cocc strain|this cp spasticity als sci|kernicterus|entity is a cerebral palsy-like condition in which the patient lacks muscle tone and motor control , cannot operate self-sufficiently , and typically requires long-term care .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|presence nodal none cerebrospinal lymph|lymphocytes erythrocytes fibroblasts platelets macrophages|cytotrophoblasts|high complexity probes according to claim 28 wherein said fetal cells are leukocytes and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes neurons astrocytes axons fibroblasts|oligodendrocytes|the pathology of spinal cord injury involves extensive loss of the myelin sheath produced by entity at the site of injury .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|pericytes fibroblasts oligodendrocytes macrophages cells|oligodendrocytes|was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , astrocytes , microglial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|neurons interneurons astrocytes myelin nerves|oligodendrocytes|occurs in a diffuse fashion throughout the adult brain and appears to reflect a loss of axonal support by local entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes astrocytes neurons opcs fibroblasts|oligodendrocytes|in our preclinical research , we have shown that hucns-sc cells differentiate into entity , the myelin producing cells , and produce myelin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes opcs oligodendrocyte myelin neurons|oligodendrocytes|mechanism of action underlying the enhanced remyelination in vivo and shown that multistem cells and secreted factors increase differentiation of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes myelin axons synapses opcs|oligodendrocytes|remyelination remyelination is the process propagating oligodendrocyte precursor cells to form entity to create new myelin sheaths on demyelinated axons in the cns .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|they neurons astrocytes interneurons mitochondria|oligodendrocytes|entity are natures neuronal insulating cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes opcs astrocytes neurons fibroblasts|oligodendrocytes|deficient in myelin production , transplantation of hcns-sc into the brain resulted in widespread engraftment of human cells that matured into entity , the myelin producing cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes microglia neurons pericytes fibroblasts|oligodendrocytes|q-cells produce astrocytes and entity , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|neurons they astrocytes cells mitochondria|oligodendrocytes|entity are natures neural insulating cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|cells ipscs mscs biomaterials exosomes|oligodendrocytes|japan patent 2011-047716 – entity derived from human embryonic stem cells for remyelination and treatment of spinal cord injury are described .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes astrocytes neurons neurones fibroblasts|oligodendrocytes|myelin sheath that insulates nerve fibres , or axons , in the central nervous system and the cells that make myelin , the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|they tdcs electrodes nerves nets|oligodendrocytes|like the insulation covering an electrical wire , entity enable the conduction of electrical impulses along nerve fibers throughout the central and peripheral nervous system .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|neurons astrocytes fibroblasts cells oligodendrocytes|oligodendrocytes|$ 4 , 000 tissue culture - culture of primary entity derived from mixed glial cultures .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes neurons cells astrocytes glia|oligodendrocytes|financial statements gpc program our gpc program aims to deliver healthy allogeneic gpcs , the precursors to both astroglia and myelin-producing entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|ipscs cells exosomes embryos dna|oligodendrocytes|the patent relates to methods of making entity from human embryonic stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|oligodendrocytes mature oligodendrocyte myelin immature|oligodendrocytes neurons microglia pericytes fibroblasts|oligodendrocytes|the resulting differentiated cells ( astrocytes and entity , shown in figure 2 ) then can perform the support functions of these glial cells in vivo as described above .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|cell osteocytes cells cellular oste|osteocytes osteoclasts osteoblasts bmscs fibroblasts|osteocytes|sclerostin is produced in entity , which are mature bone cells that are thought to be the mechanoreceptor cells that regulate the activity of bone-building osteoblasts
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell osteocytes cells cellular oste|chondrocytes osteocytes osteoblasts pericytes cardiomyocytes|osteocytes|the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least adipocytes , entity , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell osteocytes cells cellular oste|osteoclasts chondrocytes osteocytes fibroblasts macrophages|osteocytes|merits bone formation involves the migration of undifferentiated mesenchymal cells , differentiation into cartilage , and subsequent bone replacement by osteoblasts and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast osteocytes macrophages|osteoclasts|in addition , unlike currently marketed ra 1 table of contents drugs , fpa008 directly inhibits bone-destroying cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoclastogenesis osteoclast apoptosis fibroblasts|osteoclasts|gallium acts upon bone by enhancing the formation of osteoblasts and inhibiting entity , thereby increasing bone deposition and reducing bone turnover .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast macrophages rankl|osteoclasts|up to now , bisphosphonates have been most effective in tumors where bone destruction is caused primarily by overstimulation of entity , which abnormally accelerate the breakdown of bone .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoclast fibroblasts osteocytes macrophages|osteoclasts|two main types of cells are responsible for this process : entity , which break down bone tissue , and osteoblasts , which secrete new bone tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast rankl osteoblast|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone‑resorbing cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteocytes macrophages osteoclast|osteoclasts|entity resorb bone by secreting protons and generating an acidic extracellular microenvironment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast osteocytes rankl|osteoclasts|sct is a hormone that inhibits the bone-tissue resorbing activity of specialized bone cells called entity , enabling the bone to retain more of its mass and functionality .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoclast osteocytes osteoblasts osteoclastogenesis|osteoclasts|bone health is maintained through regulation of the competing activities of bone forming cells ( osteoblasts ) and bone resorbing cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|neutrophils lymphocytes microglia monocytes granulocytes|osteoclasts|treatment of ra in which it reversibly blocks signaling in multiple cell types involved in inflammation and tissue degradation ( e . g . macrophages , entity , mast cells and b cells ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast rankl osteocytes|osteoclasts|( osteopenia ) • ( a ) when bone marrow derived macrophages ( bmdm ) from nomid mice are stimulated with rankl ( rank ligand ) , they differentiate into entity • : 1315-1325 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts mature osteoclast cell differentiation|from derived plus by via|osteoclasts|rankl stimulation macrophages entity nomid bmdm nomid bmdm plus ati-450 ( a ) ( b ) bone marrow derived macrophages ( bmdm ) from nomid mice 19© copyright 2020 aclaris
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteocytes osteoclast macrophages|osteoclasts|zoledronic acid is the most potent bisphosphonate , a class of drugs known to inhibit entity , which are key cells involved in the maintenance , repair and remodeling of bone .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts macrophages osteoclast osteocytes cells|osteoclasts|cells called osteoblasts cause new bone formation while other cells called entity remove old bone through a process called resorption .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast osteoblast osteocytes|osteoclasts|axs‑02 is a potent inhibitor of entity , which are bone remodeling cells that break down bone tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast macrophages osteoblast|osteoclasts|bisphosphonate drugs slow down the rate at which entity , which are cells which resorb or take away bone , reduce the bones mass .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts mature osteoclast cell differentiation|bones muscles osteoclasts osteoblasts teeth|osteoclasts|in people with osteopetrosis , this balance is not maintained because their entity do not function properly .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteoclast rankl macrophages|osteoclasts|bisphosphonates are compounds that bind with high affinity to bone mineral and inhibit the bone-resorbing cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|osteoclasts mature osteoclast cell differentiation|osteoclasts osteoblasts osteocytes bones cells|osteoclasts|calcitonin , a peptide , inhibits bone resorption by acting on specific receptors on entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|osteoclasts mature osteoclast cell differentiation|densitometry osteoclasts enzymes measuring radiography|osteoclasts|ntx serum became the first and only commercially available test in the united states that measures specific bone breakdown by entity using a blood sample .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|osteoclasts mature osteoclast cell differentiation|lymphocytes cells macrophages hscs monocytes|osteoclasts|the drug appears to be selectively toxic for activated entity , displaying a negligible effect on bone marrow stromal cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes microglia mdscs osteoclasts granulocytes|monocytes|csf-1r is expressed on the surface of specific immune cells known as macrophages and their precursor cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|phenotype subpopulations cd14 monocytes cd16|cells lymphocytes tissue dna fibroblasts|monocytes|this is an exclusive license to a stem cell technology in which adult pluripotent stem cells are derived from entity obtained from the patient  s own blood .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|phenotype subpopulations cd14 monocytes cd16|marrow sample population bm body|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes neutrophils microglia granulocytes lymphocytes|monocytes|targets the colony stimulating factor-1 receptor , or csf-1r , a cell surface protein thought to control the survival and function of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|phenotype subpopulations cd14 monocytes cd16|cells fibroblasts islets myoblasts chondrocytes|monocytes|researchers have been able to turn these dedifferentiated entity into several different types of cells including islet cells , nerve cells , liver cells , blood vessel cells and skin cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|phenotype subpopulations cd14 monocytes cd16|neurons leukocytes macrophages fibroblasts nerves|monocytes|in january 2017 , we reported that targeting of mospd2 inhibits chemotaxis of entity and neuropils , and that unpublished vbl data also show mospd2 expression on certain tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes microglia neutrophils lymphocytes monocyte|monocytes|fpa008 ( cabiralizumab ) : an investigational antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|macrophages monocytes lymphocytes neutrophils basophils|monocytes|cells ; and  these proteins secondarily activate other innate immune cells such as natural killer cells and entity , which become able to recognize and kill some tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes monocyte microglia dendritic granulocytes|monocytes|eascs exhibit broad immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , entity or macrophages and neutrophils .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes macrophages pbmcs pbmc leukocytes|monocytes|when applied to human immune cells such as entity , selective immunoproteasome inhibitors , like kzr-616 and onx 0914 , blocked the release of inflammatory cytokines following cell stimulation .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|phenotype subpopulations cd14 monocytes cd16|cells samples lymphocytes tissues donors|monocytes|the companys stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes granulocytes dendritic neutrophils mdscs|monocytes|patients with various diseases , as well as established cell lines from immune and non-immune cell lineages , including t cell subsets , entity , macrophage subpopulations and cancer cell lines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes neutrophils lymphocytes granulocytes microglia|monocytes|fcgri is expressed in certain human immune cells including entity , macrophages and dendritic cells and may function to activate these immune cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|phenotype subpopulations cd14 monocytes cd16|cells samples lymphocytes leukocytes monocytes|monocytes|our stem cell technology isolates novel multipotent stem cells derived from peripheral blood entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes monocyte microglia dendritic neutrophils|monocytes|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and entity / macrophages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|phenotype subpopulations cd14 monocytes cd16|marrow sample population bm body|monocytes|these mdsc can be derived from a patients entity , expanded ex vivo , and then administered to the same patient .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes neutrophils granulocytes basophils microglia|monocytes|cells with the cd4 receptor are critical components of the immune system and include t lymphocytes , entity , macrophages and dendritic cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes microglia neutrophils lymphocytes granulocytes|monocytes|developments clinical pipeline : cabiralizumab ( fpa008 ) : an antibody that inhibits csf1r and has been shown to block the activation and survival of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|phenotype subpopulations cd14 monocytes cd16|monocytes lymphocytes cells leukocytes fibroblasts|monocytes|our novel multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|phenotype subpopulations cd14 monocytes cd16|cells lymphocytes monocytes fibroblasts leukocytes|monocytes|our multi-potent stem cell is derived from peripheral blood entity which when cultured under defined conditions are able to further differentiate into several cellular lineages .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblast fibroblasts cell genetic leukocyte|samples cells aliquots specimens preparations|fibroblasts|the entity are then harvested , tested by quality control and released by quality assurance prior to shipment .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells xenografts macrophages cultures|fibroblasts|of disease causing ability , was accomplished by making over 500 passages of the virus in chicken embryos or chick embryo entity which resulted in large genomic deletions .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells fibroblast cell tissue|fibroblasts|products and reagents like avian cell substrates have rt activity that does not represent adventitious infectious retroviruses ( e . g . chicken embryo entity , dermal cells and eggs ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblast neutrophil endothelial fibroblasts angiogenesis|fibroblasts|method of enhancing wound healing by stimulating entity and keratinocyte growth in vivo , utilizing amphipathic peptides .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells lymphocytes hepatocytes pbmc|fibroblasts|the company has produced clonal populations of human entity which have been transfected to express factor viii in vitro , demonstrated that the protein is properly processed and achieved protein
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts melanocytes macrophages collagen dermis|fibroblasts|hses are composed of both a dermal layer containing entity and an epidermal layer containing keratinocytes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts hepatocytes keratinocytes melanocytes lymphocytes|fibroblasts|cold selectively inhibits akt activation in human cancer cells compared to normal proliferating cells ( e . g . , human entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|fibroblast fibroblasts cell genetic leukocyte|regenerative progenitor transplanted mesenchymal autologous|fibroblasts|used are fat injections and cell injections , which are mainly based on enriching the damaged tissue with external source of entity cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells keratinocytes tissues melanocytes|fibroblasts|furthermore , ccl24 is constitutively expressed by skin and dermal entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|cells fibroblasts macrophages lymphocytes leukocytes|fibroblasts|pierer m , brentano f , rethage j , et al . the tnf superfamily member light contributes to survival and activation of synovial entity in rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblast macrophages fibroblasts macrophage myofibroblasts|fibroblasts|● increase in apoptosis of inflammatory cells , including neutrophil and pro-fibrotic cells , including entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|cells cell fibroblasts melanoma tissue|fibroblasts|product consisting of a cream vehicle blended with the conditioned media extract from the cell culture of a customers own entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts pbmcs myoblasts neurons cells|fibroblasts|we isolated and cultured entity from lhon-nd4 patients .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells fibrosis tissue tissues|fibroblasts|the rheumatic diseases 72 adenosine a2a receptor activation stimulates collagen production in sclerodermic dermal entity either directly and through a cross-talk with the cannabinoid system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblast fibroblasts cell genetic leukocyte|experiments mice assays models cells|fibroblasts|in these entity , we demonstrated that gs010 restores mitochondrial function , including complex i activity and atp production , to the level of normal entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts monocytes macrophages pericytes leukocytes|fibroblasts|in ssc patients , increased production of no is suggested by increased expression of inos in endothelial cells , entity , mononuclear cells infiltrating ssc skin and alveolar macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts keratinocytes melanocytes fibroblast keratinocyte|fibroblasts|much of tkt  s work has focused on gene therapy using entity , a cell type present in the skin ( and throughout the body ) that is readily obtained from patients and propagated in
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts metalloproteinases proteins enzymes cells|fibroblasts|entity are also found in the dermis and are responsible for creating collagen and elastin that provide strength and flexibility to
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells fibroblast tissue matrix|fibroblasts|dermagraft dermagraft is a dermal substitute grown from human dermal entity and has received pma approval for the treatment of dfus .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|fibroblast fibroblasts cell genetic leukocyte|fibroblasts cells keratinocytes cardiomyocytes lymphocytes|fibroblasts|von zglinicki t , saretzki g , docke w , lotze c . mild hyperoxia shortens telomeres and inhibits proliferation of entity : a model for senescence? .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|cells from cell abstract by|lymphocytes thymus thymocytes proteins cells|thymocytes|description thymoglobulin* [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1), ('DRUG', 1)])|cell|cells from cell abstract by|monocytes lymphocytes macrophages thymocytes neutrophils|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells , known as t cells , created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2)])|cell|cells from cell abstract by|tregs lymphocytes monocytes thymocytes inkt|thymocytes|under control conditions , lps kills entity , which are important immune system precursor cells created in the thymus to fend off infection .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cells from cell abstract by|dp cells dc populations dcs|thymocytes|implants in the haart and nanoviricide treatment groups exhibited 80-85% cd4+ , cd8+ dp cells while the vehicle control groups had only approximately 30% cd4+cd8+ entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|cells from cell abstract by|lymphocytes thymus thymocytes proteins antibodies|thymocytes|description thymoglobulin® [ anti-thymocyte globulin ( rabbit ) ] is a purified , pasteurized , gamma immune globulin , obtained by immunization of rabbits with human entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|cells from cell abstract by|monocytes macrophages others microglia neutrophils|thymocytes|its cognate receptor , pd-1 , is a co-inhibitory transmembrane protein expressed on t cells , b cells , natural killer cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|cells from cell abstract by|cells bacteria organisms mice strains|thymocytes|senescos technology allowed for approximately 90% greater survival of these entity in the presence of lps .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|consciousness balance cognition memory delirium|neutrophils|the effect of the drug on the recovery of entity is slow .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|neutrophils monocytes macrophages lymphocytes leukocytes|neutrophils|in preclinical studies , plinabulin increased the survival of entity , a type of white blood cell important in the prevention of bacterial infections .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|proteases complement toxins antibiotics pathogens|neutrophils|factor in promoting bacterial invasion as well as rendering the bacteria resistant to attack from reactive oxygen species ( ros ) and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|neutrophils cells granulocytes lymphocytes leukocytes|neutrophils|neulasta selectively stimulates the production of entity that are depleted by cytotoxic chemotherapy , a condition called neutropenia that makes it more difficult for the body to fight
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|that which cytokines chemokines c5a|neutrophils|role of c5a and c5ar in hs entity are believed to play an important disease-promoting role , as well as certain cytokines and mediators commonly found in autoimmune diseases ,
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|anc engraftment neutrophils cd4 counts|neutrophils|patients treated with omidubicel recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|cells eosinophils neutrophils macrophages leukocytes|neutrophils|in addition , 10150 decreased sm-induced increase in the numbers of bal entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|others neutrophils cytokines platelets lymphocytes|neutrophils|immunomodulatory properties , including the regulation of immune cells such as b lymphocytes , t lymphocytes , natural killer cells , monocytes or macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|lymphocytes neutrophils monocytes basophils eosinophils|neutrophils|addition to its expression on b cells , cd32b is also expressed on other immune cells such as dendritic cells , macrophages , entity , and mast cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|leukocytes lymphocytes neutrophils granulocytes cells|neutrophils|these cells are programmed to end up as blood cells of a specific type , such as entity , red blood cells and platelets .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|nkt monocytes treg nk myeloid|neutrophils|blood versus the lymphoid tissues , you have a preferential depletion of cd4 , cd8 and b cells , much greater than nk , entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|platelets counts neutrophils anc wbc|neutrophils|in addition , the treatment is associated with considerable adverse events like neutropenia ( low entity ) and neuropathy ( damage to the peripheral nervous system ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|neutrophils cells leukocytes neutrophil granulocytes|neutrophils|although these conditions have multiple causes , each involves neutrophil adhesion to the blood vessel wall and the subsequent migration of entity into the tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|neutrophils lymphocytes cytokines eosinophils leukocytes|neutrophils|also treated with viprovex , did not develop the clinical symptoms of viral infection , which included increases in alveolar macrophages and entity in broncho-alveolar lavage fluid .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|anc neutrophils platelets granulocytes engraftment|neutrophils|the studys primary endpoint was time to neutrophil engraftment , and was met based on recovery of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|anc engraftment cd4 counts platelets|neutrophils|patients treated with nicord recovered their entity ( 500 cells per microliter ) with a median recovery of 11 . 5 days after transplantation , which is significantly shorter than the 21
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|cytokines mediators markers biomarkers pathways|neutrophils|animal studies to allow manipulation and control of oxidative biomarkers of protein and dna , nitric oxide , antioxidant enzymes and inflammatory entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|neutrophils lymphocytes monocytes macrophages leukocytes|neutrophils|second , pep005 activates the bodys immune system , causing entity , a type of white blood cell , to infiltrate the treated site .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|immunity hematopoiesis healing tolerance survival|neutrophils|companies such as amgen inc . have developed or are developing products to boost entity after chemotherapy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neutrophils neutrophil polymorphonuclear blasts immature|they lymphocytes cells macrophages exosomes|neutrophils|once in the tissue , entity release toxins which attack normal cells as well as the antigen .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells differentiation involvement hematopoiesis defects|lymphocytes|approximately 80% of all all cases involve lineage entity in the bone marrow .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes cell responses checkpoints|lymphocytes|were generated in the t cell transfer model which utilizes immunodeficient mice which are deficient in functional b and t entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|lymphocytes cells tils lymphomas cytokines|lymphocytes|there are two main categories of entity : b-entity , or b-cells , and t-entity , or t-cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells cell entity entities lymphocytes|lymphocytes|the immune system is composed of a network of immune cells that include t entity ( t cells ) and b entity ( b cells ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|lymphocytes macrophages monocytes tregs dcs|lymphocytes|the most crucial types of cells are antigen-presenting cells , or apcs , and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cytokines tregs lymphocytes cytokine antibodies|lymphocytes|to the occurrence and severity of these adverse events due to its role in inducing lymphopenia , or low levels of entity in the blood , and enhanced car t cell activity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes populations cell subpopulations|lymphocytes|or more diagnostic antigens for detection of tuberculosis infection by measuring g-ifn ( gamma-interferon ) ( or , in field b , other cytokine- ) secreting entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes pathogens viruses microorganisms|lymphocytes|allogeneic bone marrow transplant in which tissues of the host , most frequently the gut , liver , and skin , are attacked by entity in the donor ( graft ) marrow .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes leukocytes granulocytes neutrophils|lymphocytes|abnormally large numbers of immature , abnormal entity called lymphoblasts are produced and released into the bloodstream .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes cell lymphocyte responses|lymphocytes|as shown below , following gp2 immunotherapy , cd8+ cytotoxic t entity recognize and destroy her2 / neu-expressing cancer cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes cell lymphocyte leukocytes|lymphocytes|lymphokine any of a number of soluble physiologically active factors produced by t entity in response to specific antigens .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes proteins antigens antibodies|lymphocytes|ceplene is designed to protect entity responsible for immune-mediated destruction of residual leukemic cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes cell lymphocyte leukocytes|lymphocytes|white blood cells that have differentiated to produce a specific antibody are called b entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|macrophages lymphocytes leukocytes monocytes phagocytes|lymphocytes|the type of immune response is characterized by the way the response was initiated through specialized cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|lymphocytes lymphocyte leukocytes cells tils|lymphocytes|as predefined in the clinical protocol , patient subgroups were evaluated for levels of tumor infiltrating entity ( til ) and for pd-l1 checkpoint protein expression on tumor cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes antibodies individuals ctl|lymphocytes|consequently , in each persons bloodstream , only a relatively few entity will recognize the same antigen .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|lymphocytes cells leukocytes lymphocyte tils|lymphocytes|til means tumor infiltrating entity that are collected from a tumor cell , including naturally-occurring t cells with specificity against such tumor .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes leukocytes macrophages phagocytes|lymphocytes|itk , an enzyme that functions in t‑cell signaling and differentiation , is expressed predominantly in t‑cells , which are entity that play a vital role in immune responses .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|lymphocytes lymphocyte leukocytes cells leukocyte|lymphocytes|) – lion biotechnologies , inc . ( otcqb : lbio ) , a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating entity ( til )
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|lymphocytes cytotoxic lymphocyte cell cd8|cells lymphocytes cell subsets counts|lymphocytes|although the exact mechanism of action for alemtuzumab is unknown , it is presumed to deplete circulating t and b entity after each treatment course .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|platelets synthetic functions counts single|vwf fviii env adamts ag|platelets|genetically linked by an amino acid linker , targeting the a1 domain of vwf and inhibiting the interaction between ulvwf and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|platelets synthetic functions counts single|platelets immunoglobulins erythrocytes proteins eggs|platelets|the ellipse in the upper left- hand corner contains the phrase " virally inactivated red blood cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|platelets synthetic functions counts single|fibrinogen platelets collagen fibronectin albumin|platelets|against acutect® because fibrimage® binds to fibrin , which comprises 75-80% of an actively forming blood clot , whereas acutect® binds to entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|platelets synthetic functions counts single|platelets proteins hormones nerves vessels|platelets|blood and immune systems , including : t cells and b cells to fight infections ; red blood cells to carry oxygen and entity to control bleeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|platelets synthetic functions counts single|platelets iron thrombocyt neutrophils cells|platelets|immune thrombocytopenia ( itp ) - itp is an uncommon autoimmune bleeding disorder characterized by insufficient entity in the blood .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|platelets synthetic functions counts single|proteins platelets cells dna monocytes|platelets|these agents work by preventing the ability of entity to aggregate together .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|platelets synthetic functions counts single|counts cells sugar count flow|platelets|we have contributed novel research and technologies for approved medicines that treat cancer , osteoporosis , fungal infections and low blood entity , among others .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DIS', 1)])|cell|platelets synthetic functions counts single|platelets lymphocytes monocytes hematocrit neutrophils|platelets|are overproduced in the bone marrow affecting the synthesis of normal blood cells , causing a decrease in red blood cells , entity and normal white blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|platelets synthetic functions counts single|cells platelets leukocytes tissues vessels|platelets|glutamate release by a platelet acts to stimulate release of glutamate from other entity , potentially leading to aggregation and the formation of the thrombus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|platelets synthetic functions counts single|platelets tissues organs cells proteins|platelets|banks or transfusion centers because the main objective of these banks and centers is to obtain the blood cells and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|platelets synthetic functions counts single|cells neurons axons astrocytes macrophages|platelets|released glutamate acts by binding cell surface glutamate receptors expressed on entity themselves .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|platelets synthetic functions counts single|antigens proteins cells platelets dna|platelets|the affected individuals make antibodies against their own entity leading to the entity  destruction , which in turn leads to the abnormal bleeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 2), ('BIO', 1)])|cell|platelets synthetic functions counts single|atherosclerosis cardiomyocytes myocardium hf bnp|platelets|the effects of integrilin are specific to entity , avoiding interference with other normal cardiovascular processes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|platelets synthetic functions counts single|platelets lymphocytes monocytes leukocytes erythrocytes|platelets|in many hematological disorders , there is abnormal proliferation and differentiation of the progenitor cells for red blood cells , entity and neutrophils .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|platelets synthetic functions counts single|platelets counts count clotting flow|platelets|in addition to anemia , fatigue , hair-loss , reduction in blood entity and white and red blood cells , and bone pain , one of the most common side effects of chemotherapy is nausea
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|platelets synthetic functions counts single|platelets neutrophils itp erythrocytes leukocytes|platelets|our laboratory personnel had previously developed a pre-clinical itp model with data showing that prtx-100 inhibits the phagocytosis ( ingestion ) of entity in vitro .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|platelets synthetic functions counts single|platelets leukocytes neutrophils cells erythrocytes|platelets|integrilin is a small synthetic peptide administered by injection that prevents the aggregation of entity by blocking the platelet receptor glycoprotein , or gp , iib-iiia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 3)])|cell|platelets synthetic functions counts single|microglia astrocytes leukocytes macrophages platelets|platelets|a2 ( blocked by aspirin ) and adenosine diphosphate ( blocked by plavix® ) , researchers have recently demonstrated the release of glutamate by entity during platelet activation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|platelets synthetic functions counts single|platelets albumin immunoglobulins lymphocytes erythrocytes|platelets|plasma donation means that donors give only plasma but not the other blood components such as entity , red cells and infection-fighting white cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|platelets synthetic functions counts single|angiogenesis vegf her2 mtor hsp90|platelets|training he performed basic research at the royal prince of wales hospital to develop a new monoclonal antibody to inhibit entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|surfaces surface endothelium cells membrane|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd‑peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|medicines healthcare technology medicine equipment|leukocytes|the costs and availability of entity are subject to fluctuation depending on a variety of factors beyond our control , including competitive factors , changes in technology , and
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|humans cells antibodies individuals primates|leukocytes|human entity produce millions of different types of antibodies , all with varying shapes that allow them to attach to and , as a
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|surfaces surface endothelium cells αvβ3|leukocytes|integrins are subdivided into those on entity , and those that recognize rgd-peptide , collagen and laminin ligands .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|leukocytes lymphocytes monocytes platelets granulocytes|leukocytes|manufacture of interferon human white blood cells , also known as entity , and a stimulating agent are needed to produce human leukocyte derived interferon .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|material supplies quantities data funds|leukocytes|if we are unable to obtain the necessary entity , we may be required to scale back our operations or stop manufacturing multiferon® .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|wbc leukocytes lymphocytes cells pbmcs|leukocytes|in inflammation , white blood cells ( entity ) move out of the bloodstream into the inflamed tissue , for example , the cns in ms , and the lung airways in
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|electron position charge slot affinity|leukocytes|comprising phosphosugar residues , that play a central role in the entry of is , sugar residues bearing at least one entity into inflammatory sites .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|cells fibroblasts tumors surfaces leukocytes|leukocytes|the next stage of development of integrins as drug targets has focused on integrin receptors on entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|milk tissue saliva tissues muscle|leukocytes|edinburgh , scotland , and has the physical and , with the company  s proprietary technology , the technical capacity to manufacture omniferon ( tm ) from human entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|leukocytes eosinophils neutrophils lymphocytes macrophages|leukocytes|in addition , the bronchoalveolar lavage of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|leukocytes cells bacteria lymphocytes microorganisms|leukocytes|revenue was derived from the commercial sales of its leukonet system , a medical device designed for the removal of contaminating entity from donated blood .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|eosinophils leukocytes neutrophils lymphocytes macrophages|leukocytes|in addition , the bronchoalveolar lavage ( bal ) of anti-siglec-8 treated mice displayed reduced levels of infiltrating entity that were similar to sham treated animals .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|monocytes lymphocytes leukocytes macrophages neutrophils|leukocytes|chemokines are cytokines which regulate the trafficking patterns of entity , the effector cells of the human immune system .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|lymphocytes leukocytes cells neutrophils immunoglobulins|leukocytes|antibodies are made in the immune system by human white blood cells , called entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|donors banks draws collected stored|leukocytes|by the first quarter 2007 , we anticipate preparing new alferon n injection ( r ) lots from blood entity at our new jersey facility .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|cells elements proteins constituents vessels|leukocytes|typically by extraction with vegetable oil and hydrophobic chromatography , and sterile filtering to remove bacteria , parasites and all undesirable blood entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|cells monocytes lymphocytes leukocytes proteins|leukocytes|monocytes phagocytic blood entity , originating from the bone marrow .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|leukocytes cells platelets leukocyte lymphocytes|leukocytes|addition of sialyl lewis x ( " slex " ) carbohydrate side chains yielding scr1sle x . slex is a carbohydrate which mediates binding of entity including neutrophils to selectin proteins .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 2)])|cell|leukocytes leukocyte polymorphonuclear cd45 eosinophils|crp bilirubin hematocrit glucose wbc|leukocytes|risk of poorer clinical outcomes as measured by atlas score , a tool for evaluating cdi in patients by age , temperature , entity and albumin levels , and use of systemic antibiotics .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages monocytes lymphocytes cancers tumors|macrophages|abx-cbl the cbl antigen is selectively over-expressed on activated immune cells including t-cells , b-cells and certain entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages microglia leukocytes monocytes neutrophils|macrophages|activated entity release a variety of mediators of inflammation that contribute to a broad range of diseases , such as rheumatoid arthritis , osteoarthritis ,
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|phagocytosis tlr9 macrophages tlr4 lps|macrophages|the targeting of cd47 to make cancer cells susceptible to entity , a component of the innate immune system , is analogous to the approach that has been applied with checkpoint inhibitors and
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages monocytes lymphocytes microglia neutrophils|macrophages|beyond cancer , we have discovered that activated entity , a type of white blood cell found at sites of acute and chronic inflammation , also over-express the folate receptor .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|lymphocytes neutrophils macrophages basophils eosinophils|macrophages|this is carried out primarily by some specialized cells in the blood ( e . g . , monocytes and entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages lymphocytes complement caspases cells|macrophages|these compounds , intended for use as immuno- pharmaceutical agents , activate entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages macrophage chemokines neutrophils basophils|macrophages|immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , granulocytes , mast cells and monocytes / entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages cells myeloid type m2|macrophages|in patients with cancer , immuno-evasion occurs as a result of suppressor entity ( m2 ) and inhibitory myeloid suppressive cells and treg cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|lymphocytes antibodies macrophages neutrophils phagocytes|macrophages|entity are cells found in the blood which recognize and destroy malignant cells and invading microbes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages cells lymphocytes monocytes microglia|macrophages|the mt-2000 series is designed to modulate activated entity from a classically activated phenotype to the alternatively activated phenotype .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages fibroblasts lymphocytes melanocytes cells|macrophages|recent experiments have shown that complex polynucleotides administered topically are absorbed by cells such as keratinocytes and entity within the superficial skin .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|cells macrophages lymphocytes hscs monocytes|macrophages|the mt-1000 series is designed to deplete activated entity via apoptosis and / or alter the phenotype of entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|monocytes macrophages lymphocytes dcs ctls|macrophages|expressed by tumor cells and have been modified to more efficiently attract immune effector cells , such as nk cells and entity , to effectively kill tumor cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|lymphocytes eosinophils macrophages basophils cd8|macrophages|phagocytes are a class of white blood cells , which include monocytes , entity and neutrophils , found in abundant quantities in and around tumors and areas of infection .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages lymphocytes neutrophils granulocytes basophils|macrophages|we believe that by inhibiting csf-1r activation on monocytes and entity , that axatilimab has the potential to be used to treat cgvhd .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|macrophages cytokines cytokine intracellular dendritic|cells lysosomes macrophages hepatocytes adipocytes|macrophages|entity affected by the disease become highly enlarged due to the accumulation of glccer and are referred to as “gaucher cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages monocytes macrophage adipocytes microglia|macrophages|our anti-mirs promotes reverse cholesterol transport , or rct , which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells called entity in atherosclerotic plaques .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages monocytes basophils lymphocytes neutrophils|macrophages|absence of an active gcd enzyme leads to the accumulation of glccer in lysosomes of certain white blood cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|macrophages monocytes macrophage basophils lymphocytes|macrophages|the surface of almost all nucleated cells , and mhc class ii , expressed constitutively on professional antigen presenting cells ( apc ) , including entity and dendritic cells .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|macrophages cytokines cytokine intracellular dendritic|monocytes macrophages ctls tils tregs|macrophages|growth factor receptors known as her2 and her3 , as well as recruit immune killer cells , such as nk cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clonal mature cell new cd5|mature proliferating precursor primitive immature|plasmablasts|promising approach for the treatment of rrmm patients due to the restriction of bcmas expression solely on the surface of entity and differentiated plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|clonal mature cell new cd5|these they lymphocytes that samples|plasmablasts|entity are highly enriched for vaccine-specific b cells and , therefore , negligible in pre-vaccination , day 0 samples .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1), ('DRUG', 1)])|cell|clonal mature cell new cd5|lymphocytes autoantibodies antibodies cd20 immunoglobulins|plasmablasts|disease , and other conditions such as kidney transplant , are associated with autoantibodies secreted by a subset of b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|clonal mature cell new cd5|cells lymphocytes cell follicular lymphomas|plasmablasts|cd19 is a cell surface molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|clonal mature cell new cd5|expression repertoire populations cells responses|plasmablasts|we presented data from the study demonstrating that our vaccine elicited a significant expansion of mucosal homing receptor entity to approximately 60% of all activated b cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|clonal mature cell new cd5|they biomarkers these concentrations markers|plasmablasts|if entity are elevated in a particular sample , we then employ a multi-step process to generate a potential product candidate .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1), ('DRUG', 1)])|cell|clonal mature cell new cd5|lymphocytes autoantibodies antibodies basophils cd20|plasmablasts|other conditions such as kidney transplant desensitization , are associated with autoantibodies secreted by a subset of immune b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|clonal mature cell new cd5|lymphocytes autoantibodies antibodies macrophages basophils|plasmablasts|in the autoantibody pathway , autoantibodies are secreted by a subset of immune system b cells known as entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clonal mature cell new cd5|responses markers findings biomarkers antigens|plasmablasts|we believe these mucosal entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|clonal mature cell new cd5|cells lymphocytes clones cell phenotype|plasmablasts|in in vitro studies using human immune cells , cpi-006 led to activation of b cells and differentiation into antibody producing entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|clonal mature cell new cd5|cells lymphocytes cell follicular centers|plasmablasts|cd19 is a molecule broadly expressed on b cells , including some antibody-secreting entity and plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|clonal mature cell new cd5|lymphocytes macrophages autoantibodies monocytes cells|plasmablasts|mechanism of action a number of autoimmune diseases , including nmosd , are associated with autoantibodies secreted by entity and some plasma cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|clonal mature cell new cd5|they these cytokines this titers|plasmablasts|we believe entity are a key indicator of a protective mucosal immune response and a unique feature of our vaccines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|clonal mature cell new cd5|cd3 cd4 cd14 exosomes cd8|plasmablasts|pbmcs were collected at day 0 and day 7 , enriched for entity and analyzed in elisas against either the prefusion or the postfusion version of the f protein antigen .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|clonal mature cell new cd5|cd19 tregs autoantibodies cd20 tfh|plasmablasts|for those patients , we then examine their samples for rare antibody-producing b cells called entity that are elevated during an active immune response .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|clonal mature cell new cd5|cells lymphocytes clones antibodies leukocytes|plasmablasts|we start by isolating single entity and determining the sequences of the co-expressed antibody genes using our proprietary immune repertoire capture® technology .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|pericytes vessels vessel neurovascular junction|monocytes pericytes lymphocytes chondrocytes keratinocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 2)])|cell|pericytes vessels vessel neurovascular junction|pericytes macrophages fibroblasts neovascularization microglia|pericytes|in wet amd abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|pericytes vessels vessel neurovascular junction|they macrophages cells pericytes fibroblasts|pericytes|entity then intimately cover the outside of these blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|pericytes fibroblasts collagen capillaries myofibroblasts|pericytes|these normal , blood vessel endothelial cells have matured , and have much greater supporting structures such as entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|they chemokines cytokines platelets macrophages|pericytes|entity locally supply the endothelial cells with growth and survival factors , including vegf , and play a major role in endothelial cell survival .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|they melanomas tumors these melanocytes|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for anti-endoglin antibodies
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|cells pericytes sutures capillaries endothelium|pericytes|after the entity are stripped from the new blood vessels , endothelial cells located inside the newly formed blood vessels are left unprotected and
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|pericytes vessels vessel neurovascular junction|cells fibroblasts platelets pdgf hscs|pericytes|the binding of pdgf provides an important cell survival signal to entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|pericytes vessels vessel neurovascular junction|11 31 13 16 19|pericytes|function of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal cells ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|they vessels cells could might|pericytes|entity also physically support and stabilize the abnormal new blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|pericytes vessels vessel neurovascular junction|31 11 13 16 21|pericytes|of multiple growth factors involved in blood vessel formation and angiogenesis in the retina while sparing key retinal -21- cells ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|pericytes vessels vessel neurovascular junction|resistance angiogenesis vegf hypoxia neovascularization|pericytes|this increased resistance to vegf inhibitors is thought to be related to the presence of entity as a result of cancers up-regulating other angiogenesis pathways including those involving pdgfrβ .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|pericytes vessels vessel neurovascular junction|pericytes macrophages fibroblasts leukocytes platelets|pericytes|( va ) from baseline over time abnormal new blood vessels are predominantly made up of two cell types , endothelial cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|pericytes epcs macrophages myofibroblasts vsmcs|pericytes|pdgfrβ signaling is responsible for recruiting cells called entity which play a key role in the development and stabilization of blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|pericytes vessels vessel neurovascular junction|pericytes fibroblasts macrophages leukocytes neutrophils|pericytes|pdgf also recruits entity to the abnormal new blood vessel , where they mature and cover the endothelial cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|pericytes vessels vessel neurovascular junction|they melanomas tumors melanocytes these|pericytes|entity are not targeted by vegf inhibitor therapies , but because they express endoglin , they are an additional target for endoglin 13
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|pericytes vessels vessel neurovascular junction|cells pericytes sutures macrophages platelets|pericytes|after the entity are stripped from the new blood vessels , endothelial cells lining the inside of the newly formed blood vessels are left
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|pericytes vessels vessel neurovascular junction|monocytes pericytes lymphocytes chondrocytes keratinocytes|pericytes|in contrast , svf is merely a heterogeneous fraction including preadipocytes , endothelial cells , smooth muscle cells , entity , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|pericytes vessels vessel neurovascular junction|pericytes myofibroblasts fibroblasts epcs macrophages|pericytes|in addition , the impact of vegf inhibitors may be limited by the activity of entity , which are the cells that cover the outside of blood vessels and support and stabilize newly formed vessels .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|lymphocytes monocytes neutrophils granulocytes leukemias|granulocytes|the enzyme tyrosine kinase in the bone marrow , which causes too many stem cells to develop into white blood cells ( entity or blasts ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|aml blasts ips osteoclasts hscs|granulocytes| enables aml blast cells to differentiate into entity and may be applicable in a broad range of aml patients .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|cell cells granulocytes lymphocytes granulocyte|neutrophils lymphocytes macrophages eosinophils granulocytes|granulocytes|oncology biosimilar udenyca™ stimulates production of entity ( a type of white blood cell ) in order to promote the bodys ability to fight infections .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5)])|cell|cell cells granulocytes lymphocytes granulocyte|csf saliva feces stool erythrocytes|granulocytes|for up to two years after treatment , as well as preliminary efficacy as measured by changes in cystine levels in entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|lymphocytes neutrophils basophils tregs eosinophils|granulocytes|of naive and activated immune system cells , including cd4+ and cd8+ t effector cells , t regulatory cells , natural killer cells , entity , mast cells and monocytes / macrophages .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|monocytes neutrophils lymphocytes granulocytes microglia|granulocytes|responses detected in treated pts  klh carrier as immune stimulant  gm-csf stimulates entity and macrophages antigen binding site = idiotype ( id ) biovaxld : id-klh + gm-csf  first in a
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells granulocytes lymphocytes granulocyte|cells granulocytes lymphocytes leukocytes neutrophils|granulocytes|in apl , there is an abnormal accumulation of immature entity called promyelocytes .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|neutrophils leukocytes fibrinogen monocytes erythrocytes|granulocytes|soluble fibrin and formed elements in the blood , maintains the deformability of red blood cells , non-adhesiveness of unactiviated platelets and entity and the normal viscosity of blood .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|monocytes neutrophils granulocytes lymphocytes microglia|granulocytes|immune cells recruited by the antibody to kill the cancer include entity , macrophages and nk cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells granulocytes lymphocytes granulocyte|granulocytes cells leukocytes neutrophils lymphocytes|granulocytes|cml is a clonal bone marrow stem cell disorder in which proliferation of mature entity ( neutrophils , eosinophils , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|cell cells granulocytes lymphocytes granulocyte|complement gentamicin lps colistin gp120|granulocytes|in an animal model of infection , the antibacterial activity of sivextro was reduced in the absence of entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|neutrophils eosinophils neutrophil basophils granulocytes|granulocytes|mg / kg alx377 in mouse models and measured red blood cell , or rbc , platelet and white blood cell ( lymphocyte , monocytes and entity ) counts .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|monocytes neutrophils granulocytes lymphocytes microglia|granulocytes|gm-csf stimulates the growth and differentiation of entity and macrophages .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|lymphocytes neutrophils basophils macrophages granulocytes|granulocytes|however , cll-1 is also expressed on normal hematopoietic cells such as entity and monocytes .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 4), ('BIO', 1), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|blasts aml monocytes osteoclasts lineages|granulocytes|aslan003 has demonstrated the ability to differentiate aml blast cells into entity in a variety of aml cell lines that do not respond to atra .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell cells granulocytes lymphocytes granulocyte|neutrophils monocytes erythrocytes platelets granulocytes|granulocytes|evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , metamyelocytes and entity ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cell cells granulocytes lymphocytes granulocyte|granulocytes cells granules leukocytes neutrophils|granulocytes|in aml , blast cells are unable to differentiate and form entity , such as neutrophils and eosinophils , causing depletion of white blood cells .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells granulocytes lymphocytes granulocyte|neutrophils monocytes basophils macrophages granulocytes|granulocytes|lymphocytes : the white blood cells ( leukocytes ) that include the b cells and t cells , but not the others ( such as entity and eosinophils ) .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|cell cells granulocytes lymphocytes granulocyte|osteoclasts osteoblasts adipocytes erythroid macrophages|granulocytes|the lead compound , lg7455 , activates the gcsf-gcsfr signaling pathway and induces the differentiation of human bone marrow cells into entity .
OrderedDict([('OTHER', 5), ('BIO', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|cell cells granulocytes lymphocytes granulocyte|lymphocytes lymphoid myeloid erythroid monocytes|granulocytes|clone 818-18 produces a murine igg1 monoclonal antibody which recognizes a nuclear antigen expressed in human entity and myeloid precursors and acute and chronic myeloid leukemia .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|tregs macrophages th17 eosinophils monocytes|eosinophils|it has also been shown to impact some diseases , such as asthma , that are driven by entity , another important class of immune cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils basophils macrophages ige neutrophils|eosinophils|despite the knowledge that entity and mast cells drive many pathological conditions , there are no approved therapies that selectively target both entity and mast cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|ige basophils eosinophils macrophages neutrophils|eosinophils|believes that it is helpful to provide investors with an overview of the types of diseases that are affected by entity and / or mast cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|basophils macrophages eosinophils neutrophils lymphocytes|eosinophils|ak002 binds to siglec-8 , an inhibitory receptor found on entity and mast cells , which represents a novel way to selectively deplete or inhibit these important immune cells and thereby resolve
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils lymphocytes neutrophils leukocytes cells|eosinophils|eg is a rare disease that is characterized by chronic inflammation due to patchy or diffuse infiltration of entity into layers of the stomach .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils monocytes lymphocytes platelets eosinophil|eosinophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , entity , and basophils ) and their precursors is the main finding .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|microglia macrophages monocytes astrocytes neutrophils|eosinophils|in ad , entity are important effector cells that promote inflammation and tissue damage .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|expressed macrophages upregulated also increased|eosinophils|eotaxin-1 is expressed on type 2 t helper ( “th2” ) cells and entity in bp lesions and an increasing body of data documents the role of these cells in both the innate and
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|infiltrating reactive cd4 activated cells|eosinophils|** ** prs-060 48-hr 1 1006 ** * 0 total macrophages entity lymphocytes 48hr timepoint anticaln control *p 34 . 5 µm 60?
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|lymphocytes neutrophils monocytes platelets leukocytes|eosinophils|entity are a type of white blood cell .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils neutrophils leukocytes monocytes granulocytes|eosinophils|bertilimumab may prevent eotaxin-1-induced chemotaxis of entity and neutralize eotaxin-1 in the circulation , preventing eosinophil migration .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|biomarkers troponin cardiotoxicity lvef suspicion|eosinophils|cardiac screening should be considered in patients with hes / cel , and patients with mds / mpd with high level of entity ( echocardiogram , serum troponin level ) .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils neutrophils leukocytes lymphocytes basophils|eosinophils|background on eoe and current treatments eoe results from a dysregulation of th2-mediated immunity that drives recruitment of entity to the esophagus .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|th1 lymphocytes macrophages cd4 nk|eosinophils|provided data on the mechanism of anticancer activity for il-17e , showing that il-17e activated the immune system , specifically acting on entity and b cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|monocytes eosinophils platelets lymphocytes macrophages|eosinophils|in aml , blast cells are unable to differentiate and form granulocytes , such as neutrophils and entity , causing depletion of white blood cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|neutrophils eosinophils macrophages basophils tregs|eosinophils|importantly , and in contrast to other agents , hgen005 appears to have an effect solely on entity , without impacting other populations , such as mast cells .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|samples sampling draws tests sample|eosinophils|outcomes associated with asthma symptoms , as measured using the asthma control questionnaire 5 and biomarker levels as measured using blood entity .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils neutrophils basophils leukocytes granulocytes|eosinophils|eotaxin  a protein that attracts entity into tissues , where they degranulate and cause tissue damage .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|monocytes lymphocytes eosinophils monocyte microglia|eosinophils|in addition to the effects on neutrophils and cytokines , a trend towards reduction in other immune cells in sputum , namely entity and macrophages , was also observed .
OrderedDict([('OTHER', 4), ('DIS', 4), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|eosinophils eosinophil eosinophilic eosinophilia neutrophils|eosinophils leukocytes cells lymphocytes neutrophils|eosinophils|wo 97 / 00960 also discloses methods of use of the eotaxin proteins in the recruitment of entity to a particular site or in the treatment of allergic conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|saline erythrocytes erythrocyte intact water|proteins compounds molecules substances genes|erythrocytes|we are aware of an issued patent outside the united states that is directed to entity that comprise exogeneous polypeptides .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|saline erythrocytes erythrocyte intact water|platelets erythrocytes lymphocytes cells granulocytes|erythrocytes|shown that our imids ( r ) can interact with stem cells and modulate them in such a way that they differentiate into entity , or red blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|saline erythrocytes erythrocyte intact water|cells lymphocytes neurons oocytes spermatozoa|erythrocytes|dna , genes , and transcription factors dna is present in all cells , except mature entity , and encodes the inherited characteristics of all living organisms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|saline erythrocytes erythrocyte intact water|high low optimal highest peak|erythrocytes|ra101495 protects against complement-mediated hemolysis of type dose response iii pnh entity drug concentration no drug ra101495
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|saline erythrocytes erythrocyte intact water|cells carriers donors molecules units|erythrocytes|bilirubin entity ( red blood cells ) circulating in the blood stream have a life expectancy of 120 days .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|saline erythrocytes erythrocyte intact water|platelets lymphocytes monocytes leukocytes macrophages|erythrocytes|these cells have a limited life span ; neutrophils live a few hours and entity or red blood cells survive for a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|saline erythrocytes erythrocyte intact water|neutrophils erythrocytes monocytes granulocytes platelets|erythrocytes|with an increased likelihood of sle . test method description results were obtained using flow cytometry for complement c4d fragment bound to entity ( ec4d ) and b-lymphocytes ( bc4d ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes rbcs mitochondria neutrophils haemoglobin|erythrocytes|and inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ; red cells that carry oxygen through our bodies ( entity ) ; and platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes capillaries cells bubbles vesicles|erythrocytes|the entity are then separated from the other blood compounds and opened by osmotic hemolysis , thus releasing the hemoglobin molecules .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|brain muscle tissues kidneys liver|erythrocytes|drugs like ribavirin to infected liver cells while reducing the amount of drug going to other cells and tissues , including entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes platelets rbcs neutrophils leukocytes|erythrocytes|up to 20 percent of the eculizumab-treated population , is most commonly attributable to extravascular hemolysis driven by intense c3 deposition on entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes rbcs mitochondria neutrophils haemoglobin|erythrocytes|inflammations ( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|half all cells most exclusively|erythrocytes|the nine month post-infusion data point , with total hemoglobin levels of 11 . 9 g / dl , 10 . 1 g / dl fetal hemoglobin and 99 . 8 percent f-cells ( entity expressing fetal hemoglobin ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|saline erythrocytes erythrocyte intact water|monocytes fibroblasts macrophages melanomas platelets|erythrocytes|( hsa ) , a glycoprotein expressed on the surface of many human cell types , including immature human hematopoietic cells , peripheral blood lymphocytes , entity , and many human carcinomas .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|saline erythrocytes erythrocyte intact water|parasites macrophages spleen monocytes hepatocytes|erythrocytes|strong cell mediated immunity ( e . g . th1 biased cd4+ ad cd8+ ) to reduce parasitemia by clearing infected cells ( liver cells or entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DIS', 1), ('DRUG', 1)])|cell|saline erythrocytes erythrocyte intact water|hematocrit nitrite glutathione albumin platelets|erythrocytes|blood : this test is based on the pseudo peroxidase action of hemoglobin and entity which catalyzes the reaction of 3 , 3 , 5 , 5-tetramethyl-benzidine and buffered organic peroxide .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|saline erythrocytes erythrocyte intact water|they that but which people|erythrocytes|it provides vital oxygen supplies to places in the human body entity cannot reach for instance due to arterial sclerosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes rbcs mitochondria haemoglobin neutrophils|erythrocytes|( leukocytes ) and form the basis of the immune system ( lymphocytes ) ;  red cells that carry oxygen through our bodies ( entity ) ; and  platelets that help blood to clot .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes erythrocyte c5 cells platelets|erythrocytes|for example , the deposition of the c4d fragment to entity forms erythrocyte c4d , or ec4d .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|saline erythrocytes erythrocyte intact water|erythrocytes platelets sera rbcs igg|erythrocytes|unlike cd47-blocking antibodies , tti-622 bound minimally to human entity and did not induce hemagglutination in vitro .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|liver hepatocytes tissue macrophages hepatocyte|hepatocytes|target of 10% enzyme replacement at all doses in otc-deficient mouse model lunar-otc treatment increases otc expression in mouse periportal entity ( main site of ureagenesis )
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|neurons fibroblasts hepatocytes pbmc chondrocytes|hepatocytes|in the companys preclinical studies , transduction of primary human entity with aavs3 pseudotyped vectors was significantly higher as compared with the other vectors listed above .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|humans question particular vivo vitro|hepatocytes|our initial focus is on monogenic diseases with clear biology linking the missing activity of a gene in entity to a disease outcome .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cells hepatocytes macrophages membranes surface|hepatocytes|the polymer is targeted to the asialoglycoprotein receptor on liver entity by the inclusion of a galnac moiety to one end of the polymer .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cells cell fibroblasts chondrocytes mscs|hepatocytes|improvements in the function of our immortalized entity will open more markets and expand the usage in the current markets for our cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|mice humans cells neurons fibroblasts|hepatocytes|mrt5201 , is designed to address the underlying cause of otc deficiency by delivering mrna encoding fully functional otc enzyme to entity through intravenous administration .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|tissue tissues hepatocytes cells liver|hepatocytes|have shown that the rap receptor , lrp1 , is well expressed on human hcc and under-expressed on non-cancerous , but otherwise diseased , entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cells macrophages fibroblasts biopsies microsomes|hepatocytes|we recently demonstrated that liver entity show a rapid , primary nf-kb activation response following in vivo administration of cblb502 in mice and nhps .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|tissues individuals cells populations conditions|hepatocytes|however , combining multiple interventions , particularly multiple small molecules , places an additional burden of drug metabolism and clearance upon already stressed entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|hepatocytes hepatocyte fibroblasts liver mitochondria|hepatocytes|these cells have been shown to retain many key synthetic and metabolic processes of normal human entity , the primary functional cell of the liver .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|microsomes enzymes cells tissue extracts|hepatocytes|pmx-30063 has been tested for stability in the presence of mouse and human liver entity to investigate the extent to which liver metabolism could be a factor upon compound administration .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|enzymes microsomes enzyme tissue cirrhosis|hepatocytes|pmx-30063 demonstrated high stability in the presence of liver entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|biopsies cells lesions hepatocytes islets|hepatocytes|percentage of entity showing steatosis , or fatty change , mean ± sd ( n ) 54 . 8 ± 21 . 2 49 . 9 ± 24 . 3
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cognition memory swallowing neurogenesis neurotransmission|hepatocytes|it has been previously demonstrated that impairment of entity by ethanol is associated with the production of free radical and oxidative stress .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cells cell cultures fibroblasts hscs|hepatocytes|these efforts have been towards improving the functionality of our immortalized entity , introducing products utilizing these cells and expanding our intellectual property base .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|cells hepatocytes organoids xenografts tissue|hepatocytes|our liversafe 3d™bioassay system uses our stem cell-derived entity , or liver cells .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|neurons astrocytes brain muscle adipocytes|hepatocytes|for example , the asg receptor exists primarily in entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|aggregates themselves plaques lysosomes granulomas|hepatocytes|patient has a mutation in both copies of the serpina1 gene , which causes aat to aggregate inside liver cells , or entity , rather than being secreted from the liver .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|mitochondria cells adipocytes hepatocytes fibroblasts|hepatocytes|entity are the most biochemically complex cells in the human body and play an important role in the synthesis and metabolism
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hepatocellular intrahepatic tubular hepatocytes carcinomas|hepatocytes macrophages hepatocyte enterocytes cells|hepatocytes|apoptosis of entity manifests as ballooning of the cells , a characteristic microscopic feature of nash liver tissue .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|mature megakary immature maturation differentiation|platelets hscs neutrophils osteoblasts epcs|megakaryocytes|lx-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|mature megakary immature maturation differentiation|platelets erythrocytes cardiomyocytes epcs hscs|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hescs or ipscs as the starting materials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|mature megakary immature maturation differentiation|ipscs osteoclasts tregs ips hscs|megakaryocytes|in addition , bet proteins promote the generation of entity from hematopoietic stem cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mature megakary immature maturation differentiation|platelets erythrocytes cells fibroblasts hscs|megakaryocytes|we have developed a manufacturing process for generating entity , proplatelet forming cells and ultimately platelets using either hes or ips cells as the starting materials .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|mature megakary immature maturation differentiation|platelets hscs neutrophils leukocytes monocytes|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelet counts .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|macrophages neutrophils monocytes hscs leukocytes|megakaryocytes|we believe that the blood cells most responsible for bone marrow scarring in mf are dysfunctional entity , which produce inflammatory molecules in part through elevated nf-kb signaling .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|progenitors platelets lymphocytes hematopoiesis malignancies|megakaryocytes|the angiopoietins are in preclinical studies for their abilities to promote growth and mobilization of hemopoietic stem cells and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|mature megakary immature maturation differentiation|hematopoiesis genetics epigenetics leukemias leukaemia|megakaryocytes|an editorial entitled , myelodysplasia , entity , and methylation was also published in the same issue of leukemia research ( steensma , leuk .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mature megakary immature maturation differentiation|platelets hepatocytes liver monocytes erythrocytes|megakaryocytes|precursors of the red blood cells or of the granulocytes and macrophages , which are also of the immune system , and entity , which produces platelets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mature megakary immature maturation differentiation|platelets neutrophils hscs leukocytes tpo|megakaryocytes|tpo-ras , like tpo , stimulate the activation , proliferation and maturation of entity , resulting in an increase in circulating platelets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mature megakary immature maturation differentiation|they platelets neutrophils leukocytes basophils|megakaryocytes|entity normally function to produce platelets , which are small blood cells involved in blood clotting .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|neutrophils monocytes granulocytes macrophages leukocytes|megakaryocytes|entity , which are large cells found in the bone marrow , are the source of platelets that are released into the bloodstream .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|mature megakary immature maturation differentiation|hscs platelets cd34 neutrophils apc|megakaryocytes|these cells , known as entity , are found in the bone marrow and are the precursor cells to platelets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|mature megakary immature maturation differentiation|progenitors platelets both hscs monocytes|megakaryocytes|specifically , jak2 activation leads to proliferation of red blood cell progenitors and platelet progenitors , or entity , that fail to mature to platelets .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|mscs bmscs hscs chondrocytes cells|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow ,
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|mature megakary immature maturation differentiation|platelets they neutrophils monocytes these|megakaryocytes|entity are the bone marrow cells that give rise to blood platelets . 13 about eltrombopag eltrombopag was given accelerated approval by the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|platelets neutrophils hepatocytes hematopoiesis leukocytes|megakaryocytes|itp can also result in damage to entity , leading to impaired platelet production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|mature megakary immature maturation differentiation|differences individuals species people them|megakaryocytes|we could not readily identify entity in our conditions on morphological grounds despite some effort with mgdf and therefore do not know which of our sampled
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|mature megakary immature maturation differentiation|mscs bmscs hscs cells chondrocytes|megakaryocytes|the inability of entity to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow , which further exacerbates the
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|podocyte podocytes kidney cell glomeruli|podocytes|inhibition of calcineurin within the entity can prevent the dephosphorylation of synaptopodin which in turn inhibits the degradation of the actin cytoskeletion within the podocyte .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|hippocampus genome synapse brain cns|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity : 931-8 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|vasculature microenvironment cells endothelium ecm|podocytes|additionally , recent evidence suggests that inhibition of calcineurin has direct physical impacts on the entity within the kidney .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|antibody antibodies immunoglobulin agents igg|podocytes|voclosporin also potentially stabilizes disease modifying entity , which protects against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|podocytes podocyte mice proteinuria glomeruli|podocytes|( a and b ) gl-3 reduction in entity was closely paralleled by a reduction in podocyte volume .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|cell genome bbb body hippocampus|podocytes|immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity 8 of the entity : 931-8 .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|albumin antibodies microtubules igg iga|podocytes|voclosporin also potentially stabilizes entity , which can protect against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|igg albumin iga sm hb|podocytes|voclosporin also potentially stabilizes entity , s-12 table of contents which can protect against proteinuria .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|receptor positive expressing ar receptors|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 29 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|receptor positive expressing by ar|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 30 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|proteins milk casein erythrocytes albumin|podocytes|there were statistical trends towards associations between 24-hr urine protein and % change in gl-3 inclusion content of entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|they proteins podocytes glomeruli these|podocytes|entity form part of the barrier that enable the glomerulus to filter the blood in a manner that retains large molecules
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|humans rats diabetes glomeruli individuals|podocytes|curr pharm des 21 overactive cannabinoid 1 receptor in entity drives type 2 diabetic nephropathy .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|podocyte cell glomerular junction podocytes|macrophages podocytes monocytes fibroblasts glomeruli|podocytes|gas6 is upregulated in either endothelial / mesangial cells or entity in igan dual involvement of growth arrest-specific
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|vasculature tissues mitochondria glomeruli endothelium|podocytes|combined with reduction of local hypoxia , plxdc2 can improve the health and homeostasis of renal epithelial cells and entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|receptor positive expressing ar express|podocytes|affinity of melanocortin peptides and distribution of receptor subtypes 32 mcr prevalent tissue / cells with receptor mc3r cns macrophages mc4r entity renal mesangial cells ( ? )
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|podocyte cell glomerular junction podocytes|csf striatum neurons astrocytes gbm|podocytes|( c ) volume fraction of gl-3 inclusions in entity did not change during the 6 months migalastat treatment .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|podocyte cell glomerular junction podocytes|macrophages platelets monocytes fibroblasts others|podocytes|endothelial cells , tubular epithelial cells , cns mc5r cns , exocrine glands , lymphocytes , entity adapted from gong 2011 , catania 2004 , schioth 1997
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|podocyte cell glomerular junction podocytes|brain hippocampus bbb cns retina|podocytes|these immunologic impacts recent data suggests that cnis have another subtle but important impact on the structural integrity of the entity .
OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|podocyte cell glomerular junction podocytes|podocytes pericytes fibroblasts myofibroblasts podocyte|podocytes|fsgs is understood to start with damage to entity , cells that wrap around capillaries of the glomerulus .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|monocytes basophils lymphocytes macrophages leukocytes|basophils|neutrophils , eosinophils and entity , which are types of mature leukocytes , are normally formed only in the bone marrow and are stored there until they
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|basophils eosinophils lymphocytes leukocytes basophil|bind against contain express bound|basophils|high affinity anti-human ige- 12 / 31 / 87 s / n 140 , 036 u . s . monoclonal antibody which bind to igge-bearing b cells and not entity tnx87-12a change et al .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|monocytes basophils lymphocytes platelets macrophages|basophils|cml is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes ( neutrophils , eosinophils , and entity ) and their precursors is the main finding .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|lymphocytes basophils tregs eosinophils nkt|basophils|vista is an immunoregulatory receptor and is highly expressed on various immune system cells including neutrophils , monocytes , macrophages , entity and dcs .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|basophils eosinophils lymphocytes leukocytes basophil|lymphocytes cultures fibroblasts leukocytes cells|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic 50 of approximately 1 . 5 nm , which is approximately 15-fold greater
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|basophils eosinophils lymphocytes leukocytes basophil|against bind binds bound murine|basophils|high affinity anti-human ige- 7 / 29 / 88 s / n 226 , 421 u . s . monoclonal antibody which binds to ige-bearing b cells and not entity tnx87-12aa chang et al .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages eosinophils neutrophils monocytes|basophils|e25 blocks ige from binding to mast cells and entity , thereby inhibiting the allergic response .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|basophils eosinophils lymphocytes leukocytes basophil|cultures lymphocytes fibroblasts cells neutrophils|basophils|anb020 inhibits secretion of il-5 from primary entity purified from peripheral blood of healthy subjects with an ic50 of approximately 1 . 5 nm , which is approximately 15-fold greater than
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|macrophages eosinophils lymphocytes neutrophils fibroblasts|basophils|mast cells , entity , goblet cells and other cells also play a role .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages lymphocytes monocytes eosinophils|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity through specific ige receptors on the cell surface .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils eosinophils macrophages lymphocytes neutrophils|basophils|pci-32765 is a potent inhibitor of histamine release ( also known as degranulation ) from mast cells and entity , which are specific immune cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages eosinophils lymphocytes leukocytes|basophils|to the antigen , or allergen in this case , by producing ige . ige binds to the surface of mast cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages eosinophils lymphocytes monocytes|basophils|these ige molecules attach to the surfaces of mast cells or entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages eosinophils lymphocytes neutrophils|basophils|and masking the binding site for the ige receptor which prevents ige from binding to and arming mast cells and entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|cells lymphocytes leukocytes eosinophils basophils|basophils|similarly , calcium ions also play a central role in the activation and degranulation of tissue mast cells and circulating counterpart entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages eosinophils lymphocytes monocytes|basophils|these ige molecules circulate in the blood stream and find their way to attach to the mast cells or entity , thereby arming these cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|macrophages neutrophils lymphocytes granulocytes eosinophils|basophils|in animal models that ccr2 is important for host defense , inflammation and immunity mediated through hematopoietic cells including monocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils neutrophils lymphocytes macrophages monocytes|basophils|siglec-8 is an inhibitory receptor located selectively on eosinophils , mast cells and , to a lesser extent , on entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils eosinophils macrophages neutrophils monocytes|basophils|omalizumab works by binding to the immune mediator immunoglobulin e , or ige , and inhibiting ige-mediated activation of mast cells and entity , types of white blood cells .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|basophils eosinophils lymphocytes leukocytes basophil|basophils macrophages lymphocytes keratinocytes chondrocytes|basophils|cd123 is also expressed by plasmacytoid dendritic cells , or pdcs , entity , endothelial cells and , to a lesser extent , monocytes and eosinophils .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|cells fibers fibres neurons nerves|neurons|in parallel , electrophysiology recordings of single ganglion entity that innervate the craniofacial muscles were performed ( 33 masticatory muscle mechanoreceptors ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons cells nerves neurones tissues|neurons|amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons cells enzymes proteins muscles|neurons|these entity are responsible for producing dopamine , an essential brain signaling chemical , or neurotransmitter , that enables smooth , coordinated movements of both voluntary
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|network intrinsic neurons single integration|cells cell photoreceptors nuclei neurons|neurons|these results suggest that the photoreceptor entity and pigmented retinal epithelial cells  cell types that are both lost in ga  are sandwiched between deposits of
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons cells they nerves muscles|neurons|as a result , entity are unable to respond to normal stimuli and can become over-stimulated by a neurotransmitter or be unable to respond to
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|network intrinsic neurons single integration|neurons brain synapses cells neurites|neurons|in ad , tau protein is misfolded , becomes hyperphosphorylated and aggregates into neurotoxic oligomers that ultimately form neurofibrillary tangles within entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons cells axons fibers neurones|neurons|these symptoms are caused by the degeneration of dopaminergic entity in the substantia nigra and depletion of dopamine in the striatum .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1), ('DRUG', 1)])|cell|network intrinsic neurons single integration|neurons cells neuron memory neurotransmitters|neurons|can transition into mild , moderate and , finally , severe stages of alzheimers disease that are characterized by greater systemic loss of entity and synapses in the brain tissue .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|network intrinsic neurons single integration|neurons transmission cells neurotransmission production|neurons|parkinsons disease ( the “mptp model” ) showed that when administered orally , aeol 11207 crosses the blood brain barrier and protected dopamine entity in a dose-dependent manner .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|network intrinsic neurons single integration|brain neurons neuron cns nerves|neurons|the dendrites and axons , or nerve endings , of the entity contain an elaborate series of thin tubes , or microtubules , which serve to support them and transport nutrients down to the
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons neuron cells axons motoneurons|neurons|sma is caused by a genetic defect in the smn1 gene that codes smn , a protein necessary for survival of motor entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|network intrinsic neurons single integration|neurons cells neuron neuronal myelin|neurons|accumulation of mhtt protein causes progressive loss of entity in the brain .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|network intrinsic neurons single integration|neurons astrocytes interneurons neurones neuron|neurons|cord in commercial quantities , and the ability to control the differentiation of these cells constitutively into mature , physiologically relevant human entity and glia .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|cells neurons humans others brain|neurons|neurotoxic peptiderefers to a small protein ( called a peptide ) that can be toxic to entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|network intrinsic neurons single integration|hearing cochlea brain nerves neurons|neurons|· ep1937352 sub-threshold stimulation to precondition entity for supra-threshold stimulation – opposition hearing is scheduled for january 21 , 2015 in munich , germany .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons fibers nerves pathways neuron|neurons|limitations of current therapies als is a neurodegenerative disorder that involves gradual breakdown of motor entity leading to muscle weakness , disability , and ultimately death .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|network intrinsic neurons single integration|neurons cells motoneurons neurones oligodendrocytes|neurons|which leads to production of a mutant huntingtin protein that is thought to be neurotoxic and promote the degeneration of entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|network intrinsic neurons single integration|brain mice amygdala brainstem cns|neurons|to further demonstrate this , we utilized in vivo electrophysiology where cbn blocked the pain signals in the entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons nerves cells synapses muscles|neurons|loss of dopamine causes critical nerve cells , or entity , in the brain , to fire out of control , leaving patients unable to direct or control their movement in a normal
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|network intrinsic neurons single integration|neurons cells fibers neuron axons|neurons|about sma sma is a severe neuromuscular disease characterized by the loss of motor entity leading to progressive muscle weakness and paralysis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cardiomyopathy structural native atrioventricular studying|cardiomyocytes fibroblasts myoblasts cardiomyocyte mscs|cardiomyocytes|we have derived human entity ( grncm1 ) from hescs for the potential treatment of heart disease .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|cardiomyopathy structural native atrioventricular studying|congestive nyha refractory diastolic systolic|cardiomyocytes|cm1 – entity heart failure 6 million total patients in u . s . cells derived and characterization studies performed ( parameters analyzed showed normal cell functions
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cardiomyopathy structural native atrioventricular studying|neurons hardware cells producers users|cardiomyocytes|product sales for both 2012 and 2013 is primarily attributable to an increase in unit volume sales of our icell entity and , in 2012 , to our icell neurons .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyopathy structural native atrioventricular studying|cf refractory lv treated stage|cardiomyocytes|cm1 - entity heart failure 6 million total patients in u . s . cells derived and fully characterized ( all normal cell functions verified in vitro ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|cardiomyopathy structural native atrioventricular studying|cells therapies ipscs cardiomyocytes mscs|cardiomyocytes|gerons grncm1 program is developing hesc-derived entity for the treatment of heart failure .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cardiomyopathy structural native atrioventricular studying|cardiomyocytes myocytes fibroblasts myocardium cells|cardiomyocytes|in human entity isolated from the left ventricle of patients with end-stage heart failure , serca2a levels were correlated with improved diastolic function .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cardiomyopathy structural native atrioventricular studying|cardiomyocytes myocardium myocytes hearts ventricles|cardiomyocytes|isolated entity from aav-s100a1 treated pig heart showed superior systolic and diastolic performance .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cardiomyopathy structural native atrioventricular studying|cardiomyocytes myocardium hearts myocytes vivo|cardiomyocytes|moreover , old g5terc-null mice exhibited shorter telomeres in entity than did younger counterparts , and this led to ventricular dilation , page .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cell|cardiomyopathy structural native atrioventricular studying|proteins therapies cells peptides treatments|cardiomyocytes|the targeted entity are expected to produce sustained therapeutic protein levels in the myocardium where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyopathy structural native atrioventricular studying|skeletal smooth muscle limb lung|cardiomyocytes|such cells include entity or heart muscle cells , neural cells , hepatic cells and pancreatic ( logo ) islet cells .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cardiomyopathy structural native atrioventricular studying|cells embryos ipscs erythrocytes cartilage|cardiomyocytes|the first product developed under the alliance , human entity derived from hescs , was launched in october 2010 by gehc .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cardiomyopathy structural native atrioventricular studying|hearts cardiomyocytes myocardium ventricles ventricle|cardiomyocytes|specific precursor cells which , together with a specific combination of growth factors , develop full culture wells of functional , beating human entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cardiomyopathy structural native atrioventricular studying|myocytes cells cardiomyocytes fibroblasts vesicles|cardiomyocytes|the product is predominantly composed of ventricular entity which have been shown to electrically and mechanically couple to the animal myocardium in which they are injected and contract
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cardiomyopathy structural native atrioventricular studying|cells genes embryos ipscs tissues|cardiomyocytes|u . s . patent no . 7 , 425 , 448 was issued to geron with broad claims to entity derived from hescs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('BIO', 1)])|cell|cardiomyopathy structural native atrioventricular studying|cells vaccines therapeutics therapies vectors|cardiomyocytes|that asterias will reach an agreement for support in the manufacture of vac2 or the development of hes cell derived entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cardiomyopathy structural native atrioventricular studying|cardiomyocytes cms hc mscs hcm|cardiomyocytes|heart muscle cells ( entity ) do not regenerate during adult life .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cardiomyopathy structural native atrioventricular studying|fibroblasts cardiomyocytes hepatocytes collagen myofibroblasts|cardiomyocytes|dbcm is caused by metabolic derangements in entity that result in cell death and fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cardiomyopathy structural native atrioventricular studying|mscs cells fibroblasts cytokines exosomes|cardiomyocytes|cm1 , hes cell-derived entity , have been extensively characterized in vitro and in vivo .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cell|cardiomyopathy structural native atrioventricular studying|hc hesc hcs hescs hpc|cardiomyocytes|we used our hpsc-derived entity ( human heart cells ) in cardiosafe 3d™ , our novel , customized in vitro bioassay system for predicting potential cardiotoxicity of drug rescue
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cardiomyopathy structural native atrioventricular studying|both cells neurons more fibroblasts|cardiomyocytes|today we have entity , two types of neural cells -- dopaminergic neurons and oligodendrocytes -- and hematopoietic cells in animal models , and we hope
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|chondrocytes keratinocytes cardiomyocytes myofibroblasts pericytes|keratinocytes|these supported isolation , expansion and long-term culture of entity , fibroblasts , smooth muscle cells and mesenchymal stem cells .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes macrophages leukocytes fibroblasts neutrophils|keratinocytes|il-17 binding to il-17ra on entity stimulates and perpetuates the inflammation cascade of psoriasis .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|keratinocyte cell keratinocytes cells cellular|cells keratinocytes lesions tissue tissues|keratinocytes|believes that the therapeutic utility of 2-cdap in psoriasis would result from its ability to gain direct access to hyperproliferating entity in a form that would be rapidly effective .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes melanocytes lymphocytes keratinocyte epithelial|keratinocytes|apligraf contains living human skin cells , entity and fibroblasts , organized in an epidermal and dermal layer .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes melanocytes fibroblasts cells lymphocytes|keratinocytes|hyperproliferation of entity contributes to psoriasis , and work by sugen and others has demonstrated that egf tk signalling is required for the growth of entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes melanocytes fibroblasts cells keratinocyte|keratinocytes|hemidesmosome formation also occurs during normal differentiation of entity as they mature from the basal layer , not only in a wound-healing situation .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|hpv when papillomavirus lesions virus|keratinocytes|etiology – entity infected by human papillomavirus ( hpv ) ; manifests as common warts , plantar warts or genital warts virus spreads via direct contact or
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes fibroblasts cells melanocytes keratinocyte|keratinocytes|revitix provides a more complete array of growth factors than those produced by dermal fibroblasts or epidermal entity alone , which helps to speed the healing process of skin .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|epidermis dermis cornea retina sun|keratinocytes|tanning is mediated by melanocytes producing melanin , which is subsequently transferred to the entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocyte cell keratinocytes cells cellular|cells keratinocytes lesions epidermis keratinocyte|keratinocytes|in in vitro skin models , p529 was shown to inhibit keratinocyte proliferation ( growth of entity ) and induce apoptosis ( cause death of hyperproliferating entity ) .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|dermis epidermis keratinocytes cells macrophages|keratinocytes|in preclinical studies , xcur17 inhibited il-17ra in the entity of the skin .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes melanocytes fibroblasts lymphocytes keratinocyte|keratinocytes|entity are the most abundant cells in the epidermis and account for 80 to 90% of the total epidermal cellular population .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocyte cell keratinocytes cells cellular|ak keratinocytes cells fibroblasts ks|keratinocytes|kx-01 inhibits the proliferation of entity and up-regulates p53 so its utility in clinically treating ak was of interest .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes fibroblasts melanocytes myofibroblasts crypts|keratinocytes|the epidermis is comprised mainly of cells known as entity that are continually regenerated and move toward the skin surface where they flatten , lose their nucleus , and become the outermost
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|keratinocyte cell keratinocytes cells cellular|cells fibroblasts melanocytes hepatocytes progenitors|keratinocytes|this exposure can lead to oncogenic changes , such as inactivation of p53 , and consequential hyper-proliferation of mutated entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes melanocytes fibroblasts lymphocytes cells|keratinocytes|entity are the predominant cell type in the epidermis , the outermost layer of the skin .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes keratinocyte fibroblasts fibroblast melanocytes|keratinocytes|first , il-8 is produced by a type of skin cell called entity , and is a potent growth factor for these skin cells .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|keratinocyte cell keratinocytes cells cellular|inflammation psoriasis angiogenesis vegf cytokines|keratinocytes|as p529 has been shown to inhibit neovascularization , together with its effect on entity , p529 is expected to show activity in psoriasis and atopic dermatitis .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes fibroblasts macrophages lymphocytes melanocytes|keratinocytes|barrier function and inflammation in atopic dermatitis the most abundant cells in the epidermis are entity , shown in figure 16 below .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|keratinocyte cell keratinocytes cells cellular|keratinocytes fibroblasts melanocytes myofibroblasts crypts|keratinocytes|the epidermis is comprised mainly of cells known as entity which are continually regenerated and move toward the skin surface where they flatten , loose their nucleus and become the outermost
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|macrophages astrocytes neuroinflammation chemokines neurons|astrocytes|the chronic activation of microglia and entity has been implicated as an important disease mechanism in huntingtons disease , progressive ms , and other neurodegenerative disorders .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|microglia macrophages leukocytes inflammation monocytes|astrocytes|when innate immune dysfunction causes chronic inflammation , activated microglial cells produce soluble tnf that activates entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|interneurons astrocytes neurons motoneurons axons|astrocytes|in addition , the target cells , motor neurons and entity , or cells supporting the neurons , reside within and surrounding the spinal cord and brain stem , which we believe can be
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes neurons microglia opcs myelin|astrocytes|when ipsc-derived hgpcs were transplanted into these mice , the cells spread widely throughout the brain , developing as entity and oligodendrocytes .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|macrophages astrocytes lymphocytes macrophage monocytes|astrocytes|cells that repair damage to myelin and neurons and prevent chronic activation of inflammatory cells of the brain , microglia and entity , which is implicated in neurodegenerative diseases .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|brain brains neurons microglia astrocytes|astrocytes|jun ; 71 : 1500-4 ; modulation of interleukin-1beta mediated inflammatory response in human entity by flavonoids : implications in neuroprotection . brain res bull .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes neurons fibroblasts microglia cells|astrocytes|entity and oligodendrocytes , the other two principle types of central nervous system cells , are also generated from the human neural stem
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|neurons astrocytes microglia glia bbb|astrocytes|av-101s ability to activate entity for focal delivery of an anti-epileptic principle , and its dual action as a nmdar glyb antagonist and quinolinic acid synthesis
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|microglia astrocytes cardiomyocytes monocytes neurons|astrocytes|together , these activities lead to a cascade of enhanced disease responses in neurons , oligodendrocytes , and entity , cell types that are most vulnerable to energetic deficiencies .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|cells neurons them microglia macrophages|astrocytes|spinal cord are damaged , guanosine , which is present normally in every cell , can be released in high concentrations to stimulate entity to produce these protective factors .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|neurons cells synapses axons astrocytes|astrocytes|conditions anavex®3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes fibroblasts neurons lymphocytes monocytes|astrocytes|pre-clinical data suggest that ccr2 , and mcp-1 , are upregulated in cells , such as macrophages , microglial cells and entity which play a central role in the origination of pain signals .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|permission them assistance companies efforts|astrocytes|customers frequently request entity to build a more complete human neurological model .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|neurons cells synapses astrocytes axons|astrocytes|anavex 3-71 demonstrated the formation of new synapses between neurons ( synaptogenesis ) without causing an abnormal increase in the number of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes fibroblasts glia pericytes lymphocytes|astrocytes|the effect of iw-6463 was studied in rat brain 3d microtissues , a 3d cell model containing a mix of neurons , entity , microglial cells and oligodendrocytes .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes fibroblasts brain melanocytes hepatocytes|astrocytes|clr1501 uptake was visualized with confocal microscopy and compared to matched sergbm , normal human entity , and human nscs .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes fibroblasts glia gliomas oligodendrocytes|astrocytes|glioblastoma are tumors that arise from entity , which are star-shaped cells making up the supportive tissue of the brain .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 2)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|myelin astrocytes neurons oligodendrocytes opcs|astrocytes|q-cells produce entity and oligodendrocytes , the support cells that enable the normal function of neurons .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|special specific glial specialized these|astrocytes|entity cells found in the brain that support neuronal function these cells are synergistic with icell neurons .
OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 3)])|cell|astrocytes astrocytic dysfunctional interstitial junctional|astrocytes glia neurons macrophages microglia|astrocytes|aß peptides are derived from the amyloid precursor protein , or app , an integral membrane protein , in neurons and entity in the brain .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|preadip differentiation fibroblasts subpopulations proliferative|leukocytes cardiomyocytes myocytes lymphocytes monocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts , and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|preadip differentiation fibroblasts subpopulations proliferative|leukocytes cardiomyocytes myocytes lymphocytes monocytes|preadipocytes|in contrast , svf is merely a heterogeneous fraction including entity , endothelial cells , smooth muscle cells , pericytes , macrophages , fibroblasts and adipose-derived stem cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|preadip differentiation fibroblasts subpopulations proliferative|adipocytes cells fibroblasts adipocyte fibroblast|preadipocytes|a paper entitled “chromium picolinate depressed proliferation and differentiation of 3t3-l1 entity” was published in nutrition research .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast osteoclasts osteocytes fibroblasts|osteoblasts|only a portion of the bone remodeling process : they either block bone breakdown by osteoclasts or stimulate bone formation by entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteocytes osteoblast macrophages microglia|osteoblasts|small areas of bone are constantly being broken down by special cells called osteoclasts , then made again by cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cell osteoblasts cells differentiation osteoblast|treatments therapeutics methods aiming hypothesis|osteoblasts|entity for osteoporosis and non-union bone fractures we have made osteoblasts from hescs and are now conducting preclinical tests in animals .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoclasts osteocytes macrophages osteoblast|osteoblasts|n / a ( generic ) ​ in osteoporosis patients , who have normal basal levels of pth , therapeutic administration of pth activates osteoclasts and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell osteoblasts cells differentiation osteoblast|cells osteoblasts osteoclasts progenitors chondrocytes|osteoblasts|it has a potent anabolic effect on bone tissues , stimulating the formation and maturation of bone-forming entity which in turn causes significant increases in new bone formation .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast macrophages osteocytes monocytes|osteoblasts|k , arris and its partner believe that a new drug may be able to re-balance the activity of osteoclasts and entity and arrest the bone-destroying effects of osteoporosis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteocytes osteoclasts sos osteoblast|osteoblasts|intravenously administered antibody that is designed to inhibit sclerostin , a protein that inhibits the activity of bone-forming cells , known as entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoclasts osteocytes cells chondrocytes|osteoblasts|while both types of cells are activated when pth is administered , entity are activated to a greater extent , increasing net bone formation and bone mass .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|cells neurons such hesc xenografts|osteoblasts|current work focuses on confirming their characteristics as entity , improving cell yields , testing function in vitro and then testing the cells in animals .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cell osteoblasts cells differentiation osteoblast|cells mscs fibroblasts ipscs exosomes|osteoblasts|we intend to infuse entity derived from hescs to treat osteoporosis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast osteoclasts osteoblastic bones|osteoblasts|bone loss ( mediated by osteoclasts  cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity  cells which form new bone ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|adolescence adolescents childhood bones osteosarcoma|osteoblasts|because osteosarcoma usually develops from entity , it most commonly affects children and young adults experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell osteoblasts cells differentiation osteoblast|cells cell all both these|osteoblasts|while both types of cells are activated when pth is administered , entity 92 table of contents are activated for a longer period , increasing bone formation and bone mass .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast osteocytes osteoclasts microglia|osteoblasts|cells called entity cause new bone formation while other cells called osteoclasts remove old bone through a process called resorption .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast osteocytes macrophages osteoclasts|osteoblasts|the condition is the stimulation of a population of normal bone cells ( osteoclasts ) relative to another population of bone cells ( entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts childhood osteosarcoma adolescence bones|osteoblasts|because osteosarcoma usually develops from entity , it most commonly develops in teenagers who are experiencing their adolescent growth spurt .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoclasts osteoblast bmscs macrophages|osteoblasts|forteo ( marketed as forsteo in europe ) builds bone primarily by increasing the activity of entity ( cells that deposit bone ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts also osteocytes macrophages they|osteoblasts|osteoclasts mediate destruction of bone and entity are responsible for bone growth and mineral production .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteoblast osteoclasts osteocytes fibroblasts|osteoblasts|bone loss ( mediated by osteoclasts -- cells which resorb bone ) that is incompletely compensated by new bone formation ( mediated by entity -- cells which form new bone ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell osteoblasts cells differentiation osteoblast|osteoblasts osteocytes osteoblast macrophages osteoclasts|osteoblasts|normal functioning of bone depends on osteoclasts and entity acting in concert .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|completely properly fully mature them|cells counterparts tissues ones muscles|erythroblasts|b , which are more immature entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|completely properly fully mature them|monocytes platelets neutrophils macrophages erythrocytes|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|completely properly fully mature them|cells oocytes neurons lymphocytes neutrophils|erythroblasts|c , which is the population of mature entity , in comparison to ery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|completely properly fully mature them|platelets erythrocytes monocytes rbcs blasts|erythroblasts|reactivation of hbf occurs in immature rbcs , known as entity and reticulocytes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|completely properly fully mature them|monocytes platelets neutrophils macrophages leukocytes|erythroblasts|it is well-known that fetal cells , including trophoblasts , lymphocytes , and entity , circulate in the peripheral blood of pregnant women , in some cases as early as five weeks gestation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|adverse side negative detrimental positive|transitional|the initial application of ifrs 9 at january 1 , 2018 has resulted in no significant entity effects for immunic .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|regulatory washout approval exclusion warning|transitional|after the expiry of any applicable entity period , only ivds that have been ce marked under the ivd regulation may be placed on the market in the
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|insurance public consumer economic affordable|transitional|as per the benefit arrangement contemplated by the entity services agreement , the existing stock shall be delivered to purchaser exw - incoterms 2010 , delivery in monheim or other sellers
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|visual hearing memory vision speech|transitional|the provisions of sfas 142 require that a entity impairment test be performed as of the beginning of the year the statement is adopted .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|transitional urothelial squamous basal germ|transitional|entity cell carcinoma of the bladder frequently occurs in adolescents with costello syndrome , a presentation that is rare in the general
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|all indirect business financial incurred|transitional|“entity costs” shall mean all costs incurred by seller that are identified in exhibit “j” .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|this online mandatory optional via|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|rev surg opin trans inst|insurance bms pharmaceutical supply company|transitional|will also pay bms for any required product supply at a price approximating the product cost as well as negotiated entity service fees .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|corresponding optional mark highest respective|transitional|( ii ) and section 2 . 2 , in no event shall aetna use or permit any affiliate to use any mark or the entity mark
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|more least most optimal best|transitional|we elected to use the entity practical expedient allowing the standard to be applied only to contracts that were previously identified as leases under ias 17
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|regulatory data reporting registration funding|transitional|retrospectively from january 1 , 2019 , but has not restated comparatives for the 2018 reporting period , as permitted under the specific entity provisions in the standard .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|shared private registered financial new|transitional|and the buyer are expected to enter into related transaction agreements at the closing of the proposed transaction , including a entity services agreement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|protection regulatory ethical authority specific|transitional|respect to any grant ( including the grant made on the effective date ) a-3 to secure the benefit of any applicable entity rule promulgated under section 409a of the code .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|insurance nhs integrated respective government|transitional|internal costs and out-of-pocket expenses shall not exceed the corresponding agreed to budget for such services set forth in the entity service plan .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|regulatory financial data administrative specific|transitional|the entity requirements of sfas 148 are effective for all financial statements for fiscal years ending after december 15 , 2002 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|policy technical user online regulatory|transitional|we elected the optional entity guidance under asc 842 that allowed the initial recognition of the operating right-of-use assets and the corresponding lease liabilities as
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|financial economic budget project policy|transitional|the entity impact was finalized during the fiscal year ended june 30 , 2019 , with no significant impact on income tax expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|technical these administrative financial regulatory|transitional|acquisition by cytyc corporation , a diagnostic and medical device company , he served as a consultant to cytyc to assist with entity matters from 2001 to 2002 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|this online mandatory optional via|transitional|entity small business disclosure format ( check one ) :
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|rev surg opin trans inst|technology by design policy model|transitional|we adopted these changes using the prospective application entity alternative in accordance with the entity provisions of cica handbook section 3870 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|into immature maturation mature quality|ucb embryos cells pbmc mscs|oocytes|we anticipate that in the unites states cryopreservation of entity will be regulated similarly to viacords family umbilical cord blood cryopreservation product .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|oocytes follicles embryos eggs blastocysts|oocytes|if successful , the ovature treatment could reduce , or possibly eliminate , the need for hormonal hyperstimulation for the maturation of multiple entity prior to egg retrieval in the ivf process .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|eggs embryos semen oocytes cells|oocytes|with a number of in vitro fertility clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|cells oocytes embryos blastocysts spermatozoa|oocytes|media supplier will be required to obtain 510 ( k ) clearance for the technology we have licensed for use in the cryopreservation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|extract material tissue powder eggs|oocytes|“raw material” means conforming rana pipiens entity to be supplied to spl by alfacell .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|into immature maturation mature quality|oocytes cells eggs embryos tissues|oocytes|cancer research technology limited rnai uses in mammalian entity , preimplantation embryos and somatic cells ( ep only : wherein the rnai compound is at least 25 base pairs ) 11 / 19 / 1999
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|into immature maturation mature quality|dna fibroblasts embryos cells mrna|oocytes|which includes the production of human differentiated cells from stem cells and involves the use of nuclear transfer technology , human entity , and embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|eggs embryos semen cells oocytes|oocytes|a number of in vitro fertility ( “ivf” ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|oocytes eggs embryos spermatozoa oocyte|oocytes|the first patent covers the use of fertilized human entity for the creation of human embryonic stem cell lines , and was issued in great britain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|oocytes spermatozoa follicles eggs ovaries|oocytes|another opportunity in the use of cells for therapy relates to entity , which are female egg cells essential to reproduction .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|into immature maturation mature quality|saliva cells tissue specimens dna|oocytes|of health information we obtain from research collaborators or from providers who enroll patients and collect cord blood or human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|eggs embryos semen oocytes cells|oocytes|a number of in vitro fertility ( ivf ) clinics in the southern california region enrolling individuals who are willing to donate entity for research purposes in order to create new hpsc lines .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|eggs oocytes spermatozoa embryos ova|oocytes|iscos core technology , parthenogenesis , results in the creation of pluripotent human stem cells from unfertilized entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|into immature maturation mature quality|tissues donors biologics tissue genes|oocytes|is focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|eggs embryos oocytes cells ova|oocytes|viacyte , a product expected to offer women the ability to preserve or extend their fertility through the cryopreservation of their entity ( eggs ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DRUG', 1)])|cell|into immature maturation mature quality|tissues donors tissue biologics genes|oocytes|are focused on human cell therapy , which includes the production of human differentiated cells from stem cells and involves human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|embryos spermatozoa oocytes erythrocytes cells|oocytes|the second and third patents , both covering parthenogenetic activation of human entity , were 47 table of contents issued in japan and korea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|into immature maturation mature quality|oocytes cells eggs ova blastocysts|oocytes|for ovature , ovascience was exploring different subculture systems that allow for even further maturation of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|eggs oocytes embryos egg ova|oocytes|although our focus is on stem cells derived from unfertilized entity , certain aspects of that work may involve the use of nuclear transfer technology or material deemed to be embryonic material .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|into immature maturation mature quality|eggs oocytes egg embryos ova|oocytes|although our focus is on parthenogenetic stem cells derived from unfertilized entity , certain aspects of that work may involve the use of embryonic stem cells .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells cellular chondrocytes semin|cells lymphocytes pbmc cell fibroblasts|chondrocytes|autologous cultured entity ( " carticel ( tm ) aucc " ) .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell cells cellular chondrocytes semin|biomarkers genes biomarker markers gene|chondrocytes|chnd1 : entity for cartilage disorders and degenerative disc disease articular cartilage is the shock absorber for joints .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell cells cellular chondrocytes semin|cells chondrocytes myoblasts matrix macrophage|chondrocytes|maci® ( autologous cultured entity on porcine collagen membrane ) is an autologous cellularized scaffold product indicated for the repair of symptomatic , single or multiple full-thickness
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell cells cellular chondrocytes semin|chondrocytes mscs hmscs cartilage ascs|chondrocytes|use of hystem® hydrogels with purestem™ progenitors resulting in a combined product that produces cartilage- producing cell masses known as entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|cell cells cellular chondrocytes semin|pharmaceuticals claims services tablets healthcare|chondrocytes|some third party payers , however , do not cover carticel entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|cell cells cellular chondrocytes semin|india australia italy denmark russia|chondrocytes|the commercial success of carticel-registered trademark- entity will depend on many factors , including the following : - positive results from post-marketing studies .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell cells cellular chondrocytes semin|grafts patches cells transplants implants|chondrocytes|compared to the same period a year ago due primarily to decreased shipments of both epicel skin grafts and carticel entity during the three months ended march 31 , 2002 .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|cell cells cellular chondrocytes semin|registration companies registered access approval|chondrocytes|some third-party payers , however , do not cover carticel-registered trademark- entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells cellular chondrocytes semin|chondrocytes cells cartilage fibroblasts mscs|chondrocytes|preclinical studies have shown that entity embedded in bst-gel ( tm ) produce a matrix having the characteristics of normal cartilage tissue .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|cell cells cellular chondrocytes semin|manufactured free usa sponsored japan|chondrocytes|genzyme biosurgery has developed a device to improve the procedure for implanting carticel-registered trademark- entity and has filed for marketing approval with the fda .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells cellular chondrocytes semin|chondrocytes mscs cells msc fibroblasts|chondrocytes|as reported in this article , 19 of 23 patients had restored or improved joint function after treatment with cultured autologous entity .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|cell cells cellular chondrocytes semin|tm monotherapy sodium pharmaceuticals first|chondrocytes|since the fda approved carticel entity , genzyme has seen a substantial increase in the number of third party payers who cover it .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells cellular chondrocytes semin|chondrocytes cells chondrocyte mscs fibroblasts|chondrocytes|gtr is aware of at least one other company that is culturing autologous entity for cartilage repair in europe .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell cells cellular chondrocytes semin|cartilage chondrocytes structures plate tissues|chondrocytes|there are two type of entity , “articular” and “growth plate” .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell cells cellular chondrocytes semin|chondrocytes cartilage chondrocyte plates bones|chondrocytes|articular entity are responsible for cartilage that lines our joints , whereas growth plate entity are involved with new bone formation .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|cell cells cellular chondrocytes semin|sweden which pharmaceuticals italy llc|chondrocytes|the increase in sales of carticel-registered trademark- entity was a result of continued increases in the numbers of patients treated and surgeons trained as well as an increase
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|cell cells cellular chondrocytes semin|chondrocytes cells mscs fibroblasts tissue|chondrocytes|the process used by gtr to grow autologous entity is not patentable , and gtr does not yet have significant patent protection covering the other methodologies used in providing carticel ( tm )
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5)])|cell|cell cells cellular chondrocytes semin|pfizer novartis japan roche merck|chondrocytes|since the fda approved carticel-registered trademark- entity , genzyme has seen a substantial increase in the number of third-party payers who cover it .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell cells cellular chondrocytes semin|cells chondrocytes cartilage biomaterials materials|chondrocytes|solid tissue cell therapies one of the newest areas of cell therapy involves the production of entity for the restoration of cartilage .
OrderedDict([('OTHER', 5), ('BIO', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cell cells cellular chondrocytes semin|chondrocytes chondrocyte cartilage cells tissue|chondrocytes|chondrocyte therapy involves the surgical removal of a small amount of tissue from the patient  s knee and a therapeutic quantity of entity is produced from this surgical biopsy .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|cell cells cellular transmembrane neoplasia|myofibroblasts apoptosis myofibro fibrosis fibrotic|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic tissues .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|stroma macrophages stromal endothelium microvessels|myofibroblasts|in a sampling of approximately 200 tumors , epha2 was found to be expressed in tumor cells , entity and / or tumor-associated blood vessels .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|myofibroblasts pericytes keratinocytes collagen fibroblasts|myofibroblasts|fezagepras has been observed to regulate several cell types involved in the fibrotic pathway : macrophages , fibroblasts / entity and epithelial cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts myofibroblasts leukocytes macrophages glomeruli|myofibroblasts|the number of entity and hydroxyproline ( i . e . , collagen ) content was also significantly reduced in both organs .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|cell cells cellular transmembrane neoplasia|myofibroblasts fibroblasts macrophages pericytes cafs|myofibroblasts|moreover , ehp-101 has been shown to inhibit the tgfβ-associated differentiation of cells ( called entity ) that are responsible for fibrosis .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts monocytes neutrophils microglia pericytes|myofibroblasts|vla-1 is found on a variety of cells associated with tissue inflammation and fibrosis , including activated t-cells , macrophages and entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts myofibroblasts fibroblast pericytes macrophages|myofibroblasts|ctgf increases the abundance of entity , a cell type that drives wound healing , and stimulates them to deposit ecm proteins such as collagen at the site of tissue injury .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|macrophages lymphocytes fibroblasts neutrophils leukocytes|myofibroblasts|in the skin , it has been shown to reduce scar formation by reduction of infiltration of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|myofibroblasts fibroblasts fibrosis fibroblast collagen|myofibroblasts| anti-fibrosiscysteamine blocks tgf-ß signaling and thereby inhibits the production and proliferation of entity .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts myofibroblasts mmps macrophages fibroblast|myofibroblasts|constant myofiber breakdown results in persistent activation of entity and altered production of ecm resulting in extensive fibrosis in skeletal muscles of dmd patients .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts myofibroblasts hscs macrophages mmps|myofibroblasts|in fibrotic conditions , excess ctgf results in chronic activation of entity , which leads to chronic ecm deposition and fibrosis ( see figure above ) .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|endothelial hypertrophic myofibroblasts smooth muscle|myofibroblasts|anti-tshr antibodies also increase the proliferation of adipose or fat cells as well as entity , smooth muscle-like cells .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|cell cells cellular transmembrane neoplasia|myofibroblasts apoptosis myofibro fibrosis fibrotic|myofibroblasts|tgf-b is a cytokine that is a key driver of fibrosis and acts by activating fibroblasts into entity , which in turn drives the production of fibrotic connecting tissues .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cell cells cellular transmembrane neoplasia|cardiomyocytes cells hearts fibroblasts myocardium|myofibroblasts|research programs involving cell-based approaches to restoring cardiac function and a research program involving a gene therapy approach to converting entity into cardiac muscle .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts cells chondrocytes myofibroblasts macrophages|myofibroblasts|in the case of normal healing of a limited tissue injury , entity eventually die by programmed cell death , or apoptosis , and the fibrous scarring process recedes .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|fibroblasts macrophages leukocytes fibroblast myofibroblasts|myofibroblasts|fibrosis is the formation of excess connective tissue ( collagen and other proteins plus cellular elements such as entity ) in response to damage , inflammation or repair .
OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell cells cellular transmembrane neoplasia|hepatocytes myofibroblasts hscs cells macrophages|myofibroblasts|additionally supported by the anti-inflammatory effects , including downregulation of tnf and il-6 , that can reduce the proliferation and activation of entity in the liver .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 4), ('OTHER', 4), ('DIS', 3)])|cell|preadip mature cell adipocyte differentiation|adipocytes cells hepatocytes necrosis macrophages|adipocytes|the ultrashape system targets and selectively destroys fat cells ( entity ) , leaving critical surrounding structures such as blood vessels , nerves and connective tissue unharmed .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|arteries vasculature vessels limb liver|adipocytes|in addition , the fraction also contains blood cells from the capillaries supplying the entity and the extracellular matrix .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|adipocytes macrophages hepatocytes enterocytes fibroblasts|adipocytes|in non-cancerous tissues , it is predominantly found at low levels on entity , or fat cells , and briefly on precursors to b-cells , or pre-b-cells , during normal b-cell maturation .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|macrophages enterocytes muscle adipocytes cells|adipocytes|vitro studies have shown that activation of the beta-3 adrenergic receptor in the colon causes the release of somatostatin from entity , or fat cells , which causes pain relief .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|keratinocytes lymphocytes adipocytes chondrocytes monocytes|adipocytes|antibodies form against the thyroid-stimulating hormone receptor , or tshr , which is present in the thyroid and other cells such as entity and fibroblasts .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|preadip mature cell adipocyte differentiation|cartilage cells tissue tumors tissues|adipocytes|this attenuation by protein-rich tissue results in the preferential destruction of entity by atx-101 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|adipocytes muscle liver hepatocytes adipose|adipocytes|mechanism of action atx-101 is designed to be a locally-injected drug that causes proximal , preferential destruction of entity , or fat cells , with minimal effect on surrounding tissue .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|preadip mature cell adipocyte differentiation|humans cells vivo mice tumors|adipocytes|believe that rnai could potentially be a reliable method to selectively inhibit certain genes and their corresponding protein expression in entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|adipocytes fibroblasts adipocyte cells hepatocytes|adipocytes|the research is focused on using cultured entity ( fat cells ) as a model system for studying the regulation of gene expression involved in adipocyte differentiation and function .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|preadip mature cell adipocyte differentiation|humans tumors cells vitro animals|adipocytes|rnai delivery for therapeutic gene silencing in cells and animals ; and  inhibition of gene expression in entity using rnai .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|adipocytes cells fibroblasts myoblasts tumors|adipocytes|initial product development plans include : pluripotent stem cell-derived brown entity ( agex-bat1 ) ; vascular progenitors ( agex-vasc1 ) ; and induced tissue regeneration ( itr ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|preadip mature cell adipocyte differentiation|adipocytes adipose fats tissue tissues|adipocytes|the destruction of entity , or adipocytolysis , elicits a natural response in which macrophages are attracted to remove cellular debris and fat particles through the
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|adipocytes tumors islets cardiomyocytes osteoclasts|adipocytes|in addition , msi-1436 was shown to reduce the size of entity , reduce body fat with no reduction of lean mass , and improve glucose tolerance via inhibition of a unique combination of
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|cells adipocytes fibroblasts tissue bulk|adipocytes|cells obtained from the blood vessels in the lipoaspirate from the small volume of fat harvested , minus the fat cells ( entity ) and non-cellular material .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|chondrocytes adipocytes fibroblasts osteoblasts macrophages|adipocytes|by the presence and absence of particular biological markers , and the ability of the cell to differentiate into at least entity , osteocytes , endothelial cells and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|macrophages keratinocytes lymphocytes monocytes chondrocytes|adipocytes|these antibodies activate certain cell types , such as fibroblasts and entity , present in the extraocular space , which are known to highly express tshr .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|adipocytes fibroblasts myofibroblasts macrophages osteoblasts|adipocytes|namodenoson was also shown to inhibit the proliferation of entity , further hampering the expansion of fat producing cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|preadip mature cell adipocyte differentiation|adipocytes enterocytes fibroblasts hepatocytes neurons|adipocytes|metabolic benefits of the lancl2 signaling axis are observed in hepatocytes , entity and myocytes through uptake and oxidation of glucose to improve the systemic glucose homeostasis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|cells adipocytes mice humans muscle|adipocytes|pending delivery of sirna into entity for treatment of diabetes and obesity michael p . czech qiong l . zhou zhen y . jiang 12 / 11 / 2002 exclusive
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|preadip mature cell adipocyte differentiation|adipocytes cells muscle tissue fibroblasts|adipocytes|liposarcomas arise by malignant transformation of entity , not necessarily entity from within a lipoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cystic hemangi cell undifferentiated abnormal|cells mscs hscs melanocytes fibroblasts|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell-forming , and angiogenic , meaning blood vessel endothelium-forming ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cystic hemangi cell undifferentiated abnormal|cells mscs melanocytes fibroblasts hscs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic ( blood cell forming ) and angiogenic ( blood vessel endothelium forming )
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cystic hemangi cell undifferentiated abnormal|cells origin dna origins lineage|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 5 / 19 / 2015 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cystic hemangi cell undifferentiated abnormal|cells mscs pericytes melanocytes hscs|hemangioblasts|entity are a newly-characterized stem cell capable of differentiating into both hematopoietic , meaning blood cell forming , and angiogenic , meaning blood vessel
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cystic hemangi cell undifferentiated abnormal|cells origin dna origins lineage|hemangioblasts|no . 6 , 338 , 942 selective expansion of target cell populations 10 / 7 / 2014 us patent no . 6 , 429 , 012 cell population containing non-fetal entity and method for producing same
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cystic hemangi cell undifferentiated abnormal|rpe tissue epidermal muscle cartilage|hemangioblasts|development of its rpe cells for conditions involving retinal degeneration · act is evaluating research and development programs for esc-derived entity and dermal regeneration .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cystic hemangi cell undifferentiated abnormal|cells erythrocytes fibroblasts ipscs cardiomyocytes|hemangioblasts|this patent broadly covers the derivation and growth of human entity from a non-fetal source .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|neutrophils granulocytes leukocytes wbc lymphocytes|myeloblasts|acute myeloid leukemia aml is a type of cancer in which the bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells or platelets .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|undifferentiated myel blasts cells leuk|monocytes immature basophils blasts both|myeloblasts|comprises normalizing peripheral blood counts , resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells , or entity , to less than 5% .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|cells blasts lymphocytes neutrophils granulocytes|myeloblasts|leukemia aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|undifferentiated myel blasts cells leuk|cscs malignancies tumors cancers sarcomas|myeloblasts|which both failure to differentiate and excessive proliferation in the stem cell compartment result in accumulation of non-functional cells termed entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|monocytes platelets blasts lymphocytes neutrophils|myeloblasts|the myeloid cells are predominantly immature platelet cells called entity , or blasts , which are the leukemia cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 2)])|cell|undifferentiated myel blasts cells leuk|tumors gliomas cells gbm glioma|myeloblasts|this suggests that differentiation of entity  made possible by inhibition of mutated idh2  may drive the clinical efficacy of enasidenib .  targeting idh mutations is
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|cell|undifferentiated myel blasts cells leuk|myeloid monocytes macrophages neutrophils hematopoietic|myeloblasts|the gm-csf receptor is expressed on entity and other progenitor cells , and binding results in differentiation and maturation into monocytes .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|cells blasts lymphocytes neutrophils progenitors|myeloblasts|aml is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional entity that do not mature into healthy blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|undifferentiated myel blasts cells leuk|monocytes lymphocytes neutrophils leukocytes granulocytes|myeloblasts|immature white blood cells known as entity , or blasts proliferate in the bone marrow rather than mature into normal blood cells .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|undifferentiated myel blasts cells leuk|neutrophils granulocytes leukocytes wbc blasts|myeloblasts|acute myeloid leukemia market • bone marrow makes abnormal entity ( a type of white blood cell ) , red blood cells , or platelets • if left untreated , aml progresses rapidly to death
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cell|undifferentiated myel blasts cells leuk|blasts neutrophils neutropenia leukemias hematopoiesis|myeloblasts|acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|cells blasts blast cell lymphocytes|myeloblasts|blast ( % ) refers to the percentage of leukemic entity , or blood cells affected by disease , compared to all blood cells in the sample .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|undifferentiated myel blasts cells leuk|blasts blast neutrophils wbc lymphocytes|myeloblasts|from this trial show that patients with relapsed , refractory acute myeloid leukemia , or aml , experienced a decrease in peripheral blood entity , a measure of clinical activity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated myel blasts cells leuk|neutrophils cells blasts lymphocytes erythrocytes|myeloblasts|aml is a type of cancer in which the bone marrow makes abnormal entity , a type of white blood cell , red blood cells or platelets .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cell|clonal cells new abnormal mature|melanoma adenocarcinoma glioblastoma myofibroblasts macrophages|proerythroblasts|on stained slides the cells had the features of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|clonal cells new abnormal mature|blasts erythrocytes eosinophils progenitors neutrophils|proerythroblasts|increase in overall numbers of entity in mice the rapid expansion of the pro-e population also coincided with decreased numbers of erythroid burst-forming units and erythroid
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|interneurons junction zone gabaergic inhibitory|neurons interneurons synapses cells circuits|interneurons|specifically , inhibitory gabaergic entity are susceptible to excessive excitatory amino acid release .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 2)])|cell|interneurons junction zone gabaergic inhibitory|neurons interneurons cells neuronal synapses|interneurons|this loss of nav1 . 1 channels in inhibitory entity and other nerve cells results in dravet syndrome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|fibroblasts myoblasts myotubes chondrocytes cells|myotubes|in non-clinical studies with human entity grown from 35 different nmdmd patients , ataluren also exhibited a bell-shaped dose-response curve with maximal dystrophin staining observed at 10
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|fibroblasts samples cells families muscle|myotubes|force increased exon skipping in human dmd entity with exon 51 mutation *** p < 0 . 001 in studies in the mdx mouse dmd model , a validated and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|cells fibroblasts samples pbmcs transcriptome|myotubes|we used rna-sequence ( rna-seq ) analysis of the entity from dm1 patients to create a splice score for control human subjects cells treated with sidmpk . 19 or the inactive sirna , sidmpk . 29 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|cells samples controls clones mice|myotubes|mock treated dm1 entity ( open black diamonds ) show the full splice derangement .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|data samples groups responses sera|myotubes|when patient entity were analyzed , there was a marked improvement in the splice score of the entity treated with the sidmpk . 19 compared to the inactive sidmpk . 29 ( see figure 11 below ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|cells fibroblasts mice neurons oocytes|myotubes|as shown in the figure on the right below , we also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuromuscular vesicular muscle skeletal segmental|myotubes myoblasts fibroblasts muscle myocytes|myotubes|effect of ataluren on dystrophin staining scores in entity isolated from nmdmd mice myotubes from nmdmd patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|controls donors fibroblasts myoblasts embryos|myotubes|able to sustain utrophin protein expression based on in vitro data generated in myoblast cells from dmd patients and human entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|fibers cells myotubes muscle muscles|myotubes|the proprietary compounds bio101 and bio103 on muscle cells in particular regarding protein syntheses and growth in the diameter of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|cells fibroblasts adipocytes myotubes mitochondria|myotubes|as depicted below , results from an in vitro study demonstrate that human entity are larger in muscle cells treated with sarconeos ( bio101 ) as compared to untreated control cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|neuromuscular vesicular muscle skeletal segmental|genes samples tissue tissues cells|myotubes|the splice signature approached that of control entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|cells fibroblasts xenografts lymphocytes pbmc|myotubes|the studies used gymnotic uptake , or no transfection reagents , in patient-derived entity ( in vitro ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|cells mice fibroblasts neurons oocytes|myotubes|as shown in the figure on the right below , also observed reduced cell death , or apoptosis , in fshd entity , as measured by active caspase-3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|neuromuscular vesicular muscle skeletal segmental|adipocytes myotubes fibroblasts cardiomyocytes myofibroblasts|myotubes|fgfs can also induce or inhibit differentiation in a variety of cell types ( e . g . of myoblasts into entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|humans keratinocytes mice fibroblasts vivo|myotubes|in the study , we demonstrated that mbd3l2 was representative of broader dux4-driven gene expression changes in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|fibroblasts sera samples pbmcs tissues|myotubes|administration of our proprietary aso conjugated to a fab targeting tfr1 reduced expression of key dux4 biomarkers in fshd patient entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuromuscular vesicular muscle skeletal segmental|myoblasts cells fibroblasts myotubes also|myotubes|and 50% , respectively , based on our in vitro studies that were undertaken in myoblast cells from patients with dmd and entity from healthy individuals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|neuromuscular vesicular muscle skeletal segmental|vitro mice cells vivo humans|myotubes|we used active caspase-3 to quantify cell death because it is a protein that has been shown to be an important regulator of the apoptosis pathway in entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|neuromuscular vesicular muscle skeletal segmental|mice rats animals pigs fibroblasts|myotubes|human entity when dosed with smt c1100 for 7 days demonstrated and increase of utrophin protein of around 50% when compared to
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cell|neuromuscular vesicular muscle skeletal segmental|infarction infarct damage necrosis infarcts|myotubes|the four hearts and in one heart diacrin noticed an increase in small vessel formation at the site of surviving entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|cells myoblasts prp fibroblasts mscs|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|segmental cell developmental fusion vesicular|myoblasts myoblast mscs cells they|myoblasts|entity are precursors to muscle cells that have the capacity to fuse with other myoblasts or with damaged muscle fibers to regenerate skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|myoblasts fibroblasts cells muscle myocytes|myoblasts|genvec , genzyme , and bioheart are all developing products consisting of skeletal entity isolated from muscle , expanded in culture , and injected into a patients heart to repair dead tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|segmental cell developmental fusion vesicular|cells pbmc platelets pbmcs lymphocytes|myoblasts|bv , was previously awarded a manufacturing permit from the netherlands ministry of health for the in vitro culture of autologous entity for use as human medications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|cells tissue myoblasts muscle tissues|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|segmental cell developmental fusion vesicular|tissue cells tissues material cardiomyocytes|myoblasts|in the capacity that we have at diacrin without stressing the facilities and continuing to also be able to produce entity for cardiac repair .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|cells myoblasts prp fibroblasts mscs|myoblasts|we use a number of proprietary processes to create therapeutic quantities of entity from a patients thigh muscle biopsy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|cells fibroblasts lymphocytes exosomes myoblasts|myoblasts|at the cell culturing site , our proprietary techniques are used to isolate and remove entity from the muscle tissue .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|segmental cell developmental fusion vesicular|mice cells cardiomyocytes fibroblasts aav|myoblasts|histopathology confirmed that entity expressing sdf-1a resulted in increased muscle and blood vessel formation in the damaged areas of the hearts , which was not
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|segmental cell developmental fusion vesicular|mscs cells bmscs myoblasts msc|myoblasts|when injected into scar tissue within the heart wall , entity have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|segmental cell developmental fusion vesicular|cells particles materials scaffolds stents|myoblasts|after expansion , the entity are packaged and delivered to the clinical site for implantation into the injured heart tissue by a surgeon or interventional
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|myoblasts muscle cells fibroblasts tissue|myoblasts|intellectual property in connection with products , processes or services developed or provided by genvec other than autologous and allogenic skeletal entity for cardiac therapy .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|segmental cell developmental fusion vesicular|myoblast myoblasts muscle myotubes tendon|myoblasts|similarly , the fusion of entity with other entity is essential for the formation , growth , and regeneration of skeletal muscle .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|segmental cell developmental fusion vesicular|muscle fibroblasts myoblast myoblasts autologous|myoblasts|for example , some of our competitors are exploring whether the use of cells , other than entity , is safer or more effective than myocell .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 1)])|cell|segmental cell developmental fusion vesicular|everolimus adenosine stents tacrolimus bevacizumab|myoblasts|implantation during coronary artery bypass graft ( cabg ) surgery may lead to similar effects , as do recent studies using percutaneous delivery of entity as a stand-alone procedure .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|myoblasts myotubes fibroblasts cardiomyocytes mscs|myoblasts|ctgf treatment of entity induced their de-differentiation , or failure to become mature muscle cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|cells tissue myoblasts muscle tissues|myoblasts|by using entity obtained from a patients own body , we believe myocell is able to avoid certain challenges currently faced by other types
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|segmental cell developmental fusion vesicular|fibroblasts myotubes cells myoblasts mscs|myoblasts| wve-n531 induced a dose-dependent increase in dystrophin production ( up to 71% ) in vitro in dmd patient-derived entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|segmental cell developmental fusion vesicular|muscle myoblasts myoblast cells regeneration|myoblasts|cellular based therapies such as skeletal entity and embryonic stem cells are being pursued by companies such as bioheart , mg biotherapeutics , a joint venture created by medtronic
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|segmental cell developmental fusion vesicular|cells fibroblasts tissue material mscs|myoblasts|clinical therapy designed to improve cardiac function by populating regions of scar tissue within a 8 patients heart with entity derived from a biopsy of a patients thigh muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemic leukemias|lymphoblastic|we are developing marqibo for the treatment of acute entity leukemia and other blood cancers including lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic myel lymphoid phase|lymphoblastic|exclusive license agreement pursuant to which we licensed the patent rights to a specific gene mutation with respect to chronic entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid myel leukemias|lymphoblastic|achieve the primary endpoint of efficacy in the phase 2 clinical trial of blinatumomab in patients with acute entity leukemia 10 % 12 . 5 % 6 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias neutrophil|lymphoblastic|in the second quarter , we initiated a pharmacokinetic study in phase 2 for erwinaze for the treatment of acute entity leukemia in the young adult population .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias lymphocyte|lymphoblastic|all patients receiving autologous sb-modified t cells had non-hodgkin lymphoma , and most patients receiving allogeneic car+ t cells had acute entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphatic lymphocyte|lymphoblastic|of the most important potential uses of annamycin is in the treatment of children with either aml or all ( acute entity leukemia , which is more common in children ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias myel|lymphoblastic|nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute entity leukemia after at least two prior regimens .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias myel|lymphoblastic|candidate blinatumomab ( mt103 ) is currently the subject of a european pivotal trial in patients with minimal residual disease positive acute entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphocyte lymphatic|lymphoblastic|erwinaze , a biologic product , is used in conjunction with chemotherapy to treat patients with acute entity leukemia , or all , with hypersensitivity to e . coli-derived asparaginase .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphocyte lymphatic|lymphoblastic|pbcar0191 , is an allogeneic car t cell therapy targeting the well-validated tumor target cd19 and is being developed for acute entity leukemia , or all , and non-hodgkin lymphoma , or nhl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias myel|lymphoblastic|oncaspar is a first-line biologic used as part of a chemotherapy regimen to treat patients with acute entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphatic lymphocyte|lymphoblastic|for iclusig is bcr-abl , an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia ( cml ) and philadelphia-chromosome positive acute entity leukemia ( ph+ all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphatic leukemias|lymphoblastic|sar3419 targets cd19 and is a potential new treatment for cd19-expressing b-cell malignancies including nhl and b-cell acute entity leukemia , or b-all .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphatic lymphocyte|lymphoblastic|the fda approved kymriah ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias monocytic|lymphoblastic|it is in a phase 2 clinical trial for the treatment of patients with acute entity leukemia and a phase 1 clinical trial for the treatment of patients with non-hodgkin  s lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid leukemias neutrophil|lymphoblastic|patients , in august 2011 , we initiated a phase 1 clinical trial of quizartinib in pediatric patients with either relapsed acute entity leukemia , or all , or relapsed aml .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid solid refractory|lymphoblastic|may 2005 , we commenced an open-label , multicenter phase i and ii study of talotrexin in the treatment of refractory adult entity leukemia or “all .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid neutrophil leukemic|lymphoblastic|the company also acquired the u . s . and canadian marketing rights to oncaspar ( tm ) for use in the treatment of acute entity leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|should question theory which opinion|lymphocytic myeloid lymphoid lymphatic lymphocyte|lymphoblastic|u . s . for advanced non-hodgkins lymphoma , and vincristine sulfate liposome injection ( marqibo® ) approved in the u . s . for advanced adult ph- acute entity leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cell|should question theory which opinion|myeloid lymphocytic lymphoid monocytic myel|lymphoblastic|two other sar3419 phase ii trials are ongoing in relapsed / refractory dlbcl and in acute entity leukemia .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|cell junction junctional cells transport|epithelium cells mucosa enterocytes fibroblasts|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum low-density lipoprotein ,
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell junction junctional cells transport|enterocytes epithelium cells colon intestine|enterocytes|by inhibiting nhe3 on the apical surface of the entity , tenapanor reduces absorption of sodium from the small intestine and colon , resulting in an increase in water secretion into the
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|cell junction junctional cells transport|liver body stomach feces intestine|enterocytes|we believe that kp201 is then completely hydrolyzed down to hydrocodone and the ligand in the entity , which then release the hydrocodone directly into the blood stream .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell junction junctional cells transport|enterocytes epithelium receptors cells transporters|enterocytes|it can thus inhibit iron absorption from the gi tract by interacting with duodenal entity and limit the release of iron in the bone marrow by interacting with macrophages .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell junction junctional cells transport|cells epithelium mucosa enterocytes macrophages|enterocytes|fxr activation in intestinal entity results in the secretion of fibroblast growth factor 19 , or fgf19 , which has been associated with increased serum ldl cholesterol
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell junction junctional cells transport|crypts enterocytes mucosa cells epithelium|enterocytes|believe that due to kp201s low binding affinity to the µ-opioid receptors it is absorbed largely intact into the intestinal entity , which are the cells lining the small intestine .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|cell junction junctional cells transport|enterocytes epithelium cells mucosa epithelia|enterocytes|the cellular trans-membrane protein ferroportin , which functions as an export channel for intracellular iron in macrophages , liver hepatocytes , and duodenal entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell junction junctional cells transport|muscle adipocytes muscles mice pancreas|enterocytes|this was observed in a preclinical study in mice in which kd026 caused fat accumulation in entity and prevented fat accumulation in the liver tissues .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cell junction junctional cells transport|enterocytes macrophages epithelia hepatocytes fibroblasts|enterocytes|lomitapide also blocks mtp in entity ( cells lining the gastrointestinal tract ) , leading to an accumulation of fat in the intestinal mucosa .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|cell stage terminal nuclear residual|testosterone androgen androgens estradiol estrogen|spermatids|hormone ) drives synthesis of testosterone in the leydig cells of the testes and fsh ( follicle stimulating hormone ) drives production of entity in the sertoli cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 2), ('DIS', 1)])|cell|cell stage terminal nuclear residual|spermatozoa spermatogenesis cells lymphocytes spermatocytes|spermatids|clinical dose on a mg / m2 basis ) in a 6-month iv study had bilateral degeneration of the seminiferous epithelium with retained entity and atrophy of interstitial cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cell|cell stage terminal nuclear residual|androgens cells spermatocytes follicles oocytes|spermatids|entity mature over a 72 day cycle in the seminiferous tubules in the testes under the influence of endogenous testosterone produced
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|cell stage terminal nuclear residual|fibroblasts embryos oocytes eggs fibroblast|spermatids|to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse entity and murine lymphocytes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|oocyte embryo egg spermatozoa cell|sperm|taken from the womans ovarian follicles and fertilized in vitro with either standard insemination , or icsi , in which a single entity is injected by needle into the egg .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|brain liver tissue free world|sperm|the decrease is due to a smaller demand for the entity bank services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|embryo fetus uterus blastocyst placenta|sperm|each parent , including recombination , or the exchange of dna within the parent chromosomes that occurs during the formation of the entity and the egg that become the fetus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|seminal semen residual cell cytoplasmic|tissue cell gene hair marrow|sperm|the company operates in two distinct reporting segments , one for the entity bank division and one for its stem-cell and skin care divisions as of december 31 , 2009 and 2008 and for
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|cd4 cell testosterone psa hair|sperm|this trial showed that androxal® was able to maintain entity counts in men being treated for their low testosterone levels , whereas testim® resulted in suppressed entity levels .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|fluid spermatozoa oocyte cell substance|sperm|the latter include , among other technologies , in vitro fertilization , or ivf , and intracytoplasmic entity injection , or icsi .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|spermatozoa cells follicles oocytes chromosomes|sperm|lastly , semen samples that had fewer normal entity had slightly , but not significantly , higher sorp values .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|number cohort subset population numbers|sperm|of the protocol or for other unanticipated reasons , and we may be unable to achieve the same results with the entity of infertile donors that have been achieved with entity of fertile donors .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|lymphocyte cell neutrophil leukocyte rbc|sperm|those with an abnormally low entity concentration or overall total number , have significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|spermatozoa semen oocytes embryos couples|sperm|o application as an enhancement in human intercourse - for couples prone to male factor infertility from immotile or poorly motile entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|seminal semen residual cell cytoplasmic|primates adults cells humans tissues|sperm|the university of pennsylvania safety and efficacy laboratory studies with atp ( the active ingredient in atpotent ) using human and animal entity as well as animal eggs and animal embryos .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|all access utilize ensure acquire|sperm|the contractor must provide full service cryobiology program to include storage of embryos and entity all laboratory equipment and staffing as work load requires .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|ova spermatozoa eggs oocytes embryos|sperm|conducted in 20 women and published in the journal of reproductive medicine® in 2009 , ovaprene demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|cells entities spermatozoa segments vesicles|sperm|abnormally few motile entity or few entity with a progressive motility were also associated with significantly higher sorp values than those in the normal range .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|fetus cell muscle spleen pig|sperm|transgenic animal  shall mean a non-human animal , or an egg , entity or embryo of such animal , which bears in its germline a foreign gene derived from another animal species .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|seminal semen residual cell cytoplasmic|cell tissue marrow gene bio|sperm|continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its entity bank division .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|seminal semen residual cell cytoplasmic|either both testosterone this that|sperm|that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce entity or both .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|seminal semen residual cell cytoplasmic|oocytes cells embryos spermatozoa fetuses|sperm|not viable , the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs , entity , and embryos .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cell|seminal semen residual cell cytoplasmic|sexual erectile prostate testicular testosterone|sperm|program with androxal as a treatment for men being treated for low testosterone that want to maintain or improve their entity function during treatment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|seminal semen residual cell cytoplasmic|ova spermatozoa eggs oocytes embryos|sperm|conducted in 21 women and published in the journal of reproductive medicine in 2009 , ovaprene® demonstrated the ability to immobilize entity and prevent their progression into the cervical mucus .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|embryonic cell single new developmental|oocytes eggs tissues cells tissue|gametes|( b ) donors of entity , embryos , somatic cells or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|cells eggs embryos spermatozoa material|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or " art " , services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes eggs embryos cells platelets|gametes|( e ) individuals who consented to donate stored entity , embryos , somatic cells , or human tissue were not reimbursed for the cost of storage prior to the decision to donate .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|eggs embryos oocytes cells dna|gametes|( c ) a person may not knowingly , for valuable consideration , purchase or sell entity , embryos , somatic cells , or human tissue for research purposes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|cells eggs spermatozoa embryos material|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology , or art , services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes eggs cells embryos spermatozoa|gametes|ivf treatment while the procurement , processing and distribution of entity and embryos for use in ivf and other assisted reproduction treatments falls within the scope of the eu rules governing
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes eggs embryos cells fetuses|gametes|national stem cell oversight committee , or · been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells , or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes embryos spermatozoa haploid cells|gametes|enactment of this act , that is derived by fertilization , parthenogenesis , cloning , or any other means from one or more human entity or human diploid cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|embryonic cell single new developmental|cells eggs embryos spermatozoa tissues|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as art services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|embryonic cell single new developmental|oocytes eggs tissues embryos cells|gametes|( b ) donors of entity , embryos , somatic cells , or human tissue did not receive valuable consideration .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|cells eggs spermatozoa embryos material|gametes|procedures that require entity ( sperm and eggs ) to be handled in 3 vitro ( outside the body ) are classified as assisted reproductive technology , or " art " ,
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes eggs embryos cells fetuses|gametes|national stem cell oversight committee , or ● been derived under the following conditions : ( a ) donors of entity , embryos , somatic cells or human tissue gave voluntary and informed consent .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes embryos eggs cells fetuses|gametes|of a duly authorized institutional review board ( irb ) ; and prohibits the knowing purchase , sale or transfer of human embryos or entity for valuable consideration for research purposes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|cells eggs embryos spermatozoa material|gametes|procedures that require entity ( sperm and eggs ) to be handled in vitro ( outside the body ) are classified as assisted reproductive technology ( " art " ) services .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|embryonic cell single new developmental|oocytes eggs embryos cells fetuses|gametes|( d ) donation of entity , embryos , somatic cells , or human tissue was overseen by an irb ( or , in the case of foreign sources , an irb-equivalent ) .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|hormone pituitary prolactin hypothalamic gland|cells neurons parts part tissues|somatotrophs|gh is an anabolic hormone synthesized , stored in , and secreted from entity of the anterior pituitary gland in response to chemical modulators from the hypothalamus and stomach .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|pituitary hormone gland prolactin hypothalamic|fibroblasts cardiomyocytes macrophages astrocytes hepatocytes|corticotrophs|similarly , dipyridamole did not amplify prednisolone effects in entity , cells that mediate the hpa axis suppression of high-dose glucocorticoid treatment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|collagen mature basal terminal cell|keratinocytes fibroblasts melanocytes adipocytes seb|sebocytes|because there are no preclinical models of acne , human entity , which are the cells that make up the sebaceous glands and secrete sebum , are a useful research tool for a
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|collagen mature basal terminal cell|muscle brain nmj muscles nerve|sebocytes|it has also been shown in a laboratory study that a chemical that blocks acetylcholine from reaching the entity reduces sebum production .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|collagen mature basal terminal cell|keratinocytes melanocytes fibroblasts adipocytes seb|sebocytes|acetylcholine has been shown in laboratory studies to increase activity in the sebum-producing skin cells called entity , which form sebaceous glands .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|synovi synovial interstitial sclerosis proliferation|cells macrophages fibroblasts lymphocytes monocytes|synoviocytes|synoviocyte inhibitory moa : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|synovi synovial interstitial sclerosis proliferation|tissues cartilage macrophages tissue platelets|synoviocytes|rheumatoid arthritis results from interactions between immune cells and entity that leads to joint swelling , pannus formation and bone loss .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|synovi synovial interstitial sclerosis proliferation|macrophages fibroblasts monocytes platelets adipocytes|synoviocytes|the synovium is lined by cells , or entity , which produce a small amount of liquid called synovial fluid that nourishes and lubricates the joint .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 2)])|cell|synovi synovial interstitial sclerosis proliferation|cells macrophages fibroblasts adipocytes monocytes|synoviocytes|the entity , in turn , secrete a variety of chemicals that contribute to inflammation , tissue degradation and harmful new blood vessel formation .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|synovi synovial interstitial sclerosis proliferation|fibroblasts chondrocytes osteoblasts cartilage osteoclasts|synoviocytes|of articular joints and joint surfaces , characterized by the rapid , uncontrolled growth of the cells that line the joints , called entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|synovi synovial interstitial sclerosis proliferation|cells cell macrophages leukocytes lymphocytes|synoviocytes|of most individuals with rheumatoid arthritis , which drive the production of tnf and the recruitment of neutrophils and fibroblast like entity .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|synovi synovial interstitial sclerosis proliferation|cells lymphocytes macrophages fibroblasts monocytes|synoviocytes|synoviocyte inhibition : pro-inflammatory entity in the ra joint proliferate highly and secrete multiple cytokines involved in ra disease pathogenesis .
OrderedDict([('OTHER', 5), ('DIS', 4)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|synovi synovial interstitial sclerosis proliferation|cells cell fibroblasts cultures xenografts|synoviocytes|data published today demonstrate that ppi-2458 potently inhibits the growth of both human fibroblast-like entity derived from rheumatoid arthritis patients and human endothelial cells .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|sympathetic autonomic afferent vasodilator receptors|pairs fibers units samples groups|mechanoreceptors|in parallel , electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed ( 33 masticatory muscle entity ) .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|cell cells differentiation new daughter|cells cell mscs fibroblasts myoblasts|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to assess the safety and efficacy of the cells in
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|cell cells differentiation new daughter|cardiomyocytes vessels pericytes mesoderm cells|angioblasts|recyte will also develop ips cells into primitive entity , which are cells believed to be capable of reconstituting and repairing age-related changes in the vascular system .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|cell|cell cells differentiation new daughter|cells cell mscs fibroblasts mice|angioblasts|the young entity will be tested in preclinical mouse models of accelerated aging to test the safety and efficacy of the cells in
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|dendritic vesicular role cell transport|complement antibodies neutrophils antibody autoantibodies|phagocytes|binding of ar-101 to p . aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|dendritic vesicular role cell transport|cells phagocytes subsets populations macrophages|phagocytes|important entity include macrophages , that rid the body of dead cells and other debris , and granulocytes , including neutrophils , that contain granules filled
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|dendritic vesicular role cell transport|h2o2 ros superoxide o2 ozone|phagocytes|t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|dendritic vesicular role cell transport|h2o2 ros superoxide o2 ozone|phagocytes|nk / t cells have been shown to be sensitive to oxygen free radical-induced apoptosis when these immune cells were exposed to entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|dendritic vesicular role cell transport|macrophages cells mitochondria phagocytes neutrophils|phagocytes|these defective entity cannot generate superoxide , leading to an inability to kill harmful microorganisms such as bacteria and fungi .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|dendritic vesicular role cell transport|macrophages phagocytes monocytes neutrophils leukocytes|phagocytes|one part of the innate immune system involves large white blood cells called entity ( literally , " cell-eaters " ) that can engulf and digest foreign microorganisms and other antigens .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|dendritic vesicular role cell transport|neutrophils phagocytes macrophages lymphocytes monocytes|phagocytes|have been shown to induce antibodies that are protective in animal models and that facilitate killing of bacteria by human entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 1), ('BIO', 1)])|cell|dendritic vesicular role cell transport|mitochondria neutrophils h2o2 superoxide glutathione|phagocytes|laboratory research has demonstrated that ceplene reduces formation of oxygen radicals from entity , inhibiting nadph oxidase and protecting il-2-activated nk-cells and t-cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|dendritic vesicular role cell transport|macrophages monocytes neutrophils phagocytes leukocytes|phagocytes|entity were depleted using clodronate loaded liposomes through day 21 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2), ('DRUG', 1)])|cell|dendritic vesicular role cell transport|enterocytes macrophages bacteria probiotics monocytes|phagocytes|and increasing anti-inflammatory mediators , the production of antimicrobial effectors and increased absorption of pathogens by specially adapted cells known as entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|dendritic vesicular role cell transport|apcs dcs leukocytes macrophages pbmcs|phagocytes|we observed that depletion of entity , including myeloid apcs , significantly reduced our bdc-1001 surrogate-mediated anti-tumor activity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|dendritic vesicular role cell transport|cd4 cd8 cd3 nk innate|phagocytes|furthermore , significant increases in entity and cd8 t cells were measured in tumors following bdc-1001 surrogate treatment , further supporting a mechanism that bridges the innate
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|dendritic vesicular role cell transport|il2 cd3 scid mice mouse|phagocytes|figure 4 : bdc-1001 surrogate activity dependent on presence of entity scid / beige were dosed systemically with 5 mg / kg on day 0 , 5 and 10 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|dendritic vesicular role cell transport|cells cell macrophages endothelium platelets|phagocytes|or other molecules in the class known as histamine type-2 ( h ) receptor agonists bind to the h receptor on the entity , the production and release of free radicals is temporarily prevented .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|dendritic vesicular role cell transport|ros mitochondria neutrophils caspases superoxide|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|dendritic vesicular role cell transport|ros mitochondria caspases superoxide neutrophils|phagocytes|the release of free radicals by entity results in apoptosis ( programmed cell death ) of nk cells and t cells , thereby destroying their cytotoxic capability and rendering the
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|dendritic vesicular role cell transport|ros mitochondria caspases neutrophils phagocytes|phagocytes|the release of free radicals by entity results in apoptosis , or programmed cell death , of nk , t and nk / t cells , thereby destroying their cytotoxic capability and rendering
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|dendritic vesicular role cell transport|monocytes lymphocytes neutrophils macrophages leukocytes|phagocytes|entity are a class of white blood cells found in abundant quantities at the site of tumors and viral infections .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|dendritic vesicular role cell transport|interferon cytokines ifn ifnγ glucocorticoids|phagocytes|maxim  s researchers have shown , however , that nk cells and t cells are suppressed by entity , another component of the body  s immune system .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|dendritic vesicular role cell transport|leukocytes cells neutrophils macrophages monocytes|phagocytes|table of contents results in a dramatic increase in the production of cytokines that orchestrate the proliferation and recruitment of entity to the site of damage , resulting in inflammation .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|nonspecific antin cd8 sv40 cell|cells lymphocytes pbmcs samples pbmc|splenocytes|entity were analyzed by flow cytometry to confirm effector / memory phenotype , and cultured with anti-human cd3 antibodies at 2 . 5 mg / ml and anti-human
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|cells pbmcs macrophages fibroblasts monocytes|splenocytes|entity were lysed and assayed for phospho- nuclear factor kappa b ( nfb ) p65 using an enzyme-linked immunosorbent assay .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|nonspecific antin cd8 sv40 cell|pbmcs pbmc sera supernatants lymphocytes|splenocytes|figure 11 : entity from eae mice treated with edp1815 produced an anti-inflammatory cytokine profile .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nonspecific antin cd8 sv40 cell|vector cells cell recipients into|splenocytes|svp 1 3 week week naïve recipient lmb-100 transfer entity lmb-100 + / -lmb-100 + / -
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|nonspecific antin cd8 sv40 cell|elispot pbmcs pbmc elisa supernatants|splenocytes|cell responses will be assessed by in vivo cd4 and cd8 cell depletion and measure cytotoxicity and gamma-ifn release by entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|nonspecific antin cd8 sv40 cell|pbmc pbmcs leukocytes monocytes lymphocytes|splenocytes|administration for 14 days ( 10 mg / kg , sid , ip ) : no effect on blood count , blood chemistry and cytokine secretion by isolated entity no herg inhibition observed ( in vitro )
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|challenge vector cmv immunization ctl|splenocytes|svp prime challenge donor transfer entity day 0 14 aav8-hfix day 0 19 20 21 32 recipient anti-cd25 treg depletion day 0 1 28 anti-aav8 igg
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|pbmcs monocytes pbmc macrophages fibroblasts|splenocytes|in vitro studies demonstrated that treatment of isolated entity with virulizin ( r ) result in increased il-17e mrna expression .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|macrophages cells monocytes lymphocytes leukocytes|splenocytes|entity from either young or older atherosclerotic apoe ko mice were isolated from the spleen .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nonspecific antin cd8 sv40 cell|sera lymphocytes csf supernatants leukocytes|splenocytes|to explore further the mechanisms of cns remyelination , we made a panel of monoclonal antibodies ( mabs ) derived from entity of sjl / j mice injected with homogenized spinal cord .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nonspecific antin cd8 sv40 cell|pbmc pbmcs lymphocytes cells splenocytes|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in elispot ( depicted in
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|nonspecific antin cd8 sv40 cell|pbmc lymphocytes pbmcs cells leukocytes|splenocytes|stimulation of entity harvested 7 days post last vaccination with respective peptides demonstrated strong induction of antigen specific t cells in enzyme-linked immune absorbent
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nonspecific antin cd8 sv40 cell|pbmcs cells pbmc lymphocytes them|splenocytes|t cell responses were measured on day 15 by re-stimulating entity with either control ( medium ) or peptides corresponding to each antigen ( 1 , 2 , 6 , 9 , and 12 ) in the mrna vaccine
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nonspecific antin cd8 sv40 cell|sera cells lymphocytes organs erythrocytes|splenocytes|before transfer , immunized entity were separated or fractionated .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|nonspecific antin cd8 sv40 cell|pbmcs pbmc vivo vitro mice|splenocytes|robust and specific antigen specific cd8+ifng+ t cell responses were detected in entity after re-stimulation with kras mutation 1 peptide and kras mutation 2 peptide .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|macrophages models mice pbmcs leukocytes|splenocytes|cgen-25007 exhibited anti-inflammatory activity in both human pbmcs and murine entity challenged with various inflammatory stimuli as well as in an animal model of endotoxemia .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|nonspecific antin cd8 sv40 cell|macrophages lps monocytes were mice|splenocytes|enumeral platform used for antibody discovery • mice were immunized with pd - 1 - his • entity activated with lps for 3 days •
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|nonspecific antin cd8 sv40 cell|livers tissues pups hearts models|splenocytes|these methods were applied to analyze gene expression data from mouse entity exposed to either copaxone® or the purported generic ga .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|nonspecific antin cd8 sv40 cell|pbmcs pbmc lymphocytes sera splenocytes|splenocytes|cd4+ and cd8+ t cells from entity isolated from bnt162b2-immunized mice were strongly positive for ifn-ɣ and il-2 , producing high levels of the th1 cytokines but minute
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 2)])|cell|nonspecific antin cd8 sv40 cell|virus monocytes cells bacteria adenovirus|splenocytes|preincubation of the endothelial cells with blocking antibodies to eotaxin-2 was found to attenuate the adhesion of the entity to these cells ( fig . 15a ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|collagen capillary lamellar capillaries basement|fibers cells elements fibrils structures|corneocytes|in addition , to providing most of the mechanical strength of the tissue , these entity provide a stabilizing scaffold for the mortar .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|collagen capillary lamellar capillaries basement|shells rods surfaces prostheses bridges|corneocytes|the bricks ,  or entity , provide a durable defense against the ordinary frictional wear and tear of life .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|collagen capillary lamellar capillaries basement|cells keratinocytes bilayers fibroblasts vesicles|corneocytes|the stratum corneum , consisting of flattened and hardened non-living entity held together by a lipid matrix , acts as the main barrier to drug delivery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|collagen capillary lamellar capillaries basement|walls cells disks bodies teeth|corneocytes|the mortar is primarily made up of fats or lipids that are organized into broad sheets or membranes .  stacks of these membranes fill the spaces between the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|collagen capillary lamellar capillaries basement|collagen phospholipids vesicles caveolae ceramide|corneocytes|keratinocytes , the most common cell type in the outer layer of skin , has been shown to increase the formation of entity and the production of lamellar lipids .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|single mono simplex hetero singleton|comparisons pairs translation comparison hybridization|heterokaryons|elegans to isolate innate immunity mutations , and implementing species specific primers to distinguish rat transcipts from mouse transcripts in rat-mouse entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 3)])|cell|immature cholangi ciliary differentiation duct|fibroblasts hepatocytes adipocytes macrophages pericytes|cholangiocytes|the licensed technology describes advanced methods for the production of mature hepatocytes and entity , the primary cell types of the liver .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|immature cholangi ciliary differentiation duct|hepatocytes myofibroblasts macrophages ducts cholangiocarcinoma|cholangiocytes|specific and robust ccl24 staining was also shown in entity , the epithelial cells of the bile ducts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|immature large giant alveolar sept|cells aec macrophages keratinocytes airways|pneumocytes|sars - cov - 2 infects type ii entity in lung alveoli 1 these cells also serve as progenitor cells for repairing damaged alveoli .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|immature large giant alveolar sept|cells fibroblasts keratinocytes hepatocytes isolates|pneumocytes|type it entity , known to be primary targets / reservoirs for flu , are plated in a transwell system , which essentially suspends the polarized cell monolayer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|immature large giant alveolar sept|aec airways cells adenovirus macrophages|pneumocytes|in covid - 19 , infection of type ii entity results in impaired gas exchange and fluid leakage into alveoli .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|funding they this which novartis|oncocyte|as of december 31 , 2017 , entity had $2 . 1 million outstanding and payable to biotime and affiliates in connection with the costs incurred under the shared facilities
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|they funding employees authors novartis|oncocyte|entity incurred no royalty expenses to date as of december 31 , 2014 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|prototype kp bioreactor io spm|oncocyte|importantly , entitys methods appear to be compliant with commercial manufacturing processes .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|this our its common that|oncocyte|the fact that certain of our executive officers and directors own shares of entity common stock should not be considered to mean that they constitute or are acting in concert as a “group” with
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|clin endocrin onc rev dis|diagnostics pharmaceutical pharmaceuticals biotech technology|oncocyte|the patent is useful for biotimes subsidiary entity corporation for its cancer diagnostic product development .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|they funding was compensation were|oncocyte|on july 2 , 2018 , entity entered into a lease schedule under the lease agreement no . 2 for certain equipment costing approximately $209 , 000 , requiring payments of
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|clin endocrin onc rev dis|cell novartis miltenyi bayer cells|oncocyte|another subsidiary , entity corporation , focuses on the therapeutic applications of stem cell technology in cancer , including using vascular progenitor cells engineered to destroy
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|novartis miltenyi genomics roche quest|oncocyte|additional information about biotime , recyte therapeutics , cell cure , orthocyte , entity , biotime asia , lifemap sciences , and esi can be found on the web at www . biotimeinc . com .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|novartis nih abbott lab bard|oncocyte|in concert with the protocol development , entity has established a broad range of support assays to monitor and measure vascular progenitor cell differentiation processes .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|they was but being novartis|oncocyte|on may 11 , 2017 , entity entered into another master lease line agreement ( “lease agreement no . 2” ) with the same finance company on terms similar to lease agreement no . 1 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|this its our that each|oncocyte|to beneficially own the shares owned by broadwood , in the aggregate beneficially own approximately 18 . 9% of the outstanding shares of entity common stock as of april 22 , 2019 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|clin endocrin onc rev dis|they individuals authorities persons others|oncocyte|under the provisions of the contracts , entity may be required to incur severance obligations for matters relating to changes in control , as defined , and involuntary terminations .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|pfizer share bayer novartis insurance|oncocyte|you should direct any requests to : entity corporation 15 cushing irvine , california 92618 409-7600 s-11 3 , 523 , 776 shares common stock january
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|they gsk novartis irb fda|oncocyte|entity will reimburse sbmri for 25% of the costs incurred in filing , prosecuting , and maintaining patent protection , subject to entity&#8217 ; s approval of the costs .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|employee also student employment some|oncocyte|entity has entered into employment contracts with certain executive officers .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|us our ours they humans|oncocyte|references to “entity , ” “we , ” “us , ” and “our” are references to entity corporation .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|manufacturer company institution department fda|oncocyte|of royalty bearing products commence , the annual fee will be credited towards entity  s royalty payment obligations for the applicable year .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|species fish stock animal atlantic|oncocyte|in note 3 , the asterias shares of common stock lineage held generated similar deferred tax liabilities to lineage as the entity shares discussed above .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|company lab hes ec nih|oncocyte|entity has expanded and banked large numbers of vascular progenitor cells derived from multiple hes cell lines , including clinical-grade stem cells provided by us and our subsidiary esi .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|clin endocrin onc rev dis|fda gsk which ec novartis|oncocyte|except as required by law , entity disclaims any intent or obligation to update these forward-looking statements .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|nucleated leukocyte leukocytes number cell|cells samples chromosomes specimens embryos|amniocytes|fluorescence images demonstrating hybridization of the cep x / y and lsi 21 probes on uncultured entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|vitro cytokine subpopulations cytokines viability|lymphocytes macrophages neutrophils eosinophils granulocytes|promonocytes|two leukine treated patients had progressive increase in circulating monocytes and entity and blasts in the marrow which reversed when leukine was discontinued .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|immature reticul count abnormal platelets|platelets hematocrit ferritin albumin erythropoietin|reticulocytes|to six months have shown a profound and durable reduction in hemolysis ( red blood cell destruction ) as assessed by hemoglobin , entity and / or bilirubin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|immature reticul count abnormal platelets|platelets antibodies dasatinib additives cytokines|reticulocytes|the streck patents relate to the addition of entity to hematology controls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|immature reticul count abnormal platelets|ngs platelets epinephrine reagents cytokines|reticulocytes|is successful , after cancellation of the streck patents , the company may be issued a patent covering integrated hematology controls containing entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|immature reticul count abnormal platelets|rbcs platelets they these erythrocytes|reticulocytes|ldh and bilirubin are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|immature reticul count abnormal platelets|erythrocytes rbcs rbc csf pbmcs|reticulocytes|mg / kg , *** ) , elevated hemoglobin concentrations in entity ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|immature reticul count abnormal platelets|hba1c mortality aes deaths pfs|reticulocytes|we observed an 18% reduction in entity in the 10 mg treatment arm relative to the placebo arm .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|immature reticul count abnormal platelets|cells myotubes nuclei cardiomyocytes myocytes|reticulocytes|then exposed to a defined media formulation to promote further expansion and differentiation until they differentiate and mature into enucleated entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cell|immature reticul count abnormal platelets|mortality hospitalizations proteinuria crp morbidity|reticulocytes|improvement in the hemolytic anemia would be expected to result in a decrease in entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|immature reticul count abnormal platelets|erythrocytes monocytes neutrophils rbcs immature|reticulocytes|products provide a means of assessing the linearity of hematology analyzers for white blood cells , red blood cells , platelets and entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cell|immature reticul count abnormal platelets|rbcs platelets they these erythrocytes|reticulocytes|bilirubin and ldh are released when rbcs undergo hemolysis , and entity are young rbcs that are released by the bone marrow in response to the ongoing hemolysis ; thus we believe that
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|immature reticul count abnormal platelets|rbcs erythrocytes rbc monocytes pbmcs|reticulocytes|these controls are designed for manual and automated counting of entity ( immature red blood cells ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|immature reticul count abnormal platelets|hematocrit platelets rbcs rbc ferritin|reticulocytes|the increase in hemoglobin levels was preceded by an increase in entity showing that an increase in hemoglobin levels is a result of a physiologic increase in rbc production .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|immature reticul count abnormal platelets|platelets leukocytes lymphocytes wbc eosinophils|reticulocytes|dose ( mg / kg / day ) average bodyweight at end ofstudy hematology results at end of study entity ( x 103 / µl ) neutrophils ( x 103 / µl ) control - 603 m / 324 f
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|immature reticul count abnormal platelets|cells lymphocytes oocytes nuclei erythrocytes|reticulocytes|at this stage , the enucleated entity are rcts that express one or more biotherapeutic proteins in the cytosol or on the cell surface .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cell|immature reticul count abnormal platelets|ck ferritin platelets hematocrit crp|reticulocytes|while gbt4 showed improvement in hemoglobin , entity and ldh levels in the first 15 days , these values worsened after day 15 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|immature reticul count abnormal platelets|conjugated bilirubin conjugates fractionated free|reticulocytes|levels and improved clinical measures of hemolysis at 16 weeks , as evaluated by changes from baseline in hemoglobin , percent of entity , and percent of unconjugated bilirubin .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|immature reticul count abnormal platelets|hematocrit platelets ferritin erythropoietin albumin|reticulocytes|robust and sustained increase in red blood cells , hemoglobin and entity , supporting monthly or less frequent dosing .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|immature reticul count abnormal platelets|hematocrit platelets ferritin erythropoietin albumin|reticulocytes|receiving the 300 mg dose , measuring changes in parameters over the 14-day treatment and 7-day follow-up period including hemoglobin and entity , as well as tolerability and safety .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|immature reticul count abnormal platelets|cells lymphocytes nuclei hepatocytes erythrocytes|reticulocytes|standard in vivo genotoxicity studies in rodents , including a 2-day comet assay and a 28-day evaluation of micronucleated entity , revealed no test-article effects on genotoxicity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|immature reticul count abnormal platelets|hematocrit platelets ferritin erythropoietin hb|reticulocytes|( 700 mg ) 8 ( 900 mg ) 9 ( 3 per cohort ) akb-6548 was well tolerated , and dose responsive increases in entity and hemoglobin levels were demonstrated .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|undifferentiated leuk mature hematopoietic differentiation|blasts neutrophils monocytes granulocytes eosinophils|promyelocytes|in apl , there is an abnormal accumulation of immature granulocytes called entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated leuk mature hematopoietic differentiation|neutrophils blasts monocytes granulocytes lymphocytes|promyelocytes|in apl , immature white blood cells called entity accumulate in the bone marrow .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|undifferentiated leuk mature hematopoietic differentiation|cytokine neutrophil immature monocyte progenitor|promyelocytes|in addition , the data showed that plinabulin has a superior immune profile compared to neulasta based on entity and immature neutrophil data from the clinical study .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|undifferentiated leuk mature hematopoietic differentiation|bacteria platelets cells lymphocytes microorganisms|promyelocytes|the overgrowth of entity leads to a shortage of normal white and red blood cells and platelets in the body , which causes many of
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated leuk mature hematopoietic differentiation|cells blasts lymphocytes cell progenitors|promyelocytes|differentiation therapy causes leukemic entity to mature and undergo cell death .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('BIO', 3), ('DRUG', 1)])|cell|undifferentiated leuk mature hematopoietic differentiation|cells lymphocytes blasts monocytes iron|promyelocytes|the accumulation of entity in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|undifferentiated leuk mature hematopoietic differentiation|platelets monocytes neutrophils lymphocytes granulocytes|promyelocytes|this fusion gene leads to the overproduction of immature white blood cells called entity and the underproduction of healthy blood cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|immature mature maturation differentiation undifferentiated|monocytes lymphocytes macrophages erythrocytes platelets|metamyelocytes|associated with evidence that normal cell maturation is returning , as noted by the increase in normal maturing cells ( promyeocytes , myeocytes , entity and granulocytes ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|pituitary cerebrospinal hypothalamic hormone cell|hypothalamus fibroblasts pituitary cells gh|pituicytes|mechanism of action of lum-201 ghsr1a activation via lum-201 binding induces gh release , as demonstrated in vitro in rat entity ( lum-201 ec50 1 . 3 nm ) .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|pituitary cerebrospinal hypothalamic hormone cell|rats rat mice animals rodents|pituicytes|in addition , the treatment of entity with lum-201 augments the effect of ghrh on gh secretion , as the two compounds synergistically stimulated gh release from rat
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 2)])|cell|kerat lamellar junctional stromal giant|fibroblasts macrophages microglia myofibroblasts hscs|keratocytes|activated entity have been associated with increased collagen deposition and collagen disorganization which correlate with corneal haze and regression of the correction
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|kerat lamellar junctional stromal giant|cells lymphocytes elements melanocytes fibroblasts|keratocytes|the superficial entity initially undergo apoptosis , followed by proliferation and activation of the remaining entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|kerat lamellar junctional stromal giant|fibroblasts macrophages neutrophils fibroblast monocytes|keratocytes|treatment resulted in a reduction of pro-fibrotic gene expression from day 7-14 post-injury , indicating that target engagement was achieved in entity and myofibroblasts in the corneal stroma .
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|cytokines cytokine dendritic eosinophils cell|myofibroblasts fibroblasts osteoblasts adipocytes mscs|fibrocytes|igf-1r , the receptor for igf-1 , is highly expressed in entity , cells that are derived from the bone marrow and that have the potential to differentiate into either myofibroblasts or fat
OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|cytokines cytokine dendritic eosinophils cell|mediators cytokines molecules receptors pathways|fibrocytes|inflammation and when chronically activated , drives the development of fibrosis via several pathways and several cell inflammatory cell types and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes keratinocytes cells they macrophages|melanocytes|entity produce melanin , the pigment that determines skin color and protects the body from ultraviolet radiation .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes neutrophils keratinocytes fibroblasts macrophages|melanocytes|tanning is mediated by entity producing melanin , which is subsequently transferred to the keratinocytes .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes cell cells cutaneous melan|melanocytes keratinocytes fibroblasts melan lymphocytes|melanocytes|vitiligo is an autoimmune condition in which the skin turns white due to the loss of entity , cells that produce the pigment melanin , which gives skin color .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes melanomas keratinocytes melanin melan|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes cells humans mammals bacteria|melanocytes|melanin is produced by entity and is the pigment that gives human skin , hair and eyes their color .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes keratinocytes fibroblasts macrophages epidermis|melanocytes|the skin cells that produce the melanins are called entity and comprise 5 to 10% of the total cellular population in the epidermis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes melanoma melanomas dermis hair|melanocytes|melanoma is a malignant tumor of entity , a potentially dangerous form of skin cancer .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes cell cells cutaneous melan|cells melanocytes keratinocytes cell glands|melanocytes|cutaneous melanomamelanoma tumors originate in the pigment-producing entity in the basal layer of the epidermis .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes keratinocytes melanomas fibroblasts melanoma|melanocytes|· melanoma : melanoma is a cancer that begins in specific skin cells called entity , and exposure to ultraviolet rays is a major risk factor for most melanomas .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|fibroblasts melanocytes epidermis lymphocytes macrophages|melanocytes|the epidermis is comprised of specialized cells such as keratinocytes and entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|pigmented dividing melanoma certain forming|melanocytes|melanoma begins in entity cells that make a pigment called melanin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|melanocytes cell cells cutaneous melan|melanocytes keratinocytes melanomas fibroblasts melan|melanocytes|melanoma melanoma is a type of cancer which originates in the entity , the cells responsible for pigmentation of the skin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes fibroblasts melanomas melanoma lymphocytes|melanocytes|melanoma is a disease in which pigmented cells in the skin , called entity , turn into cancer cells .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes cell cells cutaneous melan|melanocytes cells melanomas fibroblasts keratinocytes|melanocytes|melanoma occurs when entity ( pigment cells ) become malignant .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|melanocytes cell cells cutaneous melan|cells melanocytes fibroblasts keratinocytes tissues|melanocytes|normal entity do not express mcam , but expression is turned on and continues to increase as the cells become more malignant .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes cell cells cutaneous melan|tumors cancers tumours tissues cells|melanocytes|malignant melanoma - predominantly a skin cancer , malignant melanoma can also occur in entity found in the bowel and the eye .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melanocytes cell cells cutaneous melan|melanocytes cells melanomas lymphocytes keratinocytes|melanocytes|melanoma is a cancer of the entity , the cells that produce pigment in the skin .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanocytes melanomas melanoma keratinocytes fibroblasts|melanocytes|melanoma melanoma is a cancer that begins in specific skin cells called entity .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5)])|cell|melanocytes cell cells cutaneous melan|region retina periphery stroma body|melanocytes|melanoma is primarily a skin tumor , although it may also occur less frequently in the entity of the eye .
OrderedDict([('OTHER', 5), ('BIO', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|melanocytes cell cells cutaneous melan|melanoma body melanocytes epidermis retina|melanocytes|melanoma is a malignant tumor of the entity .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 2)])|cell|chlamydia species genus taxa strains|bacteria bacterium cells bacterial virus|endospores|proteins and cross-linking of unprotonated proteins thereby denaturing the proteins to corrupt and penetrate the bacterial walls to kill the entity and other microorganisms .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1)])|cell|neuroblast sister cell developmental nodal|neurons neuroblastoma ganglion melanocytes nerves|neuroblasts|a neuroblastoma tumor develops from immature nerve cells called entity and arises predominantly in the adrenal glands and abdomen .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|cell|neuroblast sister cell developmental nodal|antibodies compounds mabs proteins pharmaceuticals|neuroblasts|the license also covers methods for the production and screening of entity .
OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|cell|somatic cell gene virus sv40|cells lymphocytes fibroblasts cell macrophages|protoplasts|electroporation is a method for increasing dna uptake by entity through prior exposure to a high voltage , which results in the temporary formation of small pores in the cell membrane .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|melan melanin photorecep pigment ciliary|they cells melanocytes photoreceptors osteocytes|melanophores|entity are pigment-bearing cells .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|melan melanin photorecep pigment ciliary|melanocytes photoreceptors pigments they melanin|melanophores|for most types of lower animals , entity are the primary chromatophores responsible for skin color control .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|melan melanin photorecep pigment ciliary|melanocytes melanin melanomas tyrosinase melanoma|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|cell|melan melanin photorecep pigment ciliary|melanocytes keratinocytes fibroblasts photoreceptors cells|melanophores|entity are amphibian cells that are responsible for skin color .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cell|melan melanin photorecep pigment ciliary|melanocytes melanin melanomas tyrosinase melanoma|melanophores|receptor targets melanophore technology melanophore technology is a unique screening technique based upon the use of pigment bearing cells called entity .
OrderedDict([('OTHER', 5), ('DRUG', 2)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|melan melanin photorecep pigment ciliary|cells melanocytes they pigments eyes|melanophores|entity undergo a color change in response to light or stimulation by chemicals .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cell|mature spher inclusion sickle immature|thrombocytopenia hemolysis namely erythrocytes anaemia|spherocytes|the laboratory evaluation of waiha begins with a peripheral blood analysis revealing evidence of extravascular hemolysis ( entity , low haptoglobin , elevated bilirubin and elevated ldh ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis erythropoiesis cells positivity morphology|sideroblasts|treatment of anemia failing an erythropoiesis stimulating agent in adult patients with very low- to intermediate-risk mds who have ring entity and require rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis erythropoiesis cells morphology features|sideroblasts|patients to evaluate the efficacy and safety of luspatercept in patients with anemia due to lower-risk mds with ring entity who require regular rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis morphology features cells rods|sideroblasts|the medalist trial , a global phase 3 study in patients with very low , low , or intermediate risk , mds with ring entity who require red blood cell transfusions , is currently enrolling .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|ring cell malformations rare differentiation|positive stained shaped rods cells|sideroblasts|when at least 15% of the cells in an mds patients bone marrow are ring entity , this patient is considered rs positive .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis erythropoiesis mds blasts splenomegaly|sideroblasts|new class of therapy , for the treatment of adult patients with very low- to intermediate-risk mds-associated anemia who have ring entity and require red blood cell ( rbc ) transfusions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis erythropoiesis cells morphology finger|sideroblasts|the phase 3 mds medalist trial targets patients with very low , low or intermediate risk mds with ring entity who require rbc transfusions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cell|ring cell malformations rare differentiation|chromosomes hematopoiesis sider hands chromosome|sideroblasts|patients with mf that has transformed into aml , known as blast-phase mf , and in patients with refractory anemia with ringed entity , or rars , a subpopulation of mds .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis chromosomes fish finger 21|sideroblasts|the majority of patients with mds that develop cytopenias lack ring entity or a single , defining splicing factor mutation and are termed non-rs .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|cell|ring cell malformations rare differentiation|chromosomes rods sider hematopoiesis cells|sideroblasts|clinical safety and efficacy data on imetelstat from patients with a form of mds known as refractory anemia with ringed entity ( mds-rars ) enrolled as part of the mayo clinic pilot study .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cell|ring cell malformations rare differentiation|bodies rods formation forms macrophages|sideroblasts|of contents subgroup of patients with mds that show the presence of iron deposits around the mitochondria , known as ring entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|ring cell malformations rare differentiation|that but which they anaemia|sideroblasts|all patients presented with ring entity were rbc transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent ( esa ) therapy , or were esa naïve
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cell|ring cell malformations rare differentiation|hematopoiesis cells morphology blasts rods|sideroblasts|and safety of luspatercept versus placebo in patients with anemia due to very low , low , or intermediate-risk mds with ring entity ( ≥ 15% ) who require red blood cell transfusions .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cell|ring cell malformations rare differentiation|defects deficiencies breaks mutations cells|sideroblasts|these ring entity are associated with ineffective erythropoiesis and anemia .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cell|ring cell malformations rare differentiation|rods hematopoiesis chromosomes erythropoiesis mds|sideroblasts|in the overall trial population , the rate of ≥8-week rbc ti did not differ based on the presence of ringed entity , indicating activity of imetelstat across different subtypes of mds .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|abstract question statement aim tab|wbc hematocrit platelets plt ptt|retic|g / dl . this was thought to be not clinically possible for a hgb at this level in conjunction with markedly elevated entity and low rbc counts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|abstract question statement aim tab|reticul retic meth metam polyn|retic|mg / kg , *** ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|abstract question statement aim tab|reticul retic meth metam polyn|retic|mg / kg ) , elevated hemoglobin concentrations in entityulocytes ( retic ch ) were observed on day 30 compared to pre-treatment ( pre-dose ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cell|abstract question statement aim tab|mrd new first assay pcr|retic|the entity procedure , which is now implemented , measures the number of entityulocytes ( immature red blood cells produced in the bone marrow ) and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|abstract question statement aim tab|reticul retic metam prop ch|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p < 0 . 005 , *
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|abstract question statement aim tab|reticul retic metam ch prop|retic|elevated hemoglobulin concentrations in entityulocytes ( retic ch ) as determined on day 30 ( ** : p 2 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|abstract question statement aim tab|reticul leuc polyn micron fib|retic|in may 1996 , the company received fda 510 ( k ) clearances for two additional commonly performed microscope procedures : entityulocyte count ( entity ) and anti-nuclear antibodies ( anas ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cell|subcl single molecular multiple somatic|clones cells variants tumors mutations|subclones|progressive disease to elucidate whether these alterations were newly acquired following ibrutinib exposure or represent selective expansions of pre-existing small entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|cell|subcl single molecular multiple somatic|cultures samples lysates cells populations|subclones|evidence against the existence of mammalian tpe comes from a comparison of mrna levels for a telomeric neo gene in entity of sv40-transformed human fibroblasts with varying telomere lengths .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|testing collection production development expansion|subclones|such non-limiting examples include : entity of unmodified cell lines , purified or fractionated subsets of materials provided by atcc , proteins expressed by dna / rna supplied by atcc ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|testing expression culture collection production|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by university , monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|subcl single molecular multiple somatic|culture cultures production testing collection|subclones|some examples include : entity of unmodified or modified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|subcl single molecular multiple somatic|substances antibodies articles patents items|subclones|the term " moab 7e11 " includes all entity claimed in such patent .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|subcl single molecular multiple somatic|establishment culture cultures derivation generation|subclones|some examples include : entity of cell lines ; purified or fractionated subsets of the original materials or progeny ; dna or rna ; genetic material ; secreted or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|testing expression culture translation production|subclones|some examples include : entity of unmodified cell lines , purified or fractionated sub-sets of the original material , proteins expressed by dna / rna supplied by genencor or
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cell|subcl single molecular multiple somatic|insertions mutations additions substitutions insertion|subclones|with information concerning the enzymes being used for ongoing subcloning to determine -9- 11 the absolute orientation and position of entity and deletions with respect to the original clone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|modified unmodified mutated derived modifications|subclones|( i ) licensed products means materials and all progeny , entity , and unmodified derivatives of the cell clones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|subcl single molecular multiple somatic|samples sequencing sequences chips reads|subclones|concentrate samples and load curagen  s dna sequencing gels , allowing the integrated system to generate base called sequences directly from dna entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|testing expression production panels collection|subclones|some examples include : entity of unmodified cell lines , purified or fractionated subsets of the material , proteins expressed by dna / rna supplied by m . i . t . , or monoclonal
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|subcl single molecular multiple somatic|fragments units metabolites variants monomers|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|subcl single molecular multiple somatic|reagents specimens samples supplements materials|subclones|biological materials means the materials identified in appendix a together with any progeny , entity , or derivatives thereof provided by the foundation or created by licensee .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|subcl single molecular multiple somatic|tumors cells clones antigens tumours|subclones|in the face of immune pressure , entity susceptible to t cell killing are eliminated , leaving behind resistant tumor clones that are mhc deficient , and hence no longer
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|subcl single molecular multiple somatic|fragments units metabolites variants monomers|subclones|with any refills of the material and any progeny and unmodified derivatives of the material ( including , without limitation , expression products , entity , sub-units or fractionations ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|subcl single molecular multiple somatic|material materials others derivatives parts|subclones|materials shall mean the tangible material specifically described in exhibit a and physically transferred to licensee and any unmodified copies , progeny and entity made therefrom .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|allograft transfer cell versus single|allo star taxol mdx con|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( “licensed products” ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|allograft transfer cell versus single|taxol star allo mdx bortezomib|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|allograft transfer cell versus single|taxol star mdx allo bortezomib|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vaz tm ( &#8220 ; licensed products&#8221 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|allograft transfer cell versus single|star taxol cell allo xen|allostim|the license granted covered two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( &#147 ; licensed products&#148 ; ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|allograft transfer cell versus single|allo star taxol cell xen|allostim|the license granted covers two experimental products for the treatment of cancer in clinical development called entity tm and allo vax tm ( “licensed products” ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|commercial natural raw ln bulk|carticel|the improvement in gross margin is primarily the result of an increase in entity [ r ] aucc sales and a reduction in labor and manufacturing expenses and decreased material expenses .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|stock pump cell vehicle from|tm buprenorphine novartis bayer pfizer|carticel|through june 30 , 1997 , gtr had received approximately $5 . 1 million in revenues from u . s . sales of entity ( tm ) acc since its market introduction in march 1995 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|repair humans most adults some|carticel|efficacy data demonstrating durability of repair is now out to 20 years for entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|tm novartis ce bayer roche|carticel|the following table summarizes the early results of the commercialization of entity ( tm ) acc in the u . s . :
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|by from under through via|carticel|if gtr were prohibited from marketing entity ( tm ) aucc in the u . s . , its results of operations would be materially adversely affected .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|similar its amp mac medicare|carticel|the company recognizes maci ( or entity ) kit revenue upon delivery of the biopsy kit at which time the customer ( the doctor ) is in control of the
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|stock pump cell vehicle from|tenofovir tm cyp2c19 warfarin adalimumab|carticel|in august 1997 , the fda approved gtr  s bla for entity ( tm ) aucc .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|stock pump cell vehicle from|market apple energy star price|carticel|for the first half of 2015 , total entity and epicel net product revenues increased approximately 17% over pro-forma net product revenues for the same period in 2014 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|autologous this bovine allogeneic new|carticel|the blue cross blue shield association has determined that its technology assessment committee does not believe that entity chondrocytes meets all of its published criteria for new treatments .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|epic janssen mac cart novartis|carticel|the cambridge facility has been used for u . s . manufacturing and distribution of entity , worldwide manufacturing and distribution of epicel and production of maci for clinical testing .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|stock pump cell vehicle from|plus versus vs injectable sodium|carticel|orthopaedics gabi*  sepra  synvisc®  provisc® ( alcon )  entity  hylaform® ( inamed ) focused on treating disease and restoring health through local effects on biology
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|market apple medicare global industry|carticel|total entity and epicel net product revenues in the second quarter increased approximately 31% over pro-forma second-quarter net product revenues in 2014 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|stock pump cell vehicle from|gtr titanium rhb prp oss|carticel|the commercial success of entity ( tm ) aucc will also depend materially on the ability of gtr to increase the approval rate for reimbursement of the product
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|stock pump cell vehicle from|dental all titanium cochlear metal|carticel|total revenues for the quarter ended june 30 , 2015 were $13 . 6 million and included $9 . 1 million in net sales of entity implants and surgical kits and $4 . 3 million in net sales of epicel .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|technology services equipment access healthcare|carticel|the increase is primarily due to higher demand for entity , offset , in part , by a decline in sales of epicel due to a decrease in patients requesting this service .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|this autologous bovine porcine these|carticel|genzyme believes that entity chondrocytes does in fact meet all of these criteria and are discussing the evaluation with the blue cross blue shield
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|stock pump cell vehicle from|tm bevacizumab irinotecan egfr peg|carticel|( 5% ) 16 ( 76% ) 1 ( 5% ) 4 ( 19% ) gtr has compiled safety data on 460 patients who have undergone treatment with entity ( tm ) acc .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|stock pump cell vehicle from|tka arthroplasty implant implantation repair|carticel|entity is indicated for the repair of symptomatic cartilage defects of the femoral condyle ( medial , lateral or trochlea ) caused by acute
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|cell|stock pump cell vehicle from|cartilage chondrocytes osteoarthritis biologics arthroplasty|carticel|market opportunity for entity in the u . s . annually , there are approximately 1 million arthroscopic procedures and more than 250 , 000 cartilage surgical procedures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cell|stock pump cell vehicle from|tm 510 prp er pk|carticel|gtr is conducting additional research relating to entity ( tm ) aucc pursuant to a sponsored research agreement with the university of gotenburg in sweden and certain physicians , including the two
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|everolimus versus vs brachytherapy combination|rituximab novartis bortezomib llc rtx|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t-cell product designed to accelerate immune recovery after hsct and to reduce relapse of leukemia following
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|cell|everolimus versus vs brachytherapy combination|cel cmv cytomegalovirus hev endotoxin|rivogenlecleucel|rimiducid will be administered to inactivate entity ( rivo-cel ) in the event of gvhd not responsive to standard of care treatment updated 8 nov 2018 .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|everolimus versus vs brachytherapy combination|llc rituximab cel rtx novartis|rivogenlecleucel| rivo-cel ( entity , formerly known as bpx-501 ) is a product candidate intended to improve hsct outcomes in the treatment of hematologic malignancies , including
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|everolimus versus vs brachytherapy combination|rituximab bortezomib novartis llc 501|rivogenlecleucel|about rivo-cel ( bpx-501 ) rivo-celtm ( entity ) is an allogeneic polyclonal t cell product designed to reduce the rate of relapse of leukemia following a stem cell
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kh ja al district province|regulatory early technology premature commercial|kymriah|– conserving the clinically validated cd19 car cell manufacturing process minimizes confounding risks penn process , not novartis process ; avoids entity release
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kh ja al district province|manufactured produced both developed sponsored|kymriah|the fda has also approved two non-aav gene therapy products , entity by novartis international ag , for pediatric and young adult patients with a form of acute lymphoblastic leukemia and yescarta by
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kh ja al district province|dota boost quest novartis smart|kymriah|two such companies , novartis international ag ( entity® ) and kite pharma inc . / gilead sciences , inc . ( yescarta® ) , have now commercialized autologous car+ t cells against cd19 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5), ('DIS', 1)])|cell|kh ja al district province|colistin adalimumab etanercept buprenorphine infliximab|kymriah|the company did not recognize royalty revenue in the comparative periods in the prior year given that entity was first approved for commercial sale in the second half of 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cell|kh ja al district province|crs sle itp ra ics|kymriah|only 20% of entity or yescarta patients treated with tocilizumab had resolution of signs and symptoms 6 days after onset of crs and ~50%
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|kh ja al district province|entity alliance therapeutics pivotal orphan|kymriah|nomenclature ‘zuma-19 , may be the basis for the registration of lenzilumab , given the similar trial design to yescartas and novartiss entity® ( “entity” or “entity®” ) registration trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kh ja al district province|google english fda novartis pros|kymriah|both entity and yescarta carry “black box” warnings in their labels for nt and crs and are subject to a rems program ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|kh ja al district province|from aug by data audit|kymriah|maintaining clear leadership in share of voice entity polivy xpovio yescarta share of voice aug sep oct monjuvi compared to >50% monjuvi monjuvi 50% 30% 0% hcp engagement
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|cell|kh ja al district province|nivolumab immunotherapy rituximab trastuzumab ipilimumab|kymriah|the fda approved entity ( tisagenlecleucel ) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia ( all ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3), ('DIS', 1)])|cell|kh ja al district province|etanercept infliximab dexamethasone rituximab adalimumab|kymriah|because of the risk of cytokine release syndrome and neurological events , entity is being approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cell|kh ja al district province|kit platform vector cell cells|kymriah|september 2018 , we entered into a license and collaboration agreement with novartis to manufacture and supply their car-t cell therapy entity® in china .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 5)])|cell|kh ja al district province|celecoxib bevacizumab erlotinib docetaxel gemcitabine|kymriah|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to yescarta or entity source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|kh ja al district province|gene genes omega quest novartis|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , namely , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cell|kh ja al district province|namely viz notably genes omega|kymriah|in 2017 , three gene therapies were approved for the first time in the united states , entity , yescarta , and luxturna .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|kh ja al district province|novartis marketing bms nivolumab ipilimumab|kymriah|in august 2017 , novartis received fda approval for entity and paid the company $2 . 5 million as a result of the achievement of a related milestone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cell|kh ja al district province|this ipilimumab immunotherapy nivolumab trail|kymriah|entity is a genetically-modified autologous t-cell immunotherapy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 2)])|cell|kh ja al district province|cell corporation therapeutics pharmaceuticals cells|kymriah|there are currently two car-t therapies approved in the u . s . and eu , novartis entity ( tisagenlecleucel ) and gilead / kites yescarta ( axicabtagene ciloleucel ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 4)])|cell|kh ja al district province|nivolumab rituximab bortezomib immunotherapy ipilimumab|kymriah|commenting on the results , joseph jimenez , ceo of novartis , said : “novartis became the first company to commercialize a car-t therapy , entity , in q3 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|kh ja al district province|tis this rituximab rtx nivolumab|kymriah|• entity ( tisagenlecleucel ) is a cd19-directed genetically modified autologous chimeric antigen receptor t-cell ( car-t ) therapy delivered as an intravenous infusion .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cell|kh ja al district province|also fda recently possibly rituximab|kymriah|yescarta has been approved for the treatment of relapsed or refractory large b-cell lymphoma and entity for the treatment of relapsed or refractory b-cell precursor acute lymphoblastic leukemia .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 4), ('OTHER', 4)])|cell|forget al audio tar ban|rituximab smart cd19 rtx nivolumab|yescarta|in 2017 , the fda approved the first two car-t cell therapies , kymriah and entity , after these products demonstrated strong efficacy in select relapsed or refractory b cell malignancies .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|forget al audio tar ban|epoch rituximab chop bortezomib nivolumab|yescarta|one of these therapies , entity® obtained accelerated approval for treatment of refractory non-transplant-eligible dlbcl patients in october 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|forget al audio tar ban|smart artemis epoch abl alk|yescarta|finally , two car-t cell therapies were just approved for the treatment of all – kymriah™ ( novartis ) and entity™ ( gilead ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|cell|forget al audio tar ban|therapeutics tm cell sciences gene|yescarta|novartis kymriah™ and gileads entity™ , two gene-modified cell-based therapies , are approved in both the united states and europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('BIO', 1)])|cell|forget al audio tar ban|medicines supplies cells pharmaceuticals equipment|yescarta|further , if contaminants are discovered in our supply of entity or in the manufacturing facilities , such manufacturing facilities may need to be closed for an extended period of time to
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|forget al audio tar ban|rituximab nivolumab ipilimumab bortezomib sunitinib|yescarta|in october 2017 , kite obtained fda approval to commercialize entity for the treatment of adults with relapsed / refractory diffuse large b-cell lymphoma .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|forget al audio tar ban|celecoxib erlotinib olanzapine thalidomide losartan|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3), ('DIS', 1)])|cell|forget al audio tar ban|tmz gemcitabine sunitinib bcg gsk|yescarta|no head to head trials have been conducted that would enable a direct safety and efficacy comparison to entity or kymriah source : uspi unless otherwise noted a aacr , 2017 .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|forget al audio tar ban|nivolumab ipilimumab infliximab bevacizumab thalidomide|yescarta|the objective of the phase 2 trial is to determine the effect of mavrilimumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cell|forget al audio tar ban|this ph all these sildenafil|yescarta|kite has published data on entity in all as well .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2), ('DIS', 1)])|cell|forget al audio tar ban|trap star etanercept rituximab smart|yescarta|arcalyst® is a registered trademark of regeneron pharmaceuticals , inc . and entity® is a registered trademark of gilead sciences , inc . , or its related companies . ​5 table of contentspart 
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|forget al audio tar ban|star omega silk boost quest|yescarta|the royalties stem from sales and milestones related to the entity® product .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 3)])|cell|forget al audio tar ban|nivolumab rituximab everolimus crizotinib ipilimumab|yescarta|additionally , in october 2017 , kite received approval from the fda for entity ( axicabtagene ciloleucel ) , formerly known as kte-c19 , for treatment of patients with r / r nhl .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cell|forget al audio tar ban|silk acth henry vip rainbow|yescarta|both kymriah® and entity® were approved with a rems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 3), ('DRUG', 2), ('DIS', 1)])|cell|forget al audio tar ban|rituximab cd19 alk cll chop|yescarta|two car-t therapies have been approved to treat large b-cell lymphoma , kymriah® and entity® , and others are being tested in clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|forget al audio tar ban|rituximab ipilimumab nivolumab mab epoch|yescarta|pipeline , building on current marketed products and late-stage clinical candidates for patients with hematological malignancies at kite and gilead , including entity® , tecartus® and magrolimab .
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|forget al audio tar ban|celecoxib erlotinib olanzapine thalidomide losartan|yescarta|the primary objective of the study is to determine the effect of lenzilumab on the safety of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cell|forget al audio tar ban|ac acc acl asc adc|yescarta|the initial results of axicabtagene ciloleucel ( entity ) , the prognosis of high-grade chemo refractory nhl , is dismal with a medium survival time of a few weeks .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|forget al audio tar ban|this thalidomide sunitinib immunotherapy ipilimumab|yescarta|entity is a therapy for patients who have not responded to or who have relapsed after at least two other kinds
OrderedDict([('OTHER', 5)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cell|forget al audio tar ban|bevacizumab rituximab sunitinib bortezomib ipilimumab|yescarta|this was notable given the patient had relapsed following treatment with entity® .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 2)])|cell|tab vaginal versus cream av|match rituximab novartis immunotherapy nivolumab|tabelecleucel|recent highlights and anticipated upcoming milestones tab-cel® ( entity ) • two phase 3 clinical studies are ongoing ( match and allele ) to evaluate tab-cel® for patients with ebv+ ptld
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cell|tab vaginal versus cream av|this nivolumab ipilimumab immunotherapy cetuximab|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda- and ema-approved therapy for
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 3)])|cell|tab vaginal versus cream av|this ipilimumab nivolumab immunotherapy cetuximab|tabelecleucel|we believe that entity has the potential to be the first commercially available off-the-shelf t-cell immunotherapy and the first fda and ema approved therapy
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 3)])|cell|tab vaginal versus cream av|ipilimumab this nivolumab immunotherapy rituximab|tabelecleucel|with entity poised to potentially become the first approved off-the-shelf t-cell therapy and a robust pipeline of high potential candidates , our ambition
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|spinal vertebral spine lumbar cranial|tendon|and adcon-t / n to be marketed in the 19 european union countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|tendon ligament capsular acl tear|tendon|warnings and precautions risk of tendinitis , entity rupture , peripheral neuropathy and central nervous system effects is increased with use of fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|tendon cartilage meniscus ligament meniscal|tendon|and / or product development for various treatments for or involving fracture repair , spine fusion surgery , cartilage defect repair and ligament and entity repair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|repair ligament tendon running rupture|tendon cartilage meniscal tendons meniscus|tendon|graftjacket® maxforce extreme is a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of entity and ligament repairs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|repair ligament tendon running rupture|orthopaedic spinal orthopedic neurosurgical neurosurgery|tendon|now being sold in all major countries in the eu , as well as australia and new zealand for use in entity and peripheral nerve surgeries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|tendon ligament muscle cartilage nerve|tendon|therapeutic devices utilizing its nonthermal ultrasound technology ( " orthosound " ) for use in medical applications that relate to bone , cartilage , ligament or entity diagnostics and healing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|tendon meniscus collagen bones muscle|tendon|extent the gingiva functions as part of the apparatus holding the tooth to the jaw ) , ligament ( including the periodontal ligament ) , entity and / or cartilage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|repair ligament tendon running rupture|gastrointestinal neurologic clotting adverse thrombotic|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|brain body mind kidney muscle|tendon|bone & entity pill it consists of extracts of a variety of chinese medicinal herbs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|repair ligament tendon running rupture|gastrointestinal neurologic clotting adverse thrombotic|tendon|quinsair is contraindicated in patients with hypersensitivity to levofloxacin , a history of entity disorders related to fluoroquinolones , epilepsy , or who may be pregnant or breast feeding .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|cartilage muscle tendon marrow nerve|tendon|the medicinal product is to be taken orally for the purpose of curing bone and entity disorders .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|repair ligament tendon running rupture|antibiotic ciprofloxacin antimicrobial antibiotics multidrug|tendon|warnings regarding the risk of entity related adverse events were already included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|repair ligament tendon running rupture|tendon tendons cartilage muscle tissue|tendon|graftjacket® is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|repair ligament tendon running rupture|tissue tendon cartilage repair ligament|tendon|by augmenting the strength of the entity repair and incorporating biologically , graftjacket® regenerative tissue matrix increases surgeons confidence in the surgical outcome .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|repair ligament tendon running rupture|tendon tendons cartilage muscle tissue|tendon|graftjacket® matrix is a human-derived soft tissue graft designed for augmentation of entity and ligament repairs such as those of the rotator cuff in the shoulder and achilles entity in the ankle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|repair ligament tendon running rupture|cyst cholecyst cellul pneumon enter|tendon|fluoroquinolones are 26 known for several undesirable effects such as entityitis , achilles entity rupture , c . difficile colitis , and hepatotoxicity and central nervous system side effects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|repair ligament tendon running rupture|spinal spine vertebral lumbar brain|tendon|adcon-l and adcon-t / n to be marketed in the 19 european countries which recognize ce marking for lumbar disc surgery and entity and peripheral nerve surgeries , respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|tissue|repair ligament tendon running rupture|antibiotic ciprofloxacin antimicrobial antibiotics multidrug|tendon|currently , warnings regarding the risk of entity related adverse events are included in the prescribing information , as part of a class labeling , for all fluoroquinolones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|repair ligament tendon running rupture|tendon ligament cartilage tissue fracture|tendon|ligament and entity repair ligaments are the soft tissues that connect bone to bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|repair ligament tendon running rupture|myocardial kidney muscle dna ocular|tendon|further , in july 2008 , the fda requested manufacturers of fluoroquinolones to include a black box warning for entity damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macular macula mac fundus intravitreal|macula|optina for diabetic entity edema on october 7 , 2013 , we received positive results from the interim analysis of optina trial for diabetic macular edema .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|macula macular av al subclinical|retina ophthalmology ocular vision cataract|macula|company presented preclinical data at the association for research and vision in opthalmology conference in may 2012 , and at the entity society meeting in june 2012 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|macula macular av al subclinical|tissue tissues vessels body plaques|macula|the leakage of fluid , solutes , proteins and immune cells cause the entity to swell and thicken .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|nerve ganglion macula lens brain|macula|described as a partial or total loss of visual field resulting from certain progressive disease or degeneration of the retina , entity or nerve fiber bundle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macula choroid retina vitreous macular|macula|in patients with dme , leakage from these abnormal blood vessels occurs in the central portion of the retina , called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|retina macula eyes vision choroid|macula|introduction to amd amd is a progressive and irreversible disorder of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macula lens retina choroid cornea|macula|the entity is the central portion of the retina in the eye and is responsible for both high acuity vision and color
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|va us american nih uk|macula|according to the entity vision research foundation , as many as 15 million people in the united states suffer from some form of amd , with more
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|retina macula nerve lens cornea|macula|these vessels can leak fluid and blood , which may lead to swelling and damage of the entity causing vision loss .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|macula retina field vf eyes|macula|implies , usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) because of damage to the retina .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|mac medulla pigment gla macula|macula|for age-related entityr degeneration , or amd , which is a disorder of the central portion of the retina , known as the entity , that may result in blindness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|retina vision eyes cornea macula|macula|or neovascularization , causes vision loss due to blood and protein - 94 - table of contents leakage below the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|endocrine pediatrics spine pituitary myeloma|macula|the principal investigator of study 003 presented a case report from the first patient to complete the protocol at the entity society meeting on february 19 , 2014 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macula retina eyes choroid cornea|macula|in the dry form , there is a breakdown of retinal pigment epithelial cells in the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macula choroid lens vitreous macular|macula|the wet form is caused by growth of abnormal blood vessels ( cnv ) under the central part of the retina or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|choroid retina macula vitreous rpe|macula|an eye disease characterized by the growth of abnormal blood vessels under the central part of the retina , called the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|medulla hen wet grid dme|macula|entityr edema is the build-up of fluid that can cause abnormal swelling of the macula , the portion of the retina responsible for central vision and color perception .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|macula macular av al subclinical|macula retina lens cornea fundus|macula|the central portion of the retina is the entity , which is the region responsible for seeing color and the acute central vision necessary for activities such as reading , face
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|macula macular av al subclinical|macula retina field vf cup|macula|that usually affects older adults and results in a loss of vision in the center of the visual field ( the entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|macula macular av al subclinical|vitreous macula choroid stroma cornea|macula|this process , known as angiogenesis or neovascularization , results in fragile blood vessels that leak fluid and blood into the entity , the center portion of the retina .
OrderedDict([('OTHER', 3), ('DRUG', 2)])|OrderedDict([('OTHER', 5)])|tissue|epidural intrathecal nerve bupivacaine lidocaine|ecm dermis collagen epidermis nerve|perineurium|the lamellar structure of the entity and a deficiency in collagen packing in the endoneurium was observed more frequently and to a larger extent in fibromyalgia
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|epidural nerve sclerosis spinal sensory|dermis fascia nerve nerves epidermis|endoneurium|the lamellar structure of the perineurium and a deficiency in collagen packing in the entity was observed more frequently and to a larger extent in fibromyalgia patients than in controls .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium mucosa fascia stroma endothelium|urothelium| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium mucosa fascia endothelium epidermis|urothelium|months post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial permeability uroth neoplasia intrav|urothelial superficial uroth muscle submucosal|urothelium|bladder carcinoma is a specific form of bladder cancer resulting from the development and progression of cancerous tumors within the entity layer .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial permeability uroth neoplasia intrav|kidney pelvis ureter kidneys tract|urothelium|eligible patients included those with transitional cell carcinoma of the entity , including renal pelvis , ureters , urinary bladder , and urethra .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|tissue urethra hydrogel gel prostate|urothelium|not effectively permeating the entity  rtgel delivered treatment to the bladder as expected with dwell time of up to 10 hours
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium egfr cilia endothelium permeability|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium mucosa fascia endothelium stroma|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|urothelial uroth lining urethra epithelium|urothelium|upper tract urothelial carcinoma ( utuc ) utuc refers to malignant changes of the entity ( the epithelial lining ) of the upper urinary tract of the calyces , renal pelvis and ureter .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium endothelium fascia mucosa stroma|urothelium|three months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of entity , submucosa and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium mucosa epidermis dermis muscle|urothelium|beneath the entity , there is a layer called the lamina propria .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial permeability uroth neoplasia intrav|retina dermis epidermis brain bbb|urothelium|apollo trial did not meet the primary endpoint , believed to be the result of botox not effectively permeating the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium egfr cilia endothelium cilium|urothelium|one theory of pbss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|urethra epithelium mucosa body ureter|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag , layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium egfr cilia endothelium permeability|urothelium|one theory of cpps pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial permeability uroth neoplasia intrav|vasculature bbb endothelium vessel circulation|urothelium|implantation of stray " floating " tumor cells in areas in which the entity has been disrupted may be followed by the growth of the implanted cells to form a new tumor .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|epithelium egfr cilia endothelium diaphragm|urothelium|one theory of bpss pathological cause implicates a dysfunction of the bladder epithelium surface called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|urothelial permeability uroth neoplasia intrav|transitional epithelial urothelial stromal luminal|urothelium|the innermost lining is comprised of cells called urothelial or transitional cells , and this inner layer is called the entity or transitional epithelium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|urothelial permeability uroth neoplasia intrav|urethra epithelium mucosa body ureter|urothelium|normally , the entity is covered with a mucus layer , the glycosaminoglycan , or gag layer , which is thought to protect the bladder from urinary
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|urothelial permeability uroth neoplasia intrav|integrity anatomy inflammation pathology innervation|urothelium|be well positioned , as it will address both the acute pain the patient experiences and the dysfunctional aspect of the entity of the bladder wall .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|mucosa ligaments epithelium vasculature stroma|epithelium|overview of ibd ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the entity and the submucosa of the colon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|junction squamous junctional lining epithelial|epithelium membrane cells epithelial layer|epithelium|key portions of the eye that were evaluated for levels of drug remaining were the sclera-choroid-retinal pigmented entity , or scr , the neural retina and the vitreous .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|epithelium epithelial epithelia membrane apparatus|epithelium|in occult lesions , all of the blood vessels are below the retinal pigment entity , or rpe , and the areas on angiograms have a stippled appearance .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|lining mucosa epithelium organs integrity|epithelium|this includes injuries to the hematopoietic and immune systems , the entity of the digestive tract and hair follicles .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|junction squamous junctional lining epithelial|matrix epithelium tissue tissues fibroblasts|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|junction squamous junctional lining epithelial|epithelium matrix tissue fibroblasts tissues|epithelium|tamibarotene does not bind the rar-g receptor , the major retinoic acid receptor in the dermal entity , which should lessen the occurrence of ras .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|epithelium epithelial epithelia rpe membrane|epithelium|by the much greater amount of the fluorescent protein expressed ) with aav8 as compared to aav2 in the retinal pigment entity ( rpe ) and to the photoreceptor ( pr ) layer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|junction squamous junctional lining epithelial|cells cell epithelium body mucosa|epithelium|of calcium and phosphate ions , which are hypothesized to exert their beneficial effects by diffusing into intracellular spaces in the entity and permeating the mucosal lesion in mucositis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|epithelium allograft endothelium implant flap|epithelium|these events are commonly observed following removal of the corneal entity and in the treatment group of our trials , occurred at a higher incidence than observed in control patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|junction squamous junctional lining epithelial|morphology histology proliferation density architecture|epithelium|pathologic analysis showed marked effects on breast duct entity in ducts treated with either drug compared with untreated ducts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|junction squamous junctional lining epithelial|mucosa wall epithelium tissue cells|epithelium|blood causes a prolonged period of low blood flow to the intestines that can lead to damage to the intestinal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|mucosa epithelium tract wall lumen|epithelium|the expression of il-15 in the intestinal entity is necessary for villous atrophy in animal models of celiac disease and circumstantial evidence suggests this to be the case
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|epithelium endothelium cornea cortex retina|epithelium|the procedure involves the removal of " bowman  s layer , " an intermediate layer between the entity ( outer corneal layer ) and the stroma ( middle corneal layer ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|junction squamous junctional lining epithelial|cell cells fibroblast epithelium fibroblasts|epithelium|the hair matrix entity is one of the fastest growing cell populations in the human body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1), ('DRUG', 1)])|tissue|junction squamous junctional lining epithelial|hormones immunity collagen cells dna|epithelium|the gi tract is highly sensitive due to the continuous need for crypt stem cells and production of mucosal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|junction squamous junctional lining epithelial|epithelium epithelial epithelia surface cells|epithelium|loss of the functional oca2 protein results in a lack of pigment in the retinal pigment entity and the underlying choroid layers .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|junction squamous junctional lining epithelial|epithelium epithelial epithelia cells membrane|epithelium|for lca2 , retinal function was restored by reconstituting gene function in the retinal pigment entity ( rpe ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|junction squamous junctional lining epithelial|cavity mucosa circulation passages fluid|epithelium|the nasal administration is intended to determine if physiologic measurement of cftr function can be obtained in the nasal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|epithelium mucosa wall surface membrane|epithelium|our vaginal products adhere to the vaginal entity until discharged upon normal cell turnover , a physiological process that can take 72 hours , or longer , and provide sustained and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|junction squamous junctional lining epithelial|mucosa epithelium cavity sinus septum|epithelium|however , the nasal entity is the most accessible site for measuring cftr function in humans and provides a human model of epithelial cell uptake
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ectoderm embryonic chord surface distal|ectoderm pns ens medulla stroma|ectoderm|and the capability to differentiate into cells representing the three germ layers - endoderm ( gut epithelium ) , mesoderm ( striated muscle ) and entity ( neural epithelium ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|embryonic gene ring all stop|hematopoietic dendritic muscle endothelial therapeutic|endoderm|the third patent , granted in the united states , covers the method for deriving entity cells using stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|embryonic gene ring all stop|mesoderm mesenchymal pluripotent mes embryo|endoderm|territory patent no . general subject matter expiration us 7 , 763 , 466 method to produce entity cells may 2025 us 7 , 955 , 849 method of enriching population of mesoderm cells may 2023 us
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|embryonic gene ring all stop|mast these nk dendritic epithelial|endoderm|in particular , entity cells make cells of internal organs such as the lung , pancreas , and liver as well as other internal cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|embryonic gene ring all stop|dendritic neural pluripotent therapeutic ips|endoderm|by way of example , we are currently a party to an interference proceeding that involves patent filings for making entity cells from hescs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|embryonic gene ring all stop|mesoderm ectoderm endoderm provision limb|endoderm|that the derivation of any of the entityal lineage cells from embryonic stem cells would necessarily pass through the definitive entity stage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|embryonic gene ring all stop|testing diagnosis proof trials endpoints|endoderm|if we are not successful in the viacyte appeal , viacyte would retain its patent claims directed to definitive entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|embryonic gene ring all stop|pancreas hepatocytes hepatocyte liver islet|endoderm|definitive entity is an early pre-cursor of numerous cell types including liver and β-cells of the pancreas that could potentially treat diabetes ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|embryonic gene ring all stop|these stromal hematopoietic epithelial mesenchymal|endoderm|entity cells develop into the internal organs such as the heart , liver , pancreas and intestines , among other cell types .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|embryonic gene ring all stop|epithelial keratinocyte hematopoietic fibroblast endothelial|endoderm|australia patent 2010200610 – the claims in this patent relate to cell cultures comprising entity cells , one of the three major lineages of cells that make up the human body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|embryonic gene ring all stop|mesoderm tissue muscle tissues ectoderm|endoderm|stem cells and pluripotency stem cell primative and thus unspecialized self-renewing can differentiate into cells with specific functions ectoderm mesoderm entity skin hair brain nerves etc .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|embryonic gene ring all stop|endoderm ectoderm cardiomyocytes osteoblasts dermis|endoderm|mesentity cells are precursor cells that differentiate into mesoderm and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|embryonic gene ring all stop|embryonic mesenchymal hematopoietic neural lymphoid|endoderm|these rulings related to interference proceedings involving patent filings relating to definitive entity cells .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|lung placenta placental embryonic embryo|mesoderm|emt is essential for numerous developmental processes including entity formation and neural tube formation .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|developmental gene segmental position cell|these mesenchymal hematopoietic progenitor endothelial|mesoderm|entity cells develop into muscle , bone and blood , among other cell types .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|mouse molecular molecule mammalian murine|mesoderm|developing a drug-targeting platform based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|developmental gene segmental position cell|angiogenesis hematopoiesis embryonic myeloid developmental|mesoderm|the libraries and screens will focus on genes important to entity and early hematopoietic development .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|developmental gene segmental position cell|mesoderm ectoderm embryo hematopoietic epidermis|mesoderm|produce such cells , and applications of such cells for es cell-derived immature pluripotent precursors of all the cells of the entity and endoderm lineages .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|developmental gene segmental position cell|molecular mammalian melanoma marrow early|mesoderm|table of contents raptors entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|molecular multiple mammalian matrix gene|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|cortex stroma mesoderm epidermis endothelium|mesoderm|in the early embryo , the middle layer of cells ( known as the entity ) and certain portions of the outer cell layers give rise to groups of cells that differentiate into bone marrow stroma ,
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|under upon ms sequencing sequence|mesoderm|promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|molecular multiple matrix mammalian gene|mesoderm|- 38 - table of contents our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|mouse molecular mammalian molecule murine|mesoderm|are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein , or rap , and the entity development protein , or mesd .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|mesoderm ectoderm mesenchyme epidermis embryo|mesoderm|mesendoderm cells are precursor cells that differentiate into entity and endoderm .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|under ms upon sequencing worth|mesoderm|and drug delivery platform , based on the proprietary use of a human protein called receptor-associated-protein , or rap and the protein entity development , or mesd .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|developmental gene segmental position cell|mesenchymal hematopoietic neural embryonic mesoderm|mesoderm|the seven new cell lines have markers of diverse entity and neural crest cell types and are designated w11 , z2 , sk31 , sm35 , t36 , en51 , and en55 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|mouse mammalian molecular early matrix|mesoderm|is a promising novel drug-targeting platform , based on the proprietary use of a human protein called receptor-associated protein ( rap ) and entity development protein ( mesd ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|molecular new preclinical gene translational|mesoderm|· our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|molecular multiple mammalian matrix gene|mesoderm|our entity development protein ( mesd ) platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|preclinical new gene molecular translational|mesoderm|• our entity development protein , or mesd , platform consists of wnttide™ for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|gene molecular preclinical new translational|mesoderm| our entity development protein , or mesd , platform consists of wnttide for the potential treatment of breast cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|developmental gene segmental position cell|body world organism animal skeleton|mesoderm|mesenchymal stem cells ( mscs ) : embryonic-like cell capable of differentiating into multiple tissues of the entity , including cartilage , bone , tendon , ligament , muscle , stroma and fat .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina optic retina iris macula|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial ( ht-29 ) cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular propria stratum fascia|lamina|beneath the urothelium , there is a layer called the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina dura canal cross del|lamina muscular intestinal lymphoid propria|lamina|the adaptive response is mediated by gluten-reactive cd4+ t cells in the entity propria that recognize gluten-derived peptides when presented by the hla class ii molecules dq2 or dq8 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular intestinal propria stratum|lamina|gliadin fragments in celiac disease , they are able to pass thru the leaky paracellular pathway from the lumen to the entity propria , where the immune cells reside and are then activated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular pars propria layer|lamina|targeted localization of amt-101 to the gi tissue entity propria is expected to translate into clinically meaningful reductions in inflammation and disease activity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular propria glia stratum|lamina|gi tissue or entering into systemic circulation : when designing our product candidates , we can target the therapeutic payload to the entity propria of the local gi tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular propria dura stratum|lamina|in healthy bowel wall , bacteria cannot pass from the lumen to the entity propria because tight junctions are maintained between the epithelial cells ( intact barrier function of the bowel wall ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|gsk novartis pfizer ec lilly|lamina|on february 25 , 2015 , the company entered into the license agreement with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular propria glia stratum|lamina|at any given time , over 70% of an individuals immune system resides in the entity propria , which is the target-rich tissue of the intestinal tract .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|dura spine disc pedicle facet|lamina|in a decompressive laminectomy , the surgeon removes bone , known as the entity , from the back part of the symptomatic vertebrae over the spinal canal to create more space for , and relieve pressure
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina dura canal cross del|lamina propria muscular lymphoid de|lamina|cell-secreted gp96-ig-peptide complexes induce entity propria and intraepithelial cd8+ cytotoxic t lymphocytes in the intestinal mucosa .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|this which singapore llc india|lamina|entity is a private corporation over which dr . raouf guirguis has sole control .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|american oxford equine world metropolitan|lamina|&#160 ; on february 25 , 2015 , the company entered into a license agreement with entity equities corporation ( &#8220 ; entity&#8221 ; ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina dura canal cross del|vitreous lamina ciliary rpe iris|lamina|these data were collected in tests in human entity cribrosa cells grown from human optic nerve heads and from human intestinal epithelial cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|disc vertebra disk lamin spine|lamina|of all or part of a damaged disc , and laminectomy , which is the removal of all or part of a entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina dura canal cross del|lamina propria muscular lymphoid glia|lamina|in the gut antigens such as gluten are processed by resident dendritic cells in the entity propria which then migrate to the local mesenteric 31 lymph nodes .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|lamina dura canal cross del|lamina muscular propria lymphoid stratum|lamina|disease activity index , colonic leukocytic infiltration , entity propria neutrophils and colonic tnf expression were used as endpoints .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina optic iris retina macula|lamina|in-vitro experiments have shown that sirnas against factor 5a protected human entity cribrosa ( optic nerve ) and colon epithelial cells from tnf alpha induced apoptosis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|lamina dura canal cross del|lamina muscular stratum propria plexus|lamina|ta and cis are limited to the urothelial layer , and t1 is limited to the layer below , which is the entity propria .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|lamina dura canal cross del|transfected cultured cho rat lncap|lamina|by inhibiting factor 5a , we were able to reduce tnf-a induced apoptosis by 80% in entity cribrosa cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|body muscle limb tissue muscles|myocardium|finally , the cells could promote regeneration of viable new tissue , improving the functional capacity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium arteries circulation vessels lungs|myocardium|thus such a molecule should have desirable properties in experiments aimed at inducing collateral circulation in the entity of patients with coronary stenosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium cardiomyocyte mitochondria cardiomyocytes ventricles|myocardium|may also provide information on cardiac mitochondrial membrane potential , enabling global and regional assessment of the electro-physiologic integrity of the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|lungs body brain extremities chest|myocardium|characterized by thoracic pain and a feeling of suffocation , most often due to anoxia ( lack of oxygen supply ) to the entity precipitated by physical exertion or excitement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium aorta hearts vasculature arteries|myocardium|the primary objectives of this trial are to evaluate the safety and efficacy of injecting 150 million mpcs into the native entity of lvad recipients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|tissue muscle cell myocardium cells|myocardium|cm1 has been shown to couple electrically and mechanically with the host entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium tissue cardiomyocytes myocardial damage|myocardium|the death of myocardial cells first occurs in the area of entity that is most distal to the arterial blood supply , the endocardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|muscle wall myocardium myocytes chamber|myocardium|potassium channels that control normal functioning of the middle layer of heart wall composed of cardiac muscle , or the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium tissue tissues hearts muscle|myocardium|the hesc-cm treated heart ( right ) shows a large graft of human heart muscle ( green ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocytes pacemaker myocardium myocyte chambers|myocardium|appear to target these channels which mediate atrial arrhythmia without disrupting potassium channels that control normal functioning of the ventricular entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium tissue cardiomyocytes tissues hearts|myocardium|the heart of an nhp by hesc-cm transplantation the saline-treated heart ( left ) shows infarct scar tissue ( blue ) replacing the entity lost to infarction .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|tissue myocardium tissues muscle regions|myocardium|responsive relationship , with higher doses of bone marrow mononuclear cells resulting in reduced fibrosis and increased microvascular change in infarcted entity 60 days after treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|tissues tissue region muscle organs|myocardium|the targeted 24 table of contents cardiomyocytes are expected to produce sustained therapeutic protein levels in the entity where it is needed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|mice rats animals tissue myocardium|myocardium|when injected into ischemic entity , mlcs are very potent inducers of large caliber arteriogenesis compared to 104 table of contents index to financial statements
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium brain body tissue liver|myocardium|bfpet has been designed to effectively differentiate among those cells of the entity that are ischemic , infarcted and those that are healthy .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|grafts myocardium vessels arteries hearts|myocardium|physicians to screen for coronary artery disease , to assess flow rates and flow reserve , and to distinguish viable from nonviable entity for bypass and transplant candidates .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium tissues organs tissue regions|myocardium|if blood flow can be restored to at-risk entity , more heart muscle can be saved from irreversible damage or death .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|myocardium ventricle septum ventricles myocytes|myocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the entity and ultimately to the epicardium .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|circulation brain capillaries bloodstream microcirculation|myocardium|this results in the solution entering the entity via post capillary venules .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|ventricular myocardium myocardial cardiomyopathy ventricle|tissue myocardium muscle ventricle structure|myocardium|we believe that ik-5001 will work as a temporary structural support while the damaged entity heals by replacing the dead tissue that would normally support the wall of the heart .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|this his each another its|mesothelium|the company will license entity mab from the nih and in return the agreement , requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|peritoneum pleural peritoneal diaphragm mesothelioma|mesothelium|mesothelioma mesothelioma is a rare form of cancer in which malignant cells develop in the entity , a protective lining that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|permeability adhesion structural sclerosis collagen|new novel chimeric targeted melanoma|mesothelium|of march 22 , 1999 , the company and nih entered into an exclusive worldwide licensing agreement to develop and commercialize a entity antigen therapy ( mesothelin mab ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|this each his another its|mesothelium|the company will license entity mab from the nih and in return , the agreement requires the company to make a $75 , 000 non-refundable license issue payment
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|pleural peritoneum diaphragm mesothelioma lung|mesothelium|malignant pleural mesothelioma is an aggressive form of cancer that occurs in the entity , the thin layer of tissue that covers the lungs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|peritoneum lung pleural lungs abdomen|mesothelium|differentiating mesothelioma from adenocarcinoma mesothelioma is a cancer that develops in the entity - a protective sac that covers most of the bodys internal organs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|permeability adhesion structural sclerosis collagen|remainder most lining surface tissues|mesothelium|when ovarian cancer spreads to the entity of the organs within the peritoneal cavity , it can result in encasement of these organs with significant pain and eventual
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|permeability adhesion structural sclerosis collagen|peritoneum mesothelioma mesoth pleural stroma|mesothelium|about malignant mesothelioma malignant mesothelioma is a cancer that originates in the entity – the tissue that surrounds different organs in the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|caries dentin thickness material cement|dentin cement roots teeth matrix|dentine|the lactic acid erodes the mineral in enamel and entity , weakening the tooth and ultimately resulting in decay .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|caries enamel composite classroom mineralization|enamel extracellular oligomeric experimental injectable|enamel|ongoing dental projects include : o an entity matrix protein-based product for endodontic therapy ( treatment of dental pulp ) - a phase i trial is underway .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|caries enamel composite classroom mineralization|surface cells tissues root tissue|enamel|fluorinex has developed a unique device that delivers fluoride ions directly to the tooth entity via a sophisticated electro-chemical technique .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|caries enamel composite classroom mineralization|enamel extracellular oligomeric injectable experimental|enamel|o an entity matrix protein-based product to reduce pain and discomfort following scaling and root planing of periodontal pockets - a phase ii
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|caries enamel composite classroom mineralization|polish nail replacement bank medicine|enamel|in nail entity , sally hansen® , the number one brand , increased its market share to 27 . 4% .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|blue green paper dental rubber|enamel|toilet core walls shall receive 2 coats latex entity paint .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|caries enamel composite classroom mineralization|amber cotton black dental acrylic|enamel|d . exposed columns and ironwork at open ceiling areas shall be cleaned , primed painted with semi-gloss entity paint to cover .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|dental caries restorative tooth liquid|enamel|entity care is the first toothpaste to combine the cleaning and whitening properties of baking soda with fluoride and patented liquid calcium to fill tooth surfaces and restore enamel luster .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|enamel natural dentin extracellular tooth|enamel|the active ingredient is the entity matrix protein amelogenin and the product has been launched in north america , europe and japan for treatment of patients who
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|caries enamel composite classroom mineralization|surface matrix enamel structure epithelium|enamel|derives its energy from carbohydrate metabolism as it converts dietary sugar to lactic acid which , in turn , erodes the tooth entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|dental tooth self caries root|enamel|- more - early in the quarter , the company launched arm & hammer entity care toothpaste , its most important oral care initiative in several years .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|work cleaning water machine clean|enamel|wash and polish all mirrors , powder shelves , bright work and entity surfaces , including flushometers , piping , toilet set hinges , and all metal .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|polish beds substitute clips extensions|enamel|will continue to market multiple nat robbins color cosmetics items including lipliner pencils , lipsticks , eyeliner pencils , eye shadow , mascara , nail entity and assorted accessories .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|industrial indoor artificial apple olive|enamel|simply wow™ was compared to orange clean , fantastik and formula 409 for the ability to remove cooked-on grease from an entity stovetop .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|polish substitute nail clip type|enamel|number of its principal product categories in the u . s . mass-market distribution channel , including the lip , eye , face makeup and nail entity categories .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|caries enamel composite classroom mineralization|tissues tissue matrix enamel cells|enamel|hap is naturally found in bone and tooth entity and is rapidly integrated into the human body .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|caries enamel composite classroom mineralization|beds surfaces polish samples wear|enamel|remover and nail care products in certain countries outside the u . s . in 2003 , the company launched colorstay always on nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|preparation polish substitute spray filler|enamel|on net sales of a hair-off mitten that is a depilatory-product accessory , and nutra nail 60 , a fast- acting nail entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|enamel tooth dentin structure material|enamel|as a person ages the adult teeth often become darker due to changes in the mineral structure of the tooth , as the entity becomes less porous and phosphate-deficient .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|body paper water screen front|enamel|floors , hand brush corners and hand brush toilet edges with approved germicidal detergent solution . 2 . wash completely all partitions , tile walls and entity surfaces .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|caries enamel composite classroom mineralization|enamel pulp collagen resin keratin|enamel|tooth decay is characterized by the dissolution of entity and dentin , eventually resulting in the destruction of the entire tooth .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cement canal resorption collagen dura|canal junction interface ligament complex|cementum|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root entity , gingiva and / or periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cement canal resorption collagen dura|surfaces canals walls structures structure|cementum|by coating the surface of the exposed dental root with emdogaingel during periodontal surgery , new root entity , periodontal ligament fibers , and surrounding bone tissue can be formed .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cement canal resorption collagen dura|surface sheath canal cap epithelium|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jawbone and cushions the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cement canal resorption collagen dura|sheath surface canal cap epithelium|cementum|a healthy tooth attachment apparatus is made up of the root entity , the outer layer of the root ; the periodontal ligament , which both anchors the root to the jaw bone and cushions
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cement canal resorption collagen dura|dentin keratin cement teeth stroma|cementum|the extent , the gingiva functions as 6 7 part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cement canal resorption collagen dura|tendons bones teeth ligaments osteoblasts|cementum|the periodontal setting , these agents do not directly stimulate the repair of other important tissues such as periodontal ligaments or entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|cement canal resorption collagen dura|dentin cement teeth keratin cartilage|cementum|only to the extent , the gingiva functions as part of the apparatus holding the tooth to the jaw ) , alveolar bone , entity , enamel and periodontal ligament .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cement canal resorption collagen dura|tendon cartilage muscle tendons dermis|cementum|are utilized even though these methods do not have the same capability as emdogain of regenerating the tissues - bone , entity and ligament - that make up the tooth-supporting structures .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodontal ligament caries periodon sclerosis|teeth gum tongue mucosa palate|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provide a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodontal ligament caries periodon sclerosis|teeth gum mucosa tongue palate|periodontium|data indicate that the presence of streptococcus oralis and streptococcus uberis provides a good indication of the health of the entity ( gums ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|periodontal ligament caries periodon sclerosis|tissue nerve skeleton tissues body|periodontium|these patents relate to the biodegradable in situ forming implants and the biodegradable system for regenerating the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|periodontal ligament caries periodon sclerosis|jaw gum teeth periodon tooth|periodontium|dr . caton has conducted many studies evaluating various treatment modalities for periodontitis and other diseases involving the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|endothelial dependent endothelium vasodil vasodilation|cells endothelium tissue beds tissues|endothelium|drug candidate indicates that consistent increases in gb3 levels were measured in cardiomyocytes ( as opposed to decreases measured in vascular entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial dependent endothelium vasodil vasodilation|journal club editors forum industry|endothelium|research articles , serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium endothelial ecm intima fibrin|endothelium|in the inflammatory component , white blood cells begin to roll along and then adhere to the entity , the thin layer of cells that lines the interior surface of blood vessels .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|brain arteries lungs kidneys kidney|endothelium|that the company believes may be important in identifying unique sites on the lining of the blood vessels or the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endothelial dependent endothelium vasodil vasodilation|tissue myocardium tissues endothelium vessel|endothelium|atherosclerotic plaque to 732 nanometer light delivered through a catheter resulted in elimination of the lesions without damage to the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium vasculature intima endothelial surface|endothelium|atherosclerotic apoe ko mice corresponding to initial steps of atherosclerosis that comprise cell to cell adhesion of monocytes / macrophages to the entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium macrophage monocyte endothelial cell|endothelium|the interaction between certain cell adhesion molecules on the surface of both the leukocyte and the entity facilitates these contacts .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|leukocytes platelets endothelium lymphocytes macrophages|endothelium|into inflamed areas because sle ( x ) present on the surface of white blood cells binds to selectin molecules present on activated entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium cells enos macrophages nos|endothelium|nitric oxide produced by the entity also inhibits the clumping of platelets , which are cells in the blood that promote clotting , and the adhesion of platelets
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|aorta intima aaa arteries atherosclerosis|endothelium|initially , this new tissue consists of healthy cells from the lining of the arterial wall ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial dependent endothelium vasodil vasodilation|number formation development presence network|endothelium|large caliber arteriogenesis compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the entity of capillaries .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|both thrombus tissue thrombosis otherwise|endothelium|clot is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|tissue|endothelial dependent endothelium vasodil vasodilation|both thrombosis inflammation endothelium thrombus|endothelium|cascade is most often triggered when there is damage or disruption to the lining of the blood vessel wall , or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium cells myocytes endothelial beds|endothelium|these experiments used cells important in human disease and aging--retinal pigment epithelium , fibroblasts , and vascular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|surfaces endothelium walls tissue surface|endothelium|white blood cells express carbohydrates on their surfaces that bind to e-selectin that is present on inflamed vascular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium ecm epithelium lung vasculature|endothelium|specifically , we believe that by inhibiting selectin-mediated adhesion of white blood cells to the entity , rivipansel prevents propagation of voc and promotes early resolution .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium aorta endothelial intima vasculature|endothelium|the entity , a single-cell lining of the arteries that acts as an interface between the blood and arterial wall , is impaired in
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|endothelial dependent endothelium vasodil vasodilation|vasculature cells vessels endothelium vessel|endothelium|protein markers , unique to the surface of the entity in specific organs and those markers that distinguish tumor blood vessels from those vessels in healthy tissue , are thought to
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium tissue intima epithelium membrane|endothelium|an overgrowth of the entity that forms capillaries and lines blood vessel interiors contributes to atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|endothelial dependent endothelium vasodil vasodilation|endothelium surface selectin vasculature surfaces|endothelium|binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|free fracture repair tendon bridging|patella meniscus chondrocytes cartilage chondrocyte|fibrocartilage|another type of cartilage ( entity ) serves a shock-absorbing function in the knee and in the spine between the vertebrae .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|free fracture repair tendon bridging|tissue structures cells tissues features|fibrocartilage|biopsies from 135 of 141 of these re-looks showed the development of meniscus-like entity , confirming the devices effectiveness as a surgical mesh .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|tissue|thickness transverse extension without posterior|osteoblasts chondrocytes osteocytes fibroblasts astrocytes|perichondrium|model was completed and bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 1)])|tissue|thickness transverse extension without posterior|osteoblasts chondrocytes fibroblasts osteocytes astrocytes|perichondrium|by dr . yu yamaguchi , bmp signaling was shown to be enhanced in the outermost cells of the growth plate , or entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|sclerosis focal interstitial fibrosis diffuse|matrix basement surface capillaries wall|mesangium|igan is a nonsystemic renal disease that is characterized by predominant iga deposition in the glomerular entity , causing mesangial proliferation and fibrosis .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|sclerosis focal interstitial fibrosis diffuse|surface basement matrix walls wall|mesangium|iga nephropathy igan is a common glomerulopathy diagnosed by the predominant histologic presence of galactose-deficient iga1 deposits in the glomerular entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|tissue|sclerosis focal interstitial fibrosis diffuse|walls periphery surface wall capillaries|mesangium|these iga containing immune complexes deposit in the entity of glomeruli in the kidney and are proinflammatory .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|sclerosis focal interstitial fibrosis diffuse|kidney glomeruli kidneys nephron podocyte|mesangium|chronic activation of inflammatory pathways also leads to long-term structural alterations in the entity , which results in reduced glomerular surface area and gfr .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|developmental position gene global comparative|these epidermal progenitor fibroblast epithelial|neuroectoderm|entity cells are committed to developing into cells of the skin and nervous systems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|developmental position gene global comparative|ectoderm mesoderm endoderm embryonic embryo|neuroectoderm|with the differentiation signals resulting from the physical attributes of the cell culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|developmental position gene global comparative|these progenitor hematopoietic cd34 stromal|neuroectoderm|entity cells are committed to developing into cells of the skin and cells of the nervous system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|developmental position gene global comparative|ectoderm mesoderm cardiomyocytes mesenchyme epidermis|neuroectoderm|van rooijen m , xu x , zweigerdt r , mummery c , passier r . insulin redirects differentiation from cardiogenic mesoderm and endoderm to entity in differentiating human embryonic stem cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|developmental position gene global comparative|ectoderm mesoderm endoderm embryonic embryo|neuroectoderm|together with the differentiation signals resulting from the physical attributes of the culture techniques , induce the epiblasts to differentiate into entity or mesendoderm cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|surg repair al ring review|cutting cut burn washing sponge|tonsil|the company introduced during fiscal 1995 a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|surg repair al ring review|suture vaginal umbilical mesh tension|tonsil|( b ) entity sponges - a round , fiber filled gauze constructed with a strong abdominal tape string sewn into the sponge to anchor
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|surg repair al ring review|cervix prostate pancreas lung gallbladder|tonsil|tumor shrinkage was also seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|tissue|surg repair al ring review|leukemic cll activated mature memory|tonsil|tjx7 has been shown to completely inhibit the migration of primary human entity b cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|surg repair al ring review|cutting suction sponge packing washing|tonsil|the company has also introduced a line of specialty sponges , including eye spears , dissecting , stick and entity sponges , all of which are used in a variety of surgical procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|surg repair al ring review|cervix prostate pancreas lung gallbladder|tonsil|tumor shrinkage also was seen in patients with renal cell cancer , liver cancer , sarcoma , and cancer of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|surg repair al ring review|cutting suction packing hemostatic washing|tonsil|products used primarily in the operating room environment ; medical action introduces a line of specialty sponges , which include dissecting sponges , entity sponges , stick sponges and eye spears .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|cartilage bones mobility muscle functions|cartilage|it has a dual method of action that could provide the unique benefit of protecting bones and preserving entity in patients with osteoarthritis and osteoporosis , all in one medication .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cartilage structural repair matrix native|tissue cartilage tendon muscle porcine|cartilage|in comparison with tissue stiffness , streaming potentials measured showed almost identical behavior for the normal and degraded entity explant .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cartilage structural repair matrix native|cartilage meniscal chondrocyte meniscus tissue|cartilage|developed and commercialized chondrocelect , the first cell-based medicinal product to receive marketing authorization from the ema , which was indicated for entity repair in the knee .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cartilage structural repair matrix native|cartilage meniscal meniscus successful arthroscopic|cartilage|the secondary endpoints were entity repair at 12 months by assessment of changes of the knee joint entitys volume measured with 3d spgr quantitative mri ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|osteoblasts osteoclasts osteoblast callus cartilage|cartilage|these compounds induce the formation of entity and regenerates new bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|signal data its image recording|cartilage|the handle ; o software for the acquisition of electrical signals and for the analysis and interpretation of data to quantify entity quality ; and o a computer system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|image semen hair visual egg|cartilage|the simplicity of the technique for the assessment of entity quality was demonstrated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|cartilage muscle spine tendon marrow|cartilage|in both of these prior positions dr . christgau worked in the area of bone and entity research .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cartilage structural repair matrix native|cartilage structure tissue tissues structures|cartilage|disease that affects almost 1% of the adult population worldwide and it ultimately results in irreversible damage of the joint entity and bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cartilage structural repair matrix native|cartilage matrix surface surfaces chondrocytes|cartilage|oa background oa is a joint disorder involving the degeneration of the articular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|cartilage surface surfaces cavity matrix|cartilage|treatment of various injuries and degeneration of other tissue structures such as the intervertebral disc of the spine and articular entity of degenerated joints .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|cartilage liver tendon ligament ligaments|cartilage|sarcomas are cancers of the bone , entity , fat , muscle , blood vessels , or other connective or supportive tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cartilage structural repair matrix native|cartilage tissue tissues cells receptors|cartilage|entity on any of these surfaces can be damaged due to disease or injury , leading to pain and inflammation requiring knee
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cartilage structural repair matrix native|collagen tissue cartilage cells tissues|cartilage|it assists in regained mobility as it refurbishes entity in the bone end of joints , consisting of the same cellular structure , collagen type ii .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|cartilage cruciate chondrocyte collagen acl|cartilage|a fully functional clinical version of the arthro-bst ( tm ) was presented at the third meeting of the international entity repair society ( icrs ) in sweden in april 2000 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|cartilage structural repair matrix native|cartilage tendons muscle tendon nerves|cartilage|from a mouse with cia with no treatment showing severe inflammation in the joint with sever damage to bone and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cartilage structural repair matrix native|cells fluid tissue lining matrix|cartilage|major teaching hospital and other institutions have demonstrated that the use of the company  s compounds inhibit the loss of synovial entity in the joint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cartilage structural repair matrix native|cartilage surfaces matrix tissues tissue|cartilage|this condition grows more severe over time and leads to progressive thinning of articular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cartilage structural repair matrix native|nerves cartilage muscle organs muscles|cartilage|product development programs utilize adult bone marrow stem and progenitor cells for forming solid tissues such as bone , vascular tissue , entity , and blood and immune system cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cartilage structural repair matrix native|tissue expected tumour nerve potential|cartilage|additional studies are being carried out to confirm the entity regrowth .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|position gene cell development developmental|differentiation development morphology maturation mesenchyme|mesenchyme|the scientific publication demonstrates that 4d20 . 8 cells possess site-specific markers of craniofacial entity , in particular , markers of proximal mandibular entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3), ('DIS', 3)])|tissue|ependym cerebrospinal dural epidural dura|cells microglia macrophages fibroblasts pericytes|ependyma|filters toxins 1 cerebrospinal fluid ( csf ) – brain barrier / glymphatic system : extracts toxins from the brain 2 ventricle brain entity ( glial cells ) astrocytes ( glial cells )
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|transverse under midline penile visible|scalp nose lips vagina teeth|umbilicus|it usually involves the face , digits , arms , inguinal area , anogenital area , entity and nipples , and can also affect the hair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|transverse under midline penile visible|waist thigh vertex midline perimeter|umbilicus|reductions observed in the circumference at the entity and treatment area volume were the same in both the placebo and lipo-202 treatment groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|transverse under midline penile visible|endpoint waist midpoint visit mid|umbilicus|manual tape measure procedure , the 0 . 4 µg total weekly dose of lipo-202 produced significant reductions in abdominal circumference at the entity compared to placebo .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epidermis component junction layer epidermal|epidermis dermis epithelium keratinocytes face|epidermis|most common form of skin cancer , is an uncontrolled growth of abnormal cells arising from the squamous cells in the entity , the skins outermost layer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|epidermis component junction layer epidermal|tissue tissues body cells dermis|epidermis|skin in order to achieve enough heating at the required depth significantly increases the risk of damaging or burning the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|epidermis component junction layer epidermal|epidermis epithelium keratinocytes cell cells|epidermis|bcc develops in the basal , or lower , layer of the entity , and accounts for approximately 80% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|lesions plaques body cells nodules|epidermis|psoriasis , for example , which is characterized by inflammation and accelerated growth of the entity , can sometimes be triggered by a simple cut or abrasion to the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis hair follicle tissue embryo|epidermis|removal is based upon the selective heating of hair follicles while cooling the surface of the skin to protect the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis dermis face keratinocytes neck|epidermis|scc usually develops in the entity , the upper layer of the skin , and accounts for approximately 16% of all new cases of skin cancer annually .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis epidermal subcutaneous stroma epithelium|epidermis|autologous skin regeneration construct of its kind , which can regrow full-thickness and functional polarized skin , including all layers ( dermis & entity ) , hair , and skin appendages .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epidermis component junction layer epidermal|epidermis muscle cornea mucosa fascia|epidermis|by precisely focusing ultrasound energy to cause permanent disruption , or ablation , of fat cells , or adipocytes , without damage to the entity , dermis or underlying tissues and organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis epidermal epithelium basal water|epidermis|to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , entity and dermis level .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|tissue laser follicle retina cornea|epidermis|the cold sapphire tip protects the entity while allowing the laser light to efficiently destroy the target follicles .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis keratinocytes dermis melanocytes keratinocyte|epidermis|plaque psoriasis is a disease marked by hyperproliferation of the entity , resulting in inflamed and scaly skin plaques .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis epidermal epithelium stroma outer|epidermis|designed to penetrate below the skin  s surface to correct damage in all layers of the skin ( the stratum corneum , the entity and the dermis ) and accelerate cellular turnover .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|epidermis component junction layer epidermal|cervix mucosa epithelium cells tissue|epidermis|topical interferon alpha-2b is intended to deliver interferon alpha-2b therapy to the viable entity , combating hpv infections where they would otherwise cause abnormal cellular proliferation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|epidermis component junction layer epidermal|epidermis epidermal epithelium basal mucosa|epidermis|the ability to effectively penetrate the skin barrier , reducing their ability to improve the health of the skin at the entity and dermis level .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|epidermis component junction layer epidermal|body face dermis lip muscle|epidermis|these changes can visibly affect the shape of the entity and resemble an orange peel-like dimpling of the skin . 1 in the normal subcutaneous fat layer directly under the skin , there
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epidermis component junction layer epidermal|epidermis dermis keratinocytes epithelium epidermal|epidermis|keratinocytes are the predominant cell type in the entity , the outermost layer of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|epidermis component junction layer epidermal|epidermal epidermis outer subcutaneous muscle|epidermis|our products will be naturally infused into hair follicles , dermis and entity layers of the scalp through the direct application and use of all-natural products .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|epidermis component junction layer epidermal|epidermis dermis fascia epidermal stroma|epidermis|vii collagen , or col7 , that forms anchoring fibrils that bind the dermis , or inner layer of the skin , to the entity , or outer layer of the skin .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|epidermis component junction layer epidermal|body cells dermis epidermis cell|epidermis|concentration of hydroquinone , which is designed to correct skin pigmentation problems by normalizing the production of new melanin in the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|epidermis component junction layer epidermal|aureus epidermidis pneumoniae mutans staphylococcus|epidermis|azitra inc . is developing azt-02 , a staphylococcus entity strain engineered to express lekti in preclinical development .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|appendix section table part figure|anlage|thereof ; 4 . 1 . 3 all running expenses as defined in appendix 3 to section 27 , subsection 1 , of the second computation order ( entity 3 zu section 27 abs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|fur und university avenue city|anlage|the business address for each of the persons listed below other than christopher k . norton is messeturm , friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|entity entities instance order figure|anlage|l . der verkaufer verkauft und ubertragt hiermit samtliche vertrags-erfindungen und vertrags-schutzrechte , die in den in entity 1 und entity 2 beigefugten schutzrechtskaufvertragen definiert sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|der von und stage step|anlage|des verschmelzungsplans ) wird die übernehmende gesellschaft die neue satzung , wie sie als entity 2 dem verschmelzungsplan beigefügt ist , beschließen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|von und der wi zur|anlage|zeitpunkt dieser lizenzerklärung im eigentum der sag stehen , darin insbesondere eingeschlossen die patente und patentanmeldungen gemäss entity 2 , die sich auf die substanz prostone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|stage step phase der type|anlage|verkauft und ubertragen werden daher insbesondere die in der entity 3 aufgefuhrten vermogensgegenstande und rechte ( insgesamt der , , kaufgegenstand " ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|der von und wi zur|anlage|schutzrechtsanmeldungen , die vom dkfz parallel dazu gemäß entity 2 vorgenommen worden sind .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|und fur university gmbh berlin|anlage|the principal business address of each of gscp ii germany and gs ohg is messeturm friedrich-ebert- entity 49 , 60308 frankfurt am main , germany .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|der vivo trials groups advance|anlage|belastungen des in entity 1 . 1 beschriebenen grundbesitzes in abteilung iii des grundbuchs werden vom käufer nicht übernommen .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|von der und og wi|anlage|schutzrechtsanmeldungen gemäß entity 2 zugrundeliegenden erfindungen zu zahlen ist , steht den erfindern von asta pharma ein anteil von 20% zu .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|der und von zur wi|anlage|​ die satzung der übernehmenden gesellschaft , als aus der gesellschaft hervorgehende gesellschaft , ist als entity 1 zu diesem verschmelzungsplan beigefügt .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|14 13 germany berlin 15|anlage|dr . thomas drosdeck beiten burkhardt rechtsanwaltsgesellschaft mbh bockenheimer entity 15 mozartplatz 60322 frankfurt am main germany 30 . 13 execution by counterpart .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|available prev contain date stock|der phase vivo advance vitro|anlage|rechten und ansprüchen gegen sie an pcof 1 llc ( der zessionar ) im wege der sicherungsabtretung abgetreten haben , einschließlich der in entity 1 genannten forderungen .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|oste fracture cyst collapse intra|muscle cartilage marrow liver cortical|osteoid|the six patients had mean entity volume / bone volume decreases from 24 . 3 percent to 7 . 0 percent , representing a 71 percent improvement .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5)])|tissue|oste fracture cyst collapse intra|cortical trabecular marrow osteoclast muscle|osteoid|at 48 weeks , all ten patients with evaluable paired bone biopsies demonstrated meaningful improvements from baseline in mean entity volume / bone volume .
OrderedDict([('OTHER', 5), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|oste fracture cyst collapse intra|cortical trabecular cartilage mean tissue|osteoid|the patients also demonstrated mean improvements of 32% and 26% in entity thickness and entity surface / bone surface parameters respectively .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|fascia space junction wall anatomy|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery and are not good candidates for a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|fascia true transverse iliac tension|muscles muscle fold tissue surface|fascia|background dupuytrens disease is a slowly progressive fibroproliferative disease of the palmar entity in the hand .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|icf original signature written legal|fascia|any changes or additions to the entity sign shall be subject to landlords prior written approval , in landlords sole discretion , and shall be made at tenant  s sole cost and expense .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|fascia true transverse iliac tension|fascia dermis muscle tissue tendon|fascia|plantar fibromatosis is a non-malignant thickening of the feets deep connective tissue or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|final thumb main key right|fascia|for all purposes under the lease , the entity sign shall be deemed to be tenant  s off-premises equipment . 7 . brokerage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|building floor body fabric surface|fascia|tenant shall repair , paint , and / or replace the building entity surface to which its signs are attached upon vacation of the premises , or the removal or alteration of its signage ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|walls interior porosity edges lining|fascia|no alteration shall ( i ) affect the exterior walls , entity or fenestration of the building or the demising walls of the premises , ( ii ) affect any part of the project other than
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|epidermis muscle subcutaneous fascia peritoneum|fascia|are you going to start accepting dermis , entity and pericardium recoveries?
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|fascia patent proprietary new native|fascia|the revenue increase was primarily due to an increase in the demand for our entity lata products to treat incontinence and urologic and gynecologic defects .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|bones nerves ligaments cartilage others|fascia|muscoloskeletal conditions  means conditions of the muscles , bones , joints ( including the intervertebral discs ) , ligaments , tendons , cartilage and entity of the body .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|fascia space junction ligament anatomy|fascia|this procedure may be done without disrupting the endopelvic entity and is especially valuable for women who have scarring from previous abdominal surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|warning paper door green house|fascia|green  s dairy road a . all entity signs to be single faced cabinets , and shall be constructed of 100% aluminum with stencil cut aluminum backgrounds with white
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|epidermis face dermis extremities lips|fascia|cutaneous eosinophilias are inflammatory diseases that manifest in dermal and subcutaneous layers including the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|name object date address ink|fascia|signage no entity , sign , name plate , bill , notice , placard , advertisement or similar device shall be affixed to or displayed in or on any
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|tissue|fascia true transverse iliac tension|fascia acta dura lenti vena|fascia|meanwhile , the company is offering alternative tissues such as entity lata and bovine pericardium to the market .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|screws sutures clips wires markers|fascia|kind and quality and having made good any material physical damage resulting from the removal of any tenant  s fixtures , fittings , entity or signs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|fascia true transverse iliac tension|fascia ligament flexor tendon muscle|fascia|the plantar entity is the foots shock absorber .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia true transverse iliac tension|liver tendons nerves tendon brain|fascia|a therapeutic protein and / or bioactive rna for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|fascia true transverse iliac tension|these price commercial new industry|fascia|entity inventories are higher than normal by $720 due to reduced demand and the anticipation of the launch of a new
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|fascia true transverse iliac tension|tendons liver nerves tendon brain|fascia|therapeutic protein and / or bioactive ribonucleic acid for the treatment of autoimmune and non-infectious inflammatory disorders that manifest in cutaneous tissues , entity and / or muscle .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|intra enter presence toxin exclusion|ecm matrix muscle membrane sarcomere|endomysium|- 5 - in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|intra enter presence toxin exclusion|ecm matrix muscle membrane dermis|endomysium|in muscle tissue , collagen serves as a major component of the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|differentiation septum layer segmental region|olfactory epithelium brain mucosa nose|neuroepithelium|the entity is the tissue by which man detects the presence of odor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|differentiation septum layer segmental region|nerve nerves epithelium pathway cortex|neuroepithelium|smell ) can result from a number of causes , including mechanical obstruction of the nasal cavity and damage to the olfactory entity , the olfactory bulb , or the nerves between them .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|per press mole cell single|trophoblast melanoma neoplasia adenocarcinoma endometriosis|mole|the major histologic entities for this disease include complete molar pregnancy , partial molar pregnancy , invasive entity , and choriocarcinoma .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|cube square person mill mm|mole|mm  shall mean one-thousandth of a entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|tissue|per press mole cell single|trophoblast melanoma neoplasia adenoma tumors|mole|the term gestational trophoblastic neoplasia ( gtn ) is used when molar and non-molar pregnancies become malignant , and comprise the morphologic entities of invasive entity and choriocarcinoma .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|entity entities eruption bcc ak|mole|to 12-month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|tissue|per press mole cell single|lesions tumors edema lymphadenopathy metastasis|mole|cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|entity entities eruption bcc ak|mole|to 12 month period in order to detect new or changing entitys through total body photography , by monitoring a specific entity or entitys .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|tissue|per press mole cell single|lesions tumors metastasis lymphadenopathy edema|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|per press mole cell single|melanoma nodule scar mole neoplasm|mole|present in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|person case snake mutation condition|mole|we believe that their software , at present , cannot define whether a entity is a new one or not .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|min m2 minute hour nm|mole|referred to antibodies excluded from the licence 1all antibodies to alpha tumour necrosis factor having an association constant greater than 106l / entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|cul sens fasci partic fun|mole|tks , tps , stks and related downstream signalling entitycules ( target identification ) and vali- dation of the role , if any , of those entity- cules in a given disease ( target valida- tion ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|per press mole cell single|entity neoplasm nodule nature entities|mole|the abcd rule is defined as follows : a ● asymmetry , a benign entity that is not asymmetrical ; b ● border , a benign entity has smooth , even borders , unlike melanomas ; c ● color .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|per press mole cell single|melanoma pattern focus color nodule|mole|one of the best early indicators of melanoma is a new or changing entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|per press mole cell single|lund williams lang colleagues thomas|mole|/ s / weisberg , polansky , kulberg , einhorn & entity , llp carle place , new york july 30 , 1996 exhibit 23 . 8 consent of independent certified public accountants we consent to the
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|per press mole cell single|abortion removal transformation ablation hysterectomy|mole|choriocarcinoma metastasizes hematogenously and can follow any type of pregnancy , but most commonly develops after complete hydatidiform entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|per press mole cell single|melanoma nodule neoplasm scar mole|mole|itself in two forms , nodular bcc , which appears as a shiny bump or nodule that may be confused with a entity , and superficial bcc , which has a slightly raised , ulcerated or crusted surface .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|tissue|per press mole cell single|lesions tumors metastasis lymphadenopathy edema|mole|american cancer societys abcde criteria , which includes asymmetric , irregular border , variegated or dark color , diameter greater than 6 mm , or evolving entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|per press mole cell single|tissue melanoma person cell body|mole|it may begin in a entity as skin melanoma , but can also begin in other pigmented tissues , such as in the eye or in the intestines .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|dermis tissue ecm body muscle|dermis|the entity is comprised largely of connective tissue fibers made of collagen and elastin .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|brain nerves kidneys kidney body|dermis|muscle cells , azx100 may inhibit the scarring that results from wound healing and may mitigate fibrotic disease states in the entity , blood vessels , lungs , liver and other organs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|cartilage muscle ligaments muscles dermis|dermis|type 1 collagen is the primary fibril-forming collagen in bone , entity , tendons and ligaments and is the most abundant protein in the human body .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|face dermis scalp thigh lip|dermis| hst-002 is a human-derived collagen and extracellular matrix dermal filler intended to be injected into the entity for the treatment of facial folds and wrinkles .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|component cell fibroblast vessel junction|dermal collagen tissue matrix cellular|dermis|our acellular entity scaffolds are utilized in wound care and plastic and reconstructive procedures .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|dermis epidermis bloodstream capillaries microcirculation|dermis|temporarily permeable , allowing a drug to diffuse through the stratum corneum in the epientity , and then into and through the entity , where it can enter the bloodstream through the capillaries .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|component cell fibroblast vessel junction|muscle tendon body tendons muscles|dermis|we believe that the fibroblasts created by our isolagen process and injected into the patient  s entity continue to multiply and lead to the production of collagen and elastin .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|resources resource services development rights|dermis|human entity initiatives training sales force product introduced in 2nd quarter to clinical sites product launched july 2007 markets currently a $50
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|these autologous dermal new tissue|dermis|with the dermavac , entity mos are rapidly harvested under local anesthetic from just under the skin to provide unique tissue structures with long-term viability
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|face scalp abdomen neck legs|dermis|( mos )  our proprietary device , the dermavac , is used to extract a small piece of tissue from the skins lower level , the entity of the patient .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|epidermis cellular epidermal collagen capillary|dermis|penetrate the skin barrier , reducing their ability to improve the health of the skin at the stratum corneum , epientity and entity level .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|sponsored va laboratories co all|dermis|at ciba-geigy , novartis , prosanos , adventrx participated / led development and launch of voltaren , apligraf , femara and exjade 4 5 epientity dermis subcut .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|epidermis dermis keratinocytes layers fascia|dermis|in undamaged skin , the epientity , or the surface layer of skin , and entity , the deeper layer , form a protective barrier against the external environment .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|component cell fibroblast vessel junction|cells material tissue semen materials|dermis|in october 2001 , the company entered into a project with mentor for use of tutoplast ( r ) processed entity in urological and gynecological indications .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|epidermis dermis layer surface membrane|dermis|due to the structure of the skin , its two main layers , the outer epientity and inner entity , effectively inhibit the transdermal delivery of most therapeutics .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|intestine bloodstream intestines liver colon|dermis|small molecular weight sodium hyaluronate can penetrate into the entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|epidermis surface lining epithelium hairs|dermis|skin means that part of the human anatomy consisting of the entity , the epientity , and the appendages of the skin , to wit , the nails , the hair and hair follicles , the sudoriferous and
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|component cell fibroblast vessel junction|tissue tendon cartilage collagen tendons|dermis|currently rely on single source suppliers for the silicone and fabric used in our male prostheses and for the porcine entity and mesh used in many of our female products .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|component cell fibroblast vessel junction|space spaces vessels arteries intestine|dermis|small molecular weight sodium hyaluronate can penetrate into the 7 table of contents entity where it combines with water to promote microcirculation , nutrient absorption , and metabolism .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|component cell fibroblast vessel junction|electrodes electrode sensor sensors scalp|dermis|the faces handpiece uses a vacuum to fold the skin between two electrodes , ensuring tight contact and positioning the entity in direct alignment with the path of radio frequency energy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|contiguous ventricular conduction adjacent vessel|myocardium ventricle aorta atrium infarct|endocardium|of myocardial cells first occurs in the area of myocardium that is most distal to the arterial blood supply , the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|contiguous ventricular conduction adjacent vessel|aorta endothelium vessel vasculature vessels|endocardium|as the duration of the occlusion increases , the area of myocardial cell death enlarges , extending from the entity to the myocardium and ultimately to the epicardium .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|periodontal keratin gingival intact ging|periodontal keratin epithelium nerve pulp|gingiva|dental field  means the field of treatment , repair or replacement of the tooth , dentin , alveolar bone , tooth-root cementum , entity and / or periodontal ligament .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|mucosa tongue gum teeth palate|gingiva|exposure of the gel on the strips to the entity ( gums ) should be avoided since it can cause irritation to the tissue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|gum teeth chewing tongue saliva|gingiva|in heart rate ; ( ii ) focal hyperpigmentation ( darkening of the skin on certain parts of the body ) , including the face , gums ( entity ) and breasts ; and ( iii ) nausea .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|tongue tooth teeth mucosa palate|gingiva|in the case of the dental product , a 1mm biopsy is taken from the patient  s entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|scalp arms extremities ears neck|gingiva|focal hyperpigmentation : reported by 1% of patients who received up to 8 doses per month , including involvement of the face , entity and breasts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|lungs brain kidneys liver extremities|gingiva|lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , sinuses , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|periodontal keratin gingival intact ging|brain lungs kidneys liver skeleton|gingiva|common lesion , congenital plasminogen deficiency is a multi-systemic disease that can also affect the ears , tracheobronchial tree , genitourinary tract , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament muscle cartilage plate tendon|ligament|a high strength form of graftjacket® matrix which provides maximum suture holding power for the most challenging of tendon and entity repairs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|ligament repair cross rev coll|dermal muscle cornea corneal dermis|ligament|begun to earn royalties on a portion of the estimated 2005 $800 million to $1 billion u . s . tissue market , which includes entity , tendon and bone allografts .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|tendon muscle cartilage nerve ligament|ligament|first albany annual growth conference page 15 entity and tendon repairs , we mentioned , is still in preclinical work .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament cartilage muscle tendon nerve|ligament|group ; and  use our glucan technology to develop product candidates for intra-operative and injection applications in tendon , entity and bone surgeries and injuries .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament ligaments tear cruciate column|ligament|the impact of fortetropin® on reducing muscle atrophy in dogs after tibial-plateau-leveling osteotomy ( tplo ) surgery to repair the cranial cruciate entity ( ccl ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament repair cross rev coll|muscle nerve cartilage ligament musculoskeletal|ligament|svf is a regenerative treatment for a number of conditions including osteoarthritis , tendon repair , entity injuries and other traumatic and degenerative diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament ligaments tendon plate tear|ligament|announced receipt of the technical section complete letter for effectiveness for nocita to provide local post-operative analgesia for cranial cruciate entity surgery in dogs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament repair cross rev coll|dental orthopedic foot implant ear|ligament|continues to develop a collagen based tissue patch , a collagen and calcium phosphate based bone cement , and a collagen based entity prosthesis .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|ligament repair cross rev coll|ligament ligaments tissue tissues cells|ligament|of periodontal pockets ( spaces between the gum and tooth ) resulting from loss of the tooth  s supporting structure ( bone and periodontal entity ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|muscle tendon ligament cartilage nerve|ligament|for the technology include pressure ulcer ( bed sore ) prevention , chronic wounds , burns , dermatology , and product testing and superficial tendon and entity pathology .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|tendon meniscal acl meniscus muscle|ligament|college of veterinary medicine at kansas state university&#160 ; to study the impact of fortetropin on reducing muscle atrophy in dogs after entity tear repair surgery .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|muscle ligament ligaments cartilage tendon|ligament|stimulation of growth factors and the potential use of ultrasound technology in diagnostic and therapeutic applications relating to bone , cartilage , entity or tendon .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament ligaments tear tendon cruciate|ligament|for example , attempts to replicate mouse anterior cruciate entity , or acl , transection findings using different animal models of osteoarthritis , or oa , have proven to be challenging , as it is
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament ligaments tendon patella cartilage|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity performed annually in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament repair cross rev coll|tendon tendons ligaments ligament cartilage|ligament|studies with engineered cartilage and bone for reconstructive applications and have constructed an entire joint consisting of bone , cartilage and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament ligaments tendon tear reconstruction|ligament|the agreement covers such products as , bone-tendon-bone ( btb ) implants used for acl ( anterior cruciate entity ) procedures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligament muscle meniscus tendon nerve|ligament|to extend its worldwide license for chrysalin to include the rights for orthopedic " soft tissue " indications , including cartilage , tendon and entity repair .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|ligaments muscles muscle nerves gum|ligament|of protein synthesis at a particular site in the body and can be used in soft tissue such as skin , entity , tendons and cartilage , as well as hard tissue such as bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|ligament repair cross rev coll|space ligament ligaments junction spaces|ligament|the spacer is placed between the spinous processes through the interspinous entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|ligament repair cross rev coll|ligament ligaments tendon tendons cartilage|ligament|there are over 1 . 2 million arthroscopic procedures for repair of the knee , including procedures involving articular cartilage , meniscus and entity , performed annually in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin fibrous outer nerve membrane|myelin|we refer to the axon and its surrounding entity sheath as a nerve fiber .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|nerve myelin tendon these brain|myelin|the disease is believed to be caused by the destruction of entity sheaths by the body  s own immune system .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|electrical sensory myelin synaptic structural|myelin|loss of entity insulation in surviving axons can cause nerve impulses to be delayed or lost entirely , resulting in impaired neurological function .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|these nerve tendon myelin dural|myelin|we believe a therapy that could repair entity sheaths has the potential to restore neurological function to those affected by deentityating conditions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin fibrous axonal axon elastic|myelin|the entity sheath that surrounds axons in the brain and spinal cord provides insulation that facilitates the transmission of nerve impulses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin nerve axon axonal neural|myelin|ms attacks the covering surrounding nerve cells , or entity sheaths , leading to loss of entity ( deentityation ) and nerve damage .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin nerve neural axonal axon|myelin|the entity sheath is composed of multiple layers of tightly packed cell membrane and is vulnerable to damage in conditions like ms
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|myelin structural structure brain oligodendrocyte|outer cellular myelin inner membrane|myelin|by neurons as well as remove compounds that are toxic to them ; and  form the insulating entity layer around the axons of neurons , enabling their normal function for signal transmission .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin nerve axon axonal glial|myelin|multiple sclerosis , or ms , is an autoimmune disease in which immune cells attack and destroy the entity sheath , which insulates neurons in the brain and spinal cord .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin nerve neural axon outer|myelin|when the entity sheath is destroyed , nerve messages are sent more slowly and less efficiently .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('BIO', 1)])|tissue|myelin structural structure brain oligodendrocyte|myelin oligodendrocytes aqp4 myelination neurons|myelin|the loss of entity disrupts the conduction of nerve impulses , producing the symptoms of multiple sclerosis including vision loss , incontinence , short-term memory loss , fatigue ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|myelin axon nerve axonal neural|myelin|reentityation reentityation is the process propagating oligodendrocyte precursor cells to form oligodendrocytes to create new entity sheaths on deentityated axons in the cns .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin structural structure brain oligodendrocyte|myelin brain adipose dermis this|myelin|entity is the fatty tissue that surrounds and protects the nerve fibers of the central nervous system and facilitates the flow of nerve impulses to and from the brain .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin structural structure brain oligodendrocyte|neuronal brain nerve cns axonal|myelin|clene also has state of matter claims for entity protection , remyelination , neuroprotection that will last until 2032 and manufacturing device and process patents that will last beyond 2030 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|myelin structural structure brain oligodendrocyte|myelin insula acetylcholine collagen ito|myelin|in laboratory studies , dalfampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer , called entity , has been damaged .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|myelin structural structure brain oligodendrocyte|neural neuronal myelin nervous parenchymal|myelin|the identified autoimmune mechanisms directed at entity tissue of the cns may play an important role in the pathogenesis of ms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|myelin structural structure brain oligodendrocyte|myelin tissue nerve cells dna|myelin|currently , there is no available therapy indicated to repair entity that has been destroyed in ms or other deentityating diseases .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|myelin structural structure brain oligodendrocyte|brain neuronal axonal mitochondrial oxidative|myelin|to evaluate the effect of ehp-101 on entity damage in a cuprizone-induced deentityation murine model , brain coronal sections from animals after 6 weeks of cpz 0 . 2% diet and
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|myelin structural structure brain oligodendrocyte|adipose dermis myelin muscle tissue|myelin|entity , a fatty tissue , surrounds and protects the nerve fibers of the cns and helps those nerve fibers to conduct electrical impulses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|myelin structural structure brain oligodendrocyte|autologous hla tcr mhc ebv|myelin|to formulate tovaxin t cell vaccine , the patient  s own entity peptide-specific activated t cell lines are harvested and attenuated on the day of vaccine administration .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cystic intestinal somatic developmental single|ipscs these they ips mscs|organoids|as a stem cell derived system , entity are a renewable model permitting repeat testing from a single patients biopsy .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|population cohort registry database data|organoids|out of the hubrecht institute , knaw and university medical center utrecht in the netherlands to evaluate the nonsense-bearing cf patient entity in its biobank .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 4)])|tissue|cystic intestinal somatic developmental single|fibroblasts cells mice xenografts tissues|organoids|entity derived from nonsense mutation cf patients lack apparent swelling in this system due to their lack of functional cftr .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|fibroblasts cells tissues samples tissue|organoids|in a poster titled : “cftr protein detection in entity from healthy and cf patients with nonsense mutations support using organoid model to test elx-02 mediated cftr read-through restoration” , we
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|tissue|cystic intestinal somatic developmental single|mice genotypes clones individuals alleles|organoids|significant restoration of cftr protein expression as measured via a capillary-based immunoassay approach in multiple g542x or w1282x nonsense carrying entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cystic intestinal somatic developmental single|cells mice homozygotes fibroblasts heterozygotes|organoids|·g542x entity treated with elx-02 demonstrate proper cell surface cftr localization on the apical surface , which is consistent with increased cftr , mrna ,
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cystic intestinal somatic developmental single|fibroblasts pbmcs cells mscs pbmc|organoids|the ex vivo portion of the study will quantify the functional response of patient-derived entity to pti investigational agents dirocaftor , posenacaftor and nesolicaftor .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cystic intestinal somatic developmental single|samples cells data fibroblasts pbmcs|organoids|entity from over 100 individuals bearing rare nonsense mutations in the cftr have been collected and are being tested for responsiveness to elx-02 in the laboratory .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|tissue|cystic intestinal somatic developmental single|xenografts tumors tumours cancers sarcomas|organoids|the first dataset evaluated elx-02 in 31 patient-derived entity and demonstrated activity in the majority of them .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|organoids chips organs omics xenografts|organoids|to change the classic model of drug discovery using 3d bioprinted human tissues and other 3d models ( sometimes known as “entity” or “organs on a chip” ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cystic intestinal somatic developmental single|xenografts cells models samples tissues|organoids|high content imaging to identify mcla-158 after screening hundreds of bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|protocols laboratories model infrastructure models|organoids|going concern the company has a history of operating losses as it has developed its human entity for drug toxicity and efficacy testing .
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5), ('DIS', 1)])|tissue|cystic intestinal somatic developmental single|cells fibroblasts neurons tissue tissues|organoids|we also plan to test the editor for editing efficiency in human retinal entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|model models xenografts dataset cohort|organoids|the internal position was subject to change upon review of additional clinical and ex vivo data from the patient derived entity when such data were made available .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cystic intestinal somatic developmental single|xenografts cells models samples specimens|organoids|content imaging to identify mcla-158 after screening more than 500 bispecific antibodies for activity in more than 20 patient-derived colorectal cancer entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cystic intestinal somatic developmental single|xenografts these organoids they cultures|organoids|entity are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the
OrderedDict([('OTHER', 5)])|OrderedDict([('BIO', 5), ('OTHER', 5)])|tissue|cystic intestinal somatic developmental single|cells genes tissue cell tissues|organoids|of cancers . 1 they may include : smarca4 , arid1a , and smarcb4 swi / snf complex mutations sensitize to lsd1 immunomodulatory effects , turning cold tumor entity hot .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1), ('BIO', 1)])|tissue|cystic intestinal somatic developmental single|neuroblastoma myeloma tumors cll dlbcl|organoids|the intent of the program is to use these positive results to enroll patients with responsive entity in a prospective trial with elx-02 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cystic intestinal somatic developmental single|data samples specimens sera dna|organoids|hit-cf recently announced completion of the first phase of the program with the collection of entity from patients at 47 of the biggest cystic fibrosis centers in 16 countries throughout europe .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 3)])|tissue|cystic intestinal somatic developmental single|xenografts tissue tissues tumors biopsies|organoids|humanized anrp2-10 decreased viability , inhibited formation of mammospheres and anchorage-independent growth in cells or entity from tnbc patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|dura perioste exposed overlying surrounding|tissues tissue cartilage defects organs|periosteum|graftjacketò regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|dura perioste exposed overlying surrounding|tissues tissue cartilage tendons wounds|periosteum|graftjacket® regenerative tissue matrix is an onlay for repair or replacement of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dura perioste exposed overlying surrounding|lining membrane wall cartilage covering|periosteum|● the pericranium is the entity ( a membrane that lines the outer surface of all bones ) of the skull bones and provides nutrition to the bone
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dura perioste exposed overlying surrounding|muscle tissue nerve tendon needle|periosteum|for maci is less invasive than for carticel , entailing a mini-arthrotomy or even arthroscopic delivery , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dura perioste exposed overlying surrounding|membrane dura dermis epidermis fascia|periosteum|the entity is a membrane covering the shin bone .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dura perioste exposed overlying surrounding|cortical perioste skeletal trabecular vertebral|periosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of entity and endosteum bone mineral mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dura perioste exposed overlying surrounding|fascia suture muscle tissue tendon|periosteum|a small piece of entity , the membrane that covers bone , is taken from the patient  s lower leg and sutured over the defect to hold the cells in place .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|tissue|dura perioste exposed overlying surrounding|analgesia vision csf callus tissue|periosteum|at surgery , entity was lacking ; the wound was debrided , and the bone fragments realigned .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dura perioste exposed overlying surrounding|bones skeleton body perioste surface|periosteum|the periosteal patch is a thin collagen membrane that is cross linked and functions as a patch on the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|dura perioste exposed overlying surrounding|muscle nerve tendon tissue capsular|periosteum|the implant procedure for maci is less invasive than for carticel , entailing a mini-arthrotomy , eliminating the need for a entity harvest and sutures .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|dura perioste exposed overlying surrounding|dermis muscle scalp ear epidermis|periosteum|the cultured cells are then implanted under the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum abdomen liver stomach uterus|peritoneum|it is also used in surgery for treating a wide range of localized infections in the entity ( the lining of the abdominal cavity ) , as well as the eye , ear , nose and throat , and sinuses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum pelvis abdomen liver uterus|peritoneum|it is formed by small , round cancer cells surrounded by scar-like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum peritoneal diaphragm abdomen membrane|peritoneum|peritoneal dialysis removes waste products and excess fluids from the blood by use of the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum lungs lung aorta myocardium|peritoneum|antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the pleura , pericardium and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|abdomen peritoneum bowel colon intestine|peritoneum|peritonitis is a bacterial infection of the entity which can result in serious adverse health consequences , including death .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|body brain lungs environment bloodstream|peritoneum|a machine is used to " cycle " solution to and from the patient  s entity during sleep .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|tip needle peritoneum body probe|peritoneum|upon immediate penetration of the entity , the membrane that forms the lining of the abdominal cavity , our kii® fios® first-entry creates a space for the tip
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum diaphragm peritoneal fascia mesothelioma|peritoneum|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , pleura , entity ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|fluid peritoneal empty dead extracellular|peritoneum|peritoneal dialysis uses the entity space in the abdomen as a dialyzer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum liver rectum prostate lung|peritoneum|these studies established that local injection of up to one billion mak cells in the pleural cavity , bladder or entity is well-tolerated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|filter cartridge membrane tubing electrode|peritoneum|the entity operates as the filtering membrane and , after a specified dwell time , the solution is drained and disposed .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|brain pancreas muscle stomach intestine|peritoneum|fibrosis can affect any tissue and organ system , and is most common in the heart , liver , lung , entity , and kidney .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum pelvis abdomen liver uterus|peritoneum|it is formed by small , round cancer cells surrounded by scar‑like tissue and is often found in the entity ( the tissue that lines the inside of the abdomen and pelvis ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum peritoneal diaphragm abdomen membrane|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|lungs lung brain spleen peritoneum|peritoneum|aggressive human pancreatic cancer cell line , l3 . 6pl , that is known to metastasize from the pancreas to the liver and the entity in mice .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|ovaries peritoneum endometrium diaphragm uterus|peritoneum|ovarian cancer by age 70 . ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|pancreas liver abdomen islets kidneys|peritoneum|experiments were conducted using encapsulated pig islets transplanted into the entity of a diabetic rat model .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|tubing latter bag peritoneum lumen|peritoneum|introduces a sterile 77 85 dialysis solution from a solution bag through a tube into the peritoneal cavity and the entity operates as the filtering membrane .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|ovaries peritoneum endometrium diaphragm pelvis|peritoneum|ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the entity and via local invasion of bowel and bladder .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|peritoneal peritoneum into intraperitoneal intra|peritoneum peritoneal diaphragm abdomen kidney|peritoneum|peritoneal dialysis removes toxins from the blood using the entity , the membrane lining covering the internal organs located in the abdominal area , as a filter .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|lungs lung diaphragm airways thorax|pleura|however , the distinction between mesothelioma and carcinomas that involve the entity , in particular peripheral pulmonary adenocarcinoma , can be challenging .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|sq mesothelioma rd cx t1|pleura|entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and 104 table of contents entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|pleural lungs lung diaphragm airways|pleura|malignant mesothelioma is a rare cancer , primarily affecting the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|fascia ple pleural mesothelioma bow|pleura|microrna to help differentiate malignant entityl mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|lining peritoneum wall surface walls|pleura|mesothelioma overview malignant mesothelioma is a malignant tumor of mesothelial cells which make up the entity , or tissue lining , of many internal organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|lung lungs kidney spleen muscle|pleura|and certain of annapurnas scientific founders teams demonstrated that this aav serotype also allows very efficient delivery to the heart , entity and liver , as well as additional organs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|pleural visceral transverse epidural ple|diaphragm tissue lung this muscle|pleura|entity refers to the thin layer of tissue that lines the chest cavity and covers the lungs .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|lungs lung pleural airways diaphragm|pleura|malignant mesothelioma is a rare cancer , primarily affecting 8 the entity ( lining of the lungs ) , and is usually associated with asbestos exposure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|pleural lung peritoneum diaphragm mesothelioma|pleura|malignant mesothelioma is an aggressive tumor of serosal surfaces ( e . g . , entity , peritoneum ) that is often caused by exposure to asbestos .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|liver peritoneum abdomen colon pancreas|pleura|mirview™ meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|liver peritoneum abdomen pancreas esophagus|pleura|mirviewtm meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|spleen kidneys brain nodes kidney|pleura|dissemination through the blood may also occur , affecting the lungs and entity , liver , and bones .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|lung lungs peritoneum diaphragm pleural|pleura|targets mesothelin , an antigen commonly found on mesotheliomas , ovarian cancers , and nsclc , as well in healthy cells that line the entity , pericardium and peritoneum .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|peritoneum liver brain abdomen pelvis|pleura|and is able to accurately diagnose mesothelioma and distinguish it from lung adenocarcinoma and other malignancies involving the lung and entity with very high sensitivity and specificity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pleural visceral transverse epidural ple|nerves nerve tendons liver tendon|pleura|visceral pain is defined as pain that originates within muscle , entity , connective tissue , nervous system or solid organs within the abdomen or peritoneum .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|liver peritoneum colon pancreas kidney|pleura|is increasingly important to determine with certainty whether a carcinoma is mesothelioma or a different carcinoma of the lung or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|peritoneum abdomen liver esophagus pancreas|pleura|squamous non-small cell lung cancer ; and · mirviewtm meso : for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|pleural visceral transverse epidural ple|peritoneum tissue fascia tissues parenchyma|pleura|mesothelioma most commonly occurs in the entity surrounding the lung , but occasionally involving the peritoneum surrounding internal organs of the digestive tract , the lining of the heart
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|liver peritoneum abdomen colon pancreas|pleura|mirview® meso - for differentiating mesothelioma from other carcinomas in the lung and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pleural visceral transverse epidural ple|peritoneum liver abdomen esophagus colon|pleura|squamous from non squamous non-small cell lung cancer ; and 3 . mirview® meso — for differentiating mesothelioma from carcinomas in the lung and entity .
OrderedDict([('OTHER', 4), ('DRUG', 1), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|species spor enter cyst strain|regulate maintaining maintain regulates regulating|endosteum|marrow stromal cells and osteoblast precursors are directly involved in the modeling and remodeling of periosteum and entity bone mineral mass .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|station vagina subs dist vaginal|peritoneum fascia mucosa vessels muscle|subserosa|tumor penetrates muscularis propria and invades entity t4 : tumor directly invades other organs or structures or perforates visceral peritoneum nodal status ( n ) nx : regional lymph nodes cannot
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|tissue|adventi vessel sheath sclerosis collagen|endothelium sheath aneurysm lumen thrombus|adventitia|delivery catheter that allows prt-201 to be administered locally in the outer layer of the artery , which is called the entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vessel submuc sclerosis vessels mucosa|walls lining lumen epithelium wall|submucosa|it is associated with hyperplasia and hypertrophy of the mucus-producing glands found in the entity of large cartilaginous airways .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|stroma mucosa tissue segments tissues|submucosa|development and manufacture of the regentys ecmh™ ( extracellular matrix hydrogel ) rectal solution , an extracellular matrix hydrogel derived from small intestinal entity ( sis ) of pigs .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vessel submuc sclerosis vessels mucosa|mucosa epithelium intestine intestines jejunum|submucosa|sites include the dermis , gut mucosa and entity , conjunctiva and pulmonary alveoli and airways .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|vessel submuc sclerosis vessels mucosa|mucosa stroma lining lumen crypts|submucosa|ulcerative colitis ( uc ) description uc is a chronic gi inflammatory disorder which involves the surface mucosa , the epithelium and the entity of the colon .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|urothelial fibroblasts epithelium epithelial stroma|submucosa|post-implantation , the bioabsorbable scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vessel submuc sclerosis vessels mucosa|stroma mucosa muscle epithelium dermis|submucosa|tx : primary tumor can not be assessed tis : carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|urothelial fibroblasts epithelial epithelium myofibroblasts|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like urinary tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|urothelial fibroblasts epithelial epithelium stroma|submucosa|months post-implantation , the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|tissue|vessel submuc sclerosis vessels mucosa|lumen opening wall inside neck|submucosa|this material is injected into the entity of the bladder at the junction of the ureter and bladder in order to reduce the size of the opening
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|urothelial fibroblasts epithelial epithelium myofibroblasts|submucosa|months post-implantation the scaffold is no longer present and is replaced by a tri-layered native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|vessel submuc sclerosis vessels mucosa|mucosa stroma epithelium muscle epidermis|submucosa|carcinoma in situ t1 : tumor invades entity t2 : tumor invades muscularis propria t3 : tumor penetrates muscularis propria and invades subserosa t4 : tumor directly invades other organs or
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|vessel submuc sclerosis vessels mucosa|urothelial fibroblasts myofibroblasts epithelial epithelium|submucosa| by three months post-implantation , the scaffold is replaced by native-like bladder tissue consisting of urothelium , entity and smooth muscle cells .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pericardial septal ventricular myocardial septum|aorta atrium myocardium diaphragm thorax|epicardium|extensive adhesions form between the surface of the heart ( entity ) and the inner surface of the sternum after virtually every open-heart surgical procedure .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pericardial septal ventricular myocardial septum|cardiomyocyte myocardium endothelium myocyte nucleus|epicardium|the entity plays a critical role in the differentiation , expansion , and maturation of cardiomyocytes during development , or during cardiac repair responses .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pericardial septal ventricular myocardial septum|surface lining side sides surfaces|epicardium|heart toxicity ( epicardial hyperplasia with inflammation primarily on the entity of the atria ) was observed in the 0 . 75 and 1 . 5 mg / kg / day groups .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pericardial septal ventricular myocardial septum|periphery inside surface body ventricles|epicardium|to the inside of the heart ; and surgical cardiac ablation devices , which are used to ablate cardiac tissue from the entity ( outside the heart ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|pericardial septal ventricular myocardial septum|myocardium ventricle aorta ventricles scar|epicardium|occlusion increases , the area of myocardial cell death enlarges , extending from the endocardium to the myocardium and ultimately to the entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|pericardial septal ventricular myocardial septum|muscle myocardium bloodstream liver spleen|epicardium|• mpc-150-im , injected directly into the entity , is being evaluated in a phase 2b trial in patients with nyha class iv / end-stage heart failure who have received a
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|thickness 1mm lesions intima from|intimal neoin endothelial prostatic luminal|intima|in a rat model of percutaneous transluminal balloon angioplasty , the researchers demonstrated that elafin administration prevented entity hyperplasia .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|300 press half 600 quarter|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , gentlelase , vbeam perfecta , picoway , co2re , co2re entity , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|intima root intimal wall thickness|intima|the study did not show any statistically significant difference in carotid entity media thickness between subjects in the two treatment arms .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|ultra gel prime trace plus|intima|the company has a wide portfolio of trusted , leading products including ultrashape , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elos plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|thickness 1mm lesions intima from|intima endothelium epithelium adventi intimal|intima|similarly , okuda et al53 reported a higher rate of age-dependent telomere attrition in both the entity and media of the distal versus proximal human abdominal aorta .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|intima thickness imt intimal echo|intima|the fda  s primary grounds for rejecting the claim relate to the clinical utility of evaluating skin cholesterol with carotid wall entity thickness ( cimt ) as the clinical endpoint .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|intima intimal wall cross inner|intima|the study also showed that tesamorelin improved triglycerides , c-reactive protein and carotid entity medial thickness , a cardiovascular marker , without aggravating glucose .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|ultra prime trace gel boost|intima|the company has a wide portfolio of trusted , leading products including ultrashape power , velashape , co2re , co2re entity , gentlelase , vbeam perfecta , picoway , profound and elōs plus .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|intima intimal wall carotid cross|intima|sterol levels ( university of wisconsin ) l determine relationship between skin sterol and cad as measured by carotid entity medial thickness
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|tissue|thickness 1mm lesions intima from|intimal neoin prostatic endothelial carotid|intima|in 2013 , the researchers demonstrated that elafin administration prevented entity hyperplasia in a rat model of percutaneous transluminal balloon angioplasty .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|lining wall inside walls endothelium|intima|the saline / chemical irritates the entity ( lining ) of the vein , causing it to collapse .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|delivery implant platform repair prototype|intima|we are positioned to address this growth segment with our core entity device , which we anticipate releasing internationally in 2016 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|arteries vasculature vessels vessel endothelium|intima|smooth muscle cell migration into the entity mediated by growth factors such as platelet-derived growth factor ( " pdgf " ) is thought to play an important role in the entityl
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|thickness 1mm lesions intima from|intima intimal carotid wall neoin|intima|this trial is called restore-it , or the randomized evaluation of short-term rifalazil treatment on carotid atherosclerosis and entity media thickness .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|tissue|thickness 1mm lesions intima from|intima muscle oxide wall propria|intima|it is characterized by the thickening of the tunica entity of a blood vessel as a complication of a reconstruction procedure or endarterectomy , the surgical removal of plaque from an
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|integrate incorporate introduce translate convert|clone|blunt ends , however , have a slight affinity for one another , which makes it possible for researchers to entity these fragments into blunt-ended cloning vectors .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|identify characterize validate map isolate|clone|the company is utilizing this technology to discover and entity the genes that code for human receptor subtypes that may be associated with specific disorders .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|phenotype microenvironment milieu pathway environment|clone|several cases , including cmml and aml , tumor microenvironmental pdcs have been shown to be neoplastic and part of the malignant entity , indicating a potential need for therapeutic targeting .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|tissue|clone clonal cell candidate mixture|mutation gene translocation variant transcript|clone|in fact , the presence of the hmga2 entity has steadily declined over time to the point that it is no longer the most common entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|tissue|clone clonal cell candidate mixture|cell myeloma clone cells clonal|clone|multiple myeloma is a condition in which these plasma cells become malignant , with a single entity growing at an uncontrolled pace .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|culture isolate expand clone manipulate|clone|following leaps identification of the cell of interest , we entity the cell , thereby generating millions of cells that produce high concentrations of the biological molecule of interest .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|model description structure characterization understanding|clone|heska has produced a molecular entity of the cellular receptor for the ige antibody .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|formulation candidate prodrug peptide molecule|clone|a entity with a “highly similar” profile to herceptin has been chosen for further process development .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|clone clonal cell candidate mixture|cells clone cell lineage population|clone|these data suggest that imetelstat inhibits the progenitor cells of the malignant entity believed to be responsible for the underlying disease in a relatively selective manner .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|identify characterize validate map analyze|clone|it is utilizing this technology both to discover and entity the genes that code for human receptor subtypes associated with specific disorders and to design compounds that can potentially be
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|cdna genomic genome exome gene|clone|our omnibank mouse entity library and its backup are stored in liquid nitrogen freezers located at our facility in the woodlands , texas , and our
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|identify screen detect extract sequence|clone|in addition , we plan to utilize our high-throughput capabilities to rapidly entity and expression-test thousands of genes for drug development and agriculture .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|novartis invest bax pfizer janssen|clone|the company , on the following boards of directors of the companys partners and affiliates ( each , a p & a board ) : entity international pty .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|isolate modify introduce sequence amplify|clone|in addition , conventional genetic engineering techniques for protein production may face technical limitations arising from the need to first entity the gene of interest .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|isolate modify manipulate treat clone|clone|these companies are competing with one another to be the first to identify , entity and express the finite number of genes thought to be of commercial importance .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|identify map locate investigate detect|clone|tools and approaches in bacterial molecular genetics , which allow it to create and use gene mutants to quickly and directly entity essential bacterial genes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|amplify sequence clone create isolate|clone|pcr cloning is another method that can be used to entity a dna fragment when some information about its sequence is known .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|identify clone construct select isolate|clone|in 1998 we began marketing our " high-throughput " gene cloning and expression technology , which allows us to entity and expression-test genes on an industrial scale .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|type set number population pair|clone|a mab is a type of protein that is produced by a single entity of cells or cell line and made to bind to a specific substance in the body .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|clone clonal cell candidate mixture|validate characterize identify isolate map|clone|this strategy consists of four principal objectives , the first of which is to aggressively discover and entity g protein-coupled receptor genes .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|floor next fourth fifth sixth|basement|situated in the building upon lot c and adjacent to said common area leading from the second floor to the entity ; all as set forth in said deed recorded in book 7370 , page 304 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|floor ceiling south front house|basement|scope 1 . 1 location altarex will occupy the west wing on the first floor plus some space in the entity as shown on the attached plan .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|past future netherlands internet field|basement|some hospitals have constructed a dedicated o . r . in the entity to reduce the transportation distance .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|vicinity city neighborhood east street|basement|this termination option will not apply to any space in the entity of 320 bent street if the company has exercised its option to continue to lease such entity space .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|three four five six seven|basement|but these entity o . r .  s are remote from the surgical center , creating staffing and logistical difficulties .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|body vaginal pelvic enclosed bodily|basement|any vault or entity space not within the property line of the building , which tenant may be permitted to use or occupy , shall be
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cross basement cell zone junctional|basement cell epithelial cellular mucous|basement|additional biological activities shown to reduce inflammation , stimulate the formation of collagen , and up-regulate the expression of laminin-5 , a subepithelial entity membrane protein .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|tissue|cross basement cell zone junctional|basement cell synovial extracellular inner|basement|separating the two is the specialized type of extracellular matrix , known as the entity membrane .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|basement filtration filter surface epithelial|basement|as is caused by a genetic defect in type iv collagen , a component of the glomerular entity membrane in the kidney , resulting in defects in its structure and function .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|wireless remote mobile server secure|basement|) sublessor and sublessee each agree to log access to the server room on the 2nd floor and entity network room , and to provide these access logs to the other party if requested .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|storage packaging collection transport packing|basement|use of any mezzanine , entity or storage space shall be at no additional charge and the area of such space shall not be included in
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|house buildings housing shelter street|basement|in particular , access to the building and courtyard , vehicle passage , building and entity or other open areas and spaces must not be blocked with objects of any kind .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|waiting public remaining available private|basement|if landlord leases the entity space to other tenants before service of a notice from the tenant exercising this additional right of first offer , the
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cross basement cell zone junctional|basement cell cellular mucous membrane|basement|tumors must ordinarily degrade the entity membrane and extracellular matrix of surrounding tissues in order to grow and heparanase is an enzyme that facilitates this process .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|body another adjacent even internal|basement|no vault or entity space not within the property line of the building is leased hereunder , anything to the contrary indicated elsewhere in this lease notwithstanding .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|front place house water houses|basement|f of dry bulb , 74 ( degrees ) f wet bulb of zero f . new equipment to be placed on the roof and in entity ( location to be determined as tenant requirements are finalized ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|tissue|cross basement cell zone junctional|basement mucous amniotic nasal cell|basement|by definition , carcinomas that originate on the epithelial side of the entity membrane are considered to be benign , as long as the cells forming them remain on the same side .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|tissue|cross basement cell zone junctional|basement stromal cell epithelial cellular|basement|however , many carcinomas acquire the ability to penetrate the entity membrane , and individual cancer cells or groups of cancer cells begin to invade the stroma .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|tissue|cross basement cell zone junctional|floor walls roof wall bottom|basement|tenant shall not enter into or upon the roof or entity of the building or any storage , heating , ventilation , air-conditioning , mechanical or elevator machinery housing areas .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioblastoma gbm medulloblastoma glioma high|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|astrocytoma glioma gbm gliomas glioblastoma|oligodendroglioma|the patients in the resection injection trial predominantly had gbm ( 79 . 1% ) with other histologies including aa ( 11 . 6% ) , anaplastic entity ( 2 . 3% ) and other ( 7 . 0% ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioblastoma glioma astrocytoma oligodendrogl medulloblastoma|oligodendroglioma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , astrocytoma , entity , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioblastoma gbm medulloblastoma glioma high|oligodendroglioma|two patients , one suffering from entity and another from low grade astrocytoma , have now been alive for over 14 years since pathology diagnosis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|gbm medulloblastoma glioblastoma neuroblastoma glioma|oligodendroglioma|p / 19q loss is diagnostic for entity , and helps to determine sensitivity to response to chemotherapy , radiation and temozolomide treatment .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioblastoma glioma medulloblastoma astrocytoma meningioma|oligodendroglioma|the main glioma types are astrocytoma ( which includes glioblastoma ) , entity , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioma astrocytoma gliomas medulloblastoma glioblastoma|oligodendroglioma|three patients have completed the study to date , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|oligodendrogl ependym glioblastoma diffuse astrocytic|glioma astrocytoma gliomas glioblastoma medulloblastoma|oligodendroglioma|patients had completed the study at the time of the abstract , including one with glioblastoma multiforme , one with grade 3 entity and one with colorectal brain metastasis .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma mesothelioma gliomas nsclc|astrocytoma|bt-8 phase ii study of antineoplastons a10 and as2-1 in patients with anaplastic entity ; revised 4 / 14 / 97 ; revised 9 / 15 / 97 .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ependym diffuse astrocytoma cns oligo|glioblastoma glioma gliomas medulloblastoma astrocytoma|astrocytoma|based on phase i and ii data , the company may conduct additional phase ii clinical trials in entity ( a type of primary brain cancer ) , ovarian and non-small cell lung cancers .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ependym diffuse astrocytoma cns oligo|glioma glioblastoma gbm gliomas astrocytoma|astrocytoma|we intend to commence a pivotal 396-patient phase iii randomized , multicenter clinical trial of tvi-brain-1 in newly diagnosed grade 4 entity patients .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma tumors adenoma neoplasm|astrocytoma|afinitor is also approved for subependymal giant cell entity ( sega ) and renal angiomyolipoma associated with tuberous sclerosis complex ( tsc ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma glioblastoma astrocytic gliomas|astrocytoma|the main glioma types are entity ( which includes glioblastoma ) , oligodendroglioma , ependymoma , and mixed glioma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma tumors meningioma gliomas|astrocytoma|afinitor is also approved for subependymal giant cell entity and renal angiomyolipoma associated with tuberous sclerosis complex .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ependym diffuse astrocytoma cns oligo|glioma astrocytoma gliomas glioblastoma gbm|astrocytoma|glioblastoma multiforme , or gbm , also called grade iv entity , is the most common type of malignant primary brain tumor , comprising about 30% of all primary brain tumors in adults .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|melanoma mesothelioma glioma hyperthermia neoplasm|astrocytoma|the patient died in december 2003 , and the case was originally reported by a clinical trial investigator as malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|ependym diffuse astrocytoma cns oligo|glioma gliomas tumors neoplasms astrocytoma|astrocytoma|center at san antonio initiated a clinical trial of th-302 in combination with bevacizumab in patients with recurrent high grade entity including glioblastoma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma gliomas npc lymphomas|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the u . s . food and drug administration .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|ependym diffuse astrocytoma cns oligo|dengue rabies encephalitis measles cholera|astrocytoma|hospital and select , dated august 15 , 2000 , to perform and conduct a clinical trial study of verotoxin for treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma gliomas tumors neoplasms|astrocytoma|current treatments for glioblastoma and anaplastic entity involve surgical resection , radiation therapy , and chemotherapy .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|glioma gliomas astrocytoma melanoma mesothelioma|astrocytoma|initially primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma adenoma aneurysm glioma tumors|astrocytoma|in november , the japanese health authority approved afinitor for the treatment of renal angiomyolipoma and subependymal giant cell entity ( sega ) associated with tsc .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma gliomas glioblastoma histology|astrocytoma|the time from the initial brain tumor diagnosis to enrollment on the study ranged from four months to 301 months ( this last timing for a patient diagnosed with childhood anaplastic entity ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma gliomas npc gbm|astrocytoma|cotara has been granted orphan drug status and fast track designation for the treatment of gbm and anaplastic entity by the fda .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma gliomas glioblastoma meningioma|astrocytoma|the protocol included the provision to enroll up to 24 patients with recurrent supratentorial anaplastic entity and glioblastoma multiforme ( " gbm " ) .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|glioma gliomas astrocytoma melanoma mesothelioma|astrocytoma|our initial focus is on patients with brain cancer malignancies such as glioblastoma and malignant entity .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma glioblastoma medulloblastoma gliomas|astrocytoma|complete and partial responses were obtained in patients diagnosed with glioblastoma multiforme , entity , oligodendroglioma , mixed glioma , medulloblastoma , and malignant meningioma .
OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|ependym diffuse astrocytoma cns oligo|astrocytoma glioma glioblastoma gliomas histology|astrocytoma|patients ( 69% ) entered the study with a diagnosis of glioblastoma multiforme , seven of which were secondary to transformation from anaplastic entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell synovial ewing retroperitoneal chord|sarcomas stroma polyps melanoma tumors|carcinosarcoma|additional cabozantinib data presentations included results from trials in endometrial cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell synovial ewing retroperitoneal chord|adenocarcinoma cavity melanoma epithelial cancers|carcinosarcoma|four patients ( three ovarian cancer patients and one uterine entity patient ) had a partial response , and 17 patients had stable disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell synovial ewing retroperitoneal chord|melanoma adenocarcinoma neoplasm tumour cervix|carcinosarcoma|one patient , a 63 year old female with a poorly differentiated uterine entity , had a complete response .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|cell synovial ewing retroperitoneal chord|lung colorectal ovarian esophageal prostate|carcinosarcoma|objective responses were seen in eight patients including ovarian , breast , entity , and peritoneal mesothelioma , seven of whom had prior therapy with paclitaxel or docetaxel .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell synovial ewing retroperitoneal chord|tnbc mbc nsclc crpc eoc|carcinosarcoma|the study has been expanded to include dkn-01 monotherapy and paclitaxel combination cohorts in patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell synovial ewing retroperitoneal chord|mesothelioma melanoma glioblastoma nsclc tnbc|carcinosarcoma|partial responses in patients with endometrial cancer , and dkn-01 plus paclitaxel has generated a partial response in a patient with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cancer|cell synovial ewing retroperitoneal chord|egfr pi3k pten nf1 notch|carcinosarcoma|patients , including those with entity and wnt pathway alterations , have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell synovial ewing retroperitoneal chord|included recruited treated 2000 surviving|carcinosarcoma| gynecologic cancers study : updated follow-up data from the entity patients is expected in late 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell synovial ewing retroperitoneal chord|endometrial cervix cavity epithelial papillary|carcinosarcoma|over 40% of uterine entity cancers and 10% to 20% of ovarian and stomach cancers harbor ccne1 amplification .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cell synovial ewing retroperitoneal chord|melanoma mm malignancies cll nsclc|carcinosarcoma|patient follow-up is continuing in this study , which has been expanded to include focused cohorts of patients with entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|cell synovial ewing retroperitoneal chord|sarcomas cancers tumors cervix adenocarcinoma|carcinosarcoma|the partial responses occurred in patients with ovarian cancer and uterine entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell synovial ewing retroperitoneal chord|three experimental parallel interventional focus|carcinosarcoma|enrollment has recently completed in the entity groups .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|cell synovial ewing retroperitoneal chord|adenoma adenocarcinoma adenomas hyperplasia neoplasia|carcinosarcoma|no mammary adenoma was diagnosed by the pathologists who provided the original study report ; the incidence of mammary entity did not change from the initial report .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cancer|cell synovial ewing retroperitoneal chord|nsclc mesothelioma gist sclc combination|carcinosarcoma|odkn-01 plus paclitaxel in entity : fifteen patients with carcinosarcoma were enrolled in the dkn-01 plus paclitaxel arm , six of whom were evaluable for response as of the data-cut off
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|cell synovial ewing retroperitoneal chord|cll melanoma dlbcl crpc nsclc|carcinosarcoma|in addition , based on the clinical activity observed in part 1 , we have added a cohort for patients with entity in part 2 of the study .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|terat cell mature cord residual|hemorrhage metastasis recurrence necrosis encephalitis|teratoma|were not only insufficient for regeneration or reconstruction of the damaged cns , but also accompanied by unacceptably high incidents of entity and / or neoplasm formation .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|terat cell mature cord residual|apoptosis proliferation invasion metastasis hypoxia|teratoma|there was no evidence of entity , or tumor growth , in these cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|terat cell mature cord residual|global quantitative technical comprehensive prospective|teratoma|$ 47 , 535 project 2 : entity assessment of the generation of three germ layers scope of work the goal of this project is to assess the
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|terat cell mature cord residual|xenograft granuloma spleen ipsc fibrosis|teratoma|pluripotent properties of wolfram syndrome-ipscs were also assessed by entity formation on intramuscular injection of undifferentiated wolfram syndrome-ipscs into scid mice .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|terat cell mature cord residual|xenografts engraftment colonies ipscs tumors|teratoma|in a humanized mouse model on left : human ipsc proliferate ( as visualized by luminescence of live cells ) and form entity in nsg mice ( n=3 ) with adoptive transferred human nk cells .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cancer|terat cell mature cord residual|granuloma callus fistula xenograft cyst|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1), ('BIO', 1)])|cancer|terat cell mature cord residual|callus granuloma cyst scar tissue|teratoma|because adult stem cells have a limited ability to multiply and are more differentiated , entity formation has not been 264 table of contents observed in clinical studies to date .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cancer|terat cell mature cord residual|cyst scar hematoma granuloma aneurysm|teratoma|included in the safety package were studies that showed no evidence of entity formation 12 months after injection of clinical grade grnopc1 into the injured spinal cord of rats and mice .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|terat cell mature cord residual|cancerous malign benign solid good|teratoma|know that one of the scientific tests to determine that the cells are hescs , is whether they can produce a entity or benign tumor .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cancer|semin situ histological cell basal|dizziness headache dyspnea depression insomnia|seminoma|dyspnoea 1 chest pain 1 entity 1 weight increased 1 hot flush 1 mood swings 1 erectile dysfunction 1 uri 1 hot flush 1 headache 1
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|cell ewing clin para angio|sarcomas tumors malignancies cancers reconstruction|sarcoma|based on the outcome of picasso 3 in soft tissue entity and the resulting revision in the companys development plans for palifosfamide , enrollment in this study was suspended with 188 patients
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|cell ewing clin para angio|sarcomas osteosarcoma tumors neuroblastoma ewing|sarcoma|institute of health ( which we refer to as nih ) and physician collaborators , salarius believes that there are approximately 500 ewing entity patients diagnosed annually in the united states .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell ewing clin para angio|oncology nci translational therapeutic melanoma|sarcoma|contracts and agreements nci entity vaccine grant in july 2010 , the national cancer institute ( “nci” ) awarded the company a small business innovation research
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors sarcomas tumour osteosarcoma neuroblastoma|sarcoma|endorex has received orphan drug designation for immther ( r ) by the fda for two types of bone cancer , ewings entity and osteogenic entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell ewing clin para angio|diagnosis cancers pathology melanoma biopsies|sarcoma|but pathologists ( doctors who specialize in diagnosing cancers by how they look under the microscope ) , may not always agree on the exact type of entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cancer|cell ewing clin para angio|sarcomas ks tumors lymphomas dementia|sarcoma|thalidomide , as well as to the orphan drug designations we already received for its use in brain cancer and kaposi  s entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell ewing clin para angio|oncology cooperative steering consensus advisory|sarcoma|he holds the position of the french entity group , and acts as network director of the european reference network for rare adult cancers ( euracan ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|cell ewing clin para angio|sarcomas tumors malignancies cancers conditions|sarcoma|we also received orphan drug designation from the fda and the ema for trc105 for the treatment of soft tissue entity , including angioentity , in 2016 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell ewing clin para angio|sarcomas mf tumors mesothelioma neoplasms|sarcoma|the most common types of entity in adults are undifferentiatedpleomorphic entity ( previously called malignant fibrous histiocytoma ) , lipoentity , and leiomyoentity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors masses neoplasms lesions sarcomas|sarcoma|for example , leiomyoentitys are the most common abdominal entity , while lipoentitys and undifferentiated pleomorphic entity are most common in legs .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell ewing clin para angio|fibromyalgia epilepsy vision diabetes autism|sarcoma|patel is a member of the board of directors for the entity foundation of america .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors tumour osteosarcoma sarcomas neuroblastoma|sarcoma|ewing entity is driven by an easily diagnosed chromosomal translocation , i . e . , ews-fli sankar et al . clinical cancer research 20 . 17 oncogenes ( tumor growth )
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell ewing clin para angio|sarcomas mesothelioma adenocarcinoma melanoma osteosarcoma|sarcoma|synovial entity is an ini1-deficient tumor of particular interest for treatment with an ezh2 inhibitor .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell ewing clin para angio|cardiology oncology expert acs academic|sarcoma|“the entity community has been very supportive following the esmo presentation in which we showed a clear benefit for adp-a2m4 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors sarcomas osteosarcoma tumours tumour|sarcoma|and mcl and are also conducting a dose-escalation phase 1 trial of tk216 in patients with relapsed or refractory ewing entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell ewing clin para angio|ks herpesvirus sarcomas lesions keratitis|sarcoma|kaposis entity the novel mt-1000 class constructs are designed to specifically deliver doxorubicin , a chemotoxin , which can kill ks tumor cells
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors sarcomas neuroblastoma osteosarcoma tumour|sarcoma|during the three months ended sept . 30 , 1998 , the company expanded the clinical trial for immther ( r ) in ewings entity to memorial sloan-kettering , a major cancer center .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|cell ewing clin para angio|sarcomas malignancies tumors mesothelioma cancers|sarcoma|our preclinical data for synovial entity we have generated in vivo proof of concept data that demonstrates antitumor activity of fhd-609 in synovial sarcoma cdx models .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors sarcomas tumour osteosarcoma tumours|sarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyoentity , ewings entity and osteoentity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell ewing clin para angio|tumors sarcomas tumours tumour osteosarcoma|sarcoma|current treatment for ewing entity consists of an intensive chemotherapy regime , radiation and often disfiguring surgeries .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma cell cutaneous chondro secondary|experimental combined respective xenograft single|osteosarcoma|+ mbil-15 nk cells ( graphical ) the graphical data above are an average of the mice studied in the entity mouse model shown above .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|osteosarcoma medulloblastoma neuroblastoma retinoblastoma sarcomas|osteosarcoma|rare pediatric disease designations for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|osteosarcoma cell cutaneous chondro secondary|survival interim preliminary registry randomised|osteosarcoma|: 93 , 1995 junovan : phase iii entity results overall survival years proportion surviving 0 1 2 3 4 5 6 0 . 0 0 . 2 0 . 4 0 . 6 0 . 8 1 . 0 -
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|neuroblastoma medulloblastoma pediatrics osteosarcoma tnbc|osteosarcoma|overexpressed , including her2+ gastric , endometrial , ovarian , colorectal , lung , pancreatic , cervical , and bladder cancers , as well as her2+ pediatric indications including entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 1)])|cancer|osteosarcoma cell cutaneous chondro secondary|toxicity neurotoxicity toxicities hepatotoxicity cardiotoxicity|osteosarcoma|typically , treatment duration is limited to two years because of the risk of entity revealed in preclinical testing .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|osteosarcoma cell cutaneous chondro secondary|osteosarcoma neuroblastoma myeloma sarcomas metastasis|osteosarcoma|her2 is overexpressed in certain solid-tumor cancers , including pediatric bone cancer ( or entity ) , breast cancer , esophageal , and gastric cancer .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|all neuroblastoma medulloblastoma retinoblastoma osteosarcoma|osteosarcoma|according to the childrens oncology group , the survival of children with entity has remained at 60-65 percent since the mid-1980s .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|osteosarcoma this gct myeloma neuroblastoma|osteosarcoma|entity is a bone tumor that occurs predominantly in adolescents and young adults .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma cell cutaneous chondro secondary|hypoglycemia osteoporosis fracture fractures hypoglycaemia|osteosarcoma|because of the potential risk of entity , natpara is recommended only for patients who cannot be well-controlled on calcium and active forms of vitamin d alone .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|osteosarcoma cell cutaneous chondro secondary|ms melanoma als ad dm1|osteosarcoma|assuming similar prevalence as in the united states , we estimate approximately 1 , 500 patients diagnosed with entity per year in europe .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|diabetes t1d amd melanoma copd|osteosarcoma|any revenues generated will be limited by the number of patients with entity , our ability to obtain appropriate pricing and reimbursement for junovan , and the effects of competition .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|melanoma nsclc ms copd myeloma|osteosarcoma|each year , approximately 1 , 000 new patients are diagnosed with entity in the united states .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|osteosarcoma cell cutaneous chondro secondary|ovarian sarcomas melanoma mammary mastitis|osteosarcoma|filed for a product license from the usda for at-014 , a novel her2 / neu-directed cancer immunotherapy for the treatment of canine entity and other cancers .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|melanoma this nf1 myeloma neuroblastoma|osteosarcoma|entity is an orphan disease with fewer than 1 , 000 new cases diagnosed in the united states each year .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|osteosarcoma cell cutaneous chondro secondary|nsclc melanoma crc osteosarcoma hcc|osteosarcoma|cxcr4 antagonist to determine whether inhibition of cxcr4 leads to a decrease of lung metastases in a mouse model of entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|osteosarcoma medulloblastoma neuroblastoma melanoma retinoblastoma|osteosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , rhabdomyosarcoma , ewings sarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|osteosarcoma cell cutaneous chondro secondary|tumors myopathy cancers toxicity malignancies|osteosarcoma|it is unknown if tymlos will cause entity in humans .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|osteosarcoma cell cutaneous chondro secondary|osteosarcoma medulloblastoma melanoma glioblastoma myeloma|osteosarcoma|in subsequent testing in mouse xenograft models of neuroblastoma , ewing sarcoma , rhabdomyosarcoma and entity , clr 131 provided significant benefits on tumor growth rates and survival .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|osteosarcoma cell cutaneous chondro secondary|tnbc nsclc mbc gbm hcc|osteosarcoma|the standard treatment for entity is tumor resection with combination chemotherapy before and after surgery .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|osteosarcoma cell cutaneous chondro secondary|animal experimental murine mouse osteosarcoma|osteosarcoma|the presentation will discuss the work related to the anti-metastatic properties of ctce-9908 in an entity model and the potential mechanisms involved .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|chondro cell differentiation chord synovial|these bony such osseous musculoskeletal|chondrosarcoma|the most common locations for entity tumors are the bones of the extremities and the pelvis .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|chondro cell differentiation chord synovial|osteosarcoma this myeloma mm gct|chondrosarcoma|entity is a rare , life-threatening bone cancer .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|chondro cell differentiation chord synovial|sarcomas neuroblastoma osteosarcoma nsclc glioblastoma|chondrosarcoma|idh2 mutations have also been found in several solid tumor types such as melanoma , glioma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|chondro cell differentiation chord synovial|nsclc mesothelioma ovarian lung peritoneal|chondrosarcoma|we expect to announce additional data from the entity and malignant pleural mesothelioma treatment cohorts in the fourth quarter of 2020 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cancer|chondro cell differentiation chord synovial|medulloblastoma osteosarcoma sclc sarcomas neuroblastoma|chondrosarcoma|idh1 mutation alterations are seen in aml , glioma , entity , and intrahepatic cholangiocarcinoma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|chondro cell differentiation chord synovial|osteosarcoma mesothelioma sarcomas melanoma gist|chondrosarcoma|partial responses were seen , in one patient each , with entity , extra-skeletal myxoid entity , leiomyosarcoma and a desmoid tumor .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cancer|chondro cell differentiation chord synovial|osteosarcoma sarcomas gist mesothelioma sts|chondrosarcoma|” in this phase 2 study , the single agent activity of krx-0401 is being evaluated in patients with entity , alveolar soft part sarcomas and extra-skeletal myxoid entitys .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|melanoma glioblastoma mesothelioma nsclc cll|chondrosarcoma|at the 3 . 1 mg / m2 dose level , one patient with prostate cancer and one with entity had no dlt during 4 and 9 cycles of treatment , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cancer|chondro cell differentiation chord synovial|rcc nsclc crc melanoma hcc|chondrosarcoma|entity predominantly affects middle-aged and older adults , usually occurring in patients over 40 years old , with the incidence gradually increasing up
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|nsclc mesothelioma sclc ascites glioblastoma|chondrosarcoma|both malignant pleural mesothelioma and entity are serious , life-threating medical conditions with very limited treatment options , for which inbrx-109 could fulfill an unmet medical need .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|nsclc melanoma rcc crc malignancies|chondrosarcoma|the preclinical data support infinitys ongoing phase 2 double-blind , randomized , placebo-controlled trial of ipi-926 in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|sarcomas osteosarcoma mesothelioma melanoma neuroblastoma|chondrosarcoma|and tolerability as a single agent in patients with advanced solid tumors with an idh1 mutation , including glioma , cholangiocarcinoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|glioma glioblastoma gbm melanoma nsclc|chondrosarcoma|includes 2 patients with triple negative breast cancer , 1 renal cell carcinoma patient , 1 mesothelioma patient and 1 idh1 mutant entity patient .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|chondro cell differentiation chord synovial|nsclc melanoma hcc rcc hnscc|chondrosarcoma|in particular , there are no approved effective systemic therapy options for recurrent , unresectable and metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|chondro cell differentiation chord synovial|osteosarcoma this melanoma gct myeloma|chondrosarcoma|in the united states , entity accounts for approximately one-third of the 2 , 000 cases of primary bone cancer 5 table of contents diagnosed each year .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cancer|chondro cell differentiation chord synovial|nsclc rcc melanoma malignancies tumors|chondrosarcoma|initiated a phase 2 clinical trial evaluating ipi-926 as a single agent in patients with metastatic or locally advanced , inoperable entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|cyst ovarian cell epiderm familial|epithelial papillary borderline cell predominant|cystadenocarcinoma|reactivity was higher in particular subsets of these cancers ; for example , over 80% of serous entity ovarian cancer tumors were reactive .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|cyst ovarian cell epiderm familial|serous adenocarcinoma urothelial cell histology|cystadenocarcinoma|the patients tumor types were as follows : colon , rectal , breast , pancreatic , esophageal , gastric , papillary entity , cholangiosarcoma , carcinoid , unknown primary .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell neuroendocrine situ basal clin|carcinomas adenoma neoplasms adenocarcinoma fibrosis|carcinoma|hepatitis c viral infection ( " hcv " ) is a potentially deadly disease that , if not treated , may lead to cirrhosis and hepatocellular entity , or liver cancer .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas rcc cancers tumors adenocarcinoma|carcinoma|dart study , a randomized , double-blind study of dalantercept plus axitinib , compared to placebo plus axitinib in patients with advanced renal cell entity ( rcc ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas hcc adenoma adenocarcinoma tumors|carcinoma|we are working to develop and potentially commercialize tivozanib in the u . s . as a treatment for rcc and hepatocellular entity , or hcc .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell neuroendocrine situ basal clin|hcc carcinomas adenoma cancers adenocarcinoma|carcinoma|trials in colon cancer , gastric cancer , small cell lung cancer and hepatocellular entity are investigator-sponsored .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell neuroendocrine situ basal clin|carcinomas hcc adenoma adenocarcinoma cirrhosis|carcinoma|ended march 31 , 2002 , we disclosed plans to pursue phase 3 clinical studies with t67 for the treatment of hepatocellular entity , or primary liver cancer .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas cancers tumors adenocarcinoma malignancies|carcinoma|in addition , argx-110 is being evaluated in an open-label phase 1 clinical trial in patients with nasopharyngeal entity .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas cancers rcc tumors malignancies|carcinoma|programs of archexin and will cease enrollment in the current phase iia clinical study of archexin in metastatic renal cell entity ( mrcc ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas adenocarcinoma cancers adenoma tumors|carcinoma|by approximately 20 weeks of age , mice began to develop hepatocellular entity ( hcc ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|derived cell replacement culture membrane|carcinoma|net revenue from our two collaborations with genentech unless and until we obtain fda approval to commercialize our basal cell entity product candidate .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|rcc carcinomas tumors cancers malignancies|carcinoma|approved in more than 80 countries and regions including the us , eu member states and japan for advanced renal cell entity following vascular endothelial growth factor-targeted therapy .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cancer|cell neuroendocrine situ basal clin|epithelium tissue implants glands ducts|carcinoma|; 32 : 1207–1218 vx15 ( pepinemab ) anti-sema4d antibody for cancer sema4d expression is concentrated at invasive margin of tumor mammary entity ( tubo .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell neuroendocrine situ basal clin|carcinomas adenoma hcc adenocarcinoma cancers|carcinoma|our focus on hepatocellular entity , or hcc , is based on the fact that liposomal nanoparticle formulations have a tendency to deliver their payload to the
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell neuroendocrine situ basal clin|carcinomas hcc adenoma cirrhosis adenocarcinoma|carcinoma|t67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular entity , a refractory malignancy for which there are no approved systemic chemotherapeutic agents .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 2)])|cancer|cell neuroendocrine situ basal clin|rcc carcinomas cancers tumors cell|carcinoma|archexin received " orphan drug " designation from the fda for five cancer indications ( renal cell entity ( rcc ) , glioblastoma , ovarian cancer , stomach cancer and pancreatic cancer ) .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1), ('DIS', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas tumors cancers malignancies tumours|carcinoma|we initiated a phase ii clinical trial in the third quarter of 2002 in patients with renal cell entity expressing the muc1 antigen .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas rcc cancers tumors malignancies|carcinoma|when used in combination with the checkpoint inhibitor opdivo , nktr-214 showed important clinical responses in melanoma , renal cell entity and nsclc patients .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell neuroendocrine situ basal clin|carcinomas hcc hepatoma cholangiocarcinoma adenoma|carcinoma|with tekmira to develop sirna to silence the csn5 gene , which could represent a novel therapeutic target to treat hepatocellular entity ( hcc ) and other cancers .
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DIS', 1)])|cancer|cell neuroendocrine situ basal clin|cancers carcinomas tumors cell adenocarcinoma|carcinoma|lung cancer , including nsclc and small cell lung entity , or sclc , is the most common form of human cancer , and about 80% of diagnosed lung cancer cases are categorized
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|cell neuroendocrine situ basal clin|ductal cervix cancerous cis squamous|carcinoma|bacillus calmette-guérin ( bcg ) -refractory entity in situ ( cis ) bladder cancer—cis of the urinary bladder is a rare form of bladder cancer , affecting about 7 of
OrderedDict([('OTHER', 5), ('BIO', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cell neuroendocrine situ basal clin|carcinomas rcc tumors cancers adenocarcinoma|carcinoma|renal cell entity doesn  t respond to chemotherapy and 15 to 20% of the patients respond to cytokine ( il2 or ifn-y ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|mesothelioma melanoma cholangiocarcinoma glioblastoma others|cholangiocarcinoma|phase 1 / 2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer ( nsclc ) , ovarian cancer , malignant pleural / peritoneal mesothelioma , and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|cholangiocarcinoma pancreatic liver intrahepatic pancreas|cholangiocarcinoma|biliary cancers , including entity , gallbladder and ampullary carcinoma , are cancers originating in the bile duct , a vessel that transports bile from the liver to
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma nsclc aml rcc cml|cholangiocarcinoma|[ *** ] after a specified period of time following regulatory approval of varlitinib for the treatment of entity in south korea and ( ii ) milestone payments of $
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|taiwan japan asia korea australia|cholangiocarcinoma|additionally , we made a payment of $325 , 000 to hyundai in order to buy back the rights to commercialize varlitinib in entity ( cca ) and recorded as operating costs in february 2019 .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma nsclc cholangiocarcinoma glioma glioblastoma|cholangiocarcinoma|that ros1 is rearranged in non-small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , gastric cancer patients and entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|setting nsclc settings monotherapy regimens|cholangiocarcinoma|in november , the fda accepted the new drug application ( nda ) for pemigatinib in second-line entity for priority review .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma cholangiocarcinoma osteosarcoma mesothelioma glioblastoma|cholangiocarcinoma|compared to phenoxodiol , triphendiol has substantially greater activity in laboratory testing against pancreatic cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma nsclc cholangiocarcinoma mesothelioma glioblastoma|cholangiocarcinoma|dkn-01 is in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|gbm glioblastoma hcc glioma melanoma|cholangiocarcinoma|the fda has also granted fast-track designation to ivosidenib for treatment of patients with previously treated , unresectable or metastatic entity with and idh1 mutation .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|gallbladder cholangiocarcinoma liver biliary hepatocellular|cholangiocarcinoma|had been granted orphan drug status by the fda for the treatment of pancreatic cancer and for the treatment of entity , or bile duct cancer .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|cholangiocarcinoma cancers adenocarcinoma tumors malignancies|cholangiocarcinoma|biliary tract cancer consists of intra-hepatic and extra-hepatic entity ( cancer of the bile duct ) , cancer of the gall bladder and papilla of vater ( the final portion of the bile
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|hcc cholangiocarcinoma lc crc cca|cholangiocarcinoma|one type of liver cancer ( entity ) that is rare in most parts of the world has high incidence rates in thailand and other parts of asia
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|cholangiocarcinoma icc hcc fibrosis cholestasis|cholangiocarcinoma|the development of rly-4008 will focus on solid tumor patients with fgfr2 alterations , including intrahepatic entity ( icc ) patients harboring fgfr2 gene fusions .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|cholangiocarcinoma icc cholestasis fibrosis macrophages|cholangiocarcinoma|“icca” means intrahepatic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|liver pancreatic cholangiocarcinoma colorectal ovarian|cholangiocarcinoma|in october 2017 , we initiated a phase 1b / 2 clinical trial to assess tecentriq with pegph20 in patients with entity and gall bladder cancer ( halo 110-101 / matrix ) .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma rcc mesothelioma amd neuroblastoma|cholangiocarcinoma|opaganib received orphan drug designation from the u . s . fda for the treatment of entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma nsclc cholangiocarcinoma mesothelioma glioblastoma|cholangiocarcinoma|dkn-01 is currently being studied in clinical trials in esophageal cancer and entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|nsclc melanoma mesothelioma tnbc cholangiocarcinoma|cholangiocarcinoma|breast cancer gastric cancer , nsclc pancreas cancer , gastric cancer gall bladder cancer , entity robust pan-tumor testing of pegph20 17 1 pending continued enrollment rate .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|melanoma osteosarcoma mesothelioma neuroblastoma medulloblastoma|cholangiocarcinoma|studies suggest that ros1 is rearranged in non small cell lung adenocarcinoma cancer patients , stomach cancer patients , glioblastoma patients , and entity patients .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cancer|cholangiocarcinoma intrahepatic pancreatic colorectal hepatocellular|nsclc these gbm mesothelioma crpc|cholangiocarcinoma|the company commenced a second combination trial , examining the combination of prolindac and gemcitabine in entity patients , in the fourth quarter of 2011 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell mole melanoma type epitheli|cus scc ecc uc csc|keratoacanthoma|in the pooled safety population , cuscc and entity occurred in 7% and 1 . 9% of 351 patients , respectively .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|cell mole melanoma type epitheli|toxicity hemorrhage thrombocytopenia neurotoxicity neutropenia|keratoacanthoma|the two trsaes included a grade 2 infusion reaction and a grade 1 entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell mole melanoma type epitheli|sarcomas nsclc hnscc scc melanoma|keratoacanthoma|tafinlar results in an increased incidence of cutaneous squamous cell carcinoma ( cuscc ) , entity and melanoma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell mole melanoma type epitheli|melanoma cutaneous cis bcc scc|keratoacanthoma|in the columbus trial , cutaneous squamous cell carcinoma , including entity , occurred in 2 . 6% and basal cell carcinoma occurred in 1 . 6% of patients .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell mole melanoma type epitheli|melanoma cutaneous bcc basal scc|keratoacanthoma|cutaneous squamous cell carcinoma , including entity , occurred in 7% of patients receiving the combination and 19% of patients receiving tafinlar as a single agent .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2), ('DRUG', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma cancers tumors cell ductal|adenocarcinoma|treatment of cervical cancer and other solid tumors , including head and neck cancer , squamous non-small-cell lung cancer , or nsclc , pancreatic entity and colorectal cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma histology head tissue pancreas|adenocarcinoma|entity of the pancreas , which accounts for approximately 95% of all cases of pancreatic cancer , has a median overall survival of
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|junction histology adenocarcinoma cell positive|myeloma melanoma oncology neuroblastoma immunocompromised|adenocarcinoma|o ing-1 is a human engineered ( tm ) monoclonal antibody developed by us to specifically target tumor cells in entity patients .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas exocrine pancreatic cholangiocarcinoma|adenocarcinoma|it is estimated that around 65 , 000 patients were diagnosed with pancreatic cancer ( mainly entity ) in the united states and the top 5 eu countries .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma cancers tumors malignancies neoplasms|adenocarcinoma|of medicine , which investigated marker therapeutics , inc . s ( the “company” ) multitaa t cell therapy for the treatment of patients with pancreatic entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma tumors cancers malignancies adenocarcinomas|adenocarcinoma|clinical trial led by baylor college of medicine ( bcm ) , evaluating the companys multitaa t cell therapy in patients with pancreatic entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas neoplasms tumors neoplasm|adenocarcinoma|am0010 development for the treatment of pancreatic ductal entity in our phase 1 / 1b clinical trial , we treated 22 pdac patients with am0010 monotherapy and 21 patients with am0010 in
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma cancers tumors adenocarcinomas malignancies|adenocarcinoma|trial evaluating keytruda as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas nsclc neuroendocrine undifferentiated|adenocarcinoma|types of nsclc include squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 2)])|cancer|junction histology adenocarcinoma cell positive|lung cell tissue cancers squamous|adenocarcinoma|studies suggest that ros1 is rearranged in non small cell lung entity cancer patients , stomach cancer patients , glioblastoma patients and cholangiocarcinoma patients .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas cancers carcinomas tumors|adenocarcinoma|the u . s . food and drug administration ( fda ) approved abraxane in combination with gemcitabine as first-line treatment of patients with metastatic entity of the pancreas .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas nsclc neuroendocrine undifferentiated|adenocarcinoma|about 85% of lung cancers are nsclc , which has different subtypes , including squamous cell carcinoma , entity , and large cell carcinoma .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma melanoma carcinomas dcis malignancies|adenocarcinoma|the study will target enrolling 35 patients with histologically or cytologically confirmed diagnosis of invasive entity originating in the breast .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|cancers adenocarcinoma carcinomas tumors tumours|adenocarcinoma|and multiple myeloma , and expects to commence clinical trials of maxamine for the treatment of additional cancers , such as prostate entity , in 1998 .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|cancers adenocarcinoma tumors adenocarcinomas carcinomas|adenocarcinoma|high msi is present in about 15% of gastrointestinal tumor cancers , including in approximately 22% of stomach entity and 16% of colorectal cancer .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma this melanoma prostate hnscc|adenocarcinoma|entity is a general term that refers to a cancer that starts in glandular tissues anywhere in the body .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|junction histology adenocarcinoma cell positive|std hpv neoplasia lb mtc|adenocarcinoma|· inability to detect entitys — pap tests are unable to detect the presence of the more virulent entity ( clinical laboratory medicine , 20 : 140 ) .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas cancers carcinomas tumors|adenocarcinoma|abraxane® was approved for the treatment of metastatic entity of the pancreas in the united states in september 2013 and the european union in december 2013 . net sales of abraxane®
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma adenocarcinomas carcinomas tumors neoplasms|adenocarcinoma|our phase 1 clinical trial , which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal entity .
OrderedDict([('OTHER', 5), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cancer|junction histology adenocarcinoma cell positive|adenocarcinoma cancers malignancies carcinogenesis tumors|adenocarcinoma|the first target of the collaboration is early stage lung entity .
OrderedDict([('OTHER', 5), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell dural rupture cyst chord|monitor technology gel valve vision|blastoma|neuroentity - market insights , epidemiology and market forecast - 2027 the market of neuro entity in 7mm was found to be usd 733 . 58 million in 2016 , and is expected to increase at from 2016 -
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell uve cutaneous melanoma mucosal|cns first brain multiple distant|melanoma|five patients experienced entity relapses shortly after inclusion in the trial and despite initiation of standard treatment had progressing metastases at start of their
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2)])|cancer|cell uve cutaneous melanoma mucosal|randomised therapeutic bevacizumab adjuvant ipilimumab|melanoma|that our cash reserves are sufficient to fund two years of anticipated operating activities , including our recently announced phase ii entity combination trial .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|cell uve cutaneous melanoma mucosal|melanoma glioblastoma glioma neuroblastoma prostate|melanoma|in preclinical studies conducted by the company  s scientists , tlc ell-12 has been shown to be active in tumor models of entity , lung cancer , leukemia and multiple drug resistant cell lines .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell uve cutaneous melanoma mucosal|melanoma malignancies cancers rcc nsclc|melanoma|provectus has completed phase 2 trials of pv-10 as a therapy for metastatic entity , and of ph-10 as a topical treatment for atopic dermatitis and psoriasis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell uve cutaneous melanoma mucosal|melanoma ovarian rcc hnscc crc|melanoma|• data from the nsclc and entity cohorts of the encore 601 trial will each be featured during oral presentations at the american association of cancer research
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cancer|cell uve cutaneous melanoma mucosal|ms diabetes melanoma epilepsy neuroblastoma|melanoma|bms / p  s most advanced program involves a vaccine called gmk that incorporates qs-21 with a ganglioside preparation called gm2 to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell uve cutaneous melanoma mucosal|melanoma malignancies cancers rcc crc|melanoma|what im trying to say here is we have completely changed the outcome and treatment of patients with metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma nsclc mesothelioma rcc myeloma|melanoma|we introduced canvaxin that was manufactured using this new process into our two phase 3 clinical trials for advanced-stage entity in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell uve cutaneous melanoma mucosal|cancers malignancies melanoma nsclc cholangiocarcinoma|melanoma|triphendiol has recently been granted orphan drug status by the fda for pancreatic and bile duct cancers , and late stage entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell uve cutaneous melanoma mucosal|cholangiocarcinoma hcc liver hepatocellular melanoma|melanoma|the company has received orphan drug designations from the fda for its entity and hepatocellular carcinoma indications .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1), ('DRUG', 1)])|cancer|cell uve cutaneous melanoma mucosal|hcc malignancies tumors therapies melanoma|melanoma|accordingly , a comparable distribution of patients with liver metastases is important in clinical trials of metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma rcc nsclc crc cancers|melanoma|it was approved to treat metastatic entity by the fda in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma nsclc glioblastoma cancers hcc|melanoma|the first oncolytic immunotherapy , imlygic , also known as t-vec , which was approved by the fda for the treatment of advanced entity in 2015 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma nsclc rcc neuroblastoma glioblastoma|melanoma|have completed enrollment in part i of a phase 3 trial for renal cell carcinoma and a phase 3 trial for metastatic entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|cancer|cell uve cutaneous melanoma mucosal|melanoma glioma mesothelioma tumors tumour|melanoma|the improvement in two and three year survival remained statistically significant in the subpopulation of advanced malignant entity patients with liver metastases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma aml hcc nsclc osteosarcoma|melanoma|the pivotal phase iii study in high-risk entity patients completed enrollment in 1999 .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma glioblastoma neuroblastoma myeloma nsclc|melanoma|product has potential utility in adjuvant therapy and for the treatment of advanced cancers that express the gd2 ganglioside , including entity , small cell lung cancer and sarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell uve cutaneous melanoma mucosal|melanoma nsclc crpc rcc crc|melanoma|we  re recruiting patients with metastatic entity for a phase i safety study in israel .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1), ('DRUG', 1)])|cancer|cell uve cutaneous melanoma mucosal|melanoma tumors diseases mesothelioma ascites|melanoma|and metastatic breast cancer ; and intron a injection , marketed for numerous anticancer indications worldwide , including as adjuvant therapy for malignant entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell uve cutaneous melanoma mucosal|previous therapeutic earlier past influenza|melanoma|the most common adverse events associated with our entity trials have consisted of flu-like symptoms such as fever , chills and nausea .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma glioblastoma gist melanoma sarcomas|leiomyosarcoma|or cbr , rates was achieved in the three most prevalent types of sarcoma , namely bone sarcoma ( cbr rate of 30% ) , entity ( 33% ) and liposarcoma ( 30% ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma others mesothelioma neuroblastoma glioblastoma|leiomyosarcoma|these include patients with osteosarcoma , ewing sarcoma family tumours , malignant fibrous histiocytoma , synovial sarcoma , fibrosarcoma and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell synovial leiomy chondro ewing|main proposed feasibility prospect original|leiomyosarcoma|the entity study was initiated and screening of patients began in early 2006 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cancer|cell synovial leiomy chondro ewing|evaluable nsclc single treated hundred|leiomyosarcoma|we also enrolled a first entity patient in the phase 2 basket arm evaluating ide196 as monotherapy , expanding the tissue-agnostic approach to additional solid tumors harboring
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|cell synovial leiomy chondro ewing|melanoma nsclc tnbc adenocarcinoma mbc|leiomyosarcoma|out of 2 heavily pre-treated stage iv entity patients and 1 heavily pre-treated triple negative breast cancer patient experienced stable disease as best response .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cancer|cell synovial leiomy chondro ewing|ovarian neuroblastoma pancreatic lung solid|leiomyosarcoma|developed a fully-human antibody , designated imc-3g3 , that effectively blocks the function of pdgfra and inhibits the growth of glioblastoma and entity tumors in animal models .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|cell synovial leiomy chondro ewing|melanoma lymphomas sarcomas others melanomas|leiomyosarcoma|elevated cd47 has been reported in solid tumors , including breast , colon , ovarian , brain , liver and prostate cancers and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|gist osteosarcoma this sts tnbc|leiomyosarcoma|doxorubicin has historically been the standard of care for the treatment of entity and other sts .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma glioblastoma melanoma mesothelioma gist|leiomyosarcoma|this multicenter clinical trial is to assess the efficacy of ap23573 in four groups of sarcomas : bone sarcoma , entity , liposarcoma , and other soft tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|cell synovial leiomy chondro ewing|glioblastoma glioma gliomas medulloblastoma gbm|leiomyosarcoma|●results by year end are expected from ongoing clinical trials evaluating ptc596 in entity and diffuse intrinsic pontine glioma ( dipg ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|melanoma lung nsclc ovarian prostate|leiomyosarcoma|on these findings , as well as pre-clinical data , the phase 2 dose employed in the arq 501 monotherapy trials in entity and head and neck cancer is 450 mg / m2 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|mds mm aml sts gist|leiomyosarcoma|ptc596 is also being evaluated in entity , or lms , in patients who have relapsed or are refractory to current treatments .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma mesothelioma melanoma leiomy neuroblastoma|leiomyosarcoma|the most common types of sarcoma in adults are undifferentiatedpleomorphic sarcoma ( previously called malignant fibrous histiocytoma ) , liposarcoma , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma sarcomas melanoma glioblastoma mesothelioma|leiomyosarcoma|clinical-benefit responses were demonstrated in 39% of bone sarcoma patients , 50% of entity , 21% of liposarcoma , and 24% of other soft-tissue sarcomas .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma neuroblastoma melanoma gist glioblastoma|leiomyosarcoma|the 246 patients with entity or liposarcoma comprise 57% of the total trial population .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|cell synovial leiomy chondro ewing|main extension pivotal original expansion|leiomyosarcoma|interim data from the entity study show a 17 . 5 percent objective response rate among patients to monotherapy treatment with arq 501 .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 1), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|lung liver muscle sarcomas gist|leiomyosarcoma|-- the cbr rates were not statistically different among the four sub-groups ( i . e . , bone , 30% ; entity , 33% ; liposarcoma , 30% ; and other , 23% ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma sarcomas neuroblastoma gist medulloblastoma|leiomyosarcoma|axl is a tyrosine kinase receptor that is highly expressed and activated in numerous human sarcomas , including aggressive subtypes of entity , ewings sarcoma and liposarcoma .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma sarcomas glioblastoma melanoma gist|leiomyosarcoma|entity and liposarcoma are the two most common types of sts and accounted for 57% of the patients enrolled in the
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 3), ('DRUG', 1)])|cancer|cell synovial leiomy chondro ewing|osteosarcoma mesothelioma gist neuroblastoma melanoma|leiomyosarcoma|trabectedin ( yondelis® ) was approved in 2015 for patients with entity or liposarcoma that have had prior treatment with an anthracycline such as doxorubicin .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 3), ('DIS', 2)])|cancer|ewing cell oligo osteosarcoma synovial|neuroblastoma malignancies medulloblastoma oncology cancers|rhabdomyosarcoma|indications for our impact therapeutic vaccines and have developed cell lines for ovarian cancer , triple negative breast cancer and pediatric entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|lymphomas amyloidosis medulloblastoma osteosarcoma neuroblastoma|rhabdomyosarcoma|vincristine is used to treat hodgkin  s disease , leukemia , entity , neuroblastoma , and wilms  tumor .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|medulloblastoma osteosarcoma neuroblastoma retinoblastoma ewing|rhabdomyosarcoma|rare pediatric disease designations and odds were granted for the treatment of , neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma medulloblastoma neuroblastoma retinoblastoma ewing|rhabdomyosarcoma|in 2018 , the fda granted orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cancer|ewing cell oligo osteosarcoma synovial|neuroblastoma medulloblastoma retinoblastoma sclc cml|rhabdomyosarcoma|granted orphan drug designation to clr 131 , the companys lead phospholipid drug conjugate™ ( pdc ) product candidate , for the treatment of entity , a rare pediatric cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma neuroblastoma medulloblastoma retinoblastoma sarcomas|rhabdomyosarcoma|since then the drug has been used to treat various types of cancer , including wilms tumor , entity , ewing  s sarcoma , trophoblastic neoplasm , and testicular cancer .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma medulloblastoma neuroblastoma ewing myeloma|rhabdomyosarcoma|in 2018 , the fda granted od and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cancer|ewing cell oligo osteosarcoma synovial|medulloblastoma retinoblastoma neuroblastoma osteosarcoma cml|rhabdomyosarcoma|pv-10 is also undergoing preclinical study for pediatric solid tumor cancers ( including neuroblastoma , ewing sarcoma , entity , and osteosarcoma ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma medulloblastoma neuroblastoma myeloma cml|rhabdomyosarcoma|in 2018 , the fda granted odd and rpdd for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma neuroblastoma medulloblastoma sarcomas retinoblastoma|rhabdomyosarcoma|description / conclusion the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5)])|cancer|ewing cell oligo osteosarcoma synovial|combination conjunction combinations humans tandem|rhabdomyosarcoma|the nci has initiated a phase i / ii clinical trial in entity of ganitumab with the kinase inhibitor dasatinib based on promising preclinical animal model data with this combination .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma medulloblastoma neuroblastoma cml lymphomas|rhabdomyosarcoma|multiple myeloma as well as orphan drug and rare pediatric disease designations for clr 131 for the treatment of neuroblastoma , entity , ewings sarcoma and osteosarcoma .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma this sarcomas gist sts|rhabdomyosarcoma|“entity is the most common type of tissue sarcoma in children .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma neuroblastoma medulloblastoma sarcomas retinoblastoma|rhabdomyosarcoma|the poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma neuroblastoma medulloblastoma sarcomas retinoblastoma|rhabdomyosarcoma|the poster covered preclinical work using reovirus in combination with radiation in mice implanted with pediatric entity and ewings sarcoma tumours .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cancer|ewing cell oligo osteosarcoma synovial|osteosarcoma ewing sarcomas myeloma that|rhabdomyosarcoma|entity is a skeletal muscle neoplasm occurring primarily in the first decade of life , while osteosarcoma , a bone neoplasm , occurs primarily
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cancer|ewing cell oligo osteosarcoma synovial|retinoblastoma neuroblastoma rhabdomy medulloblastoma osteosarcoma|rhabdomyosarcoma|is to investigate the gene expression patterns stimulated by sca using two malignant tumor cell lines , saos-2 ( osteosarcoma ) and rd ( entity ) .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1), ('BIO', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cancer|ewing cell oligo osteosarcoma synovial|melanoma ad crpc nsclc mesothelioma|rhabdomyosarcoma|the nci has conducted pk / pd and dose escalation studies in preclinical models of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|autoimmune_disease|neur sclerosis cerebrospinal optic spinal|syndromes diseases lesions conditions cns|polyradiculoneuropathy|oral 2008 2015 / iii chronic inflammatory demyelinating entity 2012 2016 / iii hsc835 tbd stem cell regeneration stem cell transplantation
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|autoimmune_disease|neur sclerosis cerebrospinal optic spinal|diseases conditions syndromes condition lesions|polyradiculoneuropathy|a phase ii / iii study of gilenya in patients with chronic inflammatory demyelinating entity was initiated in 2012 .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|autoimmune_disease|neur sclerosis cerebrospinal optic spinal|diseases conditions syndromes states lesions|polyradiculoneuropathy|development work for a u . s . pediatric indication to treat primary immunodeficiencies and a phase 3 indication in chronic inflammatory demyelinating entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|diabetes hemorrhage thrombocytopenia complications labor|hypertension|addition , matria provides home healthcare services for the management of other complicated obstetrical and gynecological conditions , such as pregnancy induced entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|hypotension bradycardia nausea vomiting tremor|hypertension|however , the letter indicated that such a boxed warning could be reconsidered if suitable data demonstrating a lack of severe entity in a fully supine position were provided .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|osteoporosis psoriasis epilepsy osteoarthritis depression|hypertension|aventis claims its therapeutic innovations rank among the leading treatments for lung and breast cancer , thrombosis , seasonal allergies , diabetes and entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|fibrosis ph edema angiogenesis remodeling|hypertension|pulmonary entity in interstitial lung diseases market there are no therapies currently approved for ph-ild .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|cardiology electrophysiology medicine neurology echocardiography|hypertension|dr . oparil has an extensive bibliography in clinical cardiology and entity , including over 350 journal articles , books and book chapters .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|malaria candidiasis leishmaniasis uti ben|hypertension|the subpoena requests documents relating to benicar® , benicar hct® , and azor® , prescription medications approved for the treatment of entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|chf hypotension bradycardia angina hf|hypertension|the king board made note of mylans proprietary product nebivolol , a beta blocker for the treatment of entity , the nda for which was accepted for filing in june by the fda .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|hypoplasia fibrosis edema vasoconstriction hypoxemia|hypertension|he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary entity of the newborn .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|thrombosis remodeling edema hypertrophy fibrosis|hypertension|release announcing united states food and drug administration approval of intravenous dosing of remodulin for the treatment of pulmonary arterial entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|melanoma neovascularization inflammation fibrosis amyloidosis|hypertension|rhopressa® , and our product candidate , roclatantm , are designed to lower intraocular pressure ( iop ) in patients with open-angle glaucoma or ocular entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|alopecia dizziness pruritus diarrhoea dermatitis|hypertension|most common non-hematologic adverse reactions : ( ≥20% ) were entity , rash , abdominal pain , fatigue , headache , dry skin , constipation , arthralgia , nausea , and pyrexia .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|smoking dyslipidemia hypercholesterolemia atherosclerosis nephropathy|hypertension|have been found to be an independent predictor of a number of cardiovascular risk factors including obesity , abnormal lipid levels , entity , type 2 diabetes , and systemic inflammation .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|arrhythmias hypotension arrhythmia bradycardia epilepsy|hypertension|about plendil plendil ( felodipine ) is a calcium antagonist for the treatment of entity and angina .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|acne psoriasis t2dm ms diabetes|hypertension|lotrel ( +11% us ) , the leading us fixed combination treatment for entity , sustained double-digit sales growth well ahead of market ( +6% ytd ) .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|tremor depression hypothyroidism insomnia sleepiness|hypertension|therapy for depression , is approved in the united states as inversine for the management of moderately severe to severe essential entity .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|epilepsy hyperthyroidism alcoholism depression schizophrenia|hypertension|phentolamine has been approved by the fda for the treatment of entity and for use in the diagnosis of certain tumors of the adrenal gland , and has been used " off-label " by urologists ,
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 3), ('DIS', 1)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|analgesia analgesic analgesics headache pca|hypertension|partner product / candidate application status teva clonidine tds entity marketed par fentanyl tds pain marketed p&g crest whitestrips ( 5 products )
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|ph edema fibrosis involvement hypoxemia|hypertension|pulmonary entity may be present in as many as 74% of patients depending on how the pulmonary entity ( “ph” ) is defined .
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|melanoma amd gbm myeloma malaria|hypertension|we cannot be certain that darusentan for the treatment of resistant entity will be approved in the united states or in countries outside of the united states or whether marketing approvals will
OrderedDict([('OTHER', 4), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|normotensive autonomic antihypertensive carotid subclinical|scoliosis diabetes myopia epilepsy asd|hypertension|except for inversine for the management of entity , neither the fda nor any foreign regulatory authority has approved any of our product candidates for marketing .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|ra itp ms sle vasculitis|vasculitis|dr . jaynes research includes investigator-initiated international trials and the introduction of newer therapies in entity and sle with collaborators on five continents .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis anca thrombocytopenia sle|vasculitis|ifx-1 is currently being developed for various inflammatory indications , including hidradenitis suppurativa , anca-associated entity and pyoderma gangraenosum .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis nephritis nephropathy thrombocytopenia|vasculitis|rituxan we are currently planning for phase iii clinical trials in systemic lupus eruthematosus , lupus nephritis and anca-associated entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|entity entities vasculitis glomerulonephritis nephritis|vasculitis|ccx168 for anca-associated entity understanding anca-associated entity ancas are autoantibodies that attack certain type of white blood cells called neutrophils .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis thrombocytopenia pneumonia sle|vasculitis|ifx-1 is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and covid-19 induced pneumonia .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|atherosclerosis vasculitis thrombosis inflammation this|vasculitis|entity is an inflammatory process of blood vessels , histopathologically characterized by vessel wall destruction and occlusion of the vascular lumen .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|psoriasis lupus sle vasculitis colitis|vasculitis|test could be used by clinicians in the management of several autoimmune diseases , including but not limited to rheumatoid arthritis , entity and irritable bowel disease .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|sle moderate early nephritis lupus|vasculitis|in 2012 , we plan to initiate phase 3 trials of benlysta in entity and active lupus nephritis .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis hus anca inflammation|vasculitis|of those cells to do damage in response to c5a activation , which is known to be the driver of anca-associated entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis thrombocytopenia amyloidosis lupus hus|vasculitis|all iga protease-mediated diseases , including iga nephropathy , linear iga bullous dermatitis , iga pemphigus , and henoch-schonlein purpura ( also known as iga entity ) .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|observed detected determined quantified verified|vasculitis|the method of claim 1 , wherein the adverse effect is entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis anca sle ra|vasculitis| completed enrollment of the companys pivotal phase iii advocate trial of avacopan for the treatment of anca-associated entity ; top line data expected in the fourth quarter of 2019 .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|reaction formation lysis reactivity markers|vasculitis|toxicological findings included changes in hematologic and chemistry parameters and fibrinoid entity .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|lupus psoriasis sle diabetes fibromyalgia|vasculitis|actually , my first experience outside of ms was treating a condition called entity and thats another autoimmune disease .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis diseases nephropathy nephritis|vasculitis|rituxan is also being evaluated in lupus nephritis and anca-associated entity in collaboration with biogen idec .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|pathology condition inflammation phenotype pathogenesis|vasculitis|in egpa , patients usually develop asthma initially , before the entity extends to inflammation in the walls of small blood vessels that supply tissues in the lungs , sinuses , skin , nerves and
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis thrombocytopenia reaction anaemia glomerulonephritis|vasculitis|as basal cell cancer in the area of laviv® injections and the risk of immune-mediated hypersensitivity reactions such as leukocytoclastic entity ) , which must be completed by 2016 .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis sle nephritis nephropathy|vasculitis|anca-associated entity is a rare autoimmune disease that largely affects the small blood vessels of the kidneys , lungs , sinuses , and a variety
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis sle anca thrombocytopenia|vasculitis|vilobelimab is currently being developed for various indications , including hidradenitis suppurativa , anca-associated entity , pyoderma gangraenosum and severe covid‑19 .
OrderedDict([('DIS', 5), ('OTHER', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|vasculitis lupus erythematosus autoimmune uveitis|vasculitis glomerulonephritis nephritis diseases nephropathy|vasculitis|evaluated in phase iii clinical trials for anti-tnf ( tumor necrosis factor ) refractory rheumatoid arthritis , primary progressive multiple sclerosis , and anca-associated entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|encephalitis vasculitis myocarditis granuloma aneurysm|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-large blood vessels .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|lesions vasculitis myocarditis encephalitis tumors|arteritis|abbvie initiated a phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|aneurysm aneurysms arteri vasculitis encephalitis|arteritis|targeting gm-csfrα ) ·kiniksa recently announced positive data from the global phase 2 clinical trial of mavrilimumab in giant cell entity ( gca ) .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|aneurysms aneurysm vasculitis arteri atherosclerosis|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|myocarditis vasculitis myopathy encephalitis uveitis|arteritis|in 2013 , servier also began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|arteri vasculitis myocarditis aneurysm encephalitis|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , or gca , an inflammatory disease of the blood vessels .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|vasculitis myocarditis encephalitis aneurysms aneurysm|arteritis|current treatment landscape for giant cell entity glucocorticoids , a type of corticosteroid , are the mainstay for the treatment of gca because they normalize inflammatory markers and resolve
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|myocarditis vasculitis myopathy encephalitis uveitis|arteritis|testing gevokizumab in a variety of small clinical studies , including polymyositis / dermatomyositis and schnitzler syndrome ; a third study in giant cell entity , is expected to open shortly .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|vasculitis myopathy myocarditis encephalitis uveitis|arteritis|in 2013 , servier began testing gevokizumab in a variety of poc studies , including polymyositis / dermatomyositis , schnitzler syndrome , and giant cell entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|nephropathy fibrosis atherosclerosis vasculitis inflammation|arteritis|developed to address the accelerated inflammation of grafted blood vessels common in chronic organ transplant rejection and known as transplant entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 3), ('DIS', 2), ('BIO', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|tumors lesions astrocytoma vasculitis tumours|arteritis|an ongoing phase iii study , announced in november 2015 , is currently investigating sirukumab in giant cell entity .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|aneurysms vasculitis aneurysm arteri atherosclerosis|arteritis|background and market opportunity for giant cell entity gca is an inflammatory disease of the blood vessels that strikes older adults and causes headaches , jaw and other muscle
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|encephalitis vasculitis myocarditis myopathy uveitis|arteritis|the focus of these compounds appears to be in chronic autoimmune disorders such as rheumatoid arthritis , ankylosing spondylitis , giant cell entity and related disorders .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|myocarditis aneurysm arteri vasculitis aneurysms|arteritis|we are evaluating mavrilimumab for the potential treatment of giant cell entity , a chronic inflammatory disease of the medium-to-large arteries .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|lesions tumors encephalitis vasculitis myocarditis|arteritis|· kiniksa plans to advance to a phase 2 clinical trial of mavrilimumab for the treatment of giant cell entity in the second half of 2018 .
OrderedDict([('DIS', 3), ('OTHER', 3)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|sclerosis vasculitis arteri erythematosus obliter|vasculitis aneurysm arteri aneurysms encephalitis|arteritis|in november 2015 gsk announced the start of a phase iii study of sirukumab for patients with giant cell entity ( gca ) , and plans to start a study in asthma were disclosed at gsk  s r&d day .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|complications aes toxicity toxicities reaction|phlebitis|intermune requested this self-imposed clinical hold in part due to the observance of entity at the infusion site judged to be unexpectedly greater in incidence and severity than anticipated .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis hemorrhage ulceration swelling edema|phlebitis|levels were generally well tolerated with one subject at the 5 mg / kg dose level experiencing moderate localized blood vessel inflammation , or entity , that was attributed to the study drug .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis hypotension swelling erythema pruritus|phlebitis|the product may also cause entity ( vein irritation ) in approximately one-third of treated patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis embolism thrombus vessels tissue|phlebitis|for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery - thrombus deep entity , etc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis embolism thrombus vessels dissection|phlebitis|hepatitis ) propylgallate for injection : used for preventing and treating cerebral thrombosis , coronary heart disease , and complication after the surgery-thrombus deep entity , etc .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|hematoma swelling clotting erythema ulceration|phlebitis|blood collection by venipuncture is associated with mild discomfort , and the possibility of localized bruising , entity , or extravasation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis inflammation vasoconstriction hemorrhage hemolysis|phlebitis|other events such as entity , mechanical block of the capillaries or arterioles , activation of platelets , or subsequent generation of microthrombi are also possible .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis thromboembolism sepsis pneumonia endocarditis|phlebitis|peripheral venous catheters have been associated with a 7% to 9% incidence of entity and a 0 . 2% to 0 . 4% incidence of bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|hypotension thrombosis inflammation toxicity hemorrhage|phlebitis|sdp-016 is designed to reduce the vein irritation and entity associated with the iv-delivered drug .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|orr toxicity pfs survival mtd|phlebitis|in terms of entity , which is another thing that the fda mentioned in their complete response , that is something that we feel has been
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|erythema pruritus hematoma swelling edema|phlebitis|patients who received dyloject ( tm ) also had a lower incidence and severity of entity at the site of intravenous administration compared to those given voltarol ( r ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|thrombosis thromboembolism sepsis bacteremia colonization|phlebitis|peripheral venous catheters have been associated with entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|toxicity neurotoxicity this nephrotoxicity resistance|phlebitis|we believe that some clinicians elect to use a central line or a different chemotherapeutic regimen as a means to avoid entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|swelling irritation edema toxicity dryness|phlebitis|we believe the current formulations of these drugs have limitations , such as entity , erythema and hypersensitivity reactions , that present opportunities for improvement .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|pruritus vomiting edema swelling weakness|phlebitis|the most common adverse reactions in clinical trials associated with cinryze were rash , headache , nausea , erythema , entity and local reactions at the injection site .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('BIO', 1)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|superficial deep mucosal cutaneous tissue|phlebitis|local none pain pain and swelling with inflammation or entity ulceration plastic surgery indicated fever of unknown origin
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|vasculitis thrombosis aneurysms embolism others|phlebitis|cerebral infarction and thrombosis , brain damages like apoplectic sequela , cerebral trauma , brain surgery sequela , also used for thromboangitis obliterans and entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|dermatitis neurotoxicity dyspnea dehydration alopecia|phlebitis|clinically significant toxicities observed to date include neutropenia , thrombocytopenia and mild to moderate entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|headache toxicity thrombocytopenia vasodilation erythema|phlebitis|the main side effect at the maximum dose tested was moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|pelvic phleb sinus sclerosis tract|headache vasodilation thrombocytopenia swelling toxicity|phlebitis|the main side effect at the maximum dose tested has been moderate entity ( blood vessel inflammation ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|thrombosis without fistula embolism superficial|thrombosis embolism thromboembolism dvt ulceration|thrombophlebitis|eight of the patients had pulmonary embolism and / or deep vein thrombosis with three additional patients reporting an event of superficial entity .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|thrombosis without fistula embolism superficial|amylase lipase pancreatitis ast triglycerides|thrombophlebitis| 1 % elevated lipase   1 % entity ( associated with infusion sites )  1 %  a for the
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|thrombosis without fistula embolism superficial|thrombosis embolism dvt thromboembolism ulceration|thrombophlebitis|events included : deep venous thrombosis , pulmonary embolism , superficial entity , and retinal vein thrombosis with vision loss .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|thrombosis without fistula embolism superficial|thrombosis hematoma thromboembolism dvt ulceration|thrombophlebitis|no venous thromboembolism events or occurrences of superficial entity were observed or reported .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|thrombosis without fistula embolism superficial|thrombosis embolism thrombus thromboembolism puncture|thrombophlebitis|thalidomide in combination with other agents may have an increased incidence of thromboembolic events such as pulmonary embolism , deep vein entity , entity , or thrombosis .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|thrombosis without fistula embolism superficial|first remaining subsequent previous 2nd|thrombophlebitis|both saes have subsequently resolved , with the entity sae verbally reported to the company as resolved following the safety data cut-off date .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|thrombosis without fistula embolism superficial|irritation erythema reaction pruritus swelling|thrombophlebitis|entity ( vein irritation ) was significantly less with dyloject than with ketorolac or placebo .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|single arteriovenous solitary composite vte|vte embolism pa pae pes|thromboembolism|pulmonary embolism : a pulmonary embolism , or entity , occurs when a blood clot , generally a venous thrombus , becomes dislodged from its site of formation and embolizes to the
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis pneumonia embolism hemorrhage|thromboembolism|poaf is independently associated with an increased risk of morbidity and mortality caused by stroke , heart failure , ventricular arrhythmias , entity and bleeding from anticoagulation .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis insufficiency embolism complications|thromboembolism|james d . extended-duration prohylaxis against venous entity after total hip or knee replacement : a meta-analysis of the randomized trials .  the lancet .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|single arteriovenous solitary composite vte|angiogenesis thrombosis hemorrhage inflammation tumorigenesis|thromboembolism|inhibition of intracellular signaling involved in tumor growth and metastases and 2 ) inhibition of early coagulation processes associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism vte endocarditis|thromboembolism|risk factors for arterial vascular disease and / or venous entity ( vte ) should be managed appropriately .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thrombosis dvt thromboembolism vte thrombocytopenia|thromboembolism|heparin is also used to prevent the occurrence of entity and to prevent clotting during dialysis and other surgical procedures , particularly vascular surgery .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism insufficiency puncture|thromboembolism|and states that esas increase the risk of death and major adverse cardiovascular events , such as myocardial infarction , stroke , venous entity and thrombosis of vascular access .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism vte thrombotic|thromboembolism|a risk associated with hormonal contraceptives is a rare but serious adverse event called venous entity , or vte , which involves the formation of a blood clot in a vein .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism puncture access|thromboembolism|fdas approval of annovera™ , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism insufficiency endocarditis|thromboembolism|xa in phase 3 development for extended duration prophylaxis , or preventive treatment , of a form of thrombosis known as venous entity , or vte , in acute medically ill patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|single arteriovenous solitary composite vte|infarction hemorrhage vasculitis aneurysms infarcts|thromboembolism|similarly , cerebral entity and cerebral vasculitis would be unexpected ( by virtue of greater specificity ) if the labeling only listed cerebral vascular accidents .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 3)])|cardiovascular_disease|single arteriovenous solitary composite vte|atherosclerosis dyslipidemia cvd inflammation hypercholesterolemia|thromboembolism|pipeline we aim to broaden our cv portfolio into the areas of entity , dyslipidaemia , type 2 diabetes / metabolic syndrome , atrial fibrillation and vascular disease prevention .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism insufficiency puncture|thromboembolism|are in danger of forming life-threatening blood clots as a result of atrial fibrillation , prosthetic heart valve replacement or venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis dvt embolism insufficiency|thromboembolism|the committees concluded that users of evra have an increased risk of venous entity , or vte compared to users of second generation contraceptives , such as those containing lng .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|single arteriovenous solitary composite vte|ms ra osa dm malaria|thromboembolism|patients and physicians are advised to be observant for the signs and symptoms of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism vte thrombotic|thromboembolism|of the ag200-15 patch , levonorgestrel ( lng ) , is considered as one of the safest progestins , with the lowest risk for venous entity ( vte ) when combined with ee .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis embolism puncture access|thromboembolism|the approval of annovera , the fda has required a post-approval observational study be performed to measure the risk of venous entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|single arteriovenous solitary composite vte|thrombosis thromboembolism dvt strokes embolism|thromboembolism|in the ats heart valve is intended to lower the likelihood of blood clot formation and the resulting incidence of entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|single arteriovenous solitary composite vte|pneumonia diabetes angina pancreatitis cardiomyopathy|thromboembolism|response clinical tests are commercially available for the aid in early detection of heart attack , congestive heart failure , entity , sepsis , influenza a and b and rsv .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|single arteriovenous solitary composite vte|thromboembolism thrombosis insufficiency access ulcers|thromboembolism|there were approximately 510 , 000 patients being treated for venous entity in the united states in 2005 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism exacerbation thromboembolism hemorrhage edema|embolism|pulmonary entity is the most common preventable cause of hospital death and a leading cause of increased length of hospital stay .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism oedema haemorrhage edema hemorrhage|embolism|to sell abbokinase for the treatment of acute massive pulmonary entity , we are required to continue an ongoing 200-patient immunogenicity clinical trial that commenced in 2003 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|thrombosis thrombus inflammation strokes hemorrhage|embolism|will look natural to blood as it passes through the valve , thus inhibiting platelet aggregation that may later lead to entity or blood clots .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism hemorrhage edema infarction haemorrhage|embolism|urokinase is an fda-approved thrombolytic , or clot-dissolving agent , indicated for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism thromboembolism hemorrhage embol infarction|embolism|the primary efficacy endpoint is the occurrence of venographically-confirmed dvt , pulmonary entity , or death during the treatment phase , when measured at day 30 .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism thromboembolism hemorrhage infarction edema|embolism|allegedly sustained as a result of their product use ; the most common alleged injuries are deep vein thrombosis and pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism fibrosis diseases edema complications|embolism|used berlex hrt products together with other hrt products and suffered injuries , including breast cancer , ovarian cancer , stroke and pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism overdose necrosis infarction burn|embolism|one patient in the mst-188 group died due to cardiopulmonary arrest , which was considered secondary to a fat entity based on autopsy .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|edema embolism congestion abscess oedema|embolism|patients were dyspnea ( 7 percent ) , pneumonia ( 5 percent ) , hypoxia ( 4 percent ) , neoplasm progression ( 4 percent ) , pyrexia ( 2 percent ) and pulmonary entity ( 2 percent ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism edema hemorrhage infarction oedema|embolism|abbokinase is fda approved and marketed for the treatment of acute massive pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism edema fibrosis obstruction exacerbation|embolism|the blood clots can travel to the lung and cause a pulmonary entity development all activities required to bring a new drug to the market .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism abscess infiltrate fibrosis edema|embolism|in two cases , the patient developed a pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism edema hemorrhage embolization haemorrhage|embolism|numerous companies either offer or are developing competing treatments for ischemic stroke , massive pulmonary entity and catheter occlusion , the three indications we are currently targeting .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism thromboembolism hemorrhage complications edema|embolism|ivc filters have been shown in several studies to significantly reduce the risk of pulmonary entity and related mortality in certain high risk patient populations .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism thromboembolism hemorrhage infarction edema|embolism|triage d-dimer test as an aid in the assessment and evaluation of patients suspected of having thromboembolic events , including pulmonary entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism edema hemorrhage infarction thromboembolism|embolism|in some cases , a venous clot can cause lung injury ( pulmonary entity ) by migrating from the veins to the lungs .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|exacerbation infiltrate reaction embolism edema|embolism|were a total of 48 serious adverse events , two of which were determined to be related to glybera , a pulmonary entity and fever .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism thromboembolism embolization embol infarction|embolism|patients at high risk for pulmonary entity are typically patients undergoing a significant surgical procedure , trauma patients or patients that have experienced a previous embolic event .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|embolism abscess fibrosis edema tuberculosis|embolism|the most frequent ( >1% ) principal diagnoses were als , sepsis , respiratory failure , aspiration pneumonia , pneumonia , pulmonary entity , and urinary-tract infection ( table 2 ) .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteriovenous brain embolism paradoxical lung|nodule edema infiltrate hemorrhage fibrosis|embolism|in addition , one patient was reported to have a pulmonary entity ( grade 4 ) that was an incidental finding on ct scan .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis hemorrhage clotting rupture hemolysis|thrombosis|pnh is a rare chronic blood disease characterized by severe anemia and risk of blood clotting or entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|sepsis dvt bacteremia aki ulcers|thrombosis|crbsis and entity represent key complications among hemodialysis , intensive care , cancer and total parenteral nutrition , or tpn , patients with cvcs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis complications restenosis insufficiency patency|thrombosis|the angiojet system is marketed in the united states for treatment of dialysis access graft entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis dvt thromboembolism thrombus embolism|thrombosis|potential applications of catheter delivered thrombolytics include apao ( acute peripheral arterial occlusion ) , dvt ( deep vein entity ) , and ischemic stroke .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis vasculitis atherosclerosis hemorrhage thromboembolism|thrombosis|the most devastating consequence of chronic hemolysis is entity , which can occur in blood vessels throughout the body , damaging vital organs and causing premature death .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thrombus thromboembolism dvt ulcers|thrombosis|cs-3030 is an oral direct factor xa inhibitor used to treat deep vein entity , or blood clots , and pulmonary embolism .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thromboembolism thrombus embolism insufficiency|thrombosis|in early 2003 , lovenox will be submitted in japan for the prevention of deep-vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thromboembolism thrombus insufficiency diseases|thrombosis|venous clots occur principally in the arms or legs ( deep vein entity ) , and may cause local inflammation , chronic pain and other complications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 1)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|complications edema complication conditions condition|thrombosis|candidates include kaitong , a lipid emulsion of alprostadil for the treatment of peripheral vascular diseases , cardiocerebral microcirculation disorder and post-surgery entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|arrhythmias cardiology diabetes cardiomyopathy arrhythmia|thrombosis|rnapc2 was originally developed as a cardiovascular therapy for entity and other indications .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|diastole inspiration origin below filling|thrombosis|angina is caused by partial blockage of a coronary artery from entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis stiffness thromboembolism access diseases|thrombosis|positioned angiomax as a replacement for heparin , which is a widely used , inexpensive , generic drug used in patients with arterial entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombin healthcare va medicine global|thrombosis|we are initially targeting three segments of the entity market in which safe and rapid removal of blood clots is essential for patient care , including ischemic stroke , pulmonary embolism
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|they thrombosis vte dvt this|thrombosis|entity can be treated surgically or through drug therapy with anticoagulant and thrombolytic drugs .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thrombus thromboembolism embolism dvt|thrombosis|patients withdrew due to adverse events ( one due to a recurrence of crohns disease and one due to deep vein entity ) .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|vte fx dvt thrombosis falls|thrombosis|may 2015 , we entered into an exclusive license agreement with bayer to develop and commercialize ionis-fxirx for the prevention of entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|others epilepsy diabetes psoriasis thrombosis|thrombosis|the therapeutic areas pursued by celera included oncology , autoimmunity , respiratory diseases and entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thromboembolism thrombosis embolism insufficiency dvt|thrombosis|each year in the u . s . , over 270 , 000 patients are diagnosed with venous entity and approximately 50 , 000 patients die from pulmonary embolisms .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thrombus thromboembolism puncture dvt|thrombosis|that trial was discontinued due to the hypotension and because defibrotide can also be administered orally to prevent deep vein entity .
OrderedDict([('OTHER', 5), ('DIS', 3)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|thrombosis arteriovenous sinus av thrombus|thrombosis thrombus thromboembolism puncture embolism|thrombosis|as an anticoagulant , or blood thinner , to prevent clotting of blood in the vein , commonly referred to as deep vein entity , and acute coronary syndromes .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|inflammation primates neuroinflammation immunity humans|arteriosclerosis|served as vice president of research at the winters institute , a non-profit biomedical research institution , at which dr . waitz studied entity in primates .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|atherosclerosis thrombosis aneurysms aneurysm vasculitis|arteriosclerosis|the skin , copd in the lung , fibrotic disease in the liver and kidney , crohn  s disease in the intestine , chf and entity in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|infarction hemorrhage aneurysms aneurysm embolism|arteriosclerosis|pharmaceutical research conducted to date indicates that aso 989 has the potential to treat ischemia of extremities , cerebral thrombosis , cerebral entity and coronary heart disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|insufficiency atherosclerosis spasm angioplasty revascularization|arteriosclerosis|designed to treat the symptoms of coronary entity , angina pectoris and hyperlipemia .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 4)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|diabetes dyslipidemia hyperlipidemia hypercholesterolemia atherosclerosis|arteriosclerosis|the product can be used in treatment of anoxemic cardiovascular and cerebrovascular disease , as well as hypertension and entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|diabetes gastrointestinal epilepsy angina hyperlipidemia|arteriosclerosis|this product is used to treat ischemic heart and cerebrovascular diseases , entity and cerebral thrombosis bezoar antipyrotic tablet .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|inflammation thrombosis swelling edema vasoconstriction|arteriosclerosis|moreover , damage to the blood vessels may cause blockage due to entity and lead to the tearing of the vessels .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|mortality strokes pancreatitis complications deaths|arteriosclerosis|claims fabacs , including aramchol , as well as methods for preventing or dissolving cholesterol gallstones in bile and reducing or preventing entity using fabacs .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 2)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|diabetes osteoporosis atherosclerosis dyslipidemia inflammation|arteriosclerosis|of variations in a gene which control blood levels of a protein and predict increased disposition or susceptibility to osteoporosis , entity , cancer and immune disorders .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|atherosclerosis inflammation hemostasis circulation thrombosis|arteriosclerosis|he is also a member of the american heart association council on stroke , and council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|complications comorbidities mortality morbidity atherosclerosis|arteriosclerosis|million patients require bypass surgery each year because of age related entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|atherosclerosis thrombosis angiogenesis hemostasis aneurysm|arteriosclerosis|on april 20 , 2012 , alnylam presented aln-pcs data at the american heart associations entity , thrombosis , and vascular biology ( atvb ) 2012 scientific sessions held in chicago , il .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|infarction hemorrhage embolism infarct aneurysm|arteriosclerosis|used for coronary heart disease , angina , cerebral entity , ischemic cerebrovascular disease .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|melanoma gbm ad glioblastoma crpc|arteriosclerosis|in vivo validation of this model , enabling a route to screen for compounds against this target specifically to treat entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|engineering biomedical biotechnology hyperthermia bioinformatics|arteriosclerosis|since 1973 , he has served as director of the entity center at the massachusetts institute of technology ( " mit " ) , of which he was the founder .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|atherosclerosis diabetes inflammation hemostasis circulation|arteriosclerosis|with non hdl -c ( ³130 mg / dl ) in type 2 diabetes mellitus” was given at the american heart association , council on entity , thrombosis and vascular biology .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|cvd chd atherosclerosis diabetes mortality|arteriosclerosis|balancing female hormones may lower the risk of entity by utilizing the bodys natural protection against heart diseases before menopause .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|thrombosis diabetes atherosclerosis vasculitis alcoholism|arteriosclerosis|and chronic peripheral vascular-metabolic disorders , brain occlusion , occlusion of retina central vein , acute and chronic cerebral vascular-metabolic disorders caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|cancers inflammation dyslipidemia strokes diabetes|arteriosclerosis|excess dietary fat is the primary cause of obesity , heart disease , high blood pressure , diabetes , entity and other diseases .
OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|arteri atherosclerotic atherosclerosis subclinical sclerosis|diabetes epilepsy strokes atherosclerosis thrombosis|arteriosclerosis|angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer , blindness and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|acne psoriasis periodontitis melanoma alopecia|atherosclerosis|patent applications also cover estrogen-related compounds with anti-fungal activity and the treatment of localized entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis dyslipidemia inflammation thrombosis hypercholesterolemia|atherosclerosis|chd usually results from entity , a hardening and narrowing of the arteries caused by a buildup of fatty plaque composed of cholesterol and other lipids ,
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4), ('DIS', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|hypercholesterolemia chd cvd hyperlipidemia atherosclerosis|atherosclerosis|current treatments : most patients with entity have high levels of a particular type of cholesterol particle known as ldl-c . the current standard of care is treatment
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis cvd t2dm nafld chd|atherosclerosis|several studies have demonstrated that lxr agonists will promote rct in vivo in mice and prevent the development of entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|smoking diabetes atherosclerosis aging hyperlipidemia|atherosclerosis|test cleared by the fda to aid in assessing risk for both coronary heart disease and ischemic stroke associated with entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis hypercholesterolemia diabetes inflammation hyperlipidemia|atherosclerosis|preclinical studies conducted by pharmacyclics and our collaborators have demonstrated that texaphyrins also accumulate in vascular plaque caused by entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|inflammation atherosclerosis pathogenesis prognosis mortality|atherosclerosis|chlamydia pneumoniae ( " c . pneumoniae " ) infections may play a role in entity in heart diseases .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis inflammation hf fibrosis cardiomyopathy|atherosclerosis|oxidative stress ( the physiological condition of inadequate oxygen supply ) may worsen entity and make heart muscle more susceptible to damage .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|inflammation autoimmune neurodegenerative epilepsy osteoporosis|atherosclerosis|mitochondrial-derived peptides ( mdps ) into mbts offers the potential to address a broad range of diseases including type 2 diabetes , cancer , entity and neurodegenerative disorders .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|diabetes atherosclerosis osteoarthritis inflammation psoriasis|atherosclerosis|inhibitors of certain classes of pdes , in particular pde4 , may be novel compounds for the treatment of inflammation related to entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis diabetes smoking inflammation thrombosis|atherosclerosis|entity is the major cause of cardiovascular disease , peripheral artery disease and cerebral artery disease , and can cause heart attack , loss
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|photodynamic antiplatelet antioxidant antioxidative new|atherosclerosis|entity therapy antrin for photoangioplasty of atherosclerosis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|others thalassemia vasculitis syphilis thrombocytopenia|atherosclerosis|including hemorrhage , severe trauma , ischemic heart disease , diabetes , acute myocardial infarction , acute transient cerebral ischemic attack , sickle cell disease and entity .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|cardiology diabetes basic interventional arrhythmia|atherosclerosis|spent 11 years at bristol-myers squibb ( nyse : bmy ) , from 1986 to 1997 , in various capacities , including executive director , heart failure and entity clinical research .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis this which calcification fibrosis|atherosclerosis|entity is a disease that is commonly referred to as a hardening of the arteries and is characterized by the deposition
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|arteries vessel lumen plaques particle|atherosclerosis|ldl and hdl particle in coronary entity size were also important predictors of disease progression .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|psoriasis lupus diabetes colitis osteoarthritis|atherosclerosis|thc has been found to reduce inflammation in chronic inflammatory diseases , such as entity and rheumatoid arthritis .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 2)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis cvd chd atherosclerotic restenosis|atherosclerosis|elevated plasma cholesterol and triglycerides are independent risk factors for entity , the buildup of cholesterol rich lesions and plaques in the arteries .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|melanoma psoriasis glioblastoma als crpc|atherosclerosis|in february 2005 , we initiated phase i trials on rus 3108 , our drug candidate for the treatment of entity , in ireland .
OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|subclinical atherosclerosis carotid aortic premature|atherosclerosis diabetes ckd cvd amd|atherosclerosis|the medical literature that increased vascular oxidative stress is a primary mechanism of impaired blood vessel elasticity in patients with entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|brain neuro cerebro complex al|shock sickness strokes encephalopathy syncope|stroke|ep-4104 ( dantrolene ) for exertional heat entity exertional heat stroke , or ehs , is a rare , emergency and serious medical condition that is potentially life-threatening .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|brain neuro cerebro complex al|micro triage mini rapid meter|stroke|the triage meter , triage micro product line and triage entity panel are not included .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|brain neuro cerebro complex al|preconditioning reperfusion insult damage shock|stroke|kingdom to determine the safety , efficacy and pharmacokinetics of ldp-01 for the reduction of reperfusion tissue damage associated with ischemic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|brain neuro cerebro complex al|orthopedic spinal musculoskeletal orthopaedic muscle|stroke|the majority of people with ms and sci experience some form of spasticity , as do many people following entity or brain injuries .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|brain neuro cerebro complex al|strokes cardiomyopathy encephalopathy shock attacks|stroke|and drug administration , or fda , to initiate a third clinical study administering multistem to patients for the treatment of ischemic entity , a leading cause of death and disability .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|brain neuro cerebro complex al|these more all such new|stroke|pfizer is expected to conduct additional safety and tolerability studies in entity patients later this year .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|brain neuro cerebro complex al|cardiomyopathy encephalopathy attacks strokes migraine|stroke|the last subjects follow-up assessment in the company  s non-gcp phase ii trial evaluating nsi-566 , for the treatment of chronic ischemic entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|brain neuro cerebro complex al|diabetes alcoholism smoking copd cvd|stroke|entity is currently the third leading cause of death , and the leading cause of disability , in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|brain neuro cerebro complex al|cardiomyopathy shock chf hf chest|stroke|there is a tremendous need for new ways to treat ischemic entity patients ,  said anne legrand , senior vice president and general manager , ultrasound , for philips medical systems .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|brain neuro cerebro complex al|aging alcoholism autism neurology psychiatry|stroke|$30 , 000 that is part of the $342 , 000 small business innovation research grant from the national institute of neurological disease and entity , and $10 , 000 in licensing revenue .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|brain neuro cerebro complex al|europe japan germany australia israel|stroke|if the company  s anticipated phase i / iia study in entity is supportive , the company will consider pursuing an ind filing for myocardial infarction in the united states .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|brain neuro cerebro complex al|dementia alzheimer als ad encephalitis|stroke|currently , the company  s parkinson  s disease , aids dementia and entity product candidates are all in or have just recently completed phase i clinical trials .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DRUG', 2), ('DIS', 2)])|cardiovascular_disease|brain neuro cerebro complex al|sepsis tox troponin strep bnp|stroke|shortness of breath panel , triage d-dimer test and triage tox drug screen and others currently under development , including the triage entity panel .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|brain neuro cerebro complex al|neuronal brain nerve neurologic neural|stroke|recent advances in entity recovery by stem cell therapy highlight the regenerative potential of stem cell therapies for neurodegenerative conditions and further support the
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|brain neuro cerebro complex al|osteoporosis strokes dyslipidemia depression inflammation|stroke|individuals that are clinically obese have elevated rates of cardiovascular disease , entity , certain types of cancer and diabetes .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|brain neuro cerebro complex al|epilepsy strokes dementia neurodegenerative hypoxic|stroke|of researching , developing and providing medical technologies to restore the vision of patients with neurological visual loss predominantly resulting from entity or traumatic brain injury .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|brain neuro cerebro complex al|strokes angina mortality revascularization thrombosis|stroke|factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or entity .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('BIO', 1)])|cardiovascular_disease|brain neuro cerebro complex al|tumors repair injuries damage regeneration|stroke|our initial targeted medical conditions are brain entity and wound healing .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|brain neuro cerebro complex al|accident complication embolism infarction recurrence|stroke|study in the u . s . to evaluate the safety and efficacy of the starflex® closure technology to prevent a recurrent embolic entity and / or tia in patients with a pfo .
OrderedDict([('OTHER', 5)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|brain neuro cerebro complex al|epilepsy dementia encephalitis strokes hydrocephalus|stroke|these underlying neurologic conditions include but are not limited to als , ms , alzheimers disease , parkinsons disease , entity and traumatic brain injury .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aneurysms aaa aorta fistula|aneurysm|procedures in which these catheters are used include angioplasty , embolization , abdominal aortic entity ( aaa ) stent-grafts and vena cava filter placements .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|orthopedic liver spine emergency orthopaedic|aneurysm|studies in which hetacool will be used to replace all of the patient  s circulating blood volume at near-freezing temperatures in entity surgery .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|valve root neck aneurysm ring|aneurysm|usually aortic entity reconstruction surgery involves much more blood loss than post cardiopulmonary bypass surgery .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm neurosurgical aneurysms neurovascular endovascular|aneurysm|needs of neurosurgeons with a range of implantable and single-use products , including cerebral spinal fluid shunts , external drainage products and entity clips .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm dissection stricture rupture valve|aneurysm|in patients with a known aortic entity or patients who are at greater risk for aortic entitys , reserve baxdela for use only when there are no alternative
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|new osteosarcoma melanoma evaluable nsclc|aneurysm|as of december 18 , 2001 , a total of 39 entity cases have been treated in the trial .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm rupture aneurysms perforation fistula|aneurysm|fluoroquinolones have been associated with an increased risk of aortic entity and dissection , especially in elderly patients .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aaa asd av aorta|aneurysm|however , transcatheter devices currently used to repair an entity are often too large to be considered a truly minimally invasive procedure .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm obstetric hemorrhage vaso subarachnoid|aneurysm|outcomes and transform the management of entityal subarachnoid hemorrhage , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aneurysms hydrocephalus aaa lesions|aneurysm|patients who require an external ventricular drain ( evd ) , and undergo either neurosurgical clipping or endovascular coiling for repair of their entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aneurysms dissection rupture dilatation|aneurysm|in the united states each year , abdominal aortic entity -- a weakening of the walls of one of the body  s main arteries , sometimes to the point of rupture --
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm av implant aaa id|aneurysm|the les utilizes a material which is delivered as a liquid that fills and conforms to the shape of an entity or avm .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|bypass aneurysm endovascular outflow fistula|aneurysm|company is considering for study are peripheral avms , uterine fibroid tumors , liver tumors and persistent endoleaks related to abdominal aortic entity graft treatments .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aaa aorta sac acl|aneurysm|after the ruptured entity is repaired , these patients remain at risk for multiple complications that are managed over the course of the patients treatment
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aneurysms dissection rupture repair|aneurysm|endologix  s first product , the powerlink system , is a catheter-based alternative treatment for abdominal aortic entity , or aaa .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm obstetric aneu hemorrhage aneurysms|aneurysm|transform the management of entityal subarachnoid hemorrhage , or asah , which is bleeding around the brain due to a ruptured brain entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|metastasis neoplasm tumour entity aneurysm|aneurysm|in a surgical procedure to treat a brain entity , a clip is placed across the base , or neck , of the entity for the purpose of excluding the entity from further blood flow .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aneurysms dissection rupture diseases|aneurysm|it is a direct side effect of an aortic clamping procedure during a surgical operation to treat abdominal aortic entity .
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm endovascular aneurysms nail neck|aneurysm|titanium entity clip was developed in collaboration with biotek engineering , inc . ( " biotek " ) under an exclusive worldwide royalty bearing license to the patents
OrderedDict([('OTHER', 5), ('DIS', 2)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|aneurysm rupture aortic intra intracranial|aneurysm aaa aorta hernia aneurysms|aneurysm|be treated through a combination of pharmacological therapy and non-invasive monitoring or undergo a major surgical procedure to repair the entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|angio cystic cutaneous sclerosis cell|pneumonia endocarditis gastroenteritis bacteremia encephalitis|angiomatosis|he discovered two previously uncharacterized , uncultivated bacterial pathogens , agents of bacillary entity and whipple  s disease .
OrderedDict([('OTHER', 5), ('DIS', 1), ('BIO', 1)])|OrderedDict([('DIS', 4), ('OTHER', 2)])|cardiovascular_disease|angio cystic cutaneous sclerosis cell|syndromes retardation sws sclerosis palsy|angiomatosis|sws , also known as encephalofacial entity , is a neurocutaneous disorder that occurs as a sporadic congenital condition .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|diseases epilepsy diabetes hypercholesterolemia cancers|angioedema|members of the medical and regulatory teams that successfully developed the orphan drug , cinryze , which is used to treat hereditary entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|eczema hypercholesterolemia ataxia amyloidosis epilepsy|angioedema|firazyr for hereditary entity ( “hae” ) in the us prior to shires acquisition , in april 2008 jerini received a not approvable letter for firazyr for
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|hemolysis pah acidosis syndromes diseases|angioedema|our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary entity , or hae .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angio vasculitis childhood cystic edema|migraine headache vasculitis attacks epilepsy|angioedema|submitted a therapeutic biologic application ( bla ) to the fda for ruconest® seeking approval for the treatment of acute attacks of entity in patients with hereditary entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|eczema histamine atopic epilepsy eosinophil|angioedema|clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary entity ( “hae” ) attacks .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|angio vasculitis childhood cystic edema|autism epilepsy eczema amyloidosis ataxia|angioedema|disease description • hereditary entity ( hae ) is a rare , autosomal dominant genetic disorder 1 • hae is characterized by recurrent , unpredictable , debilitating and potentially life
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|migraine headache gout spider these|angioedema|identified several proprietary , small molecule kallikrein inhibitors in an effort to produce an orally administered therapy for the prevention of entity attacks .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|diseases hypercholesterolemia syndromes conditions immunodeficiency|angioedema|therapeutic compounds for the treatment of chronic inflammatory diseases , with initial development to be focused on the treatment of hereditary entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|angio vasculitis childhood cystic edema|eczema eosinophilia amyloidosis eosinophils elastase|angioedema|the most advanced indication for dx-88 is in the treatment of hereditary entity ( hae ) , a potentially life-threatening inflammatory condition .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|migraine gout headache ich hus|angioedema|the study is designed to examine the use of c1-inh in both treating acute attacks of entity and in preventing the onset of such attacks .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 2), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|amyloidosis autism emphysema hypercholesterolemia esterase|angioedema|includes product candidates designed to treat wet age-related macular degeneration ( wamd ) and rare diseases alpha-1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|hypercholesterolemia ataxia hypothyroidism thrombocytopenia diabetes|angioedema|company completes the randomization of 68 evaluable subjects in its phase iii clinical trial for the acute treatment of hereditary entity on or before december 31 , 2006 ( the “options” ) .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|angio vasculitis childhood cystic edema|genetic testing mutation carrier sequencing|angioedema|dyax retains exclusive rights to dx-88 in all other indications , including its hereditary entity program , currently in its second phase 3 trial , as well as for the manufacturing of dx-88 .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|anaphylaxis ear histamine eczema episodic|angioedema|two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily , oral treatments for the prevention of hereditary entity ( hae ) attacks .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|diseases immunodeficiency anaphylaxis ataxia hypercholesterolemia|angioedema|( berotralstat ) for prophylaxis to prevent attacks of hereditary entity in adults and pediatric patients 12 years and older .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 2)])|cardiovascular_disease|angio vasculitis childhood cystic edema|amyloidosis autism emphysema ataxia elastase|angioedema|gene therapy programs to address unmet needs in wet amd and rare diseases alpha 1 antitrypsin ( a1at ) deficiency and hereditary entity ( hae ) .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|angio vasculitis childhood cystic edema|inflammation thrombocytopenia vasculitis complications damage|angioedema|of c1-inh activity , activated c1 and plasmin generate certain inflammatory mediators which are thought to be causal factors of the entity observed in patients with hae .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('DIS', 4), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|angio vasculitis childhood cystic edema|syndromes diseases ataxia cancers diabetes|angioedema|and senior medical director , where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary entity .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|angio vasculitis childhood cystic edema|thrombosis hus ich dvt proteinuria|angioedema|published studies by others have shown c1-inh treatment to resolve entity in 30 minutes to two hours , compared to 24-72 hours when untreated .
OrderedDict([('OTHER', 3), ('DIS', 2)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|angio vasculitis childhood cystic edema|migraine headache ear gout asthmatic|angioedema|we market and sell cinryze in the united states for routine prophylaxis against entity attacks in adolescent and adult patients with hae .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|headache diarrhoea alopecia dizziness pruritus|hypotension|the most frequently observed adverse events in both the placebo and treatment groups were nausea , vomiting and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|anaemia thrombocytopenia dehydration hemorrhage neutropenia|hypotension|the most common were neutropenia , thrombocytopenia , and entity ( 19% each ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|arrhythmias hypotension vasoconstriction complications bradycardia|hypotension|we believe that this characteristic would offer a safety advantage over current vasodilators , which can cause dangerous entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|hypotension headache hyperthermia tachycardia headaches|hypotension|of symptoms associated with idiopathic and diabetic gastroparesis , and our norepinephrine and serotonin reuptake inhibitor ( " nsri " ) td-9855 in neurogenic orthostatic entity ( " noh " ) .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|toxicity hypotension gvhd aes vomiting|hypotension|in the 50 mcg dex-in treatment group and one in the 35 mcg dex-in treatment group ) discontinued due to symptomatic entity and one subject ( 35 mcg dex-in ) due to fever .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|hypotension tachycardia dizziness bradycardia arrhythmia|hypotension|no patients with blood pressure decrease , entity nor with bradycardia required medication to treat these events .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|hypotension dizziness syncope reaction tachycardia|hypotension|like other opioids ( e . g . , heroin , methadone , oxycodone , morphine ) , bunavail may produce orthostatic entity ( dizzy spells ) in ambulatory individuals .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 4)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|bevacizumab metformin nsaids interferon statins|hypotension|profile , in particular its ability to provide clinical benefit without adding to the systemic effects of other therapies such as entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|hypotension tachycardia tolerance syncope dizziness|hypotension|our preclinical studies indicate that ( s ) -doxazosin exhibits potential for a reduction in orthostatic entity and is potentially more potent than the parent drug .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 3), ('OTHER', 3), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|edema swelling pruritus burning necrosis|hypotension|these reactions consisted of erythema , pruritus , and entity and occurred within hours of administration of chemotherapy .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 2)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|erythema hypotension pruritus swelling nausea|hypotension|reactions are characterized by transient entity and an allergic type response , which appear to cease upon stopping drug administration .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|arrhythmias bradycardia aes hypotension complications|hypotension|vazculep is indicated for the treatment of clinically important entity occurring in the setting of anesthesia .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|bradycardia hypotension hyperglycemia myopathy arrhythmias|hypotension|benefit from aliskiren and there was a higher incidence of adverse events related to non-fatal stroke , renal complications , hyperkalaemia and entity in this high-risk population .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|depression complications toxicity sequelae toxicities|hypotension|however , such patients may be subject to protracted severe entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DRUG', 1), ('DIS', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|toxicity toxicities prolongation discontinuation delays|hypotension|in the acute care setting , this should allow the physician to alter the dose and avoid prolonged entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|nausea headache dizziness alopecia constipation|hypotension|in humans , and it was shown to be well tolerated , with the most common adverse events reported being gi toxicities , entity and fatigue .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 4), ('DIS', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|constipation insomnia vomiting headache pruritus|hypotension|the most frequently reported aes included somnolence , dizziness , nausea , headache , and entity .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DRUG', 5), ('OTHER', 4)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|bevacizumab irinotecan sunitinib methotrexate docetaxel|hypotension|the data suggest that the limiting side effect of entity is related to peak plasma drug level , which means that slower infusions could allow delivery of more drug .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('DIS', 4), ('OTHER', 4), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|vomiting dizziness constipation headache pruritus|hypotension|dosing , seven of the 40 olinciguat-treated subjects reported headache , seven reported tachycardia , three 78 table of contents ​ ​ reported entity and three reported nausea .
OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1), ('DRUG', 1)])|cardiovascular_disease|hemodynamic hypotension neuromuscular spinal residual|hypotension interest ttp onset origin|hypotension|no other adverse events of symptomatic entity were seen in the 95 patients treated .
OrderedDict([('OTHER', 5)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|telangiect familial inherited genetic autosomal|31 11 19 15 18|angiodysplasia|the gi blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled , leaky capillaries ( entity ) .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|telangiect cutaneous dermatitis alopecia malformation|amd pws fd bcc rd|telangiectasis|treatment options for entity are limited to corrective surgery or mixed light pulse therapy , known as photoderm , which directs a series of light pulse
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|telangiect cutaneous dermatitis alopecia malformation|plaques scars ulcers psoriasis vesicles|telangiectasis|rosacea progresses to a severe stage , dilated blood vessels that become distended under the surface of the skin , known as entity , appear .
OrderedDict([('OTHER', 4), ('DIS', 3)])|OrderedDict([('OTHER', 4), ('DIS', 3)])|cardiovascular_disease|telangiect cutaneous dermatitis alopecia malformation|erythema dryness swelling scarring atrophy|telangiectasis|however , local side effects are common , in particular skin thinning , entity , bruising , hypopigmentation , acne , striae and secondary infection .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 4)])|cardiovascular_disease|valve endocarditis av complex chord|sepsis bacteremia pneumonia endocarditis neutropenia|endocarditis|as you saw from our press release yesterday , we have continued to make progress in our phase 3 trail in entity and bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|valve endocarditis av complex chord|endocarditis shock colitis peritonitis foot|endocarditis|exebacase to potentially re-sensitize mrsa to penicillin derivatives and first generation cephalosporins , both in vitro and in the rabbit infective entity model .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|valve endocarditis av complex chord|bacteremia endocarditis lesions isolates abscesses|endocarditis|the primary efficacy endpoint is clinical response at day 14 in patients with mrsa bacteremia , including right-sided entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|valve endocarditis av complex chord|mrsa pneumonia endocarditis bacteremia cdi|endocarditis|in addition to background standard of care soc antibiotics compared to soc antibiotics alone for the treatment of staph aureus bacteremia , including entity in adult patients .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|valve endocarditis av complex chord|bacteremia endocarditis osteomyelitis sepsis thrombosis|endocarditis|these infections may lead to complications associated with staphylococcal bacteremia , including infectious arthritis , pneumonia , septic shock , entity and abscesses .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 4)])|cardiovascular_disease|valve endocarditis av complex chord|bacteremia endocarditis sepsis sided abscesses|endocarditis| data from this study , if positive , could support an expansion of the current label to include right-sided entity and / or complicated bacteremia due to s . aureus .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3), ('BIO', 1)])|cardiovascular_disease|valve endocarditis av complex chord|tumors cardiomyopathy chf rcc hf|endocarditis|key points from the meeting with the fda are highlighted below :  further enrollment of patients with left-sided entity is not required .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|valve endocarditis av complex chord|endocarditis wounds pneumonia colitis ulcers|endocarditis|especially cardiac devices which contribute substantially to the growing prevalence of staph aureus bacteremia , and secondary infections such as infective entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|valve endocarditis av complex chord|resistance susceptibility pathogenicity virulence tropism|endocarditis|for the expanded label for cubicin® ( daptomycin for injection ) in the treatment of staphylococcus aureus bacteremia with known or suspected entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 1)])|cardiovascular_disease|valve endocarditis av complex chord|nail pneumonia lung oropharyngeal head|endocarditis|that patients acquire while being treated or cared for in a hospital or out-patient setting and include , among others , pneumonia , entity and bloodstream infections , or bacteremia .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 5), ('DRUG', 1)])|cardiovascular_disease|valve endocarditis av complex chord|endocarditis gastroenteritis pneumonia diseases syphilis|endocarditis|of further concern , the incidence of infective entity is increasing , with over 47 , 000 cases in 2011 , due to the growth of the at-risk populations , such as adults with
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|valve endocarditis av complex chord|sepsis endocarditis osteomyelitis pneumonia bacteremia|endocarditis|gentamicin is an antibiotic used to treat entity , septicemia and bacterial , bone , respiratory tract , soft tissue , urinary tract and other infections .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5), ('DIS', 3)])|cardiovascular_disease|valve endocarditis av complex chord|resistance endocarditis bacteremia pneumonia biofilm|endocarditis|taken either drug has any invasive procedure for which antibiotic prophylactic treatment is recommended to prevent the development of bacterial entity .
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('OTHER', 5)])|cardiovascular_disease|valve endocarditis av complex chord|intended objective individual easy adverse|endocarditis|to get just what  hopefully get what youre looking for or do you feel like youre at loggerheads on an entity indication?
OrderedDict([('OTHER', 5), ('DIS', 1)])|OrderedDict([('DIS', 5), ('OTHER', 5)])|cardiovascular_disease|valve endocarditis av complex chord|endocarditis osteomyelitis bacteremia sepsis pneumonia|endocarditis|the silzone® coating was intended to reduce the risk of entity , a bacterial infection affecting heart tissue , which is associated with replacement heart valves .
#Masked F1-score:0.91|CLS F1-score:0.86|Masked Confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 1050), ('OTHER', 207), ('DIS', 33), ('BIO', 5)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 97), ('OTHER', 168), ('DIS', 1443), ('BIO', 27)])), ('BIO', OrderedDict([('DRUG', 97), ('OTHER', 421), ('DIS', 242), ('BIO', 760)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.81), ('OTHER', 0), ('DIS', 0.83), ('BIO', 0.5)]), 'f1_score': OrderedDict([('DRUG', 0.9), ('OTHER', 0), ('DIS', 0.91), ('BIO', 0.67)]), 'max_f1': 0.91}|CLS confusion matrix:{'matrix': OrderedDict([('DRUG', OrderedDict([('DRUG', 970), ('OTHER', 151), ('DIS', 164), ('BIO', 10)])), ('OTHER', OrderedDict([('DRUG', 0), ('OTHER', 0), ('DIS', 0), ('BIO', 0)])), ('DIS', OrderedDict([('DRUG', 169), ('OTHER', 305), ('DIS', 1160), ('BIO', 101)])), ('BIO', OrderedDict([('DRUG', 61), ('OTHER', 540), ('DIS', 343), ('BIO', 576)]))]), 'precision': OrderedDict([('DRUG', 1.0), ('OTHER', 0), ('DIS', 1.0), ('BIO', 1.0)]), 'recall': OrderedDict([('DRUG', 0.75), ('OTHER', 0), ('DIS', 0.67), ('BIO', 0.38)]), 'f1_score': OrderedDict([('DRUG', 0.86), ('OTHER', 0), ('DIS', 0.8), ('BIO', 0.55)]), 'max_f1': 0.86}
